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Background: The Pressure UlceR Programme Of reSEarch (PURPOSE) consisted of two themes. Theme 1
focused on improving our understanding of individuals’ and organisational risk factors and on improving
the quality of risk assessments (work packages 1–3) and theme 2 focused on developing patient-reported
outcome measures (work packages 4 and 5).
Methods: The programme comprised 21 individual pieces of work. Pain: (1) multicentre pain prevalence study
in acute hospitals, (2) multicentre pain prevalence study in community localities incorporating (3) a comparison
of case-finding methods, and (4) multicentre, prospective cohort study. Severe pressure ulcers: (5) retrospective
case study, (6) patient involvement workshop with the Pressure Ulcer Research Service User Network for the
UK (PURSUN UK) and (7) development of root cause analysis methodology. Risk assessment: (8) systematic
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review, (9) consensus study, (10) conceptual framework development and theoretical causal pathway, (11) design
and pretesting of draft Risk Assessment Framework and (12) field test to assess reliability, validity, data
completeness and clinical usability. Quality of life: (13) conceptual framework development (systematic
review, patient interviews), (14 and 15) provisional instrument development, with items generated from
patient interviews [from (1) above] two systematic reviews and experts, (16) pretesting of the provisional
Pressure Ulcer Quality of Life (PU-QOL) instrument using mixed methods, (17) field test 1 including (18) optimal
mode of administration substudy and item reduction with testing of scale formation, acceptability, scaling
assumptions, reliability and validity, and (19) field test 2 – final psychometric evaluation to test scale
targeting, item response categories, item fit, response bias, acceptability, scaling assumptions, reliability and
validity. Cost–utility: (20) time trade-off task valuations of health states derived from selected PU-QOL items,
and (21) validation of the items selected and psychometric properties of the new Pressure Ulcer Quality of
Life Utility Index (PUQOL-UI).
Key findings: Pain: prevalence studies – hospital and community patients experience both pressure
area-related and pressure ulcer pain; pain cohort study – indicates that pain is independently predictive of
category 2 (and above) pressure ulcer development. Severe pressure ulcers: these were more likely to develop
in contexts in which clinicians failed to listen to patients/carers or recognise/respond to high risk or the
presence of an existing pressure ulcer and services were not effectively co-ordinated; service users found the
interactive workshop format valuable; including novel components (interviews with patients and carers) in root
cause analysis improves the quality of the insights captured. Risk assessment: we developed a Pressure Ulcer
Risk Assessment Framework, the PURPOSE-T, incorporating the Minimum Data Set, a screening stage, a full
assessment stage, use of colour to support decision-making, and decision pathways that make a clear
distinction between patients with an existing pressure ulcer(s) (or scarring from previous ulcers) who require
secondary prevention and treatment and those at risk who require primary prevention (http://medhealth.leeds.
ac.uk/accesspurposet). Quality of life: the final PU-QOL instrument consists of 10 scales to measure pain,
exudate, odour, sleep, vitality, mobility/movement, daily activities, emotional well-being, self-consciousness
and appearance, and participation (http://medhealth.leeds.ac.uk/puqol-ques). Cost–utility: seven items were
selected from the PU-QOL instrument for inclusion in the PUQOL-UI (http://medhealth.leeds.ac.uk/puqol-ui);
secondary study analysis indicated that item selection for the PUQOL-UI was appropriate and that the index
was acceptable to patients and had adequate levels of validity.
Conclusions: The PURPOSE programme has provided important insights for pressure ulcer prevention and
treatment and involvement of service users in research and development, with implications for patient
and public involvement, clinical practice, quality/safety/health service management and research including
replication of the pain risk factor study, work exploring ‘best practice’ settings, the impact of including skin
status as an indicator for escalation of preventative interventions, further psychometric evaluation of
PU-QOL and PUQOL-UI the measurement of ‘disease attribution.’
Funding: The National Institute for Health Research Programme Grants for Applied Research programme.
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Glossary
Algorithm The equation that enables conversion of responses on the health state classification system
(i.e. the Pressure Ulcer Quality of Life Utility Index) to health state utility values.
Backing-off procedure The revision of the valuation design (in particular the corner states) to avoid
implausible health states.
Construct/variable The main topic or outcome under investigation, for example quality of life.
Corner state/s When one domain only is at the most severe level and all others are at the least
severe level.
Direct causal factor A factor that directly impacts the outcome (or the likelihood of the outcome).
Domain The higher-level grouping of related topics/issues that are closely associated to the outcome of
interest (or variable). For example, a domain of the construct quality of life could be ‘physical functioning’.
Domain level The ‘response’ level of the measure being considered, that is, level 1 refers to ‘no bother’,
level 2 refers to ‘a little bother’ and level 3 refers to ‘a lot of bother’.
Health-related quality of life A multidimensional construct that represents an individual’s perception of
how a given disease or medical condition and its treatment affect, at a minimum, his or her psychological,
physical and social functioning.
Independent risk factor A risk factor that retains its statistical association with the outcome when other
established risk factors for the outcome are included in a statistical model.
Indirect causal factor A factor that impacts the outcome (or affects its likelihood of occurrence) by
changing a direct causal factor. If the direct causal factor is prevented from changing, then changes in the
outcome will not be produced.
Instrument Encompasses any method used to measure the variable or construct of interest, including
rating scales, questionnaires, clinical assessments and electronic devices.
Inverse corner state/s When one attribute only is at the least severe level. These states provide
information on the weight of the domain.
Item Refers to a single question intended to assess or measure a particular variable. A variable is usually
measured by an instrument or a scale consisting of multiple items representing aspects relevant to the
particular variable.
Minimum Data Set A list of key data that should be recorded in all settings to allow comparison of
patient groups.
Non-independent risk factor A risk factor that loses its statistical association with the outcome when
other established risk factors for the outcome are included in a statistical model.
Patient-reported outcome A measurement of any aspect of a patient’s health status that comes directly
from the patient without any interpretation of the patient’s response by physicians or others, about how
he or she functions or feels in relation to a health condition or its therapy.
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Ping-pong procedure Interview technique when eliciting preferences in which the number of years to be
traded switches alternatively from high to low offers until the point of indifference is reached.
PITS A term used to denote the worst health state in which all of the domains are at the most
severe level.
Pressure area A body site where pressure ulcers commonly develop; most commonly these include the
sacrum, buttocks, ischial tuberosities, hips, heels, ankles and elbows.
Pressure area-related pain Pain, soreness or discomfort in any pressure area.
Pressure ulcer pain Pain, soreness or discomfort at a body site with an observable pressure ulcer.
Quality of life A multidimensional construct referring to all aspects of a person’s well-being influenced by
the person’s perceived level of satisfaction in a variety of circumstances.
Response options The choices available to select when answering a particular question, used to quantify
items. For example, ‘not at all’/’a little’/’moderately’/’quite a bit’/’extremely’ are response categories for the
Short Form questionnaire-12 items health status instrument.
Risk factor A variable with a significant statistical association with a clinical outcome.
Subdomain A further breakdown of the domain into its constituent parts, for example ‘walking’ could be
a subdomain of the higher-level domain ‘physical functioning’.
Time trade-off A preference elicitation technique in which respondents consider how much time in a
given ill-health state they are willing to trade for less time in full or perfect health.
Unattributed pressure area-related pain Pain, soreness or discomfort reported by patients on a
pressure area/pressure ulcer but in which the body site is not specified/recorded.
Utility Health state utility values typically range from 1 (perfect health) through 0 (dead) to minus infinity.
They are used to weight life-years to produce quality-adjusted life-year estimates for use in
cost–utility analyses.
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Plain English summary
Background
Pressure ulcers (sometimes called bedsores or pressure sores) are areas of damaged skin and tissue.
They are usually caused by limited mobility and often occur as a complication of another illness or injury.
They can lead to extended hospital stays, reduced quality of life and, rarely, death.
Pressure ulcer programme of research
The Pressure UlceR Programme Of reSEarch (PURPOSE) comprises two themes: risk assessment and quality
of life. Each theme was split into work packages.
Theme 1: risk assessment
Work package 1: pain
We found that many patients reported pressure ulcer and pressure area pain and that pressure area pain
is a pressure ulcer early warning sign. We demonstrated the importance of assessing and reacting to
pressure ulcer and pressure area pain.
Work package 2: severe pressure ulcers
We investigated the development of particularly severe pressure ulcers and found that they are more likely
to occur in environments where:
l clinicians fail to listen to patients and carers
l clinicians fail to recognise and react to signs that patients are at risk of, or already have, pressure ulcers
l services are not organised effectively.
Work package 3: risk assessment
Risk assessment tools are used to identify people at risk of pressure ulcers. We have developed and tested
an up-to-date risk assessment tool.
Theme 2: quality of life
Work package 4: Pressure Ulcer Quality of Life
General health questionnaires may not capture what is important to people with a specific health problem.
We have developed and tested a pressure ulcer questionnaire to assess issues that are important to patients.
Work package 5: pressure ulcer cost–utility
To determine whether or not new treatments are good value for money, we have developed a pressure
ulcer-specific economic measure to evaluate the cost-effectiveness of pressure ulcer treatments more accurately.
Patient and public involvement
The Pressure Ulcer Research Service User Network (PURSUN UK) was established as part of PURPOSE.
PURSUN UK is made up of service users with personal experience of pressure ulcers or pressure ulcer risk.
Members have contributed throughout the programme and continue to be involved in research.
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Scientific summary
Background
Pressure ulcers are a widespread, cross-speciality problem. They represent a major burden to patients and
carers, having a detrimental effect on health-related quality of life (HRQoL), and are costly to the NHS.
Programme aims
The Pressure UlceR Programme Of reSEarch (PURPOSE) was developed by a clinical–research collaborative.
The work was organised into two themes with the following aims:
1. theme 1: to reduce the impact of pressure ulcers on patients through early identification of patients at
risk of developing pressure ulceration
2. theme 2: to reduce the impact of pressure ulcers on patients through the development of methods to
capture patient-reported HRQoLs and health utilities for routine clinical use and future research.
Patient and public involvement
We set up the Pressure Ulcer Research Service User Network (PURSUN UK) and with members have
developed innovative patient and public involvement (PPI) methods to underpin programme development,
delivery and dissemination. Examples of innovative activity include adaptation of the Patient Learning
Journey preparation model for use in a research context; use of role play and video to facilitate PPI in the
interpretation of qualitative data; integration of PPI into consensus methods; integration of service user
narratives into dissemination materials; and the development of a live interview model to facilitate
meaningful PPI at professional conferences and training events.
Rationale and aims
Theme 1 focused on improving our understanding of individuals’ and organisational risk factors and on
improving the quality of risk assessments (work packages 1–3). Theme 2 focused on developing
patient-reported outcome (PRO) measures (work packages 4 and 5).
Work package 1: pain
Patients have reported that pressure ulcer pain is their most distressing symptom, that pain at ‘pressure
areas’ was experienced before pressure ulcer manifestation and that their reports of pain are ignored by
nurses. The primary aim of the research was to determine the extent of pressure area and pressure ulcer
pain and explore the role of pain as a predictor of category 2 (and above) pressure ulcers in acute hospital
and community populations.
Work package 2: severe pressure ulcers
There is good evidence that pressure ulcer risks are associated with patient health status but also
suggestive evidence that the organisation of care can influence the risks. We aimed to describe and
explain the ways in which the organisation of treatment and care influences the development of severe
pressure ulcers and identify ways to improve root cause analyses.
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Work package 3: risk assessment
Increasing evidence makes it timely to update pressure ulcer risk assessment and how to prompt an escalation
of interventions for secondary prevention and treatment. The primary aim of the research was to agree a
pressure ulcer risk factor Minimum Data Set to underpin the development and validation of an evidence-based
Risk Assessment Framework to guide decision-making about the risk of developing pressure ulceration and
the risk of progression to more severe ulceration.
Work package 4: quality of life
Patient-reported outcome instruments are used to inform patient care and compare treatment effectiveness.
The principal aim of this work package was to develop a PRO measure of HRQoL specifically for people with
pressure ulcers: the Pressure Ulcer Quality of Life (PU-QOL) instrument.
Work package 5: cost–utility
Cost–utility analysis is the gold standard for economic evaluation and, in some therapeutic areas,
condition-specific utility measures are developed to provide assessment of the impact of conditions and a
measure of treatment benefit. The aim of the study was to create a preference-based index (Pressure Ulcer
Quality of Life – Utility Index; PUQOL-UI) that could be used to generate utility values suitable for use in
cost–utility-based economic evaluations of pressure ulcer interventions.
Methods
The programme comprised 21 research studies, methodological substudies and projects as follows:
1. Pain: (1) multicentre acute hospital pain prevalence study; (2) multicentre community pain prevalence study
incorporating (3) a comparison of case-finding methods; and (4) multicentre prospective cohort study.
2. Severe pressure ulcers: (5) retrospective case study; (6) patient involvement workshop with PURSUN UK;
and (7) development of root cause analysis methodology.
3. Risk assessment: (8) systematic review; (9) consensus study; (10) conceptual framework development
and theoretical causal pathway; (11) design and pretesting of the draft Risk Assessment Framework;
and (12) field test to assess reliability, validity, data completeness and clinical usability.
4. Quality of life: (13) conceptual framework development (systematic review, patient interviews);
(14 and 15) provisional instrument development; (16) pretesting of the provisional PU-QOL instrument
using mixed methods; (17) field test 1 including (18) an optimal mode of administration substudy and
item reduction with testing of scale formation, acceptability, scaling assumptions, reliability and validity;
and (19) field test 2 – final psychometric evaluation to test scale targeting, item response categories,
item fit, response bias, acceptability, scaling assumptions, reliability and validity.
5. Cost–utility: (20) time trade-off task valuations of health states derived from selected PU-QOL items and
(21) validation of the items selected and the psychometric properties of the new PUQOL-UI.
Key findings
Theme 1
Work package 1: pain
Pressure area-related pain prevalence was 16.3% (327/2010) in the hospital population. Of 1769 hospital
patients with no observable pressure ulcers, 12.6% (233) reported pressure area-related pain. The prevalence
of pressure area-related pain in patients with pressure ulcers was 43.2% (104/241) in hospital patients and
75.6% (133/176) in community patients. A detailed pain assessment of 197 patients identified pressure
area-related pain on skin areas assessed as normal as well as on pressure ulcers. The distribution of pain
intensity was similar for all grades and both inflammatory and neuropathic pain were observed. The
community trusts utilised different methods of case ascertainment and different pressure ulcer prevalence rates
were observed (locality 1= 0.77 and locality 2= 0.40 per 1000 adult population).
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The prospective cohort study of 632 acutely ill hospital and community patients identified significant evidence
that the presence of pain at a skin site is an independent predictor for developing a category 2 or above
pressure ulcer in four multivariable models as follows: (1) a priori logistic regression, (2) overdispersion logistic
regression model and (3) an Accelerated Failure Time model for analyses conducted on a patient level, and
(4) a multilevel logistic regression model for the analysis conducted on a skin-site level.
Work package 2: severe pressure ulcers
For seven of eight patients the best explanation of the evidence was that the general organisational
context played a significant role in severe pressure ulcer development. In four accounts, specific events
contributed to development. One patient’s ulcer was deemed unavoidable. Severe pressure ulcers were
more likely to develop in contexts in which clinicians failed to listen to patients/carers or recognise/respond
to high risk or the presence of an existing pressure ulcer and services were not effectively co-ordinated.
Service users found the interactive workshop format and the use of a ‘simulated patient’ account valuable.
Including novel components (interviews with patients/carers) and sensitivity to the contexts within which
health professionals work in root cause analysis can improve the quality of the insights captured.
Work package 3: risk assessment
1. The systematic review identified 15 risk factor domains and 46 subdomains, with three primary risk
factor domains of mobility/activity, skin/pressure ulcer status and perfusion (including diabetes). It
suggests that no single factor can explain pressure ulcer development.
2. The consensus study facilitated agreement of risk factors/assessment items for the Minimum Data Set
(including immobility, pressure ulcer and skin status, perfusion, diabetes, skin moisture, sensory
perception and nutrition), and draft Risk Assessment Framework [subsequently named Pressure Ulcer
Risk Primary or Secondary Evaluation Tool (PURPOSE-T)] development.
3. The new conceptual framework incorporates five key components [(1) mechanical boundary conditions,
(2) physiology and repair, (3) mechanical properties of tissue, (4) geometry of tissue/bone and (5) transport
and thermal properties] and their impact on internal strains, stresses and damage thresholds. The
theoretical causal pathway identifies direct, key indirect and other potential causal factors for pressure
ulcer development.
4. The design and pretesting of the draft PURPOSE-T led to improved usability over the course of three
pretest sessions, demonstrated by increased data completeness and appropriate pathway allocation.
5. The field test demonstrated that inter-rater and test–retest agreement for the PURPOSE-T was ‘very
good’ (kappa) for the assessment decision overall. The inter-rater and test–retest percentage agreement
for ‘problem/no problem’ ranged from 79.1% to 94.2% for the main risk factors. Convergent validity
demonstrated moderate to high associations. Field notes highlighted positive and problem aspects in
relation to using the PURPOSE-T in the clinical environment.
6. A follow-up meeting of experts and service users allowed consideration of the pain cohort study results
and led to revisions of the PURPOSE-T and inclusion of pressure area-related pain.
7. The final PURPOSE-T has the following features: Minimum Data Set, screening stage to target
assessment towards those in need, full assessment stage, use of colour to weight risk factors, and
decision pathways that distinguish between patients with an existing pressure ulcer or scarring who
require secondary prevention and treatment and those at risk who require primary prevention.
Theme 2
Work package 4: quality of life
Our conceptual model includes four HRQoL domains [(1) symptoms, (2) physical functioning, (3) psychological
well-being, and (4) social participation] divided into 13 subdomains. The final PU-QOL instrument consists of
10 scales to measure pain, exudate, odour, sleep, vitality, mobility/movement, daily activities, emotional
well-being, self-consciousness and appearance, and participation. We established that self-administration is
not suitable for hospital inpatients with pressure ulcers and it is intended for administration following a user
manual. Respondents rate the amount of ‘bother’ attributed on a 3-point scale. The final PU-QOL instrument
mostly satisfies psychometric criteria for acceptability, reliability and validity.
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Work package 5: cost–utility
Seven items were selected from the PU-QOL instrument for inclusion in PUQOL-UI on the basis of best practice
psychometric and Rasch methods. Of the large number of potential health states constructed from the items
and response option variants, 52 were valued by the general population, with the remaining health state
values being predicted using ordinary least squares and random-effects regression models. Although both
models exhibited satisfactory predictive power and acceptably low levels of error, the random-effects model is
recommended for use. The secondary study analysis indicated that item selection for the PUQOL-UI was
appropriate and acceptable to patients and that items had adequate levels of validity.
Conclusions
The PURPOSE programme supported the development of a network of 30 acute and community NHS
trusts and accrual of a total of 6735 patients to the National Institute for Health Research portfolio. The
PURPOSE programme has provided important insights for pressure ulcer prevention and treatment and
the involvement of service users in research and development, with implications for PPI, clinical practice,
quality/safety/health service management and future research.
Implications for patient and public involvement in research
1. Patient and public involvement requires explicit commitment to involving services users and their
perspectives throughout every aspect of the research process.
2. Presenting research data in live and interactive formats can make the interpretation process more
engaging and accessible to service users and can support meaningful dialogue between service users
and professionals.
Implications for clinical practice development
1. Front-line health-care professionals should respond to patient symptoms including pain (soreness and
discomfort), alterations to intact skin and category 1 pressure ulcers and instigate/escalate
care provision.
2. Patients with pressure ulcers should have pain assessment, including type of pain, to inform treatment.
3. In circumstances in which clinicians do not have the skills necessary to address needs, patients should
be referred to appropriate colleagues.
4. Some clinicians blamed patients for the development of severe pressure ulcers. In circumstance in which
the provision of effective pressure ulcer prevention interventions is impacted by a patient’s mental
capacity or physical disability, advice (consultation) should be sought from colleagues with appropriate
multidisciplinary specialist expertise and a problem-solving approach adopted.
5. Development of an electronic version of PURPOSE-T in health-care settings would facilitate large-scale
multivariable modelling and the refinement of PURPOSE-T.
6. The implementation of key research findings may be facilitated through the use of the active
monitoring model of care – Pressure Ulcer Prevention Pathways (PUPPs) – which incorporates risk
assessment using the PURPOSE-T (including skin status and pain), the allocation of patients to primary
and secondary prevention pathways and active monitoring of individual patients’ skin responses to
preventative interventions. It details required actions and escalation in response to deterioration and
pressure ulcer development.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxxiv
Implications for quality, safety and health service management
1. To maximise learning, root cause analysis could be extended in two ways:
i. interview patients and carers to capture their accounts of events
ii. increase awareness of the possibility that staff are working in contexts in which risky practices are
tolerated and be able to assess whether or not this is the case.
2. It is important to co-ordinate services effectively so that pressure ulcer risks are communicated to
everyone involved (patients, carers, all members of the multidisciplinary team).
3. Service reconfiguration/ward reorganisation planning needs to ensure continuity of clinical leadership
and oversight/delivery of clinical care to high-risk patients.
4. A standardised case ascertainment method in the community setting should be developed.
Implications for future research
Pain
1. Replication of the pain cohort study is required.
2. The impact of including pain as an indicator for the escalation of preventative interventions
requires investigation.
Severe pressure ulcers
1. The severe pressure ulcer study is the first of its kind and the findings should be confirmed by further
empirical research.
2. There may be merit in studying ‘best practice’ settings to better understand how patients’ and
organisational risks are identified and effectively acted on.
Risk assessment
1. Development of objective measurement methods of mechanical boundary conditions, individual
susceptibility and tissue tolerance, and early indicators of damage.
2. Further evaluation of the PURPOSE-T is required including sensitivity and specificity in different patient
populations, impact on decision-making/processes of care and effectiveness in reducing pressure ulcer
incidence in practice.
3. The pressure ulcer risk factor Minimum Data Set should be incorporated into future research.
4. Development of appraisal methods for risk factor research.
5. Development of a lay version of PURPOSE-T that can be used by patients and carers to facilitate
self-assessment.
6. The impact of including skin status as an indicator for the escalation of preventative interventions
requires investigation.
Quality of life
1. The PU-QOL instrument requires further evaluation through assessment of responsiveness to provide
evidence to support score interpretation and to explore utility in routine practice.
2. The PU-QOL can be used in pressure ulcer research on the proviso that studies undertake parallel
psychometric analysis to assess the performance of the scales in future samples.
3. The PU-QOL instrument requires translation and validation for international utilisation.
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Cost–utility
1. The PUQOL-UI can be used in pressure ulcer prevention/treatment trials to enable cost–utility analyses.
2. Further research is required to determine the responsiveness of the PUQOL-UI.
3. Further research is required to establish the benefits of the PUQOL-UI (and other condition-specific
utility measures) over generic utility measures; this must take into consideration the impact that
condition-specific utility measures may have on decision-making and efforts to achieve
allocative efficiency.
4. Further research is required to determine the extent to which patients completing HRQoL measures
consider (and are able to consider) ‘disease attributable’ impact only.
Access to PURPOSE tools and instruments
1. PURPOSE-T: http://medhealth.leeds.ac.uk/accesspurposet (accessed July 2015).
2. PUPPs: http://medhealth.leeds.ac.uk/accesspurposet (accessed July 2015).
3. PUQOL: http://medhealth.leeds.ac.uk/puqol-ques (accessed July 2015).
4. PUQOL-UI: http://medhealth.leeds.ac.uk/puqol-ui (accessed August 2015).
Funding
This study was funded by the Programme Grants for Applied Research programme of the National Institute
for Health Research.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxxvi
Chapter 1 Background
Introduction
Pressure ulcers are defined as ‘localised injury to the skin and/or underlying tissue usually over a bony
prominence, as a result of pressure, or pressure in combination with shear’ (p.16).1 They are a
widespread2–4 and costly health-care issue.5–8 Pressure ulcers represent a major burden to patients and
carers and have a detrimental effect on patients’ quality of life.9,10
For the past two decades pressure ulcers have been identified in successive Department of Health policies as a
key quality indicator,11,12 with associated guidelines for prevention13,14 and treatment.15 There have been
widespread changes in clinical practice during this period including the introduction of systematic risk
assessment processes, investment in pressure-relieving mattresses, and quality improvement initiatives.
However, reflecting the belief that the development of pressure ulcers remains an indicator of service quality
that impacts on patients and health-care costs, more recently the Department of Health have set out the
ambitious aim of eliminating all avoidable pressure ulcers in NHS-provided care,16 developed a Commissioning
for Quality and Innovation Payment Framework to facilitate this,17 identified pressure ulcers as a high-impact
action for nursing and midwifery18 and incorporated them into the national Operating Framework.19 Despite
the prominence and profile afforded the problem, the research basis to inform practice in this area is limited,
partly because we do not understand the clinical and organisational risks sufficiently well and partly because of
the dearth of high-quality randomised controlled trials of preventative and treatment interventions.14,15,20 Our
programme of work was established to provide the foundation for the development of an evidence base for
practice through improved identification of patients at risk of pressure ulcer development and improved
methods of evaluating outcomes that are important to patients.
In 2004, UK costs associated with pressure ulcer prevention and treatment were estimated to be
£1.4–2.1B annually, equivalent to 4% of total NHS expenditure,5 because of increased length of hospital
stay, hospital admission, community nursing, treatments (reconstruction surgery/mattresses/dressings/
technical therapies) and complications (serious infection). Litigation is also a burden on NHS resources and
is predicted to increase because of both general societal trends and changes in the law, which has led to
investigation of severe pressure ulcers by government agencies to detect institutional and professional
neglect of vulnerable adults.21,22 The NHS focus on pressure ulcer prevention is mirrored elsewhere. In the
USA, for example, health insurance companies have incentivised prevention through widespread changes
to reimbursement policies. Hence, health-care providers are liable for the treatment costs arising from
pressure ulcers that develop during care (organisation-acquired avoidable pressure ulcers).17
Pressure ulcer classification
Numerous classification systems have been developed to categorise the severity of pressure ulcers. Before the
start of the programme grant (in 2008) the two most commonly used systems classified pressure ulcers through
four levels (1–4) of ‘stage’ or ‘grade’.15–17 The descriptors ranged from non-blanching erythema of intact skin at
level 1 (stage 1/grade 1) to full-thickness tissue loss at the most severe level (stage 4/grade 4).23–25 In 2009 the
American National Pressure Ulcer Advisory Panel (NPUAP) and European Pressure Ulcer Advisory Panel (EPUAP)
developed joint guidelines and a revised classification system.1 The two main differences were the use of the
term ‘category’ (to distance the description from the ordinal properties assumed by the use of stage and grade)
and the inclusion of two new descriptors: ‘unstageable’ and ‘deep tissue injury’. In the following chapters we
have adopted the use of the NPUAP/EPUAP (2009) classification and use the term ‘category’ (with Arabic
numerals rather than roman for ease of reading) to classify pressure ulcers in general reference to the literature
and the terms ‘stage’ or ‘grade’ when reporting directly from individual studies, to accurately report the
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classification system used by the authors. In addition, the terms ‘superficial’ and ‘severe’ pressure ulcers are
used to summarise pressure ulcer severity. A superficial ulcer is a category 2 ulcer and the term ‘severe’ is used
to describe category 3, category 4 and unstageable pressure ulcers.
For clarification, the programme excluded consideration of ulcers caused by medical devices (e.g.
nasogastric tubes, surgical drains, oxygen masks, urinary catheters, cannulas and prosthetic limbs).
Summary of the programme of research
The Pressure UlceR Programme Of reSEarch (PURPOSE) was developed by a clinical/academic research
collaborative to address a number of research questions. The areas of work were organised into two
themes with the following aims:
1. theme 1 – to reduce the impact of pressure ulcers on patients through:
i. early identification of patients at risk of developing pressure ulceration and
ii. improved identification and investigation of patients at risk of progression to severe pressure ulceration
2. theme 2 – to reduce the impact of pressure ulcers on patients through the development of methods to
capture patient-reported health-related quality of life (HRQoL) and health utilities for routine clinical use
and in clinical trials.
Theme 1 focused on improving our understanding of risk factors and risk assessment and consisted of
three work packages with the following objectives:
l work package 1 – pain: to determine the extent of pressure area and pressure ulcer pain and explore
the role of pain as a predictor of category 2 and above pressure ulcers in acute hospital and
community populations
l work package 2 – severe pressure ulcers: to identify individual and organisational factors that
contribute to the development of severe pressure ulcers and develop a critical incident/adult neglect
investigation methodology for their review
l work package 3 – pressure ulcer risk assessment: to agree a pressure ulcer risk factor Minimum Data
Set to underpin the development and validation of an evidence-based Risk Assessment Framework to
guide decision-making about the risk of developing pressure ulceration and the risk of progression to
more severe ulceration.
Theme 2 had a focus on the development of patient-reported outcome (PRO) measures and consisted of
two work packages with the following objectives:
l work package 4 – pressure ulcer quality of life: to determine outcomes important to patients who
develop pressure ulcers and develop a psychometrically rigorous PRO measure that is reliable and valid
and suitable for use in the NHS.
l work package 5 – pressure ulcer quality of life utility instrument: to create a preference-based index
that could be used to generate utility values suitable for use in cost–utility-based economic evaluations
of pressure ulcer prevention and treatment interventions.
Both themes 1 and 2 were planned to progress in parallel. Within each theme, planning ensured that
the early work contributed to later studies. Work packages 1 and 2 contributed to work package 3, and
work package 4 contributed to work package 5 (Figure 1). In addition, within each work package we
utilised a range of research methods in sequential phases including (for example) systematic reviews,
prevalence studies, prospective cohort study, case study consensus methods, psychometric evaluation and
time trade-off (TTO) task valuations of health states (Table 1).
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Programme Steering Committee
Programme Management Group
Theme 1 risk assessmentPrincipal
investigators and
tissue viability
teams
NHS centres
Service users
and carers
Establishment of
PURSUN UK
Involvement
throughout the
programme
Theme 2 QoL
Work package 4Work package 1 Work package 2
Work package 3
RAF
Stage 1 MDS
Stage 2 RAF
Stage 3 Eval
Pain
Stage 1
prevalence
Stage 1 cohort
Severe pressure
ulcers
Work package 5
Patient-reported
outcome measures
Phase 1
Phase 2
Phase 3
Healthy utility
FIGURE 1 Outline of the programme. Eval, evaluation; MDS, minimum data set; PURSUN UK, Pressure Ulcer
Research Service User Network UK; QoL, quality of life; RAF, Risk Assessment Framework.
TABLE 1 Summary of PURPOSE research and associated projects
WP1 – pain
(see Chapter 3)
WP2 – severe
pressure ulcers
(see Chapter 4)
WP3 – risk
assessment
(see Chapter 5)
WP4 – pressure ulcer
quality of life
(see Chapter 6)
WP5 – pressure
ulcer quality of life
utility instrument
(see Chapter 7)
l Hospital pain
prevalence
l Community
pain prevalence
l Pain cohort
l Community PU
prevalence
methodology
substudya
l Main study
l PURSUN UK
interpretation
workshopa
l Implementation
project
(including
PURSUN UKa)
l Systematic
review
l Consensus
study
(including
PURSUN UKa)
l Conceptual
frameworka
l Pretest
(including
PURSUN UKa)
l Field test
l Systematic review of
existing measuresa
l Systematic review of
pain descriptorsa
l Conceptual framework
l Pretest
l Field test 1 (including
traditional vs. Rasch
psychometricsa)
l Administration
mode substudya
l Field test 2
l Valuation survey
(including
PURSUN UKa)
l Validation
substudy (including
PURSUN UKa)
PU, pressure ulcer; PURSUN UK, Pressure Ulcer Research Service User Network UK; WP, work package.
a Methodological and patient and public involvement work undertaken in addition to the work in the original grant
application plan.
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Development of the research programme
During the course of the programme, delivery enhancements to the original proposal were made including NHS
capacity development, patient and public involvement (PPI) and additional reviews and methodological research.
NHS research capacity development
Patient populations in pressure ulcer research are characterised by high levels of comorbidity, and are
distributed across multiple care environments. This poses challenges in study design, recruitment and
follow-up. The programme grant application was underpinned by a strong network of NHS collaborators
across 13 acute and community NHS trusts (see Figure 1). During the programme of research (2008–13) this
was further developed through support from the West Yorkshire Comprehensive Local Research Network,
National Institute for Health Research (NIHR) portfolio adoption and incorporation onto the Dermatology
and Primary Care portfolios, facilitating access to service support costs through the NIHR Comprehensive
Local Research Networks and the participation of 30 acute and community NHS trusts (see Appendix 1
and Acknowledgements).
Patient and public involvement in pressure ulcer research
In addition, our original PPI plan was limited and this was significantly enhanced. We established a
partnership with service users through the set-up of the UK Pressure Ulcer Research Service User Network
(PURSUN UK) (see Figure 1 and Chapter 2). Service-user involvement underpinned our development and
delivery of the programme of research as well as the dissemination and identification of ongoing research
priorities. Indeed, PURSUN UK made a major contribution to the design, conduct and interpretation of the
research, with the use of innovative involvement activities (see Table 1 and Chapter 2).
Additional reviews and methodological research
The original programme of work was enhanced through an additional two systematic reviews and five
methodological substudies (see Table 1) addressing methodological issues with wider relevance to the
applied health research field.
Structure of this report
Within each work package there are a number of components, including systematic reviews, primary
research and methodological substudies. In total, 21 pieces of work have been undertaken, as illustrated
in Table 1.
The monograph is structured as follows:
l Chapter 2 provides an overview of the PPI activities, innovation and support
l Chapters 3–7 present the rationale and research (including substudies), PPI and implementation
components of each work package
l Chapter 8 describes the wider benefits accrued through the PURPOSE programme award and 5-year
investment period and summarises the key findings and their implications for practice, PPI, policy
and research.
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Chapter 2 Patient and public involvement
Chapter written by Delia Muir, Susanne Coleman, Lyn Wilson, Nikki Stubbs, Justin Keen,Elizabeth McGinnis and Jane Nixon.
Background
The importance of PPI within PURPOSE was recognised at the start of the programme. PPI in pressure ulcer
research has not been strong to date and the project team identified an opportunity to address this through
the programme. PPI can contribute at all stages of the research process, from commissioning and priority
setting through to dissemination and implementation.26–28 There is a danger, however, that PPI activities can
become tokenistic, particularly when driven by ‘top-down’ policy initiatives rather than a genuine desire to
learn from, and with, service users.29
In recent years there has been a growth in PPI literature;26 however, inconsistencies in reporting and the variety
of research methodologies covered by this literature make comparing studies and establishing quality
challenging.26,27 Recent reviews do highlight some general good practice principles. Shippee and colleagues30
describe four key components of involvement: (1) service user initiation (i.e. preparation, negotiating roles,
establishing shared interests and goals), (2) building reciprocal relationships between service users and
researchers (i.e. establish service users as valued members of the team rather than an optional addition),
(3) co-learning (i.e. development of both service users and researchers) and (4) feedback (i.e. ongoing, iterative
evaluation of PPI processes). This review also highlights the importance of involvement starting as early as
possible in the research process. In addition, advocates of the co-production approach (used mainly in a service
design and delivery context) highlight the need for peer support networks; to recognise and build on people’s
strengths; and to build communities.31
There is a paucity of literature related specifically to PPI in pressure ulcer research. The only other pressure
ulcer PPI initiative that we are aware of is the James Lind Alliance Pressure Ulcer Partnership. This ran in
parallel to this programme and focused on setting future research questions rather than on involvement in
carrying out that research (see Supporting further research for additional information).
The PURPOSE project team set out to develop mechanisms for working in partnership with service users,
to have a positive impact on the research methods and outputs for all strands of the programme. In line
with the principles set out above, we also wanted to ensure that involvement would be a positive and
rewarding experience for the individuals taking part.
Challenges
In the early stages of the programme PPI proved challenging. The project team tried to identify individuals
with experience of pressure ulcers or people managing the risk of pressure ulceration (e.g. people with
chronic conditions that limit mobility or people who have experienced periods of very acute illness). During
the first year, two service users were identified (through clinical members of the project team) and agreed
to be members of the PURPOSE steering committee. Finding more people proved difficult for a number of
reasons. First, there was no infrastructure to support PPI in this field, unlike in some other areas that have
established PPI networks that can support recruitment to research and offer guidance on working with
particular populations. Some health and social care charities also support research and promote PPI
activities. However, pressure ulcers are a cross-specialty problem; they are secondary to other serious
illnesses/conditions and do not fit easily into existing national/charitable structures.
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Despite efforts to recruit through generic PPI networks, our only success in identifying service users was
through the project team’s clinical contacts. This approach raised some ethical considerations. There were
concerns that service users might feel obliged to become involved to ‘repay’ good care or for fear of
future care being affected. It was also felt that there needed to be a clear distinction between ‘caring for
patients’ and ‘working with service users’. Clinical members of the team recruiting and supporting their
own patients could potentially blur these boundaries and create unequal relationships within the team.
This was a consideration when developing a PPI recruitment strategy for the programme.
Another challenge was provided by the complex health needs of many people with experience of pressure
ulcers or pressure ulcer risk. As pressure ulcers affect people with serious long-term conditions or acute
illness/injury, many service users with relevant experience may be unable to take part in traditional
involvement activities.
To address these challenges, a PPI officer post was created. The aim of this post was to develop a pressure
ulcer-focused service user network, which would both facilitate PPI throughout the programme and build
PPI capacity within pressure ulcer research more generally.
The Pressure Ulcer Research Service User Network UK
The Pressure Ulcer Research Service User Network UK was established in 2010 and now has 18 members.
The network is made up of service users and carers with personal experience of pressure ulceration and/or
risk of pressure ulceration. Members have been identified through:
l local, generic PPI groups/networks
l snowball recruitment, whereby existing PURSUN UK members contact friends, colleagues or
family members
l advertising meetings and events in the local media and via e-mail networks
l engaging with charities that focus on a topic related to pressure ulcer risk, such as conditions that limit
mobility, for example the Multiple Sclerosis Society and Spina bifida, Hydrocephalus, Information,
Networking, Equality (SHINE)
l social media (@PURSUN_UK)
l the distribution of PURSUN UK leaflets alongside recruitment of study participants
l tissue viability nurse specialists.
Concerns about clinical members of the research team approaching their own patients, thereby blurring
roles and boundaries, have been addressed by the introduction of the PPI officer as a neutral party. Nurses
in practice hand out information about PURSUN UK and service users then have the option to contact the
PPI officer for further discussions and induction to the network if desired.
The Pressure Ulcer Research Service User Network UK (www.pursun.org.uk) has a minimum of two
management meetings a year at which a core group of the most active members consider the direction of
the network, the terms of reference, recruitment, the website and other network materials. Research
involvement opportunities are sent out via the mailing list as they arise, for example invitations to help
interpret data, become co-authors or input into the study methods.
All members of PURSUN UK are prepared for involvement through a minimum of one induction meeting
with the PPI officer (either face-to-face or by telephone). During this meeting service users are encouraged
to discuss the skills and experience that they bring to the group, as well as any support that they may
need. The remit of PURSUN UK is also discussed along with practical issues such as payment of fees and
expenses. Ongoing support is provided based on the individual needs of each member. Many of the core
group have also been through a more in-depth process of preparation based on the Patient Learning
Journey model.32 The Patient Learning Journey model was originally developed by the Leeds Institute for
PATIENT AND PUBLIC INVOLVEMENT
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Medical Education as a way of preparing service users for involvement in the education of health
professionals. The model was adapted for use in a research context, keeping the original Patient Learning
Journey principles of sharing stories with other service users in a safe, facilitated environment and working
together to identify themes within those experiences. Participants are also encouraged to think about
which aspects of their stories they feel happy sharing with professionals and how best to communicate
key messages. This novel approach to research preparation aims to help service users recognise the
expertise that they have developed through their personal experiences. It also helps with group forming,
encouraging empathy and peer support. Further development opportunities have been sought for
members where possible, such as conference attendance and local research training. Offering a range of
development opportunities has been useful: some members have travelled to large, national conferences
whereas others have found shorter, local events or one-to-one meetings more manageable.
Pressure UlceR Programme Of reSEarch involvement activities
Between 2008 and 2010, PPI was limited by our ability to recruit service users. Following the establishment
of PURSUN UK in late 2010, involvement activities increased across the programme. Furthermore, the
methodology and focus of each work package have guided the nature of involvement. An overview of PPI
activities at different stages of the programme of research is given in the following sections. Involvement in
individual PURPOSE studies is also discussed in subsequent chapters.
Programme management
The PURPOSE steering committee includes two service user members. This led to the identification of the
need for further PPI not only in the PURPOSE programme but also in the field of pressure ulcer research
more generally. This recommendation was supported by the steering committee and led to the decision
to appoint a PPI officer. A service user was involved in the recruitment process for the PPI officer post,
including being a member of the interview panel.
Protocol and patient information leaflet development
Members of PURSUN UK have formally reviewed all of the PURPOSE study protocols via the PURPOSE
steering committee. In addition, PURSUN UK members have made more detailed contributions to the
design of the risk assessment (see Chapter 5) and Pressure Ulcer Quality of Life – Utility Index (PUQOL-UI)
(see Chapter 7) studies. This has been through contributing to study protocols and advising on the
development of patient information leaflets.
Data interpretation
The results of the pain studies (see Chapter 3) have been presented to PURSUN UK. Members have helped to
put the pain results in context from a service user perspective and consider next steps for the research.
They also worked with the project team to interpret qualitative data from the severe pressure ulcer study
(see Chapter 4). This was achieved through a workshop utilising video and role play to make the interpretation
process engaging and accessible for service users with little or no experience of data analysis and
interpretation. This workshop is described in more detail in Chapter 4 (see Patient and public involvement).
Staff training
Case studies based on the real experiences of PURSUN UK members were developed. These were then
used as part of the Pressure Ulcer Risk Primary or Secondary Evaluation Tool (PURPOSE-T; a pressure ulcer
risk assessment tool) pretest training sessions with nurses (see Chapter 5, Phase 3: development of a new
conceptual framework and theoretical causal pathway for pressure ulcer development). This allowed nurses
to apply the tool to authentic case studies, in a safe learning environment.
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Instrument development
Pressure Ulcer Research Service User Network UK has had considerable input into developing PURPOSE-T, with
particular focus on making the tool acceptable for patients in practice. Its involvement was integrated within
the consensus methodology and had a direct influence on the items included in the tool. This is discussed
further in Chapter 5. Members also reviewed the Pressure Ulcer Quality of Life (PU-QOL) instrument (see
Chapter 6), providing feedback about clarity, comprehension, design, layout and item wording. This process
led to some modifications to the PU-QOL instrument (e.g. clarification of instructions, revisions to the wording
of some items). Members with experience of living with a pressure ulcer have also been involved in developing
the PUQOL-UI (see Chapter 7). This involved giving feedback on the questionnaire through ‘think out loud’
interviews and document review.
Dissemination and knowledge transfer
Three members of PURSUN UK are currently contributing to a paper in which their real-life narratives are
used to illustrate findings from the pain studies and emphasise the relevance to clinical practice. They will
be co-authors on the paper. Video podcasts are also being developed with service users. Their stories
will be combined with input from clinicians and used to highlight key messages from the programme.
The videos will be available online.
Implementation
Members of PURSUN UK reviewed the user manual for the PU-QOL instrument. One member is also
involved in piloting a new method for investigating the development of severe pressure ulcers in practice
(following on from the work described in Chapter 4).
Wider impact of the Pressure Ulcer Research Service User
Network UK
In addition to PPI throughout the programme, PURSUN UK has begun to impact the wider tissue viability
and PPI communities, as described in the following sections.
Professional development activities
Members of PURSUN UK have been invited to speak about their experiences at several events. Locally, this
has included training for tissue viability link nurses, presenting to PURPOSE principal investigators, speaking
at the launch of the NIHR Bradford Wound Prevention & Treatment Healthcare Technology Co-operative
and working with medical students. Nationally, members have presented at the Tissue Viability Society
conference, tissue viability education events and the INVOLVE (a national PPI advisory group) conference.
We have developed an effective model for presenting service users’ experiences in which the PPI officer
interviews a member of PURSUN UK in front of a live audience. This provides an alternative to a traditional
presentation for people who do not feel confident presenting personal experiences in that way. This model
has received very positive feedback from both audiences and the service users involved. We have found
that real-life stories are extremely powerful and can create a common focus for professionals from a variety
of backgrounds.
Collaboration with industry
Medical devices play an important role in pressure ulcer prevention and treatment. With this in mind,
PURSUN UK has collaborated with industry partners on projects such as education days and product
development workshops. This collaboration has helped to diversify the involvement opportunities offered
to PURSUN UK members and has been useful in terms of members’ personal development, as it has
given people an insight into another aspect of tissue viability research. This work has also generated some
funds for PURSUN UK, moving the network towards a sustainable model post PURPOSE.
PATIENT AND PUBLIC INVOLVEMENT
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Supporting further research
One member of PURSUN UK is a co-applicant on PRESSURE 2 [a NIHR Health Technology Assessment (HTA)
programme-funded trial comparing two mattresses; http://medhealth.leeds.ac.uk/info/423/skin/1717/
pressure_2 (accessed 31 August 2015)]. The wider network both helped to develop this trial and
continues to be involved with it. PURSUN UK has also been a partner in the James Lind Alliance
Pressure Ulcer Partnership, with members contributing to the prioritisation of pressure ulcer treatment
and prevention uncertainties. These uncertainties are publicly available to inform future research
[see www.jlapressureulcerpartnership.co.uk (accessed 20 February 2015)].
Developing materials
A website has been developed by PURSUN UK [see www.pursun.org.uk (accessed 20 February 2015)]. In
addition, PURSUN UK has contributed to the international consensus document Optimising Wellbeing in
People Living with a Wound, published by Wounds International [see www.woundsinternational.com/
clinical-guidelines/international-consensus-optimising-wellbeing-in-people-living-with-a-wound (accessed
20 February 2015)].
Developing and sharing patient and public involvement methods
Developing a completely new service user network has given us the opportunity to be creative in our
approach and develop innovative involvement models. These models have been shared with the UK PPI
community. The PPI model used as part of the severe pressure ulcer study (see Chapter 4, Patient and
public involvement) has been presented at three national conferences (INVOLVE, Involving People Wales
and Tissue Viability Society) and forms part of an INVOLVE video resource on PPI in data interpretation
and analysis [see www.invo.org.uk/resource-centre/conference/involve-conference-gallery/ (accessed
20 February 2015)]. A video about the Severe Pressure Ulcer PPI event was also made by PURSUN UK and
has been widely disseminated online [see https://youtu.be/bgg6zkbILrg (accessed 21st July 2015)]. The
novel approach of using the Patient Learning Journey as a model for service users contributing to research
rather than health education has also been included as a case study in the INVOLVE training and
development guidelines [see www.invo.org.uk/training-case-study-13-2/ (accessed 20 February 2015)].
Media
Working with service users has enabled us to more effectively engage with local and national media. Members
of PURSUN UK have been interviewed for the Yorkshire Evening Post [see www.yorkshirepost.co.uk/news/
at-a-glance/general-news/yorkshire-group-spearheads-bedsores-care-drive-1-3786988 (accessed
20 February 2015)] and the Daily Mail [see www.dailymail.co.uk/health/article-2093904/Bed-sores-How-
does-local-hospital-compare.html (accessed 20 February 2015)] and we have found that journalists are
more likely to run a health-related story if it has a real-life, human interest aspect to it.
Discussion
Our patient and public involvement methods
The growing role of PPI throughout the PURPOSE programme has been described. This likely reflects the
situation in other research projects that need to recruit service users once the project is already under way,
especially when projects span a number of years. This may be because of recruitment challenges or because it
is determined that additional input from a particular group of people is needed or may be because of existing
service user partners stepping down. Introducing service users to studies that are already under way can be
challenging, particularly when relationships have already been formed within the project team.
Although members of PURSUN UK were not involved at the grant application stage and were therefore not
part of setting the programme themes, they have found common ground with both each other and the
project team. These shared goals have made collaboration possible. We recognise that early involvement is
considered good practice30 and that there are areas throughout the PURPOSE programme (particularly in the
early stages of programme delivery) where additional PPI might have been useful, for example involvement in
DOI: 10.3310/pgfar03060 PROGRAMME GRANTS FOR APPLIED RESEARCH 2015 VOL. 3 NO. 6
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Nixon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
9
the qualitative part of the PU-QOL study. However, the lack of a PPI infrastructure in the field made this
difficult. The establishment of PURSUN UK and associated innovative approaches to PPI has addressed this
need and is just one way in which PURPOSE intends to leave a legacy beyond the life of the programme.
Facilitating PPI effectively requires specialist skills. The creation of the PPI officer post brought specialist
engagement expertise, dedicated time, innovative solutions, continuity and a single point of contact for service
users. This enabled us to provide the individualised support that members of PURSUN UK require to be actively
involved, for example briefing and debriefing meetings; information technology tuition and support; peer
support opportunities; and practical support such as accessible venues and large-print documents.
The development of the PURSUN UK network has allowed us to move from ad hoc PPI activities at the
start of the programme to a more strategic approach. Furthermore, we have found that members of
PURSUN UK have helped to bridge the gap between research and practice, for example putting the
PURPOSE findings in a NHS context and thinking about how findings can have the most impact. They
have also highlighted continued gaps in the research and unanswered questions from the service
user perspective, which will be taken forward in a future programme of work.
Our model involves a small number of service users in programme management and working with the wider
network at key milestones throughout each study; this has worked well throughout the programme. We
recognise that not all service users will feel comfortable in formal research environments such as the
PURPOSE steering committee meetings. More informal meetings and workshops, which focus on the service
user perspective, have proved invaluable. These meetings have highlighted key issues such as the importance
of patient engagement in pressure ulcer prevention and treatment; the anxiety and stigma that can be felt
as a result of a pressure ulcer; and the need to raise awareness of pressure ulcers with both patients
and professionals.
To effectively engage with this group we have adopted a highly flexible and innovative methodology. We have
used an asset-based approach.31 This means building on the strengths of network members by adapting our
research processes, rather than risk excluding people from traditional PPI activities. For example:
l the use of role play and video to facilitate PPI in the interpretation of data from the severe pressure
ulcer study (see Chapter 4, Patient and public involvement)
l the adaptation of the Patient Learning Journey model32 for use in a research context
l the use of a live interview model as an alternative to traditional presentations
l the addition of a service user group to the consensus methodology used in the risk assessment study
(see Chapter 5, Service user group participants)
l individualised support for steering committee members, including one-to-one debriefs with the
PPI officer
l the integration of service user narratives into the dissemination of the quantitative pain studies.
The value of the Pressure Ulcer Research Service User Network UK to the
service users involved
The reciprocal nature of engagement has been central to the success of PPI in this programme. In addition to
PPI having a positive impact on research processes and outputs, service users have also reported that it has
been a positive and rewarding experience for them. People have commented on increased confidence,
self-worth, knowledge of research and awareness of their own health. They have valued the peer support that
PURSUN UK provides and the opportunities to enter into an equal dialogue with researchers and clinicians.
I’ve loved putting my input into the work the group are doing. I had to give up everything [because of
my severe pressure ulcer] and it has given me something to do. I feel like I’m back in the world again!
PURSUN UK member
PATIENT AND PUBLIC INVOLVEMENT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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PURSUN is a safe place to learn from sharing experiences with each other, and the comfort that comes
from knowing that it is a safe environment cannot be underestimated. This should be acknowledged,
even if it wasn’t originally on the radar of those wanting to set up a service user group
PURSUN UK member
The networks formed as part of their work with PURSUN UK have led to other opportunities for people,
including paid positions. For example, people have become involved in teaching activities elsewhere in the
University of Leeds and have joined research projects/service user groups in other topic areas.
Conclusion
This chapter outlines both the challenges and advantages of engaging with a previously seldom-heard
group. A mixture of established good practice techniques and innovative PPI approaches has allowed us to
move beyond the PPI plan outlined in our grant application and beyond what others have achieved in this
field. Although we have worked exclusively within pressure ulcer research, the strategies outlined here
could help service users and researchers work together in other contexts.
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Chapter 3 Work package 1: pain
Chapter written by Jane Nixon, Isabelle L Smith, Michelle Collinson, Elizabeth McGinnis, Michelle Briggs,Sarah Brown, Susanne Coleman, Carol Dealey, Delia Muir, E Andrea Nelson, Rebecca Stevenson,
Nikki Stubbs, Lyn Wilson and Julia M Brown.
Abstract
Introduction: Patients with pressure ulcers have reported that pain is their most distressing symptom and
that pain at ‘pressure areas’ was experienced before the clinical manifestation of pressure ulcers but that
the pain was ignored by nurses. The primary aim of the research was to determine the extent of pressure
area and pressure ulcer pain and explore the role of pain as a predictor of category 2 and above pressure
ulcers in acute hospital and community populations.
Methods: The pain work package comprised three research projects: (1) a nested multicentre pain
prevalence study in three NHS acute hospital trusts, including all inpatients; (2) a nested pain prevalence
survey in two community NHS trust localities incorporating a comparison of case-finding methods,
including only patients with pressure ulcers; and (3) a multicentre prospective cohort study of pressure
ulcer risk factors in acute hospital and community patients.
Results: In the hospital prevalence study a total of 3397 patients in nine acute hospitals were included in
routine pressure ulcer prevalence audits and, of these, 2010 (59.2%) participated in the nested pain
prevalence study. The community routine pressure ulcer prevalence audit identified 287 patients with pressure
ulcers and, of these, 176 (61.3%) participated in the nested pain prevalence study. The overall prevalence of
pressure ulcers was 0.58 per 1000 adult population, with differences observed between localities (locality
1= 0.77 and locality 2= 0.40). The unattributed pressure area-related pain prevalence was 16.3% (327/2010)
in the hospital population, which included patients with and without pressure ulcers. In the hospital
population with no observable pressure ulcers, 12.6% (223/1769) reported unattributed pressure area-related
pain. The prevalence of unattributed pressure area-related pain in patients with pressure ulcers was 43.2%
(104/241) in hospital patients and 75.6% (133/176) in the community patients. The detailed pain assessment
of 160 hospital and 37 community patients identified pressure area-related pain on skin areas assessed as
normal as well as all grades of pressure ulcer. The distribution of pain intensity measured using a 0–10
nominal rating scale was similar for all grades. The dominant type of pain in hospital patients was
inflammatory pain (70.3% torso and 60.3% limb), whereas in the community patients neuropathic pain was
dominant (54.5% torso and 61.1% limb). The cohort study of 632 acutely ill hospital and community patients
identified significant evidence that the presence of pain at a skin site (assessed as normal, altered but intact
or category 1) is an independent predictor for developing a category 2 or above pressure ulcer in four
multivariable models: a priori logistic regression model, overdispersion logistic regression model and an
accelerated failure time model for analyses conducted on a patient level and a multilevel logistic regression
model for the analysis conducted on a skin-site level.
Conclusions: We have identified that a significant minority of hospital inpatients without pressure ulcers
suffer pressure area-related pain, that approximately 40% of hospital patients and 75% of community
patients with pressure ulcers report pain, that pain severity is not related to the severity of the ulcer and that
both inflammatory and neuropathic pain are observed. Differences in pressure ulcer prevalence rates highlight
the need for effective case ascertainment in the community setting. We have also established that the
presence of pain (on skin areas assessed as normal, altered but intact or category 1 pressure ulcer) increases
the risk of development of category 2 and above pressure ulcers and accelerates the time to their development.
This is an area of practice that requires improved pain assessment; the incorporation of pain into risk
assessment; preventative interventions in response to pain; and treatment strategies to alleviate pain.
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Introduction
Our pre-programme grant qualitative work33,34 and systematic review of the pressure ulcer quality-of-life
literature9 found that patients with pressure ulcers report that pain is their most distressing symptom. In
addition, the work highlighted that pain at ‘pressure areas’ (see Definition of terms) was experienced by
patients before the clinical manifestation of pressure ulcers but that the pain was ignored by nurses. Patients
blamed nurses when a pressure ulcer developed subsequently, because of the lack of action. ‘Patients felt that
they were responsible for communicating pain and that their care provider was responsible for attending to it,
but patients’ views and concerns did not always prompt action and many healthcare professionals dismissed
patients’ reports of pain at pressure areas’.9,33,35
As part of the programme grant we carried out a mixed-methods systematic review, in which qualitative
and quantitative studies of patients’ reports of pressure ulcer pain were identified and synthesised36
(see Chapter 6, Pressure ulcer-related pain: systematic review). Pain was reported as debilitating, reducing
the individual’s ability to participate in physical and social activities, adopt comfortable positions, move,
walk and undergo rehabilitation.36 Patients with pressure ulcer pain described their experience as ‘endless
pain’ characterised by a constant presence, needing to keep still and equipment and treatment pain.9,34,37
This confirmed the importance of pain as a feature of living with a pressure ulcer.
Reviews of the epidemiological literature carried out by Girouard and colleagues38 and Pieper and colleagues39
identified eight studies reporting the prevalence of pain associated with pressure ulcers in study populations
ranging from 20 to 186 participants, in diverse settings including hospitals and community and palliative care.
In the four largest studies (> 100 participants), pressure ulcer pain prevalence estimates ranged from 37%
to 66%.40–43 The reviews highlight the limitations of the existing literature, including small sample sizes, the use
of non-validated measures of pain, including nurse-assessed pain outcomes, and an absence of studies that
report the dominant types of pain: nociceptive pain (inflammatory) and neuropathic pain (resulting from nerve
damage or tissue ischaemia).44 “Understanding the characteristics of pain is important as successful pain
management depends upon using interventions that address the cause(s) of the pain. A further problem with
research in the field is that pain reports are limited to Category 2 and above PUs [pressure ulcers].35,38,39,45 Pain
associated with Category 1 PUs is not reported in most studies, nor is the presence of pain at ‘pressure
areas.’” Despite patient reports that pain at ‘pressure areas’ preceded pressure ulcer development, our risk
factor systematic review46 (see Chapter 5) did not identify any risk factor studies that included pain as a
candidate risk factor in univariate or multivariable analysis.
‘In summary, qualitative evidence identifies pain preceding PU development and in PU management
[as an important issue for patients]. Previous epidemiological research has focused on patients with existing
PUs and a limitation of the literature is the lack of evidence relating to the extent of pain preceding PU
development, the extent of pain associated with Category 1 PUs (the most prevalent PU Category), the
type of pain (i.e. inflammatory or neuropathic)’45 and the relationship between pain at ‘pressure areas’ and
subsequent category 2 pressure ulcer development. We therefore proposed to determine both the extent
of the problem and explore the role of pain as a predictor of pressure ulcer development in acute hospital
and community populations.
Research overview
Work package 1 comprised the following pain prevalence and cohort studies:
1. the prevalence of pressure area-related and pressure ulcer pain in hospitalised patients (see Pain
prevalence in the hospital population)
2. the prevalence of pressure area-relataed and pressure ulcer pain in community patients (see Pain
prevalence in the community population), including a substudy comparing community pressure ulcer
case-finding methods (see see Routine pressure ulcer audit: community setting)
3. pain cohort study exploring the role of pain as a predictor of category 2 pressure ulcers in acute
hospital and community populations (see Pain and pressure ulcer risk: cohort study)
WORK PACKAGE 1: PAIN
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Definition of terms
This is the first pain research undertaken in patient populations with and without pressure ulcers. To
describe pain in the study populations, we developed and used the following four terms: (1) pressure area;
(2) pressure area-related pain; (3) pressure ulcer pain and (4) unattributed pressure area-related pain as
follows (see Glossary for description of terms):
l Pressure area. A body site where pressure ulcers commonly develop; most commonly these include the
sacrum, buttocks, ischial tuberosities, hips, heels, ankles and elbows.
l Pressure area-related pain. Defined as pain, soreness or discomfort on any pressure area.
l Pressure ulcer pain. Defined as pain, soreness or discomfort on a body site with an observable pressure
ulcer of category 1 or above.
l Unattributed pressure area-related pain. Defined as pain, soreness or discomfort reported by patients
on a pressure area/pressure ulcer but in which the body site is not specified/recorded.35
Pain prevalence in hospital and community populations
To assess the extent of pressure area-related and pressure ulcer pain we undertook two cross-sectional studies
in three acute and two community NHS trusts to estimate prevalence. In the hospital setting we were able to
nest the pain prevalence study into routine annual pressure ulcer audit methods and pain was assessed for
all patients able to respond to pain screening questions, including those with and those without pressure
ulcers. Our original plan (see the protocol in Appendix 3) assumed that community prevalence methodology
was similar to long-standing and well-established acute hospital methods, with nurses undertaking a
comprehensive skin assessment of each patient.47 However, the two participating community trusts had
developed different case-finding methods48 and this, together with the scale of the data collection task in the
community setting, led to an adaptation of the original plan and limited the pain prevalence estimates to the
patient population with pressure ulcers, which is reflected in the objectives.
Objectives
Pain prevalence in the hospital population
Objectives were to:
i. estimate the unattributed pressure area-related pain prevalence in a hospital population of patients with
and without pressure ulcers
ii. estimate the pressure area-related pain prevalence in patients with no observable pressure ulcers
iii. estimate the pressure ulcer pain prevalence in patients with pressure ulcers
iv. describe the intensity and type of pressure area-related and pressure ulcer pain in a hospital population
of patients with and without pressure ulcers
v. explore the association between pain intensity, type of pain and pressure ulcer classification in a
hospital population of patients with and without pressure ulcers.
Pain prevalence in the community population
Objectives were to:
i. estimate the prevalence of unattributed pressure area-related pain within a community population of
patients with pressure ulcers
ii. assess the intensity and type of pressure area-related and pressure ulcer pain within a community
population of patients with pressure ulcers
iii. describe the intensity and type of pressure area-related and pressure ulcer pain within a community
population of patients with pressure ulcers
iv. explore the association between pain intensity, type of pain and pressure ulcer classification within a
community population of patients with pressure ulcers
v. compare and contrast community pressure ulcer prevalence case-finding methods.
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Methods
Study design
We undertook nested, multicentre, cross-sectional studies in three acute hospital NHS trusts35 and two
large community trusts in England45 embedding the pain prevalence study into routine pressure ulcer
audits. To identify patients who had unattributed pressure area-related pain, questions about pain were
added to the routine annual pressure ulcer prevalence audits undertaken in the participating NHS trusts.
To estimate the prevalence of pressure area-related and pressure ulcer pain and to explore the association
between pain and pressure ulcer classification, patients who reported pain were invited and consented to
undergo a full pain assessment (see Appendix 5 for the consent form).
Nesting the pain prevalence study within routine pressure ulcer prevalence audits meant that we collected
data for the total eligible patient population in each setting. The routine NHS audits collect unlinked
anonymous data and patient consent is not required to ensure that accurate pressure ulcer prevalence
data are obtained for the total eligible population. Nesting the study within routine pressure ulcer
prevalence audits, however, limited the number of data items that could be collected. Furthermore, in
the community the two trusts defined their denominator population differently and adopted different
pressure ulcer case-finding methods.48
Setting
Three acute NHS hospital trusts took part. One trust included three district general hospitals. The other
two NHS trusts were large teaching hospitals and together included four main and two satellite hospitals.
This meant that the patient population consisted of those in general secondary care and regional/
supraregional specialist services from a total of nine hospitals.
The community NHS trusts consisted of locality 1, serving an urban population of 292,179, and locality 2,
serving a rural population of 311,991.49
Each NHS community trust provides general and tissue viability specialist nursing care to patients residing in
their own homes and residential homes as well as community/rehabilitation/hospice inpatient facilities. In
addition, each trust provides tissue viability specialist nursing care to patients residing in nursing home settings.
Routine pressure ulcer audit: hospital setting
Eligibility
The population included ‘all inpatients of 18 years of age or older who were in hospital on the date of the
participating Trusts’ PU prevalence audit. Patients in paediatric, obstetric and psychiatric care settings were
excluded from the study as the prevalence of PU in these settings is very low, and hence the data collection
to information burden ratio is unacceptably high in these settings.’50
Patient identification method
Routine pressure ulcer prevalence audits in the participating acute trusts included training of a responsible
nurse for each ward, completion of an audit form for each inpatient at 06.00 on the audit day, cross-referencing
of the number of occupied beds on each ward and the number of audit forms submitted by an audit team
and verification of data by an audit team comprising the tissue viability team and members of the mattress
suppliers of the participating NHS trusts (as part of their mattress supply contract). The date of the prevalence
audit for each hospital was determined locally.
Routine pressure ulcer audit: community setting
Eligibility
The target population was all patients aged ≥ 18 years who were identified as having a pressure ulcer.
Patients in paediatric, obstetric and psychiatric community care settings were excluded.
WORK PACKAGE 1: PAIN
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Patient identification method
A number of challenges are faced when determining ‘community prevalence’: (1) defining the time period
for data collection, (2) defining the term ‘community’ for case ascertainment to estimate the numerator and
(3) defining the denominator population. ‘In the UK, within each locality there are six key healthcare providers
in the community including community nursing services, residential homes, rehabilitation units, specialist
palliative care units, nursing homes and General Practitioners. NHS community trusts provide general and
specialist community nursing services to patients residing at home and also tissue viability specialist nursing to
high risk patients and those with complex wounds residing in independent sector residential and nursing
home facilities. Residential home facilities provide only social care and therefore a patient in this setting with a
pressure ulcer would be referred to the community nursing service. Rehabilitation units, specialist palliative
care units and nursing home facilities include ‘nursing care’ and only complex patients are referred to the
community nursing service. General Practitioners usually refer patients with a pressure ulcer to community
nursing services. To establish true community prevalence would require named patient data from each
health-care provider. However, this is not achievable without considerable resource’48 and the data burden
and use of named patient data in routine audits is not considered justified for the gain in precision of
prevalence estimates.
Both localities completed data collection over a 6- to 8-week period. ‘The two localities applied different
methods for case finding as per their local pressure ulcer audit practice.’48 Locality 1 requested that
community nurses assess all of the patients on their community nursing caseload and that a nominated
nurse in each residential home, specialist palliative care unit, rehabilitation unit and nursing home in the
locality assess all inpatients/residents to identify patients with pressure ulcers.47 An audit form was
completed for each patient (i.e. those with and those without pressure ulcers). Locality 2 identified patients
with known pressure ulcers from the community nursing caseload records and the community nurses
completed an audit form only for those patients identified as having a pressure ulcer48 [note that patients
treated by a general practitioner only (i.e. not also under the care of a general or specialist community
nursing service) were not identified in the case-finding method by either locality 1 or locality 2]. In both
trusts each patient identified through case finding as having a pressure ulcer had a tissue viability team
member visit to verify the skin assessment recorded by the community nurse.
Pain prevalence eligibility criteria
Pain prevalence inclusion criteria
In addition to the standard pressure ulcer audit data, the ward/community nurses were asked to
consider whether each patient was able to report the presence or absence of pain. Patients who were
considered able to report pain were eligible for inclusion in the pain prevalence study and were asked two
screening questions (see following section on assessments) relating to pressure area-related pain by a
member of the tissue viability team.
Pain prevalence exclusion criteria
Patients were excluded from the pain prevalence study when it was considered ethically or clinically
inappropriate by the ward nurse/clinical team, for example very sick patients or those for whom death was
considered to be imminent. When patients were assessed as not able to report pain, this was recorded
along with the reason for ineligibility.
Detailed pain assessment inclusion criteria and consent
Patients in the hospital and community settings who answered ‘yes’ to both pain screening questions were
provided with a verbal explanation of the detailed pain assessment component of the study and a written
information leaflet (see Appendix 4) by the tissue viability team member and were then invited to take part
in a full pain assessment. Consenting patients underwent a detailed pain and skin assessment (see Detailed
pain assessment).
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Assessments
Unlinked anonymised individual patient audit data were recorded by a designated ward or community
nurse trained in the use of the data collection form and skin assessment as part of the preparation for the
audit. Data recorded included place of assessment (hospital/community and ward specialty, patient’s own
home, nursing home, residential home, hospice, community bed), date of birth, gender, height, weight,
ethnicity, mobility and risk assessment scale total score (using either the Waterlow score50 or the Braden
scale51 as per local policy). Skin was assessed using the 1998 EPUAP24 classification and recorded for a
minimum of 13 skin sites (sacrum, left and right buttocks, ischial tuberosities, hips, heels, elbows and
ankles). The 1998 EPUAP classification (and not the revised EPUAP/NPUAP 2009 version)1 was used as this
was the version in routine use at the participating centres/localities. In addition, the presence of an
unstageable pressure ulcer, other type of wound or normal skin were confirmed or skin status was
recorded as not applicable (e.g. amputation) or unable to assess.
When patients were assessed as not able to report pain this was recorded along with the reasons for
ineligibility. When ward/community staff indicated that the patient was well and able to report pain,
a member of the tissue viability team asked the patient two pain screening questions as follows:35,45
1. At any time, do you get pain, soreness or discomfort at a pressure area (prompt: back, bottom, heels,
elbows or other as appropriate to the patient)? (Yes or no)
2. Do you think this is related to either your pressure ulcer OR lying in bed for a long time OR sitting for
a long time? (Yes or no)
These questions were adapted from the case screening questions used in a large postal survey of pain
prevalence in the UK.35,52 Unlinked anonymous individual patient data were recorded for both questions.
The site of the pain, soreness or discomfort was not recorded (i.e. the pressure area/pressure ulcer pain
was unattributable to individual body sites).
Detailed pain assessment
Patients who answered ‘yes’ to both pain screening questions and who consented to further assessment
underwent a detailed pain and skin assessment by a member of the tissue viability team that included pain
intensity, type of pain and skin status/grade of ulcer (as above) on a minimum of 13 skin sites (as above).
The patient risk profile was assessed using the Braden scale subscales to allow description of the patient
population and comparison with the wider literature.
‘Pain was assessed by asking patients to report the pain intensity (for most severe pain over the past week)
for all pressure area sites using a numerical rating scale of 0–10.’45,53,54 Patients were also asked to identify
their ’most painful torso and limb skin sites and these were assessed using the Leeds Assessment of
Neuropathic Symptoms and Signs (LANSS) Pain Scale.55 The LANSS Scale is a clinically validated tool which
allows assessment of neuropathic and inflammatory pain [and has been used in a wide variety of clinical
settings55]. It consists of a brief assessment and is easy to score in the clinical setting. The questionnaire
contains 5 symptom items and 2 clinical sensory testing items associated with neuropathic pain.’45 The
responses to each of the seven items are scored and summed to provide a total score. If the LANSS total
score is < 12, neuropathic mechanisms are unlikely and the pain is classified as inflammatory pain. If the
LANSS total score is ≥ 12, neuropathic mechanisms are likely to be contributing to the pain and it is classified
as neuropathic.
Staff training and preparation
Ward and community nurses were trained locally as per local trust standard pressure ulcer audit practice.
Members of the tissue viability team were trained in study procedures, including pain assessment and skin
assessments, by the programme manager (LW). No formal inter-rater reliability assessment was undertaken
as previous research has demonstrated high agreement between specialist nurses and clinical research
nurses in skin assessment and pressure ulcer classification.56
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Data processing
All data returned to the Clinical Trials Research Unit (CTRU) for data processing were anonymous. Data
were entered into a bespoke MACRO (version 3; MACRO, Infermed, London, UK) database and range and
consistency data checks were carried out to assess the accuracy of the data.
Sample size
For the priori sample size we planned to use a minimum of two acute NHS trusts with an estimated patient
population of 2000 and two community NHS trusts with an estimated community nursing caseload of
6000 community patients; therefore, it was planned to include approximately 8000 patients in the
prevalence audit.
The a priori sample size was based on the following assumptions:
l the prevalence of pressure ulcers in hospital patients is 10% and in community patients is 5%2
l 30% of patients have pressure ulcers of grades 2–4/unstageable ulcers, of whom 25–50% would
report pressure-area related pain40–43
l 70% of patients have pressure ulcers of grade 1, of whom 10–30% would report pressure
area-related pain
l 90% of hospital and 95% of community patients have no pressure ulcers
l 2.5–5% of patients without pressure ulcers would report pressure area-related pain.
Based on these assumptions we estimated that between 259 and 555 patients would report pressure
area-related pain (i.e. that 3–7% of patients would report pressure area-related pain; Table 2). A sample
of 8000 patients would enable us to estimate a pressure area-related pain prevalence of 3% to within
±0.38% (n= 7742) and a pressure area-related pain prevalence of 7% to within ±0.56% (n= 7975).
Analysis
Analysis included data summaries and no inferential statistical testing was planned or undertaken. The
denominator for the acute hospital pressure ulcer prevalence was the total inpatient population. The
community pressure ulcer prevalence was calculated per 1000 of the estimated total population of adults
aged ≥ 18 years for each site (240,038 locality 1 population aged ≥ 18 years; 251,891 locality 2
population aged ≥ 18 years).49
TABLE 2 Pain prevalence: estimated number of patients with pressure area-related pain
Setting Pressure ulcer status
Pressure area-related pain
n %
Hospital (n= 2000) No PU (90%; n= 1800) 45–90 2.5–5
PU (10%; n= 200) Category 1 (70%; n= 140) 14–42 10–30
Categories 2–4 (30%; n= 60) 15–30 25–50
Community (n= 6000) No PU (95%; n= 5700) 142–285 2.5–5
PU (5%; n= 300) Category 1 (70%; n= 210) 21–63 10–30
Categories 2–4 (30%; n= 90) 22–45 25–50
PU, pressure ulcer.
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‘Percentages were calculated using the total number of patients from the relevant population as the
denominator (i.e. including all patients with missing data for that variable).’45 When another skin condition
or chronic wound was indicated, the specific skin site was excluded from the analysis. ‘All analyses were
carried out using SAS software [version 9.2; SAS Institute Inc., Cary, NC, USA]. All percentages were
rounded to 1 decimal place. Means, medians, standard deviations [SDs] and ranges were summarised to
one more decimal place than the data collected.’45
Type of pain was determined using the results of the seven-item LANSS scale,5 with the responses to each
of the seven items scored and summed to provide a total score. Pain was classified as inflammatory pain
when the LANSS total score was < 12 and neuropathic pain if the LANSS total score was ≥ 12.
Ethical approval
The studies were approved by the Leeds Central Research Ethics Committee prior to data collection
(reference number 09/H1313/14).
Results
Pressure ulcer prevalence: hospital population
Data collection was undertaken between 15 September 2009 and 3 March 2010. From across nine acute
hospitals, a total of 3397 patients (see Appendix 1) were included in the routine pressure ulcer prevalence
surveys and this is our target hospital population.50 Figure 2 details the flow of patients through each stage
of the process. The number of patients audited by specialty is presented in Table 3.
PU prevalence audit
n = 3397
Asked the pain
screening questions
n = 2010/3397
(59.2%)
Patients with UPAR
pain
n = 327/2010
(16.3%)
Did not provide consent/was
ineligible for detailed pain
assessment
n = 164/327 
(50.2%)
7 (4.3%)
2 (1.2%)
17 (10.4%)
47 (28.7%)
39 (23.8%)
14 (8.5%)
1 (0.6%)
37 (22.6%)
Patients without
UPAR pain
n = 1683/2010
(83.7%) 
Consented to detailed
pain assessment
n = 163/327
(49.8%)
Detailed pain
assessment population
n = 160
Considered unsuitable for the pain
screening questions
n = 1387/3397
(40.8%)
144 (10.4%)
27 (1.9%)
20 (1.4%)
339 (24.4%)
93 (6.7%)
206 (14.9%)
139 (10.0%)
26 (1.9%)
393 (28.3%)
too unwell
end of life
unconscious
patient off the ward
isolation/barrier nursing
patient confused
communication difficulties
other
reason missing
Withdrawn
n = 3/163 
(1.8%)
1 (33.3%)
1 (33.3%)
1 (33.3%)
nursing advice
refused
pain not related to PU
missed by tissue
viability team member
transferred to another
health-care setting
refused without any
reason
refused, does not want
to be involved in research
refused, feels poorly
or unwell
unable to provide
written informed
consent
other
reason missing
FIGURE 2 Participant flow: hospital population. PU, pressure ulcer; UPAR, unattributed pressure area-related.
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The median age of patients was 70 years [mean 65.8 (SD 19.23), range 18–103 years]. The numbers of
men and women were similar (48.7% male; 1655/3397) and 7.2% (243/3397) were non-Caucasian.35
In total, 53.9% of patients (1830/3397) were assessed using the Waterlow scale and of these 1062
(58.0%) were classified as ‘at risk’ (score of ≥ 10); 46.1% of patients (1567/3397) were assessed using the
Braden scale and of these 532 (34.0%) were classified as ‘at risk’ (score of ≤ 18) (Table 4).
Of the 3397 patients included, 502 (14.8%) were reported to have 1066 pressure ulcers [median 1.0,
mean 2.1 (SD 1.63), range 1–13 per patient]. The majority (70.5%; 752/1066) of reported pressure ulcers
were grade 1, approximately one-fifth were grade 2 (22.2%; 237/1066) and a small percentage (7.2%;
77/1066) were grades 3–4/unstageable.35
Pain prevalence: hospital population
Of the 3397 hospital patients in the pressure ulcer audit sample, 2010 (59.2%) were considered well enough
to respond to the pain questions and hence were eligible for the pain prevalence study (see Figure 2).
The pain prevalence population demographics were similar to those of the total hospital prevalence
population (see Table 4). The median age of patients was 68 years [mean 64.8 (SD 18.57), range
18–100 years], almost half (980/2010; 48.8%) were male and 122 (6.1%) were non-Caucasian. In total,
49.6% (997/2010) were assessed using the Waterlow scale and of these 504 (50.6%) were classified as ‘at
risk’ (score of ≥ 10); 50.4% (1013/2010) were assessed using the Braden scale and of these 263 (26.0%)
were classified as ‘at risk’ (score of ≤ 18).
A total of 241 patients (12.0%) were reported to have 491 pressure ulcers [median 1.0, mean 2.0
(SD 1.44), range 1–9 per patient]. As shown in Table 4, there were similar grades of pressure ulcers in
both the total hospital prevalence population and the pain prevalence population. The majority (357/491;
72.7%) of reported pressure ulcers in the pain prevalence population were grade 1, 20.4% (100/491)
were grade 2 and 6.9% (34/491) were grades 3–4/unstageable.
TABLE 3 Pressure ulcer prevalence hospital population by specialty
Specialty Numbers of participants %
Medicine 1348 39.7
Surgery 868 25.6
Elderly medicine 380 11.2
Orthopaedic and trauma 305 9.0
Oncology 211 6.2
Critical care 179 5.3
Rehabilitation 79 2.3
Burns 15 0.4
Clinical decision units 8 0.2
Missing 4 0.1
Total 3397 100
Reproduced from Briggs et al.35 © 2013 Briggs et al.; licensee BioMed Central Ltd. This is an Open Access article distributed
under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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‘Of the 2010 people asked the pain questions, 327 said yes to both questions, indicating they had pain on
one or more skin sites with or without a PU, providing an overall UPAR [unattributed pressure area-related]
pain prevalence of 16.3%’ (see Figure 2). In total, 1769 patients did not have any pressure ulcers and 223
of these patients ‘reported pain, an UPAR pain prevalence of 12.6%. Of the 241 people with PUs, 104
patients reported pain at one or more PU site, an UPAR pain prevalence of 43.2%.’35
Detailed pain assessment: hospital population
Of the 327 who answered ‘yes’ to both pain screening questions, 164 (50.2%) were not able, or declined,
to participate in the full pain assessment and 163 (49.8%) consented. Three patients were subsequently
withdrawn and therefore the analysis population of eligible patients with unattributed pressure
area-related pain who participated in the detailed pain assessment was 160 (Figure 3).
TABLE 4 Demographics for the total, pain and detailed pain assessment hospital populations
Characteristic
Total hospital prevalence
population
Pain prevalence
population
Detailed pain assessment
population
Total population, n 3397 2010 160
Age (years)
Median 70.0 68.0 69.0
Mean (SD) 65.8 (19.23) 64.8 (18.57) 66.2 (18.23)
Range 18.0–103.0 18.0–100.0 18.0–99.0
Male, n (%) 1655 (48.7) 980 (48.8) 80 (50.0)
‘At risk’, n/N (%)
Waterlow 1062/1830 (58.0) 504/997 (50.6)
Braden 532/1567 (34.0) 263/1013 (26.0) 114/160 (71.3)
Ethnicity, n (%)
White 2963 (87.2) 1774 (88.3) 154 (96.3)
Other 243 (7.2) 118 (5.9) 4 (2.5)
Missing 191 (5.6) 118 (5.9) 2 (1.3)
Patients with PUs, n (%) 502 (14.8) 241 (12.0) 75 (46.9)
Total number of PUs 1066 491 139
Number of PUs per patient
Median 1.0 1.0 1.0
Mean (SD) 2.1 (1.63) 2.0 (1.44) 1.9 (1.23)
Range 1.0–13.0 1.0–9.0 1.0–5.0
Grade of PUs reported, n (%)
Grade 1 752 (70.5) 357 (72.7) 97 (69.8)
Grade 2 237 (22.2) 100 (20.4) 32 (23.0)
Grade 3 45 (4.2) 18 (3.7) 4 (2.9)
Grade 4 18 (1.7) 10 (2.0) 3 (2.2)
Unstageable 14 (1.3) 6 (1.2) 3 (2.2)
PU, pressure ulcer.
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The median age of these 160 patients was 69.0 years [mean 66.2 (SD 18.23), range 18–99 years] and half
(80/160; 50.0%) were men. Almost three-quarters (114/160; 71.3%) of patients with unattributed
pressure area-related pain were assessed as ‘at risk’ on the Braden scale and four (2.5%) were
non-Caucasian. A total of 75 (46.9%) patients were reported to have 139 pressure ulcers [median 1.0,
mean 1.9 (SD 1.23), range 1–5 per patient] (see Table 4).
A total of 2090 skin sites were assessed (see Figure 3), with 1933 skin sites assessed as normal, 139
assessed as pressure ulcers and skin status was not able to be assessed for 18 sites. The majority (69.8%)
of reported pressure ulcers were grade 1, 23.0% (32/139) were grade 2 and 7.2% (10/139) were grades
3–4/unstageable (see Table 4).
Pain was reported by 157 patients on 298 skin sites (mean 1.9, SD 1.17, range 1–7 per patient). This
included pressure area-related pain reported on 9.8% (190/1933) of skin sites assessed as ‘normal’ and
pressure ulcer pain for 68.0% (66/97) of grade 1 pressure ulcers, 84.4% (27/32) of grade 2 pressure ulcers
and 90.0% (9/10) of grades 3–4/unstageable ulcers (Table 5). The worst pain intensity reported by each
patient ranged from 1 to 10, with a mean of 5.4 (SD 2.30) and median of 5.0.
Patients
n = 160
Skin assessments
n = 2090
(minimum of 13 sites per patient)
Pain reported at
n = 298/2090
(14.3%) skin sites; 1.9 (1.17) per patient,
range 1 – 7
Completed LANSS (torso), n = 118
Completed LANSS (limb), n = 68
FIGURE 3 Participant flow: detailed pain and skin assessments: hospital population.
TABLE 5 Detailed pain assessment: number of times pain reported by skin classification: hospital population
Skin classification Yes, n (%) No, n (%) Missing, n (%) Total, n (%)
Normal skin 190 (9.8) 1730 (89.5) 13 (0.7) 1933 (100.0)
Grade 1 66 (68.0) 30 (30.9) 1 (1.0) 97 (100.0)
Grade 2 27 (84.4) 5 (15.6) 0 (0.0) 32 (100.0)
Grade 3 4 (100.0) 0 (0.0) 0 (0.0) 4 (100.0)
Grade 4 3 (100.0) 0 (0.0) 0 (0.0) 3 (100.0)
Unstageable 2 (66.7) 1 (33.3) 0 (0.0) 3 (100.0)
Unable to assess 2 (22.2) 1 (11.1) 6 (66.7) 9 (100.0)
Classification missing 4 (44.4) 5 (55.6) 0 (0.0) 9 (100.0)
Total 298 (14.3) 1772 (84.8) 20 (1.0) 2090 (100.0)
Note: 160 patients completed the detailed pain assessment. Each patient had 13 skin assessments and there were 10
‘other’ sites assessed. The overall total therefore corresponds to (160 × 13)+ 10= 2090 skin assessments.
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The distribution of pain intensity is similar for each grade of pressure ulcer (Figure 4). In total, 128 patients
identified one skin site for LANSS assessment (89 torso and 39 limb skin sites) and 29 patients identified
both a torso and a limb skin site for LANSS assessment, providing 118 torso and 68 limb LANSS
assessments. Nociceptive pain was dominant in both torso and limb skin sites, with 70.3% (83/118) of
painful torso skin sites and 60.3% (41/68) of painful limb skin sites scoring < 12 on the LANSS assessment
(Table 6). Neuropathic pain was observed on skin assessed as normal as well as for all grades of pressure
ulcer (see Table 6).
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FIGURE 4 Pain intensity by skin classification: hospital population. (a) Normal skin; (b) grade 1 pressure ulcers;
(c) grade 2 pressure ulcers; and (d) grades 3–4/unstageable pressure ulcers.
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Pressure ulcer prevalence: community population
Locality 1 collected data between 8 February and 2 April 2010 and locality 2 collected data between
12 April and 7 May 2010. Figure 5 shows the patient flow through the stages of the process.45
‘The two community NHS Trusts identified 287 patients with Grade 1–4/Unstageable pressure damage.
The case finding methods resulted in differing prevalence rates. In locality 1, 1680 patients were assessed,
and of these 185 patients were assessed as having a pressure ulcer ≥ Grade 1, a prevalence rate of 0.77
per 1000 [(185/240,038) × 1000 adults]. In locality 2, 102 patients were identified from the community
nursing caseloads and assessed as having a Grade ≥ 1 pressure ulcer, a prevalence rate of 0.40 per 1000
[(102/251,891) × 1000 adults]’45. A notable difference between the two sites, and one that could also
contribute to the difference in reported prevalence, was the patients’ place of residence. In locality 1, 93
out of 185 (50.3%) patients were resident in a nursing home, whereas in locality 2 only five out of 103
(4.9%) patients were resident in a nursing home.
The median age of patients with pressure ulcers was 81 years (mean 77.8, SD 13.44, range 23–106 years),
just over one-third of patients were male (100/287; 34.8%),45 89.6% (251/280) were assessed as being
‘at risk’ using either the Waterlow scale or the Braden scale and only 1.4% (4/287) were non-Caucasian
(Table 7).
The 287 patients with pressure ulcers were reported to have 440 ulcers [median 1, mean 1.5 (SD 0.83),
range 1–5 per patient]. About one-third of pressure ulcers (155/440; 35.2%) were grade 1, 40.2%
(177/440) were grade 2 and 24.5% (108/440) were grades 3–4/unstageable.45
TABLE 6 Type of pain by skin classification for the most painful torso and limb areas: hospital population
Location Skin classification Nociceptive, n (%) Neuropathic, n (%) Missing, n (%) Total, n (%)
Torso Normal skin 56 (76.7) 17 (23.3) 0 (0.0) 73 (100.0)
Grade 1 12 (54.5) 8 (36.4) 2 (9.1) 22 (100.0)
Grade 2 12 (70.6) 5 (29.4) 0 (0.0) 17 (100.0)
Grade 3 2 (66.7) 1 (33.3) 0 (0.0) 3 (100.0)
Grade 4 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Unstageable 1 (100.0) 0 (0.0) 0 (0.0) 1 (100.0)
Missing 0 (0.0) 1 (50.0) 1 (50.0) 2 (100.0)
Totala 83 (70.3) 32 (27.1) 3 (2.5) 118 (100.0)
Limb Normal skin 27 (61.4) 16 (36.4) 1 (2.3) 44 (100.0)
Grade 1 11 (73.3) 3 (20.0) 1 (6.7) 15 (100.0)
Grade 2 1 (20.0) 4 (80.0) 0 (0.0) 5 (100.0)
Grade 3 0 (0.0) 1 (100.0) 0 (0.0) 1 (100.0)
Grade 4 1 (100.0) 0 (0.0) 0 (0.0) 1 (100.0)
Unstageable 1 (100.0) 0 (0.0) 0 (0.0) 1 (100.0)
Missing 0 (0.0) 0 (0.0) 1 (100.0) 1 (100.0)
Totalb 41 (60.3) 24 (35.3) 3 (4.4) 68 (100.0)
a The denominator here is the number of patients who completed the LANSS assessment for a torso skin.
b The denominator here is the number of patients who completed the LANSS assessment for a limb skin site.
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FIGURE 5 Participant flow: community population. Grade 1-U, grade 1 or above. a, Locality 1 audited all patients
on the caseload whereas locality 2 audited all patients with existing pressure damage. Adapted from McGinnis
et al.45 © 2014 McGinnis et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the
terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.45
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TABLE 7 Demographics for the total, pain and detailed pain assessment community populations
Characteristic
Total community prevalence
population
Pain prevalence
population
Detailed pain assessment
population
Total population, n 287 176 37
Age (years)
Median 81.0 79.0 75.0
Mean (SD) 77.8 (13.44) 76.2 (13.27) 72.6 (15.31)
Range 23.0–106.0 23.0–99.0 23.0–98.0
Male, n (%) 100 (34.8) 71 (40.3) 9 (24.3)
‘At risk’, n/N (%)
Waterlow 38/38 (100) 16/16 (100)
Braden 213/242 (88.0) 132/156 (84.6) 25/37 (67.6)
Ethnicity
White 272 (94.8) 171 (97.2) 37 (100.0)
Other 4 (1.4) 2 (1.1) 0 (0.0)
Missing 11 (3.8) 3 (1.7) 0 (0.0)
Place of assessment, n (%)
Own home 134 (46.7) 108 (61.4) 26 (70.3)
Nursing home 98 (34.1) 44 (25.0) 6 (16.2)
Residential home 36 (12.5) 10 (5.7) 3 (8.1)
Rehabilitation unit 12 (4.2) 9 (5.1) 1 (2.7)
Specialist palliative care
unit
5 (1.7) 4 (2.3) 1 (2.7)
Missing 2 (0.7) 1 (0.6) 0 (0.0)
Total number of PUs 440 285 54
Number of PUs per patient
Median 1.0 1.0 1.0
Mean (SD) 1.5 (0.83) 1.6 (0.88) 1.5 (0.65)
Range 1.0–5.0 1.0–5.0 1.0–3.0
Grade of PUs reported, n (%)
Grade 1 155 (35.2) 87 (30.5) 20 (37.0)
Grade 2 177 (40.2) 118 (41.4) 17 (31.5)
Grade 3 63 (14.3) 45 (15.8) 8 (14.8)
Grade 4 32 (7.3) 25 (8.8) 5 (9.3)
Unstageable 13 (3.0) 10 (3.5) 4 (7.4)
PU, pressure ulcer.
Adapted from McGinnis et al.45 © 2014 McGinnis et al.; licensee BioMed Central Ltd. This is an Open Access article
distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly credited.
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Pain prevalence: community population
Of the 287 patients with pressure ulcers, 176 (61.3%) were asked the pain screening questions. The
median age of patients with pressure ulcers was 79.0 years (mean 76.2, SD 13.27, range 23–99 years),
40.3% were male (71/176), 86.0% (148/172) were assessed as being ‘at risk’ using either the Waterlow
scale or the Braden scale and only 1.1% (2/176) were non-Caucasian (see Table 7).
The 176 patients with pressure ulcers were reported to have 285 pressure ulcers [median 1, mean 1.6
(SD 0.88), range 1–5 per patient]. Under one-third of pressure ulcers (87/285; 30.5%) were grade 1,
41.4% (118/285) were grade 2 and 28.1% (80/285) were grades 3–4/unstageable. The prevalence of
unattributed pressure area-related pain in the community patient population who had existing pressure
ulcers was 75.6% (133/176) (see Figure 5).
Detailed pain assessment: community population
‘Of the 133 patients with unattributed pressure area-related pain, 96 were not able or declined to
participate in the full pain assessment [see Figure 5]. Therefore, the analysis population of eligible patients
who consented to the detailed pain assessment was 27.8% (37/133) of the population reporting pain.’45
The median age of these 37 patients was 75.0 years (mean 72.6, SD 15.31, range 23–98 years). Most (70.3%)
patients were assessed in their own home, with the remainder assessed in residential or nursing homes,
rehabilitation units or palliative care units. Nine patients (24.3%) were male and all were white (see Table 7).45
‘A total of 481 skin sites were assessed [Figure 6], including 427 skin sites assessed as normal and 54 PUs
(mean 1.5 per patient, SD 0.65, range 1–3). Approximately a third of PUs were Grade 1 (37.0%; n= 20/54),
Grade 2 (31.5%; n= 17/54) and Grade 3–4/U (31.5%; n= 17/54) [see Table 7], with 29 (53.7%) located on
a torso skin site and 25 (46.3%) located on a limb skin site.’45
The 37 patients reported pain on 53 out of 481 (11.0%) skin sites [median 1.0, mean 1.4 (SD 0.65), range
1–3 per patient]. ‘No pressure area related pain was reported on normal skin whilst patients reported PU pain for
98.1% (n= 53/54) of all PUs [Table 8]. Pain intensity ranged from 1–10, with a mean of 6.4 (SD 2.53) and
median of 7.0. There is a slightly skewed distribution of pain intensity with very similar pain levels for each grade
of PU [Figure 7]. Thirty-one patients identified one skin site for LANSS assessment (n= 19 torso and n= 15 limb)
and six patients identified both a torso and a limb skin site for LANSS assessment providing a total of 22 torso
and 18 limb LANSS assessments. Neuropathic pain was slightly dominant in both torso and limb skin sites, with
54.5% (n= 12/22) of torso PUs and 61.1% (n= 11/18) of limb PUs scoring ≥ 12 on the LANSS assessment’
(Table 9).
Patients
n = 37
Skin assessments n = 481
(minimum of 13 sites per patient)
Pain reported at n = 53/481 (11.0%) skin sites;
1.4 (SD 0.65) per patient, range 1 – 3
Pain reported at n = 53/54 PU sites
LANSS completed (torso), n = 22
LANSS completed (limb), n = 18
FIGURE 6 Participant flow: detailed pain and skin assessments: community population. PU, pressure ulcer.
Reproduced from McGinnis et al.45 © 2014 McGinnis et al.; licensee BioMed Central Ltd. This is an Open Access
article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/
licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly credited.
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TABLE 8 Detailed pain assessment: number of times pain reported by skin classification: community population
Yes, n (%) No, n (%) Total, n (%)
Normal skin 0 (0.0) 427 (100.0) 427(100.0)
Grade 1 19 (95.0) 1 (5.0) 20 (100.0)
Grade 2 17 (100.0) 0 (0.0) 17 (100.0)
Grade 3 8 (100.0) 0 (0.0) 8 (100.0)
Grade 4 5 (100.0) 0 (0.0) 5 (100.0)
Unstageable 4 (100.0) 0 (0.0) 4 (100.0)
Total 53 (11.0) 428 (89.0) 481 (100.0)
Reproduced from McGinnis et al.45 © 2014 McGinnis et al.; licensee BioMed Central Ltd. This is an Open Access article
distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
0.0
10.5
0.0
10.5
5.3
21.1
5.3
15.8
21.1
10.5
0.0 0.0
0
5
10
15
20
25
30
(a)
Pe
rc
en
ta
g
e
Pain intensity
0 1 2 3 4 5 6 7 8 9 10 Missing
(b)
0
5
10
15
20
25
30
Pe
rc
en
ta
g
e
0.0
5.9 5.9
11.8
5.9 5.9 5.9 5.9
17.6
11.8
17.6
5.9
Pain intensity
0 1 2 3 4 5 6 7 8 9 10 Missing
(c)
0
5
10
15
20
25
30
Pe
rc
en
ta
g
e
0.0
5.9
11.8
0.0
5.9 5.9 5.9
23.5 23.5
11.8
5.9
0.0
Pain intensity
0 1 2 3 4 5 6 7 8 9 10 Missing
FIGURE 7 Pain intensity by skin classification: community population. (a) grade 1; (b) grade 2; and (c) grades 3–4/
unstageable. Reproduced from McGinnis et al.45 © 2014 McGinnis et al.; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly credited.
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Pain and pressure ulcer risk: cohort study
To explore the role of pain as a predictor of category 2 pressure ulcer development we undertook a
multicentre prospective cohort study in acute and community NHS trusts.
Aims and objectives
The main aim of this study was to explore the role of pain as an early predictor of category 2 pressure
ulcer development.
Objectives were to:
l assess whether the presence/absence of pressure area-related pain is a predictor of category 2 or above
pressure ulcer development, after adjusting for other known variables
l explore the relationship between skin classification category and reported pain
l identify variables that are independently predictive of category 2 or above pressure ulcer development.
Methods
Study design
We undertook a multicentre prospective cohort study. We recorded the presence of key risk factors, skin
status and pain at baseline with twice-weekly follow-up for up to 30 days from registration to identify the
development of new category 2 or above pressure ulcers (see Appendix 6 for the study protocol).
Setting
Hospital patients were recruited from vascular, trauma, orthopaedic and medical/elderly wards and
community NHS patients were recruited from their place of normal residence (own/residential/nursing
home) and community inpatient facilities.
TABLE 9 Type of pain by skin classification for the most painful torso and limb areas
Location Skin classification Nociceptive, N (%) Neuropathic, N (%) Missing, N (%) Total, N (%)
Torso Grade 1 3 (42.9%) 4 (57.1%) 0 (0.0%) 7 (100.0%)
Grade 2 3 (33.3%) 6 (66.7%) 0 (0.0%) 9 (100.0%)
Grade 3 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Grade 4 4 (80.0%) 1 (20.0%) 0 (0.0%) 5 (100.0%)
Unstageable 0 (0.0%) 1 (100.0%) 0 (0.0%) 1 (100.0%)
Totala 10 (45.5%) 12 (54.5%) 0 (0.0%) 22 (100.0%)
Limb Grade 1 2 (50.0%) 2 (50.0%) 0 (0.0%) 4 (100.0%)
Grade 2 1 (20.0%) 4 (80.0%) 0 (0.0%) 5 (100.0%)
Grade 3 2 (33.3%) 3 (50.0%) 1 (16.7%) 6 (100.0%)
Grade 4 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Unstageable 1 (33.3%) 2 (66.7%) 0 (0.0%) 3 (100.0%)
Totalb 6 (33.3%) 11 (61.1%) 1 (5.6%) 18 (100.0%)
a The denominator here is the number of patients who completed the LANSS for a Torso skin site.
b The denominator here is the number of patients who completed the LANSS for a Limb skin site.
Source: reproduced from McGinnis et al.45 © 2014 McGinnis et al.; licensee BioMed Central Ltd. This is an Open Access
article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly credited.45
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Eligibility criteria
Inclusion criteria
Patients were eligible for study inclusion if they met all of the following criteria:
l there was evidence of acute illness through one or more of the following:
¢ acute vascular, orthopaedic, medical or care of the elderly admission to secondary care hospital
¢ recent hospital discharge to home/intermediate care/community care
¢ existing community nursing patient with deterioration in overall condition or onset of acute illness
¢ new referral to community nursing because of acute illness, deterioration in existing condition or
care package breakdown
l age ≥ 18 years
l at high risk of pressure ulcer development because of one or more of the following:
¢ bedfast/chairfast and completely immobile/very limited mobility51
¢ localised skin pain on any pressure area skin site
¢ category 1 pressure ulcer on any pressure area skin site
l able to give their written informed consent to participate
l expected to be able to comply with follow-up schedule.
Exclusion criteria
Patients were excluded from the study if one or more of the following criteria applied:
l obstetric, paediatric, day-case surgery or psychiatric patients in both acute and community settings
l unable to provide written informed consent
l unable to comply with follow-up assessment schedule
l deemed by the attending health-care professional to be too unwell to be approached and/or complete
the study assessment schedule
l unable to report the presence/absence of pain (e.g. unconscious)
l with two or more category 2 or above pressure ulcers on any key pressure area skin sites (sacrum,
buttocks, heels or hips).
Screening
Participating research sites were required to complete a log of all patients screened for eligibility. The
following anonymised information was collected: age, gender, ethnicity and reason not eligible for study
participation or the reason eligible but declined.
Recruitment and consent
When eligibility was indicated by the attending clinical team, patients were flagged to a member of the
trust tissue viability team. A full verbal explanation of the study patient information leaflet (see Appendix 7)
was provided for the patient to consider, including detailed information about the rationale, design and
personal implications of the study. Assenting patients were then invited to provide written informed
consent/witnessed consent (see Appendix 8) and eligibility was confirmed prior to registration using a
central 24-hour telephone registration system.
Assessments
At registration, baseline demographics, skin status, pain status, analgesic use, mattress intervention, the
Braden subscales51 and risk factors, including diabetic status, presence of other chronic wounds, history of
weight loss and body mass index (BMI) were recorded.
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Skin status
Thirteen key skin sites (sacrum, left and right buttocks, ischial tuberosities, hips, heels, elbows and ankles)
were assessed for pressure ulcers and for the presence, duration and intensity of pain. Pressure ulcers were
classified as categories 1–4 or unstageable.1 In addition, as general skin condition is predictive of category
2 pressure ulcer development,37,57,58 observations of any alteration to intact skin (e.g. redness, scar,
excoriation, dry, scaly) were recorded as ‘A’ and the presence of healthy skin was confirmed (see
Appendix 6).
Pain status
To determine whether or not patients had localised skin pain on any pressure area skin site they were
asked the two screening questions and, when pain was indicated, a detailed pain assessment was
completed (see Pain prevalence in hospital and community populations, Methods).
Pressure ulcer interventions
All participating trusts had pressure ulcer prevention policies and guidelines, which included risk
assessment, mattress and repositioning guidance. The cohort study participants received pressure ulcer
prevention interventions as allocated by the attending clinical teams and as per local policies and
guidelines. We recorded mattress provision, which was categorised as non-pressure relieving (e.g. domestic
mattress or silicone fibre overlay), static pressure relieving (e.g. high-specification foam, viscoelastic foam,
air filled, gel filled) and dynamic pressure relieving (e.g. alternating pressure, low air loss, air fluidised).
Frequency of assessments
A maximum of eight follow-up assessments were undertaken to establish the primary end point for
patients who continued to be at high risk of pressure ulcer development during the 30-day period. Patients
were followed up across health-care settings (i.e. hospital patients discharged home and community
patients admitted to hospital) until 30 days from registration or they were assessed as being no longer at
high risk, withdrawal or death. At follow-up, skin status, Braden subscales, pain status, analgesic use,
mattress provision and serious adverse events were recorded.
Staff training and preparation
Consistent with methods used for the pain prevalence study, members of the tissue viability team were
trained and no formal assessment of inter-rater reliability was undertaken (see Pain prevalence in hospital
and community populations, Methods).
Data processing
Data processing methods were consistent with those described in Pain prevalence in hospital and
community populations (see Methods). In addition, data queries and missing data were chased until the
data were confirmed as correct or unavailable. Batch validation and consistency data checks were also
carried out to check the accuracy of the data.
Sample size
For risk factor studies using logistic regression it is recommended that at least 10 patients with the event of
interest are needed for reliable estimation of effects.59 Our aim was to assess whether or not the presence
of localised skin pain is predictive of new category 2 (or above) pressure ulcer development, after adjusting
for the effects of other known risk factors.
We prespecified seven risk factors identified from our risk factor systematic review and emerging
conceptual framework46 (see Chapter 5): age, diabetes status, nutritional status, Braden mobility subscale
score, presence of skin alterations, presence of a category 1 ulcer on any site and patient setting (hospital
or community). In addition, because a patient’s perception of pain is likely to be affected by the use of
analgesics or other forms of pain relief, this was also included as a prespecified covariate, resulting in a
model potentially including nine factors (i.e. pain, the seven prespecified risk factors and analgesic use).
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A nine-factor model would therefore require a minimum of 90 patients to develop a new pressure ulcer of
category 2 or above. In the absence of prospective data for community-based patient populations,46 the
sample size estimate was based on previous research in acute hospital patients,37,58,60 suggesting that
approximately 15% of patients would develop a new pressure ulcer of category 2 or above within 30 days
of entering the study. Based on this assumption and allowing for potential loss to follow-up of 5%, we
estimated that we would require 632 patients to be recruited to this study.
A further consideration in appraising the sample size estimate was the prevalence of pain at study entry.
As no previous work in this field had been undertaken we considered a range of prevalence rates.
Table 10 shows the largest difference in pressure ulcer incidence that could be detected with a minimum
of 80% power if 10% or 20% of patients reported pain at study entry. We estimated pressure ulcer event
rates in the patients without pain of 10% and 15% for each case and assumed that patients with pain at
study entry are more likely to develop a new ulcer than those without pain at entry.
We estimated that, if we recruited 600 patients (after accounting for 5% loss to follow up) with 60 (10%) of
them having pain on study entry, this would allow us to detect a statistically significant difference (p< 0.05) of
13.2% between those with and those without pain using a chi-square test (80% power, 5% significance) if
10% of patients without pain and 23.2% of those with pain developed a new pressure ulcer within the 30-day
follow-up period, corresponding to an odds ratio (OR) of 2.72 [95% confidence interval (CI) 1.40 to 5.27].
As this was an exploratory study and there was uncertainty around the assumptions made to estimate
the sample size, the proportion of patients with pain at baseline and the incidence of pressure ulcer
development was monitored by the statistical team and chief investigator and reported to a subgroup of
the programme steering committee.
End point definition
The primary end point was defined as the development of a new category 2 or above pressure ulcer on
any skin site after registration and before the end of follow-up. End of follow-up was defined as no longer
at high risk (see Inclusion criteria), patient transferred to a non-participating setting, death or the end of
study follow-up (30 days), whichever was the earliest event.
The secondary end point was defined as the time in days after registration to development of the first new
category 2 or above pressure ulcer or to the end of follow-up for patients who were not observed to develop
a new category 2 or above pressure ulcer during follow-up. Patients who were not observed to develop a
new category 2 or above pressure ulcer were censored at the end of follow-up.
TABLE 10 Pain cohort study: estimation of differences detectable with 80% power
Total n
Baseline pain PU incidence PU incidence
With pain,
n (%)
Without
pain, n (%)
With
pain, %
Without
pain, % Difference, %
With
pain, %
Without
pain, % Difference, %
600 60 (10) 540 (90) 23.2 10.0 13.2 30.0 15.0 15.0
OR 2.719 (95% CI 1.402 to 5.217) OR 2.429 (CI 1.332 to 4.428)
600 120 (20) 480 (80) 19.8 10.0 9.8 26.2 15.0 11.2
OR 2.222 (95% CI 1.296 to 3.809) OR 2.021 (CI 1.248 to 3.244)
CI, confidence interval; OR, odds ratio; PU, pressure ulcer.
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Analysis population
The defined analysis population was all patients for whom a primary end point could be determined, that is,
patients with at least one follow-up skin assessment completed.
Analysis methods
Primary end point analysis
Univariate logistic regression was conducted to assess the candidate variables for inclusion in a
multivariable model. Candidate variables were considered statistically significant if the p-value of the
associated likelihood ratio test was < 0.1.
A multivariable analysis was then conducted to build a logistic regression model for the odds of developing
a new category 2 or above pressure ulcer, using forwards and backwards stepwise variable selection.
Candidate variables were included in the model if their inclusion led to a reduction in deviance with a
corresponding p-value of < 0.1 for the associated likelihood ratio test; similarly, candidate variables were
retained in the model if their exclusion led to an increase in deviance with a corresponding p-value of
> 0.1 for the associated likelihood ratio test. The candidate variables of interest, defined at baseline
(study entry) and based on a conceptual framework46 (see Chapter 5), were age, diabetes status, history
of weight loss, Braden mobility subscale score (category 3 or 4 vs. category 1 or 2), presence of skin
alterations, presence of a category 1 pressure ulcer, setting (hospital, community), use of analgesics/pain
relief and presence of pain on a skin site assessed as healthy, altered or a category 1 pressure ulcer.
The primary analysis focused on using unconditional logistic regression61 to determine whether or not the
presence or absence of pain at study entry was predictive of the development of a new category 2 or
above pressure ulcer, after allowing for the other a priori factors of interest. Parameter estimates (ORs),
their 95% CIs and associated p-values are presented. Methods for assessing the appropriateness of the
model and the influence of observations were applied (e.g. the Hosmer and Lemeshow goodness of
fit test62).
Overdispersion analysis
An additional analysis was carried out to determine if there was overdispersion in the model and, if so,
whether or not this could be explained by the inclusion of other variables for which data have been
collected, irrespective of whether or not the presence of pain is an important predictor of pressure ulcer
development. Further variables were assessed for inclusion in the final logistic regression model obtained in
the primary analysis using forwards and backwards stepwise variable selection. Candidate variables were
retained in/excluded from the model if the p-value was < 0.1 for the associated likelihood ratio test. An
assessment of whether or not the variables included in the primary analysis were still significant was also
undertaken as part of the variable selection process. The other baseline candidate variables assessed for
inclusion were gender, BMI, Braden scale domains (activity, friction, moisture, nutrition and sensory
perception), the presence of a category 2 or above pressure ulcer, the presence of a chronic wound and
mattress category.
The relationship between skin classification and the presence or absence of pain was examined using
descriptive statistics (mainly cross-tabulations). Baseline data for each patient were tabulated using
frequencies and summary statistics. Missing or unobtainable data were noted. Characteristics were also
summarised by whether the patient presented in an acute hospital or a community setting. Correlations
between the explanatory variables were also examined.
WORK PACKAGE 1: PAIN
NIHR Journals Library www.journalslibrary.nihr.ac.uk
34
Time-to-event analysis
The relationship between presence or absence of pain at study entry and time to onset of a new category 2
or above pressure ulcer was initially investigated using Cox proportional hazards regression.63 The
assumptions of the Cox proportional hazards model were assessed using log-log plots, Cox–Snell residuals
and Schoenfeld residuals and by fitting a time-dependent covariate term in the model for the presence of
pain.64 However, the proportional hazards assumptions of the model obtained did not hold and an
accelerated failure time model65 was fitted. Unlike the Cox proportional hazards model, the accelerated
failure time model is a parametric model that required the distribution of the hazard function to be
prespecified and, for this analysis, the gamma distribution was the most appropriate distribution. As for the
logistic regression analysis, univariate analyses were conducted to determine which variables were
associated with time to onset of a new category 2 or above pressure ulcer and were therefore candidates
for the multivariable analyses. The final multivariable accelerated failure time model was obtained using
forwards and backwards stepwise variable selection. Candidate variables were retained in/excluded from
the model if the p-value was < 0.1 for the associated likelihood ratio test. The results are presented as
parameter estimates (ratio of the time to onset of a category 2 or above pressure ulcer) with 95% CIs and
associated p-values. The time to onset of a category 2 or above pressure ulcer was also assessed using
cumulative incidence functions.
Skin site analysis
The relationship between presence or absence of pain at baseline on a healthy, altered or category 1
pressure ulcer skin site and the development of a new category 2 or above pressure ulcer at the same skin
site was examined, taking account of the nesting of skin sites within patients using multilevel logistic
regression (specifically, a two-level random-intercept logistic model was used). Univariate analyses and a
multivariable analysis using forwards and backwards variable selection were conducted as for the primary
logistic regression analysis. Candidate variables were included in the model if their inclusion led to a
reduction in deviance with a corresponding p-value of < 0.1 for the associated likelihood ratio test;
similarly, candidate variables were retained in the model if their exclusion led to an increase in deviance
with a corresponding p-value of > 0.1 for the associated likelihood ratio test. The results are presented as
parameter estimates (ORs), their 95% CIs and associated p-values.
Results
In total, 3819 patients were assessed for eligibility for the study and 634 patients were registered between
26 October 2009 and 17 November 2011. There were 26 recruiting centres across 18 NHS trusts in
England, with the number of patients registered at each centre ranging from 1 to 86 (see Appendix 1).
The centres consisted of eight teaching hospitals (four acute NHS trusts), 10 general hospitals (four acute
and two community NHS trusts) and eight community care NHS trusts.
Of the 634 patients who were registered to the study, a primary end point could not be determined for 32
because they did not have any follow-up visits. Therefore, the analysis population included a total of
602 patients (Figure 8).
Baseline characteristics
In total, 397 (65.9%) patients were registered from the acute setting and 205 (34.1%) patients were
registered from the community setting, half of whom were located in rehabilitation inpatient settings
(104/205, 50.7%; Table 11).
Patient characteristics are detailed in Tables 12 and 13. In summary, across both groups there were fewer
male patients (38.7%), all but one patient was Caucasian (99.8%) and one-quarter of patients were
diabetic (25.4%). The median age of patients was 80 years (range 21–101 years). One-quarter of patients
had a history of weight loss (24.4%), with 10.6% assessed as underweight by BMI and 22.3% assessed
as obese. In total, 21.1% of patients had a chronic wound. The majority of patients recruited to the study
had alterations to intact skin (62.0%), almost half had a category 1 pressure ulcer (48.2%) over one-quarter
had a category 2 ulcer (27.2%) and 4.0% had a category 3, 4 or unstageable ulcer.
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TABLE 11 Pain cohort study: specialty or place assessed by setting
Specialty or place assessed Acute (n= 397), n (%) Community (n= 205), n (%) Total (n= 602), n (%)
Vascular 42 (10.6) 0 (0.0) 42 (7.0)
Orthopaedic 155 (39.0) 0 (0.0) 155 (25.7)
Medical 90 (22.7) 0 (0.0) 90 (15.0)
Elderly 32 (8.1) 0 (0.0) 32 (5.3)
Medical/elderly 78 (19.6) 0 (0.0) 78 (13.0)
Patient’s own home 0 (0.0) 49 (23.9) 49 (8.1)
Nursing home 0 (0.0) 27 (13.2) 27 (4.5)
Residential home 0 (0.0) 18 (8.8) 18 (3.0)
Rehabilitation unit 0 (0.0) 104 (50.7) 104 (17.3)
Other place assessed 0 (0.0) 7 (3.4) 7 (1.2)
TABLE 12 Pain cohort study: baseline characteristics by setting
Characteristic Acute (n= 397) Community (n= 205) Total (n= 602)
Age (years)
Mean (SD) 75.6 (12.9) 80.7 (11.7) 77.3 (12.7)
Median (range) 79 (21–101) 83 (30–100) 80 (21–101)
Sex, n (%)
Male 156 (39.3) 77 (37.6) 233 (38.7)
Female 241 (60.7) 128 (62.4) 369 (61.3)
Ethnicity, n (%)
Caucasian 396 (99.7) 205 (100.0) 601 (99.8)
Non-Caucasian 1 (0.3) 0 (0.0) 1 (0.2)
Is the patient diabetic, n (%)
Yes 98 (24.7) 55 (26.8) 153 (25.4)
No 299 (75.3) 149 (72.7) 448 (74.4)
Missing 0 (0.0) 1 (0.5) 1 (0.2)
History of weight loss, n (%)
Yes 95 (23.9) 52 (25.4) 147 (24.4)
No 302 (76.1) 152 (74.1) 454 (75.4)
Missing 0 (0.0) 1 (0.5) 1 (0.2)
BMI
Mean (SD) (kg/m2) 27.1 (9.3) 26.0 (9.9) 26.7 (9.5)
Median (range) (kg/m2) 25 (11–94) 24 (11–111) 25 (11–111)
Underweight (< 18.5 kg/m2), n (%) 38 (9.6) 26 (12.7) 64 (10.6)
Normal weight (18.5 to < 25 kg/m2), n (%) 143 (36.0) 81 (39.5) 224 (37.2)
Overweight (25 to < 30 kg/m2), n (%) 106 (26.7) 50 (24.4) 156 (25.9)
continued
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TABLE 12 Pain cohort study: baseline characteristics by setting (continued )
Characteristic Acute (n= 397) Community (n= 205) Total (n= 602)
Obese (≥ 30 kg/m2), n (%) 98 (24.7) 36 (17.6) 134 (22.3)
Missing, n (%) 12 (3.0) 12 (5.9) 24 (4.0)
Chronic wounds, n (%)
Yes 75 (18.9) 52 (25.4) 127 (21.1)
No 322 (81.1) 152 (74.1) 474 (78.7)
Missing 0 (0.0) 1 (0.5) 1 (0.2)
Skin alterations at baseline, n (%)
Yes 242 (61.0) 131 (63.9) 373 (62.0)
No 155 (39.0) 74 (36.1) 229 (38.0)
Category 1 at baseline, n (%)
Yes 198 (49.9) 92 (44.9) 290 (48.2)
No 199 (50.1) 113 (55.1) 312 (51.8)
Existing category or above at baseline, n (%)
Yes 116 (29.2) 48 (23.4) 164 (27.2)
No 281 (70.8) 157 (76.6) 438 (72.8)
Pain at a healthy, altered or category 1 skin site, n (%)
Yes 301 (75.8) 163 (79.5) 464 (77.1)
No 96 (24.2) 42 (20.5) 138 (22.9)
Worst skin status at baseline, n (%)
Healthy intact skin 45 (11.3) 25 (12.2) 70 (11.6)
Alterations to intact skin 99 (24.9) 55 (26.8) 154 (25.6)
Category 1 137 (34.5) 77 (37.6) 214 (35.5)
Category 2 98 (24.7) 42 (20.5) 140 (23.3)
Category 3 10 (2.5) 3 (1.5) 13 (2.2)
Category 4 2 (0.5) 2 (1.0) 4 (0.7)
Unstageable 6 (1.5) 1 (0.5) 7 (1.2)
Analgesic use, n (%)
Yes 366 (92.2) 182 (88.8) 548 (91.0)
No 31 (7.8) 23 (11.2) 54 (9.0)
Mattress category, n (%)
Non-pressure relieving 5 (1.3) 31 (15.1) 36 (6.0)
Static pressure-relieving 168 (42.3) 105 (51.2) 273 (45.3)
Dynamic pressure-relieving 224 (56.4) 68 (33.2) 292 (48.5)
Missing 0 (0.0) 1 (0.5) 1 (0.2)
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TABLE 13 Pain cohort study: baseline characteristics by setting – Braden subscales
Braden subscale Acute (n= 397), n (%) Community (n= 205), n (%) Total (n= 602), n (%)
Sensory perception
Very limited 5 (1.3) 3 (1.5) 8 (1.3)
Slightly limited 68 (17.1) 15 (7.3) 83 (13.8)
No impairment 324 (81.6) 187 (91.2) 511 (84.9)
Moisture
Constantly moist 2 (0.5) 3 (1.5) 5 (0.8)
Very moist 25 (6.3) 13 (6.3) 38 (6.3)
Occasionally moist 105 (26.4) 55 (26.8) 160 (26.6)
Rarely moist 265 (66.8) 134 (65.4) 399 (66.3)
Activity
Bedfast 96 (24.2) 8 (3.9) 104 (17.3)
Chairfast 221 (55.7) 92 (44.9) 313 (52.0)
Walks occasionally 76 (19.1) 81 (39.5) 157 (26.1)
Walks frequently 4 (1.0) 24 (11.7) 28 (4.7)
Mobility
Completely immobile 9 (2.3) 12 (5.9) 21 (3.5)
Very limited 204 (51.4) 58 (28.3) 262 (43.5)
Slightly limited 142 (35.8) 89 (43.4) 231 (38.4)
No limitation 42 (10.6) 46 (22.4) 88 (14.6)
Nutrition
Very poor 13 (3.3) 6 (2.9) 19 (3.2)
Probably inadequate 130 (32.7) 28 (13.7) 158 (26.2)
Adequate 163 (41.1) 95 (46.3) 258 (42.9)
Excellent 91 (22.9) 76 (37.1) 167 (27.7)
Friction and shear
Problem 62 (15.6) 39 (19.0) 101 (16.8)
Potential problem 295 (74.3) 118 (57.6) 413 (68.6)
No apparent problem 40 (10.1) 48 (23.4) 88 (14.6)
Total score
At risk (≤ 18) 324 (81.6) 115 (56.1) 439 (72.9)
Not at risk (> 18) 73 (18.4) 90 (43.9) 163 (27.1)
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Pain was reported on healthy, altered and category 1 skin sites by 77.1% of patients (see Table 12). Only
3.5% of patients were completely immobile, with the majority of patients assessed as having either very
limited (43.5%) or slightly limited (38.4%) mobility according to the Braden mobility subscale (see Table 13).
The majority of patients were receiving either a static pressure-relieving (45.3%) or a dynamic pressure-relieving
(48.5%) mattress. In the community 15.1% of mattresses were described as non-pressure relieving whereas in
the hospital setting this was the case for only 1.3% of patients (see Table 12).
Primary end point analysis
The primary end point was whether or not a patient developed a new category 2 or above pressure ulcer
on any skin site after registration and before the end of follow-up. Skin sites with a category 2 or above
pressure ulcer or recorded as not applicable/unable to assess (e.g. amputated limb or bandage/dressing in
situ) at baseline were excluded from the primary end point analysis. The overall incidence of new category
2 or above pressure ulcers in the analysis population was 152 out of 602 (25.2%).
A total of 464 (77.1%) of the study population reported pressure area pain on skin assessed clinically as
normal, altered or with a category 1 pressure ulcer and, of these, 130 (28.0%) developed a category 2
(or above) pressure ulcer compared with 22 (15.9%) patients with no pain at baseline (Table 14).
TABLE 14 Pain cohort study: baseline characteristics by pressure ulcer development
Characteristic
Develops new
PU (n= 152)
Does not develop new
PU (n= 450)
Total
(n= 602)
Age
Mean (SD) (years) 78.1 (12.0) 77.1 (13.0) 77.3 (12.7)
Median (range) (years) 81 (25–99) 80 (21–101) 80 (21–101)
< 65 years, n (%) 21 (22.1) 74 (77.9) 95 (15.8)
65–74 years, n (%) 29 (25.4) 85 (74.6) 114 (18.9)
75–84 years, n (%) 51 (24.9) 154 (75.1) 205 (34.1)
≥ 85 years, n (%) 51 (27.1) 137 (72.9) 188 (31.2)
Sex, n (%)
Male 68 (29.2) 165 (70.8) 233 (38.7)
Female 84 (22.8) 285 (77.2) 369 (61.3)
Ethnicity, n (%)
Caucasian 151 (25.1) 450 (74.9) 601 (99.8)
Non-Caucasian 1 (100.0) 0 (0.0) 1 (0.2)
Is the patient diabetic, n (%)
Yes 47 (30.7) 106 (69.3) 153 (25.4)
No 105 (23.4) 343 (76.6) 448 (74.4)
Missing 0 (0.0) 1 (100.0) 1 (0.2)
History of weight loss, n (%)
Yes 38 (25.9) 109 (74.1) 147 (24.4)
No 114 (25.1) 340 (74.9) 454 (75.4)
Missing 0 (0.0) 1 (100.0) 1 (0.2)
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TABLE 14 Pain cohort study: baseline characteristics by pressure ulcer development (continued )
Characteristic
Develops new
PU (n= 152)
Does not develop new
PU (n= 450)
Total
(n= 602)
BMI
Mean (SD) (kg/m2) 27.0 (10.0) 26.6 (9.3) 26.7 (9.5)
Median (range) (kg/m2) 25 (11–91) 25 (11–111) 25 (11–111)
Underweight (< 18.5 kg/m2), n (%) 16 (25.0) 48 (75.0) 64 (10.6)
Normal weight (18.5 to < 25 kg/m2), n (%) 61 (27.2) 163 (72.8) 224 (37.2)
Overweight (25 to < 30 kg/m2), n (%) 30 (19.2) 126 (80.8) 156 (25.9)
Obese (≥ 30 kg/m2), n (%) 38 (28.4) 96 (71.6) 134 (22.3)
Missing, n (%) 7 (29.2) 17 (70.8) 24 (4.0)
Chronic wounds, n (%)
Yes 45 (35.4) 82 (64.6) 127 (21.1)
No 107 (22.6) 367 (77.4) 474 (78.7)
Missing 0 (0.0) 1 (100.0) 1 (0.2)
Skin alterations at baseline, n (%)
Yes 109 (29.2) 264 (70.8) 373 (62.0)
No 43 (18.8) 186 (81.2) 229 (38.0)
Category 1 at baseline, n (%)
Yes 105 (36.2) 185 (63.8) 290 (48.2)
No 47 (15.1) 265 (84.9) 312 (51.8)
Existing category 2 or above at baseline, n (%)
Yes 54 (32.9) 110 (67.1) 164 (27.2)
No 98 (22.4) 340 (77.6) 438 (72.8)
Pain at a healthy, altered or category 1 skin site, n (%)
Yes 130 (28.0) 334 (72.0) 464 (77.1)
No 22 (15.9) 116 (84.1) 138 (22.9)
Analgesic use, n (%)
Yes 137 (25.0) 411 (75.0) 548 (91.0)
No 15 (27.8) 39 (72.2) 54 (9.0)
Braden mobility subscale, n (%)
Completely immobile 5 (23.8) 16 (76.2) 21 (3.5)
Very limited 61 (23.3) 201 (76.7) 262 (43.5)
Slightly limited 63 (27.3) 168 (72.7) 231 (38.4)
No limitation 23 (26.1) 65 (73.9) 88 (14.6)
Setting, n (%)
Acute 98 (24.7) 299 (75.3) 397 (65.9)
Community 54 (26.3) 151 (73.7) 205 (34.1)
PU, pressure ulcer.
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The results of the univariate analysis are presented in Table 15. Factors that had a statistically significant
association with the odds of developing a new category 2 or above pressure ulcer included presence of
skin alterations (OR 1.79, 95% CI 1.20 to 2.66; p= 0.0045), presence of at least one category 1 pressure
ulcer (OR 3.20, 95% CI 2.63 to 4.74; p< 0.0001) and presence of pain on a healthy, altered or category 1
skin site at baseline (OR 2.05, 95% CI 1.25 to 3.38; p= 0.0047). There was marginal evidence that
diabetic status was associated with the odds of developing a new category 2 or above pressure ulcer, with
the odds higher for patients with diabetes than for patients without diabetes (OR 1.45, 95% CI 0.97 to
2.18; p= 0.0722). The following factors were not statistically significant: age, history of previous weight
loss, Braden mobility subscale score, setting and analgesic use. Therefore, there was no evidence of an
association between these factors and the odds of developing a new category 2 or above pressure ulcer.
TABLE 15 Pain cohort study: results of the univariate analysis of the odds of developing a category 2 or above
pressure ulcer
Covariate OR 95% CI p-value
Age (continuous) 1.01 0.99 to 1.022 0.3936
Age (categorical) (reference= ‘< 65 years’)
≥ 85 years 1.31 0.73 to 2.35 0.4192
65–74 years 1.20 0.63 to 2.29 0.3885
75–84 years 1.17 0.65 to 2.08 0.2996
Diabetic statusa (yes vs. no) 1.45 0.97 to 2.18 0.0722
History of weight lossb (yes vs. no) 1.04 0.68 to 1.60 0.8462
Braden mobility subscale score (1 or 2 vs. 3 or 4) 1.21 0.84 to 1.76 0.3055
Skin alterations (yes vs. no) 1.79 1.20 to 2.66 0.0045
Category 1 PU (yes vs. no) 3.20 2.63 to 4.74 < 0.0001
Setting (acute vs. community) 0.92 0.62 to 1.35 0.6576
Analgesic use (yes vs. no) 0.87 0.46 to 1.62 0.6542
Pain on healthy, altered or category 1 skin site (yes vs. no) 2.05 1.25 to 3.38 0.0047
Covariates considered for overdispersion analysis
Gender (female vs. male) 0.72 0.49 to 1.04 0.0780
BMI (continuous) 1.00 0.99 to 1.02 0.6702
Braden sensory subscale (reference= no impairment)
Slightly limited 0.92 0.54 to 1.58 0.6886
Very limited 0.41 0.05 to 3.40
Braden moisture subscale (reference= rarely moist)
Occasionally moist 1.83 1.22 to 2.74 0.0277
Very moist 1.11 0.51 to 2.44
Constantly moist 2.39 0.39 to 14.55
Braden activity subscale (reference= bedfast)
Chairfast 1.83 1.05 to 3.19 0.0775
Walks occasionally 1.43 0.77 to 2.65
Walks frequently 0.75 0.23 to 2.40
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The final multivariable model obtained from the variable selection carried out included three variables:
the presence of a category 1 pressure ulcer (OR 3.25, 95% CI 2.17 to 4.86; p< 0.0001), the presence of
skin alterations (OR 1.98, 95% CI 1.30 to 3.00; p= 0.0014) and the presence of pain on a healthy, altered
or category 1 skin site at baseline (OR 1.56, 95% CI 0.93 to 2.63; p= 0.0931) (Table 16). Therefore, there
was significant evidence that the presence of a category 1 pressure ulcer and presence of skin alterations
are risk factors for developing a category 2 or above ulcer. After adjusting for these risk factors, there was
marginal evidence that the presence of pain is a further risk factor for developing a category 2 or above
pressure ulcer.
Overdispersion analysis
The model obtained in the primary end point analysis was further developed by considering the inclusion
of other variables for which data were collected using further forwards and backwards stepwise variable
selection. The results of the univariate analyses are shown in Table 15.
TABLE 15 Pain cohort study: results of the univariate analysis of the odds of developing a category 2 or above
pressure ulcer (continued )
Covariate OR 95% CI p-value
Braden nutrition subscale (reference= excellent)
Adequate 0.93 0.59 to 1.47 0.6058
Probably inadequate 1.26 0.77 to 2.06
Very poor 1.10 0.37 to 3.23
Braden friction and shear subscale (reference= no apparent problem)
Potential problem 1.06 0.62 to 1.82 0.8036
Problem 1.22 0.64 to 2.36
Mattress category (reference= dynamic high-risk pressure relieving)
Static risk pressure relieving 1.28 0.87 to 1.87 0.2430
Non-pressure relieving 0.95 0.41 to 2.17
Chronic wound 1.89 1.24 to 2.88 0.0032
Category 2 or above PU 1.70 1.15 to 2.53 0.0083
PU, pressure ulcer.
a Missing diabetic status set to ‘no’ for one missing patient.
b Missing history of weight loss status set to ‘no’ for one missing patient.
TABLE 16 Pain cohort study: final model for the odds of developing a category 2 or above pressure ulcer (n= 602)
Covariate OR 95% CI p-value
Category 1 PU (yes vs. no) 3.25 2.17 to 4.86 < 0.0001
Skin alterations (yes vs. no) 1.98 1.30 to 3.00 0.0014
Pain on healthy, altered or category 1 skin site (yes vs. no) 1.56 0.93 to 2.63 0.0931
PU, pressure ulcer.
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The final multivariable model obtained from the further variable selection carried out included six variables.
These included (1) the presence of a category 1 pressure ulcer (OR 3.20, 95% CI 2.11 to 4.85; p< 0.0001),
(2) the presence of skin alterations (OR 1.90, 95% CI 1.24 to 2.91; p= 0.0032), (3) the presence of pain
on a healthy, altered or category 1 skin site at baseline (OR 1.85, 95% CI 1.07 to 3.20; p= 0.0271), (4) the
presence of a category 2 ulcer (OR 2.09, 95% CI 1.35 to 3.23; p= 0.0009), (5) the presence of a chronic
wound (OR 1.66, 95% CI 1.04 to 2.62, p= 0.0277; Table 17). In addition, (6) there was significant evidence
that Braden activity was related to the odds of developing a new category 2 or above pressure ulcer
(p= 0.0476). As shown in Table 17, the odds of developing a category 2 or above ulcer were greater for
patients who were chairfast than for patients who were bedfast (OR 1.86, 95% CI 1.03 to 2.29) whereas
there was no evidence that patients who walk occasionally or frequently were more likely to develop a
category 2 or above pressure ulcer than patients who were bedfast (the 95% CIs for the ORs straddle 1).
After adjusting for these risk factors, there was significant evidence that the presence of pain is a further
risk factor for developing a category 2 or above pressure ulcer.
Correlations between explanatory variables were examined and each of the comparisons yielded low
associations. Table 18 shows the associations between the explanatory variables. Cross-tabulations of
explanatory variables were also produced for further information and are shown in Appendix 9.
Time-to-event analysis
The variables that were statistically significantly (at the 10% level) associated with the time to onset of a
new category 2 or above pressure ulcer in the univariate analyses were age [acceleration factor (AF) 1.01,
95% CI 1.00 to 1.03; p= 0.0354], Braden mobility subscale score (AF 1.37, 95% CI 1.00 to 1.87;
p= 0.0498), the presence of a category 1 pressure ulcer (AF 2.63, 95% CI 1.93 to 3.58; p< 0.0001)
and the presence of pain on a healthy, altered or category 1 skin site (AF 2.68, 95% CI 1.86 to 3.86;
p< 0.0001). In addition, there was marginal evidence that the presence of skin alterations was associated
with the time to onset of a new category 2 or above pressure ulcer (AF 1.40, 95% CI 0.99 to 1.97;
p= 0.0593; Table 19).
TABLE 17 Pain cohort study: final model for the odds of developing a category 2 or above pressure ulcer from the
overdispersion analysis (n= 602)
Covariate OR 95% CI p-value
Category 1 PU 3.20 2.11 to 4.85 < 0.0001
Skin alterations 1.90 1.24 to 2.91 0.0032
Pain on a healthy, altered or category 1 skin site 1.85 1.07 to 3.20 0.0271
Category 2 PU 2.09 1.35 to 3.23 0.0009
Braden activity: chairfast vs. bedfast 1.86 1.03 to 3.36 0.0476
Braden activity: walks occasionally vs. bedfast 1.19 0.62 to 2.29
Braden activity: walks frequently vs. bedfast 0.71 0.21 to 2.46
Chronic wound 1.66 1.06 to 2.62 0.0277
PU, pressure ulcer.
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TABLE 18 Pain cohort study: associations between explanatory variables
Explanatory variable 1 Explanatory variable 2
Correlation
coefficient
Level of
association
Category 1 PU Skin alterations –0.07 Low
Category 1 PU Pain on a category 0, 1 or A skin site 0.19 Low
Category 1 PU Category 2 PU –0.02 Low
Category 1 PU Braden activity –0.01 Low
Category 1 PU Chronic wound 0.09 Low
Skin alterations Pain on a category 0, 1 or A skin site 0.11 Low
Skin alterations Category 2 PU –0.02 Low
Skin alterations Braden activity –0.10 Low
Skin alterations Chronic wound 0.07 Low
Pain on a category 0, 1 or A skin site Category 2 PU –0.21 Low
Pain on a category 0, 1 or A skin site Braden activity –0.16 Low
Pain on a category 0, 1 or A skin site Chronic wound 0.07 Low
Category 2 PU Braden activity –0.02 Low
Category 2 PU Chronic wound 0.04 Low
Braden activity Chronic wound –0.15 Low
PU, pressure ulcer.
TABLE 19 Pain cohort study: univariate analyses for time to onset of a category 2 or above pressure ulcer
Factor
Ratioa of time to develop new
category 2 or above PU 95% CI p-value
Age (continuous) 1.01 1.00 to 1.03 0.0354
Skin alterations (yes vs. no) 1.40 0.99 to 1.97 0.0593
Analgesic use (yes vs. no) 1.05 0.61 to 1.83 0.8577
Braden mobility (1 or 2 vs. 3 or 4) 1.37 1.00 to 1.87 0.0498
Category 1 PU (yes vs. no) 2.63 1.93 to 3.58 < 0.0001
Diabetic (yes vs. no) 1.24 0.85 to 1.80 0.2591
History of previous weight loss (yes vs. no) 0.90 0.62 to 1.30 0.5715
Pain (yes vs. no) 2.68 1.86 to 3.86 < 0.0001
Setting (acute vs. community) 1.13 0.81 to 1.58 0.4652
PU, pressure ulcer.
a Ratio corresponds to the AF.
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The final accelerated failure time multivariable model obtained from forwards and backwards variable
selection included the covariates presence of a category 1 pressure ulcer and presence of pain on a
healthy, altered or category 1 skin site and so both are risk factors for reducing the time to develop a
category 2 or above pressure ulcer (Table 20). Unlike the primary analysis, the presence of skin alterations
has not been included in the final model but was shown to have a significant association with time to
onset of a new category 2 or above pressure ulcer in the univariate analysis and therefore may explain why
skin alterations were not included in the final model. The cumulative incidence function for the presence
of skin alterations is very similar to the cumulative incidence function for the presence of pain on a healthy,
altered or category 1 pressure ulcer skin site, although the cumulative incidence functions indicate that
there is a larger difference between pain categories than between skin alteration categories. The final
model shows that patients are likely to develop a new category 2 or above pressure ulcer 2.32 times faster
if they have a category 1 pressure ulcer at baseline than if they do not have a category 1 pressure ulcer at
baseline (AF 2.32, 95% CI 1.73 to 3.12; p< 0.0001). In addition, patients are likely to develop a new
category 2 or above pressure ulcer 2.28 times faster if they have pressure area-related pain at a healthy,
altered or category 1 skin site than if they do not have pressure area-related pain at a healthy, altered or
category 1 skin site (AF 2.28, 95% CI 1.59 to 3.27; p< 0.0001).
Cumulative incidence functions for the presence of skin alterations, the presence of a category 1 pressure ulcer
and the presence of pain on a healthy, altered or category 1 skin site at baseline are presented in Figure 9.
Skin site-level analysis
The analysis population of 602 patients had a combined total of 7863 potential skin sites assessed (Table 21),
of which the majority (77.5%) were observed as being healthy skin sites. Pain was reported more frequently
with more severe skin status, that is, 63.1% of category 1 skin sites were observed to have pain compared with
40.3% of skin sites with alterations and 6.4% of healthy skin sites (see Table 21).
Of the total 7863 skin sites, 7483 (95.2%) were evaluable in the analysis, that is, all skin sites that were
observed as being healthy, altered or category 1 at baseline and which had at least one follow-up
assessment (i.e. the end point could be derived for that skin site). Overall, 223 (3.0%) of the evaluable skin
sites developed a new category 2 or above pressure ulcer, and the incidence for skin sites with pain at
baseline was higher at 10.3% than that for skin sites with no pain at baseline (1.7%) (Table 22). Similarly,
the incidence of a new category 2 or above pressure ulcer was observed to increase with the severity of
skin status at baseline (i.e. the incidence for skin sites with a category 1 pressure ulcer at baseline was
18.2% compared with 6.4% for sites with skin alterations and 1.1% for healthy skin sites at baseline).
TABLE 20 Pain cohort study: final model for time to onset of a category 2 or above pressure ulcer (n= 602)
Factor Ratioa of time to develop new category 2 or above PU 95% CI p-value
Category 1 PU (yes vs. no) 2.32 1.73 to 3.12 < 0.0001
Pain (yes vs. no) 2.28 1.59 to 3.27 < 0.0001
PU, pressure ulcer.
a Ratio corresponds to the AF.
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FIGURE 9 Cumulative incidence plots. (a) Cumulative incidence plot of time to develop a new category 2 pressure
ulcer by presence of skin alterations at baseline; (b) cumulative incidence plot of time to develop a new category 2
pressure ulcer by presence of a category 1 PU at baseline; and (c) cumulative incidence plot of time to develop a
new category 2 pressure ulcer by presence of pain on a healthy, altered or category 1 pressure ulcer skin site
at baseline.
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The results of the univariate analysis are presented in Table 23. Factors that had a statistically significant
association with the odds of developing a new category 2 or above pressure ulcer were skin status, which
consisted of two levels – skin alterations (OR 6.29, 95% CI 4.21 to 9.40; p< 0.0001) and category 1
pressure ulcer (OR 27.34, 95% CI 18.5 to 40.4; p< 0.0001) – and the presence of pain at baseline on a
healthy, altered or category 1 skin site (OR 8.68, 95% CI 6.30 to 11.97; p< 0.0001). The following factors
were not statistically significant: age, diabetic status, history of previous weight loss, Braden mobility
subscale score, setting and analgesic use. Therefore, there was no evidence of an association between
these factors and the odds of developing a new category 2 or above pressure ulcer at the skin site level.
The final multivariable model obtained from the variable selection carried out included two variables: skin status,
which consisted of two levels – skin alterations (OR 4.65, 95% CI 3.01 to 7.18; p< 0.0001) and category 1
pressure ulcer (OR 17.30, 95% CI 11.09 to 27.00; p< 0.0001) – and the presence of pain on a healthy, altered
or category 1 skin site (OR 2.25, 95% CI 1.53 to 3.29; p< 0.0001; Table 24). Therefore, there was significant
evidence that skin status is a risk factor for developing a category 2 or above pressure ulcer after adjusting for
between-patient variation. After adjusting for skin status and between-patient variation there was strong
evidence that the presence of pain is a further risk factor for developing a category 2 or above pressure ulcer.
TABLE 21 Baseline skin and pain assessment for all skin sites
Skin classification Pain yes, n (%) Pain no, n (%) Missing, n (%) Total, n (%)
Normal skin 390 (6.4) 5700 (93.5) 6 (0.1) 6096 (77.5)
Skin alterations 342 (40.3) 504 (59.4) 3 (0.4) 849 (10.8)
Category 1 351 (63.1) 205 (36.9) 0 (0.0) 556 (7.1)
Category 2 116 (78.4) 32 (21.6) 0 (0.0) 148 (1.9)
Category 3 13 (100.0) 0 (0.0) 0 (0.0) 13 (0.2)
Category 4 3 (75.0) 1 (25.0) 0 (0.0) 4 (0.1)
Unstageable 6 (85.7) 1 (14.3) 0 (0.0) 7 (0.1)
Unable to assess 6 (7.6) 52 (65.8) 21 (26.6) 79 (1.0)
Not applicable 2 (2.3) 26 (29.9) 59 (67.8) 87 (1.1)
Other wound 0 (0.0) 6 (85.7) 1 (14.3) 7 (0.1)
Classification missing 0 (0.0) 0 (0.0) 17 (100.0) 17 (0.2)
Total 1229 (15.6) 6527 (83.0) 107 (1.4) 7863 (100.0)
Note
602 patients. Each patient had 13 skin assessments and there were 37 ‘other’ sites assessed. The overall total therefore
corresponds to (602 × 13)+ 37= 7863 skin assessments.
TABLE 22 Pain and skin status by category 2 or above pressure ulcer development
Variable
New PU (n= 223, 3.0%),
n (%)
No new PU (n= 7260, 97%),
n (%)
Total (n= 7483),
n (%)
Pain
Yes 111 (10.3) 966 (89.7) 1077 (14.4)
No 112 (1.7) 6294 (98.3) 6406 (85.6)
Skin status
Healthy intact skin 68 (1.1) 6014 (98.9) 6082 (81.3)
Alterations to intact skin 54 (6.4) 792 (93.6) 846 (11.3)
Category 1 101 (18.2) 454 (81.8) 555 (7.4)
PU, pressure ulcer.
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Discussion
The prevalence studies are the first to assess pressure area-related pain in large representative hospital and
community populations. In the hospital population, of 2010 patients asked the pain screening questions,
327 indicated that they had pain on one or more pressure areas (skin site not recorded), providing an
overall unattributed pressure area-related pain prevalence of 16.3%. The importance of the inclusion of
patients without pressure ulcers is emphasised by the finding that 12.6% (223/1769) of hospital patients
without pressure ulcers reported pressure area-related pain.35 There are no other published reports of
this type of pain. The prevalence of unattributed pressure area-related pain in patients with pressure ulcers
was 43.2% (104/241) in hospital patients and 75.6% (133/176) in community patients. This is similar
to the results of other smaller studies reporting pressure ulcer pain prevalence, with prevalence ranging
from 37% to 100%,40–43,66,67 and is comparable to the prevalence of pain in other chronic wounds in
European populations.43,68–70
The detailed pain assessment of 160 hospital and 37 community patients identified pressure area-related
pain on skin areas assessed as normal as well as on all grades of pressure ulcer. ‘The distribution of pain
TABLE 23 Pain cohort study: results of the univariate analysis of the odds of developing a category 2 or above
pressure ulcer at the skin site level
Covariate OR 95% CI p-value
Age (continuous) 1.01 0.99 to 1.02 0.4808
Diabetic statusa (no vs. yes) 0.81 0.54 to 1.21 0.3070
History of weight lossb (no vs. yes) 1.03 0.68 to 1.57 0.8914
Braden mobility subscale score (1 or 2 vs. 3 or 4) 1.14 0.80 to 1.64 0.4714
Skin status (reference= healthy skin)
Skin alterations 6.29 4.21 to 9.40 < 0.0001
Category 1 PU 27.34 18.5 to 40.4 < 0.0001
Setting (acute vs. community) 0.91 0.63 to 1.32 0.6148
Analgesic use (no vs. yes) 1.33 1.74 to 2.39 0.3350
Pain on healthy, altered or category 1 skin site (yes vs. no) 8.68 6.30 to 11.97 < 0.0001
PU, pressure ulcer.
a Missing diabetic status set to ‘no’ for one missing patient.
b Missing history of weight loss status set to ‘no’ for one missing patient.
TABLE 24 Pain cohort study: final model for the odds of developing a category 2 or above pressure ulcer at the
skin site level (n= 602, n= 7483 skin sites)
Covariate OR 95% CI p-value
Skin status (reference= healthy skin)
Skin alterations 4.65 3.01 to 7.18 < 0.0001
Category 1 PU 17.30 11.09 to 27.00 < 0.0001
Pain (yes vs. no) 2.25 1.53 to 3.29 < 0.0001
PU, pressure ulcer.
Note
602 patients. There were a total of 7483 evaluable skin sites in the analysis (a skin site was considered evaluable if it was
observed as being healthy, altered or category 1 at baseline and had at least one follow-up assessment (i.e. the end point
could be derived for that skin site).
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intensity measured using a 0–10 nominal rating scale was similar for all grades, which is consistent with
pain intensity in other disease states, where the severity of illness is not necessarily related to patients’
reports of pain intensity.68,71
It is noteworthy that in the community patient population, none of the patients reported pressure area
related pain on a skin site assessed as normal’45 whereas, of the 75 hospital detailed pain assessment
patients with a pressure ulcer, 30 (40%) did report pressure area-related pain on a skin site assessed
as normal.
The dominant type of pain in hospital patients was inflammatory pain (70.3% torso and 60.3% limb skin
sites) whereas in the community patients neuropathic pain was dominant (54.5% torso and 61.1% limb
skin sites). This is consistent with the prevalence of neuropathic pain in leg ulcer patients. For example, in a
prospective longitudinal cohort study of painful leg ulceration, 43.5% of respondents (n= 96) reported
neuropathic pain.68 It is noteworthy that both inflammatory and neuropathic pain was observed for normal
skin and all grades of pressure ulcer for both hospital and community patients. We did not record the
duration of the pain or pressure ulcer and this may be related to the type of pain and is an area of
further study.
The ‘limitations of the overall pain prevalence estimate of unattributed pain are that: skin assessment data
were recorded by clinical staff, which has inherent limitations37,56,72 and may have resulted in over or
under-reporting of pressure ulcers or misclassification of Grade or extent of tissue damage, particularly at
Grade 1, which is prone to misclassification;’45,56 the pain prevalence data were recorded at the patient
level and not by skin site; we were not able to record pain treatment and therefore the quality of pain
management may differ between wards/hospital/community settings and impact on pain reports; and the
methodology used meant that a significant proportion of hospital (40.8%) and community (38.7%)
patients were not able to participate in the pain prevalence study because of illness (too unwell, end of
life, unconscious), difficulty in assessing pain (confused or communication difficulty) or unavailability
(unable to disturb, off the ward, in isolation).
Prevalence studies provide a good measure of the extent of chronic long-lived disease and are less reliable
in the measurement of short-lived disease. Both pressure ulcers and pain can be both long-lived and
short-lived and as such there are general limitations associated with prevalence estimates for these
conditions. In the hospital population, pressure ulcer prevalence rates are affected by staff training and
awareness, admission/discharge rates and case mix, and in the interpretation of hospital prevalence rates
these factors need to be taken into account.2,73–75
‘Prevalence studies in the community are challenging and time-consuming to undertake. Few have been
undertaken4,76,77 and the true extent of the pressure ulcer problem at a population level is not well
quantified. In this study, in two localities in the North of England we report a prevalence . . . of 0.77
people with pressure ulcers per 1000 adult population [locality 1] and . . . 0.40 per 1000 adult population
[locality 2]. The prevalence rates are similar to those reported by Vowden and Vowden,4 who reported a
community prevalence rate of 0.66 per adult population.’47
‘Several previous studies have reviewed the methods for data collection for determining pressure ulcer
prevalence and incidence.2,73,74 This study provides further evidence that different methods used for case
ascertainment result in potentially important variations in the prevalence reported. Locality 1 collected
data for a much larger group of patients where pressure ulcer status not considered prior to assessment,
whereas locality 2 collected data only for patients known to have a pressure ulcer.’47 A notable difference
between the two localities resulting from the different method applied was the location of patients
assessed. In locality 1, 50.3% of patients were in nursing homes, whereas in locality 2 only 4.9%
of patients were in nursing homes. ‘As indicated in the methodology section, in the UK, nursing homes
would normally treat patients with pressure ulcers themselves and only patients with complex wounds
are referred to the community nursing service.’48 In locality 1 all nursing home residents were included
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in the prevalence study whereas in locality 2 only those patients known to community nursing services
were included, ‘highlighting the importance of clear methodological descriptions and effective case
ascertainment for study comparison and establishing the true prevalence of pressure ulcers’ in a
community setting.48
Our sample size estimates were based on limited pressure ulcer pain prevalence data,2,15 with no available data
for grade 1 or normal skin. The prevalence rates observed were much higher than those estimated in patients
with grade 1 and normal skin. In addition, the sample size calculation planned for the inclusion of 6000
patients from two community NHS trusts. However, this was an approximation as estimating the denominator
population for these trusts was difficult as no data were available regarding the number of patients on the
community nursing caseload. As a result of this and because of differences in the implementation of pressure
ulcer prevalence audit methods in the two localities, the number of community patients included in the
prevalence audit was significantly less than planned: locality 1 audited 1680 patients including those on the
community nursing caseload and in nursing homes, residential homes and palliative care environments,
whereas locality 2 audited only those 102 patients who were on the community nursing caseload and were
known to have a pressure ulcer. In addition, both community trusts asked the pain questions only of those
patients with pressure ulcers, whereas in the acute trusts the pain questions were asked of all patients,
regardless of whether or not they had a pressure ulcer. As a result, 2010 patients were asked the pain
questions in the acute trusts compared with 176 in the community trusts. Because of the differing
methodologies employed by the acute and community trusts, the two populations cannot be combined and
therefore the confidence boundaries for the overall unattributed pressure area-related pain prevalence
provided in the sample size calculation have been updated post hoc for the two settings. The hospital patient
population of 2010 patients allows us to estimate the unattributed pressure area-related pain prevalence of
16.3% to within ±1.7%. The community sample of 176 patients allows us to estimate the unattributed
pressure area-related pain prevalence of 75.6% to within ±6.4%.
Cohort study
The pain cohort study is the first risk factor study to investigate the role of pain as a factor independently
predictive of subsequent category 2 (or above) pressure ulcer development. It found that pain was an
independent predictor of category 2 (or above) pressure ulcer development in high-risk hospital and
community patients with acute illness.
Building on our previous research in the field37,60,72,78 and in our attempts to maximise the potential event
rate and so minimise the required sample size, the pressure ulcer incidence rate of 25.2% was higher than
predicted. This was achieved by the inclusion of patients with evidence of acute illness and at ‘high risk’,
where ‘high risk’ defined as one or more of the following: bedfast/chairfast and completely immobile/very
limited mobility;51 localised skin pain on any pressure area skin site; and category 1 pressure ulcer on any
pressure area skin site. The incidence rate is comparable to that in other reports of the incidence of
category 2 and above pressure ulcers. In our systematic review of risk factor studies46 (see Chapter 5),
19 studies reported incidence rates for grade/stage 2 and above pressure ulcers, ranging from 10.1%
to 45.7% in heterogeneous patient populations. Of importance in terms of generalisability was our
recruitment of community patients. The observed incidence rate in the community patient population
was 26.3%, although it is noteworthy that the majority of ‘community’ patients were recruited from
rehabilitation units, with only small numbers recruited in the home.
The age of our patient population was higher than expected from our previous prospective research,40–43
with a median of 81 years and 31.2% of those recruited aged > 85 years. The age profile is, however,
consistent with the community pressure ulcer prevalence population (median 81 years; see Pain prevalence
in hospital and community populations, Results) and suggests that the population is representative of
high-risk patients.
An unexpected finding was the high proportion of patients (77.1%) who reported pain at baseline.
Although a number of these patients also had category 1 pressure ulcers, the extent of the problem was
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underestimated in our sample size estimate (the sample size assumption was that 10% of patients would
report pain at baseline). The sample size calculation assumed that at inception 15% of patients would
have pain and that those would be an incidence rate of 10% in those patients with pain at baseline and
24.4% in those without pain. However, the incidence rate for those who reported pressure area pain
on skin assessed clinically as normal, altered or category 1 was observed to be 28.0% and the incidence
rate for those patients with no pain at baseline was observed to be 15.9%. Assuming an incidence of
28.0% for those with pain and 15.9% for those without pain, and that the proportion of patients with
pain is equal to 77.1%, we would have required a reduced sample size of 535 patients to detect a
difference between those with pain and those without pain at baseline with 80% power. Therefore, based
on the data observed, we had an increase in power to 84% to detect a statistically significant difference in
pressure ulcer incidence between those with pain and those without pain at baseline.
There was significant evidence that the presence of pain at a skin site is an independent predictor for
developing a category 2 or above pressure ulcer, after adjusting for skin status (i.e. healthy, skin
alterations, category 1 pressure ulcer) at baseline, across all four multivariable models.
At a patient level, the presence of pain on at least one skin site (healthy, altered or category 1 skin status)
increased the odds of developing a category 2 or above pressure ulcer by 30 days of follow-up (primary
end point) and also reduced the time to develop a category 2 or above ulcer compared with if pain is not
present after adjusting for skin status.
At a skin-site level, the presence of pain is a predictor for developing a category 2 or above pressure ulcer
on the same skin site by 30 days of follow-up, after adjusting for skin status and between-patient variation.
The other risk factors that emerged throughout the multivariable analyses included the presence of a
category 1 pressure ulcer at baseline, consistent with all four previous studies,37,60,79,80 which have included
this as a variable in multivariable modelling. The presence of alterations to intact skin has also emerged in
multivariable modelling in 9 of 10 studies where it has been included as a variable46 (see Chapter 5,
Research overview).
The study was designed to incorporate key quality criteria for the conduct and reporting of risk factor/
prognostic factor studies81–89 to promote generalisability and minimise bias. The study design, including
an a priori sample size estimate and data monitoring, ensured that there was a sufficient number of events
to undertake robust statistical modelling incorporating key risk factors determined through systematic
review and the development of a conceptual framework. The primary outcome, the development of
a new category 2 or above pressure ulcer, provides the most reliable outcome measure.56 Clear inclusion
and exclusion criteria were applied, screening logs were maintained to assess the generalisability of the
study population and trained clinical research nurses undertook all baseline and follow-up assessments
providing high-quality data and minimising loss to follow-up. Patients were recruited from both acute
and community settings, which were representative of UK ‘standard care’. All centres had pressure ulcer
prevention and management policies and guidelines in place, including risk assessment, mattress provision,
turning (and so on). The majority of patients received the recommended National Institute for Health and
Care Excellence (NICE) standard mattress provision of either a high-specification foam mattress or an
alternating pressure mattress15 and members of the research team did not alter standard care provision
as determined by the local ward/community teams, who remained responsible for clinical care.
The limitations of the study included a lack of blinded outcome assessment. This could have been achieved if
baseline and follow-up assessments had been undertaken by two different research nurses; however, there was
not the funding or capacity within the tissue viability teams for this approach. It is feasible that the research
nurses could have introduced bias to the outcome assessment. The feasibility of using photography for
independent blind outcome assessment is currently being determined as part of the HTA programme-funded
PRESSURE 2 trial [for details see http://medhealth.leeds.ac.uk/info/423/skin/1717/pressure_2 (accessed
13 July 2015)].
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It is acknowledged that the patient population is not representative of the general NHS population
because of exclusion of patients who had cognition problems, patients who were very sick or terminally ill
and patients who either were unable to provide consent or it was considered unethical to approach.
However, as pain is a symptom of underlying inflammation and/or nerve damage we suggest that the
results are generalisable to the wider population and that efforts to assess pain, soreness and discomfort
are made for all patients using pain assessment methods established for this group of patients.90–92
It is also acknowledged that patients with darkly pigmented skin were under-represented in the study
population. As indicated above, however, as pain is a symptom of underlying inflammation and/or nerve
damage we suggest that the results are generalisable to the wider population.
Patient and public involvement in the pain workstream
As with all of the PURPOSE studies, high-level service user input has been present throughout via the
steering committee. The majority of study-specific involvement has focused on interpreting and
disseminating findings. The results of the pain studies were presented to PURSUN UK who reported that
the work echoed many of its members’ own experiences. PURSUN UK members felt that pain is an
important and often overlooked area and as such it is important that the results of this study are
disseminated to front-line health professionals. They gave the project team feedback from the service user
perspective on questions that remained unanswered, for example the lack of clear pain management
strategies for pressure ulcers and the difficulties of assessing pressure area pain in complex, at-risk patients.
Three PURSUN UK members with experience of pressure ulcer/pressure area pain have worked with the
PPI officer to develop written vignettes about their experiences. These narratives aim to illustrate the
importance of the pain studies and put the findings in a real-life context. The vignettes will be included in
a forthcoming publication, co-authored by three members of PURSUN UK and aimed at clinical nurses.
Conclusion
A major advantage of prevalence surveys is that they provide a general estimate of the extent of a problem.
The results of this study provide a very strong indication that pressure area-related pain affects a significant
minority of patients without pressure ulcers in hospital populations and that a substantial proportion of
patients with pressure ulcers report pain. Pain severity is not related to severity of the ulcer and both
inflammatory and neuropathic pain are observed. We nested the pain prevalence studies within routine
pressure ulcer prevalence audits and in the community setting the case-finding method used was not
standard. We observed different prevalence rates in the two localities, highlighting the importance of clear
methodological descriptions and effective case ascertainment for study comparison and in establishing the
true prevalence of pressure ulcers in a community setting.
We have also established that the presence of pain (on skin areas assessed as healthy, altered but intact or
category 1) increases the probability of category 2 and above pressure ulcer development and accelerates
the time to ulcer development. This is an area of practice that requires improved assessment, incorporation
into risk assessment and treatment strategies to alleviate pain and reduce category 2 pressure
ulcer development.
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Chapter 4 Severe pressure ulcer study
Chapter written by Justin Keen, Susanne Coleman, Carol Dealey, Elizabeth McGinnis, Delia Muir,E Andrea Nelson, Malcolm Patterson, Lisa Pinkney, Nikki Stubbs, Lyn Wilson and Jane Nixon.
Abstract
Introduction: There is good evidence that pressure ulcer risks are associated with patients’ health status
or their behaviour. There is also suggestive evidence that the organisation of treatment and care can
influence patients’ risks. The principle research objective of this work package was to understand the ways
in which the organisational context influences the development of severe pressure ulcers. A second,
practical objective was to identify ways in which root cause analyses of reportable pressure ulcers could be
improved on, to maximise the chances of learning from them.
Methods: The severe pressure ulcer work package comprised three pieces of work: (1) a retrospective case
study based on eight patients who developed severe pressure ulcers; (2) a patient involvement workshop
with PURSUN UK; and (3) development of a methodology for root cause analyses of critical incidents.
Results: For seven of the eight patients in the retrospective case study the best explanation of the
evidence was that the general organisational context played a significant role in severe pressure ulcer
development. In four accounts specific events contributed to development. One patient’s severe pressure
ulcer was deemed to be unavoidable. Service users found the interactive workshop format, and the use of
a ‘simulated patient’ account within it, valuable. A methodology for root cause analysis, rooted in current
NHS practice but including novel components, can be used to improve the quality of the insights captured.
Conclusions: Severe pressure ulcers were more likely to develop in contexts characterised by one or more
of clinicians failing to listen to patients or carers, clinicians failing to recognise and respond to clear signs
that a patient had a pressure ulcer or was at risk of developing one, and services not being effectively
co-ordinated. Presenting research data in live and interactive formats can make the interpretation process
more engaging and accessible to service users and support meaningful dialogue between service users and
professionals. Current best NHS practice in root cause analyses of reportable pressure ulcers should be
augmented by interviews with patients and carers and by the construction of narratives based on key
events. Our findings suggest that there is a need to move away from identification of root causes and
towards broader explanations of events, based on identifying the ‘best fit’ between the available evidence
and the explanations available in the patient safety literature.
Background
There are two distinct ways of thinking about patients’ risks of developing pressure ulcers. The first is
based on the assumption that all pressure ulcer risks are associated with patients’ health status or their
behaviour. Clinicians should therefore focus on identifying patients who are at risk, assess the nature and
scale of their risks and design clinical interventions to reduce them.46 This approach, which highlights the
importance of risk assessment, informed our work on pain (see Chapter 3) and risk assessment (see
Chapter 5). The second way of thinking starts from a different assumption, which is that the quality of
treatment and care can also influence patients’ risks of developing pressure ulcers. Some environments
are riskier than others so that patients who are at risk are more likely to develop pressure ulcers in settings
where there is poor-quality treatment and care. The events at Mid Staffordshire NHS Foundation Trust,
where at one point dozens of pressure ulcers were being reported every month, help to underline the
significance of this point.93
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This study is rooted in the second way of thinking. It informs a number of Department of Health policies.
For example, category 2 or above pressure ulcers, as rated on the EPUAP/NPUAP 1–4 scale,1 are classed
as reportable incidents in official guidelines.94 Category 3 and 4 pressure ulcers have to be reported as
serious untoward incidents. Pressure ulcers are one of four patient safety indicators in the NHS Safety
Thermometer and there are incentive payments for avoiding pressure ulcers in the Commissioning for
Quality and Innovation (CQUIN) framework.95 The NHS has a ‘no avoidable pressure ulcers’ goal and, as a
result, pressure ulcer prevention is classed as a high-impact action for nursing and midwifery.96 Yet there is
limited evidence about the ways in which care processes influence the development of pressure ulcers and
severe pressure ulcers. This study therefore focuses on the ways in which care processes influence the
development of pressure ulcers by reconstructing events leading to the development of severe pressure
ulcers in eight patients.
Aims and objectives
To implement national policies and reduce the incidence of pressure ulcers, clinicians need to understand
how and why their actions increase or decrease the likelihood that patients will develop them. Our
principal research objective was, accordingly, to explain the influence of organisational context on the
development of pressure ulcers. Beyond this, we stated in the programme proposal that we would
investigate the implications of our findings for the conduct of root cause analyses. A second, practical
objective was therefore to identify ways in which root cause analyses of reportable pressure ulcers could
be improved on, to maximise the chances of learning from them.
Research overview
The severe pressure ulcer work package comprised three pieces of work. The first was an empirical study
designed to improve our understanding of the ways in which care processes influence the development
of severe pressure ulcers, in which we constructed detailed retrospective accounts of the development
of severe pressure ulcers in eight patients. The second presents the design and conduct of a patient
involvement workshop, drawing on one of the accounts from the empirical study. The third sets out the
development of a methodology for root cause analyses of reportable pressure ulcers.
Retrospective study of the development of severe
pressure ulcers
Aim
We undertook an empirical study designed to improve our understanding of the development of severe
pressure ulcers by constructing detailed retrospective accounts of the development of severe pressure
ulcers in eight patients.
Methods
Design
The research design was substantially influenced by two arguments. The first stemmed from discussions at
the start of the study. Although our principal objective concerned the effect of organisational context on
the development of severe pressure ulcers, we realised that we could not simply assume that a relationship
between the two existed and could be studied empirically. Indeed, the available empirical evidence is
limited, but the literature offers three distinct explanations,97,98 namely:
1. pressure ulcers develop following a mistake made by an individual clinician99,100
2. they develop as a result of a sequence of otherwise unconnected mistakes101–103
3. there are systemic weaknesses in the organisation and delivery of care, such that the regime is one in
which pressure ulcers are more likely to develop.104–106
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We decided that it would be necessary to discriminate between these candidate explanations to establish
whether, and how, the organisational context helped to explain the development of severe pressure ulcers
or alternatively played no role. We should also include two other logical possibilities, in order to identify their
role in explaining development or eliminate them from consideration, namely (1) the behaviour of clinicians
had no effect on the development of a pressure ulcer, which would have developed whatever they had
done, and (2) there was an alternative explanation, which had not previously been reported or hypothesised.
The second argument flowed from the nature of the domain that we were studying. Severe pressure ulcers
occur relatively rarely and can develop in a wide range of settings over periods of days or weeks. It is not
currently possible to predict who will develop them and who will not; it is only possible to identify people
who have already developed a severe pressure ulcer. A prospective study was therefore not feasible.
We opted to identify patients who had developed severe pressure ulcers and to reconstruct what had
happened to them. This led us to adopt a retrospective case study design. A process-tracing case study
method was used to capture the experiences of eight individuals who had developed severe pressure
ulcers.107 Accounts of their experiences were developed, which were then compared and contrasted to
identify common features and hence common explanations. The two arguments taken together led
us to develop a novel research design.
Setting
Eight patients were recruited in six NHS trusts in Yorkshire, England. Four patients’ accounts occurred
wholly or mainly in acute hospitals, three mainly in their own homes and one in a combination of a
community hospital and an acute hospital rehabilitation ward. The decision to recruit eight patients was
pragmatic: each account took approximately 4 months from initial interview to completion of analysis and
we were therefore able to complete eight accounts with the resources available to this study.
Eligibility
Inclusion criteria
The study method was piloted with the first patient, who presented with few comorbidities, on the basis
that the patient’s problems would be less likely to be confounded with organisational factors.
Subsequent patients were recruited from participating acute and community trusts if they:
l had a current or previous category 3 or 4 pressure ulcer
l were a hospital inpatient, hospital outpatient, intermediate care patient or community patient under
the care of community nursing services.
Recruitment was designed to maximise the variation and presentation of severe (category 3 and 4)
pressure ulcers, including anatomical site (e.g. heel, sacrum, buttocks).
Exclusion criteria
Patients were excluded if:
l it was considered ethically inappropriate to approach them, for example those whose death
was imminent
l they were unable to tell the story (narrative) of their experience.
Recruitment and consent
Participants were sampled partly to maximise the diversity of individuals and the contexts in which they
developed severe pressure ulcers and partly purposively (see Appendix 10). Eligible patients were identified by
members of the local tissue viability nurse teams at one of the six study sites in Yorkshire, England, who
informed them about the study and provided them with a study information leaflet and an ‘agree to be
contacted by the researcher’ form (see Appendix 11). Consent to participate was obtained from individuals
and, when appropriate, also from their main carers (see Appendix 12).
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Data collection
Data were collected by a field researcher (LP) with a non-clinical background from five sources, namely
interviews with individuals who had developed a severe pressure ulcer (and, when relevant, their main
carers), interviews with clinical and other staff who had been involved in their care, clinical records, other
documents relevant to the account such as critical incident reports, and relevant local policy documents
(e.g. on the conduct of skin risk assessments) (Figure 10, stage 1). A parallel review of patient notes was
undertaken by a tissue viability nurse at each study site.
Patients were interviewed first and invited to give their account of the reasons why, in their view, their
severe pressure ulcer had developed. Interviews were semistructured and lasted between 30 and
90 minutes. They were digitally recorded and transcribed.
The patient interview was used to direct the next phase of data collection, which involved accessing and
reviewing nursing, medical and therapist notes, clinical incident reports and other documents (e.g. staff
rotas for key periods of time in the patients’ accounts). An initial analysis of the documents was
undertaken and, on the basis of the analysis and the patient account, an initial interview schedule was
drawn up. The analysis was also used to identify members of staff who were likely to be able to provide
useful information about the development of the severe pressure ulcer. After the initial interviews, the
researcher discussed the emerging possible explanations with the site tissue viability nurse specialist and a
list of further interviewees was agreed. It is worth noting that, for this and subsequent analyses, the focus
was on understanding how severe pressure ulcers developed, but a range of contextual information was
provided in interviewees’ responses and in the documentation provided that could be used to discriminate
between the explanations identified earlier.
Stage 1
Initial analysis Document reviewStage 2
Stage 3 
Comparison
Edit account
Stage 4 Subgroup review
Stage 5
Reviews by chief investigator and independent
organisational psychologist
Data collection
Initial patient-
informed account
Specialist nurse
report
Revised account
Revised account and
summative nursing
judgement
Final ‘true and fair’
account and summative
 judgements
FIGURE 10 Analysis and review of individual accounts.
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Interviewees for hospital-based accounts included matrons, ward nurses, health-care assistants, ward
clerks, ward managers, physiotherapists and consultants. In community settings, interviewees included
district nurses, home care assistants and therapists (Table 25). At least seven interviews were conducted for
each account except for the eighth account, in which an individual developed a severe pressure ulcer in
her own home after a fall and few health professionals had useful information about her circumstances.
Few professionals were directly involved in identification of and response to her ulcer, and comprehensive
notes were available about her assessment and treatment only once she came into contact with health
services. In total, 70 interviews were conducted across the eight accounts. Judgements were made about
the time period that each account needed to cover and the extent of the documentation that was needed.
In some instances, both were extended when it became clear that the histories were longer or more
complicated than at first appeared.
Analysis
Transcripts of patients’ interviews were reviewed and key passages that set out their accounts of events
were included verbatim at the start of each account. This was done partly because the patient (and in
some cases also the carer) was the only person who had been present throughout and partly to guard
against losing sight of the ‘patient’s voice’ in subsequent analysis. A Microsoft Access® 2010 database
(Microsoft Corporation, Redmond, WA, USA) was then created for each account and used to organise
key decisions and actions into a chronological sequence. Patient- and carer-derived data were recorded in
one column, clinician interview data in a second and clinical record and other documentary sources in
a third (see Figure 10, stage 2). The presentation of data in parallel columns made it possible to develop a
chronological account of events, identify consistencies and inconsistencies between different data sources
and assess the ‘strength’ of evidence available about key events, reflected in the number and quality of
sources. These data were used as the basis of a single, provisional timeline of events.
The site principal investigator, who in each case was a nurse with a specialist interest in tissue viability,
undertook a parallel review, based solely on available patient records and on other available documentation,
including local guidelines and critical incident reports. The review followed the guidance for reviews of critical
incidents in the NHS.94 The investigator wrote a report, identifying key decisions and actions in chronological
order, including departures from local guidelines. The field researcher and site principal investigator then met
and compared their accounts, identifying consistencies and inconsistencies (e.g. actions that the nurse judged
as important that were not included in the researcher’s account). The timeline in each initial account was
revised in light of additional facts or insights generated (see Figure 10, stage 3).
Refinement of the accounts
The initial summaries of each account, supported by transcripts of all of the interviews conducted, were
reviewed by a subgroup of nursing members of the research team, one independent hospital-based and
one independent community-based tissue viability nurse specialist and one of the co-chief investigators (JN)
(see Figure 10, stage 4). The subgroups met and reviewed the summaries and transcripts, identifying points
where, in their professional opinion, there was a departure from ‘good usual care’ (e.g. category 2
pressure ulcer was recorded in the nursing notes but no additional action to treat the ulcer or prevent
deterioration was reported). The meetings were recorded and transcribed.
The subgroups were asked to make summative judgements about the best explanation for the
development of a severe pressure ulcer for each account. The method for this stage of the study drew on
Yin’s108 strategy for eliminating hypotheses in case study research. The subgroups were invited to select
one or more of the following five explanations for the development of a severe pressure ulcer:
1. it could not have been avoided
2. there was a single precipitating event
3. there was a sequence of precipitating events
4. the organisational context made development more likely
5. there was another explanation, not covered by the first four.
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The second, third and fourth explanations were derived pragmatically from the literature on patient safety,
with each representing a major class of explanation for adverse events.109,110 The other two – the first and
fifth explanations – were logical alternatives to the first three (i.e. the organisation of care played no role
and there was an explanation that was not predicted by any of the three theories). We did not define
key terms such as ‘precipitating event’ and ‘organisational context’ on the basis that subgroup members
were expected to articulate the reasons why they opted for different explanations and in so doing would
provide their own definitions in each account.
Viewed in the context of patient safety studies, this approach is novel, taking the study away from a
narrow focus on root causes (i.e. only allowing causal explanations of events to be considered) and
towards the broader classes of explanations in the safety literature. There is a technical point here, which is
that the explanations are not based on causal relationships but on identifying the ‘best fit’ between the
available data and one of the explanations.
The discussion leading up to the summative judgements, and the judgements themselves, were included in
the revised accounts. The accounts at this stage therefore had three discrete sections, namely the patient’s
account, the interpreted timeline and nurses’ summative judgement. The subgroups sometimes made
queries about details of the accounts. After each meeting the queries were checked by going back to
primary data sources and accounts were amended as appropriate.
The last two stages of the analysis were reviews of the individual accounts by a non-clinical co-chief
investigator (JK) and then by an organisational psychologist (MP) who had not been involved in the earlier
stages (see Figure 10, stage 5). The reviews focused on the coherence of each account (i.e. the extent to
which the patient’s explanation and/or the nurses’ judgements made sense of the available evidence).
In the final step in the analysis, the accounts were compared with one another to identify themes that
were common across the accounts, even though the details of the individuals, their pressure ulcers and the
care settings varied widely. The themes were analysed inductively to develop a mid-range theory of the
reasons why patients develop severe pressure ulcers.109
Results
The study demonstrates that it is possible to develop detailed retrospective accounts of events and to use them
to judge which of five possible explanations best fits the available evidence. The large volumes of data collected
and included in the timeline appear to have minimised problems that might have arisen as a result of ‘missing
data’. However, as we note in the discussion, the results may still be subject to a number of biases.
The eight accounts
The eight patients were selected, in part, to maximise diversity (Table 26). Unsurprisingly, then, there were
marked differences in the details of their treatment and care and different explanations were offered by
those interviewed for the development of severe pressure ulcers.
Seven of the eight – the exception being number 8 – exhibited widely recognised risk factors and had
complex treatment and care needs. In a number of accounts some staff who were interviewed blamed the
patients, on the basis that they had not complied with advice on managing their risks (e.g. shifting position
regularly). But patients themselves, in the same accounts, generally pointed to specific actions or omissions,
such as the failure to be turned regularly overnight, to be provided with a specialised mattress or to act on
patients’ comments about their own risks.
Participants approached interviews in very different ways. Some patients and carers were very clear in their own
minds about what had gone wrong whereas others were very reluctant to criticise any aspect of their care.
Similarly, some accounts involved individuals moving between wards, or an account developed against a
background of a major ward reorganisation. The significance attributed to these moves varied, including, for
example, the failure to transfer notes with patients, which placed receiving staff at a disadvantage, and staff
feeling harassed because they were working in an unfamiliar environment during a reorganisation.
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Elimination of hypotheses
The diverse group of individuals all had the same outcome: a severe pressure ulcer. In one account
(number 8), the review teams judged that the development of the pressure ulcer was unavoidable,
because the individual concerned developed a severe pressure ulcer in her own home, before any health
professional saw her. In another account (number 3) there was a single precipitating event and in three
other accounts (numbers 2, 4 and 6) there was a sequence of events. But the clinical subgroup and
subsequent reviewers all judged that the organisational context made development more likely in seven
of the eight accounts (Table 27). It is possible that the organisational context made the ‘key events’ in
accounts 2–4 and 6 more likely, although we cannot make causal inferences with any confidence on
the basis of our evidence. The evidence suggests that the term ‘organisational context’ covers two
distinct concepts. The first concerns the prevailing cultures in the settings where severe pressure ulcers
developed (see Cross-patient themes). The second relates to what one might term the functional
characteristics of those settings, particularly nursing staff shortages, staff who (justifiably or not) did not
believe that they had enough time for proper treatment and care and wider organisational issues,
including contemporaneous reconfigurations of services in four of the accounts.
TABLE 26 Individuals and settings
Account Individual Setting
1 38-year-old woman with paraplegia Acute hospital, surgical ward
2 65-year-old woman with a long-term chronic neurological condition and
undiagnosed infection
Acute hospital, medical ward
3 75-year-old man with multiple chronic health problems and acute infection Community hospital,
rehabilitation ward
4 37-year-old woman with a long-term degenerative congenital neurological
condition
At home
5 90-year-old man with multiple chronic health problems and undiagnosed
acute illness
Acute hospital, surgical ward
6 39-year-old woman in hospital for acute undiagnosed postoperative
surgical complications
Acute hospital, surgical ward
7 65-year-old man with quadriplegia At home, respite care and acute
hospital
8 89-year-old woman who fell at home At home
TABLE 27 Summative judgements by account
Account Unavoidable
Single/isolated
event
Sequence of
events
Environment made development
more likely
Other
explanation
1 ✓
2 ✓ ✓
3 ✓ ✓
4 ✓ ✓
5 ✓
6 ✓ ✓
7 ✓
8 ✓
SEVERE PRESSURE ULCER STUDY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
62
Cross-patient themes
The process of eliminating hypotheses, and the analysis of common themes across the eight individuals,
led to the identification of three broad themes. First, the ‘voices’ of those who developed severe pressure
ulcers, and of their carers when they were involved, were not heard by staff. As noted earlier, the
individuals themselves behaved differently and had different relationships with clinical staff, but failures to
heed information were evident in several accounts. There were examples of patients making repeated
appeals for pain and discomfort to be addressed and expressing concerns about their own well-being that
were not heeded over periods of hours or even days. In some instances, these appeals seem to have been
dismissed by staff, that is, they were heard but were not taken seriously. Patients were also blamed for the
development of their pressure ulcers on the basis that they did not comply with instructions that they were
given, and were branded as ‘difficult’, even when they had a cognitive impairment.
Second, there were failures to recognise and act on warning signs. Risk assessments were not undertaken
when they should have been and, in some cases, they were undertaken only several days after admission
to an acute hospital ward. Evidence of pre-existing clinical risks in records was not acted on in six of the
seven cases in which the environment was judged to have made development more likely. Action was not
taken promptly when overt evidence, including the presence of a category 2 pressure ulcer, was identified.
In interviews, there were a number of instances of staff blaming colleagues for these failures. Conversely,
there was evidence of poor documentation, so that adherence with patients’ care plans was not recorded
and, in some instances, direct evidence of skin redness or a pressure ulcer was not recorded. Some
health-care assistants, who provided direct care, observed that they lacked the appropriate training to
identify and record risks or were not allowed to record them.
Third, there were co-ordination failures, between patients, carers and staff, between staff in the same
setting, between staff in different settings in the same organisation (e.g. two wards) and between staff in
different organisations. Sometimes this was manifested as interprofessional communication failure and
sometimes there was poor communication between the same professional groups in two locations. One
example of the latter came in a postoperative setting where risks were not properly communicated
between the anaesthetic recovery unit and the postoperative ward. In other accounts, records were not
moved with an individual so that key information was not available in a new setting. Again, in staff
interviews these problems were often recognised but in contexts in which interviewees were defensive,
tending to blame others rather than taking responsibility for their individual or collective actions.
It would be possible to interpret these co-ordination failures as clear evidence of failure by individuals or
teams. But there is a corollary to this point: nurses and health-care assistants, in particular, could find
themselves working in conditions in which they had limited information about individuals and their risks
(e.g. patients had an unknown diagnosis) or in which records had not travelled with a patient from
another location. It is possible, therefore, that individual members of staff behaved reasonably in the
contexts in which they found themselves; the problems lay more with the overall co-ordination of
treatment and care.
The larger and broader finding – the mid-range theory arising from the findings – is that individuals
developed severe pressure ulcers in environments where there were problems with the prevailing culture.
This cultural explanation binds together the otherwise separate points made above. In most accounts there
was a combination of problems – some staff blaming colleagues or describing patients as ‘difficult’, poor
documentation and failures to act on repeated clear warning signs (i.e. to step up care provision when a
superficial pressure ulcer was observed), so that a severe pressure ulcer was ‘allowed’ to develop. In these
contexts responsibilities were not clear and staff interviews pointed to problems with team working,
extending beyond the specific accounts that we were producing.
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Discussion
This study sought to improve our understanding of the ways in which the organisational context contributes
to the development of severe pressure ulcers and in doing so to discriminate between alternative
explanations for their development in the research literature. The principal explanation is that severe
pressure ulcers are more likely to develop in particular organisational contexts. The contexts were
characterised by one or more of (1) clinicians failing to listen to patients’ or carers’ observations about their
risks or the quality of their treatment and care, (2) clinicians failing to recognise and respond to clear signs
that a patient had a pressure ulcer or was at risk of developing one and (3) services not being effectively
co-ordinated. These can all be interpreted as failures in the governance of the services in the
settings studied.
As noted in the methods section the study was designed in significant part to minimise biases in data
collection and analysis. The study suggests that a novel method, based on tracing back the course of
events retrospectively from a known outcome, can be used to reconstruct key events. The resulting
accounts can be subjected to detailed review and used to discriminate between alternative explanations
for those events, in the process preserving the ‘voices’ of the individuals affected. That said, it is important
to stress that there are a number of sources of bias, starting with selection bias: although the sampling
strategy maximised diversity, the eight accounts are of individuals who were willing and able to consent to
participate. The initial presentation of the timelines and the backgrounds of the analysts and reviewers
are also potential sources of bias. A study team with a different clinical or disciplinary background might
have arrived at different judgements, for example a team with a background in human factors psychology
might have placed greater weight on single events or sequences of events. Using a retrospective design,
there is also a risk of hindsight bias, particularly in terms of reviewers assuming that staff must have
known more than they actually did and should therefore have acted differently.110 The sequential and
iterative review process has, we hope, served to minimise these biases but we cannot say that they have
been eliminated.
We can place our findings in the context of the patient safety literature. Reason111 points out that
investigations of accidents, across many industries, have changed significantly over the last 50 years. An
early focus on equipment failure gave way, in the 1970s and 1980s, to a focus on human error and then
more recently to accounts that focused on systems and cultural issues. In spite of this, many patient safety
studies today focus on explanations based on narrowly defined human factors and relatively few focus on
the wider organisational context.112 The findings reported here do not support the kinds of explanation
that might have been advanced in the first two periods or by researchers focusing on human factors in
clinical decision-making today. They are, though, consistent with explanations that emphasise systems and
culture. This point is worth emphasising: our findings suggest that there is a need to move away from
identification of root causes and towards broader explanations of events, based on identifying the ‘best fit’
between the available evidence and the explanations available in the patient safety literature.
As we noted earlier, explanations tend to emphasise either systems-based or cultural explanations. The
results of this study suggest that, for people who developed severe pressure ulcers, both were important.
In relation to systems-based explanations, the evidence about the poor co-ordination of services is broadly
consistent with the Institute of Medicine’s arguments in To Err Is Human, namely that many safety failures
are essentially system failures.113 Drawing on the work of Perrow110 and others, the Institute argued that
accidents are more likely in systems that are inherently complex – having many interconnected elements.
The findings in this study support the observation that there were co-ordination failures between services
that were loosely coupled with one another (i.e. that are managed independently but need to co-ordinate
with one another). For example, there were communication failures between wards at times when there
were major ward reorganisations, so that key information was not passed on. Similarly, one of the
community-based accounts revealed that the individual was in receipt of a hospital service that community
staff were unaware of and hence could not take into account in risk assessment or care planning.
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The findings cannot be wholly explained as co-ordination failures. The failure to listen properly to
patients – and even dismissing their concerns – and to act when there was a superficial pressure ulcer
present emphasises the importance of prevailing cultural norms. The evidence suggests that the
environments where severe pressure ulcers developed were ones where staff were under time pressure,
where there were problematic relationships between staff groups and where staff were defensive
and prepared to attribute failures to colleagues or to the ‘difficult’ behaviour of patients. Clinicians adopted
risky work routines that were not appropriate for the vulnerable patients who were in their care. Severe
pressure ulcers developed in contexts in which risky practices had become the norm – in which there was
normalisation of deviance.114 This resonates with wider concerns about the culture in parts of the NHS in
England, where staff have been defensive and quick to blame others.46 The implication is that the effective
prevention of severe pressure ulcers requires staff to adopt appropriate behavioural norms, including
effective communication with patients, a commitment to the thorough assessment of risks and prompt
action when things go wrong.
Finally, we have noted that there were often discrepancies between patient accounts, staff interviews and
records. No one source provided all of the key information needed to understand what had happened
and, as noted, accounts could conflict with another. This provides a clue about a potentially important
weakness of existing root cause analysis processes. At present, NHS guidance recommends reviews of
clinical records and interviews with staff but not interviews with patients and carers, without whose
testimony some of the accounts would have been incomplete and might well have been interpreted
wrongly, leading to the wrong conclusions and hence the wrong remedial interventions.
Patient and public involvement
In Chapter 2 we described the creation of PURSUN UK. Members of PURSUN UK were invited to contribute
to the interpretation of some of the findings from the retrospective study (see Retrospective study of the
development of severe pressure ulcers). As we noted there, the evidence and interpretations provided by
patients who had developed severe pressure ulcers proved to be important in the analysis. Patients and
their carers were the only people who were present throughout; clinicians could be aware only of parts of
each account. There was, though, a risk that the analysis, in ensuring that the accounts were accurate and
coherent from a nursing perspective, might lose sight of patients’ and carers’ viewpoints. We therefore
wanted to establish whether or not our accounts were ‘true and fair’ as perceived by patients with
experience of having pressure ulcers.
Patients have only rarely been directly involved in the interpretation of research evidence, as opposed to
being sources of evidence, in health services research.115 A recent review of the literature on PPI found that
involvement activities tended to focus on the early stages of research, such as identifying research priorities
and aspects of study design. Only six studies were identified as having significant PPI in analysis
or interpretation.26
Aim and objectives
To design and conduct a patient involvement workshop, drawing on one of the accounts from the
empirical study. The workshop had two distinct purposes:
1. to assess the face validity of the account from the point of view of a group of service users
2. to disseminate the findings of the project to those service users.
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Methods
Design: Pressure Ulcer Research Service User Network UK workshop model
We organised a workshop that was developed and facilitated by the PURPOSE PPI officer, the severe
pressure ulcer study field researcher and one member of PURSUN UK. The workshop was designed along
the broad lines of a public enquiry – albeit a benign one – in which participants would be invited to act as
‘expert witnesses’ in a case that was presented to them.
Three types of material were prepared before the workshop. First, one patient’s account of her health
problem and treatment was used to create a brief for a simulated patient. The PURSUN UK member with
specialist expertise in health-related role play took on the role of the patient from the case. The researcher
conducting the inquiry then interviewed the simulated patient about their experiences. This was presented
live at the workshop. Various simulated patient models have been used in the UK since the late 1970s,
typically in communication skills training or assessment for health professionals.32 The approach was
adapted here for use in a research context. Second, professionals’ accounts of events were filmed and
edited into short videos. Here, actors were given a brief, prepared by the workshop facilitators, and asked
to improvise a piece to camera (they did not read from a transcript, in part to avoid using verbatim quotes,
which might have led to the patient being identified). Third, a visual timeline of events was presented
using Prezi software (Prezi, Budapest).
The workshop was held on 17 May 2012 in Leeds. It was attended by nine members of PURSUN UK,
six members of the research project team and two NHS PPI managers.
Workshop evaluation
The workshop was, as far as we were aware, innovative and we were unsure how successful it would be.
We therefore decided to evaluate it. Five participants took part in videoed interviews and one further
audio-recorded interview was carried out by the PURPOSE PPI officer. The interviews took place both
during the workshop, to provide immediate reactions, and afterwards, giving participants time to reflect
before commenting. Three participants also chose to provide written feedback. Themes from the
interviews and written feedback were then collated by the PURPOSE PPI officer. Participants were also
offered the opportunity to provide anonymous feedback through a neutral third party but in the event this
option was not used. Clips from the videoed interviews are available at http://youtu.be/bgg6zkbILrg
(accessed 24 February 2015).
Results
The workshop model
Participants found the metaphor of a public enquiry useful as it helped to convey the design of the field
study and the rationale for the ‘expert witness’ roles in the workshop. Participants found the simulated
patient interview engaging and valued the interactive nature of the session. One member of PURSUN UK
commented that she would not have become involved in the project if it had required her to take part in a
complex, paper-based exercise. The live interview also provided a snapshot into a part of the research
process that few had previously experienced. As the simulated patient stayed ‘in role’ during discussions,
workshop participants were able to briefly step into the shoes of the interviewer, asking follow-up
questions and checking assumptions.
Impact on workshop participants
Service users reported an increased understanding of research processes in general as a result of the
workshop. Some members also said that it had made them think more about their own and their family’s
health, particularly in relation to preventing pressure ulcers. Some service users also reported an increased
feeling of empathy for the health professionals dealing with such complex cases.
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Members of the project team valued the dialogue with service users in a non-clinical context, despite some
initial concerns about working in this way. Everyone felt that the collaborative nature of the workshop was
important, particularly the fact that academics and nurses got to hear service users’ opinions first hand.
Face validity
The workshop also provided us with feedback – admittedly for just one of the eight accounts – about the
validity of the account. Members of PURSUN UK arrived at a similar interpretation of events as the nurses
and other experts involved in the formal analysis reported in Retrospective study of the development of
severe pressure ulcers.
The research team had already identified a need to involve patients and carers in the critical review of
severe pressure ulcers in the NHS (see Implementation project: the review of critical incidents). This was
supported by PURSUN UK members and one member has worked with the study team during 2013.
PURSUN UK also highlighted the importance of patient/carer engagement in pressure ulcer prevention and
the role that professionals can play in facilitating that engagement. Conversely, we recognise that the
severe pressure ulcer case study findings were filtered through the materials prepared for the workshop.
This was necessary partly to make the findings accessible and partly to protect the anonymity of the
individual whose account was used.
Conclusions
Thinking carefully about how PPI activities are designed and facilitated is important as the format affects
people’s ability and willingness to contribute. Presenting research data in live and interactive formats can
make the interpretation process more engaging and accessible and support meaningful dialogue between
service users and professionals. The use of applied performance techniques, as described here, provides
one model for doing this.
Implementation project: the review of critical incidents
The programme grant proposal included a commitment to investigate the implications of the study
findings for the conduct of root cause analyses of occurrences of severe pressure ulcers.
Aim and objective
The aim was to develop a methodology that can be used to review reportable pressure ulcers in the NHS
in England. The objective was to develop and test a method for reviewing severe pressure ulcers that
incorporated two key features, namely consideration of organisational explanations for their development
and eliciting information from patients. The first feature was derived from the main study and the second
was an extension of the PPI study.
Overview of methods
The work was undertaken by two of the clinical experts who had been involved in the empirical study, the
PURPOSE PPI officer, the programme chief investigator and the severe pressure ulcer study lead. A further
member was co-opted who had a dual role, as a member of PURSUN UK, having recently experienced a
severe pressure ulcer, and as a senior analytical researcher in a NHS organisation. An expert in adult
safeguarding was also consulted in the course of the project.
The scope of the project was defined as follows: to devise an investigation process and template suitable
for use in the NHS; to pilot this in both acute and community care settings; and to establish the added
value of including the patient’s voice and any differences in findings compared with the traditional
root cause analysis process and the value of the findings for meaningful action planning and process
changes. The methodology should also encourage open contributions, to learn what could be done
better in future, learn what good practice we could disseminate and gain feedback on prevention and
management interventions.
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Based on the findings of the empirical study, the team took the view that the review methodology
should include:
l a narrative of events associated with the development of a pressure ulcer, captured in conversations
with patients and/or relatives/carers and with staff with knowledge of relevant events
l a timeline of events based on information from patient records
l identification of good practice – practices that patients might reasonably have expected
l insights from the empirical study (e.g. about the systemic nature of organisational risks)
l coverage of resource issues, to take into account current NHS resource constraints.
Initially, the team reviewed investigation methods currently used in the NHS, including the Herringbone
and 5 Whys? methods,116 both of which were endorsed by the National Patient Safety Agency before it
was closed down. Strengths and weaknesses of current NHS root cause analysis practices have been
described by Nicolini and colleagues117 and their findings were used to inform our process.
We devised a method to direct data collection and the construction of patient narratives as follows: each
scene was presented in terms of ‘actions’ taken by the actors, ‘constraints’ imposed on them, the
‘information’ they held and/or passed on and the ‘decisions’ they reached. This was initially tested
informally using the patient member’s own experience. The process can be summarised as:
l beginning, which covers setting up the study team, establishing the narrative or story of what
happened from the patient notes and identifying the people who can contribute to the study
l gathering, which involves the conversations with staff, patients and carers and reviewing the narrative
in the light of their contributions
l analysing, which is the process of sense making of the information gathered, looking at risks, good
usual care and the constraints on the incident
l reporting, which draws the analysis together into findings and actions.
The two clinical team members consulted with their host organisations and obtained agreement to pilot
the method. In preparation, a workshop took place with the tissue viability link nurses during their training
day. The nurses were given information from the records of a member of PURSUN UK relating to the
development of a severe pressure ulcer. They were asked to use a draft template to produce a timeline
of events. In parallel, a conversation then took place between an investigator and the member of PURSUN
UK, during which he described his account of events. The nurses at the workshop then considered the
differences between the two accounts and reflected on the experience of involving a patient in the process.
Some practical issues were raised, including what to do if the patient was unable or unwilling to contribute
(or there were no relatives available) and whether or not the process would increase the chances of
litigation. Overall, though, the nurses felt that including the patient’s account added information that they
would not otherwise have obtained and added value to the review process. Reviewing the event, it was
noted that the systemic issues that were central to the empirical study were not identified by the nurses at
the workshop. We judged that it would be necessary to provide prompts in any guidance for investigators,
to encourage them to focus on systemic explanations for the development of pressure ulcers.
The template for recording events and the guidance for the investigator were revised in the light of the
workshop. The two clinical team members then identified two patients and their carers within their own
organisations who were willing to take part in a further pilot review process. Conversations took place and
information was collected from patient records. The usual NHS root cause analysis process was carried out
concurrently and separately. Data that might identify any individuals involved were removed prior to
sharing with the project team. Details of time resources were considered and findings were compared with
those of the usual root cause analysis process.
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Results
Findings and reflections
The substantive findings of the reviews were consistent with those from the retrospective study (Table 28).
Both reviews using the new method identified additional contributing decisions and actions, over and
above those identified in the parallel root cause analyses. The patients and carers did not identify the key
decisions and actions themselves; their descriptions allowed the investigators to do so. In both cases the
patients and carers valued the opportunity to ‘tell their own story’.
Feedback from ward staff
A meeting was held with the staff from the ward where the hospital pressure ulcer incident had taken
place. This was to feed back the findings of the pilot investigation and to evaluate the process by eliciting
staff views. Generally, staff thought that the process was more thorough than the current root cause
analysis process and was more informative about the reasons why the pressure ulcer developed. They felt
that the patient’s account not only told them a lot about the development of the pressure ulcer but also
gave them important feedback about other aspects of care. There were observations in the patient’s
account that they could not have obtained from any other source (e.g. an existing sore on the ankle).
Some staff felt that it made ‘uncomfortable reading’ but that it was to be expected when a category 3
pressure ulcer had occurred. They agreed that it was no more uncomfortable than the current process.
They acknowledged the value of more staff involvement in the process as people may take more note of
the outcome of an investigation if they are part of the process. They also noted that nurses are currently
carrying out root cause analysis without any training. Finally, the idea that an independent person should
lead the investigation (i.e. not someone working on that ward) was supported.
TABLE 28 Summary of findings
Incident Root cause analysis findings New investigation framework findings
Community
pressure ulcer
incident
l No risk assessment
l Poor documentation
l Carers should have reported skin deterioration
to district nurses sooner
l Organisational issues (multiple care providers
but no lead or sufficient communication)
l No one managing risk of pressure ulcers
l Relative was not listened to by staff (felt she
was being a nuisance)
l Impact of shingles (further reduced mobility)
on pressure ulcer risk was not recognised
Hospital
pressure ulcer
incident
l Delay in referral to dietitian for weight loss
l Braden score did not suggest risk
l Patients low mood made him reluctant to
participate in his care
l The site where the pressure ulcer developed
was not listed on the skin checklist and was
therefore not checked
l Organisational issues (no communication of
risk or skin status between health-care
professionals, staff prioritising preventing ‘falls’
rather than pressure ulcers, ignoring
mattresses alarming)
l Risk was not reassessed/identified when
condition deteriorated because of pneumonia
l Impact of pneumonia (was too ill to move
himself) on mobility was not recognised
l Reasons for patient ‘refusing to move’ were
not explored
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Conclusions
Our conclusions, based on the pilot work, are that:
l There is value in involving patients and carers in root cause analysis – they can provide important
information that is not recorded in notes or reported by staff.
l A narrative approach also has value. Underpinning this point, we note that nurses at the workshop and
review events instinctively focused on root causes, that is, on cause–effect relationships, such as failure to
turn a patient frequently enough. The findings of the empirical study and of this implementation study
suggest that, rather than focus on root causes, teams and independent investigators should be encouraged
to consider systemic explanations, that is, they should consider different ways of interpreting the available
evidence, ranging from ‘one-off’ errors by staff to wider cultural issues that need to be addressed.
l Root cause analyses should be co-ordinated by someone who is independent of the setting in which
incidents occur and who has clinical knowledge that provides credibility and the capacity to help local
teams to identify lessons that can be learned.
Summary
The severe pressure ulcer work package comprised three pieces of work. The first was a retrospective case
study of eight patients who developed severe pressure ulcers. The second was a patient involvement
workshop with PURSUN UK. The third focused on the development of a methodology for the root cause
analysis of critical incidents.
The main field study set out to understand the ways in which the organisational context influences the
development of severe pressure ulcers. For seven of the eight patients the best explanation of the evidence
was that the general organisational context played a significant role in severe pressure ulcer development.
In four accounts specific events contributed to development. One patient’s severe pressure ulcer was
deemed to be unavoidable. We found that severe pressure ulcers were more likely to develop in contexts
characterised by one or more of clinicians failing to listen to patients or carers, clinicians failing to
recognise and respond to clear signs that a patient had a pressure ulcer or was at risk of developing one,
and services not being effectively co-ordinated.
The patient involvement workshop was an additional study that was not described in the programme
grant proposal. Service users found the interactive workshop format, and the use of a ‘simulated patient’
account within it, valuable. We found that presenting research data in live and interactive formats can
make the interpretation process more engaging and accessible to service users and can support
meaningful dialogue between service users and professionals.
We also found that a methodology for root cause analysis, rooted in current NHS practice but including
novel components, can be used to improve the quality of the insights captured. On the basis of our three
pieces of work, we conclude that current best NHS practice in root cause analysis of reportable pressure
ulcers should be augmented by interviews with patients and carers and by the construction of narratives
based on key events. Our findings suggest that there is a need to move away from identification of root
causes and towards broader explanations of events, based on identifying the ‘best fit’ between the
available evidence and the explanations available in the patient safety literature.
In conclusion, this study has not led us to a model or template that can be used for the analysis of the
development of severe pressure ulcers or other incidents. Rather, it reinforces the view, articulated by
Francis93 and others,97 that reviews are more likely to be effective if (1) they pay closer attention to details
of the functional, or systems-based, components and also (2) they are used in ways that promote learning
rather than blame. We have pointed in this chapter, and in the development of a risk assessment tool
(see Chapter 5), to the importance of collecting the right information and collating and presenting it
systematically. This is only worthwhile if clinical teams working in settings where severe pressure ulcers
develop reflect on, and work on, their local cultures. No tool yet invented will substitute for this internal
reflection and commitment to change practice.
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Chapter 5 Risk assessment
Chapter written by Susanne Coleman, E Andrea Nelson, Isabelle L Smith, Sarah Brown, Julia M Brown,Lyn Wilson, Delia Muir, Justin Keen, Carol Dealey, Elizabeth McGinnis, Nikki Stubbs and Jane Nixon.
Abstract
Introduction: Increasing evidence makes it timely to reconsider which risk factors should be considered in
pressure ulcer risk assessment and how to prompt an escalation of interventions for secondary prevention
and treatment. The primary aim of the risk assessment work package of the programme was to agree a
pressure ulcer risk factor Minimum Data Set to underpin the development and validation of a Risk
Assessment Framework for use in clinical practice. The work package consisted of five phases incorporating
a systematic review, a consensus study, conceptual framework development, design and pre-testing of the
framework and clinical evaluation of the framework.
Methods: (1) A systematic review of primary research to identify pressure ulcer risk factors; (2) a
consensus study using a modified nominal group technique based on the RAND/UCLA (Research and
Development, University of California in Los Angeles) appropriateness method, incorporating an expert
group, review of the pressure ulcer evidence and the views of PURSUN UK to agree a draft pressure ulcer
risk factor Minimum Data Set and develop a Risk Assessment Framework; (3) development of a pressure
ulcer conceptual framework and theoretical causal pathway, building on the phase 2 consensus study;
(4) design and pre-testing of the draft Risk Assessment Framework using cognitive pre-testing methods,
to assess and improve its acceptability and usability with clinical nurses; and (5) clinical evaluation of the
reliability, validity, data completeness and clinical usability of the Risk Assessment Framework through field
testing of 230 patients by expert and community/ward-based nurses.
Results: (1) The systematic review of primary research identified 15 risk factor domains and 46 related
subdomains. The review indicated that there were three primary risk factor domains of mobility/activity,
skin/pressure ulcer status and perfusion (including diabetes), but suggested that no single factor can
explain pressure ulcer development. Other risk factor domains emerged less consistently. (2) The consensus
study facilitated the agreement of risk factors and assessment items for the Minimum Data Set (including
immobility, pressure ulcer and skin status, perfusion, diabetes, skin moisture, sensory perception and
nutrition), allowing the development of a draft Risk Assessment Framework incorporating all Minimum
Data Set items. (3) The new pressure ulcer conceptual framework incorporated five key components
(mechanical boundary conditions, physiology and repair, mechanical properties of the tissue, geometry of
the tissue/bone, and transport and thermal properties) and their impact on internal strains, stresses and
damage thresholds. The theoretical causal pathway for pressure ulcer development identified direct
causal factors, key indirect causal factors and other potential indirect causal factors for pressure ulcer
development. (4) The design and pre-testing of the Risk Assessment Framework led to improved usability
over the course of the three pre-test sessions, as demonstrated by increased data completeness and
appropriate pathway allocation. (5) The field test demonstrated that inter-rater and test–retest agreement
for the PURPOSE-T was ‘very good’ for the assessment decision overall as determined by kappa. The
percentage agreement for the assessment of ‘problem/no problem’ for the eight risk factors (mobility, skin,
previous pressure ulcer, sensory perception, perfusion, nutrition, moisture and diabetes) ranged from
79.1% to 94.2% for inter-rater reliability and from 87.0% to 93.9% for test–retest reliability. Convergent
validity, assessed by comparison with the same or similar constructs on other risk assessment scales
(Braden and Waterlow), demonstrated moderate to high associations. In addition, field notes recorded by
the expert nurses highlighted positive and problem aspects of using the tool in the clinical environment.
A follow-up consensus process allowed consideration of evidence from the pain work package and an
extension of the pressure ulcer and skin status assessment items to include pressure area-related pain at
the full assessment stage of the PURPOSE-T.
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Conclusion: The work package led to the development of a new Risk Assessment Framework, the
PURPOSE-T, incorporating the Minimum Data Set; a screening stage to target assessment towards those in
need; a full assessment stage; use of colour (rather than a score) to describe risk in terms of a personal
profile to help in the planning of appropriate interventions; and decision pathways that make a clear
distinction between patients with an existing pressure ulcer(s) (or scarring from previous ulcers) who
require secondary prevention and treatment and those at risk who require primary prevention. The final
PURPOSE-T framework has content, face and construct validity, with good inter-rater reliability and very
good test–retest reliability.
Background
It is not appropriate to prevent pressure ulcers by subjecting all patients to resource-intensive interventions
(such as repositioning by nurses or expensive mattresses) that may impact on their quality of life (e.g. by
disturbing sleep) and cause harm by diverting nursing time from other areas, hence we must target care to
those patients for whom it is likely to do more good than harm. Targeting patients for whom pressure
ulcer prevention interventions are needed is achieved by considering the patients’ characteristics, a process
known as risk assesssment. It is noteworthy that this is an individualistic approach to determining if
someone is likely to develop a pressure ulcer, in contrast to the interaction/context-based explanantions
identified as also being important in our study of severe pressure ulcers (see Chapter 4). Regardless of
context, risk assessment is widely accepted as being essential for pressure ulcer prevention1,14,23 as it allows
‘at-risk’ patients to be identified so that preventative interventions can be put in place to reduce the risk of
ulcer development.
In clinical practice, risk assessment scales are commonly used to give some structure to the assessment
process, in preference to clinical ‘assessment’ or ‘judgement’ of risk. Nixon and McGough118 noted that
there were > 40 pressure ulcer risk assessment scales, with the majority being developed from a literature
review, expert opinion and/or adaptation of an existing scale. They noted that there were only seven
‘original’ scales. Many were developed in the 1970s and 1980s when the epidemiological evidence was
limited by the primary research, including there being few studies considering the relative contribution of
individual risk factors. This led to the inconsistent inclusion of risk factors between different scales, with the
variables most frequently incorporated being continence/moisture, nutrition/appetite and mobility.118 This
raises concern about the lack of agreement about what should be included in risk assessment scales to
adequately identify risk and, as a result, the validity of those scales.118,119 In addition, existing scales tend to
use ordinal scoring systems in which a comparison is made between the patient and a standard reference
value to allocate a level of risk (e.g. high risk, moderate risk, at risk), with equal weighting usually given to
included risk factors despite the fact that some may be more predictive than others. It has been argued that
pressure ulcer risk assessment scales need to be developed on the basis of multivariable analyses to identify
factors that are independently associated with pressure ulcer development118,120,121 and to advance our
understanding of the relative contribution that different risk factors make to pressure ulcer development.
Gold standard methods for the development of risk stratification tools include multivariable modelling (either
from single studies or from meta-analysis from a number of studies) to identify items for a risk tool, with
subsequent model testing on a ‘new’ prospective target population.122 This type of tool development has in
the main been undertaken only in single-centre populations, with methodological limitations including
inadequate sample sizes for both model derivation and testing.123–125
From a practical perspective there are also issues with the use of existing risk assessment scales. Many
were designed to identify risk status in patients without pressure ulcers, but in practice are often used for
all patients, including those with and without pressure ulcers and do not distinguish between these
groups. This is a limitation as nurses could discount an existing pressure ulcer in their clinical assessment
and fail to instigate suitable secondary prevention and treatment interventions, which could lead to
deterioration and the development of a more severe pressure ulcer.126 This resonates with findings from
the severe pressure ulcer study (see Chapter 4). This is important as the pain cohort study (see Chapter 3)
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and a recent systematic review of pressure ulcer risk factors,46 conducted as part of this programme
grant, indicated that the presence of a category 1 pressure ulcer is a key predictor of the subsequent
development of a category 2 or above pressure ulcer, increasing the odds by two- to threefold.126
Increasing evidence makes it timely to reconsider which risk factors should be considered in pressure ulcer
risk assessment, how these should be assessed and the overall assessment process in the development of a
Risk Assessment Framework. Furthermore, the systematic review46 conducted as part of this programme
highlighted the need to agree a pressure ulcer risk factor Minimum Data Set and further develop a
pressure ulcer conceptual framework. These would encourage the use of consistent factors across studies,
facilitating meta-analysis, provide a standardised data set for case-mix adjustment and provide the
fundamental components for pressure ulcer risk assessment in clinical practice.
Aim
The overall aim of this work package was to agree a pressure ulcer risk factor Minimum Data Set to
underpin the development and validation of a Risk Assessment Framework for use in clinical practice.
(Note: as outlined in Chapter 1, Pressure ulcer development, the Risk Assessment Framework is not
intended for the prevention or management of ulcers caused by medical devices as the primary risk factor
for such ulcers is the presence of the device.)
Research overview
The methodological approach to the development of the Minimum Data Set and Risk Assessment Framework
comprised five distinct phases: (1) developing the evidence base, (2) a consensus study, (3) conceptual
framework development, (4) design and pre-testing and (5) clinical evaluation (Figure 11).
Phase 1: systematic review of patient risk factors for pressure
ulcer development
To provide the foundation for the risk assessment work package and to ensure consideration of potential
risk factors for inclusion in the Minimum Data Set and Risk Assessment Framework, a systematic review of
primary research was undertaken to identify risk factors that are independently predictive of pressure ulcer
development in adult patient populations.
Methods
This Methods section has been largely reprinted with minor modifications from Int J Nurs Stud, vol. 50,
Coleman S, Gorecki S, Nelson E, Closs S, Defloor T, Halfens R, et al. Patient risk factors for pressure ulcer
development: systematic review, pp. 974–1003, 2013,46 with permission from Elsevier.
Design
The approach was based on the systematic review methods recommended for questions of
effectiveness20,127 and adapted to identify risk factor studies, with consideration of the methodological
limitations including bias and confounding associated with observational studies.83,85
Study eligibility
Methodological quality criteria were integrated into the inclusion and exclusion criteria of the systematic
review, developed from principles of good research conduct in observational studies and randomised
controlled trials that minimise bias.82,86,89,128
Inclusion criteria
Studies were included if they met the following criteria: primary research; adult study populations in any
setting; outcome was the development of a new pressure ulcer(s); prospective cohort study, retrospective
record review or a controlled trial; length of follow-up of at least 3 days, with the exception of operating
room studies for which no minimal time period was set; outcome clearly defined as grade/stage 1 or
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above pressure ulcer23,129 or equivalent; multivariable analyses were undertaken to identify factors affecting
pressure ulcer outcome; and the unit of analysis was the patient.
Exclusion criteria
Studies were excluded as follows: paediatric study populations; cross-sectional or case study designs;
patient recall, patient self-report or an analysis of general practitioner records to assess outcome; or
duplicate publications of a patient data set. Cohort studies (prospective and record reviews) were excluded
from the review if > 20% of the study sample was excluded from analysis for reasons including withdrawal,
death, loss to follow-up and missing records.82,83,86,89 Controlled trials were excluded unless the following
minimum criteria applied: randomised allocation to treatment and intention-to-treat analyses.127,128
No language restriction was applied.
Data sources
Fourteen electronic databases were searched, from inception until March 2010: Allied and Complementary
Medicine Database (AMED), British Nursing Index (BNI), MEDLINE, EMBASE, PsycINFO, Cumulative Index to
Nursing and Allied Health Literature (CINAHL), The Cochrane Library, ProQuest, Networked Digital Library
of Theses and Dissertations, International Theses in Progress, Theses Canada Portal, Australian Digital
Theses Program, Russian Academy of Sciences Bibliographies and Index to Theses. The search strategy
(see Appendix 14) sought to identify all published and unpublished research studies investigating risk
Phase 2
Consensus study
 
• Agree a risk factor 
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  routine collection
 
• Develop a RAF
  incorporating the
  MDS, a screening
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FIGURE 11 Risk Assessment Framework: related studies. MDS, minimum data set; PU, pressure ulcer;
RAF, Risk Assessment Framework.
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factors for the development of pressure ulcers. The search strategy was designed with guidance from
the collaborative team and included pressure ulcer search terms,130 Ovid maximum sensitivity filters for
prognosis and aetiology or harm and an Ovid maximum sensitivity filter for randomised controlled trials.127
In addition, we hand searched specialist journals and conference proceedings, contacted 13 experts,
searched the UK national research websites and performed a citation search on all included studies and
systematic reviews identified in the search (see Appendix 14).
Study selection
Abstracts were screened for relevance by one reviewer (CG) and checked by a second (JN). Articles
assessed as potentially relevant were obtained in full and reviewed against the eligibility criteria by one
reviewer (CG or SC) and checked by another (JN). When the statistical methods were unclear and eligibility
could not be determined, statistical review was undertaken (JB). Disagreements were dealt with
through consensus.
Data extraction
When studies fulfilled the eligibility criteria data were extracted by a single reviewer (CG or SC) and checked
by a second reviewer (JN). When data were missing from the publication, attempts were made to contact
the authors. When duplicate publications of patient data sets were identified, the most detailed report was
used for data extraction. Experts in the field were asked to review/data extract abstracts and articles not
published in English (see Acknowledgements).
Quality assessment
There are no guidelines for the quality assessment of risk factor studies and so we developed an assessment
framework based on guidelines for assessing quality and risk of bias in prognostic studies and on
methodological considerations in the analysis, meta-analysis and publication of observational studies.81–89
Each study was appraised by two reviewers (JN, SC) and the following methodological limitations were
noted when present: baseline characteristics not adequately described; inadequate measurement of risk
factors (e.g. record review); inappropriate cut-points used for continuous data; and time-dependent
covariates included in the analysis without appropriate adjustment.
In addition, specific consideration was given to the following criteria:
1. Is there a sufficient number of events (rule of thumb: ≥ 10 events per risk factor)?
2. Are there sufficient data to assess the adequacy of the methods and analysis?
3. Is the strategy for model building (i.e. inclusion of variables) appropriate and based on a conceptual framework?
4. Is the selected model adequate for the design?
Each of the four criteria was assessed to see whether or not they were met (yes/no/partial/unsure), which
provided a structured approach for the classification of overall study quality. We classified studies as being
of high, moderate, low and very low quality using the following criteria:
l high-quality studies: ‘yes’ for all criteria
l moderate-quality studies: ‘yes’ for criterion 1 and at least two other criteria
l low-quality studies: ‘no’ for criterion 1 and ‘no’ or ‘partial’ for two other criteria
l very low-quality studies: ‘no’ for criterion 1 and ‘no’ or ‘partial’ for all three remaining criteria.
Data synthesis
Meta-analysis of the data was not feasible for this review because of heterogeneity in the study designs,
patient populations, risk factor descriptors, interventions used and outcomes reported. As the main aim was
to identify risk factors rather than quantify the effect size of the relationship between these factors and
pressure ulcer development, a narrative synthesis was carried out.127
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For each study, all factors entered into multivariable modelling and those that emerged as significant
(p≤ 0.05) were identified. For studies using stepwise regression, we included non-significant factors
(p≥ 0.05) if these were reported in the final model as being independently associated with pressure
ulcer development.
Risk factors were categorised into domains and subdomains by collating related factors from the source
articles into a grouping (domain). An example of a domain and subdomain would be the domain of
skin/ulcer status and the subdomains of stage/grade 1, existing pressure ulcer, previous pressure ulcer and
general skin status. Evidence tables (see Appendix 15 for an example), were generated for each risk factor
subdomain, with a summary narrative synthesis by subdomain and domain. For each subdomain, the total
number of studies entering the variable, the total number of studies in which the variable emerged in the
multivariable analyses and the quality of the studies are summarised. In the evidence tables (see Appendix 15
for an example), grade and stage of pressure ulcer are recorded as reported in individual studies.
Results
The numbers of studies considered and meeting the eligibility criteria are shown in the study flowchart
(Figure 12). The 5437,57,60,79,80,125,131–178 included studies included 34,449 patients from acute and
community populations.46
Study quality
The included studies comprised seven high-quality, 10 moderate-quality, 27 low-quality and 10 very
low-quality studies (Table 29). The low- and very low-quality studies had inadequate numbers of pressure
ulcers and other methodological limitations.
Retrieved n = 5462
Not satisfying eligibility
criteria - excluded n = 5097
Assessed as potentially
relevant, obtained in full for
further scrutiny
n = 365
Included n = 54
• Prospective cohort (n = 34)
• Retrospective record review (n = 9)
• Randomised controlled trial (n = 11)
Not satisfying eligibility criteria n = 311
Cohort/Record review
• > 20% lost to follow-up (n = 14)
• No multivariable analysis used (n = 228)
• Non-independent data (n = 3)
Randomised controlled trial
• Not randomised allocation to treatment (n = 5)
• Not intention to treat (n = 21)
• No adjusted analysis undertaken (n = 39)
• Non-independent data (n = 1)
FIGURE 12 Flowchart of studies. Reprinted from Int J Nurs Stud, vol. 50, Coleman S, Gorecki C, Nelson EA, Close SJ,
Defloor T, Halfens R, Farrin A, Brown J, Schoonhoven L, Nixon J. Patient risk factors for pressure ulcer development:
systematic review. 2013; 974–1003,46 with permission from Elsevier.
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Emerging risk factor domains/subdomains
The review identified 15 risk factor domains and 46 subdomains (Table 30). The number and quality of
studies in which associated risk variables emerged in multivariable modelling and the number and quality
of studies in which associated risk variables did not emerge are detailed in Table 30 [full evidence tables
are available at: http://medhealth.leeds.ac.uk/downloads/download/657/systematic_review_evidence_tables
(accessed August 2015)]. The review highlighted three primary risk factor domains:
1. Mobility/activity (immobility), with the subdomains of mobility subscales, mobility/activity, activities of
daily living (ADL) and activity (bedfast/chairfast/immobile descriptors) emerging most consistently.
2. Skin/ulcer status, with the subdomain of stage/grade 1 pressure ulcer emerging most consistently.
General skin status was also found to be important but the diverse variables (e.g. dry sacral skin,
mottled skin, unhealthy skin, skin redness, baseline skin trauma) made interpretation difficult.
3. Perfusion, with the subdomain of diabetes emerging strongly in the high-/moderate-quality studies.
Evidence from the large number of other perfusion-related variables suggests that factors that impair
circulation increase the probability of pressure ulcer development but the evidence is limited by the
large range of variable descriptors and study quality. Further research is needed in this area.
TABLE 30 Summary of evidence for risk factor domains/subdomains
Domain summary: variable
significant/total number
studies entered variable (%)
Number and quality of studies
variable significant in
multivariable modela
Number and quality of studies
variable non-significant in
multivariable modela
Mobility/activity subdomains
Risk Assessment Scale mobility
subscale
8/14 studies (57.1%)
1 HQS – Perneger et al.164
3 LQS – Bergquist and Frantz;134
Lindgren et al.;157 Kemp et al.156
4 VLQS – Baldwin and Ziegler;131
Watts et al.;177 Ek;147 Ek et al.148
1 MQS – Salzberg et al.167
4 LQS – Vanderwee et al.;176 Tourtual et al.;175
Pancorbo Hidalgo and Garcia Fernandez;163
Halfens et al.153
1 VLQS – Bostrom et al.138
Risk Assessment Scale activity
subscale
1/16 studies (6.2%)
1 VLQS – Ek et al.148 3 HQS – Defloor and Grypdonck;57
Perneger et al.;164 Nixon et al.37
1 MQS – Salzberg et al.167
7 LQS – Bergquist and Frantz;134 Vanderwee
et al.;176 Tourtual et al.;175 Pancorbo Hidalgo
and Garcia Fernandez;163 Halfens et al.;153
Lindgren et al.;157 Kemp et al.156
4 VLQS – Baldwin and Ziegler;131 Watts et al.;177
Bostrom et al.;138 Ek147
Activity (bedfast/chairfast/
immobile) descriptors
6/11 (54.5%)
1 MQS – Nijs et al.159
5 LQS – Schnelle et al.;169 Olson et al.;161
Allman et al.;79 Berlowitz and Wilking;137
Okuwa et al.160
2 MQS – De Laat et al.;145 Baumgarten et al.133
3 LQS – Fife et al.;150 Bergquist and Frantz;134
Donnelly146
Mobility/activity ADL
4/7 (57.1%)
1 HQS – Brandeis et al.141
1 MQS – Ooi et al.162
1 LQS – Sayar et al.168
1 VLQS – Rose et al.166
1 MQS – Rademakers et al.165
2 LQS – Bergquist and Frantz;134 Donnelly146
General ADL
2/4 (50%)
1 MQS – Baumgarten et al.133
1 LQS – Bergquist and Frantz134
1 HQS – Brandeis et al.141
1 LQS – Berlowitz and Wilking137
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TABLE 30 Summary of evidence for risk factor domains/subdomains (continued )
Domain summary: variable
significant/total number
studies entered variable (%)
Number and quality of studies
variable significant in
multivariable modela
Number and quality of studies
variable non-significant in
multivariable modela
RAS friction and shear
4/12 (33.3%)
1 HQS – Perneger et al.164
1 MQS – De Laat et al.145
2 LQS – Tourtual et al.;175 Halfens et al.153
1 HQS – Defloor and Grypdonck57
4 LQS – Bergquist and Frantz;134 Vanderwee
et al.;176 Lindgren et al.;157 Kemp et al.156
3 VLQS – Baldwin and Ziegler;131 Watts et al.;177
Bostrom et al.138
Factors affecting mobility
6/13 (46.1%)
3 MQS – Rademakers et al.;165 Salzberg
et al.;167 Bourdel-Marchasson et al.139
3 LQS – Boyle and Green;140 Bergquist
and Frantz;134 Vanderwee et al.176
1 HQS – Defloor and Grypdonck57
1 MQS – De Laat et al.145
5 LQS – Fife et al.;150 Sayar et al.;168
Tourtual et al.;175 Berlowitz and Wilking;137
Feuchtinger et al.149
Interface pressures
2/2 (100%)
1 MQS – Suriadi et al.125
1 LQS – Suriadi et al.174
Skin/PU status subdomains
Stage/grade 1
4/4 (100%)
2 HQS – Reed et al.;80 Nixon et al.37
2 LQS – Allman et al.;79 Nixon et al.60
Existing PU
2/5 (40%)
1 HQS – Defloor and Grypdonck57
1 MQS – Baumgarten et al.133
1 HQS – Nixon et al.37
2 LQS – Tourtual et al.;175 Stordeur et al.173
Previous PUs
0/2 (0%)
2 LQS – Allman et al.;79 Halfens et al.153
General skin status
9/10 (90%)
2 HQS – Defloor and Grypdonck;57
Nixon et al.37
5 LQS – Compton et al.;144 Schnelle et al.;169
Allman et al.;79 Pancorbo Hidalgo and
Garcia Fernandez;163 Bates-Jensen et al.132
2 VLQS – Rose et al.;166 Marchette et al.158
1 LQS – Boyle and Green140
Perfusion subdomains
Diabetes
5/12 (41.6%)
3 HQS – Schultz et al.;171 Brandeis et al.;141
Nixon et al.37
2 MQS – Rademakers et al.;165 Ooi et al.162
7 LQS – Compton et al.;144 Vanderwee et al.;176
Berlowitz andWilking;137 Stordeur et al.;173
Halfens et al.;153 Feuchtinger et al.;149 Donnelly146
Vascular disease
4/6 (66.6%)
1 MQS – Nijs et al.159
3 LQS – Vanderwee et al.;176 Berlowitz
and Wilking;137 Feuchtinger et al.149
2 LQS – Tourtual et al.;175 Donnelly146
Circulation
3/6 (50%)
3 LQS – Compton et al.;144 Olson et al.;161
Okuwa et al.160
1 HQS – Defloor and Grypdonck57
2 LQS – Tourtual et al.;175 Feuchtinger et al.149
Blood pressure
6/11 (54.5%)
1 MQS – Bergstrom and Braden135
4 LQS – Boyle and Green;140 Vanderwee
et al.;176 Pancorbo Hidalgo and
Garcia Fernandez;163 Nixon et al.60
1 VLQS – Cobb et al.143
5 LQS – Fife et al.;150 Suriadi et al.;174
Olson et al.;161 Lindgren et al.;157 Donnelly146
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TABLE 30 Summary of evidence for risk factor domains/subdomains (continued )
Domain summary: variable
significant/total number
studies entered variable (%)
Number and quality of studies
variable significant in
multivariable modela
Number and quality of studies
variable non-significant in
multivariable modela
Smoking
2/4 (50%)
1 MQS – Suriadi et al.125
1 LQS – Suriadi et al.174
2 LQS – Feuchtinger et al.;149 Donnelly146
Oedema
1/4 (25%)
1 LQS – Compton et al.144 1 MQS – Nijs et al.159
2 LQS – Bergquist and Frantz;134 Donnelly146
Haematological measures subdomains
Urea and electrolytes
2/4 (50%)
1 MQS – Salzberg et al.167
1 LQS – Serpa and Santos172
2 LQS – Berlowitz and Wilking;137
Okuwa et al.160
Protein
1/3 (33.3%)
1 LQS – Hatanaka et al.154 1 LQS – Sayar et al.168
1 VLQS – Marchette et al.158
Albumin
7/11 (63.6%)
1 HQS – Reed et al.80
1 MQS – Bourdel-Marchasson et al.139
3 LQS – Serpa and Santos;172
Hatanaka et al.;154 Nixon et al.60
2 VLQS – Ek et al.;148 Marchette et al.158
2 MQS – Bergstrom and Braden;135
Salzberg et al.167
2 LQS – Lindgren et al.;157 Kemp et al.156
Lymphopenia
2/2 (100%)
2 LQS – Allman et al.;79 Pancorbo
Hidalgo and Garcia Fernandez163
Haemoglobin
6/11 (54.5%)
1 HQS – Nixon et al.37
5 LQS – Hatanaka et al.;154 Bergquist and
Frantz;134 Olson et al.;161 Stordeur et al.;173
Pancorbo Hidalgo and Garcia Fernandez163
1 MQS – Gunningberg et al.152
4 LQS – Serpa and Santos;172
Feuchtinger et al.;149 Nixon et al.;60
Okuwa et al.160
Moisture subdomains
Moisture subscales
4/12 (33.3%)
1 MQS – Salzberg et al.167
2 LQS – Tourtual et al.;175 Halfens et al.153
1 VLQS – Baldwin and Ziegler131
2 HQS – Defloor and Grypdonck;57
Perneger et al.164
3 LQS – Bergquist and Frantz;134
Vanderwee et al.;176 Kemp et al.156
3 VLQS –Watts et al.;177 Bostrom et al.;138 Ek147
Urinary incontinence
1/7 (14.3%)
1 LQS – Vanderwee et al.176 1 HQS – Brandeis et al.141
2 MQS – Salzberg et al.;167 Baumgarten et al.133
3 LQS – Bergquist and Frantz;134 Halfens et al.;153
Donnelly146
Faecal incontinence
2/11 (18.2%)
1 HQS – Brandeis et al.141
1 VLQS – Marchette et al.158
1 HQS – Reed et al.80
1 MQS – Baumgarten et al.133
7 LQS – Boyle and Green;140 Fife et al.;150
Suriadi et al.;174 Olson et al.;161 Allman et al.;79
Halfens et al.;153 Donnelly146
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TABLE 30 Summary of evidence for risk factor domains/subdomains (continued )
Domain summary: variable
significant/total number
studies entered variable (%)
Number and quality of studies
variable significant in
multivariable modela
Number and quality of studies
variable non-significant in
multivariable modela
Dual incontinence
3/5 (60.0%)
1 MQS – Ooi et al.162
2 LQS – Bergquist and Frantz;134
Vanderwee et al.176
1 MQS – Baumgarten et al.133
1 LQS – Tourtual et al.175
Incontinence other
1/1 (100%)
1 LQS – Pancorbo Hidalgo and
Garcia Fernandez163
Urinary catheter
1/3 (33.3%)
1 HQS – Reed et al.80 2 LQS – Compton et al.;144 Berlowitz and
Wilking137
Skin moisture
3/5 (60.0%)
3 LQS – Suriadi et al.;174 Compton
et al.;144 Bergquist and Frantz134
1 MQS – De Laat et al.145
1 LQS – Halfens et al.153
Body temperature domain
Body temperature
5/8 (62.5%)
3 MQS – Nijs et al.;159 Suriadi et al.;125
Bergstrom and Braden135
1 LQS – Suriadi et al.174
1 VLQS – Rose et al.166
2 LQS – Vanderwee et al.;176
Feuchtinger et al.149
1 VLQS – Ek147
Nutrition subdomains
Nutritional scales
1/14 (7.1%)
1 LQS – Serpa and Santos172 3 HQS – Defloor and Grypdonck;57
Perneger et al.;164 Nixon et al.37
6 LQS – Vanderwee et al.;176 Tourtual et al.;175
Pancorbo Hidalgo and Garcia Fernandez;163
Halfens et al.;153 Lindgren et al.;157 Kemp et al.156
4 VLQS – Baldwin and Ziegler;131 Watts et al.;177
Bostrom et al.;138 Ek147
Food intake
4/7 (57.1%)
1 HQS – Brandeis et al.141
1 MQS – Bergstrom and Braden135
1 LQS – Berlowitz and Wilking;137
1 VLQS – Ek et al.148
1 HQS – Defloor and Grypdonck57
1 MQS – De Laat et al.145
1 LQS – Bergquist and Frantz134
Malnourishment
1/3 (33.3%)
1 HQS – Reed et al.80 2 LQS – Schoonhoven et al.;170 Donnelly146
Weight
4/12 (33.3%)
3 LQS – Allman et al.;79 Lindgren et al.;157
Nixon et al.60
1 VLQS – Cobb et al.143
1 MQS – Bergstrom and Braden135
5 LQS – Yepes et al.;178 Boyle and Green;140
Compton et al.;144 Olson et al.;161 Kemp et al.156
2 VLQS – Inman et al.;155 Watts et al.177
BMI
2/9 (22.2%)
1 HQS – Schultz et al.171
1 LQS – Fife et al.150
2 HQS – Defloor and Grypdonck;57
Brandeis et al.141
5 LQS – Serpa and Santos;172 Compton et al.;144
Vanderwee et al.;176 Feuchtinger et al.;149
Lindgren et al.157
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TABLE 30 Summary of evidence for risk factor domains/subdomains (continued )
Domain summary: variable
significant/total number
studies entered variable (%)
Number and quality of studies
variable significant in
multivariable modela
Number and quality of studies
variable non-significant in
multivariable modela
Arm measurements
1/3 (33.3%)
1 LQS – Pancorbo Hidalgo and
Garcia Fernandez163
2 LQS – Serpa and Santos;172 Allman et al.79
Other measures
0/4 (0%)
2 LQS – Yepes et al.;178 Compton et al.144
2 VLQS – Inman et al.;155 Watts et al.177
Age domain
Increasing age
12/32 (37.5%)
4 HQS – Schultz et al.;171 Perneger et al.;164
Bergstrom et al.;136 Nixon et al.37
3 MQS – Ooi et al.;162 Bergstrom and
Braden;135 Gunningberg et al.152
5 LQS – Serpa and Santos;172
Hatanaka et al.;154 Vanderwee et al.;176
Halfens et al.;153 Lindgren et al.157
2 HQS – Defloor and Grypdonck;57
Brandeis et al.141
2 MQS – De Laat et al.;145 Baumgarten et al.133
12 LQS – Chan et al.;142 Yepes et al.;178
Fife et al.;150 Compton et al.;144 Bergquist and
Frantz;134 Tourtual et al.;175 Olson et al.;161
Allman et al.;79 Berlowitz andWilking;137
Feuchtinger et al.;149 Kemp et al.;156 Nixon et al.60
4 VLQS – Inman et al.;155 Watts et al.;177
Goodridge et al.;151 Cobb et al.143
Sensory perception domain
Braden sensory perception
subscale
2/9 (22.2%)
1 HQS – Defloor and Grypdonck57
1 LQS – Halfens et al.153
1 HQS – Perneger et al.164
3 LQS – Vanderwee et al.;176 Tourtual et al.;175
Kemp et al.156
3 VLQS – Baldwin and Ziegler;131 Watts et al.;177
Bostrom et al.138
Mental status subdomains
Mental status subscales
1/5 (20%)
1 HQS – Perneger et al.164 1 HQS – Defloor and Grypdonck57
2 LQS – Pancorbo Hidalgo and Garcia
Fernandez;163 Donnelly146
1 VLQS – Ek147
Mental status study-specific
measures
1/8 (12.5%)
1 HQS – Reed et al.80 1 HQS – Brandeis et al.141
1 MQS – Baumgarten et al.133
5 LQS – Bergquist and Frantz;134 Sayar et al.;168
Pancorbo Hidalgo and Garcia Fernandez;163
Halfens et al.;153 Donnelly146
Race domain
Race
2/5 (40%)
1 HQS – Bergstrom et al.136
1 MQS – Baumgarten et al.133
1 HQS – Brandeis et al.141
2 LQS – Bates-Jensen et al.;132 Chan et al.142
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TABLE 30 Summary of evidence for risk factor domains/subdomains (continued )
Domain summary: variable
significant/total number
studies entered variable (%)
Number and quality of studies
variable significant in
multivariable modela
Number and quality of studies
variable non-significant in
multivariable modela
Gender domain
Gender
4/15 (26.6%)
4 LQS – Compton et al.;144
Bergquist and Frantz;134
Okuwa et al.;160 Hatanaka et al.154
2 HQS – Brandeis et al.;141 Bergstrom et al.136
1 MQS – Baumgarten et al.133
6 LQS – Chan et al.;142 Serpa and Santos;172
Boyle and Green;140 Fife et al.;150
Lindgren et al.;157 Donnelly146
2 VLQS – Inman et al.;155 Goodridge et al.151
General health status subdomains
ASA
1/2 (50%)
1 MQS – Rademakers et al.165 1 LQS – Donnelly146
APACHE II
1/4 (25%)
1 LQS – Yepes et al.178 1 MQS – Nijs et al.159
1 LQS – Compton et al.144
1 VLQS – Inman et al.155
Norton score measures
0/3 (0%)
2 HQS – Defloor and Grypdonck;57
Perneger et al.164
1 VLQS – Ek147
Chronic wounds
1/2 (50%)
1 HQS – Nixon et al.37 1 LQS – Nixon et al.60
Other factors
8/26 (30.8%)
3 HQS – Schultz et al.;171 Reed et al.;80
Nixon et al.37
2 MQS – Rademakers et al.;165 Nijs et al.159
2 LQS – Yepes et al.;178 Lindgren et al.157
1 VLQS – Marchette et al.158
2 HQS – Defloor and Grypdonck;57
Brandeis et al.141
2 MQS –Salzberg et al.;167 De Laat et al.145
12 LQS – Bates-Jensen et al.132 Chan et al.;142
Serpa and Santos;172 Schoonhoven et al.;170
Fife et al.;150 Compton et al.;144 Bergquist and
Frantz;134 Halfens et al.;153 Feuchtinger et al.;149
Nixon et al.;60 Okuwa et al.;160 Donnelly146
2 VLQS – Inman et al.;155 Watts et al.177
Medication domain
Medication
3/10 (30%)
1 MQS – Nijs et al.159
2 LQS – Bergquist and Frantz;134
Stordeur et al.173
1 HQS – Brandeis et al.141
6 LQS – Yepes et al.;178 Schoonhoven et al.;170
Compton et al.;144 Vanderwee et al.;176
Olson et al.;161 Donnelly146
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Other risk factor domains that were less consistently associated with pressure ulcer development included
nutrition, moisture, age, haematological measures, general health status, sensory perception and mental
status. Additionally, only a small number of studies included body temperature and immunity and
these factors require further research. Finally, the evidence related to race and gender as risk factors
was equivocal.
The review46 indicates that there are three primary risk factor domains of mobility/activity, skin/ulcer status
and perfusion (including diabetes) but suggests that there is no single factor that can alone explain
pressure ulcer development; rather, there is a complex interplay of factors that increases pressure ulcer
probability. Although immobility is included in existing pressure ulcer risk assessment tools, the inclusion of
skin/ulcer status and perfusion (including diabetes) is not universal. This highlights the need to reconsider
the risk factors included in pressure ulcer risk assessment tools.
It is noteworthy that there were a large number of potential risk factors –15 domains and 46 subdomains
including over 250 named variables. Furthermore, there was a lack of comparable data fields for
measurement of the same constructs and key risk factors were not routinely recorded in all studies.46
These limitations prevented meta-analysis to identify an item pool for a risk stratification tool and a key
recommendation of the review was the development of a Minimum Data Set for pressure ulcer research
and institutional cohorts to facilitate future large-scale multivariate analyses and meta-analysis.
Phase 2: consensus study
Although the systematic review46 provided a foundation for the ongoing work, there remained gaps in the
evidence base and a lack of agreement over the key risk factors and data items to summarise patient risk.
This highlighted the need to consult with experts in the pressure ulcer field about the relevance of the
evidence to clinical practice and risk assessment and about other pertinent scientific (physiological and
biomechanical) evidence that ought to be considered to agree the risk factors and items to be included in
the Minimum Data Set and Risk Assessment Framework (see Appendix 16 for study protocol).
TABLE 30 Summary of evidence for risk factor domains/subdomains (continued )
Domain summary: variable
significant/total number
studies entered variable (%)
Number and quality of studies
variable significant in
multivariable modela
Number and quality of studies
variable non-significant in
multivariable modela
Risk factor subdomains
Braden scale total score
7/16 (43.75%)
2 HQS – Schultz et al.;171 Bergstrom et al.136
1 MQS – Bergstrom and Braden135
4 LQS – Bates-Jensen et al.132 Chan et al.;142
Fife et al.;150 Stordeur et al.173
6 LQS – Yepes et al.;178 Serpa and
Santos;172; Bergquist and Frantz;134
Tourtual et al.;175 Kemp et al.;156 Donnelly146
3 VLQS – Baldwin and Ziegler;131 Watts et al.;177
Goodridge et al.151
Other scales
3/7 (42.8%)
1 MQS – Bourdel-Marchasson et al.139
1 LQS – Pancorbo Hidalgo and
Garcia Fernandez163
1 VLQS – Inman et al.155
4 LQS – Compton et al.;144 Sayar et al.;168
Stordeur et al.;173 Lindgren et al.157
APACHE, Acute Physiology and Chronic Health Evaluation; ASA, American Society of Anesthesiologists.
a Study quality: HQS, high-quality study; MQS, moderate-quality study; LQS, low-quality study; VLQS, very
low-quality study.
Source: Reprinted from Int J Nurs Stud, vol. 50, Coleman S, Gorecki C, Nelson EA, Close SJ, Defloor T, Halfens R, Farrin A,
Brown J, Schoonhoven L, Nixon J. Patient risk factors for pressure ulcer development: systematic review. 2013; 974–1003,46
with permission from Elsevier.
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Aim and objectives
The Aims and objectives, Methods and Results sections are largely reproduced, with amendments, from
Coleman S, Nelson E, Keen J, Wilson L, McGinnis E, Dealey C, et al. Developing a pressure ulcer risk factor
minimum data set and risk assessment framework, J Adv Nurs, with permission from John Wiley & Sons.126
© 2014 The Authors. Journal of Advanced Nursing. Published by John Wiley & Sons Ltd. This is an open
access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License.
The aim of this study was to develop a draft pressure ulcer risk factor Minimum Data Set and Risk
Assessment Framework for pre-testing and clinical evaluation.
The objectives were to:
1. agree a list of patient characteristics to form a Minimum Data Set suitable for routine collection of key
risk factors in adult patient populations
2. develop a Risk Assessment Framework incorporating the Minimum Data Set with:
i. a simple screening stage to quickly identify not-at-risk patients
ii. a detailed full assessment stage for patients who are at potential/actual risk or who have an existing
pressure ulcer
iii. decision pathways [i.e. not currently at risk, primary prevention (at risk) or secondary prevention and
treatment pathway (with pressure ulcer)].
Methods
Design
A consensus study using a modified nominal group technique based on the RAND/UCLA appropriateness
method179 was used. This incorporated face-to face interaction and pre- and post-meeting questionnaire
completion with an expert group, as well as face-to-face interaction with a service user group (PURSUN
UK; see Chapter 2).
Expert group participants
The expert group comprised international clinical/academic leaders identified through their publication
record in pressure ulcer or relevant research (see Acknowledgements). The involvement of international
expert group members was facilitated by additional funding from a Leeds University World Universities
Network grant. The group was purposively sampled to include the perspectives of nurses, doctors,
bioengineers, epidemiologists and individuals with organisational development and decision science
expertise. A multispecialty group was developed to take account of a wide range of opinions.180 Seventeen
members were recruited to allow for attrition, as 12 was considered the optimum number in terms of
preventing co-ordination problems whilst maximising reliability.181
Service user group participants
The service user group involved members of PURSUN UK (see Chapter 2). All members were invited to take
part and seven people have been involved throughout the project. This includes people with experience of
having a pressure ulcer or living with pressure ulcer risk as well as carers.
Data collection
The consensus process incorporated an initial expert group meeting and an initial PURSUN UK meeting
followed by two consensus cycles. It was envisaged that the first consensus cycle would consider the
Minimum Data Set and the second cycle would consider the Risk Assessment Framework; however, at the
initial expert group meeting it was apparent that there were difficulties with considering the Minimum
Data Set and Risk Assessment Framework separately as the two are interlinked. Discussion at the meeting
highlighted the need to identify the key pressure ulcer risk factors and assessment items (i.e. the way in
which the risk factors are measured) that would be included in the Minimum Data Set and incorporated in
the Risk Assessment Framework. Therefore, the first consensus cycle focused on agreeing the risk factors
to be included in the Minimum Data Set and Risk Assessment Framework and the second consensus cycle
focused on the assessment items (Figure 13). The study was approved by the University of Leeds School of
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Healthcare Research Ethics Committee. Informed consent was gained from expert group members prior to
participation (see Appendices 17–22 for participant information and consent forms).
Reviewing the pressure ulcer risk factor evidence was an important element of the study and was
integrated throughout all cycles of the consensus process.46 The systematic review46 provided evidence
regarding the current state of knowledge surrounding pressure ulcer risk factors but the group also
considered wider scientific evidence that was drawn from the expertise of the group. The relevance of the
evidence to clinical practice, as well as the practicalities of pressure ulcer risk assessment, were also
considered by the group.
Questionnaires were completed by all expert group members privately before and after the cycle 1 and
2 meetings (see Figure 13). In each questionnaire, participants were asked to rate their level of support for
statements (relating to the inclusion of risk factors/assessment items in the Minimum Data Set and Risk
Assessment Framework) on a 9-point Likert scale, with 1 indicating strong disagreement and 9 indicating
strong agreement. Each statement was preceded by a relevant summary of the pressure ulcer systematic review
evidence, as well as a summary of expert group discussions, a summary of PURSUN UK group discussions
(as applicable) and follow-up/explanatory notes (as applicable). Electronic links to the full systematic review
evidence tables and the full summary of the preceding expert group discussions were also available within the
questionnaires. This allowed the research team to identify areas of agreement, uncertainty and disagreement
before each meeting and to schedule the discussion agenda accordingly. The completion of the questionnaire
after the meeting allowed individuals to change their ratings in light of discussions and/or when necessary
allowed questionnaire items to be clarified and amended.
Questionnaires were administered and completed using a commercial online survey platform. Participants
were asked to complete the questionnaire within 2 weeks of initial posting. One or two reminders were
sent (and on one occasion, because of a holiday period, a third reminder was sent) to participants who
had not completed the questionnaire within the allotted 2-week period. The surveys were closed to
response at 10 weeks following initial posting.
Initial Meetings
Introductory expert
group meeting
Introductory
PURSUN meeting
Consensus Cycle 1
PU Risk Factors
Cycle 1 pre-expert group
meeting questionnaire
completion
Cycle 2 pre-expert group
meeting questionnaire
completion
Cycle 1 expert group
face-to-face meeting
Cycle 1 post-expert group
meeting questionnaire
completion
Cycle 2 post-expert group
meeting questionnaire
completion
PURSUN meeting
Consensus Cycle 2
Assessment Items
Cycle 2 expert group
face-to-face meeting
FIGURE 13 Overview of the consensus cycle. PU, pressure ulcer. Reprinted from Coleman S, Nelson EA, Keen J,
Wilson L, McGinnis E, Dealey C, et al. Developing a pressure ulcer risk factor minimum data set and risk assessment
framework. J Adv Nurs 2014;70:2339–52.126 © 2014 The Authors. Journal of Advanced Nursing. Published by
John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is
properly cited, the use is non-commercial and no modifications or adaptations are made.
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All expert group meetings were led by trained facilitators and were audiotaped. Unlike a traditional
RAND/UCLA method in which the first face-to-face meeting occurs following questionnaire completion,
an initial face-to-face meeting was undertaken to review the pressure ulcer evidence and consider
the views of the group to inform the development of the cycle 1 risk factor questionnaire.182 At cycle 1
and 2 expert group meetings (see Figure 13), the pre-meeting collective questionnaire responses were
anonymously fed back to the group. Members were also provided with a reminder report of their
individual questionnaire responses and a copy of the summary of the discussions of the previous expert
group meeting. The questionnaire results highlighted areas of agreement and areas of uncertainty and
disagreement, which provided a focus for the group discussions to ascertain whether there was genuine
uncertainty or disagreement or if there was ambiguity in the wording of the questionnaire.
As pressure ulcer risk assessment practice is part of routine care there was a need to explore the
acceptability of proposed risk assessment elements to patients and carers; this was undertaken through
facilitated PURSUN UK meetings. PURSUN UK members’ views were fed back to the expert group at the
subsequent meeting (cycles 1 and 2) and through the cycle 2 pre-meeting questionnaire.
Data analysis
The researcher (SC) listened to the audio tapes of the expert group meetings and read the associated
transcripts in total to ensure completeness. The data were then coded, with categories based on the
pressure ulcer risk factor systematic review, in keeping with a directed content analysis approach.183 As
new themes emerged from the expert group discussions further codes were added. A summary report of
each meeting was generated by the researcher. The report was reviewed by the facilitators and members
of the working group (subgroup of the expert group that comprised the local team and incorporated three
academic nurses, three clinical nurses, one PPI officer and one member with organisational development
expertise) to ensure that it reflected group discussions.
Careful notes were taken throughout the PURSUN UK meetings and a summary of the discussions was
written by the researcher (SC). The summary was circulated to the facilitator and group participants to
ensure that it reflected the discussions at the meeting.
Questionnaire statements were summarised using the median group response as a measure of central
tendency. In keeping with the RAND/UCLA appropriateness methods and other studies179,184–186 Likert-scale
group median responses for each statement were categorised into three tertiles. For this study, the
categories were 1–3, disagree; 4–6, uncertain; and 7–9, agree. Within-group agreement was measured
using the RAND disagreement index,179 which considers the dispersion of individual scores and identifies
areas of disagreement (when panellists rate at both ends of the Likert scale). An index of > 1
indicates disagreement.
Using the group median response and the disagreement index for each statement (regarding risk factors/
assessment items) the following principles were applied following post-meeting questionnaire completion:
l group medians of 1–3 without disagreement would be excluded
l group medians of 7–9 without disagreement would be included
l when the disagreement index was > 1 or when the median was 4–6, group medians would be
excluded but noted as potential areas for further research.
Results
The expert group comprised nine female and eight male participants. There was 100% (n= 68/68)
completion of questionnaires, with 77.9% (n= 53/68) completed within the 2-week allotted time period
[13.2% (9/68) were completed up to 1 week late; 2.9% (2/68) up to 4 weeks late; 1.5% (1/68) up to
6 weeks late; 1.5% (1/68) up to 7 weeks late; and 2.9% (2/68) up to 8 weeks late]. In total, there was
86.3% attendance at the face-to-face meetings (17/17 attended the first meeting, 13/17 attended the
second meeting and 14/17 attended the third meeting). The results concerning the risk factors (cycle 1)
and assessment items (cycle 2) of the Minimum Data Set and Risk Assessment Framework are detailed in
the following sections.
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Cycle 1: risk factors
The expert group agreed that three risk factors should be incorporated into the screening stage of the
Minimum Data Set and Risk Assessment Framework for the assessment of all patients: immobility, existing
pressure ulcer and previous pressure ulcer. Table 31 shows the changes in questionnaire responses
between the pre-meeting questionnaire and the post-meeting questionnaire.
TABLE 31 Risk factors for the screening stage of the Minimum Data Set and Risk Assessment Framework
Risk factor
Pre-meeting questionnaire responses Post-meeting questionnaire responses
Group median Disagreement index Group median Disagreement index
Immobility status 9.00a 0.00 9.00a 0.00
Existing PU status 9.00a 0.13 9.00a 0.00
Previous PU status 7.00a 0.29 8.00a 0.29
General skin status 5.00b 1.87c 3.00d 0.74
Sensory perception 4.00b 0.68 3.00d 0.72
Acute illness 5.00b 0.59 3.00d 0.54
Infection 5.00b 0.98 2.00d 0.33
Body temperature 5.00b 0.97 2.00d 0.29
Nutrition 5.00b 0.55 2.00d 0.75
Friction and shear 2.00d 0.16 2.00d 0.29
Chronic wounds 3.00d 0.65 2.00d 0.29
Diabetes 4.00b 0.55 2.00d 0.37
Summary measure GHS 2.00d 0.20 2.00d 0.13
Perfusion – – 2.00d 0.75
Albumin 3.00d 0.48 2.00d 0.29
Skin moisture 4.00b 1.61c 2.00d 0.29
Dual incontinence 5.00b 1.70c 2.00d 0.33
Medication 3.00d 0.33 1.00d 0.02
Mental health status 2.00d 0.65 1.00d 0.13
Age 4.00b 0.67 1.00d 0.16
Race 2.00d 0.49 1.00d 0.02
Gender 1.00d 0.29 1.00d 0.02
Haemoglobin 2.00d 0.37 1.00d 0.16
Pitting oedema 3.00d 0.67 1.00d 0.13
Blood pressure 3.00d 0.67 – –
Smoking 2.00d 0.37 – –
Cardiovascular disease 3.00d 0.67 – –
GHS, general health status; PU, pressure ulcer.
a Group median 7–9 (inclusion supported).
b Group median 4–6 (uncertain).
c Disagreement.
d Group median 1–3 (inclusion not supported).
Reprinted from Coleman S, Nelson EA, Keen J, Wilson L, McGinnis E, Dealey C, et al. Developing a pressure ulcer risk factor
minimum data set and risk assessment framework. J Adv Nurs 2014;70:2339–52.126 © 2014 The Authors. Journal of
Advanced Nursing. Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the
original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
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The expert group agreed that 11 risk factors, namely immobility, existing pressure ulcer, previous pressure
ulcer, general skin status, perfusion, skin moisture, dual incontinence, diabetes, sensory perception, nutrition
and albumin level, should be incorporated into the full assessment stage of the Minimum Data Set and Risk
Assessment Framework for patients who were considered to be at potential/actual risk or who have an existing
pressure ulcer identified at the screening stage. Table 32 shows the changes in questionnaire responses
between the pre-meeting questionnaire and the post-meeting questionnaire. A summary of the key discussion
points relating to uncertain (group median 4–6) risk factors is detailed in Table 33. After reviewing the
evidence, the post-meeting questionnaire was revised and blood pressure, smoking and cardiovascular disease
were combined into a general category of ‘perfusion’.
TABLE 32 Risk factors for the full assessment stage of the Minimum Data Set and Risk Assessment Framework
Risk factor
Pre-meeting questionnaire responses Post-meeting questionnaire responses
Group median Disagreement index Group median Disagreement index
Immobility status 9.00a 0.16 9.00a 0.00
Existing PU status 9.00a 0.13 9.00a 0.16
Previous PU status 7.00a 0.40 8.00a 0.16
General skin status 8.00a 0.23 8.00a 0.29
Skin moisture 8.00a 0.29 8.00a 0.33
Diabetes 8.00a 0.29 8.00a 0.33
Nutrition 7.00a 0.67 8.00a 0.16
Perfusion – – 8.00a 0.40
Albumin 7.00a 0.20 7.00a 0.45
Sensory perception 8.00a 0.29 7.00a 0.29
Dual incontinence 8.00a 0.19 7.00a 0.33
Friction and shear 5.00b 1.10c 6.00b 0.52
Chronic wounds 6.00b 0.42 6.00b 0.37
Medication 5.00b 0.41 5.00b 0.08
Acute illness 7.00a 0.07 5.00b 0.59
Infection 5.00b 1.10c 5.00b 0.41
Body temperature 7.00a 0.52 5.00b 0.88
Pitting oedema 6.00b 0.30 5.00b 1.04c
Age 5.00b 0.49 5.00b 0.50
Summary measure GHS 4.00b 0.62 4.00b 0.65
Haemoglobin 5.00b 0.32 3.00d 0.72
Mental health status 5.00b 0.72 2.00d 0.75
Race 2.00d 0.49 1.00d 0.13
Gender 2.00d 0.29 1.00d 0.02
Blood pressure 5.00b 0.52 –
Smoking 5.00b 0.59 – –
Cardiovascular disease 6.00b 0.42 – –
GHS, general health status; PU, pressure ulcer.
a Group median 7–9 (inclusion supported).
b Group median 4–6 (uncertain).
c Disagreement.
d Group median 1–3 (inclusion not supported).
Source: Reprinted from Coleman S, Nelson EA, Keen J, Wilson L, McGinnis E, Dealey C, et al. Developing a pressure ulcer
risk factor minimum data set and risk assessment framework. J Adv Nurs 2014;70:2339–52.126 © 2014 The Authors.
Journal of Advanced Nursing. Published by John Wiley & Sons Ltd. This is an open access article under the terms of the
Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium,
provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
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Using the decision rules highlighted in the methods section, the Minimum Data Set and Risk Assessment
Framework comprised only those risk factors for which there was agreement (group median 7–9 without
disagreement). The progression of risk factors through the consensus study is detailed in Figure 14 (see
also Tables 31 and 32). This shows that of the original 15 risk factor domains and 46 subdomains
identified in the systematic review,46 26 risk factors were considered to potentially warrant inclusion in the
Minimum Data Set and Risk Assessment Framework and progressed to consensus cycle 1.
The risk factors for inclusion were mainly agreed in the cycle 1 post-meeting questionnaire but there were
some refinements of the risk factors in the cycle 2 pre-meeting questionnaire. The expert group had agreed
that albumin should be included at the second stage of the assessment (see Table 32). However, at a
subsequent PURSUN UK meeting, concern was raised about the need to undertake an additional blood test
for the assessment of albumin. In light of this, expert group members were asked whether there was a
clinical indication for undertaking an additional blood test to measure albumin for patients to establish the
level of pressure ulcer risk and it was concluded that this was unnecessary. The expert group also concluded
that skin moisture and dual incontinence could be combined into one measure.
TABLE 33 Uncertain risk factors
Uncertain risk factors Key discussion points from the expert group meetings
Friction and shear l Important concept in relation to biomechanics and tissue loading
l Debate about whether a patient characteristic
l Difficult to measure in practice
l Different definition of terms (e.g. nurses and bioengineers)
l Interlinked with immobility
l Should to be minimised in care
Acute illness, infection, body temperature
(elements of general health status)
l Felt to be important clinically
l Links between the three elements recognised
l Impact on mobility, perfusion and moisture acknowledged
Chronic wound l Did not emerge as a strong risk factor in the systematic review
l Link to other factors including nutritional depletion, moisture
(exudate), oedema, diabetes and general skin condition recognised
l Would be captured by other key risk factors, e.g. general skin status,
nutrition, moisture and diabetes
Pitting oedema l Relatively unexplored area in the literature
l Leads to changes in the mechanical properties of tissues
l May result in reduced mobility because of heavy oedematous legs
l Some felt that oedema should be considered under the ‘skin
status’ umbrella
Medication l Acknowledged that the systematic review evidence associated with
medication was weak
l Links between specific medications and risk factors were made
[e.g. the effects of sedation, epidurals and analgesia on sensation
and movement; the effects of steroids on skin condition (tissue
paper skin)]
l Use of vasoconstrictors in specialist areas important
l Complicated by dose-dependent effects
l Difficult to measure
Age l Some felt that age formed an important element of assessment
l Others felt that it was a proxy for other measures, e.g. skin condition
and immobility
Source: Reprinted from Coleman S, Nelson EA, Keen J, Wilson L, McGinnis E, Dealey C, et al. Developing a pressure ulcer
risk factor minimum data set and risk assessment framework. J Adv Nurs 2014;70:2339–52.126 © 2014 The Authors.
Journal of Advanced Nursing. Published by John Wiley & Sons Ltd. This is an open access article under the terms of the
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Cycle 2: assessment items for risk factors
There was support (group median 7–9 without disagreement) for all statements in the cycle 2 questionnaire
concerning the assessment items of the Minimum Data Set and Risk Assessment Framework. However,
following discussion at the cycle 2 meeting, the expert group felt that some changes should be made to specific
items. As the group were content with the majority of the pressure ulcer risk factor Minimum Data Set items
highlighted in the cycle 2 pre-meeting questionnaire, the post-meeting questionnaire focused on items that
required adjustment. The agreed assessment items for the screening and full assessment stage are detailed in
Table 34. In addition, the expert group agreed that the Risk Assessment Framework would facilitate the
identification of a risk profile for each patient, rather than condense the risk from different aspects into a single
score. This would support care planning, with interventions selected in response to specific risk factors.
TABLE 34 Minimum Data Set items to be incorporated into the Risk Assessment Framework
Risk factor Mobility
Screening stage
Mobility (a) Does the patient walk without help?
(b) Does the patient change position?
PU status (a) Current PU (category 1 or above)
(b) Reported history of PU
Full assessment stage
Immobility items to incorporate the frequency of independent
movement, e.g.
(a) Doesn’t move
(b) Moves occasionally
(c) Moves frequently
Immobility items to incorporate the magnitude of
independent movement, e.g.
(a) Doesn’t move
(b) Slight position changes
(c) Major position changes
Immobility items to incorporate general, clinically relevant
descriptions of movement, e.g.
(a) Bedfast
(b) Chairfast
(c) Walks with assistance
Sensory perception (a) Does the patient feel and respond appropriately to
discomfort from pressure
PU (existing and previous PU) (a) Category of PU (where possible for previous PU)
(b) Site of PU
(c) Presence of scar tissue (for previous PU)
General skin status (a) Confirmation of vulnerable skin, e.g. dryness, paper
thin and redness
(b) Pressure area skin site
Perfusion (a) Conditions affecting central circulation, e.g. shock,
heart failure and hypotension
(b) Conditions affecting peripheral circulation,
e.g. peripheral vascular/arterial disease
Diabetes (a) Presence of diabetes
Moisture (a) Presence of moisture due to perspiration, urine, faeces
or exudate
(b) Frequent (one or two times a day)
(c) Constant
Frequency
Nutrition (a) Unplanned weight loss
(b) Poor nutritional intake
(c) Low BMI
(d) High BMI
PU, pressure ulcer.
Reprinted from Coleman S, Nelson EA, Keen J, Wilson L, McGinnis E, Dealey C, et al. Developing a pressure ulcer risk factor
minimum data set and risk assessment framework. J Adv Nurs 2014;70:2339–52.126 © 2014 The Authors. Journal of
Advanced Nursing. Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the
original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
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Draft Risk Assessment Framework
Using the results from cycle 1 and 2 of the study, an initial draft of the Risk Assessment Framework was
produced (see Appendix 23) incorporating the screening and full assessment stage and decision pathways
of the assessment process. This underwent further graphic design prior to pre-testing.
Phase 3: development of a new conceptual framework and
theoretical causal pathway for pressure ulcer development
The Aims and objectives, Methods and Results sections are largely reproduced, with amendments, from
Coleman S, Nixon J, Keen J, Wilson L, McGinnis E, Dealey C, et al. A new pressure ulcer conceptual
framework, J Adv Nurs, with permission from John Wiley & Sons.187 © 2014 The Authors. Journal of
Advanced Nursing. Published by John Wiley & Sons Ltd. This is an open access article under the terms of
the Creative Commons Attribution-NonCommercial-NoDerivs License.
By bringing together the relevant fields of enquiry and clarifying key risk factors for pressure ulcer
development, the consensus study provided an opportunity to undertake an additional piece of work to
review and enhance the pressure ulcer conceptual framework.1 This was to bridge the gap between the
epidemiological, physiological and biomechanical evidence and enhance our understanding of the role of
individual risk factors in pressure ulcer development. This was not part of the programme outline initially
but emerged as an additional output of the work.
Aim and objectives
The aim was to develop a new pressure ulcer conceptual framework. Specific objectives were to:
1. review and update the biomechanical elements of the NPUAP/EPUAP 2009 conceptual framework
2. develop a theoretical causal pathway for pressure ulcer development
3. map risk factors identified in the consensus study to the updated conceptual framework.
Methods
The expert group reconvened in an additional facilitated meeting which was planned so that members had
access to the outcomes of the consensus study, the evidence of the systematic review46 and risk factor/
causal factor terminology before the face-to-face meeting. Familiarity with the risk factor/causal factor
terminology allowed us to explore the role of the risk factors in the pressure ulcer causal pathway. This
was facilitated by consideration of definitions from Brotman and colleagues:188
l risk factor – a variable with a significant statistical association with a clinical outcome
l independent risk factor – a risk factor that retains its statistical association with the outcome when
other established risk factors for the outcome are included in a statistical model
l non-independent risk factor – a risk factor that loses its statistical association with the outcome when
other established risk factors for the outcome are included in a statistical model.
Brotman and colleagues188 suggest that a causal factor is a risk factor that has a causal relationship with a
clinical outcome and is defined experimentally (known to affect outcome) rather than statistically. They
make a distinction between direct and indirect causal factors:
l Direct causal factor – directly impacts the outcome (or the likelihood of the outcome).
l Indirect causal factor – impacts the outcome (or affects its likelihood of occurrence) by changing a
direct causal factor. If the direct causal factor is prevented from changing then changes in the outcome
will not be produced.
In our work we further categorised indirect causal factors into key indirect causal factors (for which the
epidemiological/wider scientific evidence and/or clinical resonance was stronger) and other indirect causal
factors. Meeting discussions were audio recorded and transcribed, allowing key themes to be identified.
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Data analysis
In addition to considering the outcomes of the consensus study (see Phase 2: consensus study), the
researcher (SC) listened to the audio tapes of the conceptual framework expert group meeting discussions
and read the associated transcripts in total to ensure completeness. The analysis allowed the researcher
(SC) to draft the new pressure ulcer conceptual framework and theoretical causal pathway, which was
circulated to the expert group by e-mail to ensure content validity.
Results
The expert group discussions led to amendments to the existing NPUAP/EPUAP conceptual framework,1
as illustrated in Figure 15. Most notably, it was recognised that, although mechanical properties of the
tissues and geometry (morphology) of the tissues and underlying bones impact on the internal strains and
stresses (as an example, subjects who are either very emaciated or very obese will have enhanced strains
and stresses within the soft tissues), their impact was considered to be more relevant to the susceptibility
of the individual (i.e. impacting on the damage threshold). Furthermore, transport (perfusion and lymphatic
drainage) also impacts on the damage threshold of the individual and this would also be affected by
temperature in terms of vasodilation/vasoconstriction, thereby affecting tissue perfusion. The underlying
physiology of an individual will also have an impact on his or her repair capacity and this was an important
consideration that was captured in the amended conceptual framework (see Figure 15).
The theoretical schema of a proposed causal pathway for pressure ulcer development detailing the direct,
key indirect and other potential indirect causal factors is illustrated in Figure 16. Table 35 shows the
mapping of the direct causal factors and key indirect causal factors against the key components of the
enhanced 2009 NPUAP/EPUAP conceptual framework. Although it was recognised that the presence and
weighting of specific risk factors may vary in relation to the anatomical site of the pressure ulcer, it was not
possible to delineate the evidence to skin site-level risk factors.
Risk factors
Mechanical boundary conditions
Magnitude of mechanical load
Time duration of the mechanical load
Type of loading (shear, pressure, friction)
Internal strains
Stresses
Damage threshold
Susceptibility and tolerance of the individual
Individual mechanical properties of the tissue
Individual geometry (morphology) of the tissues
and bones
Individual physiology & repair
Individual transport and thermal properties
Pressure ulcer?
FIGURE 15 Enhanced NPUAP/EPUAP (2009) factors that influence susceptibility for pressure ulcer development.
Reproduced from Coleman, Nixon, Keen, Wilson, McGinnis, Dealey et al. A new pressure ulcer conceptual
framework. J Adv Nurs 2014;70:2222–34.187 © 2014 The Authors. Journal of Advanced Nursing Published by
John Wiley & Sons Ltd. This is an open access article under the terms of the TODO: clickthrough URLCreative
Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium,
provided the original work is properly cited, the use is non-commercial and no modifications or adaptations
are made.
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Direct causal factors
Three characteristics were classified as direct causal factors: immobility, skin/ulcer status and perfusion.
Immobility is a necessary condition for pressure ulcer development and is therefore considered a direct
causal factor (see Figure 16); through its impact on mechanical boundary conditions (see Table 35) it
directly impacts the outcome (or the likelihood of the outcome). Of note is that friction and shear is not
specified as a patient characteristic but rather as a characteristic of the mechanical boundary condition
(see Table 35).
Identifying whether skin/ulcer status (incorporating existing and previous pressure ulcers and general skin
status) and poor perfusion represent a direct or indirect risk factor is less straightforward. It could be
assumed that they are indirect factors as without some degree of immobility a pressure ulcer would not
develop. However, this is not in keeping with the definitions of causal factors and oversimplifies the
complex interplay of factors required to lead to tissue damage. There is strong epidemiological/wider
scientific evidence that poor perfusion and skin/ulcer status reduce patients’ tolerance to pressure and
increase the likelihood of pressure ulcer development, suggesting that they are direct causal factors, and
this may explain why some immobile patients develop pressure ulcers whereas others do not.
Further insight was gained by mapping skin/ulcer status and poor perfusion to the conceptual framework; it
was apparent that they were clearly implicated in the susceptibility and tolerance aspect of the framework
(see Table 35). Skin/ulcer status mapped to the individual geometry (morphology) of the tissue and bones,
the mechanical property of the tissues, the transport and thermal properties and the physiology and repair
aspects of the framework. Perfusion mapped to the individual transport and thermal properties and the
physiology and repair elements of the framework and is related to factors that impair circulation. Within the
TABLE 35 Mapping of direct causal and key indirect causal factors to the conceptual framework
Risk factor
Mechanical boundary conditions:
type of loading (shear, pressure,
friction) and magnitude and
duration of mechanical load
Individual
geometry
(morphology)
of the tissue
and bones
Individual
mechanical
property of
the tissues
Individual
transport
and thermal
properties
Individual
physiology
and repair
Immobility ✗
Skin/PU status ✗ ✗ ✗ ✗
Poor perfusion ✗ ✗
Poor nutrition (✗) in extreme
cases
(✗) in extreme
cases
✗ ✗
Moisture ✗ ✗
Poor sensory
perception and
response
(✗) through immobility
Diabetes (✗) through sensory perception (✗) through
perfusion
Low albumin
level
(✗) through
perfusion
PU, pressure ulcer.
Reproduced from Coleman, Nixon, Keen, Wilson, McGinnis, Dealey et al. A new pressure ulcer conceptual framework.
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expert group it was recognised that oxygen-carrying capacity was important in maintaining healthy tissues,
although it was also recognised that other factors such as the delivery of nutrients and waste removal were
important, and at present it is difficult to determine the most important factors relating to perfusion. Further
confirmatory research is needed to more clearly ascertain the aetiological mechanisms of importance.
Key indirect causal factors
Moisture, sensory perception, diabetes, low albumin level and poor nutrition were considered key indirect
causal factors as they impact the outcome (or affect its likelihood of occurrence) by changing a direct
causal factor (see Figure 16).
Other potential indirect causal factors
The theoretical conceptual schema (see Figure 16) was further developed to include other indirect causal
factors to illustrate the potential relationships and the impact of diverse factors that may be involved in
the causal pathway. However, it is recognised that the inter-relationships among potential and key indirect
causal factors are complex and require further elucidation. Other potential indirect causal factors include
those with weak or limited epidemiological/wider scientific evidence but which are thought to impact on
key indirect and direct causal factors. These include age, medication and pitting oedema as well as other
factors relating to general health status including infection, acute illness, raised body temperature and
chronic wound.
New pressure ulcer conceptual framework
Having considered the causal pathway for pressure ulcer development (see Figure 16) and mapped the
direct and key indirect causal factors for ulcer development against the components of the enhanced
conceptual framework (see Table 35), a new conceptual framework is proposed that enables the
epidemiological evidence to be linked to the conceptual framework (Figure 17). The new framework
shows that there is a relationship between the mechanical boundary conditions and the susceptibility and
tolerance of the individual. The risk factors that impact the mechanical boundary conditions and the
susceptibility and tolerance of the individual are detailed in the framework and are based on the direct
causal factors of immobility, skin/ulcer status and poor perfusion as well as on the key indirect causal
factors of poor sensory perception and response, diabetes, poor nutrition, moisture and low albumin level.
For simplicity, the risk factors are represented under the elements that they predominantly affect (either
mechanical boundary conditions or susceptibility and tolerance of the individual), but the broken line
running under the risk factors indicates that some risk factors may have an effect on both sides of the
framework, which is more clearly articulated in the theoretical schema (see Figure 16) and risk factor
mapping (see Table 35). The absence of risk factors on either the individual susceptibility and tolerance or
the mechanical boundary conditions side of the framework would affect the likelihood of pressure ulcer
development [i.e. a patient with good perfusion may be able to tolerate higher levels of immobility
(without developing a pressure ulcer) than a patient with poor perfusion].
Phase 4: design and pre-testing of the Risk Assessment Framework
(incorporating the risk factor Minimum Data Set)
The consensus study identified the risk factors and assessment items and suggested a structure for the
Risk Assessment Framework (incorporating the risk factor Minimum Data Set). With these elements
agreed we engaged the support of a graphic designer (see Acknowledgements) to develop the new
Risk Assessment Framework in a way that would facilitate ease of use. This incorporated the use of
colour to aid clinical decision-making. To ensure that clinicians/nurses understood and were able to use
the Risk Assessment Framework, the next study of the work package was undertaken – pre-testing of the
Risk Assessment Framework (see Appendix 24 for study protocol).
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Study aim
The aim was to assess and improve the acceptability, usability, format, design, clarity, comprehension,
language and data completeness of the draft Risk Assessment Framework (incorporating the risk factor
Minimum Data Set) with clinical nurses.
Methods
Cognitive pre-testing methods were used to evaluate how clinical nurses interpreted questions, response
categories and instructions while using the draft Risk Assessment Framework.189 This was conducted
over three pre-test sessions and incorporated three focus groups and 12 ‘think out loud’ interviews,
estimated as the number required for data saturation. It was anticipated that focus groups with nurses in
similar roles (e.g. staff nurses, senior nurses) would facilitate greater understanding of the usability of
the Risk Assessment Framework, allowing group members to ‘spark ideas off one another’, which might
lead to greater disclosure.190
In addition, one-to-one think out loud interviews191 were undertaken to allow the researcher (SC) to
identify specific problems with the risk assessment tool that would be amenable to resolution by
modification. The study was conducted to allow analysis of and adjustment to the Risk Assessment
Framework to be undertaken between pre-test sessions so that three different versions of the tool could
be pre-tested and improvements made in an interative process.
Participants
For the pre-test we recruited nurses from a large acute teaching hopsital trust, a district general hospital
and two primary care trusts. Purposive sampling was undertaken to ensure that tissue viability nurses, staff
nurses and sisters from hospital and community settings were recruited from each of the four participating
sites. Participants included those who had an interest in tissue viability (e.g. a link nurse or member of a
local pressure ulcer or wound care working group). The study was approved by the University of Leeds
School of Healthcare Research Ethics Committee. Informed consent was obtained prior to participation in
the study (see Appendices 25 and 26 for the patient information leaflet and consent form).
Data collection
The three facilitated pre-test sessions were undertaken away from the clinical environment and involved
8–12 nurses from the four participating sites, who were grouped by job role (staff nurse, sister/charge
nurse and tissue viability nurse specialist/research nurse) to facilitate openness, as the use of
heterogeneous groups can lead to inhibition in raising issues that do not seem to be shared by others.190
This was thought to be particularly important for this group as a hierarchy might have stifled disclosure
(e.g. a staff nurse might not want to disagree with the views of his/her ward sister). Having nurses from
different centres minimised familiarity, which can lead to participants relying on ‘taken for granted’
assumptions.190 At the pre-test session, the nurses were trained in how to use the Risk Assessment
Framework and were then randomly allocated to either a focus group or a one-to-one think out
loud interview.
Training involved a short presentation and demonstration on how to use the draft Risk Assessment
Framework with a simulated patient. Each nurse then completed the draft Risk Assessment Framework
using case studies and vignettes (see Appendix 27) that were accompanied by photographs of pressure
areas and ulcers. The vignettes were appropriate to the nurses’ area of practice (i.e. community nurses
used vignettes of community patients). The vignettes were co-developed by the project lead, the project
team and members of PURSUN UK to ensure that they were realistic and clinically relevant. Nurses were
encouraged to ask questions throughout the training session.
The sessions were planned to ensure that four to eight nurses192 per pre-test were assigned to the focus
group. Each was asked to complete the Risk Assessment Framework again, using three case studies
relevant to their area of practice. Nurse participants were encouraged to highlight any areas of the Risk
Assessment Framework form that they found confusing. A co-facilitator assessed data completeness and
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listed areas where data items were not completed or were not completed as required, as well as areas
noted by the nurses as confusing. The focus group meeting then convened to discuss the use of the
Risk Assessment Framework. The meeting was moderated by two facilitators and audio recorded. The
moderator promoted group interaction and guided discussions using a topic guide (see Appendix 28),
which considered the usability of the Risk Assessment Framework and any areas of confusion regarding
its use. This was informed by the data completeness assessment.
Up to four nurses from each session were assigned to the one-to-one think out loud interviews. A topic
guide (see Appendix 29) was used and the researcher first guided the nurses though the think out
loud technique. Once the nurse were content with the approach, they were asked to complete the
Risk Assessment Framework again in the presence of the researcher using three vignette case studies
appropriate to their area of practice. The researcher encouraged the nurses to vocalise their thoughts as
they completed the Risk Assessment Framework. This allowed specific issues relating to difficulty in
interpreting items or confusion about aspects of the Risk Assessment Framework to be identified. The
interviews were audio recorded.
Analysis
Data completeness of the Risk Assessment Framework forms was undertaken by calculating the
percentage of item-level missing data, the percentage of decision pathways allocated and the percentage
of item-level missing data for those for whom a decision pathway was allocated. The appropriateness of
the allocated decision pathway was also assessed based on the decision rules of the Risk Assessment
Framework and the item responses for each assessment.
The focus group meetings and the think out loud interviews were audiotaped and transcribed. The
researcher listened to the audio tapes and read the transcripts to ensure accuracy and to ensure that a
good overview of the discussions had been achieved. The data were then coded, which was directed by
the risk factor items of the Risk Assessment Framework, using a directed content analysis approach.183
The emphasis was on identifying themes across the focus groups and think out loud interviews that
impacted on the application of the Risk Assessment Framework in clinical practice. A summary report of
each meeting was reviewed by the facilitators to ensure that it reflected the discussions that had taken
place. The report was considered by a working group (consisting of clinical and academic leaders in the
pressure ulcer field) and adjustments were made to the draft Risk Assessment Framework, which was
pre-tested at the subsequent session in an iterative process. Following pre-testing, the Risk Assessment
Framework was also reviewed by PURSUN UK and the consensus study expert group.
Results
The pre-test sessions were well attended by 34 nurses from acute (n= 16) and community (n= 18)
settings. Over the three pre-test sessions, 101 Risk Assessment Framework assessments were undertaken
using vignette case studies by 11 tissue viability/research nurses (n= 32 Risk Assessment Framework
assessments), 12 staff nurses (n= 36 Risk Assessment Framework assessments) and 11 sisters (n= 33 Risk
Assessment Framework assessments). At each pre-test session, four nurses undertook the think out loud
interviews and seven or eight nurses attended the focus groups. Table 36 details the level of data
completion for each pre-test session, which can be seen to improve as the Risk Assessment Framework
was amended over the three pre-test sessions.
An inappropriate decision pathway was allocated when an assessment detailed the presence of a ulcer
and the case–study patient should have been allocated to the ‘pressure ulcer category 1 or above or
scarring’ pathway but was allocated to the ‘at-risk’ pathway. Uncertainty about the appropriateness of the
allocated pathway related to missing data, for example a patient was allocated to the ‘not currently at risk’
pathway but the skin assessment items were not fully completed and hence there was a possibility that a
higher pathway was appropriate.
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Figure 18 illustrates how the levels of missing data decreased over the three pre-test sessions overall and
when a decision pathway was allocated. Figure 19 illustrates how the number of decision pathways
allocated increased notably from the first to the second pre-test. Table 37 presents the appropriateness of
the decision pathways allocated according to the decision rules of the Risk Assessment Framework and the
item responses for each assessment.
Changes made to the Risk Assessment Framework between pre-test sessions in response to the analysis of data
completeness, think out loud interviews and focus groups are summarised in Figure 20 and related to three
main areas: flow and format, decision support and wording of specific items. An example of the changes made
to these main areas between pre-test sessions is shown in Figures 21–23 in relation to step 1 of the assessment.
It should be acknowledged that, following these changes, some nurses still completed the step 1 skin/ulcer
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FIGURE 19 Percentage of decision pathways allocated at each pre-test session.
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FIGURE 18 Percentage of missing data at each pre-test session.
TABLE 37 Appropriate decision pathway allocation
Decision pathway allocation
Pre-test session 1
(TVNs/RNs), % (n/N)
Pre-test session 2
(staff nurse), % (n/N)
Pre-test session 3
(Sisters), % (n/N)
Appropriate pathway allocation 78.6 (11/14) 91.4 (32/35) 90.6 (29/32)
Inappropriate pathway allocation 7.1 (1/14)
Pathway allocated but some uncertainty in
appropriateness because of missing data items
14.3 (2/14) 8.6 (3/35) 9.4 (3/32)
RN research nurse; TVN, tissue viability nurse.
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Flow and format
To improve data completion and to make the tool less busy and more inviting to complete the format
of the PURAF was changed from many compulsory yes/no items to a ‘no problem’ option for each risk
factor domain/subdomain section (with the exception of diabetes and previous PU history) and then
tick as applicable options
The flow of the stage 1 assessment was changed to make it clearer when it is necessary to complete
the stage 1 skin items and to allow a patient with mobility problems to move directly to the second
stage of the assessment (preventing unnecessary duplication of skin items)
A skin vulnerability item was added to the stage 1 assessment to capture the potential effects of other
medical conditions on skin condition, e.g. peripheral vascular disease. A normal skin option was also
added as it was felt that a confirmation of normal skin was needed to allow a patient to be allocated
not currently at risk at stage 1 of the assessment
Decision support
The arrows of the stage 1 assessment were adjusted to clarify that both the mobility and skin/PU status
items should be completed before a patient was deemed not currently at risk
The decision support box relating to pathway allocation was clarified
Provision to indicate the patient was not currently at risk at the first stage of the assessment was made.
Tick boxes relating to pathway allocation at the second stage were made more obvious
The order of the pathways was changed to assist with decision making (i.e. red/pink indicates
secondary prevention pathway)
Wording of specific items
Items where a positive response indicated there was not a problem (including mobility stage 1 items
and the sensory perception item) were adjusted in line with the other items so that a positive response
indicated the patient had a problem with the risk factor item
The stage 1 mobility items underwent major changes to incorporate an element of frequency of
movement, to remove terminology of ‘bedfast’ and ‘chairfast’ and to clarify what was meant by ‘help’
in relation the walking item
A normal skin option was also added to the stage 2 current detailed skin assessment (to replace the
vulnerability yes/no items). The instructions were clarified to highlight that these items related to
current rather than history. Further instructions were added to the vulnerable skin item (‘precursor to
PU’). Vulnerability examples and were amended slightly and moist was added. Other skin sites were
made into if applicable items
The wording within the analysis of movement item was changed as follows: ‘magnitude’ was replaced
with ‘extent’ and ‘relief of pressure areas’ was replaced with ‘relief of all pressure areas’. The
instructions for completing the item were slightly amended
It was clarified that the previous PU history item was an ‘if applicable item’. The category box within
the item was coloured yellow. The scar item was to be completed as applicable
The parameters of the moisture item were changed from ‘1 – 2 times a day’ to ‘2 – 4 times a day’
Flow and format
The layout of the tool was changed from landscape to portrait to allow the tool to flow more easily
and to fit in with assessment documents used in clinical practice
The stages of the assessment were changed to ‘steps' and descriptions added (step 1: screening, 
step 2: full assessment’ with instructions to ‘complete all sections’. A step 3 ‘assessment decision’
section was added to encourage pathway allocation
Decision support
The format of the step 1 of the assessment was changed to make it more obvious when the step 1
skin/PU item should be completed and when a patient should progress to step 2 or be allocated to the
not currently at risk pathway
Instructions in two decision boxes were clarified (step 1 skin/PU yellow and step 3 amber)
A summary of the EPUAP/NPUAP PU classification system was added
Wording of specific items
A ‘not diabetic’ option was added to the diabetic item
The previous PU history item was changed from a tick if applicable item to ‘no known PU history’ or
‘PU history’. If a history was indicated the approximate date, site and PU cat should be detailed
Parameters were added to the BMI items
Flow and format
The blue not currently at risk boxes were changed to green like other RAG assessment systems
Wording of specific items
The moisture ‘no problem’ item was changed to ‘no problem/occasional’
The analysis of movement title was changed to analysis of ‘independent’ movement
Changes
after first
pre-test
session
Changes
after second
pre-test
session
Changes
after third
pre-test
session
Preliminary RAF – PURPOSE-T
FIGURE 20 Changes to the Risk Assessment Framework following each pre-test session. PU, pressure ulcer;
PURAF, Pressure Ulcer Risk Assessment Framework; RAG, red, amber, green.
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FIGURE 21 Pre-test session 1 draft Risk Assessment Framework. Please note that the Risk Assessment Framework
incorporates the use of colour. These examples have been adapted with the colour key provided.
FIGURE 22 Pre-test session 2 draft Risk Assessment Framework. Please note that the Risk Assessment Framework
incorporates the use of colour. These examples have been adapted with the colour key provided.
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items despite not needing to. This could be related to the use of case studies in the pre-test sessions in which
information on skin/ulcer status was readily available, whereas in clinical practice this information may be
less obvious.
Other notable changes made over the course of the pre-test session relate to the move from landscape to
portrait orientation to improve the flow of the tool and the development of specific items (e.g. the
terminology relating to ‘bedfast’ and ‘chairfast’ in the step 1 mobility items was found to be confusing and
there was a need to incorporate an element of frequency to the items, which were subsequently amended
and tested at the next session). The think out loud participants from the first pre-test also highlighted that
items for which a positive response indicated that the patient did not have a problem were confusing. This
related to step 1 mobility items and the step 2 sensory perception item and changes were made to the
Risk Assessment Framework used at subsequent sessions.
The first pre-test focus group felt that there should be some provision within step 1 of the Risk Assessment
Framework to enable nurses to use their clinical judgement in terms of other significant risk factors
(which may be exceptions to the rule) that they should take into account when considering if a patient
should progress to the more detailed step 2 assessment. This could relate to the severity of a risk factor
(e.g. terminally ill patients, severe diabetes, perfusion problems and severe nutritional problems). Having
‘other items’ at step 1 was considered by the working group but there was concern that the screening
stage could become too large. Taking into account the causal pathway for pressure ulcer development,
it was decided that a ‘vulnerable skin’ item would be included instead to focus the assessment on the
potential impact that other medical conditions might have on the skin, rather than on the presence or
absence of many different conditions.
The data completeness assessment (see Table 36 and Figure 18) showed poor decision pathway allocation
in the first pre-test. The corresponding focus group discussions highlighted confusion over where to
indicate the pathway allocation; some nurses had attempted to indicate a pathway on the form although
they were clearly unsure of where to do this. This alerted us to a significant omission and lack of clarity
FIGURE 23 Pre-test session 3 draft Risk Assessment Framework. Please note that the Risk Assessment Framework
incorporates the use of colour. These examples have been adapted with the colour key provided.
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within the Risk Assessment Framework and the need to include a response box within the ‘not currently
at risk’ pathway at the first stage of the assessment and to make the pathway allocation tick boxes at
stage 2 of the assessment more obvious. In addition, the think out loud interviews in the first pre-test
session highlighted an issue relating to the ordering of the decision pathway boxes in the first draft Risk
Assessment Framework, that is, the first pathway (left) being the blue ‘not currently at risk pathway’, the
second pathway (middle) being the orange primary prevention pathway and the third pathway (right)
being the red secondary prevention/treatment pathway, and the resultant possibility of ticking the primary
prevention pathway before getting to the secondary prevention/treatment pathway. It was suggested that,
as ‘red trumps orange’, the boxes should be reordered so that the red one was first, and this was
undertaken for the second pre-test (see Figures 21–23).
The review of the Risk Assessment Framework by PURSUN UK and the expert group (following pre-testing)
led to a final change to the Risk Assessment Framework. Although members of PURSUN UK felt that the
Risk Assessment Framework was clear and understandable, they raised concern about the wording of the
sensory perception item; this related to the ‘ability to feel and respond’ aspect of the item. The group agreed
that the patient might be able to fulfil only one of these requirements, which should be considered a problem,
but the wording suggested that it would be a problem only if the patient could not do both. They felt that the
terminology should be ‘feel and/or respond’. This led to the wording of the sensory perception item being
reconsidered at the subsequent expert group meeting and amendments being made.
The pre-test facilitated the development of the preliminary Risk Assessment Framework (see Appendix 30),
which was easily understood by clinical nurses. The Risk Assessment Framework was subsequently named
the PURPOSE-T and will be further evaluated in clinical practice.
Phase 5: clinical evaluation of the PURPOSE-T (Risk Assessment
Framework incorporating the risk factor Minimum Data Set)
To enable the provisional Risk Assessment Framework (PURPOSE-T) to be used with confidence in clinical
practice, the fifth phase of the work package examined the fundamental properties of the instrument.
This involved a field test to assess its reliability, convergent validity and clinical usabilty (see Appendix 31
for the study protocol).
Aims
The aims of field test 1 were to assess the:
l data completeness and clinical usability of the PURPOSE-T
l inter-rater and test–retest reliability of the PURPOSE-T
l convergent validity and known groups validity of the PURPOSE-T.
Methods
Design
The PURPOSE-T was evaluated through field testing using observational descriptive methods. Hospital
inpatients and community nursing patients were invited to participate. Demographic characteristics were
collected and individual pressure ulcer risk was assessed for all patients. Paired assessments were
undertaken simultaneously using the PURPOSE-T, one by a ward/community nurse and one by an expert
nurse, with each nurse remaining blind to the corresponding assessment. A blinded retest was undertaken
by the same expert nurse at a follow-up visit.
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In addition, the expert nurses involved in data collection kept field notes of their experience of using
the PURPOSE-T in clinical practice and comments from ward/community nurses during their use of the
PURPOSE-T. The field notes were summarised and used to inform design amendments and issues of
importance for implementation.
Description of the preliminary PURPOSE-T
The PURPOSE-T (field test version) incorporates a three-step assessment process:
l step 1 – screening assessment of mobility and skin status
l step 2 – full assessment of analysis of independent movement, sensory perception, detailed skin
assessment, previous pressure ulcer history, perfusion, nutrition, moisture and diabetes
l step 3 – assessment decision of ‘no pressure ulcer not currently at risk’, ‘no pressure ulcer but at risk’
and ‘pressure ulcer category 1 or above or scarring from previous pressure ulcer’.
The tool is colour coded as follows to facilitate decision-making:
l blue – ‘no problem’ with risk factor
l yellow – ‘problem’ that may impact on pressure ulcer risk
l orange – ‘problem’ that puts the patient at risk and requires primary prevention
l pink – patient has a pressure ulcer or scar from a previous pressure ulcer and requires secondary
prevention/treatment.
The assessment decision is also colour coded using the RAG (red/amber/green) rating as follows:
l red – ‘pressure ulcer category 1 or above or scarring from previous pressure ulcer’
l amber – ‘no pressure ulcer but at risk’
l green – ‘no pressure ulcer not currently at risk’.
At step 1 there are four mobility options with ‘tick all applicable’ instructions. If only the blue-coded
criterion ‘walks independently with or without walking aids’ is ticked the instructions are to progress to
step 1 skin status. If any other mobility criteria (which are all coded yellow) are ticked, the instructions are
to progress to step 2 (see Appendix 30).
The step 1 skin status item also has four options with ‘tick all applicable’ instructions. If only the blue-coded
‘normal skin’ option is ticked the instructions are to allocate the patient to the green assessment decision – the
‘no pressure ulcer not currently at risk’ pathway. If any other skin status options are ticked (coded yellow and
pink), the instructions are to progress to step 2 full assessment (see Appendix 30).
Step 2 includes assessment of the following:
l analysis of independent movement: five options, including four coded orange (with varying limitations
to frequency and extent of independent movement) and one coded yellow (making major position
changes frequently)
l detailed skin assessment of 13 skin sites (with the option for ‘other’ skin sites), with three options for
each, including ‘normal skin’ coded blue, ‘vulnerable skin’ coded orange and ‘pressure ulcer category 1’
coded pink
l previous pressure ulcer history: two options, including ‘no known pressure ulcer history’ coded blue
and ‘pressure ulcer history’ coded yellow, with presence of scar (if applicable only) coded pink
l sensory perception: two options, including ‘no problem’ coded blue and ‘patient is unable to feel
and/or respond to discomfort from pressure’ coded orange
l perfusion: three options, including ‘no problem’ coded blue and two options coded orange: ‘conditions
affecting central circulation, for example shock, heart failure and hypotension’ and ‘conditions affecting
peripheral circulation, for example peripheral vascular/arterial disease’
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l nutrition: five options, including ‘no problem’ coded blue and four options coded yellow: ‘unplanned
weight loss’, ‘poor nutritional intake’, ‘low BMI’ and ‘high BMI’
l moisture: three options, including ‘no problem/occasional’ coded blue and two options coded yellow:
‘frequent’ and ‘constant’
l diabetes: two options, including ‘not diabetic’ coded blue and ‘diabetic’ coded yellow.
Step 3 involves allocation of an assessment decision as outlined in Table 38.
Nurse eligibility and preparation
A nurse was defined as an expert if he or she was a member of the participating trusts’ tissue viability
teams (tissue viability nurse consultant/specialist/clinical research nurse). Participating expert nurses
attended an initiation training day at which the PURPOSE-T was presented, the instruction manual was
provided and they used the PURPOSE-T through vignettes and role play until they were confident in how
to use it. In practice, all expert nurses involved in recruitment and data collection were clinical research
nurses with specialist tissue viability knowledge gained through their role in other PURPOSE programme
research projects.
The expert nurses in the acute sector identified a range of wards, sought verbal permission from ward
managers to undertake the research and arranged a mutually convenient date with a qualified member of
the ward team to undertake training and patient assessment. In the community sector the expert nurses
sought volunteers from the community nursing service and arranged a mutually convenient time to
undertake training and patient assessment.
All participating ward/community nurses underwent training in the use of the PURPOSE-T from the expert
nurses. This included a full explanation of the PURPOSE-T and the instruction manual followed by an
invitation to undertake an assessment using the same vignettes that were used by the expert group nurses
in their training, so that they were familiar with the instrument. Either the ward/community nurse or the
ward/community team budget received a per-patient or a per-hour payment to cover the funding required
to release the ward/community nurse from usual clinical duties.
Patient eligibility
Inclusion criteria
l Age ≥ 18 years.
l Inpatient in the acute setting or community nursing patient in the community setting.
l Provide written informed consent/verbal witnessed consent/consultee agreement.
l Expected to be available for the PURPOSE-T retest.
TABLE 38 Step 3 assessment decision instructions
Colour code Assessment Assessment decision
Any pink Pressure ulcer of category 1 or above or scarring
from previous pressure ulcer
Red: secondary prevention and treatment
pathway
Any orange
(but no pink)
No pressure ulcer but at risk Amber: primary prevention pathway
Only yellow and
blue
Nurse to consider risk factors present and decide Amber: primary prevention pathway OR green:
not currently at risk pathway
RISK ASSESSMENT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
132
Exclusion criteria
l Patients in obstetric, paediatric, day case surgery or psychiatric settings (acute or community).
l Patients deemed by the attending health-care professional to be too unwell to be approached and/or
complete the study assessment schedule.
Sampling strategy
Patients were purposively sampled ensuring a similar number of hospital and community patients and
representation of patients across four broad levels of risk (as defined by their mobility and ulcer status)
as follows:
l no mobility restrictions
l some mobility/activity limitations
l bedfast/chairfast
l pressure ulcer category 1 or above.
Each ward/community nurse was asked to identify four patients on his or her caseload, one from each of
the four broad levels of risk when possible.
Recruitment and consent
Ward-/community-based nurses identified suitable patients from their area of practice. A full verbal
explanation of the study and a patient information leaflet (see Appendix 32) were provided by the
attending clinical staff or a member of the tissue viability team and assenting patients were then invited to
provide informed, written consent (see Appendix 33). When patients were capable of giving consent but
physically unable to complete the written aspects of the consent form, witnessed consent was obtained
(see Appendix 34). In addition, to ensure that the study population was representative of the clinical
population assessed in the course of usual care, when patients lacked capacity ethical approval was given
for consultee agreement (see Appendices 35 and 36). Assessment of eligibility and informed consent
was undertaken by a member of the tissue viability team. Patients who both were eligible for study
participation and provided informed consent/consultee agreement were registered centrally using the
CTRU automated 24-hour telephone registration system.
Data collection/assessments
Each patient recruited to the field test was assessed by only one pair of assessors.
At baseline, demographic and clinical data were recorded for each patient by the expert nurse. Baseline
data included type of NHS facility (hospital/intermediate care/community nursing team), type of admission/
referral (e.g. elective/acute), ward specialty (hospital patients only), date of birth, gender and ethnicity.
Clinical assessment included the subscales of the Braden scale51 and the Waterlow scale.50
At baseline the PURPOSE-T was completed and recorded by a member of the ward/community team and
the expert nurse, blind to each other’s assessment. This incorporated the detailed skin assessment and,
when applicable, pressure ulcer classification.1 The blinding was maintained through the design of a
sealable research form. Both nurses were instructed to complete their assessment and seal the form prior
to collection.
Finally, the expert nurse undertook a second visit and completed the PURPOSE-T and recorded clinically
relevant changes to the patient’s condition since the baseline assessment. The PURPOSE-T assessment was
carried out blind to the baseline assessment, again maintained through the sealed research form.
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The length of the test–retest interval was planned to be short enough to ensure that clinical change in the
pressure ulcer was unlikely to occur but sufficiently long to ensure that the expert nurse did not recall his
or her responses from the first assessment. Nurses were asked to plan their retest visit between 1 and
3 days after the baseline visit for hospital patients and between 1 and 7 days after the baseline visit for
community patients, taking into account the anticipated recovery/deterioration/stability of each patient’s
condition and, for hospital patients, length of stay.
The expert nurses involved in data collection also kept field notes of their experience of using the
PURPOSE-T in clinical practice.
Analysis considerations
Study definitions of risk
The PURPOSE-T identifies three groups of patients: those patients who are not currently at risk of
developing a pressure ulcer, those patients who have no pressure ulcer but who are ‘at risk’ and require
primary prevention and those patients with an existing pressure ulcer/scar who require secondary
prevention/treatment. For the purposes of describing the study population and to assess convergent
validity with other risk assessment tools, ‘at risk’ is defined as all patients ‘who have no pressure ulcer but
who are at risk’ and all patients who have a ‘pressure ulcer category 1 or above or scarring from previous
pressure ulcers’. A patient is therefore defined as ‘not at risk’ if his or her outcome within the raw data
was recorded as ‘no pressure ulcer not currently at risk’. The cut-point used to identify patients at risk was
≤ 18 for the Braden scale193 and ≥ 10 for the Waterlow scale.50
Sample size
In the study population we aimed to recruit approximately 25% of patients ‘not at risk’ and 75% ‘at risk’.
In a two-rater study, the numbers of subjects required to detect a statistically significant kappa (two-sided
p-value ≤ 0.05) with 90% power and 75% assessed as being ‘at risk’, assuming a null hypothesis value
for kappa, are given in Table 39.
To establish whether the tool gives a high degree of beyond-chance agreement, we tested against a null
value of 0.6. With 90% power, 199 patients were required. To allow for withdrawal/non-compliance in
paired assessments of 15%, we aimed to recruit 230 patients.
TABLE 39 Inter-rater reliability sample size estimates
Kappa to detect Null value Number of required patients (90% power)
0.7 0.4 114
0.7 0.5 231
0.7 0.6 793
0.8 0.4 64
0.8 0.5 103
0.8 0.6 199
0.8 0.7 536
0.9 0.4 41
0.9 0.5 58
0.9 0.6 89
0.9 0.7 159
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No examples of formal sample size estimation methods for the evaluation of screening instruments were
identified in the literature. Therefore, literature relating to the psychometric evaluation of rating scales was
considered. The ‘rule of thumb’ recommendation of 5–10 patients for every item in a questionnaire was
used to estimate the sample size of 115–230 patients.194,195 The proposed sample size of 230 to assess the
inter-rater reliability of the instrument, with > 95% expert nurse data compliance (based on previous
research experience), was expected to provide a sufficient number of patients to assess the validity of the
risk assessment instrument.
Analysis methods
Data completeness was assessed for each element of the PURPOSE-T including the percentage of missing
item-level data and risk categories allocated.
We produced kappa (with 95% CI), prevalence-adjusted bias-adjusted kappa (PABAK) and the maximum
value of kappa (κmax.) statistics to assess the inter-rater and test–retest reliability for agreement of risk status
overall (i.e. at risk/not at risk); cross-tabulations of overall risk status by rater/retest were produced. We also
examined the extent of agreement for individual PURPOSE-T items using cross-tabulations by type of
rater/retest. In addition, we produced kappa (with 95% CI) and weighted kappa statistics to assess the
inter-rater reliability for agreement of the PURPOSE-T outcome on the 3-point scale (no risk, at risk, current
pressure ulcer or pressure ulcer scarring) and produced cross-tabulations of PURPOSE-T outcome by type of
rater/retest. We used guidelines to interpret kappa analysis as detailed in Table 40.196,197
Table 41 details the psychometric tests undertaken. Convergent validity assesses the degree to which
constructs (or scores on a measure) expected to be related are, in fact, related. The degree to which
assessment of ‘at risk’ and ‘not at risk’ is related to risk assessment status as assessed using the Braden
and Waterlow risk assessment scales was determined, using cross-tabulations.
In addition, cross-tabulations of corresponding items between the PURPOSE-T and the Braden scale and/or
the Waterlow scale were produced and correlation coefficients were calculated. The Spearman rank
correlation coefficient was used when each of the items being compared had more than two levels, for
example the Braden activity and Braden mobility subscales each have four levels and were both compared
with the PURPOSE-T analysis of independent movement (which had been reduced to a 3-point scale). The
phi correlation coefficient was calculated when dichotomous variables were compared, for example risk
status on the Braden scale compared with risk status on the PURPOSE-T. For exploratory purposes, the
following hypotheses were used as guides to the magnitude of correlations, as opposed to pass/fail
benchmarks: high correlation r> 0.7; moderate correlation r= 0.3–0.7; low correlation r< 0.3.198,199
Moderate to high correlations (r≥ 0.3) were predicted.
Known-group comparisons are used to evaluate the clinical utility of instruments or assessment tools.
This method assesses the extent to which the overall assessment or items are able to discriminate
between subgroups of patients known to differ in terms of clinical presentations.200 A chi-square test for
independence (used to compare the frequencies of cases found in the various categories of one variable
across the different categories of another variable) was planned to determine whether or not type of
hospital patient (e.g. elective vs. acute) was related to PURPOSE-T risk group as assessed by the expert
nurse at baseline. However, because of the small number of elective patients this was not appropriate.
No other known group was prespecified.
Field notes
The field notes were summarised and used to inform design amendments and issues of importance
for implementation.
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TABLE 41 Reliability and validity psychometric tests and criteria
Test property Definition/test Criteria
Data quality; acceptability/
data completeness
The extent to which PURPOSE-T items are
completed and used to allocate a risk
category; quality of data is assessed by data
completeness for each element of the
PURPOSE-T and a risk category
l % item level-data missing
l % of risk categories allocated
l % of items missing when a risk
category has been allocated
Clinical usability Compliance with the recommended
completion guidelines
l % compliance step 1
l % compliance progression to step 2
l % compliance risk allocation
l qualitative review of field notes
Inter-rater reliability Inter-rater reliability assesses the extent to
which the PURPOSE-T results obtained by
two or more raters agree for the same
population
l The kappa statistic is a measure of true
agreement and indicates the proportion
of agreement beyond that expected by
chance, i.e. the achieved beyond-
chance agreement as a proportion of
the possible beyond-chance agreementTest–retest reliability Test–retest reliability assesses the stability of
the PURPOSE-T over a period of time in
which the patient’s condition is not
expected to change
Content validity The extent to which a scale measures what
it intends to measure
l Risk factor systematic review
l Consensus study
l Pre-test ensuring that items in the scale
are representative of the construct
being measured
Convergent validity
(between-scale analysis –
analyses against external
criteria)
Evidence that PURPOSE-T constructs are
correlated with other measures of the same
or similar constructs, assessed on the basis
of correlations between the measure and
other similar measures (Braden scale and
Waterlow scale)
l Correlations are expected to vary
according to the degree of similarity
between the constructs being
measured by each instrument. Specific
hypotheses are formulated and
predictions tested on the basis
of correlations
Known group differences The ability of PURPOSE-T risk categories to
differentiate known groups, assessed by
comparing PURPOSE-T risk categories for
subgroups who are expected to differ on
the construct being measured (significant
differences between known groups or
differences of expected magnitude)
(e.g. elective/acute patients)
TABLE 40 Kappa interpretation guidelines
Value of kappa Strength of agreement
< 0.20 Poor
0.21–0.40 Fair
0.41–0.60 Moderate
0.61–0.80 Good
0.81–1.00 Very good
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Results
In total, 394 patients were screened for eligibility for the study and 230 patients were registered to the
study between 3 October 2012 and 25 January 2013 (Figure 24) from four secondary care acute hospital
NHS trusts (comprising five recruiting hospitals) and four community NHS trusts, with numbers of patients
registered at each centre ranging from 14 to 54 (see Appendix 1).
All of the 230 patients recruited were assessed in part or full using the PURPOSE-T, providing a total of
230 paired assessments undertaken by 11 expert nurses and 73 ward/community nurses. A median of
three patients were assessed by each expert nurse and ward/community nurse pair. There was good
representation from each of the four broad levels of risk with 53 (23.0%) patients having no mobility
restrictions, 70 (30.4%) having some mobility/activity limitations, 49 (21.3%) who were bedfast/chairfast
and 58 (25.2%) with an existing pressure ulcer of category 1 or above as reported at registration.
In total, 122 (53.0%) patients were recruited from community settings and 108 (47.0%) were recruited
from secondary care hospital settings (Table 42). Of the 230 patients registered, 217 (94.3%) had retest
assessments completed by the expert nurse (see Figure 24).
Not assessed for eligibility
n = 2/394 (0.5%)
1 (50.0%)
1 (50.0%)
reason not provided
ethically inappropriate 
to approach the 
patient
Not eligible for study entry
n = 42/392 (10.7%)
1 (2.4%)
12 (28.6%)
17 (40.5%)
12 (28.6%)
reason not provided
unable to give
consent/consultee
agreement
patient is not expected
to be able to comply
with follow-up schedule
patient is too unwell to
be approached
Not registered
n = 4/234 (1.7%)
1 (25.0%)
1 (25.0%)
1 (25.0%)
1 (25.0%)
feeling unwell on the day
of paired assessment
following Waterlow/Braden
assessments, patient
refused any further
assessments
not able to assess on day
of consent. Patient
changed mind at next
opportunity
unable to do paired
assessment due to patients
busy schedule
Not consented
n = 116/350 (33.1%)
58 (50.0%)
16 (13.8%)
18 (15.5%)
6 (5.2%)
18 (15.5%)
patient refused
without any reason
patient does not
want to be involved 
in research
patient feels poorly 
or unwell
patient finds
follow-up schedule
inconvenient
other reason
No Follow-up assessment
n = 13/230 (5.7%)
1 (7.7%)
1 (7.7%)
8 (61.5%)
3 (23.1%)
reason not provided
ethically inappropriate 
to approach the 
patient
patient discharged
other reason 
Screened
n = 394
Assessed for
Eligibility
n = 392/394
(99.5%)
Eligible for study
entry
n = 350/392
(89.3%)
Consented and
registered
n = 230/234
(98.3%)
Eligible and
Consented
n = 234/350
(66.9%)
Follow-up assessment
n = 217/230
(94.3%)
FIGURE 24 Flow of participants.
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The patient population comprised 99 (43.0%) men and 131 (57.0%) women. The median age was 77
years (range 19–102 years), the majority of patients were Caucasian (n= 224; 97.4%) and 79 (34.3%) had
no activity limitation (i.e. were able to walk independently with or without a walking aid) (Table 43).
Based on the PURPOSE-T assessment carried out at baseline by the expert nurses, there were 60 (26.1%)
patients who presented with a category 1 or above pressure ulcer. Within the community setting,
37 (30.3%) patients presented with a category 1 or above ulcer whereas, among secondary care hospital
patients, 23 (21.3%) presented with a category 1 or above ulcer (see Table 43). There were a total of
96 pressure ulcers across the 60 patients including 21 (21.9%) category 1, 56 (58.3%) category 2,
six (6.3%) category 3, six (6.3%) category 4 and seven (7.3%) unstageable ulcers (Table 44).
In relation to the ‘at risk’ status of the patient population, the Waterlow scale score identified 193 (83.9%)
patients as ‘at risk’, the PURPOSE-T identified 183 (79.6%) patients as ‘at risk’ (i.e. requiring primary or
secondary prevention/treatment) and the Braden scale score identified 85 (37.0%) patients as ‘at risk’.
The Braden scale score identified 145 patients as ‘not at risk’ of whom 25 (17.2%) had an existing
pressure ulcer, whereas none of the patients with a pressure ulcer was assessed as ‘not at risk’ by either
the Waterlow scale score or the PURPOSE-T (see Table 43).
TABLE 42 Specialty or place assessed by setting
Specialty or place assessed
Acute setting (n= 108),
n (%)
Community setting (n= 122),
n (%)
Total (n= 230),
n (%)
Patient’s own home – 47 (38.5) 47 (20.4)
Nursing home – 3 (2.5) 3 (1.3)
Residential home – 8 (6.6) 8 (3.5)
Rehabilitation unit – 57 (46.7) 57 (24.8)
Other place assesseda – 7 (5.7) 7 (3.0)
Medical 26 (24.1) – 26 (11.3)
Care of the elderly 3 (2.8) – 3 (1.3)
General/urological/gynaecological
surgery
19 (17.6) – 19 (8.3)
High-dependency unit 1 (0.9) – 1 (0.4)
Oncology 3 (2.8) – 3 (1.3)
Orthopaedic 19 (17.6) – 19 (8.3)
Plastics 2 (1.9) – 2 (0.9)
Renal 12 (11.1) – 12 (5.2)
Spinal injury 4 (3.7) – 4 (1.7)
Thoracic surgery 4 (3.7) – 4 (1.7)
Vascular surgery 15 (13.9) – 15 (6.5)
a Other places assessed were care closer to home unit (n= 4) and community intermediate care (n= 3).
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TABLE 43 Baseline characteristics
Variable
PU at baselinea
(n= 60)
No PU at baselinea
(n= 169)
Missing PU statusa
(n= 1b)
Totalc
(n= 230)
Age (years)
Mean (SD) 73.8 (15.9) 72.1 (18.3) 72.6 (17.6)
Median (range) 76 (29–98) 78 (19–102) 78 (78–78) 77 (19–102)
Sex, n (%)
Male 27 (27.3) 72 (72.7) 0 (0.0) 99 (43.0)
Female 33 (25.2) 97 (74.0) 1 (0.8) 131 (57.0)
Ethnicity, n (%)
Caucasian 58 (25.9) 165 (73.7) 1 (0.4) 224 (97.4)
Other 2 (33.3) 4 (66.7) 0 (0.0) 6 (2.6)
Setting, n (%)
Community 37 (30.3) 84 (68.9) 1 (0.1) 122 (53.0)
Secondary care hospital 23 (21.3) 85 (78.7) 0 (0.0) 108 (47.0)
Mobility status PURPOSE-T step 1, n (%)
Walks independently with or without
walking aids
10 (12.7) 69 (87.3) 0 (0.0) 79 (34.3)
Needs help of another person to walk 6 (22.2) 21 (77.8) 0 (0.0) 27 (11.7)
Spends all/majority of time in
bed/chair
16 (28.1) 40 (70.2) 1 (1.8) 57 (24.8)
Remains in same position for long
periods
28 (42.4) 38 (57.6) 0 (0.0) 66 (28.7)
Not completed 0 (0.0) 1 (100.0) 0 (0.0) 1 (0.4)
Braden score, n (%)
At risk (≤ 18) 35 (41.2) 50 (58.8) 0 (0.0) 85 (37.0)
Not at risk (> 18) 25 (17.2) 119 (82.1) 1 (0.7) 145 (63.0)
Waterlow total score, n (%)
At risk (≥ 10) 60 (31.1) 132 (68.4) 1 (0.5) 193 (83.9)
Not at risk (< 10) 0 (0.0) 37 (100.0) 0 (0.0) 37 (16.1)
PURPOSE-T risk categorisation, n (%)
Secondary prevention/treatment
pathway
60 (83.3) 12 (16.7) 0 (0.0) 72 (31.3)
Primary prevention pathway 0 (0.0) 111 (100) 0 (0.0) 111 (48.3)
Not currently at risk pathway 0 (0.0) 46 (97.9) 1 (2.1) 47 (20.4)
PU, pressure ulcer.
a Percentages in the PU status columns correspond to the proportion of patients within that characteristic who do (or do
not) have a PU at baseline (e.g. 27.3% of the male population were observed to have a PU at baseline).
b There was one community patient for whom PU status at baseline could not be determined as no skin assessments were
recorded by the tissue viability team member.
c Percentages in the total column correspond to the proportion of patients from the overall population with that
characteristic (e.g. 43.0% of the overall population were male).
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Data completeness and usability
Data completeness and usability were assessed by quantifying compliance with the completion guidelines
for steps 1, 2 and 3 (Tables 45–48) and data completeness (Table 49) and analysing the qualitative reports
from the expert nurses (see Summary of expert nurse field notes).
Progression/non-progression to step 2 was completed in line with the recommended assessment flow for
220 (95.7%) patients, including 185 (80.4%) patients who were appropriately assessed at step 2 and
35 (15.2%) patients who were allocated a decision pathway after completion of step 1 and who did not
require step 2 assessments. There was one (0.4%) patient for whom no step 1 assessment was completed
and there were nine (3.9%) patients who progressed to step 2 assessments when it was not required
(see Table 45). It is of note that three of these nine patients were allocated to the ‘no pressure ulcer
but at risk’ pathway after their step 2 assessments; one of these patients had at least one skin site
assessed as vulnerable skin in step 2 but had not had this skin status selected at step 1, whereas the
other two patients were assessed as ‘at risk’ because the expert nurses had assessed them as having a
condition affecting peripheral circulation in step 2.
The expert nurses allocated a step1/step 3 decision pathway to all 230 (100%) patients, with 226 (98.3%)
allocated a decision pathway as per the decision rules and four (1.7%) allocated a pathway incorrectly as
at least one orange box on the PURPOSE-T had been ticked but the patients had been allocated to the
‘not currently at risk’ pathway (see Table 46).
TABLE 44 Pressure ulcer characteristics
Variable
Expert nurse
baseline assessment
Ward/community
nurse assessment
Expert nurse follow-up
assessment
Total population 230 230 217
Number of patients
with vulnerable skin
152 156 144
Number of patients
with history of PU
61 56 61
Number of patients
with PU
60 62a 56
Total number of PUs 96 98 87
Total number of PUs per patient
Mean (SD) 1.6 (1.1) 1.7 (1.2)a 1.6 (0.9)
Median (range) 1 (1–7) 1 (1–7) 1 (1–5)
Categories of reported PUs, n (%)
Category 1 21 (21.9) 22 (22.4) 14 (16.1)
Category 2 56 (58.3) 41 (41.8) 50 (57.5)
Category 3 6 (6.3) 5 (5.1) 9 (10.3)
Category 4 6 (6.3) 10 (10.2) 5 (5.7)
Unstageable 7 (7.3) 7 (7.1) 9 (10.3)
Missing 0 (0.0) 13 (13.3) 0 (0.0)
Total 96 98 87
PU, pressure ulcer.
a Of the 62 patients who were identified by the ward/community nurses as having a PU, three were reported to have a PU
at the screening stage but a PU was not reported in the current detailed skin assessment and therefore they have not
been included in the total number of PUs reported or the grading of PUs because it is not possible to know how many
PUs they might have had.
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TABLE 45 Summary of completion of the PURPOSE-T by assessment
PURPOSE-T section
Expert nurse
baseline assessment
Ward/community
nurse assessment
Expert nurse
retest
Step 1 mobility, n (%)
Completed 229 (99.6) 229 (99.6) 217 (100.0)
Not completed 1 (0.4) 1 (0.4) 0 (0.0)
Total 230 (100.0) 230 (100.0) 217 (100.0)
Progression to step 1 skin status, n (%)
Mobility step 1 assessment – no mobility limitation
Appropriate completion of step 1 skin
status
78 (33.9) 84 (36.5) 63 (29.0)
Inappropriate non-completion of step 1
skin status
1 (0.4) 3 (1.3) 0 (0.0)
Mobility step 1 assessment – mobility limitation
Appropriate completion of step 1 skin
status
114 (49.6) 83 (36.1) 117 (53.9)
Inappropriate non-completion of step 1
skin status
36 (15.7) 59 (25.7) 37 (17.1)
Mobility step 1 assessment – not assessed
Completion of step 1 skin status 0 (0.0) 1 (0.4) 0 (0.0)
Non-completion of step 1 skin status 1 (0.4) 0 (0.0) 0 (0.0)
Total 230 (100.0) 230 (100.0) 217 (100.0)
Progression to step 2 to full assessment, n (%)
Potential risk identified at step 1
Appropriate completion of step 2 185 (80.4) 185 (80.4) 179 (82.5)
Inappropriate non-completion of step 2 0 (0.0) 1 (0.4) 0 (0.0)
Not at risk at step 1
Appropriate non-completion of step 2 35 (15.2) 32 (13.9) 35 (16.1)
Inappropriate completion of step 2 9 (3.9) 12 (5.2) 3 (1.4)
Step 1 not completed
Step 2 completed 1 (0.4) 0 (0.0) 0 (0.0)
Total 230 (100.0) 230 (100.0) 217 (100.0)
Step 1/step 3 assessment decision allocated at step 1 or 3, n (%)
Appropriate pathway 226 (98.3) 219 (95.2) 215 (99.1)
Inappropriate pathway 4 (1.7) 10 (4.3) 2 (0.9)
No pathway selected 0 (0.0) 1 (0.4) 0 (0.0)
Total 230 (100.0) 230 (100.0) 217 (100.0)
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TABLE 46 Expert nurse PURPOSE-T decision pathway by the colour of boxes ticked
PURPOSE-T decision
pathway
Colour of boxes ticked, n (%)
Total, n (%)
At least one pink
box ticked
No pink boxes and at least
one orange box ticked
Only blue and yellow
boxes ticked
PU category 1 or
above or scarring
72 (31.3) 0 (0.0) 0 (0.0) 72 (31.3)
No PU, but at risk 0 (0.0) 109 (47.4) 2 (0.9) 111 (48.3)
No PU, not currently
at risk
0 (0.0) 4 (1.7) 43 (18.7) 47 (20.4)
Total 72 (31.3) 113 (49.1) 45 (19.6) 230 (100.0)
PU, pressure ulcer.
TABLE 47 Ward/community nurse PURPOSE-T decision pathway by the colour of boxes ticked
PURPOSE-T decision
pathway
Colour of boxes ticked, n (%)
Total, n (%)
At least one pink
box ticked
No pink boxes and at least
one orange box ticked
Only blue and yellow
boxes ticked
PU category 1 or
above or scarring
63 (27.4) 0 (0.0) 0 (0.0) 63 (27.4)
No PU, but at risk 5 (2.2) 107 (46.5) 2 (0.9) 114 (49.6)
No PU, not currently
at risk
0 (0.0) 5 (2.2) 47 (20.4) 52 (22.6)
Missing 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.4)
Total 68 (29.6) 113 (49.1) 49 (21.3) 230 (100.0)
PU, pressure ulcer.
TABLE 48 Expert nurse retest PURPOSE-T decision pathway by the colour of boxes ticked
PURPOSE-T decision
pathway
Colour of boxes ticked, n (%)
Total, n (%)
At least one pink
box ticked
No pink boxes and at least
one orange box ticked
Only blue and yellow
boxes ticked
PU category 1 or
above or scarring
68 (31.3) 0 (0.0) 0 (0.0) 68 (31.3)
No PU, but at risk 2 (0.9) 104 (47.9) 1 (0.5) 107 (49.3)
No PU, not currently
at risk
0 (0.0) 0 (0.0) 42 (19.4) 42 (19.4)
Total 70 (32.3) 104 (47.9) 43 (19.8) 217 (100.0)
PU, pressure ulcer.
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TABLE 49 Summary of data completeness
Construct
Number of
items
requiring
completion
Expert nurse
baseline
assessment,
% (n/N)
Ward/community
nurse assessment,
% (n/N)
Expert nurse
follow-up
assessment,
% (n/N)
Denominator
(i.e. number of items
expected to have
been completed)
Step 1 screening
Mobility 1 of 4 99.6 (229/230) 99.6 (229/230) 100.0 (217/217) All patients, as all were
required to complete step 1
mobility
Skin status 1 of 4
(if required)
98.7 (78/79) 96.6 (84/87) 100.0 (63/63) All patients for whom only
the blue box was ticked in
step 1 mobility
Assessment
decision
1 95.3 (41/43) 85.7 (36/42) 100.0 (38/38) All patients for whom only
the blue box was ticked in
both step 1 mobility and
step 1 skin status
Step 2 full assessment
Number of step 2
assessments
195 197 182
Step 1 mobility 1 of 4 99.5 (194/195) 99.5 (196/197) 100.0 (182/182) All patients who progressed
to step 2, as all were
required to complete step 1
mobility
Step 1 skin status 1 of 4
(if required)
97.7 (43/44) 96.3 (52/54) 100.0 (28/28) All patients for whom only
the blue box was ticked in
step 1 mobility who
progressed to step 2
Analysis of
independent
movement
1 of 5 99.0 (193/195) 99.0 (195/197) 98.9 (180/182) All patients who
progressed to step 2
Sensory
perception and
response
1 of 2 96.9 (189/195) 94.9 (187/197) 98.4 (179/182)
Current detailed
skin assessment
13 95.5 (2421/2535) 95.3 (2440/2561) 97.5 (2307/2366) 13 (number of main skin
sites) times the no. of
patients who progressed
to step 2
Previous PU
history
1 of 2 99.0 (193/195) 95.9 (189/197) 98.4 (179/182) All patients who progressed
to step 2
Previous PU
details
At least 1 66.7 (40/60) 54.7 (29/53) 57.4 (35/61) All patients reported to
have a PU history in
previous construct
Perfusion At least 1 97.9 (191/195) 97.5 (192/197) 97.3 (177/182) All patients who progressed
to step 2
Nutrition At least 1 99.0 (193/195) 99.5 (196/197) 97.8 (178/182)
Moisture 1 of 3 99.5 (194/195) 97.0 (191/197) 96.7 (176/182)
Diabetes 1 of 2 99.0 (193/195) 95.9 (189/197) 96.7 (176/182)
Decision pathway
allocated
1 of 3 100.0 (195/195) 99.0 (195/197) 100.0 (182/182)
Step 1 and step 2
for those who
completed step 2
96.5 (4239/4394) 95.4 (4236/4441) 97.2 (3979/4093) Sum of all denominators
for those who progressed
to step 2
PU, pressure ulcer.
DOI: 10.3310/pgfar03060 PROGRAMME GRANTS FOR APPLIED RESEARCH 2015 VOL. 3 NO. 6
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Nixon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
143
The follow-up expert nurse step 1 assessments were completed in line with the recommended
assessment flow for 180 (82.9%) assessments (see Table 45). In 37 (17.1%) assessments the expert
nurses completed the step 1 skin status when this was not required (i.e. patient already identified as
having a mobility limitation).
Ward/community nurse assessment
The ward/community nurse form completion was similar to the expert nurse form completion. Step 1
assessments were completed in line with the recommended assessment flow for 167 (72.6%) patients. In
59 (25.7%) assessments the ward/community nurse completed the step 1 skin status assessment when this
was not required (i.e. patient already identified as having a mobility limitation).
Progression/non-progression to step 2 was completed in line with the recommended assessment flow for
217 (94.3%) patients, including 185 (80.4%) patients who were appropriately assessed at step 2 and
32 (13.9%) patients who were allocated a decision pathway after completion of step 1 and who did not
require step 2 assessments. There was one (0.4%) patient who should have progressed to step 2 and but
did not and there were 12 (5.2%) patients who progressed to step 2 when it was not required, although it
is of note that three of these patients were allocated to the ‘no pressure ulcer but at risk’ pathway after
their step 2 assessments (see Table 45). The ward/community nurses allocated a step1/step 3 decision
pathway to 229 (99.6%) patients, with 219 (95.2%) allocated a decision pathway as per the decision rules
and 10 (4.3%) allocated a pathway incorrectly; there were five patients for whom at least one pink box
had been ticked but the ‘no pressure ulcer but at risk’ decision pathway had been selected and there were
five patients for whom at least one orange box had been ticked but the ‘no pressure ulcer not currently
at risk’ decision pathway had been selected (see Table 47). It is noteworthy that the ward/community
nurses also allocated the majority of patients to the ‘not at risk’ decision pathway when they completed
only yellow and blue boxes (47/49, 95.9%; see Table 47).
At follow-up, progression/non-progression to step 2 was completed by the expert nurses in line with the
recommended assessment flow for 214 (98.6%) patients (see Table 45). Only three (1.4%) patients
progressed to step 2 when it was not required and they were subsequently assessed as ‘not currently
at risk’.
At follow-up, the expert nurses allocated a step 1/step 3 decision pathway to all 217 (100%) patients, with
215 (99.1%) patients allocated as per the decision rules and two (0.9%) patients allocated a pathway
inappropriately as the expert nurses had ticked a pink box on the PURPOSE-T form but selected the ‘no
pressure ulcer but at risk’ decision pathway (see Table 48).
It is noteworthy that when only yellow and blue boxes were completed the expert nurses allocated the
majority of patients to the ‘not at risk’ decision pathway at baseline (43/45; 95.6%) and follow-up (42/43;
97.7%) (see Tables 46 and 48).
Inter-rater reliability
There were 230 paired assessments available for comparison; at step 1 mobility there was a total of 228 paired
assessments (Table 50) and at the step 2 assessments there were 191 paired assessments (Table 51). To assess
the inter-rater reliability, the maximum number of paired assessments available was used. Non-compliance with
the recommended assessment flow was not taken into account to maximise the use of all available data, that
is, the population used for the assessment of step 2 inter-rater reliability consisted of 191 patients for whom
the step 2 assessment was completed by both raters, irrespective of whether or not they progressed to step 2
in line with the recommended assessment flow.
To compare skin assessments the ‘worst’ skin status recorded on the PURPOSE-T (i.e. from step 1 or step 2)
was used and there were a total of 230 paired assessments (Table 52).
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TABLE 50 Step 1 mobility: cross-tabulation of raters
Expert nurse
Ward/community nurse, n (%)
Walks
independently
with/without
walking aids
Needs help of
another person
to walk
Spends all or
majority of time
in bed or chair
Remains in same
position for
long periods Total
Walks
independently with
or without walking
aids
72 (31.6) 1 (0.4) 5 (2.2) 0 (0.0) 78 (34.2)
Needs the help of
another person to
walk
4 (1.8) 14 (6.1) 8 (3.5) 1 (0.4) 27 (11.8)
Spends all or the
majority of time in
bed or chair
9 (3.9) 5 (2.2) 37 (16.2) 6 (2.6) 57 (25.0)
Remains in the
same position for
long periods
2 (0.9) 2 (0.9) 29 (12.7) 33 (14.5) 66 (28.9)
Total 87 (38.2) 22 (9.6) 79 (34.6) 40 (17.5) 228 (100.0)
Light green, agreement between raters that there is a problem; dark green, absolute agreement.
TABLE 51 Cross-tabulation of step 2 completion between two raters
Expert nurse baseline
Ward/community nurse, n (%)
Completed: appropriate
(possible risk in step 1)
Completed: inappropriate
(missing/not at risk in step 1)
Not
completed Total
Completed: appropriate
(possible risk in step 1)
179 (77.8) 3 (1.3) 3 (1.3) 185 (80.4)
Completed: inappropriate
(missing/not at risk in step 1)
3 (1.3) 6 (2.6) 1 (0.4) 10 (4.3)
Not completed 3 (1.3) 3 (1.3) 29 (12.6) 35 (15.2)
Total 185 (80.4) 12 (5.2) 33 (14.3) 230 (100.0)
Light green+ dark green= step 2 completed by both assessors; therefore, inter-rater reliability population.
Light green, agreement between raters that there is a problem; dark green, absolute agreement.
TABLE 52 Cross-tabulation of overall ‘worst’ skin status as derived from the detailed skin assessment at baseline by
two raters
Expert nurse
Ward/community nurse, n (%)
Normal skin Vulnerable skin PU category Missing Total
Normal skin 54 (23.5) 11 (4.8) 1 (0.4) 2 (0.9) 68 (29.6)
Vulnerable skin 11 (4.8) 82 (35.7) 8 (3.5) 0 (0.0) 101 (43.9)
PU category 0 (0.0) 7 (3.0) 53 (23.0) 0 (0.0) 60 (26.1)
Missing 0 (0.0) 1 (0.4) 0 (0.0) 0 (0.0) 1 (0.4)
Total 65 (28.3) 101 (43.9) 62 (27.0) 2 (0.9) 230 (100.0)
PU, pressure ulcer.
Light green, agreement between raters that there is a problem; dark green, absolute agreement.
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Decision pathway
There was agreement in the decision pathway between the expert nurse and ward/community nurse for
187 (81.7%) paired assessments (Table 53). The corresponding simple kappa statistic of 0.71 (95% CI 0.63
to 79) and weighted kappa of 0.76 (95% CI 0.69 to 0.83) indicate good agreement between the raters
(although the 95% CI for the weighted kappa straddles the ‘good’ and ‘very good’ cut-off values).
When classified dichotomously as ‘at risk’/’not at risk’ there was agreement between the expert nurse and
ward/community nurse for 214 (93.4%) paired assessments (Table 54). The corresponding simple kappa
statistic of 0.81 (95% CI 0.71 to 0.90), PABAK of 0.87 and κmax. of 0.94 indicate very good agreement
between raters (although the 95% CI for the simple kappa statistic straddles the ‘good’ and ‘very good’
cut-off values).
TABLE 54 Cross-tabulation of overall risk status as assessed at baseline by two raters
Expert nurse
Ward/community nurse, n (%)
At risk Not at risk Total
At risk 172 (75.1) 10 (4.4) 182 (79.5)
Not at risk 5 (2.2) 42 (18.3) 47 (20.5)
Total 177 (77.3) 52 (22.7) 229 (100.0)
Dark green, absolute agreement.
TABLE 53 Cross-tabulation of the PURPOSE-T decision pathway as recorded at baseline by two raters
Expert nurse
Ward/community nurse, n (%)
PU category 1 or above
or scarring No PU but at risk
No PU not currently at
risk Total
PU category 1 or above or
scarring
54 (23.6) 18 (7.9) 0 (0.0) 72 (31.4)
No PU but at risk 9 (3.9) 91 (39.7) 10 (4.4) 110 (48.0)
No PU not currently at risk 0 (0.0) 5 (2.2) 42 (18.3) 47 (20.5)
Total 63 (27.5) 114 (49.8) 52 (22.7) 229 (100.0)
PU, pressure ulcer.
Dark green, absolute agreement.
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Mobility
There was overall agreement between the expert nurse and the ward/community nurse for 156 (68.4%)
paired assessments of step 1 mobility, with agreement that there was ‘no problem’ (i.e. walks
independently with or without walking aids) or that there was a ‘problem’ for 207 (90.8%) paired
assessments (see Table 50). At step 2 there was absolute agreement across the five possible categories for
the analysis of independent movement for 113 (59.2%) paired assessments, with agreement that there
was ‘no problem’ (i.e. moves frequently and major position changes) and that there was a ‘problem’ for
165 (86.4%) paired assessments (Table 55).
Skin status
For the three possible ‘worst recorded’ skin categories, there was absolute agreement for 189 (82.2%)
paired assessments, with agreement that there was ‘no problem’ (i.e. normal skin) or that there was a
‘problem’ for 204 (88.7%) paired assessments (see Table 52).
At step 2 there was agreement between raters for no known pressure ulcer history and pressure ulcer
history for 160 (83.8%) paired assessments (Table 56).
TABLE 55 Cross-tabulation of the analysis of independent movement at baseline by two raters
Expert nurse
Ward/community nurse, n (%)
Moves
frequently
and major
position
changes
Moves
frequently
and slight
position
changes
Moves
occasionally
and major
position
changes
Moves
occasionally
and slight
position
changes
Does not
move
Not
completed Total
Moves
frequently
and major
position
changes
46 (24.1) 3 (1.6) 3 (1.6) 2 (1.0) 1 (0.5) 1 (0.5) 56 (29.3)
Moves
frequently
and slight
position
changes
2 (1.0) 5 (2.6) 7 (3.7) 9 (4.7) 1 (0.5) 0 (0.0) 24 (12.6)
Moves
occasionally
and major
position
changes
10 (5.2) 4 (2.1) 20 (10.5) 10 (5.2) 0 (0.0) 1 (0.5) 45 (23.6)
Moves
occasionally
and slight
position
changes
1 (0.5) 6 (3.1) 7 (3.7) 37 (19.4) 2 (1.0) 0 (0.0) 53 (27.7)
Does not
move
0 (0.0) 1 (0.5) 1 (0.5) 4 (2.1) 5 (2.6) 0 (0.0) 11 (5.8)
Not
completed
2 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.0)
Total 61 (31.9) 19 (9.9) 38 (19.9) 62 (32.5) 9 (4.7) 2 (1.0) 191 (100.0)
Light green, agreement between raters that there is a problem; dark green, absolute agreement.
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TABLE 56 Inter-rater reliability between the expert nurses at baseline and the ward/community nurses
Expert nurse baseline
Ward/community nurse, n (%)
No known
PU history PU history Not completed Total
PU history
No known PU history 116 (60.7) 9 (4.7) 4 (2.1) 129 (67.5)
PU history 15 (7.9) 44 (23.0) 1 (0.5) 60 (31.4)
Not completed 1 (0.5) 0 (0.0) 1 (0.5) 2 (1.0)
Total 132 (69.1) 53 (27.7) 6 (3.1) 191 (100.0)
No problem
Patient unable to feel and/or
respond appropriately to
discomfort from pressure Not completed Total
Sensory perception
No problem 123 (64.4) 7 (3.7) 8 (4.2) 138 (72.3)
Patient unable to feel and/
or respond appropriately to
discomfort from pressure
17 (8.9) 28 (14.7) 2 (1.0) 47 (24.6)
Not completed 6 (3.1) 0 (0.0) 0 (0.0) 6 (3.1)
Total 146 (76.4) 35 (18.3) 10 (5.2) 191 (100.0)
No problem Problem Not completed Total
Nutrition
No problem 82 (42.9) 9 (4.7) 0 (0.0) 91 (47.6)
Problem 25 (13.1) 74 (38.7) 0 (0.0) 99 (51.8)
Not completed 0 (0.0) 1 (0.5) 0 (0.0) 1 (0.5)
Total 107 (56.0) 84 (44.0) 0 (0.0) 191 (100.0)
No Yes Not completed Total
Unplanned weight loss
No 136 (71.2) 8 (4.2) 0 (0.0) 144 (75.4)
Yes 23 (12.0) 23 (12.0) 0 (0.0) 46 (24.1)
Not completed 1 (0.5) 0 (0.0) 0 (0.0) 1 (0.5)
Total 160 (83.8) 31 (16.2) 0 (0.0) 191 (100.0)
No Yes Not completed Total
Poor nutritional intake
No 118 (61.8) 10 (5.2) 0 (0.0) 128 (67.0)
Yes 17 (8.9) 45 (23.6) 0 (0.0) 62 (32.5)
Not completed 1 (0.5) 0 (0.0) 0 (0.0) 1 (0.5)
Total 136 (71.2) 55 (28.8) 0 (0.0) 191 (100.%)
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Step 2 other risk factors
Sensory perception There was agreement between raters that there was ‘no problem’ or that there was
a ‘problem’ for 151 (79.1%) paired assessments, with disagreement for 24 (12.6%) paired assessments
(see Table 56).
Nutrition There was agreement between raters for ‘no problem’ and ‘problem’ for 156 (81.7%) paired
assessments. In terms of the individual nutritional assessments, there was agreement between raters for
159 (83.2%) paired assessments for unplanned weight loss, 163 (85.3%) paired assessments for poor
nutritional intake, 176 (92.1%) paired assessments for low BMI and 170 (89.0%) paired assessments for
high BMI (see Table 56).
Diabetes There was agreement between raters for diabetic status for 180 (94.2%) paired assessments,
with disagreement for 3 (1.6%) paired assessments (see Table 56).
TABLE 56 Inter-rater reliability between the expert nurses at baseline and the ward/community nurses (continued )
No Yes Not completed Total
Low BMI
No 163 (85.3) 6 (3.1) 0 (0.0) 169 (88.5)
Yes 8 (4.2) 13 (6.8) 0 (0.0) 21 (11.0)
Not completed 0 (0.0) 1 (0.5) 0 (0.0) 1 (0.5)
Total 171 (89.5) 20 (10.5) 0 (0.0) 191 (100.0)
No Yes Not completed Total
High BMI
No 160 (83.8) 4 (2.1) 0 (0.0) 164 (85.9)
Yes 16 (8.4) 10 (5.2) 0 (0.0) 26 (13.6)
Not completed 1 (0.5) 0 (0.0) 0 (0.0) 1 (0.5)
Total 177 (92.7) 14 (7.3) 0 (0.0) 191 (100.0)
Not diabetic Diabetic Not completed Total
Diabetic status
Not diabetic 135 (70.7) 2 (1.0) 5 (2.6) 142 (74.3)
Diabetic 1 (0.5) 45 (23.6) 1 (0.5) 47 (24.6)
Not completed 2 (1.0) 0 (0.0) 0 (0.0) 2 (1.0)
Total 138 (72.3) 47 (24.6) 6 (3.1) 191 (100.0)
PU, pressure ulcer.
Dark green, absolute agreement.
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Perfusion There was absolute agreement across the four possible categories for 125 (65.4%)
paired assessments, with agreement that there was ‘no problem’ or a ‘problem’ for 139 (72.8%) paired
assessments (Table 57).
Moisture There was absolute agreement across the three possible categories for 145 (75.9%)
paired assessments, with agreement that there was ‘no problem’ or a ‘problem’ for 155 (81.2%) paired
assessments (Table 58).
TABLE 58 Cross-tabulation of moisture status as assessed at baseline by two raters
Expert nurse
Ward/community nurse, n (%)
No
problem/occasional
Frequent (two to
four times a day) Constant
Not
completed Total
No problem/occasional 133 (69.6) 14 (7.3) 2 (1.0) 3 (1.6) 152 (79.6)
Frequent (two to four
times a day)
15 (7.9) 11 (5.8) 3 (1.6) 1 (0.5) 30 (15.7)
Constant 0 (0.0) 7 (3.7) 1 (0.5) 0 (0.0) 8 (4.2)
Not completed 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 1 (0.5)
Total 148 (77.5) 32 (16.8) 6 (3.1) 5 (2.6) 191 (100.0)
Light green, agreement between raters that there is a problem; dark green, absolute agreement.
TABLE 57 Cross-tabulation of perfusion status as assessed at baseline by two raters
Expert nurse
Ward/community nurse, n (%)
No
problem
Conditions
affecting
central
circulation
Conditions
affecting
peripheral
circulation
Conditions affecting
both central and
peripheral circulation
Not
completed Total
No problem 88 (46.1) 8 (4.2) 12 (6.3) 0 (0.0) 1 (0.5) 109 (57.1)
Conditions affecting
central circulation
12 (6.3) 15 (7.9) 2 (1.0) 2 (1.0) 1 (0.5) 32 (16.8)
Conditions affecting
peripheral circulation
12 (6.3) 2 (1.0) 21 (11.0) 1 (0.5) 1 (0.5) 37 (19.4)
Conditions affecting
both central and
peripheral circulation
0 (0.0) 3 (1.6) 4 (2.1) 1 (0.5) 1 (0.5) 9 (4.7)
Not completed 4 (2.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (2.1)
Total 116 (60.7) 28 (14.7) 39 (20.4) 4 (2.1) 4 (2.1) 191 (100.0)
Light green, agreement between raters that there is a problem; dark green, absolute agreement.
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Test–retest reliability
To assess the test–retest reliability between the baseline and the retest expert nurse assessments, the
maximum number of paired assessments available was used. From a possible 217 paired assessments,
four were excluded as a ‘change in condition’ form was received, providing an analysis population of
213 paired assessments. The median number of days between the baseline and the retest expert nurse
assessment was three (range 1–7). There were 213 paired assessments available for comparison of the
decision pathways (Table 59), 212 paired assessments for comparison of step 1 mobility (Table 60) and
177 paired assessments for comparison of the step 2 assessments (Table 61). To compare skin assessments
the ‘worst’ skin status recorded on the PURPOSE-T (i.e. from step 1 and step 2) was used and there was a
total of 213 paired assessments (Table 62).
TABLE 60 Step 1 mobility: cross-tabulation between assessment time points
Expert nurse baseline
Expert nurse follow-up, n (%)
Walks
independently
with/without
walking aids
Needs the help
of another
person to walk
Spends all or the
majority of time
in bed or chair
Remains in the
same position
for long periods Total
Walks independently
with/without walking
aids
58 (27.4) 2 (0.9) 7 (3.3) 2 (0.9) 69 (32.5)
Needs help of another
person to walk
2 (0.9) 15 (7.1) 7 (3.3) 1 (0.5) 25 (11.8)
Spends all or the
majority of time in bed
or chair
2 (0.9) 3 (1.4) 41 (19.3) 9 (4.2) 55 (25.9)
Remains in same
position for long periods
0 (0.0) 1 (0.5) 11 (5.2) 51 (24.1) 63 (29.7)
Total 62 (29.2) 21 (9.9) 66 (31.1) 63 (29.7) 212a (100.0)
a Four patients were excluded because a ‘change of condition’ form had been received and one patient was excluded
because the step 1 mobility assessment was not completed at both time points.
Light green, agreement between raters that there is a problem; dark green, absolute agreement.
TABLE 59 Cross-tabulation of the PURPOSE-T decision pathway by assessment time points
Expert nurse baseline
Expert nurse follow-up, n (%)
PU category 1 or above or
scarring
No PU but at
risk
No PU not currently
at risk Total
PU category 1 or above or
scarring
64 (30.0) 5 (2.3) 0 (0.0) 69 (32.4)
No PU but at risk 3 (1.4) 95 (44.6) 5 (2.3) 103 (48.4)
No PU not currently at risk 0 (0.0) 4 (1.9) 37 (17.4) 41 (19.2)
Total 67 (31.5) 104 (48.8) 42 (19.7) 213 (100.0)
PU, pressure ulcer.
Dark green, absolute agreement.
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Decision pathway
There was agreement over the decision pathway between the expert nurse at baseline and the expert
nurse at retest for 196 (92.0%) paired assessments (see Table 59). The corresponding simple kappa
statistic of 0.87 (95% CI 0.81 to 0.93) and weighted kappa of 0.89 (95% CI 0.84 to 0.94) indicate very
good agreement between the two assessments. When classified dichotomously as ‘at risk’/’not at risk’
there was agreement between the expert nurse at baseline and the expert nurse at retest for 204 (95.8%)
paired assessments (Table 63). The corresponding simple kappa statistic of 0.87 (CI 0.78 to 0.95), PABAK
of 0.92 and κmax. of 0.99 indicate very good agreement between raters (although the 95% CI for the
simple kappa statistic straddles the ‘good’ and ‘very good’ cut-off values).
Mobility
There was overall agreement across the four ‘worst recorded’ categories for step 1 mobility for 165 (77.8%)
paired assessments made by the expert nurse at baseline and at retest, with agreement that there was ‘no
problem’ (i.e. walks independently with or without walking aids) or a ‘problem’ for 197 (92.9%) paired
assessments (see Table 60). At step 2 there was absolute agreement across the five possible categories for
the analysis of independent movement for 114 (64.4%) paired assessments, with agreement that there
was ‘no problem’ (i.e. moves frequently and major position changes) or a ‘problem’ for 147 (83.1%) paired
assessments (Table 64).
TABLE 61 Cross-tabulation of step 2 completion by assessment time points
Expert nurse baseline
Expert nurse follow-up, n (%)
Completed:
appropriate (at risk
in step 1)
Completed:
inappropriate (not at risk
in step 1)
Not completed:
appropriate (not at risk
in step 1) Total
Completed: appropriate
(at risk in step 1)
171 (80.3) 1 (0.5) 3 (1.4) 175 (82.2)
Completed: inappropriate
(missing/not at risk in step 1)
3 (1.4) 2 (0.9) 0 (0.0) 5 (2.3)
Not completed: appropriate
(not at risk in step 1)
1 (0.5) 0 (0.0) 32 (15.0) 33 (15.5)
Total 175 (82.2) 3 (1.4) 35 (16.4) 213a (100.0)
a Four patients were excluded because a ‘change of condition’ form had been received. Step 2 was completed correctly at
both time points for these four participants.
Light green+ dark green= step 2 completed at both time points, therefore test–retest reliability population.
Light green, agreement between raters that there is a problem; dark green, absolute agreement.
TABLE 62 Cross-tabulation of overall skin status as derived from the detailed skin assessment by assessment
time points
Expert nurse baseline
Expert nurse follow-up, n (%)
Normal skin Vulnerable skin PU category Total
Normal skin 56 (26.3) 3 (1.4) 1 (0.5) 60 (28.2)
Vulnerable skin 8 (3.8) 84 (39.4) 3 (1.4) 95 (44.6)
PU category 0 (0.0) 6 (2.8) 51 (23.9) 57 (26.8)
Missing 0 (0.0) 1 (0.5) 0 (0.0) 1 (0.5)
Total 64 (30.0) 94 (44.1) 55 (25.8) 213 (100.0)
PU, pressure ulcer.
Light green, agreement between raters that there is a problem; dark green, absolute agreement.
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TABLE 63 Cross-tabulation of overall risk status by assessment time points
Expert nurse baseline
Expert nurse follow-up, n (%)
At risk Not at risk Total
At risk 167 (78.4) 5 (2.3) 172 (80.8)
Not at risk 4 (1.9) 37 (17.4) 41 (19.2)
Total 171 (80.3) 42 (19.7) 213 (100.0)
Dark green, absolute agreement.
TABLE 64 Cross-tabulation of the analysis of independent movement by assessment time points
Expert nurse
baseline
Expert nurse follow-up, n (%)
Moves
frequently
and major
position
changes
Moves
frequently
and slight
position
changes
Moves
occasionally
and major
position
changes
Moves
occasionally
and slight
position
changes
Does not
move
Not
completed Total
Moves
frequently and
major position
changes
35 (19.8) 5 (2.8) 8 (4.5) 0 (0.0) 0 (0.0) 1 (0.6) 49 (27.7)
Moves
frequently and
slight position
changes
7 (4.0) 6 (3.4) 2 (1.1) 7 (4.0) 0 (0.0) 0 (0.0) 22 (12.4)
Moves
occasionally
and major
position
changes
6 (3.4) 6 (3.4) 31 (17.5) 2 (1.1) 0 (0.0) 0 (0.0) 45 (25.4)
Moves
occasionally
and slight
position
changes
2 (1.1) 8 (4.5) 4 (2.3) 33 (18.6) 2 (1.1) 0 (0.0) 49 (27.7)
Does not
move
0 (0.0) 0 (0.0) 0 (0.0) 2 (1.1) 9 (5.1) 0 (0.0) 11 (6.2)
Not completed 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.6)
Total 50 (28.2) 25 (14.1) 45 (25.4) 44 (24.9) 11 (6.2) 2 (1.1) 177 (100.0)
Light green, agreement between raters that there is a problem; dark green, absolute agreement.
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Skin status
For the three possible ‘worst recorded’ skin categories, there was absolute agreement for 191 (89.7%)
paired assessments, with agreement that there was ‘no problem’ (i.e. normal skin) or a ‘problem’ for
200 (93.9%) paired assessments (see Table 62). At step 2 there was agreement between ratings of ‘no
known pressure ulcer history’ and ‘pressure ulcer history’ for 165 (93.2%) paired assessments (Table 65).
TABLE 65 Test–retest reliability between the expert nurse at baseline and the expert nurse at retest
Expert nurse baseline
Expert nurse follow-up, n (%)
No known
PU history PU history
Not
completed Total
PU history
No known PU history 110 (62.1) 4 (2.3) 3 (1.7) 117 (66.1)
PU history 3 (1.7) 55 (31.1) 0 (0.0) 58 (32.8)
Not completed 2 (1.1) 0 (0.0) 0 (0.0) 2 (1.1)
Total 115 (65.0) 59 (33.3) 3 (1.7) 177 (100.0)
No problem
Patient unable to feel and/or
respond appropriately to
discomfort from pressure
Not
completed Total
Sensory perception
No problem 118 (66.7) 6 (3.4) 2 (1.1) 126 (71.2)
Patient unable to feel and/or
respond appropriately to
discomfort from pressure
10 (5.6) 36 (20.3) 0 (0.0) 46 (26.0)
Not completed 3 (1.7) 1 (0.6) 1 (0.6) 5 (2.8)
Total 131 (74.0) 43 (24.3) 3 (1.7) 177 (100.0)
No problem Problem
Not
completed Total
Nutrition
No problem 77 (43.5) 7 (4.0) 3 (1.7) 87 (49.2)
Problem 12 (6.8) 77 (43.5) 0 (0.0) 89 (50.3)
Not completed 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.6)
Total 89 (50.3) 84 (47.5) 4 (2.3) 177 (100.0)
No Yes
Not
completed Total
Unplanned weight loss
No 127 (71.8) 4 (2.3) 3 (1.7) 134 (75.7)
Yes 10 (5.6) 32 (18.1) 0 (0.0) 42 (23.7)
Not completed 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.6)
Total 137 (77.4) 36 (20.3) 4 (2.3) 177 (100.0)
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TABLE 65 Test–retest reliability between the expert nurse at baseline and the expert nurse at retest (continued )
No Yes
Not
completed Total
Poor nutritional intake
No 114 (64.4) 6 (3.4) 3 (1.7) 123 (69.5)
Yes 8 (4.5) 45 (25.4) 0 (0.0) 53 (29.9)
Not completed 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.6)
Total 122 (68.9) 51 (28.8) 4 (2.3) 177 (100.0)
No Yes
Not
completed Total
Low BMI
No 152 (85.9) 0 (0.0) 3 (1.7) 155 (87.6)
Yes 3 (1.7) 18 (10.2) 0 (0.0) 21 (11.9)
Not completed 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.6)
Total 155 (87.6) 18 (10.2) 4 (2.3) 177 (100.0)
No Yes
Not
completed Total
High BMI
No 143 (80.8) 4 (2.3) 3 (1.7) 150 (84.7)
Yes 4 (2.3) 22 (12.4) 0 (0.0) 26 (14.7)
Not completed 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.6)
Total 147 (83.1) 26 (14.7) 4 (2.3) 177 (100.0)
Not diabetic Diabetic Missing Total
Diabetic status
Not diabetic 123 (69.5) 0 (0.0) 6 (3.4) 129 (72.9)
Diabetic 3 (1.7) 43 (24.3) 0 (0.0) 46 (26.0)
Not completed 2 (1.1) 0 (0.0) 0 (0.0) 2 (1.1)
Total 128 (72.3) 43 (24.3) 6 (3.4) 177 (100.0)
PU, pressure ulcer.
Dark green, absolute agreement.
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Other step 2 risk factors
Sensory perception There was agreement between ratings that there was ‘no problem’ or a ‘problem’
for 154 (87.0%) paired assessments (see Table 65).
Nutrition There was agreement between ratings that there was ‘no problem’ or a ‘problem’ for 154
(87.0%) paired assessments. In terms of the individual nutritional assessments, there was agreement
between ratings for 159 (89.9%) paired assessments for unplanned weight loss, 159 (89.8%) paired
assessments for poor nutritional intake, 170 (96.0%) paired assessments for low BMI and 165 (93.2%)
paired assessments for high BMI (see Table 65).
Diabetes There was agreement over diabetic status for 166 (93.8%) paired assessments (see Table 65).
Perfusion There was absolute agreement across the four possible categories of perfusion for 138 (78.0%)
paired assessments, with agreement that there was ‘no problem’ or ‘problem’ for 154 (87.0%) paired
assessments (Table 66).
Moisture There was absolute agreement across the three possible categories of moisture for 155 (87.6%)
paired assessments, with agreement that there was ‘no problem’ or a ‘problem’ for 159 (89.8%) paired
assessments (Table 67).
TABLE 66 Cross-tabulation of perfusion status by assessment time points
Expert nurse
baseline
Expert nurse follow-up, n (%)
No
problem
Conditions
affecting
central
circulation
Conditions
affecting
peripheral
circulation
Conditions affecting
both central and
peripheral circulation
Not
completed Total
No problem 87 (49.2) 0 (0.0) 8 (4.5) 0 (0.0) 4 (2.3) 99 (55.9)
Conditions affecting
central circulation
6 (3.4) 19 (10.7) 3 (1.7) 4 (2.3) 0 (0.0) 32 (18.1)
Conditions affecting
peripheral circulation
1 (0.6) 3 (1.7) 28 (15.8) 2 (1.1) 0 (0.0) 34 (19.2)
Conditions affecting
both central and
peripheral circulation
0 (0.0) 1 (0.6) 3 (1.7) 4 (2.3) 0 (0.0) 8 (4.5)
Not completed 3 (1.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 4 (2.3)
Total 97 (54.8) 23 (13.0) 42 (23.7) 10 (5.6) 5 (2.8) 177 (100.0)
Light green, agreement between raters that there is a problem; dark green, absolute agreement.
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Convergent validity
PURPOSE-T step 1
Mobility The mobility assessment at step 1 of the PURPOSE-T was compared with the Braden mobility
and activity subscales using dichotomous scales (i.e. ‘problem’ or ‘no problem’). The step 1 mobility
assessment on the PURPOSE-T was found to have a moderate association with both the Braden mobility
subscale and the Braden activity subscale, with phi correlation coefficients of 0.60 and 0.66 respectively
(Table 68).
Skin The ‘worst’ overall PURPOSE-T skin status was compared with the ‘worst’ Waterlow skin status.
There was a high association observed between the PURPOSE-T skin status and the Waterlow skin status,
with a Spearman rank correlation coefficient of 0.83 (Table 69).
PURPOSE-T step 2
Analysis of independent movement The PURPOSE-T analysis of independent movement was compared
with the Braden mobility and activity subscales. The analysis of independent movement was observed to
be moderately associated with both the Braden mobility subscale and the Braden activity subscale, with
corresponding Spearman rank correlation coefficients of 0.62 and 0.55 respectively (see Table 69).
Sensory perception and response The sensory perception and response assessment on the PURPOSE-T
was compared with the Braden sensory perception score. A high association between the two sensory
perception assessments was observed, with a corresponding phi correlation coefficient of 0.74
(see Table 68).
Nutrition A moderate association was observed between ‘problem’/‘no problem’ on the PURPOSE-T
nutrition construct and the Braden nutrition subscale (dichotomised to ‘excellent or adequate’/‘probably
inadequate or very poor’), with a phi correlation coefficient of 0.58, and between ‘problem’/‘no problem’
on the PURPOSE-T nutrition construct and the Waterlow malnutrition screening tool (part c: eating poorly
or has a lack of appetite), with a phi correlation coefficient of 0.60 (see Table 68).
A high association was observed between ‘poor nutritional intake’ (‘yes’/‘no’) on the PURPOSE-T and the
Braden nutrition subscale (dichotomised to ‘excellent or adequate’/‘probably inadequate or very poor’),
with a phi correlation coefficient of 0.82. A high association was also observed between ‘poor nutritional
intake’ (‘yes’/‘no’) on the PURPOSE-T and the Waterlow malnutrition screening tool (part c: eating poorly
or has a lack of appetite), with a phi correlation coefficient of 0.79; between ‘low BMI’ (‘yes’/‘no’) on the
TABLE 67 Cross-tabulation of moisture status by assessment time points
Expert nurse baseline
Expert nurse follow-up, n (%)
No
problem/occasional
Frequent (two to
four times a day) Constant
Not
completed Total
No problem/occasional 126 (71.2) 7 (4.0) 0 (0.0) 5 (2.8) 138 (78.0)
Frequent (two to four
times a day)
5 (2.8) 24 (13.6) 1 (0.6) 0 (0.0) 30 (16.9)
Constant 0 (0.0) 3 (1.7) 5 (2.8) 0 (0.0) 8 (4.5)
Not completed 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.6)
Total 131 (74.0) 34 (19.2) 6 (3.4) 6 (3.4) 177 (100.0)
Light green, agreement between raters that there is a problem; dark green, absolute agreement.
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TABLE 68 Cross-tabulation of PURPOSE-T, Braden and Waterlow construct measures
PURPOSE-T step 1 mobility
Braden mobility, n (%)
Correlation
coefficientNo limitation
Slightly/very
limited/completely
immobile Total
No problem 69 (30.1) 10 (4.4) 79 (34.5) Phi 0.60 –
moderate
Problem 37 (16.2) 113 (49.3) 150 (65.5)
Total 106 (46.3) 123 (53.7) 229 (100.0)
PURPOSE-T step 1 mobility
Braden activity, n (%)
Correlation
coefficientWalks frequently
Walks occasionally,
chairfast or bedfast Total
No problem 56 (24.5) 23 (10.0) 79 (34.5) Phi 0.66 –
moderate
Problem 11 (4.8) 139 (60.7) 150 (65.5)
Total 67 (29.3) 162 (70.7) 229 (100.0)
PURPOSE-T sensory
response and perception
Braden sensory perception, n (%)
Correlation
coefficientNo impairment
Slightly, very or
completely limited Total
No problem 134 (70.9) 7 (3.7) 141 (74.6) Phi 0.74 –
high
Patient unable to feel and/or
respond appropriately to
discomfort from pressure
11 (5.8) 37 (19.6) 48 (25.4)
Total 145 (76.7) 44 (23.3) 189 (100.0)
PURPOSE-T nutrition
Braden nutrition, n (%)
Correlation
coefficient
Excellent or
adequate
Probably inadequate
or very poor Total
No problem 93 (48.2) 1 (0.5) 94 (48.7) Phi 0.58 –
moderate
Problem 47 (24.4) 52 (26.9) 99 (51.3)
Total 140 (72.5) 53 (27.5) 193 (100.0)
PURPOSE-T nutrition
Waterlow malnutrition screening tool: patient eating poorly or
lack of appetite, n (%)
Correlation
coefficientYes No Total
Problem 64 (33.7) 35 (18.4) 99 (52.1) Phi 0.60 –
moderate
No problem 6 (3.2) 85 (44.7) 91 (47.9)
Total 70 (36.8) 120 (63.2) 190 (100.0)
PURPOSE-T nutrition: poor
nutritional intake
Braden nutrition, n (%)
Correlation
coefficient
Probably inadequate
or very poor
Excellent or
adequate Total
Yes 50 (25.9) 12 (6.2) 62 (32.1) Phi 0.82 –
high
No 3 (1.6) 128 (66.3) 131 (67.9)
Total 53 (27.5) 140 (72.5) 193 (100.0)
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TABLE 68 Cross-tabulation of PURPOSE-T, Braden and Waterlow construct measures (continued )
PURPOSE-T nutrition: poor
nutritional intake
Waterlow malnutrition screening tool: patient eating poorly or
lack of appetite, n (%)
Correlation
coefficientYes No Total
Yes 57 (30.0) 5 (2.6) 62 (32.6) Phi 0.79 –
high
No 13 (6.8) 115 (60.5) 128 (67.4)
Total 70 (36.8) 120 (63.2) 190 (100.0)
PURPOSE-T nutrition: low
BMI
Waterlow build or weight for height, n (%)
Correlation
coefficientBMI < 20 kg/m2 BMI ≥ 20 kg/m2 Total
Yes 21 (11.0) 0 (0.0) 21 (11.0%) Phi 0.72 –
high
No 16 (8.4) 154 (80.6) 170 (89.0%)
Total 37 (19.4) 154 (80.6) 191 (100.0%)
PURPOSE-T nutrition: high
BMI
Waterlow build or weight for height, n (%)
Correlation
coefficientBMI ≥ 30 kg/m2 BMI < 30 kg/m2 Total
Yes 22 (11.5) 4 (2.1) 26 (13.6) Phi 0.74 –
high
No 9 (4.7) 156 (81.7) 165 (86.4)
Total 31 (16.2) 160 (83.8) 191 (100.0)
Dark green, absolute agreement.
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TABLE 69 Cross-tabulation of PURPOSE-T, Braden and Waterlow construct measures
PURPOSE-T step 2 analysis of
independent movement
Braden mobility, n (%)
Correlation
coefficient
Completely
immobile
Very or slightly
limited No limitation Total
Does not move 7 (3.6) 4 (2.1) 0 (0.0) 11 (5.7) Spearman
rank 0.62 –
moderateMoves occasionally and slight or
major position changes or moves
frequently with slight position
changes
1 (0.5) 96 (49.7) 26 (13.5) 123 (63.7)
Moves frequently and major
position changes
0 (0.0) 12 (6.2) 47 (24.4) 59 (30.6)
Total 8 (4.1) 112 (58.0) 73 (37.8) 193 (100.0)
PURPOSE-T step 2 analysis of
independent movement
Braden activity, n (%)
Correlation
coefficientBedfast
Chairfast or
walks
occasionally
Walks
frequently Total
Does not move 6 (3.1) 5 (2.6) 0 (0.0) 11 (5.7) Spearman
rank 0.55 –
moderateMoves occasionally and slight or
major position changes or moves
frequently with slight position
changes
15 (7.8) 102 (52.8) 6 (3.1) 123 (63.7)
Moves frequently and major
position changes
0 (0.0) 31 (16.1) 28 (14.5) 59 (30.6)
Total 21 (10.9) 138 (71.5) 34 (17.6) 193 (100.0)
PURPOSE-T skin status
Waterlow skin status, n (%)
Correlation
coefficientHealthy
Tissue paper,
dry, oedematous,
clammy
Discoloured
grade 1 or
broken spots
grades 2–4 Total
Normal skin 47 (20.6) 18 (7.9) 0 (0.0) 65 (28.5) Spearman
rank 0.83 –
highVulnerable skin 11 (4.8) 79 (34.6) 13 (5.7) 103 (45.2)
PU category 1 (0.4) 0 (0.0) 59 (25.9) 60 (26.3)
Total 59 (25.9) 97 (42.5) 72 (31.6) 228 (100.0)
PURPOSE-T moisture
Braden moisture, n (%)
Correlation
coefficient
Rarely or
occasionally
moist Very moist
Constantly
moist Total
No problem/occasional 154 (79.4) 2 (1.0) 0 (0.0) 156 (80.4) Spearman
rank 0.67 –
moderateFrequent (two to four times a day) 18 (9.3) 12 (6.2) 0 (0.0) 30 (15.5)
Constant 0 (0.0) 4 (2.1) 4 (2.1) 8 (4.1)
Total 172 (88.7) 18 (9.3) 4 (2.1) 194 (100.0)
PU, pressure ulcer.
Dark green, absolute agreement.
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PURPOSE-T and the Waterlow build/weight for height construct, with a phi correlation coefficient of 0.72;
and between ‘high BMI’ (‘yes’/‘no’) on the PURPOSE-T and the Waterlow build/weight for height construct,
with a phi correlation coefficient of 0.74.
Moisture The PURPOSE-T moisture assessment was compared with the Braden moisture assessment. A
moderate association was observed between the moisture assessment on the PURPOSE-T and the Braden
moisture assessment, with a Spearman rank correlation coefficient of 0.67 (see Table 69).
Assessment decision
Overall A moderate association was observed between the overall risk status on the PURPOSE-T and the
Waterlow scale score for all patients, as assessed by the expert nurse at baseline, with a phi correlation
coefficient of 0.63 (Table 70).
Pressure ulcer-free patients There was a moderate association observed between the overall risk status
on the PURPOSE-T and the Braden scale score for pressure ulcer-free patients, as assessed by the expert
nurse at baseline, with a phi correlation coefficient of 0.40.
Summary of expert nurse field notes
The field notes (incorporating the views of expert nurses using the tool as well as the views of some ward/
community nurses who provided feedback to the expert nurses, although exact numbers are unknown)
described positive and problem aspects of using the PURPOSE-T in practice, as detailed in Table 71.
In addition, other problematic aspects of assessment that are common to all risk assessment instruments
were also reported including:
l lack of knowledge of pressure ulcer classification
l difficulty assessing mobility when the patient is unable to communicate and when the patient has been
seen for only a short period before assessment
l difficulty assessing sensory perception
l difficulty assessing medical history in the community setting
l difficulty assessing poor nutritional intake
l difficulty assessing BMI in the community setting.
TABLE 70 Cross-tabulation of overall risk status at baseline between the PURPOSE-T and the Waterlow scale
PURPOSE-T risk status
Waterlow risk status, n (%)
Correlation coefficientAt risk (≥ 10) Not at risk (< 10) Total
At risk 175 (76.1) 8 (3.5) 183 (79.6) Phi 0.63 – moderate
Not at risk 18 (7.8) 29 (12.6) 47 (20.4)
Total 193 (83.9) 37 (16.1) 230 (100.0)
PURPOSE-T risk status
Braden risk status, n (%)a
Correlation coefficientAt risk (≥ 10) Not at risk (< 10) Total
At risk 50 (29.6) 73 (43.2) 123 (72.8) Phi 0.40 – moderate
Not at risk 0 (0.0) 46 (27.2) 46 (27.2)
Total 50 (29.6) 119 (70.4) 169 (100.0)
a Only patients reported as being pressure ulcer free at baseline were included.
Dark green, absolute agreement.
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Final amendments to the PURPOSE-T
Field test amendments
The field test results informed revisions and the production of the final PURPOSE-T and associated user
manual. Revisions included:
l increasing the font size and spacing of the skin assessment section by moving the ‘vulnerable skin’
descriptors to the classification box
l further clarification of examples of skin vulnerability relating to skin redness
l amendment of the flow of step 2 by moving the skin assessment section
l simplification of the ‘previous pressure ulcer history’ item, encouraging nurses to record the number of
previous pressure ulcers and to give a detailed account of the pressure ulcer that left a scar or the
worst category pressure ulcer rather than all previous pressure ulcers.
Changes to the user manual were undertaken to reflect the changes made to the PURPOSE-T, detailed
above. In addition, further guidance was included in the manual relating to:
l parameters of weight loss and time periods
l nutritional intake and support
l assessment of BMI.
TABLE 71 Summary of the expert nurse field notes
Characteristic Positive aspects of using the PURPOSE-T Problem aspects of using the PURPOSE-T
Layout l Easy to use and self-explanatory
l Quick to use
l Easier to use with familiarity
l All on one page
l Tool looked ‘busy’ or ‘complicated’
l Font size small
l Space for skin assessment too small
Format l The RAG rating approach for assessment
decision and use of colour made distinctive
l Like the fact it did not use a score like other
risk assessment scales
l Form does not flow
l Unclear whether or not to progress to step 2
l Concern that exiting at step 1 would miss
assessment of important risk factors
l Nurses wanted to complete full skin assessment
at step 1
Content l Thorough and included important risk
factors
l Positive about the detailed skin assessment
and suggested that this encouraged a more
careful skin assessment
l Inclusion of pressure ulcer scar as a risk
factor
l Reliability of assessment of skin vulnerability
l Reliability of assessment of scarring
l Difficulty establishing history of previous pressure
ulcers: difficult and time-consuming; when
information available was of poor quality
(e.g. severity not clear)
l Duration of weight loss not specified
l Assessment of circulation items in patients with
respiratory problems
l Analysis of movement difficult to categorise
Usability l Will be easy for nurses to remember and
report red boxes at handover
l Step 1 screening is efficient in allowing the
quick identification of those who do not
require a full assessment
l Not having to visually inspect pressure areas
when a patient was not at risk
was appreciated
l Local production difficult if no colour printers
available
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Consideration of new evidence from the pain cohort study
In the original programme grant timelines the pain cohort study should have concluded before the start of
the risk assessment work package. In practice this did not happen because of the late start of the pain
cohort study and the extended recruitment period required to deliver the study. Instead, there were some
preliminary expert group discussions about pain in the expert group meetings and we adjusted the original
consensus study to enable later consideration of the pain cohort study results.
As before, the consensus process involved a face-to-face meeting with PURSUN UK members. PURSUN UK
members recognised pain as an important sign, noting that the results of the pain study reflected people’s
personal experiences of pain (e.g. feeling discomfort before redness appears on the skin). They supported
the inclusion of pain in the PURPOSE-T.
The expert group element was conducted by questionnaire alone. Expert group members privately
completed an initial questionnaire that incorporated the results of the pain cohort study, the views of
PURSUN UK and follow-up notes. They were asked to consider this evidence and rate their level of support
for the inclusion of pain at the screening and full assessment stages of the PURPOSE-T (on a 9-point Likert
scale) and to make comments regarding this. The results of the initial questionnaire, including the median
group response, disagreement index and anonymised expert group comments (as well as the evidence
included in the initial pain questionnaire), were incorporated into a follow-up questionnaire, allowing
expert group members to consider the views of others before privately re-rating their level of support for
the inclusion of pain in the PURPOSE-T. The results of this follow-up pain questionnaire determined
whether or not pain was included in the PURPOSE-T, following the same criteria used in the original
consensus study (see Phase 2: consensus study, Data analysis).
The results indicated that, although there was uncertainty regarding the inclusion of pain at the screening
stage of the assessment, there was support for its inclusion at the full assessment stage and it was
subsequently incorporated as an extension to the pressure ulcer and skin assessment section of the
PURPOSE-T.
Discussion
A new Risk Assessment Framework – PURPOSE-T [incorporating a risk factor Minimum Data Set; see
http://medhealth.leeds.ac.uk/accesspurposet (accessed July 2015)] – was developed to enhance pressure
ulcer risk assessment practice. We were unable to use gold standard methods for the development of a
risk stratification tool using multivariable modelling because of the lack of standard recording of key risk
factors and appropriate data sets to identify items for a risk tool, with subsequent model testing on a
‘new’ prospective target population.122 Rather, we undertook a systematic review incorporating a narrative
synthesis of pressure ulcer risk factors to provide the foundation for a consensus study to agree a risk
factor Minimum Data Set for inclusion in a new Risk Assessment Framework. This will facilitate the routine
and standardised recording of risk factors in clinical practice and can be used for modelling and ongoing
development. The PURPOSE-T underwent rigorous pre-testing and field testing with expert and ward/
community nurses and has good face, content and construct validity and good and very good inter-rater
and test–retest reliability respectively.
The systematic review allowed the risk factors that are independently associated with pressure ulcer
development to be identified,46 providing a clearer notion of the critical pressure ulcer risk factors.
However, there are remaining gaps in the literature for some potentially important risk factors, which
require further research. In addition, pressure ulcer risk factors were inconsistently represented in the
modelling of the primary studies of the systematic review and this limits both the interpretation and the
overall conclusions. Other limitations of the literature include poor reporting, heterogeneity of patient
populations, use of different outcomes, lack of differentiation between ulcer sites and the observation of
mainly superficial pressure ulcers. Although the evidence of the systematic review provides a good insight
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into the risk factors associated with pressure ulcer development at a population level, it does not fully
explain the underlying pathology of pressure ulcer development, and wider scientific evidence, and its
relevance to clinical practice, must also be considered. Finally, it is acknowledged that, in the absence of a
standard method for appraising the quality of risk factor research, we developed study-specific criteria and
categorised studies as high, medium, low and very low quality, which has a number of inherent limitations.
The consensus study allowed the evidence of the systematic review to be carefully reviewed by an expert
group, taking into account the wider scientific evidence, its relevance to clinical practice and the views of
PURSUN UK. The consensus methods were particularly useful in allowing the expert group to agree the
key risk factors to summarise patient risk (i.e. those that were considered to increase the probability of
pressure ulcer development). Although the methods were also useful for identifying the key principles of
the assessment items, they were inappropriate for considering the specific wording of items. Of note is the
agreement that the risk factors and assessment items should be the same for the Minimum Data Set and
the Risk Assessment Framework (i.e. no additional risk factor information was considered necessary for
assessment in clinical practice). It was acknowledged that risk factors excluded from the Minimum Data Set
and Risk Assessment Framework may still have a role in the pressure ulcer causal pathway through their
relationship with the agreed risk factors and may be important at an individual patient level (e.g. the use
of sedative medication may limit a patient’s mobility/activity and this would be addressed in the related
items of the Risk Assessment Framework). Whereas some of the agreed risk factors emerged as primary
risk factors in the systematic review [immobility, existing pressure ulcer, general skin status, perfusion
(including diabetes)], others, although still important, emerged less consistently (moisture, nutrition,
sensory perception) and two risk factors (previous pressure ulcer and pain) did not emerge in the
systematic review. Previous pressure ulcer was included on the basis of service user opinion and theoretical
bioengineering evidence (particularly relating to scarring) rather than on the basis of the epidemiological
evidence. Pain was included following the availability of the results of the pain cohort study. Although all
acknowledged that the epidemiological evidence was derived from a single study, its inclusion was
influenced by the strength of the multivariable modelling, general pathophysiological principles and service
user opinion. Conversely, albumin, which emerged more consistently in the systematic review and was
initially agreed by the expert group for inclusion (in the full assessment stage of the Minimum Data Set
and Risk Assessment Framework), was subsequently excluded because of concerns raised by PURSUN UK.
In these examples, when the group diverged from the scientific evidence, the reasons were in keeping with
some of those previously reported including clinical experience and patient preference.201
The integration of the PURSUN UK perspective throughout the study proved invaluable and to our
knowledge is the first study to use such an approach. Whereas others using consensus methods have
incorporated patient/carer representation in their expert groups,202,203 we decided to use an alternative
approach when developing the study methodology. This was because of a concern that the complexity of
the epidemiological and wider scientific evidence, as well as the complex nature of facilitating a mixed
group of patients and professionals, could have impeded the patients’ and carers’ input into the process.
Difficulties in involving patients and carers in the development of technical and clinical guidelines have
been raised previously204 and for this study there seemed to be more value in devoting whole meetings to
patient/carer insights, with particular emphasis on the acceptability of elements of assessment. This
allowed us to consider the views of a larger number of service users. We were conscious of the need to
integrate PURSUN UK members’ perspectives into the consensus process and this was carried out by
feedback at the expert group meetings or inclusion of their comments into questionnaires, so that the
group could consider the patient/carer perspective alongside other evidence.
Although the consensus study involved an expert group with considerable experience, a limitation of consensus
methodology relates to reliability and whether or not the results of this study are representative of the views of
other experts in the field. Raine and colleagues182 proposed a new approach to developing clinical guidelines
that includes checking the representativeness of the group’s ratings with a large similarly composed group.
As it is our intention to continually update the Risk Assessment Framework, further work is currently being
planned to validate the Minimum Data Set and Risk Assessment Framework through consultation with a
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larger group. This will also allow new evidence to be brought forward and integrated into the work. Another
difficulty associated with consensus methods relates to validity and assessing whether or not the judgements
made by the group are ‘good’.181 Although we developed a consensus method (incorporating group expertise,
relevant evidence and group facilitation) to facilitate ‘good judgements’ regarding the inclusion of risk factors
and assessment items in the risk factor Minimum Data Set and Risk Assessment Framework, we were unable to
assess this at the time of conducting the study. This should be assessed in future modelling work and the
ongoing development of PURPOSE-T to establish whether the judgements of the consensus study are correct.
Building on the work of the consensus study we were able to develop a theoretical causal pathway for
pressure ulcer development and a new conceptual framework, to bring together the epidemiological,
physiological and biomechanical evidence, enhancing our understanding of the role of individual risk
factors in pressure ulcer development. However, there is remaining uncertainty about how varying
combinations of risk factors and their parameters (e.g. varying levels of mobility, nutrition, moisture) impact
on pressure ulcer outcome as well as aetiological mechanisms of importance (e.g. uncertainty about the
specific mechanisms of importance relating to perfusion). The importance of individual risk factors may also
vary in relation to body site (e.g. a patient with peripheral vascular disease may have reduced tolerance to
pressure to their heels but not to their trunk areas). The development of the conceptual framework
through the combination of bioengineering and epidemiological expertise and evidence also highlights
that currently the methods that we have to assess the direct and indirect causal factors involved in pressure
ulcer development, including the mechanical boundary conditions and factors affecting tissue tolerance
(geometry, mechanical properties of tissue, transport and thermal properties and physiology and repair),
are very crude clinical assessments. The work provides a foundation for a programme of bioengineering
and translational research to develop improved assessment techniques with greater precision for
clinical use.
The pre-test allowed us to identify areas of confusion and improve the usability and acceptability of the
Risk Assessment Framework for clinical nurses. It could be argued that undertaking a pre-test using
vignette case studies is no substitute for assessing the Risk Assessment Framework in clinical practice.
However, assessing and improving the acceptability of the Risk Assessment Framework with clinical nurses
was considered a necessary and logical step to ensure face and content validity before evaluation in clinical
practice with real patients. The vignettes were developed to be realistic, with input from the clinical
members of the project team and members of PURSUN UK. The focus groups and think out loud
interviews were held in a pleasant environment and were carefully planned to encourage disclosure among
participants, which would not have been possible in a busy clinical area. In addition, topic guides were
used by trained facilitators, group numbers were conducive to facilitation, nurses from different trusts were
grouped according to job role and participants were fully briefed and had opportunities to ask questions
before the actual interviews/focus groups.
The pre-test facilitated changes to the Risk Assessment Framework relating to three main areas, including
the flow and format of the tool, decision support and the wording of specific items. This led to the
development of a preliminary Risk Assessment Framework – PURPOSE-T – in readiness for
clinical evaluation.
The field test of the PURPOSE-T involved 230 patients who were assessed by both expert and ward/
community nurses. Apart from previous pressure ulcer history, the level of data completion for expert and
ward/community nurse assessments for each construct on the PURPOSE-T was high at > 90%. The
inter-rater and test–retest agreement was ‘very good’ for the assessment decision overall as determined by
kappa. The percentage agreement for the assessment of ‘problem/no problem’ for the eight risk factors
(mobility, skin, previous pressure ulcer, sensory perception, perfusion, nutrition, moisture and diabetes)
ranged from 79.1% to 94.2% for inter-rater reliability and from 87.0% to 93.9% for test–retest reliability.
Moderate to high associations were demonstrated for convergent validity, assessed by comparison with
the same or similar constructs on other risk assessment scales (Braden and Waterlow). A known group
comparison was not possible because of the small number of patients recruited from elective wards.
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In addition, field notes recorded by the expert nurses highlighted positive and problem aspects of using the
tool in the clinical environment. Negative aspects included difficulties in assessing some of the PURPOSE-T
items and concerns about reliability, but these were not evidenced in the formal evaluation of inter-rater
and test–retest reliability.
It is of note that both expert and ward/community nurses allocated the majority of patients (> 95%) to the
‘not at risk’ category, with only ‘yellow’ and ‘blue’ boxes completed (see Tables 45–47). This means that
these patients did not have skin, sensory perception, perfusion or major mobility problems but were
characterised by minor mobility limitations with or without nutritional deficits, moisture problems or a
history of previous pressure ulcers (with no scar). This is interesting because these factors do not emerge
consistently in multivariable modelling (see Phase 1: Systematic review of patient risk factors for pressure
ulcer development, Emerging risk factor domains/subdomains), were still judged to be important in the
consensus development process, but colour coded as ‘yellow’ (i.e. requiring clinical judgement). It may be
that in practice they are judged to be not important in the absence of the other key risk factors. The next
stage of the development process will involve the dissemination of the PURPOSE-T into routine NHS care
and this will facilitate large-scale multivariable modelling and predictive validity testing, allowing further
refinement of the tool.
The main differences between the PURPOSE-T and other widely used risk assessment tools are as follows:
l a risk factor Minimum Data Set is incorporated to facilitate multivariable modelling
l involves a screening stage for all patients and a full assessment stage for those at potential/actual risk
or with an existing pressure ulcer. This allows those who are obviously not at risk to be quickly
identified, preventing the need for a more detailed full assessment, which will save time in
clinical practice
l a risk profile is identified for each patient (rather than a score condensed from different aspects of risk)
to support care planning, with interventions selected in response to specific risk factors
l there is incorporation of the symptom of pain as a risk factor
l colour is used to aid decision-making
l there is a clear distinction between primary and secondary prevention: patients with an existing
pressure ulcer or scarring from a previous ulcer are allocated to a secondary prevention and treatment
pathway. This has the potential to facilitate escalation of interventions to prevent deterioration in
existing pressure ulcers and promote healing
l development was based on a systematic review of the risk factor evidence and the pain cohort study
l development involved international and interdisciplinary experts in the field
l the tool was developed in partnership with service users.
Patient and public involvement in the risk assessment work package
Pressure Ulcer Research Service User Network UK members have been involved at various stages
throughout this work package:
l involvement in the consensus study (with particular emphasis on the acceptability of pressure ulcer risk
assessment elements for patients)
l contribution to the development of the case studies for the Risk Assessment Framework pre-test study
l reviewing the Risk Assessment Framework following the pre-test
l supporting the development of the Risk Assessment Framework clinical evaluation study, particularly
relating to the development of patient information leaflets.
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This project has provided some specific examples of the impact of PPI. The impact can be clearly seen in
changes that were made to the Risk Assessment Framework as a direct result of PURSUN UK members’
input, such as the exclusion of albumin, the inclusion of pain and a previous severe pressure ulcer and
changes to the wording of the sensory perception domain. PURSUN UK members also highlighted the
need to adapt the Risk Assessment Framework so that it can be used by patients and carers at home.
This is being incorporated into our next programme of work.
Conclusions
The risk assessment work package comprising a systematic review of pressure ulcer risk factors, consensus
study, conceptual framework development, design and pre-test and clinical evaluation led to the
development and validation of a new Risk Assessment Framework, the PURPOSE-T [see http://medhealth.
leeds.ac.uk/purposet (accessed July 2015)], with an underpinning risk factor Minimum Data Set.
The PURPOSE-T comprises two stages of assessment, the screening stage for all patients and the full
assessment stage for patients at potential/actual risk or with an existing pressure ulcer. It facilitates the
identification of a risk profile rather than a condensed score and allows patient to be allocated to a not
currently at risk, primary prevention (at risk) or secondary prevention and treatment pathway (existing
pressure ulcer or scarring from a previous pressure ulcer). The next stage of the development process will
involve dissemination of the PURPOSE-T into routine NHS care, which will facilitate large-scale multivariable
modelling and predictive validity testing, allowing refinement of the tool. The conceptual framework also
provides a foundation for a programme of bioengineering and translational research to develop improved
assessment techniques with greater precision for clinical use. The work package makes a key contribution
to the pressure ulcer field and has the potential to directly impact risk assessment in clinical practice.
The research methodologies utilised may also have a broader application to other relevant areas of
health-care research.
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Chapter 6 Development and evaluation of a
patient-reported pressure ulcer health-related quality
of life instrument
Chapter written by Claudia Rutherford, Julia M Brown, Michelle Briggs, Susanne Coleman, Carol Dealey,Elizabeth McGinnis, E Andrea Nelson, Nikki Stubbs, Lyn Wilson, Delia Muir and Jane Nixon.
Abstract
Introduction: Patient-reported outcome instruments are used to inform patient care and provide a
strong evidence base for new treatments that incorporate patient perspectives. However, no PRO
instruments for assessing the impact of pressure ulcers on HRQoL are available. Therefore, we aimed to
(1) develop a conceptual framework of HRQoL specific to pressure ulceration, (2) develop a self-report
HRQoL instrument for use with patients with pressure ulcers and (3) undertake a comprehensive evaluation
of the fundamental psychometric measurement properties of the new instrument.
Methods: We used gold standard methods to develop and evaluate a new PRO instrument for people
with pressure ulcers (PU-QOL) instrument. In phase 1 we developed a conceptual framework describing the
impact of pressure ulcers on HRQoL using three sources: a systematic review of the pressure ulcer HRQoL
literature, clinical expertise and qualitative data from 30 patient interviews. In phase 2 we developed a
provisional instrument. First, we used the conceptual framework to form the basis of the PU-QOL scales.
Next, we generated a pool of questions representing all outcomes from the conceptual framework. These
questions were generated from the phase 1 patient interviews, from two further systematic reviews of
pressure ulcer pain and existing chronic wound measures and by asking experts. The questions were then
brought together to produce a draft instrument. Finally, we pre-tested the provisional instrument using
mixed methods (cognitive interviews with 35 patients and Rasch measurement theory). In phase 3 we
undertook psychometric evaluation in two field tests. In field test 1 we undertook item reduction and
testing of scale formation; assessment of differential item functioning to determine the optimal mode of
administration (Rasch measurement theory); and assessment of acceptability, scaling assumptions, reliability
and validity (classical test theory) using PU-QOL data from 285 patients. In field test 2 we undertook
psychometric evaluation of the item-reduced version of the instrument on PU-QOL data from an additional
229 patients, using both Rasch measurement theory and classical test theory, to test scale targeting, item
response categories, item fit, response bias, acceptability, scaling assumptions, reliability and validity.
Results: Our conceptual model includes four HRQoL domains (symptoms, physical functioning, psychological
well-being, social participation) divided into 13 subdomains. The final PU-QOL consists of 10 scales to
measure pain, exudate, odour, sleep, vitality, mobility/movement, daily activities, emotional well-being,
self-consciousness and appearance, and participation. We established that a self-administration mode is not
suitable for hospital inpatients with pressure ulcers and it is therefore intended for administration following a
user manual, with respondents rating the amount of ‘bother’ attributed on a 3-point scale. The final PU-QOL
evaluation provides preliminary evidence in support of measurement reliability and validity; Cronbach’s alpha
values for the PU-QOL scales ranged from 0.89 to 0.97 and hypothesised correlations between PU-QOL and
Short Form questionnaire-12 items (SF-12) scores (r> 0.30) were consistent with predictions.
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Conclusions: We have identified HRQoL outcomes that are important to people with pressure ulcers and
developed a conceptual framework of HRQoL and the PU-QOL instrument, reflecting the conceptual
domains. The PU-QOL instrument provides a standardised method for assessing the impact of pressure
ulcers and for quantifying the benefits of associated interventions from the patient perspective, thus far
lacking in this area. It can be used in research with adults with any type of pressure ulcer and is suitable
for all UK health-care settings. Further work is needed to provide evidence in support of score
interpretation and to explore the utility of the PU-QOL in routine practice.
Introduction
Health-related quality of life
A patient’s health status can be measured through various concepts, including symptomatic outcomes
(i.e. pain), effect on ability to carry out daily tasks and more complex concepts such as HRQoL. HRQoL is a
multidimensional construct that encompasses four primary domains: psychological, physical, social and role
functioning and issues relating to well-being.205,206 Assessment of HRQoL is no longer just a relevant end
point of clinical trials but is often carried out in routine clinical practice and is considered essential to
understanding the quality of health care.207 HRQoL data provide information about the impact of a specific
disease and subsequently increase awareness of, and the ability to address, the needs and concerns most
important to patients. As such, assessment of HRQoL is particularly relevant in disease areas in which there
is a significant impact on HRQoL and a significant treatment burden, such as chronic wounds.
Impact of pressure ulcers on health-related quality of life
The impact of pressure ulcers on HRQoL is substantial, although few studies contain empirical data to
substantiate this assumption.9 Our pre-programme systematic review9 identified that the majority of work
to date has been mainly qualitative and that pressure ulcers severely compromise patient functioning: they can
affect sleep, rehabilitation, mobility and psychological, physical and social aspects of patients’ lives.34,208,209 They
also cause patients substantial pain. However, the pain is often underestimated by health-care professionals:210
patients described how their ulcer-related pain was largely unrecognised by health-care professionals, how
their reports of pain were ignored and how their ulcer-related pain was rarely formally assessed,9 findings
consistent with those from the severe pressure ulcer study (see Chapter 4).
Health-related quality of life not only is related to the presence of a pressure ulcer but also is affected by the
treatments that patients undergo to either prevent or treat a pressure ulcer. Because of the complexity of
pressure ulcers, health-care professionals face the challenge of providing effective preventative and treatment
interventions. The choice of intervention depends on the purpose, for example pressure damage prevention
using pressure-reducing/-offloading devices and repositioning, skin protection from moisture or wound
treatments to promote healing. NHS practice guidance is focused on identifying patients at risk through risk
assessment of all patients on admission to acute hospital and community nursing services (see Chapter 5),
implementing preventative care (e.g. specialist mattresses, turning, skin care) and using interventions to halt
damage and promote healing (e.g. mattresses, dressings, nutritional supplements).1,11,14,15,211 However,
these interventions can affect patient functioning and cause significant treatment burden.33 For example,
the frequency and regularity of dressing changes may affect a patient’s daily routine, increase fatigue,
restrict mobility and cause additional pain or discomfort.
Our pre-programme work has identified factors within the wider health-care context that may contribute
to reduced or improved HRQoL, such as satisfaction with health care received, inconsistencies in the health
care provided (i.e. different methods between nurses, wards and/or hospitals) and the relationship
between patient and health-care provider.9,10 These contributory factors relating to service organisation
were also evident from the severe pressure ulcer study (see Chapter 4). Assessment of HRQoL and other
contributory outcomes can facilitate patient–health-care provider communication and provide information
required for effective health-care planning and ulcer management. In addition to improving patient health
care, assessment of HRQoL can be important for indicating how satisfied patients are with the health care
received, indicators that are important for treatment and health-care effectiveness.
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Measuring health-related quality of life in people with pressure ulcers
Assessment of HRQoL is considered subjective in nature and therefore best measured by directly asking the
person involved through the use of PRO instruments or rating scales. The best PRO instruments are
designed to probe people in a structured, formal way to give reproducible, meaningful, quantitative
assessments from a personal perspective of how they feel and function.212 PRO instruments may be
generic, designed to measure concepts that are relevant across different diseases, outcomes, treatments
and populations, or disease/condition specific, designed to assess the impact of a specific disease or
condition on HRQoL, with the goal of detecting clinically important changes.213
The use of PRO instruments has become increasingly important in many disease areas214,215 and there has
been a growth in instruments to evaluate HRQoL in some chronic skin conditions. However, established
PRO instruments are currently not available for use with patients with pressure ulcers.216 PRO instruments
are used to inform and monitor the performance of patient care and health-care delivery and are
important for providing a strong evidence base for new treatments that incorporate patient perspectives
and cost-effectiveness. Cochrane reviews highlight the lack of reliable evidence for the clinical effectiveness
of a majority of pressure ulcer treatments.20 Further, few studies in this field include PROs as study
outcomes9 and national and international prevention and treatment guidance is not mandated.1,15 When
HRQoL outcomes have been assessed, generic or chronic wound-specific measures have been used.216
However, despite common conceptual domains between pressure ulcer and chronic wound HRQoL
models, existing PRO instruments do not adequately represent pressure ulcer-specific HRQoL outcomes
(e.g. content differs at the subdomain and item level; important components such as issues stemming
from treatments and symptoms, mobility, sleep, embarrassment and physical appearance are not well
represented),216 questioning their appropriateness for use in pressure ulcer research. Moreover, assessment
of outcomes in clinical trials of pressure ulcer intervention effectiveness either has been limited to
conventional clinical outcomes (i.e. prevention or healing) or has used limited, inappropriate (i.e. not fit for
purpose) or inadequately validated instruments.9,72 Importantly, clinical decision-making is not informed by
high-quality studies based on patients’ perspectives and cost-effectiveness.
We need a systematic way of considering (1) patients’ priorities for interventions and (2) health economic
evaluation (see Chapter 7 for work to derive a preference-based measure for use in cost–utility analysis).
A PRO instrument specific to pressure ulcers could facilitate clinician–patient communication, shared
decision-making and training of new staff; identify and prioritise patient problems and preferences;
monitor changes or outcomes of treatment; measure the performance of health-care providers; and
facilitate clinical audit.217–220
Aim and objectives
The principal aim of this work package was to develop a PRO measure of HRQoL specific for people with
pressure ulcers, the PU-QOL instrument. This would provide a standardised method for evaluating patients’
needs and self-reports of the impact of pressure ulcers and their treatment on HRQoL.
Specific objectives were to:
1. identify HRQoL outcomes relevant to patients with any category of pressure ulcer and the relative
ulcer burden
2. develop a PRO measure of HRQoL specific to pressure ulcers that is acceptable, reliable and valid and
suitable for use in the UK.
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Research overview
Several sequential pieces of reseach were undertaken to develop and evaluate the PU-QOL instrument
(Figure 25):
1. phase 1: conceptual framework development10,221 comprising:
– pre-programme systematic review9 (see Pre-programme systematic review overview)
– in-depth qualitative interviews10,221 (see Qualitative study)
– expert opinion10,221 (see Expert opinion)
Working
framework
Topic
guide
Qualitative study: semistructured
 interviews (n = 30)
Expert
review
Pressure ulcer-specific HRQoL conceptual framework
Revision of
preliminary PU-QoL
version
Expert
review
Item analysis and scale construction
using Rasch and traditional methods
Expert
review
Field test 2: psychometric evaluation of final
PU-QoL version (n = 229; n = 70 retested)
+
Experts: review
of item list
Systematic review: generation of broad HRQL
domains and expert opinion (pre-dating PURPOSE)
Phase 2: instrument construction and pretesting
Field test 1
(n = 285 total patients recruited)
Item reduction of preliminary PU-QOL, n = 227
Mode-of-administration substudy, n = 70
Systematic reviews: pain
and chronic wound PROs
+
Phase 3: psychometric evaluation
Patients: review of
phase 1 interview
transcripts
Pre-test: semistructured
cognitive interviews (n = 35)
Construction of PU-QoL instrument preliminary version
+
Phase 1: conceptual framework development
FIGURE 25 Flow diagram of the research undertaken to develop and evaluate the PU-QOL instrument.
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2. phase 2: instrument construction and pre-testing comprising:
i. item generation:35,216
– review of patient interview transcripts from phase 1b (see Item generation from patients)
– systematic review of existing chronic wound instruments literature216 (see Existing chronic wound
instruments: systematic review)
– systematic review of pressure ulcer-related pain literature36 (see Pressure ulcer-related pain:
systematic review)
– item generation from experts (see Item generation from experts)
ii. preliminary PU-QOL construction (see Preliminary PU-QOL construction)
iii. pre-testing through semistructured cognitive interviews with patients222 (see Pre-testing)
3. phase 3: psychometric evaluation in two parts:
i. field test 1: item reduction and scale formation; mode of administration substudy (see Field test 1
and mode of administration substudy); acceptability, scaling assumptions, reliability and validity
[classical test theory (CTT)]
ii. field test 2: a comprehensive psychometric evaluation of the final version, including scale targeting,
item response categories, item fit, response bias, acceptability, scaling assumptions, reliability and
validity, using both Rasch and traditional psychometric methods223 (see Field test 2: final
psychometric evaluation).
International PRO instrument guidelines and criteria were consulted to ensure high quality and
standardisation for PU-QOL development.192,212,224,225 Collaboration was sought from members of EPUAP
and from 29 acute and primary care NHS trusts around the UK.
Phase 1: conceptual framework development
Various parts are reprinted from Int J Nurs Stud, vol. 47, Gorecki C, Lamping DL, Brown JM, Madill A,
Firth J, Nixon J. Development of a conceptual framework of health-related quality of life in pressure ulcers:
a patient-focused approach, pp. 1525–34, 2010,221 with permission from Elsevier.
When developing a new PRO instrument, the construct intended for measurement (in this case quality of life
associated with pressure ulceration) needs to be clearly defined and the content (items) needs to reflect the
construct. The first phase of the project involved developing a conceptual framework, by tapping into three
sources. First, a systematic review and narrative analysis of the HRQoL outcomes literature relevant to pressure
ulcers was undertaken (work predating the programme).9 The review generated HRQoL issues, which were
grouped into HRQoL domains, formulating a working conceptual framework. Second, in-depth qualitative
interviews were undertaken with a sample of patients with pressure ulcers. From the information obtained
from the patient interviews and the third source, expert opinion, a final conceptual framework was produced.
Pre-programme systematic review overview
We undertook a systematic review (pre programme) of both the qualitative and quantitative pressure ulcer
and HRQoL literature to identify the impact of pressure ulcers and associated interventions on HRQoL.9 We
included studies describing the impact on HRQoL from direct patient reports. From 31 studies, including
2463 participants with pressure ulcers aged between 17 and 96 years, we extracted 293 findings, which
were divided into 46 categories and 11 themes. Our working conceptual framework consisted of HRQoL
themes (physical, social and psychological impact, symptoms, general health) and other impacts of pressure
ulcers (health-care professional–client relationships, need for vs. effect of interventions, impact on others,
financial impact, perceived aetiology, need for knowledge).9 Importantly, the systematic review highlighted
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that pressure ulcers severely impact on patients’ HRQoL and that there was no PRO instrument available to
assess pressure ulcer-specific HRQoL outcomes.
Qualitative study
An important consideration when developing PRO instruments is conceptualisation and content of the
instrument. Developers of disease-/condition-specific PRO instruments often utilise both top-down
(e.g. literature review) and bottom-up (e.g. qualitative data) approaches to develop the conceptual framework
to ensure that those aspects of HRQoL that are most important to patients with the underlying condition are
reflected. Having used the top-down approach (see Pre-programme systematic review overview) we then
undertook a qualitative study (see Appendix 38 for the study protocol) utilising the bottom-up approach.
Aim
The aim of this study was to undertake in-depth qualitative interviews with a sample of patients with
pressure ulcers. The information obtained would be used to develop a conceptual framework of HRQoL
specific to pressure ulcers. Specific objectives were to:
1. identify HRQoL outcomes relevant and important to patients with grade 1, superficial and severe
pressure ulcers
2. identify whether HRQoL outcomes for patients with grade 1, superficial and severe pressure ulcers are
the same in relation to the impact of interventions
3. gain insight into the relative ulcer burden and what it is like to live with a pressure ulcer.
Methods
Design
Top-down (literature review) and bottom-up (qualitative data) approaches were combined to develop the
conceptual framework. The top-down approach involved developing a working conceptual framework of
HRQoL in pressure ulcers, based on a systematic review of the quantitative and qualitative pressure ulcers
and HRQoL literature.9 The bottom-up approach involved further qualitative work to elicit information
pertaining to the impact of pressure ulcers on HRQoL and specific domain components. A multidisciplinary
expert group, including seven tissue viability nurse specialists, a chronic pain specialist and five outcome
methodologists (see Acknowledgements), reviewed the qualitative results and final conceptual domains.
Participants
Eligibility Patients from both acute and primary care were included because of the high pressure ulcer
prevalence in both settings and the need to obtain perspectives from people in both settings as interventions
can differ between settings. Adult patients with a pressure ulcer of any severity,1 duration or location or a
pressure ulcer that had recently healed (within 3 months) were included if they were aged ≥ 18 years, from a
hospital, rehabilitation or community setting and under the care of a tissue viability nurse specialist and
were able to reflect on and share their experience and provide informed consent to participate. Patients were
excluded if they did not currently have a pressure ulcer or one that had healed within the previous 3 months or
were unconscious, confused, cognitively impaired or unable to speak English.
Sampling A purposive sampling method was devised, with sampling of patients targeted to key factors
to reflect the range and diversity of the target population, including age (< 70 years and ≥ 70 years),
ulcer severity (superficial and severe129) and location (torso and limb sites) and health-care setting (hospital
and community). A minimum of five patients per key factor were consecutively sought and found.221
Recruitment and data collection
Eligible patients were identified and approached to participate by members of the tissue viability teams at
participating hospitals and community services, who provided information (see Appendix 39) about the
rationale, design and personal implications of the study and the ‘agree to be contacted by the researcher’
form (see Appendix 40). Following information provision, patients had as much time as they needed to
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consider participation. After receiving a signed agreement to be contacted, the researcher (CG) carried out
an interview at the patient’s home or hospital ward, which was audio recorded and transcribed verbatim.
We conducted individual face-to-face semistructured interviews, guided by an interview schedule
(e.g. questions to confirm or refute the importance of the working framework domains), open-ended
questions to elicit relevant new information (e.g. ‘Is there anything else that you want to add about how
your pressure ulcers may have impacted you?’) and clarifying questions (e.g. ‘Do you think [that] is only
because of your pressure ulcer or possibly resulting from a combination of things?) to ensure that issues
reported were in fact the result of pressure ulceration (see Appendix 41). The provisional HRQoL domains
were revised as new information emerged from the data, refining the working framework deductively, and
were incorporated into discussion in subsequent interviews to confirm the importance of new HRQoL issues.
Data analysis
First, the researcher read the transcripts while listening to the recording to confirm the accuracy of
transcription and to obtain an overview of the data collected. Any first impressions and interpretations
were noted, including thoughts about the main HRQoL domain components, general feelings about the
interview and audio cues from the patient that would be lost in transcription. Preliminary analysis was
carried out after the first three patients had been interviewed to assess whether the interview schedule’s
HRQoL domains were consistent with the emerging themes and to identify any gaps in information. Then,
two researchers (CG, JF) conducted thematic content analysis manually of textual data from the first four
interviews, identifying HRQoL issues within the transcripts and coding to a provisional coding schema
developed using a combined inductive (codes arising from transcripts) and deductive (codes developed from
the interview schedule) approach. The provisional coding schema was refined during subsequent stages of
the analysis; data collection and coding were conducted iteratively in multiple rounds of interviews so that
subsequent data collection was informed by earlier coding and confirmed in later interviews.
Expert opinion
Health-related quality of life components that emerged from the patient interviews were reviewed by a
multidisciplinary expert group (see Acknowledgements). Any issues mentioned infrequently were discussed
and those that were agreed not to be clinically relevant were either excluded or consolidated with related
components (e.g. various negative emotions such as irritated and distressed were consolidated with
‘negative mood changes’) rather than being retained as separate components in the conceptual
framework.221 Following data analysis, the group reviewed the final conceptual framework with the view
towards making a distinction between components that addressed the impact of pressure ulcers on HRQoL
and other contributory factors that may affect HRQoL.10
Ethical approval
The study was approved by the North West Research Ethics Committee prior to data collection
(reference number 07/H1010/60).
Results
Thirty-two patients with pressure ulcers from seven acute and primary care settings in England and Northern
Ireland during December 2007 to October 2008 consented to participate. However, two patients were
recruited twice and were not interviewed and so the final sample included 30 interviews (a record of those
approached to participate and refusals was not made). Participants ranged in age from 22 to 94 years
(mean age 62.2 years), 18 (60%) were male and 19 had other chronic conditions (e.g. eight had a spinal cord
injury and three had multiple sclerosis). Patients represented different settings (n= 17 hospital or rehabilitation;
n= 13 community), ulcer severity (n= 12 superficial; n= 15 severe; n= 3 mixed severity), numbers of pressure
ulcers (n= 13 had more than one ulcer), ulcer duration (few days up to 4 years) and sites (n= 15 sacrum;
n= 14 heel; others on the lower back, buttocks, ankles, hips, back of head and elbow).221
We identified both HRQoL outcomes and contributory factors that affect pressure ulcer-related HRQoL.
Contributory factors included six experience-of-care and 10 individual patient factors. Adults with pressure
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ulcers have concerns about treatment and wound management, treatment burden, communication
difficulties, their ability to cope with functional limitations, poor support networks and other health
problems and comorbidities.10 However, as the intention was to develop a HRQoL instrument, a distinction
between HRQoL outcomes and contributory factors (such as motivation and satisfaction with health care
received) that may affect HRQoL was made (see Expert opinion), resulting in a defined, conceptualised and
operationalised pressure ulcer-specific HRQoL conceptual framework.
The pressure ulcer-specific conceptual framework consists of four domains and 13 subdomains: symptoms
(pain and discomfort, exudate, odour), physical functioning (mobility, daily activities, general malaise,
sleep), psychological well-being (mood, anxiety and worry, self-efficacy and dependence, appearance and
self-consciousness) and social functioning (isolation, participation)221 (Figure 26). This study provides
qualitative evidence on HRQoL components that are important from the perspective of patients with
pressure ulcers, an essential step when developing new PRO measures. The conceptual framework
provides the basis for the development of the new pressure ulcer-specific measure of HRQoL.
Construct Domains Sub-domains Components
Sleep Disrupted
PU-
Specific
HRQL
Physical
functioning
Symptoms
Pain &
discomfort
Odour
Exudate
Mobility
Daily
activities
Washing, dressing,
housework, general
activities, dependence
Movement, sitting,
walking, transferring
Bother
Pain frequency,
severity & bother
General
malaise
Loss of appetite,
fatigue, feeling unwell,
poorly, tired
Appearance &
self-consciousness
Confidence, 
self-esteem, reliance,
helpless
Social
functioning
Psychological
well-being
Mood
Anxiety &
worry
Self-efficacy
&
dependence
Social
isolation
Participation
Feeling down,
depressed, irritated,
frustrated, angry
Physical appearance,
embarrassment
Feeling fear, concern,
surprise/shock
Social activities with
family, friends, groups,
hobbies/leisure
Feeling left out, lonely,
cut off
Bother
FIGURE 26 Pressure ulcer-specific HRQL conceptual framework. PU, pressure ulcer. Reprinted from Int J Nurs Stud,
vol. 47, pp. 1525–34, 2010, Gorecki C, Lamping DL, Brown JM, Madill A, Firth J, Nixon J. Development of a
conceptual framework of health-related quality of life in pressure ulcers: a patient-focused approach,221 with
permission from Elsevier.
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Phase 2: item generation, instrument construction and
pre-testing
Various parts are largely reprinted from J Pain Symptom Manage, vol. 42, Gorecki C, Closs J, Nixon J,
Briggs M. Patient-reported pressure ulcer pain: a mixed methods systematic review, pp. 443–59, 2011,36
with permission from Elsevier; and from Int J Nurs Stud, vol. 51, Gorecki C, Lamping DL, Alvari Y,
Brown JM, Nixon J, Patient-reported outcome measures for chronic wounds with particular reference
to pressure ulcer research: a systematic review, pp. 157–65, 2014,216 with permission from Elsevier.
The second phase of this project was the development of the PU-QOL instrument. Three sources were
utilised to generate the list of candidate items for the instrument: patient interview transcripts (see Item
generation from patients); systematic reviews of the pain literature and existing chronic wound PRO
instruments (see Item generation from existing instruments and pressure ulcer pain literature); and experts
in the field (see Item generation from experts). The item list was used to construct a preliminary version
of the PU-QOL (see Preliminary PU-QOL construction), which was pre-tested with a sample of patients
with pressure ulcers using mixed methods [cognitive interviews and Rasch measurement theory (RMT)
(see Pre-testing)]. Based on information obtained from patients and expert opinion, the pre-test version
was revised accordingly.
Item generation from patients
Item generation involved developing an exhaustive list of potential items (item pool) for each domain
within our conceptual framework. Content (patient words verbatim) from the phase 1 patient interviews
(see Qualitative study) was used to generate items. All content was grouped into HRQoL domains, with
each domain comprising a number of items describing slightly different components. We took the inclusive
approach retaining all content if reported more than once. Interview data were an excellent source for
generating items as items using patients’ words and representing variable components across the broad
spectrum of pressure ulcer-specific HRQoL outcomes were identified.
Item generation from existing instruments and pressure ulcer pain literature
We undertook two systematic reviews, first, to review generic, pressure ulcer-specific and chronic skin
wound-specific PRO instruments used to assess HRQoL in patients with pressure ulcers or other similar
chronic skin wounds216 and, second, to review patient reports of pressure ulcer-associated pain,
descriptions of the pain experience and the impact on patients’ lives.36
Existing chronic wound instruments: systematic review
Despite the impact on HRQoL, no research has been undertaken to determine the availability of PRO
instruments, either generic or condition specific, and their suitability for use in pressure ulcer research.
We developed a pressure ulcer-specific HRQoL conceptual framework (see Qualitative study). The
conceptual framework provides a structured and formal framework against which the content of available
PRO instruments can be assessed.
Aim
The aim of the systematic review was to identify generic, pressure ulcer-specific and chronic skin
wound-specific PRO instruments used to assess HRQoL in patients with pressure ulcers or other chronic
skin wounds and determine how useful or appropriate they are, based on their content, for use with
patients with pressure ulcers in assessing HRQoL outcomes.
Methods
Study eligibility Studies of any design were included if PRO measures were used to assess HRQoL or
related concepts in adult patient populations presenting with any grade of pressure ulcer or other
chronic wounds, from hospital, rehabilitation or community health settings within Europe, North America
or Australia. Studies were excluded if (1) HRQoL was assessed by the health-care provider or proxy
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(i.e. not patient reported); (2) they used an instrument intended primarily for other medical conditions,
in which pressure ulcers are a secondary outcome (e.g. Life Situation Questionnaire); (3) they used an
instrument assessing mediating or contributory outcomes only (e.g. Inventory of Socially Supportive
Behaviours, personality scales, locus of control, Coping Response Inventory, Mini Mental State Examination
for screening cognition); (4) HRQoL was assessed using a single-item rating scale [i.e. visual analogue scale
(VAS)]; or (5) they were limited to paediatric populations or wounds caused by trauma (e.g. burns).
Abstracts from conference proceedings were excluded unless additional information was provided by the
authors216 (see Appendix 42 for data sources and search strategies).
Study selection and quality assessment One researcher screened abstracts for relevance. Studies
assessed as potentially relevant or studies whose relevance was ambiguous were obtained in full for
further scrutiny. Two researchers independently assessed potentially relevant studies against the inclusion
criteria. Studies that did not meet the inclusion criteria were excluded from further analysis.216
Measures without evidence of any development or validation process (i.e. ad hoc instruments with no
formal reliability or validity testing) were excluded. Additional quality components were not used as a
threshold for the inclusion of instruments as the intention was to provide a descriptive summary of the
content domains of existing instruments used to assess HRQoL in patients with pressure ulcers and other
chronic wounds. However, empirical evidence for reliability and validity was a minimum requirement for
inclusion of PRO instruments.216
Data extraction Data were independently extracted by two reviewers. We cross-checked data extraction
for errors, omissions and consistency between extractions. Disagreements or discrepancies were discussed
between the two researchers and confirmed with a psychometrics expert (DL). We had intended to extract
data on the development and evaluation of PRO instruments to allow the appraisal of the measurement
properties216 for PRO instruments that had at least 75% of pressure ulcer-specific content (at both domain
and item level) and no more than 25% of non-relevant content. As none of the identified measures met
these criteria, the measurement properties were not extracted and assessed.
Data synthesis Our analysis systematically determined the extent to which PRO instruments covered the
pressure ulcer-specific conceptual framework (see Figure 26).216 Items from identified instruments were
mapped to the conceptual framework to determine content of relevance to pressure ulcers. Those
considered relevant could be included in the item pool.
Results
Three generic and 14 chronic wound instruments were identified but no pressure ulcer-specific instruments
(Figure 27).216 None of the available instruments cover all HRQoL domains that are important in pressure
ulcers. One condition-specific instrument, the Venous Leg Ulcer instrument, matched most closely
conceptually, but failed to represent three important domains and contained items not specific to pressure
ulcers.216 Although a potentially valuable source for generating items, few items were assessed as pressure
ulcer specific (i.e. they were worded to assess the impact of other conditions and not specifically the impact
of pressure ulcers) or were items already generated from patient reports.
Pressure ulcer-related pain: systematic review
Pressure ulcers can cause patients considerable pain and discomfort; however, little is known about how
pressure ulcer pain affects patients’ everyday lives.
Aim
The aim of this systematic review was to identify and synthesise all research that included verbal patient
reports of pressure ulcer-associated pain, including descriptions of the pain experience, intensity and
quality and impact, to interpret the complexities of the pain experienced from pressure ulcers. Specific
objectives were to describe specific characteristics of pressure ulcer pain and determine how it affects
patients’ lives.36
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Methods
Study eligibility Studies were included if the study sample consisted of adult patients with any category
of pressure ulcer from any setting with any existing comorbidity and the study used qualitative methods to
obtain patient reports of their experience of pressure ulcer pain. Studies using mixed-method designs were
included only if pressure ulcer-specific findings were reported separately from mixed wound findings or
quantitative methods to assess pain used existing validated outcome measures in which pain descriptors
were available. Studies that used patient-reported HRQoL instruments were considered if a pain scale was
included and the results were reported. Studies were excluded if the study sample consisted of those with
mixed wounds, pressure ulcer-associated pain was not patient reported (i.e. proxy assessment) or data
were collected using ratings or a VAS to obtain pain severity scores. No upper age, gender or language
restrictions were applied (see Appendix 42 for data sources and search strategies).36
Study selection and quality assessment Study selection methods were consistent with those described
in Existing chronic wound instruments: systematic review.
Individual quality components of study methodology were not used as a threshold for the selection of
primary studies. We included all available data but assessed the appropriateness of each study by making a
judgement about whether a study used appropriate methods for addressing our review questions and for
ensuring that findings about the pressure ulcer pain experience were indeed from the patient perspective
(e.g. whether data collection methods were appropriate for helping patients express their views and how
pressure ulcer pain affects them).36
Records identified through
database searching
(n = 2665)
Additional records identified
through other sources
(n = 27)
Records screened
(after duplicates removed)
(n = 1792)
Records excluded
(n = 1535)
Full-text articles assessed
for eligibility
(n = 257)
Full-text articles excluded (n = 202)
•
•
•
Not HRQoL outcome (n = 52)
Not chronic wound (n = 43)
Not patient-reported (n = 7)
Relevant studies
(n = 55a)
PROMs included and content
reviewed (n = 17)
•
•
Generic (n = 3)
Chronic-wound specific (n = 14)
Instrument excluded (n = 3)
•
•
Still in development (n = 2)
No psychometric evidence (n = 1)
FIGURE 27 Flow of studies: existing instrument systematic review. a, Duplication of instruments across studies.
PROM, patient-reported outcome measure. Reprinted from the International Journal of Nursing Studies, vol. 51,
pp. 157–65, 2014, Gorecki C, Lamping DL, Alvari Y, Brown JM, Nixon J, Patient-reported outcome measures for
chronic wounds with particular reference to pressure ulcer research: a systematic review,216 with permission
from Elsevier.
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‘Data extraction and synthesis Two reviewers independently extracted findings in the form of direct
patient quotes and allocated findings to defined categories. A category was determined by grouping
common findings (i.e. findings that reflected similar phenomena or variables). Categories that were
sufficiently similar in meaning were generated into synthesised themes. Synthesis of findings and categories
was reviewed by three reviewers until consensus. Any descriptions relating to pressure ulcer-associated pain,
including descriptions of the pain experience, intensity, quality and impact, could be included as items.’36
Results
‘Ten studies were included: six qualitative and four quantitative studies (Figure 28). These included 108
adults with pressure ulcers. We produced a biopsychosocial model of the pressure ulcer pain experience,
including five domains: communicating the pain, feeling the pain, impact of pain, self-management and
professional management. The findings of the review suggest that, to achieve the best possible outcomes
that are important to patients, improved communication of pain experienced between the individual and
health-care professional and across disciplines, interventions to help control or reduce pressure ulcer pain,
patient-centred concerns and systemic barriers need to be considered when managing pressure ulcers to
ensure more effective pressure ulcer pain management in the future.’36 These findings are consistent with
those from the severe pressure ulcer study (see Chapter 4).
With regard to potential items, similar to the existing instrument systematic review, pain-related issues had
already been identified from patient reports and no new descriptors were added to the item pool.
Item generation from experts
As patients with pressure ulcers receive specialist care from health-care professionals who have a vast range of
experience in treating patients with pressure ulcers and therefore probable insight into patients’ experiences,
a clinical expert group reviewed the item pool generated from patient interviews. The group consisted of
three community and acute care tissue viability nurse specialists (LW, NS, EM), three nurses with extensive
experience undertaking pressure ulcer research (JN, EAN, CD), one chronic wound pain specialist (MB) and
one nurse with experience of health-care policy development (SC) (see Acknowledgements). Items were
grouped by domains and the focus of the review was on item grouping and relevance, content and wording
and clinical importance. Items with similar content were highlighted and the accuracy of domain
Records identified through
database searching
(n = 539 minus duplicates)
Records excluded
(n = 509)
Full-text articles assessed
for eligibility
(n = 30)
Full-text articles excluded
(n = 20)
•
•
•
Obtained pain severity scores
rather than descriptors, n = 15
Not patient reported/proxy, n = 2
Sample mixed wounds, n = 3Relevant studies
(n = 10)
Included qualitative
study
(n = 6)
Included quantitative
study
(n = 6)
FIGURE 28 Flow of studies: pain systematic review.
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categorisation (item grouping) was discussed. Additional items were added if necessary. Items were retained if
they were considered clinically relevant, not too similar (redundant items were combined or removed) or to
pertain to HRQoL (not measuring other constructs such as personality or satisfaction). Final item elimination
decisions were based on consideration of item problems in combination.
At this stage an important conceptual decision was made to include pressure ulcer symptoms of pain, exudate
and odour into the pressure ulcer-specific model. These symptoms are important consequences of having a
pressure ulcer but initially were not considered HRQoL outcomes and were therefore excluded from the original
item pool. Counting the frequency or assessing the intensity of symptoms may not be an adequate measure of
HRQoL,226 but the impact of symptoms and the meaning that they have for individuals is an important aspect
of HRQoL assessment and therefore is considered important for inclusion in a pressure ulcer-specific PRO
instrument. Patient comments pertaining to these outcomes were identified in the qualitative work and items
were added to represent these symptoms. The amended item pool and content mapping were reviewed by a
group of seven health outcome methodologists (see Acknowledgements), who focused on the constructs
measured (e.g. whether or not items for each domain were representative of the construct being measured)
and item wording (i.e. whether any items were confusing, ambiguous, double-barrelled). The process of item
generation resulted in an initial pool of 118 items (see Appendix 43).
Construction of the preliminary Pressure Ulcer Quality of Life tool
The development of the preliminary PU-QOL instrument involved careful stepwise construction with
consideration of the design, layout and instructions, framing of questions, response format and recall
period to ensure that the way that the PU-QOL was presented was tailored to the characteristics of
patients with pressure ulcers (i.e. understood by and relevant to the intended population).
Instructions, design and layout
Consistent with recommendations,227 general information pertaining to what the PU-QOL instrument is
about and instructions about how questions should be answered were placed at the beginning of the
instrument. Instructions specific to individual questions were placed close to the relevant question.
Instructions were brief and clear and bold font was used to highlight important components (e.g. ‘during
the past week’ and ‘tick all that apply’). A statement ensuring confidentiality was included to encourage
accurate reporting.
The PU-QOL instrument was designed as a double-sided A4-size booklet on white paper. Font size 12 was
chosen as respondents are largely elderly people with some visual impairment. Questions were grouped
into item sets (scales; see Framing of questions) and numbered, not crowded or split between two pages,
with horizontal response formats (see Response options) attached, and ended with a thank you.227
Framing of questions
The US Department of Health and Human Services Food and Drug Administration (FDA) guidance for
developing PRO instruments212 recommends that items should adequately cover important conceptual
domains, relate to the instrument’s objectives, use words that are familiar to patients and not be
confrontational, upsetting or ambiguous. These recommendations were considered when constructing the
PU-QOL instrument to ensure clearly formulated and precise items.
Operationalisation
The item pool (n= 118) was transformed into scales through a process known as operationalization,
in which logically related items are grouped or blocked into scales based on their conceptual meaning to
represent coherent clinically meaningful constructs.225 Each scale represented one of the 13 subdomains
within the pressure ulcer-specific HRQoL conceptual framework (see Figure 26) and produced a scale score
rather than an overall total score. The intention was to enable the monitoring of changes within patients
on these 13 outcomes rather than a global HRQoL change.
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Item stem
As the PU-QOL is a condition-specific instrument, the item stem had to be worded in a way that focused
patients’ thinking towards their pressure ulcer so that any bother attributed related to pressure ulcer
impact rather than impact from other health problems that the patient might have (i.e. the item stem
needed to be salient to people with pressure ulcers rather than relating to overall health status). This was
considered important as people who develop pressure ulcers usually have a multitude of health problems
or comorbidities that may affect the same outcomes that pressure ulcers affect, such as pain. The item
stem for each question was, ‘During the past week, because of your pressure ulcer, how much were you
bothered by . . .’, which was followed by the item content (e.g. feeling uncomfortable).
Response options
The Likert-scale response method is commonly used in PRO measurement and was the chosen method for
the PU-QOL instrument. When constructing Likert scales the number of response categories to use and
how they should be labelled needs to be considered.212 The response option descriptors chosen for the
PU-QOL instrument relate to the amount of bother attributed (e.g. ‘How much have you been bothered
by . . .?’) rather than the frequency of the outcome (e.g. a symptom might be frequent but might not
necessarily be bothersome). ‘Bother’ was a term that was frequently used by patients during the qualitative
interviews (see Qualitative study). Both response formats (frequency of the problem and amount of bother
attributed) were presented to participants during pre-testing. Each item uses four discrete response options
scored with successive integer scores (e.g. 0= no bother at all to 3= a lot of bother). These imply a
continuum of increasing impact (bother), from less (no bother) to more (a lot of bother). This assumption
was tested by examination of threshold ordering in subsequent testing (see Phase 3: field testing).
Time frame
Important disease changes/progression and memory error (recall bias) need to be considered when
choosing a time frame. A recall period of the past week was chosen on clinical grounds, as changes in
pressure ulcer severity and symptomology often occur over days and thus a longer recall period would risk
not capturing relevant changes in HRQoL. Events that occurred over a month ago may no longer be
relevant or may have been resolved or treated.
Mode of administration
With regard to mode of administration there is essentially a choice between interviewer administered
(i.e. face-to-face, telephone) and patient self-completed (e.g. postal survey, during clinic visit). Each method
has its advantages and disadvantages and the current evidence is inconsistent in differentiating the
superiority of one method over the other in terms of quantity and quality of response.228 We considered
that patients with pressure ulcers (i.e. acutely ill, elderly) may have difficulty with self-completion, but as
the PU-QOL instrument is intended for pressure ulcer intervention effectiveness research, and there is
cost–benefit associated with self-completion methods in clinical trials that require large samples,229 the
decision was made to develop a self-completed version in the first instance. The suitability of this method
was determined during field test 1 (see Field test 1 and mode of administration substudy).
Pre-testing
Pre-testing is key in PRO instrument development. We undertook a pre-test study to evaluate patients’
understanding of the items, instructions, response options and recall period, determining whether
readability was appropriate for the target population and confirming the completeness of concepts
covered by items212 (see Appendix 44 for the study protocol).
Aim
The aim of this study was to pre-test the preliminary PU-QOL version using cognitive interviewing and RMT
methods to identify and resolve problems with layout, time frame, response options, framing of items and
administration mode. The study was also designed to determine whether or not readability was appropriate for
patients with pressure ulcers and confirm content (i.e. the need for additional items or elimination/rewording of
other items) prior to formal psychometric evaluation,222 hence it being described as ‘pre-testing’.
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Methods
Design
Mixed methods were used to pre-test the preliminary PU-QOL tool. The intention was to identify and
resolve any problems with the way in which the PU-QOL tool was constructed, by comparing RMT230
findings with the findings from cognitive interviews for consistency.222 The intention was to reduce
respondent burden and decrease data errors and non-response because of poor design and layout and
unclear, misunderstood or irrelevant items to ensure that the PU-QOL was relevant to and understood by
people with pressure ulcers.
Participants
Eligibility Adult patients from acute and primary care settings were included if they had a pressure ulcer
of any severity,1 duration or location; were aged ≥ 18 years; were from a hospital, rehabilitation or
community setting; and were able to read and write in English. Patients without a pressure ulcer or who
were unconscious, confused, cognitively impaired, unable to speak English or deemed ethically
inappropriate to approach (e.g. death was imminent) were not eligible.
Sampling The sampling method for the pre-test was consistent with that detailed in phase 1
(see Qualitative study, Sampling).
Recruitment and data collection
The recruitment method for the pre-test was consistent with that detailed above in phase 1
(see Qualitative study, Recruitment and data collection; see also Appendix 45 for the patient information
leaflet and consent form).
Structured face-to-face cognitive interviews were undertaken to gain an understanding of how patients
interpret and understand individual questions (i.e. whether questions are understood as intended) and
produce their answers.195 Emphasis was on comprehension (i.e. clarity, language), retrieval from memory
and response judgements (i.e. frequency judgements, logic decisions). Interviews were conducted in
patients’ homes, clinics or wards, as determined by the each patient’s circumstances at the time
of interview.
Two interviewing techniques were employed; however, the first three participants who were asked to
think aloud (spontaneous conversation) while completing the PU-QOL reported that the method made
completion difficult. Therefore, the remaining participants completed the preliminary PU-QOL instrument
without researcher assistance. They were instructed to flag/mark items that they found confusing, difficult
to understand, upsetting/intrusive or annoying while completing the PU-QOL and to consider the format,
design and response options. The preliminary version contained 118 items and took around 22 minutes to
complete. Many items were similar, with slight variations in wording; however, these were retained and
presented to patients for consideration.
Following completion, the researcher (CG), guided by a standard set of questions and probes
(see Appendix 46), sought to elicit the cognitive processes employed by patients while completing the
PU-QOL instrument. Patients were asked to give feedback on their understanding of each question and
associated response categories and instructions and to verbalise how they had gone about producing their
answers, with particular emphasis on retrieval from memory and subsequent judgements and decisions.
During debriefing interviews the researcher took notes, fed back to patients to ensure comprehension of
responses and reviewed recorded interviews, making notes on structured data extraction forms.222
DOI: 10.3310/pgfar03060 PROGRAMME GRANTS FOR APPLIED RESEARCH 2015 VOL. 3 NO. 6
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Nixon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
183
Data analysis
Qualitative analysis An analysis schema was developed based on the Question Appraisal System
(QAS-99).231 The QAS-99 is a coding tool that focuses on the cognitive demands required for answering a
question, and potentially problematic item characteristics that may lead to response error, such as content,
layout/length, time frame and response options, were identified across interviews. Problems from the
patient interviews included misunderstanding of the item stem, response options or instructions; unclear
wording (i.e. patients used expressions such as ‘should’, ‘needs to’, ‘must’); and negative comments about
an item (e.g. ‘that item upset me’, ‘that item is annoying, it’s like the previous one’). The focus of the
analysis was on identifying dominant trends across interviews (i.e. problems that occurred repeatedly) and
key findings (i.e. problems identified in a single interview, but indicating a potentially problematic issue).222
Rasch measurement theory Rasch measurement theory provides a formal method for evaluating scale
functioning against a sophisticated mathematical measurement model.230 The Rasch model defines how a
set of items should perform to generate reliable and valid measurements232 and evaluates the legitimacy
of summing items to generate measurements.230,233 In a Rasch analysis, the extent to which observed data
(patients’ actual responses to scale items) are concurrent with (‘fit’) predictions of those responses from
the Rasch model is examined, with the difference between expected and observed scores indicating the
degree to which rigorous measurement is achieved.234 The expected response structure is a probabilistic
Guttman pattern, which assumes that, for people with the same ability, the probability of endorsing an
easy item is higher than the probability of endorsing a more difficult item and vice versa.235 When a rating
scale is used to discriminate between those with different abilities, someone with higher ability is expected
to affirm all items endorsed by a person with lower ability in addition to items representative of higher
ability. RMT was used to examine the PU-QOL instrument’s response options, the appropriateness of the
item series and biases arising because of question ordering.
We compared the cognitive interview and Rasch analysis findings in an interactive and iterative process to
identify potential strengths and weaknesses of PU-QOL items and to guide decision-making about further
revisions to items and the questionnaire design/layout.
Expert appraisal As there is no standard method for using cognitive interview data to modify PRO
instruments,236 the outcome methodologists (see Acknowledgements) discussed and resolved aggregated
findings (both within and across interviews) after each patient interview round in an iterative process. This
was carried out on a consensus, item-by-item basis to decide whether to retain, revise, eliminate or add
items or make changes to the design and layout, with particular weight given to the same comments by
several patient respondents. Occasionally, a single negative remark led to an item revision (e.g. a remark
signalling a serious misunderstanding of an item). A group of clinical experts (see Acknowledgements)
reviewed the revisions made to ensure clinical relevance. Expert appraisal assisted in avoiding bias that
would be introduced when relying solely on the judgement of one researcher in determining the
implications of the cognitive interview findings.222
Pressure Ulcer Research Service User Network UK appraisal Pressure Ulcer Research Service User
Network UK members with experience of living with a pressure ulcer were invited to review the final
pre-test version of the PU-QOL instrument and feed back on clarity and comprehension, design and layout
and item wording. Responses from PURSUN UK members was fed back to the clinical expert group and
incorporated into the final pre-test version.
Ethical approval
The pre-test study was approved by the North West Research Ethics Committee prior to data collection
(reference number 08/H1010/112).
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Results
We screened 134 patients from 11 acute and community NHS sites across England from April 2009 to
September 2009 in three rounds of cognitive interviews. Of those screened, 66 were considered eligible
and 35 were recruited to the three rounds (10, 10 and 15 respectively). Patients ranged in age from 36 to
85 years (mean age 65 years) with half (49%) aged ≥ 70 years. In total, 16 (46%) were men and 18 (51%)
had an additional chronic condition (e.g. spinal cord injury). Patients represented different settings (n= 19
hospital; n= 4 rehabilitation; n= 12 community) and ulcer severity (n= 13 superficial; n= 18 severe; n= 4
mixed severity), duration (2 weeks up to 5 years) and skin site (n= 33 sacrum/buttocks; n= 13 heel; others:
lower back, groin, hips, back of thighs and ankles).222
Cognitive interviews identified five key problem areas: content, instruction/layout/length, recall period,
response options and administration mode. For example, patients reported that there were too many items
about odour – ‘How many different words do you need for smell, you could remove a lot of these’ – or
items used words that were too sensitive (e.g. ‘dirty smell’) or not commonly understood (e.g. ‘foisty’).
Revisions focused on using words that patients use (e.g. ‘pressure sore’ instead of ‘pressure ulcer’).222
Participants preferred responding in terms of how bothered they were about a particular problem rather
than simply reporting on the frequency. We also found that almost half of the sample (n= 15; 43%)
needed some assistance with completing the instrument, which led us to change the mode of
administration from self-complete to interview administered to ensure suitability across the wide spectrum
of pressure ulcer patients. The optimal mode of administration was tested empirically during the first field
test (see Field test 1 and mode of administration substudy).
The Rasch analysis highlighted problems with the response options (i.e. the 4-point item response options
were not supported; disordered thresholds were found in 74 of 90 items, indicating that the proposed
scoring function was not working as intended). However, as the Rasch analysis was preliminary, it was
considered premature at this stage to make changes to the response options until further empirical
evidence could be obtained.222 Consistent with the qualitative findings, the Rasch analysis identified item
redundancy; examination of item locations indicated that some items clustered at similar locations
(e.g. the item ‘lacking self-esteem’ was considered similar to the items ‘feeling self-conscious’ and ‘lacking
confidence’ by both methods and was subsequently removed).
The results guided changes to layout, administration mode and content (e.g. item selection and deletion to
reduce respondent burden, data errors and non-response). Feedback from PURSUN UK members led to
some additional clarification of the instructions and revisions to the item wording for two items (removed
item ‘upset’; merged items ‘concerned’ and ‘worried’ into one item).
Preliminary Pressure Ulcer Quality of Life instrument
The final preliminary PU-QOL instrument consisted of 13 scales (87 items): pain (11 items), exudate
(eight items), odour (six items), sleep (six items), malaise (three items), mobility (11 items), daily activities
(nine items), mood (seven items), anxiety (three items), self-consciousness and appearance (seven items),
autonomy (three items), isolation (four items) and participation (nine items). It was intended for interview
administration and responses are given in terms of the amount of bother attributed (‘During the past
week, how much have you been bothered by . . .?’) during the past week on a 4-point response scale
(0= not at all to 3= a lot).
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Phase 3: field testing
Various parts are largely reproduced from Gorecki et al.223 © 2013 Gorecki et al.; licensee BioMed
Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
To enable the PU-QOL instrument to be used with confidence in clinical practice and future research it must be
shown to meet psychometric standards for reliable and valid measurement. The third phase of this project
involved a full psychometric evaluation of some of the fundamental measurement properties of the final
pre-test version of the PU-QOL instrument.223 It included two field tests and a mode of administration substudy.
The first field test was carried out to identify any items with poor psychometric performance for possible
elimination (item reduction) and establish the optimal mode of administration for the instrument (i.e. patient
self-completion or researcher administered). The second field test involved a full psychometric evaluation
(e.g. tests for scale targeting, item response categories, scaling assumptions, acceptability, reliability and
validity) of the item-reduced version of the instrument (see Appendix 44 for the study protocol).
Field test 1 and mode of administration substudy
The first field test was required to establish the feasibility and acceptability of the PU-QOL instrument,
produce a shorter version if appropriate (i.e. reduce the instrument length without losing measurement
precision) and identify subscales and test scaling assumptions.
Aims
This study aimed to:
1. confirm the feasibility and acceptability of the instrument
2. produce a scientifically robust shorter version by selecting items that perform best against established
psychometric criteria
3. examine the legitimacy of summing items into scales and test scaling assumptions
4. carry out a preliminary evaluation of the reliability and validity of the shorter item-reduced version
5. empirically investigate the optimal mode of administration (i.e. establish whether the PU-QOL
instrument can be developed for use with both self-completion and interview-administered modes or
whether two mode-specific instruments are required).
Methods
Design
A field test was carried out to evaluate the PU-QOL instrument’s response format, scales and items in an
independent sample of patients with pressure ulcers. Part of the field test included a mode of
administration substudy to provide empirical support for the chosen mode of administration (i.e. interview
administered) for the PU-QOL instrument. Initially, the intention was for the PU-QOL instrument to be
self-completed; however, pre-testing identified problems with completion rates (see Pre-testing, Results),
questioning the appropriateness of a self-completed instrument for patients with pressure ulcers.
Participants
Eligibility Patients from selected acute and community NHS trusts in England and Scotland were included
in the field test and substudy if they were aged ≥ 18 years and were hospital, intermediate care including
rehabilitation, nursing home or community patients with an existing pressure ulcer of any category,
location or duration and were able to provide informed consent to participate.223 Patients were excluded if
they had only moisture lesions or were unconscious, confused or cognitively impaired, it was deemed
ethically inappropriate to approach them (e.g. death was imminent), they did not speak or understand
English or they were unable to provide informed consent. To ensure equivalent samples in both
administration mode groups, the eligibility criteria were adapted for the substudy to include only patients
able to read and write in English (i.e. patients able to self-complete).
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Sampling Between 200 and 250 patients with pressure ulcers were purposively sampled ensuring balanced
representation of patients across ulcer categories (superficial and severe) and location (torso and limb skin sites),
settings (acute and community), age (< 70 years and ≥ 70 years) and gender.223 No formal sample size
estimation methods for the evaluation of PRO instruments were found. The ‘rule of thumb’ sample size
recommendation for psychometric analyses of new summated scales is five to 10 subjects per item, to reduce
the effect of chance.194,195 Following this recommendation, if we take the longest potential summated scale,
assessing pain, which contains 11 items, a 110-patient sample would be required. For the Rasch analysis,
a sample of 200–250 patients was sought. This estimate was based on a need for sample selection across the
full range of measurement. Sample membership to five class interval groups [i.e. different levels (class intervals)
of a person factor, e.g. ulcer severity] of around 50 patients in each group is suggested.233,237
A subsample (60–100 patients) was recruited to the mode of administration substudy. It was anticipated
that up to 100 patients would be required to meet the data requirement for the differential item
functioning (DIF) analysis and to account for the likelihood of missing data from the self-complete group.
RMT methods are able to provide useful exploratory data in small samples (n> 30).238
Recruitment and data collection
Consecutive patients were identified and approached to participate in the study by attending clinical teams
at participating trusts. Screened patients who were eligible were provided with a study information leaflet
and consent form (see Appendix 47). Patients who provided informed consent but who were unable to
self-complete the PU-QOL instrument were registered into the field test study. Those who were eligible
and able to self-complete the PU-QOL instrument were registered and enrolled into the substudy.
The PU-QOL instrument was administered to all patients by tissue viability team members or the researcher,
following the PU-QOL user manual. The user manual was developed to provide information about how to
administer the PU-QOL questionnaire and encourage standardisation across administration. It outlines the
administration procedure, includes some helpful question and answers and provides scoring information.
Patients enrolled to the substudy and randomised to the self-completion group were provided with the PU-QOL
instrument and instructed to complete it on their own. Completion took approximately 16 minutes.
Substudy randomisation
Substudy registrants were randomised by telephone on a 2 : 1 basis to either the self-completion or the
interview-administered mode of administration. The 2 : 1 ratio was used to account for the likelihood of
there be being more missing data from self-completed questionnaires. Randomisation was stratified by age
(< 70 and ≥ 70 years) and ulcer severity (superficial vs. severe).
Analytical methods
Conventionally, PRO instruments or rating scales have been developed and evaluated according to
traditional psychometric standards derived from CTT.195,239 CTT comprises a set of principles and related
statistical techniques for developing and testing measures (e.g. PRO instruments) to determine how
successful they are at estimating unobservable (e.g. HRQoL) variables of interest.240 However, some
concerns have been raised about existing PRO instruments developed according to CTT: they may be
cumbersome for respondents, be burdensome for clinical use, not be applicable over the continuum of
care or across research settings, suffer from floor and ceiling effects and/or lack a standardised scoring
metric to allow comparisons across health conditions.241–244
More recent advances in psychometrics have seen the development and application of modern psychometric
methods such as RMT to supplement traditional approaches to rating scale development.244 Both RMT and
traditional psychometric methods were used to psychometrically evaluate the PU-QOL instrument. Using both
methods would allow the selection of scale items that are free of bias, confirm the legitimacy of summing scale
items to generate measurements (Rasch) and determine whether or not the measurements produced are valid
and reliable in line with proposed US FDA criteria for reliability and validity.212 Table 72 presents full details of
the tests and criteria used in the psychometric evaluation.
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Rasch measurement psychometric analysis First, RMT methods230 were used to investigate the PU-QOL
instrument items within the context of the instrument, response options, appropriateness of item series
(i.e. item content, response bias, dimensionality, precision) and question ordering (item fit) to evaluate how
well items, scales and response options work to measure what they are intended to measure.
A Rasch analysis, using the Andrich rating scale model,264 was performed using RUMM2030 software
(RUMM Laboratory, Perth, WA, Australia), comprising targeting of the sample to items, ordering of
response options (i.e. ordering of item thresholds)249 and item-fit statistical indicators (i.e. fit residual and
chi square256 and spread of item locations;256,258 see Table 72). PU-QOL data were tested against model
expectations and any deviations from model expectations were examined to determine whether or not
scale attributes could be improved. Final decisions on item inclusion/exclusion were made according to
appraisals of the analyses of the observed data against measurement criteria described in Table 72, and
clinical relevance (the extent to which items within proposed scales are clinically cohesive), as opposed to
examinations carried out singularly or sequentially.
Substudy analysis Response rate, data quality and DIF analyses265 were undertaken to establish
measurement equivalence across the two mode of administration groups (self-completion and interview
administered). DIF provides a method of exploring conditional relationships between item response and
group membership by examining the significance of differences observed between different levels
(class intervals) of a person factor (e.g. administration mode group).260 Groups to be studied are selected
based on theoretical considerations about whether or not the construct studied is hypothesised to have the
same conceptual meaning across groups.
Traditional psychometric analysis: preliminary psychometric evaluation To determine whether or
not the PU-QOL instrument fulfilled fundamental prerequisites for rigorous measurement as defined by
traditional psychometric criteria and the US FDA guidance,212 the Rasch model-developed PU-QOL scales
underwent a preliminary psychometric evaluation using standard psychometric tests.212,225,250,254,263,266 The
scales were examined for acceptability and data quality, scaling assumptions, targeting, reliability and
construct validity against prespecified criteria (see Table 72). As RMT provides a formal method of testing
the degree to which rigorous measurement is achieved by PRO scales, use of factor analysis to determine
scale structure was not deemed necessary. The psychometric tests were performed using SPSS 15.0
software (SPSS Inc., Chicago, IL, USA).
Ethical approval
The two field tests were approved by the North West Research Ethics Committee prior to data collection
(reference number 08/H1010/112).
Results
Sample
A total of 989 patients were screened for participation in the first field test from 21 hospitals,
10 community services and one hospice. Of those screened, eligibility was assessed for 787 (79.6%); 416
were considered eligible (52.9%) and, of those eligible, 285 (68.5%) consented to participate (Figure 29).
Cognitive impairment was the main reason for ineligibility (38.8%). Those able to self-complete were
included in the substudy (n= 75), with 54 randomised to the self-completion group and 21 randomised to
the researcher-administered group; the remaining 210 participants were registered to the main study.
The main study analysis population included those able to self-complete and randomised to the researcher-
administered group in the substudy (n= 21) plus those registered to the main researcher-administered
study (n= 206). The final analysis populations after exclusions included 70 participants in the substudy and
227 in the main study (see Figure 29). Table 73 presents the characteristics of the final analysis samples.
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Main study analysis population
(n = 227; n = 21
recruited to substudy
administered mode and n = 206
recruited to main study)
Screened
(n = 989)
Assessed for eligibility
(n = 787/989; 79.6%)
Consented
(n = 285/416; 68.5%) Can you self-complete a
questionnaire?
Y = substudy; N = main study
Enrolled to substudy (n = 75) Enrolled to main study (n = 210)
Excluded from analysis
(n = 4; 1.9%):
Patient withdrew consent, n = 2
Patient self-completed, n = 1
Patient recruited twice, n = 1Randomised to
self-complete
mode
(n = 54)
Excluded from
analysis
(n = 5;
questionnaire
not returned)
Randomised to
administered
mode
(n = 21)
Excluded from
analysis
(n = 0)
Not assessed (n = 202)
missed by clinical research team
patient died
patient transferred
patient cognitively impaired
on care pathway for dying
reason missing
24
26
19
90
42
1
Eligible
(n = 416/787; 52.9%)
Not eligible (n = 371)
patient under 18 years of age
patient does not have ulcer
patient does not speak English
unable to self-complete
unable to give consent
patient is cognitively impaired
missing
0
40
8
37
142
144
0
Substudy analysis
population
(n = 70)
FIGURE 29 Assessment flow chart for the substudy and field test 1.
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TABLE 73 Participant characteristics in the substudy and field tests 1 and 2
Characteristic Substudy (n= 70) Field test 1 (n= 227) Field test 2 (n= 229)
Age (years), range (mean, SD) 21–93 (64, 15) 24–98 (72, 13.5) 20–103 (71.3, 16.5)
Gender, n (%)
Male 47 (67.1) 90 (39.6) 119 (52.0)
Female 23 (32.9) 137 (60.4) 110 (48.0)
Ethnicity, n (%)
White NA 223 (98.2) 227 (99.1)
Asian NA 1 (0.4) 2 (0.9)
Black/African NA 2 (0.9) 0
Chinese NA 0 0
Not stated NA 1 (0.4) 0
Setting, n (%)
Hospital (surgery) 38 (54.3)a 99 (43.6) 62 (27.1)
Hospital (medicine) 21 (9.3) 74 (32.3)
Community 32 (45.7) 107 (47.1) 88 (38.4)
Missing 0 0 5 (2.2)
Pressure ulcer severity, n (%)
Category 1 40 (57.1)b 38 (11.3) 76 (18.1)
Category 2 144 (42.9) 170 (40.5)
Category 3/4 30 (42.9) 153 (42.7) 170 (40.5)
Missing 0 1 (0.3) 4 (0.9)
Pressure ulcer risk classification, n (%)
Short term NA 39 (17.2) 36 (15.7)
New medium to long term NA 71 (31.3) 87 (38.0)
Ongoing long term NA 116 (51.1) 103 (45.0)
Missing NA 1 (0.4) 3 (1.3)
Marital status, n (%)
Single (includes divorced, separated, widowed) NA 59 (26.0) 71 (31.0)
Married NA 85 (37.4) 77 (33.6)
Cohabiting NA 81 (35.7) 75 (32.8)
Missing NA 2 (0.9) 6 (2.6)
Living arrangements, n (%)
Live alone NA 84 (37.0) 86 (37.6)
Cohabit with carer NA 63 (27.8) 51 (22.3)
Cohabit with other NA 61 (26.9) 48 (21.0)
Missing NA 19 (8.4) 44 (19.2)
Education, n (%)
No formal education NA 129 (56.8) 125 (54.6)
GCSE or equivalent NA 39 (17.2) 40 (17.5)
A-Level or equivalent NA 25 (11.0) 16 (7.0)
Degree or higher NA 15 (6.6) 21 (9.2)
Missing NA 19 (8.4) 27 (11.8)
A-level, Advanced Level; GSCE, General Certification of Secondary Education; NA, information not available.
a Combined hospital sample.
b Combined category 1 and 2 sample.
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Mode of administration substudy
The substudy provided qualitative and empirical evidence for the selection of the most appropriate
administration mode for people with pressure ulcers. Qualitative findings highlighted difficulties with
patient self-completion. PU-QOL forms returned with missed items were examined to investigate patterns
in missing responses and the following observations were noted. Of the 19 self-completed PU-QOLs with
missing data, four respondents wrote ‘n/a’ next to items missed; six completed only one item per scale;
five missed items at random; two missed a page; one missed items from only the daily activities scale; and
one mostly missed items at the beginning. Of the three researcher-administered PU-QOLs with missing
data, one had one item missed and one had two items missed; in the other case the patient asked to stop
completing the PU-QOL because of feeling ill, resulting in a large amount of items (n= 26) missed towards
the end. No obvious patterns in responses emerged. We concluded that, if length was an issue for missing
data, we would expect to see more missing data towards the end of the questionnaire (i.e. when patients
became tired or fed up with completing a long questionnaire). However, this pattern was not observed.
Rather, patients were not responding to items as instructed, resulting in missing data.
Investigation of response rate and data quality indicated a difference in response rate between
administration methods: 90.7% of the self-completed PU-QOL forms compared with 100% of the
administered PU-QOL forms were returned, an overall high response rate. A difference was also observed
in data quality: a large proportion of PU-QOL forms were returned with missing data in the self-completed
group (Table 74), supporting the pre-test findings (see Pre-testing, Results). Inspecting returned PU-QOL
forms by setting, missing data were observed mostly on forms that were self-completed by patients in
hospital (see Table 74), although preliminary DIF analysis indicated that administration mode did not
impact on the way that community patients responded to PU-QOL items, supporting the equivalence of
TABLE 74 Data quality: missing data (substudy population)
Characteristic
Self-completed
(n= 49)
Administered
(n= 21)
Totala
(n= 70)
PU-QOL forms with missing data, n (%) 19 (38.8) 3 (14.3) 22 (31.4)
Total number of PU-QOL items missed (range 1–87 items per
PU-QOL), n (%)
619 (14.5) 29 (1.6) 648 (10.6)
Age
< 70 years
Number with missing data 12/25 2/14 14/39
Number (%) of items missed 336 (15.5) 3 (0.3) 345 (10.2)
≥ 70 years
Number with missing data 7/24 1/7 8/31
Number (%) of items missed 283 (13.6) 26 (4.3) 309 (11.5)
Health-care setting
Acute
Number with missing data 16/26 2/12 18/38
Number (%) of items missed 604 (26.7) 28 (2.7) 632 (19.1)
Community
Number with missing data 3/23 1/9 4/32
Number (%) of items missed 15 (0.8) 1 (0.1) 16 (0.6)
a A total of 75 patients were randomised and 70 PU-QOL forms were returned and analysed (five completed forms were
lost in the post).
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self-completed and interview-administered versions in community populations. The DIF analysis was an
important methodological step for highlighting areas warranting further investigation if pursuing a
self-completed version in the future. Based on the substudy findings we continued evaluating only a
researcher-administered version.
Item reduction and scale formation: Rasch analysis
The Rasch analysis detected important limitations of the PU-QOL scales, resulting in minor modifications.223
It detected that the four-category item scoring function did not work as intended for one or more items
within one or more scales, as demonstrated by disordered thresholds. For the other items, for which the
response categories were working as intended, thresholds were close to being disordered, suggesting that
people had difficulty distinguishing between the categories ‘a little bother’ and ‘quite a bit of bother’. This
provided good evidence that items would benefit from having fewer response categories. Consequently,
all scale items were subjected to a post hoc rescoring by collapsing adjacent categories (so that all items
had three response categories). Reanalysis of the data demonstrated that all thresholds were now correctly
ordered, producing scales with new categories (0= no bother, 1= little bother, 2= a lot of bother).
Another important finding was suboptimal scale-to-sample targeting.223 There were significant floor
effects; the largest frequency of patients was often at the floor of the scale ranges (‘least bother’),
suggesting that the scales might provide limited information about people at the extremes of the sample
distribution (those with the least disability or impairment). Ideally, there should be a good match between
the scale range and the sample range, with people falling within the range of the items. However, the
ordering of scale items along each variable was clinically sensible, providing evidence of the construct
validity of each scale variable.
Three items had notable criterion failures as defined by a fit residual level outside ±2.5, high chi-square values
with significant p-values and adherence to the item characteristic curve (significantly underdiscriminating or
overdiscriminating). Few items exceeded residual correlations of +0.3, implying that the responses to items
are independent of each other and locally independent, or –0.3, suggesting no redundant items. Departures
from item fit expectation were relatively small but when considered in combination resulted in six items being
removed (see Appendix 43). Person separation index values indicated good to reasonable reliability for scales
distinguishing between responders on each scale variable.
At this stage, items that were considered clinically important but which did not fit into existing scales were
retained as single items (e.g. itchiness). Scales that did not meet requirements for reliable and valid
measurement were either conceptually combined (e.g. items representing mood, anxiety, autonomy and
isolation were combined into an emotional well-being scale) or had items added [e.g. three items,
determined from patients transcripts (see Item generation from patients), were added to the vitality and
malaise scale to produce a six-item scale], reducing the instrument from 13 to 10 scales. The final scales
and items are presented in Appendix 43.
Preliminary psychometric evaluation: traditional analysis
The results of the psychometric evaluation using traditional psychometric tests supported the PU-QOL
scales as being reliable and valid measures of pressure ulcer-symptoms, physical and social functioning and
psychological well-being.223 The criteria were satisfied for most psychometric properties evaluated.
Briefly, data quality was high (scale scores were computable for 93–99.6% of respondents) and scaling
assumptions were satisfied [mostly similar mean item scores; corrected item–total correlation (ITC) ranges
0.525–0.920]. Scale-to-sample targeting was good [scale scores spanned the scale range but were notably
skewed for three scales (value outside ±1.0), mean scores were near the scale mid-point for six of nine
scales and ceiling effects were negligible; however, floor effects exceeded the 15% criterion for two of
nine scales]. Internal consistency reliability was high, as demonstrated by Cronbach’s alpha values (range
0.893–0.962). The ITCs, alpha coefficient and homogeneity coefficient (inter-item correlation mean and
range) provide evidence of the internal construct validity of the PU-QOL scales. A full psychometric
evaluation was planned for field test 2.
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Field test 2: final psychometric evaluation
The second field test was used to perform a full psychometric evaluation of the item-reduced version of the
PU-QOL in a large independent sample of patients with pressure ulcers223 (see Appendix 44 for the study protocol).
Aim
The study aimed to provide researchers and clinicians with a comprehensive evaluation of some of the
fundamental psychometric measurement properties of the final (10-scale/83-item) PU-QOL instrument,
including scale targeting, item response categories, item fit, response bias, acceptability, scaling
assumptions, reliability and validity.
Methods
Design
The second quantitative field test was undertaken to carry out a comprehensive psychometric evaluation of
the final PU-QOL instrument, in a large independent sample of patients with pressure ulcers. Consistent
with methods used in the first field test (see Field test 1 and mode of administration substudy, Design),
a Rasch analysis was performed first on all PU-QOL scales, followed by traditional psychometric tests
(see Table 72), in line with current US FDA guidance.212
Participants
Eligibility The eligibility criteria for the second field test were consistent with those used in the first field
test (see Field test 1 and mode of administration substudy, Eligibility).
Sampling A total of 200–250 patients with pressure ulcers was purposively sampled, consistent with
methods described in Field test 1 and mode of administration substudy (see Sampling). This provided
sufficient subjects for test–retest analysis; correlations at levels expected in test–retest situations (r≥ 0.80)
can be estimated with reasonable precision (95% CIs of ±0.1) with relatively few subjects.267,268
Recruitment and data collection
The recruitment method for the second field test was consistent with that detailed in Field test 1 and
mode of administration substudy (see Recruitment and data collection; see also Appendix 48 for the
patient information leaflet and consent forms).
A questionnaire pack containing the PU-QOL and the SF-12 was administered to all participants. The SF-12v2
Acute, English (UK) version was used269 to minimise respondent burden. This is a generic measure that asks
respondents to rate their health and functioning during the past week on eight domains: physical functioning,
role physical, bodily pain, general health, energy/fatigue, social functioning, role emotional and mental health.
A subsample of 50–60 patients completed a second PU-QOL 2–7 days after the first to evaluate test–retest
reliability. The test–retest interval had to be short enough to ensure that clinical change in the pressure
ulcer was unlikely to occur but sufficiently long so that respondents did not recall their responses from the
first administration; a short test–retest interval is necessary to evaluate stability per se, rather than clinical
change in the pressure ulcer. The tissue viability team member returned to administer the second PU-QOL
to all patients who agreed to the second administration, either on the ward or at their home, within the
specified time frame.
Analytical methods
Consistent with methods used in the first field test (see Field test 1 and mode of administration substudy,
Analytical methods), both RMT and traditional psychometric methods were used to psychometrically
evaluate the final PU-QOL instrument. Table 72 presents full details of the tests and criteria used in the
psychometric evaluation.
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Rasch measurement psychometric analysis The Rasch analysis was consistent with methods used
during the first field test (see Field test 1 and mode of administration substudy, Analytical methods,
and Table 72). Additional tests for person fit and uniform and non-uniform DIF in relation to four clinical
subgroupings [age (< 70 years and ≥ 70 years), gender (male and female), ulcer location (torso, limb, both)
and health-care setting (hospital and community)] were considered during the final psychometric
evaluation (see Table 72).
Traditional psychometric analysis The final Rasch scales underwent a psychometric evaluation using
the same traditional psychometric tests examined during field test 1 (see Field test 1 and mode of
administration substudy, Analytical methods) plus additional tests for reliability (test–retest) and validity
(convergent and discriminant validity and known-groups differences) (see Table 72).
Missing data were not imputed. The frequency of missing data was determined and items with a response
rate of < 90% were investigated.
Results
Sample
In total, 879 patients were screened for study participation, of whom eligibility was assessed for 717;
of these, 391 were considered to be eligible of whom 231 consented to participate. The final analysis
population was 229 after exclusions (Figure 30). Table 73 presents the characteristics of the
analysis sample.
Rasch analysis
The measurement properties of the PU-QOL scales were largely supported as demonstrated by items that
mapped out continua of increasing intensity and are located along those continua in a clinically sensible
order. Scale items work well together to define single variables, albeit some item misfit, local dependence
and items exhibiting DIF were detected. For example, DIF was demonstrated in three items (Table 75);
however, the deviations from model expectations were marginal, suggesting that item performance across
the four clinical subgroups is stable and that these groups can be measured on a common ruler.
The Rasch analysis detected important limitations of some PU-QOL scales. It detected that the three-category
item scoring function did not work as intended for 16 out of 82 scale items (see Table 75). Some item locations
indicated areas on the continuum within the scale range measured where the measurement could be improved
(i.e. at extreme ends of the scale range). As the sample sizes for these scales were quite small, major
modifications to items and the scoring function were deemed premature without additional empirical evidence.
Another limitation pertains to the sample distribution. For most scales the sample was not normally
distributed (normal distribution is neither expected nor wanted as sample distribution is an empirical finding
rather than a requirement, but it does suggest that assumptions about the distribution of people and the
variables measured in populations should not be made).250 The largest frequency of patients was often at
the floor of the scale ranges (‘least bother’), suggesting suboptimal targeting of the PU-QOL scales to the
study sample. Ideally, there should be a good match between the scale range and the sample range, with
people falling within the range of the items (see Table 75). For the symptom scales, the targeting can be
justified as not all patients with pressure ulcers are expected to have problems with symptoms and so it is
clinically reasonable that these people would fall outside the scale range. Importantly, when people have
symptom bother, there need to be items within the scales that will discriminate symptom bother and, in this
instance, the symptom scales perform this function.
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Not consented (n = 160)
refused without reason
not wanting research involvement
feels poorly/unwell
low-grade ulcer
comorbidity
other  
45
48
36
17
10
4
Main study analysis population
(n = 229)
Screened
(n = 879)
Eligibility assessed
(n = 717/879; 81.6%)
Consented
(n = 231/391; 59.1%)
Enrolled to main study
(n = 231)
Excluded from analysis
(n = 2, 0.9%)
• Patient died, n = 1
• Patient recruited twice, n = 1
Not assessed (n = 162)
29
20
14
50
42
7
missed by clinical research team
patient died
patient transferred
patient cognitively impaired
on care pathway for the dying
reason missing
Eligible
(n = 391/717; 54.5%)
Not eligible (n = 326)
patient under 18 years of age
patient does not have a ulcer
patient does not speak English
unable to give informed consent
patient is cognitively impaired
missing
2
47
22
90
160
5
FIGURE 30 Assessment flow chart for field test 2.
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Traditional psychometric analysis
The traditional psychometric analysis supported the final PU-QOL scales as being reliable and valid
measures of pressure ulcer symptoms, physical and social functioning and psychological well-being. The
criteria were satisfied for most psychometric properties evaluated. Briefly, data quality was high (scale
scores were computable for 95.6–99.6% of respondents; Table 76) and scaling assumptions were satisfied
(mean scale scores and SDs were mostly similar to scale mid-points; Table 77). All item–own scale
correlations were high (corrected ITC ranges 0.511–0.940; see Table 77), satisfying the recommended
criterion (> 0.3), thus providing support that items within scales measured a common underlying construct
(a corrected ITC > 0.3 indicates that items within each scale contain a similar proportion of information).
Scale-to-sample targeting was good, apart from where skew was clinically reasonable [scale scores
spanned the scale range but were notably skewed for four scales (value outside ±1.0), mean scores were
near the scale mid-point for 6 out of 10 scales and ceiling effects were negligible; however, floor effects
exceeded the 15% criterion for 4 out of 10 scales; see Table 76]. Internal consistency reliability was high,
as demonstrated by Cronbach’s alpha values for all PU-QOL scales exceeding the standard criterion of 0.7
(range 0.893–0.969; see Table 77). ITCs ranged from 0.511 to 0.940, fulfilling the recommended criterion
of > 0.3. Finally, test–retest correlations for eight out of 10 scales exceeded 0.7 (see Table 77); two scales
had correlations below the recommended criterion, but marginally, thus mostly fulfilling the recommended
minimum criteria and indicating good scale stability.
TABLE 76 Pressure Ulcer Quality of Life instrument scale-level analyses: data completeness and targeting (n= 229)
Scale
Data
completeness Targeting
Computable
scale score (%)
Possible score
(range)a
Range
mid-point
Observed
score
(range)
Mean
score SD
F/C effect
(%)b Skewness
Pain 95.6 0–16 8 0–16 6.14 4.586 15.2/3.9 0.396
Exudate 98.3 0–15 7.5 0–15 2.09 3.494 57.0/0.9 1.898
Odour 99.6 0–12 6 0–12 0.97 2.850 83.0/4.3 3.144
Sleep 99.6 0–12 6 0–12 4.66 4.302 10.7/4.1 0.434
Vitality 98.3 0–10 5 0–10 2.72 3.217 27.0/2.2 0.896
Mobility 97.8 0–18 9 0–17 7.08 5.377 1.5/0.4 0.362
Daily activities 95.6 0–16 8 0–14 3.67 4.389 3.9/0.4 1.058
Emotional
Well-being
95.2 0–30 15 0–28 10.15 9.190 8.3/1.3 0.673
Appearance &
self-consciousness
96.5 0–14 7 0–14 2.53 3.632 38.7/2.2 1.566
Participation 95.6 0–18 9 0–18 5.66 6.264 6.2/0.4 0.587
F/C, floor/ceiling.
a High scores indicate great bother/impact.
b Floor effect=% scoring 100 (greatest bother/impact); ceiling effect =% scoring 0 (least bother/impact).
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Evidence of the internal construct validity of the PU-QOL scales is provided by moderate to high ITCs, high
Cronbach’s alpha values and moderate to high inter-item correlations (means > 0.48 and ranges between
0.226 and 0.934 indicate that PU-QOL scale items were mostly correlated with scale scores; see Table 77),
indicating that each scale measures a single construct. Correlations between PU-QOL scales and
hypothesised related scales of the SF-12 were consistent with most predictions (Table 78), providing
support for PU-QOL scales measuring what they intend to measure; moderate to high correlations
(r> 0.30) were predicted. Correlations between PU-QOL scales and sociodemographic variables (age,
gender) were consistent with predictions (r< 0.30; see Table 78), thus suggesting that responses to
PU-QOL scales are not biased by age or gender.
The scales for exudate and odour were able to differentiate known groups as predicted; a significant step
increase in mean score by pressure ulcer severity groups was observed (see Table 78). All other tests of
known group differences were considered exploratory; significant step increases were observed in scores
for the scales measuring vitality, daily activities, emotional well-being and self-consciousness when patients
were grouped by pressure ulcer severity. In contrast, no step increase in scores was observed for the
scales measuring pain, sleep, mobility and movement and participation. For all scales apart from the sleep
scale, the mean score on HRQoL outcomes for category 1 ulcers was lower than that for category 3/4
ulcers, suggesting that HRQoL outcomes are worse for people with severe ulcers than for those with
superficial category 1 ulcers. It is important to note that the category 1 ulcer sample sizes were small
(range 4–14 patients) and therefore the known groups validity results are preliminary and further empirical
evidence is required to have confidence that the PU-QOL scales can detect small differences in the
constructs being measured.
Final Pressure Ulcer Quality of Life instrument
The final version of the PU-QOL consists of 10 scales (82 items) measuring symptoms, physical functioning,
psychological well-being and social participation specific to pressure ulcers [see Appendix 43; the final
PU-QOL instrument can be accessed at http://medhealth.leeds.ac.uk/puqol-ques (accessed July 2015)].
An additional item is included to assess pain severity. There are three symptom scales measuring pain
(eight items plus one descriptive pain severity item), exudate (eight items) and odour (six items) and
one descriptive itchiness item; four physical functioning scales measuring sleep (six items), movement and
mobility (nine items), daily activities (eight items) and vitality (five items); two psychological well-being
scales measuring emotional well-being (15 items) and self-consciousness and appearance (seven items);
and one social participation scale (nine items). Patients rate the amount of ‘bother’ attributed (e.g. ‘During
the past week, how much have you been bothered by . . . because of your pressure sore?’) on a 3-point
response scale (0= no bother; 1= little bother; 2= a lot of bother). In addition, respondents are given an
alternative response option enabling them to state that they are affected by the issue described in the item
but that it is not related to their ulcer (‘I have this problem but not because of my pressure ulcer’); this is
treated as descriptive information and is not part of the scale score. Scales can be selected for use
depending on the nature of the research and scale items can be summed to produce scores, without
weighting or standardisation. Scores for each domain are calculated as the sum of each individual item
score within that scale, which is then converted to a metric of 0–100; a lower score indicates better
outcome. Imputation of missing data, based on methods undertaken for scoring the Short Form
questionnaire-36 items (SF-36),270 can be undertaken, provided that at least 50% of items are complete for
an individual.
The PU-QOL instrument is appropriate for use in adults across the range of levels of pressure ulcer severity
and type (location and duration) and UK health-care settings and is suitable for group comparison. It is
intended for interview administration, supported by a user manual providing practical information necessary
for administration and scoring. The PU-QOL instrument and user manual are freely available through the
University of Leeds CTRU website [see http://medhealth.leeds.ac.uk/puqol-ques (accessed July 2015)].
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Discussion
This research established the impact of pressure ulcers on HRQoL, determined the need for a pressure
ulcer-specific PRO instrument and developed and psychometrically evaluated such an instrument. In our work
predating the PURPOSE programme we systematically reviewed the HRQoL literature in the pressure ulcer field
and found that it is mainly qualitative with an emphasis on pain and physical functioning impairment rather
than a comprehensive exploration of issues that are important to patients.9 Potential sources of bias arise
because of the use of small sample sizes (n≤ 10) and under-representation of people with superficial ulcers,
the elderly (aged > 70 years) and those acutely ill or with various comorbidities. Some HRQoL outcomes that are
unique to pressure ulceration were highlighted but these outcomes are currently not systematically included as
outcomes in clinical trials. Therefore, the pressure ulcer literature is unconvincing in terms of robust evaluation
of the impact of pressure ulcers and treatments on HRQoL (i.e. quantitative studies designed to explore HRQoL
in pressure ulceration had used measures not developed or validated for use with patients with pressure
ulcers).216 Further, no pressure ulcer-specific PRO instruments exist,216 highlighting the need for outcome
measures that can accurately depict the impact of pressure ulcers on HRQoL.
The PU-QOL instrument was developed to provide a formal method for capturing issues that are most
important to patients with pressure ulcers from their perspectives. New instrument construction needs to
be underpinned with a strong conceptual base to ensure valid measurement, one that adequately defines
the variables and relationships conceptually and gives operational meaning that guides the development
(or selection) of PRO instruments.212 Building on our earlier work9 we found that pressure ulcers impact all
aspects of HRQoL, severely compromise patient functioning and cause significant burden, pain and
increased discomfort as a result of treatment.36,221 We developed a pressure ulcer-specific conceptual
framework of HRQoL that includes conceptual domains for symptoms; difficulty with range of movement
and mobility; limitations in daily activities; psychological functioning; and ability to participate socially.221
These constructs are similar to those in generic HRQoL models;206,271,272 however, our framework
incorporates additional components specific to pressure ulceration (e.g. symptoms; appearance and
self-consciousness). The development of our conceptual framework was hampered by the poor quality and
quantity of the existing literature9 and required further qualitative interviews with patients and consultation
with experts. Elucidation of conceptual domains that are important to patients with pressure ulcers
provides a useful framework for designing future research and consequently improving the quality of
research in the pressure ulcer field by inclusion of a pressure ulcer-specific PRO instrument.
Mixed methods, including feedback from patients through cognitive interviews and a Rasch analysis of
PU-QOL data, were effective for identifying problems with PU-QOL items early in the development process.
Overall, patient input was the most important element of the development process. Despite undertaking
two systematic reviews of the literature (pressure ulcer pain and existing chronic wound PRO instruments)
intended to generate items, only a few descriptive words for pressure ulcer-related pain were added to the
item pool; the majority of the item content was generated from patient interviews. The empirically derived
pressure ulcer-specific conceptual framework informed the development of the PU-QOL instrument.
Scale development and item reduction were primarily guided by RMT, which provided a vehicle for the
detection of items deviating from model expectations with the intention of improving scale attributes.
Final decisions on item inclusion were made according to appraisals of the analyses of the observed data
against measurement criteria and clinical relevance, as opposed to examinations carried out singularly or
sequentially. A preliminary evaluation of the Rasch-produced scales using traditional psychometric methods
supported the PU-QOL instrument as being reliable and valid. In addition, an empirical investigation of the
optimal mode of administration of the PU-QOL instrument revealed that self-completion was not suitable
for patients with pressure ulcers. Consequently, the mode of administration was changed to interview
administered to ensure that the PU-QOL instrument would be applicable to a wider range of people with
pressure ulcers and potentially yield higher-quality data.
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The final psychometric evaluation supported the PU-QOL scales as being valid and reliable for use in clinical
trials according to US FDA criteria;212 however, some important limitations were identified. The Rasch analysis
highlighted that further work is required before the PU-QOL scales can be used as the main PRO measure in
future clinical trials or other research. Measurement precision could be improved by developing items that span
a wider measurement range and, in the process, maximising the potential of the PU-QOL instrument to detect
change. The appropriateness of the PU-QOL instrument for use in individual decision-making requires further
investigation. The measurement precision may need strengthening to enable assessment of individual patients
in clinical practice (e.g. revisit the qualitative work to add items to extend the measurement at the floor/ceiling
scale range; further work to ensure that the PU-QOL scales differentiate between different levels of ulcer
severity). Longitudinal studies should be undertaken to assess the responsiveness of the PU-QOL instrument
over time and following treatment, as clinical studies evaluating the effectiveness of various ulcer treatments
and interventions require accurate detection of true change. Further research is also needed to investigate
self-completion and electronic (e.g. ePRO) mode of administration methods, the feasibility of use in specific
subgroups, support for score interpretation and the utility of the PU-QOL instrument in routine practice; to
develop proxy measures and language translations given the prevalence of cognitively impaired patients with
pressure ulcers (e.g. almost 40% of screened patients in field test 1 and 30% in field test 2 were ineligible
because of cognitive impairment, consistent with findings from the pain prevalence study;48 see Chapter 3);
and to carry out an economic evaluation (see Chapter 7).
The final PU-QOL instrument consists of independent scales for assessing symptoms and physical,
psychological and social functioning specific to pressure ulcers. The PU-QOL instrument can be included as
one outcome measure among others in future pressure ulcer research on the proviso that studies have
built in a parallel psychometric analysis to indicate the performance (psychometric evaluation) of the scales
in future samples. Currently, the PU-QOL scales are most appropriate for patients with severe pressure
ulcers, as demonstrated by a lack of items to represent people with little or no bother as a result of
pressure ulcers. The exudate and odour scales are not intended for people with superficial ulcers
(category 1).
The PU-QOL instrument provides a means to comprehensively assess the impact of pressure ulcers and a way
of quantifying the benefits of ulcer interventions. It may also provide a key to discussions between health-care
providers and patients about impact that are currently not being held. Patients in our interviews repeatedly
reflected on their relationship with their tissue viability nurse, stating that the issues discussed during our
interviews were not issues that they had previously discussed with their nurse. The lack of inclusion of HRQoL
outcomes in previous pressure ulcer research is supported by the literature. Thus, PU-QOL data could facilitate
patient–health-care provider communication and increase understanding of the impact of pressure ulcers on
individuals, which ultimately could lead to adjustments in care delivery to meet patient needs. They may also
highlight important patient-orientated differences between interventions to justify resource allocation. This is
particularly important for changing practice through mandated NICE guidance. Specifically, the perceived
value of pressure ulcer interventions and evaluating PROs associated with treatment and relative burden must
have a robust evidence base212,224,273 to help inform decisions about the most appropriate ulcer management,
policies and health-care delivery in the pressure ulcer field.
Methodological issues and study limitations
This is the first outcome measure specific to pressure ulcers, reflecting the domains in a pressure
ulcer-specific conceptual framework of HRQoL outcomes, content that differs from that for other chronic
wounds. However, this study had some limitations. In the qualitative phase of PU-QOL development,
in-depth interviews were used to develop and refine the content of the scales. Additional qualitative
methods such as focus groups and interviews with the carers of people with pressure ulcers may have
provided a further opportunity to combine findings. Further, the questioning was intended to elicit the
worst aspect of having a pressure ulcer. This line of questioning may have resulted in valuable information
about patient experiences when pressure ulcer symptoms and other aspects are managed well being
missed. Better use of qualitative questioning would have resulted in the inclusion of patients with healed
or close to healed pressure ulcers, asking them asked about the entirety of their experience, with more
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thought given to covering the full spectrum of the pressure ulcer experience (e.g. experience of when
treatment was effective and when pressure ulcer impact was milder/not at its worst and words to describe
the benefit/ulcer improvement). This may have helped to improve the measurement range by including
items that represented milder ulcer impact/bother.
The validity testing of the PU-QOL scales was limited, in part by a lack of appropriate validating measures
and the inability to formulate hypotheses to enable known group difference testing. The literature is limited
about the roles that pressure ulcer severity, duration and location play in affecting HRQoL outcomes.
Such gaps in knowledge limit the ability to develop strong hypotheses to evaluate known group validity.
Further, the SF-12v2 is a generic measure that has not been developed or validated for use with people
with pressure ulcers. Given the uncertainty about the appropriateness of the SF-12 for use with people with
pressure ulcers, this was included in the validation process on an exploratory basis.
Pressure Ulcer Research Service User Network UK
Pressure Ulcer Research Service User Network UK members were involved in reviewing the different
versions of the PU-QOL instrument and associated materials throughout the development process. One of
the considerations when developing the PU-QOL user manual was ensuring that the instrument itself is
used in a way that is acceptable to patients. With that in mind, PURSUN UK members were invited to
review the manual. To help facilitate this review process, the researcher set a series of questions designed
to help guide people through a fairly complex document.
Members were also asked to give general comments about the PU-QOL instrument itself. Comments
made highlighted:
l the importance of reassuring patients that there is no right or wrong answer and that their perception
is what is important
l areas that could be clearer (e.g. instructions)
l the importance of anonymity for this particular population and the need to be clear about how the
results of the instrument will be used.
Throughout the review process, the perspective of PURSUN UK has been balanced with the need to
adhere to international guidelines on the development of outcome measures. This required an open
dialogue between members and the researcher. PURSUN UK members said that they valued the fact that
the researcher was honest about aspects that could not be changed and gave clear reasons for this rather
than simply disregarding their input.
Conclusion
This study makes important contributions to the pressure ulcer and wider health measurement fields.
The PU-QOL instrument provides a means to comprehensively assess pressure ulcer impact and quantify the
benefits of pressure ulcer interventions from the patient perspective for research use, thus far lacking in
this area. Scientifically rigorous PRO measurement needs to become more commonplace in the pressure
ulcer field so that the goal of pressure ulcer management can be to enhance and maintain the HRQoL of
people with pressure ulcers. Subject to further development, the PU-QOL instrument is a tool that can be
used to evaluate whether or not pressure ulcer treatments and the health care given achieve this,
outcomes that are ultimately best judged by patients themselves. Future use of the PU-QOL instrument will
provide the data necessary for its further development.
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Chapter 7 Deriving a preference-based measure
for use in cost–utility analyses of pressure ulcer
interventions
Chapter written by David M Meads, Carolyn Czoski Murray, Claudia Rutherford, Carol Dealey,Elizabeth McGinnis, Nikki Stubbs, Lyn Wilson, Jane Nixon, Claire T Hulme and Christopher McCabe.
Abstract
Introduction: Cost–utility analysis has become the gold standard for economic evaluation. In some
therapeutic areas where the use of the European Quality of Life-5 Dimensions (EQ-5D) is found to be
inappropriate, condition-specific utility measures are developed with the aim of providing a more accurate
assessment of the impact of conditions and to provide a more sensitive measure of the benefit of
interventions. The aim of this study was to create a preference-based index from the PU-QOL instrument
that could be used to generate utility values suitable for use in cost–utility-based economic evaluations.
Methods: The methods employed to achieve this followed those used to value the three-level EQ-5D.
Specifically, we conducted time trade-off task valuations of health states derived from selected PU-QOL
items with a sample (n= 200) of the general population. A secondary study was conducted to validate
the item selection and assess the psychometrics of the new index.
Results: Seven items were selected from the PU-QOL instrument for inclusion in the index on the basis of
best practice psychometric and Rasch methods. Of the large number of potential health states constructed
from the items and response option variants, 52 were valued by the general population with the remaining
health state values being predicted using ordinary least squares and random-effects regression models.
Although both models exhibited satisfactory predictive power and acceptably low levels of error, the
random-effects model is recommended for use. The secondary study analysis indicated that item selection
for the PUQOL-UI was appropriate and that the index was acceptable to patients and had adequate levels
of validity.
Conclusions: The PUQOL-UI is a seven-item instrument that will complement the PU-QOL instrument and
will deliver pressure ulcer-specific utility values for use in cost–utility analysis.
Introduction
In this chapter we report the design, implementation and analysis of a valuation study for the PUQOL-UI,
undertaken to facilitate the use of the PU-QOL instrument (see Chapter 6) as an outcome measure in clinical
trials of pressure ulcer prevention and treatment interventions, by supporting its use in cost-effectiveness
analyses. The chapter starts by providing some background on cost-effectiveness analysis for health-care
resource allocation and the use of generic compared with condition-specific utility measures (CSUMs) in this
context. It then goes on to describe the PU-QOL instrument, the process of identifying a short-form version and
additional changes to the response format used in the PU-QOL, to develop a measure that it would be feasible
to use in a health state valuation study. This is followed by a description of the design and implementation of
the health state valuation study and analysis of the data obtained to produce a health state utility algorithm for
the PU-QOL instrument. The fourth chapter component describes a study that was conducted to test the
PUQOL-UI item selection and provide an assessment of the psychometric properties of the measure.
The strengths and weaknesses of the research and priorities for further work are outlined in the discussion.
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Cost-effectiveness analysis for health-care resource allocation
Cost–utility analysis has become the gold standard for economic evaluation in many countries as it allows a
combined evaluation of the cost of health technologies along with a measure of the quality and survival
benefits that they confer. Another important advantage of cost–utility analysis is that it allows the
comparison of technology cost-effectiveness across therapeutic areas. The most common way to capture
health state utility values for use in cost–utility analysis is to employ multi-attribute utility questionnaires.
Such multi-attribute utility instruments as the EQ-5D,274 Short Form questionnaire-6 Dimensions (SF-6D)275
and Health Utilities Index (HUI)276 are commonly included in clinical studies for this purpose. Utility (or
‘preference-based’) measures typically produce a range of values from 1, representing full or perfect
health, through 0, representing death, to minus infinity, with negative values denoting health states
considered worse than death. These utility value weights are combined with survival information to
calculate quality-adjusted life-years (QALYs), which are the basis of cost–utility analysis. One year spent in a
health state of full or perfect health (utility= 1) is equal to 1 QALY.
In its updated health technology appraisal guidance, NICE273 states that health effects for cost-effectiveness
analyses should be expressed in terms of QALYs and that the EQ-5D is the preferred utility measure on
which QALYs should be based. As different utility measures may yield substantively divergent utility values
for the same individual, the use of a common metric and tool with which to measure it is necessary to
ensure that comparative analyses and resource allocation decisions across therapeutic areas (and time)
are possible.
European Quality of Life-5 Dimensions three-level version
The EQ-5D-3L (EQ-5D three-level version) includes five domains (questions): mobility, self-care, usual
activities, pain/discomfort and anxiety/depression. Each question has three response options (‘no problems’,
‘some problems’ and ‘extreme problems’) and utility values range from 1 (full health) to –0.59, based on a
tariff scoring system generated in the UK.277 Although the EQ-5D is quick and relatively easy to complete,
its lack of breadth may mean that it is not a suitable instrument for capturing health effects in some
populations. NICE acknowledges this and states that alternatives can be used if there is evidence that the
EQ-5D lacks content or construct validity or responsiveness in the target population. These shortcomings
may be present in patients with pressure ulcers. A qualitative examination of the impact of pressure
ulceration on patient quality of life (see Chapter 6, Qualitative study)221 suggests that there are a number
of domains of relevance to patients that are omitted from the EQ-5D. These include ulcer smell and
exudate, general malaise, fatigue and sleep impairment and a significant emotional and social impact
encompassing self-consciousness and social isolation. Furthermore, at least one item is inappropriate for a
proportion of people with pressure ulcers, specifically those using wheelchairs. Typically, people with
pressure ulcers have an antecedent condition that impairs mobility, which can then lead to the
development of ulcers. A potentially high proportion of this group will use wheelchairs and this subgroup
of patients may find it difficult to answer the EQ-5D mobility question (with response options ‘I have no
problems walking about’, ‘I have some problems walking about’, ‘I am confined to bed’). Although
wheelchair users have significant problems walking, they are not confined to bed; thus, the item is
invalidated for this group. There are a number of qualitative references highlighting this issue278–280
although the EuroQol group (understandably) does not permit revisions to the measure to make it more
acceptable in this group.279
The EQ-5D has rarely been employed in published studies including patients with pressure ulcers281,282 and
an adequate test of the validity of the measure in this group has not yet been conducted. Although there
are few data available on the performance of the EQ-5D in pressure ulcer studies, there is evidence
that the EQ-5D is unresponsive to health status change in general wound care. For example, Jull and
colleagues283 found that the measure could not distinguish between a group of venous leg ulcer patients
whose wounds had and had not healed. Although a new five-level version of the EQ-5D has now been
developed, it includes additional response categories and not domains and as such is unlikely to confer
better measurement scope in this group than the three-level version.
A PREFERENCE-BASED MEASURE FOR COST–UTILITY ANALYSES OF PRESSURE ULCER INTERVENTIONS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
216
Condition-specific utility
As a result of limitations of the EQ-5D in some therapeutic areas, a number of CSUMs have been
developed from existing condition-specific quality of life measures. These include measures in cancer,284
incontinence,285 asthma,286 mental health,287 dementia288 and pulmonary hypertension.289 The main aim of
these CSUMs is to provide a more accurate assessment of the impact of conditions and a more sensitive
measure of the benefit of interventions. Although there is a dearth of evidence to corroborate the promise
of CSUMs in this regard, the growth in their numbers continues.
Reducing the incidence of pressure ulcers and improving outcomes for those who experience them are
key targets for the NHS.17 To facilitate this there is an identified need to conduct clinical studies of
interventions and to establish the value of these interventions.14,15 However, in view of the potential limits
of the EQ-5D as a tool for capturing the health effects of pressure ulcers, there is a clear argument for the
development of a CSUM for use in this population. No CSUM currently exists for use in pressure ulcer
prevention and care. Alternative sources of utility values are limited to other generic preference-based
measures or a predictive algorithm developed using a generic preference-based measure and clinical
information,290 which would not meet the standard of NICE reference case data.273,291 This chapter
describes the generation of a CSUM from the newly developed PU-QOL instrument (see Chapter 6).
The PU-QOL instrument allows a comprehensive assessment of the impact of pressure ulcers on patients’
HRQoL, providing information to help improve patient health care and patient HRQoL and a tool for use
in intervention effectiveness research. It is already in use in clinical studies. It is likely that a CSUM, based
on the items within the PU-QOL, would provide a more appropriate, valid and sensitive assessment of
patients’ preferences associated with pressure ulcers than a generic utility measure and would therefore
be a more useful tool in cost-effectiveness analysis of associated interventions.
Aim and objective
The aim of this PURPOSE programme work package was to derive a preference-based utility index (PUQOL-UI)
from the PU-QOL, enabling the collection of utility values from the PU-QOL and therefore the calculation of
QALYs for the purpose of economic evaluation. We also sought to conduct a preliminary validation of the
PUQOL-UI.
Research overview
Two studies were conducted in this work package: study A (valuation study) involved the identification of
items for inclusion in the PUQOL-UI and the completion of a general population valuation study followed
by modelling to identify the PUQOL-UI scoring tariff; study B involved the collection of data from patients
using a revised (attribution-free) form of the PU-QOL that would allow verification of item selection and
assessment of the psychometric properties of the PUQOL-UI.
Valuation study: general population survey
The generation of a CSUM requires that health states comprising subsets of items from the target measure are
‘valued’ using preference elicitation techniques (such as the TTO method). Although debate continues about
who is the most appropriate source of such values, NICE273 currently prefers these to come from the general
population rather than from patients with the condition in question. This section describes the valuation survey
and regression modelling used to generate the PUQOL-UI (see Appendix 49 for the study protocol).
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Aim and objectives
The aim of the valuation study was to derive a preference-based utility index (PUQOL-UI) from the PU-QOL,
enabling the collection of pressure ulcer-specific utility values. Specific objectives were to:
1. test the acceptability of a revised form of the PU-QOL with a small group of patients
2. select PU-QOL items for inclusion in the PUQOL-UI
3. design and conduct a valuation survey with the general population
4. conduct analysis to derive the PUQOL-UI scoring tariff.
Methods
The Pressure Ulcer Quality of Life instrument
The PU-QOL instrument is a multidimensional measure of the impact of pressure ulcers on HRQoL
(see Chapter 6 for a full description of the PU-QOL instrument and details on the development work). It
includes 83 items and consists of 10 domains covering pain, exudate, odour, sleep, vitality, mobility/
movement, ADL, emotional well-being, self-consciousness and appearance and participation outcomes and
a single descriptive item on itchiness. Each item has a recall period of ‘the past week’ and three response
options: ‘no bother at all’, ‘a little bother’ and ‘a lot of bother’. In addition, respondents are given an
alternative response enabling them to state that they are affected by the issue described in the item but
that it is not related to their ulcer (‘I have this problem but not because of my pressure ulcer’). The items
and domains were identified on the basis of extensive interviews with patients followed by appropriate
field testing. The results of these stages indicate that the PU-QOL instrument has face, content and
construct validity and provides a reliable and comprehensive assessment of HRQoL in this group.
The incorporation of the ‘attribution’ question format was driven by a desire to create a measure that
could be used within the individual patient consultation as well as for measuring change at the patient
population level. It was also motivated by the fact that pressure ulcers tend to be a corollary of an
underlying health condition (which impairs patient mobility) and a desire for pressure ulcer impact not to
be subsumed by patients’ responses to their general health status (see Chapter 6, Preliminary PU-QOL
construction, for a full justification of this approach). The fact that the PU-QOL instrument asks
respondents to focus on the impact associated with their pressure ulcer, requesting that they disregard
their general health level, represented a methodological challenge to the generation of the utility index.
The standard approach to health state valuation locates health states described in the descriptive system
(the PU-QOL instrument in the current case) on the health utility scale using methods such as TTO and
standard gamble. It assumes that all relevant health attributes (i.e. those that will impact on the value
attached to health) are captured in the HRQoL descriptive system. Attributable condition-specific measures,
such as the PU-QOL instrument, explicitly set aside attributes of health that the respondent does not
consider to be impacted by the health condition of interest and thus are not a disaggregation of global
health but a disaggregation of one component of global health – those aspects of health that they
currently consider to be affected by the condition of interest [the pressure ulcer(s) in the current case].
To relate the information provided by the attributable condition-specific measure to global health in which
the QALY scale is anchored, it is necessary to specify the relationship between the condition-specific
measure descriptors and the other domains of health that impact on the value attached to a health state.
When the domains of health in the attributable condition-specific measure are completely independent of
the other domains of global health, then obtaining values for attributable health states would produce
estimates of the decrement from full health as a result of the ‘attributable condition-specific health status’
– in this case the pressure ulcer(s). Thus, a valuation of the PU-QOL in its original format would deliver
values representing utility decrements associated with pressure ulcer(s) but not the starting point of the
individual on the utility scale. To deal with this issue we created a separate, revised version of the PU-QOL
instrument question stem, removing the ‘because of your pressure ulcer’ attribution, and removed the
response option ‘I have this problem but not because of my pressure ulcer’.
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Study design
Figure 31 (A: valuation study) outlines the stages required for the generation of the utility index. It was first
necessary to verify the acceptability of the revised PU-QOL instrument, then select a subset of items for the
utility index, generate the health states and conduct the valuation study. The valuation study methods
followed those employed in the UK EQ-5D measurement and valuation of health study;277 specifically, we
used the TTO task in a general population sample. Study B (described in Validation study) generated data
enabling both the psychometric testing of the new utility index and verification of item selection.
Acceptability of the revised Pressure Ulcer Quality of Life instrument
Before the health states were generated for the valuation interviews, it was necessary to check the
acceptability of the revised PU-QOL instrument with a small group of people who have experience of
pressure ulcers. This involved conducting a small number (n= 16) of semistructured, face-to-face interviews
with people who currently had or had experienced an ulcer. Participants were recruited through local
support groups and PURSUN UK members and were interviewed by an experienced qualitative researcher
(see Appendix 50 for the study information leaflet). Participants completed the revised PU-QOL instrument
and were then asked whether or not they found the instrument easy to understand and complete and
whether or not there were aspects or questions that they found confusing. Participants were asked
specifically whether or not the new question stem (after the removal of the attribution) made sense in
each domain. The interview responses were analysed by two qualitative researchers who came to a
consensus about the acceptability of the reviewed measure and any necessary changes.
Create revised PU-QOL
Create health states for
valuation
Test acceptability in
service user interviews
(n = 15)
Analysis: use PU-QOL field test
data to select item subset
TTO general population
interviews
(n = 200) 
Analysis: generate PU-QOL
utility weights
Analysis: psychometric testing of
PUQOL-UI
Pre-test interviews in
general population
(n = 8) Conduct service user survey
(n = 100)
collecting revised PU-QOL data
Analysis: test PU-QOL item
selection
Verify item selection
A: valuation study B: validation study
FIGURE 31 Schematic of study design.
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Item selection
To generate the health states for valuation it was necessary to identify a reduced version of the instrument
as the original PU-QOL instrument had too many potential health states (i.e. n= 384) for direct valuation to
be feasible. Table 79 compares the domains included in the PU-QOL instrument and EQ-5D, highlighting
those that could be considered to overlap and those that are unique. The aim of the item reduction
process was to select a number of items that captured both the important generic health impact of
pressure ulcers and the antecedent health condition and also the more nuanced, condition-specific health
impacts associated with pressure ulcers. However, this had to be balanced with how much information is
presented in the health states as overburdening valuation survey respondents would lead to poor data
quality. Creating a CSUM also requires achieving balance between the inclusion of nuanced items,
capturing elements not captured by generic measures, and equally including only items that are important
to patients (considering the impact of concurrent health conditions) and that members of the general
population would be willing to trade time to ameliorate.
The reduced form was constructed using the methods reported by Brazier and Rowan292 for the development
of a number of CSUMs – including the Asthma Quality of Life – 5 Dimensions instrument293,294 – and followed
best practice recommendations. This involved secondary analysis of the PU-QOL field test 2 data set
(see Chapter 6, Phase 3: field testing) and the use of traditional psychometric and Rasch analyses to identify a
reduced PU-QOL instrument (of between seven and 10 items) that incorporated important condition-specific
dimensions of the full version. It was necessary to ensure that the items selected represented a range of severity
(i.e. not all mild or all severe items), fitted the Rasch model, were valid and had good discriminatory power.
Table 73 describes the data set used for the analysis, generated during field test 2 of the PU-QOL instrument.
In field test 2, patients also completed global items on health and the SF-12v2 health status measure, which
was converted to SF-6D utility values.275 Along with these data, information was collected on ulcer category
and care setting and demographics. As the PU-QOL instrument is a new instrument there were no available
data on its ability to detect change over time (i.e. responsiveness). However, cross-sectional analysis of pressure
ulcer category provided a proxy for this desirable attribute.
TABLE 79 Comparison of PU-QOL and EQ-5D domains
PU-QOL domain Number of items EQ-5D overlap
Pain 9 ✗
Exudate (leakage) 8
Odour 6
Sleep 6
Mobility 9 ✗
ADL 8 ✗
Vitality 5
Emotional well-being 15 ✗
Self-consciousness and appearance 7
Social functioning/participation 9 ✗
Total 82a
a The single item relating to itch was excluded from analysis as it is descriptive and not scored.
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Analysis
Rasch measurement theory295 is a valuable tool for the development and refinement of instruments and
has several advantages over CTT, such as factor analysis250,296–298 (see Chapter 6, Pre-testing, Data analysis
for additional discussion). A Rasch analysis is often employed to identify reduced forms of instruments that
will be used in preference valuation studies.288,299,300 The Rasch model is a special case of the latent-trait
item response theory model and places response data for each individual and each item on the same
spectrum of severity (logit scale). According to the model, the probability that an individual will respond in
a certain way to a particular item is a logistic function of the relative distance between the item location
(parameter) and the person location (parameter), and only a function of these two factors. Persons and
items are plotted on the same logit scale on the basis of the difference in their location on the underlying
spectrum. This difference governs the probability of the expected response for a person, of a given
severity, on a question of a given severity. If the observed data do not deviate significantly from the
expected responses, then the items fit the Rasch model. The Rasch analysis and traditional psychometric
analysis criteria used for item selection are listed in the following sections. A similar method of item
selection was employed in the original development and refinement of the PU-QOL instrument, although
here we also used factor analysis.
Rasch analysis
l Degree of fit to the Rasch model – chi-square probability and fit residual (items with non-significant
chi-square values and residuals <±2.5 are candidates for selection).
l Differential item functioning based on age and gender such that bias by these factors is minimised
(items with no DIF are candidates for selection).
l Item logit position on each construct’s measurement continuum such that items with a range of
severity (spanning the entire measurement range) can be identified (items that collectively represent
a wide spread of the latent trait are candidates for selection).
l Ordered response category thresholds (items with correctly functioning response categories are
candidates for selection).
Traditional psychometric analysis
l Distribution of scores and presence of floor/ceiling effects (items with no floor/ceiling effect are
candidates for selection).
l Item–total correlation (items with an ITC of > 0.4 are candidates for selection).
l Principal components factor analyses (items having a moderate to high factor loading within a subscale
are candidates for selection).
l Ability to discriminate between pressure ulcer severity groups – t-tests for superficial compared with
severe ulcer patient scores (highly discriminatory items are candidates).
l Pearson correlations with SF-6D and a global PU-QOL item [‘How would you rate your overall quality of
life because of your pressure sore(s)’] (items with moderate to high correlations are candidates).
An initial item selection process sought to identify a candidate item from each of the 10 existing PU-QOL
instrument domains. A second selection iteration sought to ensure a balance between scope (number of
items) and feasibility of valuing the resultant health states, removing items that were not considered of
sufficient importance. Results from these analyses were considered together with qualitative information
about the relative importance of each item and domain. Members of the PURPOSE team considered the
candidate items before reaching a consensus on the items to be included in the PUQOL-UI.
Analyses were conducted in SPSS and RUMM2030.
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Valuation
Selection of health states for valuation
The design of health state valuation studies is not currently informed by definitive experimental design
theory, but rather by good practice conventions. In line with these conventions, we selected a set of core
health states (n= 37) for use in the valuation study by constructing an orthogonal array for the PUQOL-UI
health state space. This array included the full health state of the PUQOL-UI, which automatically takes the
value of 1.0 in the TTO method used for the study, so that one fewer states (n= 36) are valued. This
orthogonal array was then supplemented with additional states to ensure broad coverage of the health
state space described by the PUQOL-UI. To this end, we also selected the following candidate states: the
corner states (n= 7) of the descriptive system; the inverse corner states (n= 7); and the PITS state (n= 1), in
which each domain of the PUQOL-UI is at level 3 (‘a lot of bother’). The corner states are those in which
one domain is at the most severe level and all others are at the least severe. In contrast, the inverse corner
states place one domain at the lowest level of severity and set all others at the highest level of severity. All
states were reviewed for face validity/feasibility and a conventional ‘backing-off’ procedure was used to
identify a feasible health state (i.e. the fewest dimension changes possible were implemented). In the
backing-off procedures, five additional health states were created. These were 2222222, 2222122,
2122222, 3332332 and 3232333, where level 1 refers to ‘no bother’, level 2 to ‘a little bother’ and
level 3 to ‘a lot of bother’.
For the purposes of validating the estimated utility models an additional small sample of states was
identified using a second orthogonal array. Eight states observed in the second orthogonal array but not in
the original array were chosen at random for inclusion in the valuation survey, but not in the estimation
sample. In addition to the 51 states already included, this produced a total of 59 states to be valued in the
valuation survey.
There is no definitive guidance on the number of observations per state required to estimate utility models,
with substantial variation observed in published studies.274,275,301 Informed by work by one of the authors of
the current study, we chose a target of 25 observations per health state on the grounds that the central
limit theorem indicates that 25 observations is sufficient to provide a robust estimate of the mean value.
This figure is considerably less than that in the UK measurement and valuation of health study277 but more
than that in the UK SF-6D valuation study.
On the basis of experience with previous valuation studies and piloting of the interview schedule
(see Appendix 51) it was decided to elicit no more than nine valuations from each respondent, to ensure that
respondent burden did not impair the quality of the data collected. Surveys were undertaken in 15 distinct
geographical regions in the counties of East, West and South Yorkshire and Lincolnshire in the UK.
Health state descriptions were randomly allocated across eight batches – four batches consisted of eight
health state cards, with the remaining batches using nine health state cards.
Preference elicitation
Preference elicitation was conducted in interviews with a sample (n= 200) of the general population.
Individuals were recruited door-to-door and offered a £5 voucher as a ‘thank you’ for participating.
Consent was gained from the individuals before they completed the interviews. Interviews were delivered
in the home, face-to-face, with responses input directly into a laptop. The screen guided respondents
through the tasks, adapting to their responses. However, the interviewer was present to make sure that
the respondents understood the task and to answer any queries.
The interview consisted of four sections. In the first section, basic socioeconomic information about
the respondent was collected and the respondent was asked to complete the EQ-5D questionnaire. The
second section required the respondent to rank the health state cards in the allocated batch, plus their
own health and ‘dead’, from ‘worst’ to ‘best’. Subsequently, they were asked to locate each of these
states on a VAS between 0 (‘dead’) and 100 (‘full health’), such that the score and the difference between
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scores represented how good or bad they felt a health state was and how much better or worse it was
than the health states below and above it on the scale.
The third section of the interview entailed a TTO valuation for each of the states (eight or nine plus one
‘test’ state) in the allocated batch using a laptop-based TTO sliding scale as a visual prop. The TTO was
based on that used in the measurement and valuation of health study,277 with a 10-year life expectancy.274
The smallest time increment allowed by the script and prop was 1 month.
The TTO task is a standard economic technique to elicit individuals’ strength of preference for various health
states.302 In the TTO task, individuals choose between two certain options: full length of life (10 years, after
which they die) in the health state to be valued or a shorter period in ‘full health’ (after which they die). The
amount of time (months, years) to be spent in full health is varied until the respondent can no longer easily
decide which option they prefer (the point of indifference), signalling the end of the exercise. The final utility
value assigned to the health state being valued is given by the time spent in full health divided by the time
spent in the health state (in this case 10 years). Thus, if the respondent was indifferent between living for
5 years in full health and living for 10 years in the health state being presented, the utility of that health state
would be 5/10= 0.50. The ‘ping-pong’ technique was employed to vary the amount of time in full health
offered. The upper anchor employed in this study was ‘full health’ rather than ‘perfect health’ (as used in the
measurement and valuation of health study278). The former is a more realistic and imaginable proposition. We
presented the best pressure ulcer health state as the upper anchor, which states ‘no bother’ on all dimensions,
as a representation of ‘full health’. Figure 32 shows a screenshot from the TTO survey.
FIGURE 32 Screenshot of the TTO interview question. Reproduced with permission from Accent London,
London, UK.
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The formulation of the TTO for health states worse than death was that proposed by Torrance and
colleagues:302 if a respondent felt that they would rather die immediately than live for any amount of time
in a given health state, the survey adapted to offer them a choice between immediate death and an
amount of time in the health state being valued followed by the remaining time in full health. The longer
the amount of time in full health required to compensate the poor health state, the worse the health state
being valued is perceived. The utility value in this case is calculated as follows:
time in full health=(10− time in full health): (1)
In line with best practice, respondents were given information regarding pressure ulceration so that they
based their interview responses on informed preferences. We chose not to include pictorial information on
ulcers as it was difficult to identify pictures of pressure ulcers that corresponded with the full range of
health states being valued.
The fourth section of the interview asked the interviewer to record how well he or she considered the
respondent had understood the interview exercises, particularly the TTO questions. All interviews were
carried out by experienced interviewers who had previous experience of using the computer-based TTO
prop. In addition, the interviewers received additional training from one of the authors with substantial
experience of undertaking health state valuation interviews. The responses to the ranking, scaling and TTO
questions were automatically captured by the computer-based prop and communicated directly to the
independent research company that carried out the interviews on behalf of the study investigators. The
survey company was responsible for ensuring that recruitment was stratified such that the sample was
representative (with consideration of gender, age, ethnicity and income) of the general population. The
interviews lasted around 50 minutes. University ethical committee approval was gained before the
survey began.
Analysis: modelling the health state valuations
The aim of the study was to construct a model that would predict the health state values for all 2187
states in the PUQOL-UI descriptive system from the measured health state data on the 52 health states in
the estimation sample.
The standard model structure for a statistical inference health state valuation model is:
Ui j = g(βxi j þ θri j)þ εi j , (2)
where i= 1,2,. . .,n represents the individual health states of the descriptive system and j= 1,2,. . .,m
represents the individual respondents to the survey. Uij is the TTO valuation for health state i provided by
respondent j. These valuations are modelled as a function of the sum of two items: xij, the vector of
dummy variables for each response level on each domain of the descriptive system, and rij, a vector of
interaction terms (which also depend on the levels of different domains). Finally, εij is the error term. Aside
from the function g, the only remaining parameters requiring estimation relate to the coefficients on the
dummy variables (β) and on the interaction terms (θ).
Using the PUQOL-UI, level 1 (‘no bother’) as the baseline for each domain so that the vector xi contains
14 dummy variables that indicate when each of the seven domains take one of the other two levels
(level 2 ‘a little bother’ and level 3 ‘a lot of bother’). The dummy variables take on a value of 1 when the
health state being valued includes that domain at the specified level and a value of 0 otherwise. For a simple
linear model, the intercept represents the value of full health and the value of any impaired health state is
calculated by summing the coefficients of the ‘on’ dummy variables and subtracting this from 1.0.
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Regression analysis of health state preference data has tended to estimate either ordinary least squares
regression (assumes independent error terms have a zero mean and constant variance) or random-effects
regression. The assumption for ordinary least squares regression means that the 1500 observations from
200 respondents are treated as though they were provided by 1500 distinct respondents. By contrast, the
random-effects model acknowledges that the error term may not be independent of the respondent and
thus separates out a within-respondent and between-respondent error term, that is:
εi j =uj þ ei j , (3)
where uj is a respondent-specific variation and is random across individuals and eij is the residual error term
for valuation i by individual j.
We report person-level main-effects models for the ordinary least squares and random-effects specification.
The models are assessed according to the standard goodness of fit tests; the sign and logical ordering of
parameters; and the predictive performance measured using the mean absolute error statistic, both within
the estimation sample and for the validation sample.
Patient and public involvement
The research plan was presented to members of PURSUN UK at a meeting in January 2012. At that
meeting the proposed valuation interviews were discussed in detail. PURSUN UK members expressed some
concerns about the ability of the general public to imagine that they had a pressure ulcer (as required by
the NICE273 reference case TTO methods). This resulted in a dialogue about the need to balance the views
of people with specific health-related experiences with those of the general public. Two members of the
network volunteered to contribute to the patient information sheets, interview schedules and study
protocols in more detail. Members of PURSUN UK who currently had or who had previously experienced a
pressure ulcer were also involved in testing the revised PU-QOL instrument interviews.
As with the PU-QOL study, there was a need to balance the input of service users with accepted methods
and guidelines in this field. Again, we found that the best way to manage this was to have an open and
honest conversation with the group. Once it became apparent that more development work was needed
(i.e. identifying a short-form version of the PU-QOL and additional changes to the question format), the
input of PURSUN UK members proved invaluable. Members not only were able to try out and provide
feedback on the new instrument, they also helped to recruit more participants to the study through
their networks.
Results
Acceptability of the revised Pressure Ulcer Quality of Life instrument
Sixteen people were included in the interview testing of the revised PU-QOL instrument. All interviewees
had previous experience of at least one pressure ulcer, lasting from 1 week up to 8 months, and three had
a pressure ulcer at the time of the interview. The age of the sample ranged from 27 to 66 years (mean age
57 years) and 10 (62.5%) of the interviewees were male.
In general, the revised instrument was well received and the removal of the attribution aspect of the
instrument caused no issues for comprehension or completion. However, some specific issues were raised
about the instrument. For example, some respondents had difficulty deciding whether they had ‘a lot of
bother’ or ‘no bother at all’ with carrying out some of the described activities either because they never did
them or because someone else always did them for them. A few of the interviewees felt that the ordering
of the different questionnaires was important. In cases in which both (attribution-free) generic and
condition-specific measures with attribution were used, generic measures should be completed
before condition-specific measures to avoid confusing respondents.
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We were interested in whether or not the use of ‘bothered’ as a description was helpful and whether or
not other terms such as ‘affected’ would be more suitable. The respondents either were indifferent or
expressed positive approval of the current terminology.
Item selection
For the purposes of the item reduction analyses, the PU-QOL items were scored as follows: ‘no bother’= 0,
‘a little bother’= 1 and ‘a lot of bother’= 2. For the Rasch analyses, when respondents reported that they
‘have this problem but not because of their pressure sore’, scores were recoded to ‘0’. This was to ensure
that these respondents were not excluded from the analysis. However, as the Rasch analysis excludes
extreme scores, a reduced sample was encountered regardless. For the traditional psychometric analyses
(except where indicated), respondents’ scores on these items were coded as ‘missing’; this was to ensure
that items were selected that reflected the greatest impact of pressure ulceration (without dilution of the
general health considerations). As the current version of the PU-QOL instrument asked patients to think
only about the impact of their pressure ulcer on aspects of their quality of life, there were significant
floor effects in some domains (especially the non-pressure ulcer-specific domains), making item
selection challenging.
Table 80 provides the correlations between the PU-QOL subscales and the global item, ‘How would you
rate your overall quality of life because of your pressure ulcer?’ The lowest correlations were observed with
the most obvious condition-specific scales: odour and exudate (leakage). The highest correlations were
observed with the emotional well-being, participation and malaise/vitality scales. This finding suggests that
the two most obvious pressure ulcer-specific dimensions have a weak impact on overall HRQoL whereas
the emotional impact appears to be more significant. The implications for item selection were that we
considered combining items from the odour and exudate domains to augment the response data and
impact and that the inclusion of two items from the emotional well-being scale might be warranted.
Given less weight in the selection process, but of interest nevertheless, were the correlations between the
PU-QOL subscales and the SF-6D (Table 81), which exhibited a similar pattern as the correlations seen with
global HRQoL.
Table 82 provides the item-by-item performance on the Rasch and traditional psychometric selection
parameters. In general, few items suffered low factor loadings in factor analysis and none had ITCs below
0.4. Substantial floor effects were observed on items in several scales (i.e. exudate, odour, daily activities
and self-consciousness). In the pressure ulcer-specific dimensions, it is possible that this was a result of the
item issue not causing a lot of bother (hence scored ‘0’).
In the more generic dimensions this was probably because the issue was not attributed to a pressure ulcer
and was therefore scored ‘0’/coded missing – useable scores for the daily activities and mobility scales
were very low for this reason. Notably, a number of items did not discriminate between ulcer categories
(superficial vs. severe). All of the pain and sleep scale items, most mobility items, around half of the daily
activities items and half of the vitality items failed to discriminate between groups. It is not clear why this
would be the case although it is possible that some clinical features of superficial pressure ulcers may
render the experience of them indistinguishable from the experience of severe pressure ulcers. Chapter 3
discusses why pain intensity may not be associated with ulcer category. For the mobility and daily activities
scales, this finding may be an artefact of the low average scores because of the floor effects.
In general, most scales and items fit the Rasch model well, with few items exhibiting significant chi-square
values, high residuals or DIF. However, there were exceptions, with the pain scale having three misfitting
items, the emotional well-being scale incurring some DIF and the participation scale exhibiting a relatively
high number of disordered thresholds.
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The items selected based on qualitative and quantitative assessments are included in Table 83 along with
the justification for selection. Two items were included from the emotional dimension as the analysis
indicated that this was one of the most significant impacts of pressure ulcers. Given that these 11 candidate
items would result in a possible 177,147 health states (311) for valuation, we explored ways to reduce or
combine items further. We combined the exudate and odour item into one joint item; however, further
item reduction was indicated (Table 84).
TABLE 83 Candidate items for inclusion in the PUQOL-UI
PUQOL-UI
item number
PU-QOL
scale/dimension
Original PU-QOL item
number and description Justification for item inclusion
1 Pain 3. Annoying pain or
discomfort
l EQ-5D dimension
l Clearest pain item
l Low floor effect
l Pain item with highest correlation with global
quality of life
2 Exudate 10. Weeping from your
pressure ulcer
l PU-specific dimension
l Lowest floor effect
l Second-highest correlation with global quality
of life
3 Odour 18. An unpleasant smell from
your pressure ulcer
l PU-specific dimension
l Lowest floor effect
l Discriminates between PU categories
4 Sleep 27. Interrupted sleep (e.g.
restless sleep or being woken
up during your sleep)
l Only moderate floor effect
l Not in the EQ-5D but likely an important
domain and captures the idea that pain and
positioning limitations from a PU interfere
with sleep
l Highest correlation with global quality of life
5 Mobility 31. Difficulty adjusting yourself
in bed
l Preferred over walking items as many of this
group will be wheelchair users
l Smallest floor effect
6 Daily activities/
self-care
39. Difficulty being able to
wash yourself in your usual
way (e.g. hand wash, bath,
shower)
l EQ-5D dimension
l Captures the idea that pressure sore and
bandages may interfere with self-care
l Only moderate floor effect
l Discriminates between PU categories
7 Malaise/vitality 49. Feeling that your energy
levels have been reduced
l Moderate floor effect
l Discriminates between PU categories
8 Emotional well-
being
60. Feeling depressed l EQ-5D dimension
l Discriminates between PU categories
l High correlation with global quality of life and
SF-6D
9 Emotional well-
being
62. Feeling like a burden or
nuisance on others
l EQ-5D dimension
l Discriminates well between PU categories
l Captures emotion and also level of care
required, which should be a function
of severity
l Two emotion items may be justified as this
scale has the highest overall correlation with
global quality of life
10 Self-consciousness 69. Lacking in confidence l Second lowest floor effect
l Discriminates between PU categories
l Third-highest correlation with global quality
of life
11 Participation 78. Difficulty going out l Lowest floor effect
l Discriminates between PU categories
l Highest correlation with SF-6D
PU, pressure ulcer.
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Thus, after the second iteration of item reduction, a final PUQOL-UI measure consisting of seven items was
settled on [available from the University of Leeds CTRU website: http://medhealth.leeds.ac.uk/puqol-ques
(accessed July 2015). Despite the level of item reduction, the Rasch item map suggests that the
seven remaining items span a relatively wide range on the latent trait continuum (Figure 33). A non-trivial
level of floor effect remains but this is likely to be related to the response data being attributable only.
Despite the loss of the odour and exudate items, the PUQOL-UI retains domains that are highly pertinent
for this group, capturing moving in bed, energy levels and the sense of being a burden on others. This is
in addition to important generic health impacts such as pain and self-care.
Health state valuation survey
In total, 200 valuation interviews were successfully completed in June 2013. Of the sample, 54% of
respondents were female, 51% were married or in a civil partnership and 67% were in some form of
employment or full-time education. Over half of the sample (56%) had completed secondary education
and 38.5% had completed post-secondary education. In terms of self-rated health, 82.5% reported their
health as ‘good’ or ‘very good’ and only 1.5% reported their health as ‘very poor’. Table 85 reports the
mean, minimum and maximum values and the number of observations for each of the health states in the
estimation sample. Figure 34 presents a histogram of the utility values.
Table 86 reports the parameter coefficients for the main-effects ordinary least squares and random-effects
models, as well as the significance values for each parameter. It also reports the adjusted R2, the mean
absolute error for each model and the t-test for the expected value of the errors being significantly
different from zero. Note that the parameters for the models are identical at three decimal places, with
some changes in the significance of some of the coefficients. It is also worth noting that we fitted terms
for interactions between level 3 on each domain. Although the resulting models produced significant
coefficients on some of the interaction dummies – notably the burden and depression interaction – the
coefficients on a number of main effects became non-significant and lost their logical ordering. Therefore,
we have not reported these models in detail.
TABLE 84 Further item reduction
Dimension Item Justification for removal
Exudate and odour Weeping or an unpleasant smell
from your pressure sore (combined
item)
Although this appears to be the most ‘condition specific’ of
the dimensions, the results indicate that the issue may have a
relatively limited impact on quality of life. Weeping and
odour items had high floor effects (71% and 84%
respectively) and low correlations with the overall PU-QOL
(0.191 and 0.171 respectively). These correlations were the
lowest observed with global pressure ulcer quality of life,
even when combined into one variable
Sleep Interrupted sleep (e.g. restless sleep
or being woken up during your
sleep)
The item did not discriminate between ulcer categories and
had a low correlation with global pressure ulcer quality of
life. It is likely that a large proportion of the impact captured
in the item will also be captured by the item relating to
vitality
Self-consciousness Lacking in confidence It is likely that the impact of this item is captured by others.
The items on depression and being a nuisance were
combined into one variable and correlated with this item to
determine the extent to which it captures unique impact. As
the correlation was relatively high (r= 0.59) it was concluded
that this item provides little additional information and
should be removed
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FIGURE 33 Item map for the final PUQOL-UI.
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TABLE 85 Summary statistics for the health state values in the estimation sample
State Mean Minimum Maximum n
1111113 0.829 0.28 1 25
1111131 0.866 0.48 1 26
1111222 0.871 0.1 1 25
1111311 0.871 0.48 1 25
1112131 0.718 –0.6 1 25
1112313 0.745 0.28 1 25
1113111 0.829 –0.01 1 25
1121133 0.646 0 1 24
1123321 0.870 0.3 1 25
1131111 0.775 0 1 49
1131211 0.793 0 1 25
1133112 0.691 0.28 1 25
1211311 0.798 0 1 25
1212113 0.742 –0.38 1 24
1221111 0.860 0 1 25
1223212 0.761 0 1 25
1311111 0.876 0 1 25
1311132 0.781 0.28 1 25
1312221 0.830 0.33 1 25
1331323 0.735 0 1 25
1333111 0.727 0 1 24
1333333 0.402 –0.74 1 25
2121331 0.686 0 1 25
2122122 0.836 0.38 1 25
2122222 0.808 0.28 1 26
2131113 0.784 –0.38 1 25
2132211 0.747 –0.48 1 25
2211231 0.806 0.38 1 25
2213123 0.728 0.28 1 25
2222122 0.727 0 1 26
2222222 0.877 0.43 1 25
2311112 0.730 –0.9 1 25
2313311 0.638 –0.21 1 25
3111111 0.766 0.28 1 25
3111121 0.700 0 1 25
3111312 0.707 0.18 1 25
3113111 0.724 0 1 25
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TABLE 85 Summary statistics for the health state values in the estimation sample (continued )
State Mean Minimum Maximum n
3113233 0.510 –0.21 1 24
3133333 0.358 –0.9 1 25
3231121 0.672 0 1 26
3232332 0.508 –0.38 1 26
3232333 0.444 –0.9 0.93 24
3313333 0.367 –0.9 1 24
3321213 0.613 0.28 1 25
3322111 0.667 0 1 25
3331333 0.353 –0.9 1 25
3332332 0.506 –0.6 1 26
3333133 0.469 –0.9 1 25
3333313 0.436 –0.9 1 51
3333331 0.317 –0.9 0.9 25
3333333 0.375 –0.9 1 200
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FIGURE 34 Histogram of utilities in the model estimation data set. Mean 0.65, SD 0.376, n= 1500.
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The mean absolute error records how far away the mean predicted value of a state (using the regression
results) is from the mean observed value of a state. The lower the mean absolute error, the better the fit
for that state. In general, the more states are within a specified distance from the observed values, the
better the fit of the model. Figure 35 plots the proportion of all estimated states (n= 51) that have mean
absolute errors below a given tolerance, as we vary that tolerance. As the parameters for both the ordinary
least squares and the random-effects models are nearly identical, the mean absolute error curves are
indistinguishable and so we have not plotted these separately. Figure 36 plots the observed and predicted
health state values and prediction errors for the states in the estimation sample. Figure 37 does the same
for eight states in the validation data set. It also reports the mean absolute error for the predictions of the
validation state mean utilities. Table 87 reports the summary statistics for the health states in the
validation sample.
TABLE 86 Main effects ordinary least squares and random-effects regression models
Dimension and level
OLS regression model RE regression model
β (SE) Significance β (SE) Significance
Constant 1.00 1.00
Pain 2 –0.056 (0.027) 0.036 –0.056 (0.024) 0.018
Pain 3 –0.138 (0.023) 0.000 –0.138 (0.018) 0.000
Mobility/adjusting self in bed 2 –0.045 (0.025) 0.075 –0.045 (0.022) 0.038
Mobility/adjusting self in bed 3 –0.074 (0.022) 0.001 –0.074 (0.022) 0.001
Self-care 2 –0.047 (0.027) 0.075 –0.047 (0.020) 0.017
Self-care 3 –0.106 (0.022) 0.000 –0.106 (0.021) 0.000
Energy 2 –0.049 (0.025) 0.055 –0.049 (0.021) 0.020
Energy 3 –0.100 (0.022) 0.000 –0.100 (0.019) 0.000
Depression 2 –0.030 (0.026) 0.243 –0.030 (0.021) 0.152
Depression 3 –0.072 (0.023) 0.002 –0.072 (0.020) 0.000
Burden 2 –0.006 (0.026) 0.821 –0.006 (0.021) 0.779
Burden 3 –0.095 (0.023) 0.000 –0.095 (0.020) 0.000
Social participation 2 –0.038 (0.026) 0.139 –0.038 (0.020) 0.050
Social participation 3 –0.093 (0.023) 0.000 –0.093 (0.022) 0.000
n 1500 1500
Mean absolute error
Estimation 0.064 0.064
Validation 0.081 0.081
Ljung–Box test 23.49 0.432 23.49 0.432
OLS, ordinary least squares; RE, random effects; SE, standard error.
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FIGURE 35 Mean absolute error curve. Proportion of predictions with target mean absolute error range.
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FIGURE 36 Observed and predicted health state utilities with prediction errors. MAE, mean absolute error.
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Validation study
The analysis for identifying the PU-QOL item subset to construct the valuation health states was based on
data generated using the original ‘pressure ulcer-attributable’ wording of the measure, which does not
reflect the ‘attribution-free’ format of the PUQOL-UI. Although there are no empirical studies in this space
to confirm this, it is possible that, when the attribution is removed, the performance of the PUQOL-UI
items may change. The validation study (study B) aimed to generate a data set using the revised
(attribution-free) PU-QOL instrument to enable item analysis, to identify whether the performance of the
selected items is adversely affected by the removal of attribution. The data set would also allow preliminary
validation of the PUQOL-UI (see Appendix 52 for the study protocol).
Aim and objectives
The aim of the validation study was to validate the PUQOL-UI (in terms of item selection and psychometric
performance). Specific objectives were to:
1. collect data on the revised attribution-free PU-QOL
2. verify the item selection for the PUQOL-UI using attribution-free PU-QOL data
3. conduct a preliminary validation of the PUQOL-UI.
1.0
0.8
0.6
0.4
U
ti
lit
y 
va
lu
es
 b
y 
st
at
e
0.2
0.0
– 0.2
Validation states
MAE = 0.081
Mean observed utility
Predicted utility
Prediction error
PUQOL-UI states, ordered by mean observed utility
FIGURE 37 Mean and predicted health state utilities and errors: validation data set. MAE, mean absolute error.
TABLE 87 Summary statistics for health states in the validation data set
State Mean Minimum Maximum n
1212232 0.86 0.82 1.00 25
1333312 0.54 0.47 0.82 25
2112323 0.67 0.50 0.93 25
2232211 0.72 0.63 0.95 24
3122312 0.61 0.42 0.88 26
3133221 0.56 0.47 0.72 25
3213113 0.66 0.42 0.88 25
3311222 0.58 0.47 0.72 25
A PREFERENCE-BASED MEASURE FOR COST–UTILITY ANALYSES OF PRESSURE ULCER INTERVENTIONS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
240
Methods
Study design
A sample of NHS patients with pressure ulcers completed the researcher-administered revised PU-QOL
instrument in hospital. The sample size was dependent on that required to obtain robust estimates from the
Rasch analysis. Linacre238 proposed that for most purposes a sample size of 100 (range 64–144) will provide
95% confidence of item calibration within ±0.5 logits. In this study we aimed for 95% confidence and
therefore a sample of 100 patients was recruited across multiple sites between July and November 2013.
Data collection
Patients who consented to participate (see Appendix 53 for the patient information sheet and consent
form) completed the revised (attribution-free) 82-item PU-QOL and the EQ-5D-3L (see Appendix 54 for the
questionnaire booklet). These were interviewer administered by research nurses in the inpatient setting.
A set of sociodemographic and pressure ulcer-related questions was also completed. The latter included
clinical grading of the pressure ulcer by the nurse. In cases in which the patient had more than one pressure
ulcer the nurse returned the highest category of any of the pressure ulcers present. Ethical committee
approval was gained for the study (National Research Ethics Service Committee North East – York;
reference number 13/NE/0152).
Item selection analyses
The item analysis described in Valuation study: general population survey, Analysis was conducted again
although on this occasion emphasis was on evaluating the items that had been selected for the PUQOL-UI
rather than item selection. In addition, correlations were conducted with the EQ-5D rather than with
the SF-6D. The internal consistency of the PUQOL-UI was evaluated as was criterion validity (through
correlations with the EQ-5D).
Pressure Ulcer Quality of Life – Utility Index validation
The PUQOL-UI was scored employing the random-effects algorithm and the following analyses
were conducted:
l examination of utility score descriptives and distribution
l assessment of criterion validity through correlations with the EQ-5D
l assessment of the ability of the PUQOL-UI to discriminate between pressure ulcer severity and general
health groups.
Analyses were conducted in RUMM2030 and Stata version 12 (StataCorp LP, College Station, TX, USA).
Results
Sample
In total, 100 patients with a current pressure ulcer participated in the study, including 52 patients from
acute hospital NHS settings and 48 from community hospital, residential and home care settings (see
Appendix 1 for recruitment by participating centre). The sample was well balanced in terms of gender,
age, educational status and pressure ulcer category. The sample was also similar for these attributes to
that which provided the data for the item selection analysis, thus ensuring that comparison is possible.
The sample details are provided in Table 88.
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TABLE 88 Validation sample characteristics
Characteristic n
Gender
Male 51
Female 49
Age (years)
Mean (SD) 77.16 (15.33)
Range 22.67–101.67
Ethnicity
White 98
Black or black British 2
Highest level of education
University or college or equivalent 13
Intermediate between secondary level and university 23
Secondary school 55
Primary school (or less) 9
Wheelchair user
Yes 50
No 50
Pressure ulcer duration (months)
Mean (SD) 9.91 (17.3)
Range 0.23–96.0
More than one pressure ulcer
Yes 14
No 86
Pressure ulcer category
1 14
2 37
3 21
4 24
Missing 4
Self-rated pressure ulcer severity
Very severe 11
Severe 19
Moderate 36
Mild 18
Very mild 13
Missing 3
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Item analyses
A summary of the item analyses is included in Table 89. The analysis did not identify any significant
problems with the seven items selected for the PUQOL-UI that would warrant their exclusion from the
measure. None of the PUQOL-UI items misfit the Rasch model, had low factor loadings or low ITCs.
The items showed minimal floor effects and all but one of the items (‘Difficulty going out’) correlated
significantly with the EQ-5D. Correlations with the global health item were generally lower although this
likely relates to the number of data points available. Only one of the selected items discriminated between
pressure ulcer category groups. However, this was the case for all of the items in the pain, sleep, mobility
and malaise/vitality dimensions when all items were analysed. A number of items in the exudate and odour
dimensions discriminated between pressure ulcer groups. However, as in the initial item selection, high
floor effects were observed in these dimensions (range 68–94% in the exudate and 87–97% in the odour
dimensions) as well as low correlations with global health and as such their exclusion from the PUQOL-UI is
vindicated. Only one item in the daily activities and emotional well-being dimensions and two items in the
self-esteem scales discriminated between pressure ulcer category groups. These may have been candidates
for inclusion in the utility index; however, it is possible, given the number of statistical tests conducted,
that the significant differences are spurious.
Overall, the item analysis based on the attribution-free PU-QOL did not identify any performance issues
with the PUQOL-UI items nor an alternative configuration of the measure that was clearly preferable to the
one that was chosen. Therefore, the PUQOL-UI format and item make-up is confirmed as an acceptable
and valid basis of pressure ulcer health states for valuation. Although of secondary importance, the scale
properties were also found to be adequate with a reasonable level of item inter-relatedness (Cronbach’s
alpha= 0.74), with good fit to the Rasch model with no individual item misfit.
TABLE 89 Item selection analysis for the PUQOL-UI
PU-QOL scale and items
Low PCF
loadinga
Floor
effect
≥ 50%b ITC
Discriminate
between PUsc
R – global
item R – EQ-5D
Pain
Annoying pain or discomfort 0.710 N 0.289d 0.313d
Mobility
Difficulty adjusting yourself in bed 0.764 N 0.224e 0.339d
Daily activities
Being able to wash yourself in your usual
way (e.g. hand wash, bath, shower)
0.741 N 0.170 0.357d
Vitality/malaise
Feeling that your energy levels have been
reduced
0.795 N 0.339d 0.250e
Emotional well-being
Feeling depressed 55.10 0.778 N 0.328d 0.411d
Feeling like a burden or nuisance to
others
0.743 N 0.166 0.368d
Social functioning/participation
Difficulty going out 0.827 Y 0.128 0.138
N, no; PCF, principal components factor; PU, pressure ulcer; R, correlation; Y, yes.
a All PCF loadings < 0.2.
b ≥ 50% of respondents obtain the lowest possible score.
c t-test for superficial vs. severe PU.
d Correlation is significant at the 0.05 level (two-tailed).
e Correlation is significant at the 0.01 level (two-tailed).
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Pressure Ulcer Quality of Life – Utility Index validation
The PUQOL-UI exhibited a greater number of missing values than the EQ-5D. This might in part be
explained by the greater number of items in the full PU-QOL and associated respondent fatigue, which may
be not be an issue when the seven-item PUQOL-UI is completed. The range of observed PUQOL-UI scores
(Table 90) were close to the possible range of the measure (0.322–1) in this sample but with no evidence of
a floor or ceiling effect that might jeopardise the responsiveness of the measure. The PUQOL-UI scores were
significantly higher than the EQ-5D scores. Correlations with the EQ-5D were moderate (r= 0.54; p< 0.001;
n= 82) indicating a moderate level of shared variance.
Neither the PUQOL-UI nor the EQ-5D were able to distinguish (to a statistically significant degree) between
patients grouped according to pressure ulcer category (categories 1 and 2 vs. categories 3 and 4).
However, the PUQOL-UI was able to discriminate between patients grouped according to number of
pressure ulcers, self-reported severity of ulcer and self-reported health. The discriminatory power of the
PUQOL-UI appeared to be greater than that of the EQ-5D, which could not discriminate between self-rated
general health groups or by number of current pressure ulcers. This suggests that the new utility index is a
valid measure of health state preferences in people with pressure ulcers.
TABLE 90 Descriptive scores and tests of validity for the utility measures
PUQOL-UI EQ-5D
n 84 94
Mean (SD) 0.70 (0.18) 0.19 (0.37)
Range 0.32 to 0.99 –0.59 to 0.85
Pressure ulcer category, mean (SD)
Superficial (categories 1–2) 0.72 (0.17) 0.24 (0.36)
Severe (categories 3–4) 0.67 (0.19) 0.15 (0.38)
p-valuea 0.17 0.28
Self-rated pressure ulcer severity, mean (SD)
Mild 0.78 (0.16) 0.29 (0.36)
Moderate 0.72 (0.17) 0.25 (0.34)
Severe 0.58 (0.17) 0.04 (0.40)
p-valueb < 0.001 0.023
Self-rated general health, mean (SD)
Good 0.75 (0.18) 0.23 (0.40)
Moderate 0.72 (0.16) 0.26 (0.35)
Poor 0.58 (0.18) 0.03 (0.40)
p-value 0.006 0.073
Number of current pressure ulcers, mean (SD)
1 0.72 (0.18) 0.21 (0.38)
> 1 0.58 (0.18) 0.07 (0.30)
p-value 0.012 0.206
a t-test.
b ANOVA.
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Discussion
The PU-QOL instrument is a comprehensive measure of HRQoL that captures a wide range of clinical,
personal, social and broader role effects of pressure ulcers. Having been developed with a view to
utilisation in both the clinical and the population research setting, it asks respondents to focus on the
component of their health that is attributable to their pressure ulcer. Both the scope of the instrument and
the attribution form of the questions created challenges to the development of a short-form preference-
based version of the instrument that could be used in the economic evaluation of pressure ulcer
prevention and treatment technologies. The challenge from the instrument attribution would not have
arisen had a non-attribution format been employed. However, the team involved in the development of
the PU-QOL had specified a priori a desire to create a measure that captured only pressure ulcer-specific
impact and that because of the prevalence of significant comorbidities in this group it was necessary for
the instrument to enquire only about pressure ulcer impact.221
The challenge represented by the scope of the PU-QOL instrument is one common to many short-form
development projects and, in line with other researchers, we used psychometric assessment and Rasch
analysis to identify a reduced set of domains and levels that were strongly related to measured global
health. The short form consists of seven domains and is thus within the accepted scope for health state
valuation – based on the psychological literature which reports that people can process between five and
nine pieces of information in arriving at a decision. Although a number of the more clinical domains of the
PU-QOL were dropped from the short version, this was based on analysis of the data rather than on any
prior judgement on the researchers’ part.
The concern with the attribution form of the PU-QOL related to the feasibility of respondents parsing the
value of pain, depression, burden, etc. attributable to their pressure ulcer if they had comorbidities that
also impacted on these domains of HRQoL. Therefore, we undertook a small interview study of people
with pressure ulcers and asked them to complete the PU-QOL questions without the attribution format.
Respondents had no difficulty completing the revised question format and did not report problems with its
meaning or relevance in the absence of the ‘attribution’ question format. On this basis we moved forward
with the development of the short-form instrument – the PUQOL-UI.
Having decided to proceed with the valuation of the PUQOL-UI we had to consider whether to obtain
patient or general population values for the health states it described. Although it is increasingly accepted
that the description of the impact of a condition on an individual’s health should come from relevant
service users, it is still recommended that, when valuations are intended to inform population health-care
resource allocation decisions, these should come from the general population rather than from the
patients. Therefore, we chose the general population as the population to sample for the health state
valuation survey. It would be interesting to know the location and the magnitude of any differences
between patient and general population values for health states described by the PUQOL-UI. However, the
additional valuation surveys necessary to address this question were beyond the resources available to
this study.
In line with recommendations from NICE,273 we chose to use the TTO method for obtaining health state
values, using props and timelines based on the UK measurement and valuation of health study,277 which
produced the algorithm for the EQ-5D. Like the measurement and valuation of health study,277 we
undertook an interviewer-administered survey to enable us to have more confidence in the quality of the
data obtained, both through interviewer training and reporting back on interviewee comprehension.
The recommended utility algorithm is, perhaps surprisingly, a simple linear additive model. However, this
was the model that best fit the data and produced acceptable predictive performance in both the
estimation and the validation data set. Additional work to assess whether or not more sophisticated model
specifications, such as generalised linear models and two-part models, produce better-performing
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algorithms could be undertaken. However, the random-effects main-effects regression model performs
acceptably and is comparable in many ways with widely used utility algorithms such as the SF-6D.
Additional efforts were expended in checking that the item selection process had been valid. This was
perhaps not critical as the psychometric properties of a utility measure can be established only ex post when
the utility weights are available and as item selection based on unweighted item responses provides only an
idea of which items are most suitable. However, the item analysis conducted in the validation study did
verify that the items selected for inclusion in the PUQOL-UI were a good representation of the long form of
the measure and confirmed the validity of the ‘attribution-free’ format. Psychometric analyses also
suggested that the PUQOL-UI has adequate levels of discriminatory power and may have greater power
than the EQ-5D. Further work is required to compare the performance of the EQ-5D and that of the
PUQOL-UI to determine whether or not the condition-specific measure indeed confers measurement
benefits and also to determine the responsiveness of the PUQOL-UI over time. PUQOL-UI values were much
higher than those observed on the EQ-5D. It is likely that this is an artefact of the much greater range on
the EQ-5D and the lower values drawing the mean lower. The EQ-5D has a much lower bound than the
PUQOL-UI and this may be because it describes more severe health states (e.g. ‘I am unable to wash or
dress myself’ in the EQ-5D vs. ‘Having a lot of bother washing yourself in the usual way’ in the PUQOL-UI).
Conclusions
The development of a condition-specific, preference-based measure for use in economic evaluations of
pressure ulcer preventative and treatment interventions has been a success. A brief measure – the PUQOL-UI –
has been identified and valued using general population TTO tasks. The subsequent modelling identified a
robust algorithm that delivers the utility values necessary for cost–utility analysis. The PUQOL-UI complements
the PU-QOL instrument as the latter delivers a comprehensive assessment of patient quality of life;
investigators should consider employing both instruments in future pressure ulcer studies. Further work is
necessary to establish the responsiveness of the PUQOL-UI, especially compared with generic preference-
based measures. Future methodological work should explore the impact of condition attribution in health
measurement and valuation, especially when comorbidities exist in the population of interest.
The final PUQOL-UI instrument and the associated utility scoring algorithm syntax (in SPSS and Stata) are
available from http://medhealth.leeds.ac.uk/puqol-ques (accessed July 2015).
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Chapter 8 Conclusions, wider impacts and
recommendations
Summary
The PURPOSE clinical and academic partnership has been successful in developing and delivering a
world-leading applied health research programme in the field of pressure ulcer prevention. The PURPOSE
programme has addressed fundamental issues identified by patients and provides the foundation for the
development of evidence-based, patient-centred practice in the field and a future clinical trials portfolio.
Our pain prevalence study has indicated that hospital and community patients experience both pressure
area-related and pressure ulcer pain and results from our cohort study indicate that pain is independently
predictive of category 2 (and above) pressure ulcer development. This is the first cohort study to have
explored pain as a risk factor and supports patient reports from previous qualitative work9 that pain had
preceded the clinical presentation of their pressure ulcer.
Similarly, our work on severe pressure ulcers is the first study to have investigated different explanations
for their development, linking the literature on pressure ulcer development to the broader literature on
patient safety, the management of clinical risks and the investigation of reportable incidents. There is an
unhelpful divide between those such as Francis,93 who stress the importance of organisational and cultural
explanations for adverse events, and the bulk of the academic literature, which continues to focus on
errors made by individual clinicians.112 Our findings show that it is possible to reconcile these perspectives:
severe pressure ulcers are more likely to occur where individuals fail to respond to clear signs, when there
are wider problems with the contexts in which they are working. This has practical implications for the
conduct of root cause analyses in the NHS. Analyses currently focus on identifying specific decisions
or actions and encourage teams to attach blame to individuals. Broader organisational and cultural
considerations should be included in root cause analyses.
The pressure ulcer risk factor systematic review highlighted the need for high-quality risk factor research in
the field, common standards for the definition of key risk factors and improved data sets underpinned by a
conceptual model for the development and testing of prediction models. We therefore developed a risk
factor Minimum Data Set and used this to form the basis of a Risk Assessment Framework, the PURPOSE-T,
using consensus methods underpinned by the best available evidence. Decisions incorporated the views of
service users. The risk assessment work incorporated key findings from the pain and severe pressure ulcer
work packages, namely the inclusion of pain in the Risk Assessment Framework and designing the
framework to distinguish between primary prevention and secondary prevention/treatment
decision pathways.
The development of PROs for the assessment of quality of life and health utilities provide tools for use in
future effectiveness research and patient-directed treatment plans that are both evidence based and
focused on important outcomes for patients.
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Related themes: practice implementation
A number of related themes have emerged from the results of the work:
(a) Patient’s reports of pain preceding pressure ulcer development are dismissed by nurses (quality of life
work package).
(b) Patients reported that pain is their most distressing symptom, but little priority was given to pain,
which is not systematically assessed or treated effectively (quality of life work package).
(c) Pain is a common problem and is reported by patients with pressure ulcers but also by a small number
of patients without pressure ulcers on ‘at-risk’ skin sites (pain work package).
(d) The presence of pain is a predictor of subsequent category 2 pressure ulcer development (pain
work package).
(e) Severe pressure ulcers were more likely to develop when:
– nurses failed to listen to patients/carers
– nurses failed to recognise deterioration in condition or acknowledge the presence of an existing
pressure ulcer (severe work package).
(f) Current risk assessment does not make a distinction between those patients who have no pressure
ulcers but who are at risk and require primary prevention and those patients who have an existing
pressure ulcer or scarring from a previous pressure ulcer who require secondary prevention and
treatment (risk assessment work package).
(g) Severe pressure ulcers developed when there was no response or escalation of care despite clear signs
that a pressure ulcer was developing (blanching redness to category 1) or deteriorating (e.g. from
category 1 to category 2) (severe work package).
(h) Severe pressure ulcers developed in situations in which effective pressure relief was difficult to achieve,
for example because of a patient’s capacity to understand and respond to advice or because of
physical limitations such as contractures. The problems were not, though, attributable solely to the
complexity of the problems. Severe pressure ulcers developed in cultural contexts in which some staff
were prepared to blame patients for what had happened.
(i) Skin status is a key risk factor for pressure ulcer development, including alterations to intact skin, and
critically the presence of a category 1 pressure ulcer is predictive of category 2 and above pressure
ulcer development (pain and risk work packages).
(j) Service provision, particularly in the community setting, is fragmented and not patient focused. This
was evident in the prevention of pressure ulcers in community patients (severe pressure ulcer work
package) and in the treatment of pressure ulcers (quality of life work package), with service provision
identified as a factor that had contributed to severe pressure ulcer development and also impacted on
quality of life because of a lack of consideration of patients’ needs in the service delivery and
organisation of treatment (e.g. unspecified dressing visit times). The severe pressure ulcer findings
showed that patients’ voices were not sought, or were not heard, when problems arose.
Together, the issues identified from the individual PURPOSE work packages highlight limitations of the
standard ‘assess, plan, implement and evaluate’ model of care. This has led to the development of an
active monitoring model of care – Pressure Ulcer Prevention Pathways (PUPPs). PUPPs incorporates risk
assessment using the PURPOSE-T (including skin status and pain), the allocation of patients to primary and
secondary prevention pathways and active monitoring of individual patients’ skin response to preventative
interventions. It details required actions and escalation in response to deterioration and pressure ulcer
development [see http://medhealth.leeds.ac.uk/accesspurposet (accessed July 2015)].
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Wider impacts
In a field characterised by little high-quality research and investment, this programme grant has led to a
number of positive impacts that extend beyond the scope of the original award.
Patient and public involvement
The PPI activity and the setting up of PURSUN UK has led to many benefits, as detailed in Chapter 2, with
examples of innovative engagement. An outcome of the programme grant is the continuation of a sustainable
network of service users who are committed to the ongoing development of public and professional awareness
of the impact of pressure ulcers and a strong user-driven and supported research agenda.
Isolating the impact of PPI within a research study is notoriously challenging.303,304 Those challenges are
magnified here given the complex nature of a programme grant, in which individual studies feed into and
influence each other. The severe pressure ulcer study was the only study in which PPI was formally
evaluated. This proved to be very valuable and is something that we would do for the entire programme in
future. Despite the challenges we have been able to identify a number of ways in which the involvement
of PURSUN UK was helpful (described throughout the monograph and summarised in Table 91).
TABLE 91 Benefits of PURSUN UK involvement
Area of impact Examples
Impact on members of
PURSUN UK
l Increased knowledge of research
l Increased confidence and self-esteem
l Personal satisfaction that improving practice
l Better understanding of pressure ulcer prevention and treatment
l Building networks
l Access to other PPI opportunities
l Peer support
l Access to training and development opportunities, such as conference attendance
Impact on the project team l Better understanding of PPI
l Better understanding of the impact of treatment, secondary prevention advice and
service provision on quality of life and daily living
l Better understanding of the long-term impact of severe pressure ulcer development on
patients and carers
l Partnership working with service users to support public and professional awareness
Management/oversight of
the research
l Clearer patient information leaflets (very few changes requested by the ethics
committees)
l Recruitment of the PPI officer
l Development of a PPI strategy for the programme
Conduct of the research l Development of PURPOSE-T, including the exclusion of albumin and the inclusion of a
previous severe pressure ulcer as a direct result of PURSUN UK feedback
l Development of the PUQOL-UI instrument
l Recruitment of other service users to the PUQOL-UI study
l Input into the training of nurses as part of the Risk Assessment Framework through
case study development
l Data interpretation as part of the severe pressure ulcer work package, feeding into a
further implementation project
l Data interpretation as part of the pain work package, leading to a further dissemination
project
Dissemination/
implementation
l Service user narratives being used as part of dissemination of the pain workstream
l Development of video podcasts
l Input into the PU-QOL user manual
l One member of PURSUN UK has played a pivotal role in the development of a
methodology for root cause analyses of severe pressure ulcers
Development of new
research
l Development of a HTA programme-funded trial
l Themes and ideas generated by PURSUN UK are currently being developed into a new
programme of work that will have service user engagement as a theme
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We identified these points through the formal severe pressure ulcer PPI evaluation; through ongoing,
informal feedback from service users and the project team; by looking at documentation such as e-mails
and meeting minutes; and through feedback during the drafting of the monograph.
National Health Service research capacity and capability
The design and delivery of large multicentre projects has extended our original network of NHS research-active
centres that have the capacity and research workforce with the clinical knowledge and experience of recruiting
the ‘hard-to-reach’ patient population.
We have had considerable support from a number of NIHR Clinical Local Research Networks and the NIHR
Dermatology Specialty Group in terms of set-up and project delivery and this has been maintained with
subsequent funding for a NIHR HTA programme-funded trial (PRESSURE 2), with seamless transition of the
NIHR infrastructure in key centres.
The programme of studies has facilitated the development of a cohort of tissue viability nurse specialists as
new principal investigators as well as partnership with dermatologists who have supported the programme
as principal investigators. In addition, the clinical research nurse roles established during the 5-year period
have resulted in a number of benefits for the NHS, including the retention of senior clinical nurses,
development opportunities for clinical research nurses through local and national dissemination activities
and the development of clinical expertise leading to promotion.
The programme grant has also supported the development of three of the programme grant co-applicants
(E McGinnis, N Stubbs and L Wilson), who have made a significant contribution to the design and delivery
of our nationally and internationally relevant programme of work whilst maintaining substantive NHS
nurse specialist/consultant posts. Again, the programme funding supporting their involvement created
development opportunities through local part-time secondment opportunities into nurse specialist roles
and has enabled the development of capacity, clinical expertise and a team approach to tissue viability
service delivery.
Academic research capacity and capability
The programme grant award has led to the development of a cohesive clinical academic research group in
Leeds with an ongoing portfolio of research and grant development.
The programme grant award has made a contribution to the successful promotion of four of the co-applicants
to professor (J Nixon, EA Nelson, C Dealey and M Briggs), including two promotional chairs and an Honorary
Professorship at the Russell Group Universities. This is a major achievement from a professional nursing
perspective, which as a profession has low numbers of professorial appointments and very few
promotional chairs.
The PURPOSE programme has also supported the development of the programme manager, four research
fellows, through their registration as part-time PhD students [C Rutherford (née Gorecki), S Coleman,
L Pinkney and C Szoski-Murray], and a trial co-ordinator, who commenced medical school and graduated
as a medical doctor (R Stevenson). To date, we have had two successful PhD completions (Rutherford
and Coleman).
International collaborations
We have established strong international collaborations through systematic reviews and consensus
methods and established the foundation for future collaborative programmes of translational research
at the basic science and implementation stages of the translational pathways.
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Emerging National Institute for Health Research portfolio
The infrastructure and tools developed during the PURPOSE programme are underpinning an ongoing
portfolio of NIHR-funded research. In 2012 the team were successful in a trial grant application to the
NIHR HTA programme (PRESSURE 2), securing the clinical academic partnerships and NHS infrastructure for
a further 4-year period. The PRESSURE 2 trial is utilising the PURPOSE-T as a method of recording the
pressure ulcer risk factor Minimum Data Set and the PU-QOL and PUQOL-UI as secondary outcome
measures. Substudies will assess the predictive validity of the PURPOSE-T and the responsiveness of the
PU-QOL instrument.
Dissemination and knowledge transfer
We developed a dissemination and knowledge transfer plan for the PURPOSE programme including
electronic communications, investigator meetings, publications (see Acknowledgements, Publications),
local, national and international conference presentations (see Acknowledgements, List of presentations
and posters), web-based resources and curriculum development.
Dissemination activity is ongoing. For example, in relation to web-based resources we are currently developing
freely available dissemination materials including podcasts, slide packs, case studies and resources for root
cause analysis training and posters for use at local events for general dissemination, training and education by
NHS providers. In addition, we have set up web access for the three tools that we have developed during this
programme of research: the PURPOSE-T, PU-QOL and PUQOL-UI. Web-based access includes copyright
agreements and permissions for the use of data for ongoing validation research and guidelines for international
translation and validation.
Recommendations
Implications for patient and public involvement in research
1. Patient and public involvement requires explicit commitment to involving service users and their
perspectives throughout every aspect of the research process.
2. Presenting research data in live and interactive formats can make the interpretation process more
engaging and accessible to service users and support meaningful dialogue between service users
and professionals.
Implications for clinical practice development
1. Front-line health-care professionals should respond to patient symptoms including pain (soreness and
discomfort), alterations to intact skin and category 1 pressure ulcers and instigate/escalate
care provision.
2. Patients with pressure ulcers should have pressure ulcer pain assessment, including type of pain, to
inform treatment.
3. In circumstances in which clinicians do not have the skills necessary to address needs, patients should
be referred to appropriate colleagues.
4. Some clinicians blamed patients for the development of severe pressure ulcers. In circumstances in
which provision of effective pressure ulcer prevention interventions is impacted by a patient’s mental
capacity or physical disability, advice (consultation) should be sought from colleagues with appropriate
multidisciplinary specialist expertise and a problem-solving approach adopted.
5. The development of an electronic version of the PURPOSE-T in health-care settings would facilitate
large-scale multivariable modelling and refinement of the PURPOSE-T.
6. Implementation of key research findings may be facilitated through the use of the PUPPS active
monitoring model of care, which incorporates risk assessment using the PURPOSE-T (including skin
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status and pain), allocation of patients to primary and secondary prevention pathways and active
monitoring of individual patients’ skin response with required actions and escalation in response to
deterioration and pressure ulcer development [see http://medhealth.leeds.ac.uk/accesspurposet
(accessed July 2015)].
Implications for quality, safety and health service management
1. To maximise learning, root cause analysis could be extended in two ways:
i. interview patients and carers to capture their accounts of events
ii. increase awareness of the possibility that staff are working in contexts in which risky practices are
tolerated and be able to assess whether or not this is the case.
2. It is important to co-ordinate services effectively so that pressure ulcer risks are communicated to
everyone involved (patients, carers, all members of the multidisciplinary team).
3. Service reconfiguration/ward reorganisation planning needs to ensure continuity of clinical leadership
and oversight/delivery of clinical care to high-risk patients.
4. Development of a standardised case ascertainment method in the community setting is required.
Implications for future research
Pain
1. Replication of the pain cohort study is required.
2. The impact of including pain as an indicator for the escalation of preventative interventions
requires investigation.
Severe pressure ulcers
1. The severe pressure ulcer study is the first of its kind and findings should be confirmed by further
empirical research.
2. There may be merit in studying ‘best practice’ settings to better understand how patients’ and
organisational risks are identified and effectively acted on.
Risk assessment
1. Development of objective measurement methods for mechanical boundary conditions, individual
susceptibility and tissue tolerance and early indicators of damage.
2. Further evaluation of the PURPOSE-T is required including sensitivity and specificity in different patient
populations; impact on decision-making/processes of care; and effectiveness in reducing pressure ulcer
incidence in practice.
3. The pressure ulcer risk factor Minimum Data Set should be incorporated into future research.
4. Development of appraisal methods for risk factor research.
5. Development of a lay person version of the PURPOSE-T that can be used by patients and carers to
facilitate self-assessment.
6. The impact of including skin status as an indicator for the escalation of preventative interventions
requires investigation.
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Pressure ulcer quality of life
1. The PU-QOL instrument requires further evaluation through an assessment of responsiveness.
2. The PU-QOL can be used as an outcome measure in future pressure ulcer research (e.g. clinical trials
and observational studies) on the proviso that studies have built in a parallel psychometric analysis to
indicate the performance (psychometric evaluation) of the scales in future samples.
3. The PU-QOL instrument requires translation and validation for international utilisation.
Pressure ulcer cost–utility analysis
1. The PUQOL-UI can be used in pressure ulcer prevention and treatment trials to enable
cost–utility analyses.
2. Further research is required to determine the responsiveness of the PUQOL-UI.
3. Further research is required to establish the benefits of the PUQOL-UI (and other CSUMs) over generic
utility measures; this must take into consideration the impact that CSUMs may have on decision-making
and efforts to achieve allocative efficiency.
4. Further research is required to determine the extent to which patients completing HRQoL measures
consider (and are able to consider) ‘disease-attributable’ impact only.
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hospitalised patients. 13th NPUAP Biennial Conference, Houston, TX, USA, February 2013
(poster presentation).
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McGinnis E, Nixon J, Briggs M, Collinson M, Wilson L, Rivers C, et al. Prevalence of pressure ulcer pain in
community patients. 13th NPUAP Biennial Conference, Houston, TX, USA, February 2013
(poster presentation).
Nixon J. Is pain a predictor of category 2 pressure ulcers? Results of the PURPOSE Pain Cohort Study.
Tissue Viability Society Conference, Kettering, UK, April 2013 (oral presentation, invited speaker).
Nixon J, Smith I, Brown S, Nelson EA, McGinnis E, Stubbs N, et al., on behalf of the PURPOSE Pain Cohort
Group. Is pain a predictor of category 2 pressure ulcers? Results of the PURPOSE Pain Cohort Study.
16th Annual EPUAP Conference, Vienna, Austria, September 2013 (oral presentation).
Muir D, Briggs M, McGinnis E and Nixon N. Pain and pressure ulcer development: the service user
perspective. TVS Conference, York, 2014 (oral presentation).
Nixon J, Smith I. Is pain a predictor of Category 2 pressure ulcers? Analysis of skin site level data from the
PURPOSE Pain Cohort Study, TVS Annual Conference, York, April 2014 (oral presentation).
Smith I, Brown S, McGinnis E, Stubbs N, Nixon J on behalf of the PURPOSE Pain Cohort Group. Is pain a
predictor of Category 2 pressure ulcers? Analysis of skin site level data from the PURPOSE Pain Cohort
Study, 17th EPUAP Meeting, Stockholm, August 2014 (oral presentation).
Smith I, Brown S, McGinnis E, Stubbs N, Nixon J on behalf of the PURPOSE Pain Cohort Group. What is
the extent of pain suffering, and is pain predictive of pressure ulcer development? 25th Conference of the
European Wound Management Association, London, May 2015 (oral presentation, invited speaker).
Chapter 4
Pinkney L, Keen J, Nixon J. Why do patients develop severe pressure ulcers? Leeds Institute of Health
Sciences Research Postgraduate Symposium, Leeds, UK, June 2010 (oral presentation).
Pinkney L, Keen J, Nixon J. Why do patients develop severe pressure ulcers? BMJ International Forum on
Quality and Safety in Healthcare, Amsterdam, Netherlands, April 2011 (poster presentation).
Pinkney L, on behalf of the Severe Pressure Ulcer Project Team. Do organizations cause pressure ulcers?
An exploratory review. 14th Annual EPUAP Conference, Oporto, Portugal, September 2011
(oral presentation).
Keen J, on behalf of the Severe Pressure Ulcer Project Team. Severe pressure ulcers: how organisational
contexts influence their development. Tissue Viability Society Conference, Kettering, UK, April 2013
(oral presentation).
Dealey C, Keen K, Nixon J, on behalf of the Severe Pressure Ulcer Project Team. Why do patients develop
severe pressure ulcers? 16th Annual EPUAP Conference, Vienna, Austria, September 2013
(oral presentation).
Keen J. Why do patients develop severe pressure ulcers? EWMA, London, May 2015 (oral presentation).
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Chapter 5
Coleman S, Nixon J, Gorecki C, Nelson EA, on behalf of the PURE Collaborative Group. A systematic
review of pressure ulcer risk factors. 14th Annual EPUAP Conference, Oporto, Portugal, September 2011
(oral presentation).
Coleman S, Wilson L, on behalf of the PURAF Project Team. Pressure ulcer risk assessment. Building Blocks
of Wound Care Conference North East Tissue Viability Nurses Regional Group, Leeds, UK, September 2011
(oral presentation, invited speaker).
Coleman S. The development of pressure ulcer minimum data set (PU-MDS) using consensus methods.
Postgraduate Research Conference, Leeds, UK, December 2012 (oral presentation)
Colman S, on behalf of the PURAF Project Team. Systematic review of pressure ulcer risk factors. 13th
NPUAP Biennial Conference, Houston, TX, USA, February 2013 (poster presentation).
Coleman S. From systematic review to clinical practice – risk factor domains to be considered in pressure
ulcer risk assessment. Tissue Viability Society Conference, Kettering, UK, April 2013 (oral presentation,
invited speaker).
Coleman S, Nixon J, Nelson EA, Farrin A, on behalf of the PURAF Study Group. From systematic review to
clinical practice: using consensus methods to develop a Pressure Ulcer Risk Assessment Framework
(PURAF). 16th Annual EPUAP Conference, Vienna, Austria, September 2013 (oral presentation).
Coleman S, Nixon J, Nelson EA, Farrin A, on behalf of the PURAF Study Group. The design and pre-testing
of a Pressure Ulcer Risk Assessment Framework (PURAF). 16th Annual EPUAP Conference, Vienna, Austria,
September 2013 (oral presentation).
Coleman S, Stubbs N, McGinnis E and Nixon J on behalf of the PUPPs and PURPOSE T Implementation
Team. Pressure Ulcer Prevention Pathways (PUPPs) and Pressure Ulcer Risk Primary Or Secondary Evaluation
Tool (PURPOSE T). TVS, York, April 2014 (workshop).
Coleman S and Nixon J. Translational gap: measuring risk factors in clinical practice, 2nd EPUAP Focus
Meeting on Skin Health and Microclimate. Southampton, April 2014, (oral presentation, invited speaker).
Nixon J and Coleman S. Pressure ulcer recognition and prevention: the value of risk assessment. Stop the
pressure student conference, Leeds, June 2014 (oral presentation, invited speaker).
Coleman S and Nixon J on behalf of the PUPPs and PURPOSE T Implementation Team. Active monitoring
model of care incorporating PURPOSE T Workshop, 17th EPUAP Meeting, Stockholm, Aug 2014
(oral presentation, invited speaker).
Coleman S on behalf of the PURPOSE RAF Project Team. Risk factors in context: from conceptual
framework to risk assessment in practice, 17th EPUAP Meeting, Stockholm, August 2014
(oral presentation, invited speaker).
Coleman S. The development of PURPOSE T. Pressure ulcer research: dissemination and implementation
conference, Leeds, February 2015 (oral presentation, invited speaker).
Coleman S behalf of the PUPPs and PURPOSE T Implementation Team. PURPOSE T Master Class. Academic
Health Science Network, Patient Safety Collaborative: Pressure Damage learning collaborative, Sussex,
May 2015 (workshop, invited speaker).
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Coleman S and McGinnis E on behalf of the PUPPs and PURPOSE T Implementation Team.
Evidenced-based pressure ulcer risk assessment and implementation in clinical practice. EWMA 2015, London,
May 2015 (workshop).
Coleman S, Muir D, Rawson B and Rawson Y. Involving patients in pressure ulcer prevention. Patient
Safety Congress, Birmingham, July 2015 (oral presentation).
Nixon J and Coleman S, Translation of pressure ulcer risk factor research into practice. Posture and Mobility
Group Conference, Leeds, July 2015 (oral presentation, invited speaker).
Chapter 6
Gorecki C, Brown J, Nelson EA, Briggs M, Dealey C, Schoonhoven L, et al. A systematic review of pressure
ulcers and quality of life. EPUAP Open Meeting, Oxford, UK, August 2007 (oral presentation).
Gorecki C, Brown J, Nelson EA, Briggs M, Dealey C, Schoonhoven L, et al. A systematic review of pressure
ulcers and quality of life. 14th Annual Conference of the International Society of Quality of Life, Toronto,
Canada, October 2007 (poster presentation).
Gorecki C, Brown J, Briggs M, Nixon J. Evaluation of 5 search strategies to locate subjective patient-
reported HRQoL data. 14th Annual Conference of the International Society of Quality of Life, Toronto,
Canada, October 2007 (poster presentation).
Gorecki C, Brown J, Lamping D, Nelson EA, Briggs M, Dealey C, et al. Pressure ulcers and quality of life:
systematic review and preliminary results from a qualitative study. Tissue Viability Society Annual
Conference, Peterborough, UK, April 2008 (oral presentation, invited speaker).
Gorecki C, on behalf of the PUQOL Project Team. Existing outcome measures used in pressure ulcers.
12th Annual EPUAP Open Meeting, Amsterdam, the Netherlands, September 2009 (oral presentation).
Gorecki C, Brown J, Lamping D, Madill A, Firth J, Nixon J, on behalf of the PUQOL Project Team.
Health-related quality of life in pressure ulceration: development of a conceptual framework. 16th Annual
Conference of the International Society for Quality of Life Research, New Orleans, LA, USA, October 2009
(oral presentation).
Gorecki C, Brown J, Lamping D, Nixon J. Using cognitive interviewing to improve a newly developed
health-related quality of life patient-reported outcome for people with pressure ulcers. 16th Annual
Conference of the International Society for Quality of Life Research, New Orleans, LA, USA, October 2009
(poster presentation).
Gorecki C, Closs J, Nixon J, Briggs M. Patient-reported pressure ulcer-associated pain: a mixed-methods
systematic review. British Pain Society Annual Scientific Meeting, Manchester, UK, April 2010
(poster presentation).
Briggs M, Gorecki C, Nixon J, Closs SJ. Words used to describe pressure ulcer pain: the results of a
systematic review and qualitative synthesis. 13th EPUAP Open Meeting, Birmingham, UK, September 2010
(oral presentation).
Gorecki C. EPUAP Novice Award Lecture 2010. What constitutes health-related quality of life in pressure
ulcers and how do we measure it? 13th EPUAP Open Meeting, Birmingham, UK, September 2010
(oral presentation, invited speaker).
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Gorecki C, Lamping DL, Nixon J, Brown J, Cano S. The benefits of mixed methods in scale development I:
the added value of Rasch analysis in pre-testing. 17th Annual Conference of the International Society for
Quality of Life Research, London, UK, October 2010 (poster presentation).
Gorecki C, Nixon J, Lamping DL, Brown J, Cano S. The benefits of mixed methods in scale development II:
selecting optimal mode of administration. 17th Annual Conference of the International Society for Quality
of Life Research, London, UK, October 2010 (oral presentation, invited speaker).
Firth J, Briggs M, Nelson EA, Gorecki C. Health-related quality of life in patients with rheumatoid arthritis
and foot ulceration: care pathways and experiences of care provision. British Health Professionals in
Rheumatology Conference, Brighton, UK, April 2011 (poster presentation).
Gorecki C. Challenges in measuring HRQoL in pressure ulcers: development of a PRO measure. Tissue
Viability Society Conference, Kettering, UK, April 2011 (oral presentation).
Claudia Gorecki. Development of a patient-reported outcome measure: impact of pressure ulcers on
HRQoL. Royal College of Nursing International Conference, Harrogate, UK, May 2011 (oral presentation).
Briggs M, Firth J, Nelson EA, Gorecki, C. Pain and foot ulceration in rheumatoid arthritis; how do patients
describe the experience? British Pain Society Annual Conference, Edinburgh, UK, June 2011
(oral presentation).
Gorecki C. Application of mixed methods in early rating scale development. International Rasch Expert
Group Meeting, Dubrovnik, Croatia, June 2011 (oral presentation, invited speaker).
Gorecki C, Nixon J, on behalf of the PUQOL Project Team. PU-QOL: a patient-reported outcome measure
of health-related quality of life for patients with pressure ulcers. 14th Annual EPUAP Conference, Oporto,
Portugal, September 2011 (oral presentation).
Nelson EA, Nixon J, Coleman S, Gorecki C. Pressure ulcer epidemiology, pain and quality of life.
4th Congress of the World Union of Wound Healing Societies, Yokohama, Japan, September 2012
(oral presentation).
Nixon J, Gorecki C, on behalf of the PUQOL Project Team. Final version of a patient-reported outcome
measure of health-related quality of life for patients with pressure ulcers (PUQOL). 13th NPUAP National
Biennial Conference, Houston, TX, USA, February 2013 (poster presentation).
Rutherford C on behalf of the PUQOL project team. A patient-reported outcome measure of health-related
quality of life for patients with pressure ulcers: the PU-QOL instrument. The 4th Australasian Wound and
Tissue Repair Society Conference, Queensland, Australia, May 2014 (oral presentation).
Chapter 7
Czoski-Murray C, Meads D, Edlin R, Hulme C, Gorecki C, Nixon J, et al. Constructing a utility algorithm for
the Pressure Ulcer Quality of Life – Utility Instrument (PuQol-UI). TVS conference, York, April 2014
(oral presentation).
Overall programme
Nixon J, on behalf of the PURPOSE Collaborative Group. Pressure UlceR Programme Of ReSEarch. Tissue
Viability Society Annual Conference, Llandudno, UK, April 2009 (oral presentation).
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Nixon J, Keen J, McCabe C, Nelson A, Dealey C, Briggs M, et al. PURPOSE – Pressure UlceR Programme Of
reSEarch. Nursing and Midwifery Conference, Leeds, UK, May 2009 (poster presentation).
Nixon J, on behalf of the PURPOSE Collaborative Group. Pressure UlceR Programme Of ReSEarch. Yorkshire
and the Humber Directors of Nursing Network Meeting, York, UK, June 2009 (oral presentation).
Nixon J, on behalf of the PURPOSE Collaborative Group. Pressure UlceR Programme Of ReSEarch.
A Practical Guide to Reducing Healthcare Associated Pressure Ulcers, Manchester, UK, July 2009
(oral presentation, invited speaker).
Wilson L, Coleman S, on behalf of the PURPOSE Collaborative Group. Pressure UlceR Programme Of
reSEarch (PURPOSE). Wounds UK 2009 Wound Care Conference, Harrogate, UK, November 2009
(oral presentation).
Nixon J Wilson L, Coleman S Gorecki C Nelson A, on behalf of the PURPOSE team. Pressure UlceR
Programme Of reSEarch (PURPOSE). 13th EPUAP Open Meeting, Birmingham, UK, September 2010
(poster presentation).
Muir D, Nixon J, on behalf of the PURPOSE team. A different type of expertise; patient and public
involvement in pressure ulcer research. Royal College of Nursing International Nursing Research
Conference, Harrogate, UK, May 2011 (Symposium: programmatic research in pressure ulcer prevention;
update on progress and how we are addressing challenges).
Nelson EA, Coleman S, Nixon J, on behalf of the PURPOSE team. Challenges in identifying risk factors for
pressure ulceration: systematic review of risk factors and problems addressed. Royal College of Nursing
International Nursing Research Conference, Harrogate, UK, May 2011 (Symposium: programmatic research
in pressure ulcer prevention; update on progress and how we are addressing challenges).
Nixon J, on behalf of the PURPOSE Pain Team. Pressure ulcer pain suffering: issues raised in a multi-centre
pain prevalence study. Royal College of Nursing International Nursing Research Conference, Harrogate,
UK, May 2011 (Symposium: programmatic research in pressure ulcer prevention; update on progress and
how we are addressing challenges)
Nixon J, Wilson L, Coleman S, Gorecki C, Nelson EA, on behalf of the PURPOSE team. Pressure UlceR
Programme Of reSEarch – PURPOSE. Royal College of Nursing International Nursing Research Conference,
Harrogate, UK, May 2011 (Symposium: programmatic research in pressure ulcer prevention; update on
progress and how we are addressing challenges)
Nixon J, Choo J, McGinnis E, Nelson EA, on behalf of the PURPOSE team. Pressure UlceR Programme Of
reSEarch (PURPOSE). 2nd International Nursing Research Conference, University of Malaya, Malaysia,
February 2012 (poster presentation).
Nelson EA, Nixon J, Coleman S, Gorecki C. Pressure ulcer epidemiology, pain and quality of life. 4th Congress
of the World Union of Wound Healing Societies, Yokohama, Japan, September 2012 (oral presentation).
Wilson L. High impact actions – PURPOSE. E4E Conference, Mid Yorkshire Hospitals NHS Trust, UK,
September 2012 (oral presentation).
McGinnis E, Stubbs N, Coleman S, Muir D, Ginn C, Hinchcliffe S, Nixon J. Pressure ulcer research:
dissemination and implementation conference, LGI, Leeds, 5 February 2015 (oral presentation).
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Research nurses
Storey C, Hemingway B. Reflections on the clinical research nurse role. Tissue Viability Society Conference,
Kettering, UK, April 2011 (poster presentation; awarded best poster prize).
Choo J, Blundell S, McGinnis E. Ethical issues and challenges in pressure ulcer research – the research
nurses’ perspective. Tissue Viability Society Conference, Kettering, UK, April 2012 (poster presentation).
Awards
l EPUAP Senior Investigator Award 2012 – Professor Carol Dealey.
l EPUAP Novice Investigator Award 2010 – Dr Claudia Rutherford (née Gorecki).
l Poster prize – Storey C, Hemingway B. Reflections on the clinical research nurse role. Tissue Viability
Society Conference, Kettering, April 2011.
l Poster prize – Briggs M, on behalf of the Project Team. The prevalence of pain and pressure ulcers in
hospitalized patients; results of a national survey. British Pain Society Annual Scientific Meeting,
Liverpool, April 2012.
l Student oral competition – Stevenson R, Collinson M, Henderson V, Cozens J, Nixon J. Pressure
ulcers in the community: a multicentre prevalence study. 15th Annual EPUAP Conference, Cardiff,
September 2012.
l Poster prize – McGinnis E, Nixon J, Briggs M, Collinson M, Wilson L, Rivers C, et al. Prevalence of
pressure ulcer pain in community patients. 13th NPUAP National Biennial Conference, Houston, TX,
USA, February 2013.
Data sharing statement
Requests for data should be made to the corresponding author.
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Appendix 3 Pain prevalence study reduced
format protocol
NB: This study protocol (version 3, dated 18 Jan 2010) is in a reduced format including only 
the study aims, methods and ethical considerations.  Sections pertaining to study background 
have been removed as they are included as a chapter section. Information pertaining to serious 
adverse events, data monitoring, quality assurance, confidentiality, archiving, statement of 
indemnity, study organisational structure, and publication policy are available upon request 
 
3 Flow diagram 
Hospital Patients 
 
 
Community Patients 
Pressure Ulcer Prevalence Audit  
Piggy-backed pain questions 
Eligibility and Consent 
Full Pain Assessment 
Patient answers ‘yes’ to both pain questions Patient answers ‘no’ to one/ both pain questions 
No further 
involvement 
 
Pressure Ulcer Prevalence Audit  
Piggy-backed pain questions 
in patients with Grade 1-U pressure 
Eligibility and Consent 
Full Pain Assessment 
Patient answers ‘yes’ to both pain questions Patient answers ‘no’ to one/both pain questions 
No further 
involvement 
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5 Objectives 
The objectives of this study are to: 
1. determine the prevalence of localised PU pain in ‘pressure areas’. 
2. assess the type and severity of localised PU pain in ‘pressure areas’ in patients with 
clinically assessed normal skin and Grade 1-U PUs (see Table 1) 
3. explore the association between pain and skin classification. 
 
Table 1. EPUAP Pressure Ulcer Classification System4. For the purpose of the research 
the classification has been adapted to enable grading of normal skin and unstageable 
pressure ulcers. 
Grade Description 
Grade 0 Normal skin 
Grade 1 
 
 Non-blanchable erythema of intact skin Discolouration of the skin, warmth, 
oedema, induration or hardness may also be used as indicators, particularly on 
individuals with darker skin. 
Grade 2 
 
Partial thickness skin loss involving epidermis, dermis, or both. The ulcer is 
superficial and presents clinically as an abrasion or blister.  
Grade 3 
 
Full thickness skin loss involving damage to or necrosis of subcutaneous tissue 
that may extend down to, but not through underlying fascia. 
Grade 4 
 
Extensive destruction, tissue necrosis, or damage to muscle, bone, or supporting 
structures with or without full thickness skin loss. 
Grade U Unstageable. Full thickness skin loss in which actual depth of the ulcer is 
completely obscured by slough (yellow, tan, gray, green or brown) and/or eschar 
(tan, brown or black) in the wound bed. 
 
 
6 Methods 
6.1 Design 
We plan to undertake pain prevalence surveys in acute and community NHS Trusts. We will 
piggy-back questions on pain onto the routine annual PU prevalence audits in NHS Trusts. 
Anonymised individual patient data is recorded by a ward/community nurse. In addition to the 
standard PU data, patients will be asked two questions relating to localised skin pain to 
establish PU pain prevalence. Where pain is indicated, consenting patients will undergo a 
detailed pain assessment using the adapted Leeds Assessment of Neuropathic Symptoms and 
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Signs (LANSS) Pain Scale (Appendix 2)8,9 and a numerical rating scale for pain severity10,11. 
Skin classification will also be verified. This will establish the type and severity of localised 
PU pain and skin classification. 
 
6.2 Eligibility 
6.2.1 Routine PU Prevalence Audit 
As per standard PU prevalence audit methodology all inpatients/community nursing case-load 
patients on the date or period of the participating Trust’s PU prevalence audit that are 18 years 
of age or older are included. Patients in paediatric, obstetric, and psychiatric care settings will 
be excluded.  
 
6.2.2 PU Pain Prevalence Audit – Hospital 
Patients will be eligible for the two pain questions where they are considered well and able to 
report the presence or absence of localised skin pain, by the clinical team. Patients will be 
excluded from the two pain questions where it is considered ethically or clinically 
inappropriate by the clinical team, for example, very sick patients or those where death is 
imminent.  
 
6.2.3 PU Pain Prevalence Audit – Community 
Patients will be eligible for the two pain questions where they have a skin area assessed as a 
Grade 1-U pressure ulcer and are considered well and able to report the presence or absence of 
localised skin pain, by the clinical team. Patients will be excluded from the two pain questions 
where it is considered ethically or clinically inappropriate by the clinical team, for example, 
very sick patients or those where death is imminent.  
 
6.2.4 Full Pain and Skin Assessment 
Patients who reply ‘yes’ to both pain prevalence questions will be eligible for the full pain and 
skin assessment. Patients will be excluded where it is considered ethically or clinically 
inappropriate by the clinical team, for example, very sick patients or those where death is 
imminent. Patients will also be excluded if they are unable to provide consent. 
 
6.3 Assessments and Data Collection 
6.3.1 Routine PU Prevalence Audit 
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Standard practice for the PU prevalence audit will be used to assess and record data. 
Anonymised individual patient data will be recorded by a ward/community nurse who is 
trained in the use of the data collection form and skin assessment as part of the PU prevalence 
audit preparation and planning. In the hospital setting all patients are assessed on one 
designated day. In the community setting all patients are assessed over a one-two week period.  
 
Data recorded will include:  
 Name of Trust 
 Ward Speciality/Community Setting 
 Date of birth 
 Gender 
 Ethnicity 
 Height 
 Weight 
 Mobility 
 Risk Assessment Scale (as per local policy) 
 Skin classification by skin site 
 Hospital or community acquired 
 Present on this hospital admission/community referral 
 Prevention/treatment interventions 
 
6.3.2 PU Pain Prevalence Audit 
In addition, the ward/community nurse will consider whether each patient is well and able to 
report the presence or absence of localised skin pain. Where patients are assessed as not able to 
report pain this will be noted. Patients assessed as able will be asked the following two 
questions:  
1. At any time, do you get pain, soreness, or discomfort on a pressure area? (Prompt: 
back, bottoms, hips, elbows, heels, or other as applicable to patient.)? 
2. Do you think this is related to either: your pressure sore OR laying in bed for a long 
time OR sitting for a long time? 
 
6.3.3 Full Pain and Skin Assessment 
Patients who reply ‘yes’ to both of the pain prevalence questions will be flagged to a member 
of the Trust Tissue Viability Team (TVT; Tissue Viability Nurse 
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Consultant/Specialist/Research Nurse), and, subject to their consent, will have a full pain 
assessment and verification of skin assessment.  
 
Patients will be asked about pain for all pressure area sites using a numerical rating scale8,9 for 
pain intensity (for most severe pain over the past week).  
 
Up to two skin areas will be assessed using the Leeds Assessment Neuropathic Symptoms and 
Signs (LANSS) Pain Scale10,11 (Appendix 2). The LANSS Scale10 (Appendix 2) consists of a 
brief clinical assessment and is easy to score in the clinical setting. The questionnaire contains 
5 symptom items and 2 clinical sensory testing items associated with neuropathic pain. The 
LANSS is a clinically validated tool which allows assessment of neuropathic and inflammatory 
pain, and has been used in a wide variety of clinical settings11.  The two sites assessed using 
the LANSS will include the most painful skin site located on the torso (i.e. sacrum, buttocks, 
ischial tuberosities, hips) and the most painful site located on a limb (i.e. heels, elbows). 
 
In addition patients will be asked if they have been offered any treatment for pain. Skin 
assessments undertaken by the ward/community nurse for the PU prevalence audit will be 
verified through nursing records or clinical assessment by the Trust TVT member. 
 
6.4 Consent 
6.4.1 Routine PU and PU Pain Prevalence Audit 
Anonymised data from all patients will be collected as part of the PU and PU pain prevalence 
audit, and consent will not be obtained. 
 
6.4.2 Full Pain and Skin Assessment 
Patients responding ‘yes’ to the two pain prevalence questions (section 6.3.2) will be provided 
with verbal and written details about the more detailed pain assessment and will be asked to 
provide consent for this study. The verbal explanation of the study and Patient Information 
Sheet and Consent Form will be provided by the attending clinical staff or a member of the 
Trust TVT for the patient to consider. This will include detailed information about the 
rationale, design, and personal implications of the study. Following information provision, 
patients will have as long as they need to consider participation and will be given the 
opportunity to discuss the study with their family and other healthcare professionals before 
they are asked whether they would be willing to take part in the study. 
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Patients will then be invited to provide informed, written consent. A record of the consent 
process detailing the date of consent will be kept in the patient healthcare records. Assessment 
of eligibility and informed consent will usually be undertaken by a member of the Trust TVT. 
The right of the patient to refuse consent without giving reasons will be respected. Further, the 
patient will remain free to withdraw from the study at any time without giving reasons and 
without prejudicing any further treatment. 
 
Should the patient be capable of giving consent but physically unable to complete the written 
aspects of the consent form, witnessed consent should be obtained using the Witnessed 
Consent Form. An appropriate witness would be a family member or friend of the patient, or 
another member of the patient’s healthcare team who is not directly involved in the research 
study. 
 
The original consent form will be retained in the Investigator Site File, a copy of the consent 
will be given to the patient and a second copy filed in the patient healthcare notes. 
 
6.4.3 Non-participation 
An anonymised log of all patients who are considered for full pain assessment but who do not 
participate will be collected, including reason for non-participation.  
7 Statistical Considerations 
7.1 Sample size 
Our aim in this study is to assess the prevalence of PU pain in hospital and community patient 
populations. We will piggy-back this work onto routine PU prevalence surveys in a minimum 
of 2 acute and 2 community NHS Trusts (2,000 hospital and 6,000 community patients) 
therefore an approximate number of 8,000 patients is planned for the PU prevalence audit. 
 
It is estimated that the prevalence of PUs in hospital patients is 10% and in community patients 
5%; 30% of these are patients with Grade 2-U PUs and we estimate that 25-50% of these 
patients will report localised PU pain; the remaining 70% of patients have a Grade 1 PU, and 
we estimate that between 5-20% of these patients will report PU pain3,5. Of the remaining 90% 
hospital and 95% community patients without PUs, we estimate that localised skin pain may be 
reported in 2.5-5% of patients. Based on these assumptions, we estimate that between 259 and 
555 patients will report localised PU-related pain (see Table 2, over page), i.e. that 3-7% of 
patients will report localised skin pain on a pressure area. 
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A sample of 8,000 patients will enable us to estimate a pain prevalence of 3% to within ± 
0.38% (n = 7,742) and a pain prevalence of 7% to within ± 0.56% (n = 7,975).  
 
8 Statistical Analysis 
8.1 General Considerations 
Statistical analysis is the responsibility of the CTRU Statistician. The analysis plan outlined in 
this section will be reviewed and a final statistical analysis plan will be written before any data 
summaries or analyses are performed. The analysis plan will be written in accordance with 
current CTRU Standard Operating Procedures (SOPs) and will be finalised and agreed by the 
following people: Trial Statistician, Supervising Statistician, Chief Investigator, Senior Trial 
Manager, and Programme Manager. Any changes to the final analysis plan and reasons for 
change will be documented. 
Table 2: Estimated number of patients with PU pain 
Setting Pressure ulcer (PU) status 
Pain 
n % 
Hospital (n = 2,000) 
No PU (90%; n = 1,800) 45-90 2.5-5% 
PU (10%; n = 
200) 
Grade 1 (70%; n = 140) 14-42 10-30% 
Grade 2-4 (30%; n = 60) 15-30 25-50% 
Community (n = 
6,000) 
No PU (95%; n = 5,700) 142-285 2.5-5% 
PU (5%; n = 
300) 
Grade 1 (70%; n = 210) 21-63 10-30% 
Grade 2-4 (30%; n = 90) 22-45 25-50% 
 
8.2 Routine PU Prevalence Audit 
Standard PU prevalence results and analysis as per usual practice will be provided to each 
participating centre and will include the overall prevalence of PU by grade, risk profile, age, 
department and gender. 
 
8.3 PU Pain Prevalence Audit 
The proportion of patients reporting localised skin pain will be summarised for the overall 
population and for each acute/community Trust. 
 
8.4 Full Pain and Skin Assessment 
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For those patients reporting pain and undergoing further assessment, the intensity and type of 
pain (whether neuropathic or nociceptive) will be summarised using means and standard 
deviations, or percentages and 95% confidence intervals, by skin site (e.g. sacrum, buttocks, 
heels) and skin classification at that site. 
 
11.2 Ethical Considerations 
This project will assess all hospital and community nursing patients including those with PUs 
and therefore will include elderly and highly dependent patients considered as vulnerable. 
Ethical issues are largely related to the involvement of vulnerable adults/elderly patients with 
high levels of co-morbidity including acute and chronic illness. The ethical issues surrounding 
these potentially vulnerable patients have been addressed through the study design and include 
piggy-backing the pain prevalence onto routine PU prevalence surveys and the use of local 
staff including experienced nurses and members of the Trust TVT to assess patients. The study 
will be submitted to and be approved by a Research Ethics Committee (REC) prior to 
identifying eligible patients. The CTRU will provide the REC with a copy of the final protocol, 
patient information leaflets, consent forms, and all other relevant study documentation. 
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Appendix 2: The LANSS Pain Scale 
Leeds Assessment of Neuropathic Symptoms and Signs10 (with adaptations)11 
 
[NB: The LANSS scale was collected however the scale is omitted due to copyright. The 
LANSS scale can be obtained from: Bennett M. The LANSS Pain Scale: The Leeds assessment 
of neuropathic symptoms and signs. Pain 2001; 92(1-2): 147-157]. 
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Appendix 4 Pain prevalence study patient
information leaflet
 [Delete this line, then print on Trust headed paper] 
Participant Information Leaflet and Consent Form 
 
Pressure UlceR Programme Of ReSEarch 
Pain Prevalence - Prevalence of localised pressure ulcer related pain 
 
A large-print version of this sheet is available on request.   
We would like to invite you to take part in a research project. Before you decide to take part, it 
is important for you to understand why the research is being done and what it would involve 
for you. Please take the time to read the following information carefully and discuss it with 
your relatives and your ward/community nurse if you wish. Ask us if there is anything that is 
not clear or if you would like more information. Part 1 tells you the purpose of this project and 
what will happen to you if you take part. Part 2 gives you more detailed information about the 
conduct of the study. 
 
Part 1 
What is the purpose of the study? 
The purpose of this study is to see how many people who are in hospital or being treated by 
community nurses have pain, soreness or discomfort in one of the areas where pressure ulcers, 
or bed sores, commonly develop (like the lower back, buttocks, and heels). This information 
will be used by healthcare practitioners to improve assessment and treatment of localised skin 
and pressure ulcer pain. 
 
Why have I been invited to participate? 
This study is looking at people like you who are in hospital or under the care of community 
nursing services and who have pain in an area that may experience pressure from being in bed 
or a chair. Participants from many hospitals and within the community will be asked to take 
part.
 
Do I have to take part? 
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Taking part in this study is entirely voluntary and you are under no obligation to take part – it 
is up to you to decide. We will describe the study to you and go through this information sheet. 
If you agree to take part you will be asked to sign the consent form at the end of this leaflet to 
show that you have agreed to take part. You will be given a copy of this information sheet and 
of the consent form to keep. You are free to withdraw at any time, without giving a reason. 
This would not affect the standard of care you receive. If you do not wish to take part this will 
not affect the care that you are currently receiving. 
 
What if I would like to take part but I have trouble with or am unable to write? 
If you would like to take part but cannot or find it difficult to write, you can have someone (a 
witness) complete the written part of the consent for you. This witness could be a friend, a 
family member, or member of your healthcare team. The witness will only act to help you 
carry out your wishes – you are free to change your mind at any time and your wishes will be 
respected. 
 
What will happen to me if I take part? 
If you agree to take part in the study, a nurse will ask you a few extra questions, assess your 
skin sensation, and check your skin (or pressure sore if you have one). This single assessment 
will take place in your own home or on the hospital ward you are on at a time convenient for 
you. 
 
What are the possible disadvantages and risks of taking part? 
This study is a one-off assessment which should take about an hour. We do not foresee any 
disadvantages or risks to you in taking part in this study. However, you are being asked to give 
some of your time for taking part. Your care and treatment will remain the same whether or not 
you decide to take part.  
 
What are the possible benefits of taking part? 
There will be no direct benefit to you as a result of participating in this study. We hope that the 
information from this study will help to improve awareness and treatment of pressure ulcer 
related pain in the future. 
 
What if something goes wrong? 
If you have a concern about any aspect of this study, you should ask to speak with your 
healthcare practitioner or other healthcare professional who will do their best to answer your 
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questions. If you remain unhappy and wish to complain formally, you can do this through the 
NHS Complaints Procedure. In the unlikely event that you think you have been harmed by 
taking part in this study, there are no additional compensation arrangements. Details about 
complaints procedures can be obtained from your healthcare practitioner. 
 
Will my taking part be kept confidential? 
Yes. All information which would be collected about you during the course of the study will be 
kept strictly confidential. We will follow ethical and legal practice and all information about 
you will be handled in confidence. 
 
This completes Part 1 of the Information Sheet. If the Information in Part 1 has 
interested you and you are considering participation, please continue to read the 
additional information in Part 2 before making any decision. 
 
Part 2 
What will happen if I don’t want to carry on with the study? 
Taking part in this study is entirely voluntary and you are free to change your mind at any 
point during or following completion of the study without giving a reason. A decision to 
withdraw at any time will not affect the standard of care you receive, nor will it affect your 
relationships with your doctors and nurses in any way. 
 
Will my taking part in this study be kept confidential? 
If you decide to participate in the study, the information collected about you during the course 
of the study will be anonymised and kept strictly confidential. This information will handled, 
processed, stored, and destructed in accordance to the Data Protection Act 1998. The study 
team have a duty of confidentiality to you and will do their very best to meet this duty. Any 
information that is collected about you, including any additional information obtained from 
your medical records, will have your name and address removed from it. All information 
obtained is strictly confidential and will be kept in locked cupboards and will only be 
accessible to members of the research team. No names or details that would identify specific 
people will be included in the outputs from this study. Outputs may include reports, 
presentations, and papers (published in a medical journal), and further healthcare and/or 
medical research, but these will not be traceable to specific individuals.  
 
Who has organised and sponsored the research? 
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The study is being organised and coordinated by the Clinical Trials Research Unit (CTRU) at 
the University of Leeds, who is sponsoring the study. This study is a part of a larger pressure 
ulcer research programme funded by the National Institute of Health Research that aims to 
reduce the impact of pressure ulcers on patients. 
 
Who has reviewed the study? 
The study has been peer reviewed by the National Institute of Health Research before approval 
for the funding was given. In addition, all research in the NHS is looked at by an independent 
group of people called a Research Ethics Committee to protect your safety, rights, wellbeing, 
and dignity. This study has been reviewed by the Leeds Central Research Ethics Committee 
(reference 09/H1313/14). 
 
Further information and contact details 
If you would like further information about clinical research, the UK Clinical Research 
Collaboration (a partnership of organisations working together on clinical research in the UK) 
have published a booklet entitled ‘Understanding Clinical Trials’.  Contact UKCRC: Tel: 0207 
670 5452; website www.ukcrc.org 
 
Your contact telephone numbers: 
(to include local PI) …………………………………………………………………………….. 
……………………………………………………………………………………………………
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[Delete this line, then print on Trust headed paper] 
PATIENT CONSENT FORM 
Where witnessed consent is required please use the Witnessed Consent Form  
 
Pressure UlceR Programme Of ReSEarch 
Pain Prevalence - Prevalence of localised pressure ulcer related pain 
 
 
1. I
 confirm that I have read and understand the information sheet dated 
18/01/2010 (version 3.0) for the above study. I have had the opportunity to 
ask questions and have had these answered satisfactorily.                                                                                      
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without my medical care or legal rights being affected. 
 
3. I understand that relevant sections of my healthcare records and data 
collected during the study may be looked at by individuals from the NHS 
Trust Teams and the Sponsor, where it is relevant to my study participation. 
I give permission for these individuals to have access to my records. 
 
4. I agree to take part in the study. 
 
 
___________________  _____________ _________________ 
Name of Patient   Date    Signature 
 
I have given written information and a verbal explanation to the person named above who has freely 
given their consent to participate. 
 
___________________ _____________ _________________ 
Name of Person   Date    Signature 
taking consent 
 
(1 copy for patient; 1 for patient records; original stored in Investigator Site File) 
Patient Study Number:  DOB:  
Principal Investigator:  Version: 3.0 
Patient initial after 
each question 
.......... 
.......... 
.......... 
.......... 
.......... 
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Appendix 5 Pain prevalence study witnessed
consent form
[Delete this line, then print on Trust headed paper]
 
WITNESSED CONSENT FORM  
 
 
Pressure UlceR Programme Of ReSEarch 
Pain Prevalence - Prevalence of localised pressure ulcer related pain 
 
 
 
1. I confirm that I have read and understand the information sheet dated 
18/01/2010 (version 3.0) for the above study. I have had the 
opportunity to ask questions and have had these answered 
satisfactorily.                                                                                         
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without my medical care or legal rights being 
affected. 
 
 
3. I understand that relevant sections of my healthcare records and data 
collected during the study may be looked at by individuals from the 
NHS Trust Teams and the Sponsor, where it is relevant to my study 
participation. I give permission for these individuals to have access to 
my records. 
 
 
4. I agree to take part in the study. 
 
 
________________________   
Name of Patient    
Patient Study Number:  DOB:  
Principal Investigator:  Version: 3.0 
Witness initial after 
each question on 
behalf of the patient 
.......... 
.......... 
.......... .......... 
.......... 
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Witness statement 
I have completed this consent form on behalf of the person named above who has freely 
given their consent to participate. 
 
_______________________    _____________ _________________ 
Name of Witness    Date    Signature 
 
 
Research person taking Consent 
I have given written information and a verbal explanation to the person named above who has 
freely given their consent to participate. 
 
_______________________   _____________ _________________ 
Name of person taking consent   Date    Signature 
 
(1 copy for patient; 1 for patient records; original stored in Investigator Site File) 
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Appendix 6 Pain cohort study reduced format
protocol
NB: This study protocol (version 4, dated 18 Jan 2010) is in a reduced format including only 
the study aims, methods and ethical considerations.  Sections pertaining to study background 
have been removed as they are included as a chapter section. Information pertaining to 
serious adverse events, data monitoring, quality assurance, confidentiality, archiving, 
statement of indemnity, study organisational structure, and publication policy are available 
upon request 
 
3 Flow diagram/trial summary 
 
 
5 Aim and objectives 
Hospital patients 
at risk of PU development 
Registration
Community patients 
at risk of PU development 
Eligibility and Consent
Baseline Assessment
Follow-up Assessments 
twice a week until 30 days after entry 
or 
no localised pain on a pressure area  
AND 
Category 0/A on all pressure areas 
AND 
improved mobility and activity 
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The main aim of this study is to explore the role of pain as an early predictor of Category 2 
PU development (see Table 1). 
Objectives are: 
1. To assess whether the presence/absence of localised skin pain is a predictor of ≥ 
Category 2 pressure ulcer development. 
2. To explore the relationship between skin classification category and reported pain and 
pain severity. 
3. To identify variables which are independently predictive of ≥ Category 2 pressure 
ulcer development. 
 
Table 1. NPUAP/EPUAP Pressure Ulcer Classification System6. For the purpose of the 
research the classification has been adapted to enable grading of normal skin and 
unstageable pressure ulcers. 
Category Description 
Category 0 
Healthy intact skin 
No skin changes. 
Category A 
Alterations to intact skin 
Alterations to intact skin. 
Category 1 
Non-blanchable erythema of 
intact skin 
Intact skin with non-blanchable erythema of a localised area usually 
over a bony prominence. Discolouration of the skin, warmth, oedema, 
hardness or pain may also be present. Darkly pigmented skin may not 
have visible blanching. 
Category 2 
Partial thickness skin loss or 
blister 
Partial thickness loss of dermis presenting as a shallow open ulcer 
with a red pink wound bed, without slough. May also present as an 
intact or open/ruptured serum or sero-sanginous-filled blister. 
Category 3 
Full thickness skin loss 
Full thickness tissue loss. Subcutaneous fat may be visible but bone, 
tendon or muscle are not exposed. Some slough may be present. May 
include undermining and tunnelling. 
Category 4 
Full thickness tissue loss 
Full thickness tissue loss with exposed bone, tendon or muscle. 
Slough or eschar may be present. Often includes undermining or 
tunnelling. 
Category U 
Unstageable 
Full thickness skin loss in which actual depth of the ulcer is 
completely obscured by slough (yellow, tan, grey, green, or brown) 
and/or eschar (tan, brown, or black) in the wound bed. 
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6 Methods 
6.1 Design 
We plan to undertake a prospective cohort study with 30 days follow-up, in acute and 
community NHS Trusts involving 632 patients at high-risk of PU development.   
 
6.2 Eligibility 
6.2.1 Acute Hospital Patients Inclusion Criteria 
1. acute vascular, orthopaedic, medical or care of the elderly admission 
2. aged  18 years  
3. have an expected total length of stay of 5 or more days 
4. at high risk of PU development due to one or more of the following: 
a. bedfast/chairfast AND completely immobile/very limited mobility (see 
Appendix 2) 
b. localised skin pain on any pressure area skin site (see section 6.2.4) 
c. Category 1 PU on any pressure area skin site (see Table 1) 
5. give their written, informed consent to participate  
6. expected to be able to comply with follow-up schedule. 
 
6.2.2 Community Patients Inclusion Criteria 
1. evidence of acute illness through one or more of the following: 
a. recent hospital discharge to home/intermediate/community 
care/hospice/specialist palliative care  
b. existing community nursing patient with deterioration in overall condition or 
onset of acute illness 
c. new referral to community nursing due to acute illness, deterioration in 
existing condition, or care package breakdown. 
2. aged  18 years  
3. at high risk of PU development due to one or more of the following: 
a. bedfast/chairfast AND completely immobile/very limited mobility (see 
Appendix 2) 
b. localised skin pain on any pressure area skin site (see section 6.2.4) 
c. Category 1 PU on any pressure area skin site (see Table 1) 
4. give their written, informed consent to participate 
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5. expected to be able to comply with follow-up schedule.  
 
6.2.3 Exclusion Criteria (Acute Hospital & Community Patients) 
1. Obstetrics, paediatrics, day case surgery, and psychiatric patients in both acute and 
community settings 
2. Unable to provide written, informed consent 
3. Unable to comply with follow-up assessment schedule 
4. Deemed by the attending healthcare professional to be too unwell to be approached 
and/or complete the study assessment schedule 
5. Unable to report the presence/absence of pain (e.g. unconscious) 
6. Patients with two or more ≥ Category 2 PUs on any key pressure area skin sites 
(sacrum, buttocks, heels, hips; see Table 1). 
 
6.2.4 Pain Questions 
To determine if patients have localised skin pain on any pressure area skin site they will be 
asked the following two questions by a member of the research team. Patients will be eligible 
for inclusion under this criteria if they answer ‘yes’ to both questions. 
1. At any time, do you get pain, soreness, or discomfort on a pressure area? Prompt – 
back, bottom, hips, elbows, heels, or other as applicable to the patient? 
2. Do you think this is related to either: your pressure sore; laying in bed for a long time; 
sitting for a long time (as appropriate)? 
 
6.3 Endpoints 
The classification scale is adapted from the international classification scales5 in order to 
meet practical data collection requirements for the purpose of research (Table 1). 
Specifically, Category 0 (no skin changes) is included to clearly distinguish skin assessment 
of normal skin from missing data and Category A (alterations to intact skin) is included as 
alterations to intact skin have been identified as independently predictive of Category 2 PU 
outcome4,7. 
 
The primary endpoint is defined as the development of a new Category ≥2 PU after 
registration and before study completion.  
 
6.3.1 Follow-up 
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In the patient population recruited to the study we anticipate that hospital patients will be 
discharged to community settings and community patients may be admitted to hospital. 
Patients will continue follow-up across healthcare settings, with ethics and R&D approval 
sought in adjacent NHS Trusts to facilitate this. Patient follow-up will be discontinued when 
the patient fulfils one of the following criteria:   
 
1. 30 days from registration OR 
2. no longer at high risk because: 
a. no localised skin pain on any pressure area skin site (see section 6.2.4) AND 
b. Category 0/A on all pressure area skin sites AND 
c. improved mobility and activity (score of 3 or 4 on both the activity and 
mobility scores of the Braden Scale8 Appendix 2) OR 
3. death. 
 
6.4 Recruitment and consent 
Where eligibility is indicated by the attending clinical team, patients will be flagged to a 
member of the Trust Tissue Viability Team (TVT; Tissue Viability Nurse 
Consultant/Specialist/Research Nurse). The attending clinical team may or may not already 
include a member of the Trust TVT. A full verbal explanation of the study Patient 
Information Leaflet will be provided by the attending clinical staff or a member of the TVT 
for the patient to consider. This will include detailed information about the rationale, design, 
and personal implications of the study. Following information provision, patients will have as  
long as they need to consider participation and will be given the opportunity to discuss the 
study with their family and other healthcare professionals before they are asked whether they 
would be willing to take part in the study. 
 
Assenting patients will then be invited to provide informed, written consent. A record of the 
consent process detailing the date of consent will be kept in the patient healthcare records. 
Assessment of eligibility and informed consent will usually be undertaken by a member of 
the TVT. The right of the patient to refuse consent without giving reasons will be respected. 
Further, the patient will remain free to withdraw from the study at any time without giving 
reasons and without prejudicing any further treatment. 
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Should the patient be capable of giving consent but physically unable to complete the written 
aspects of the consent form, witnessed consent should be obtained using the Witnessed 
Consent Form. An appropriate witness would be a family member or friend of the patient, or 
another member of the patient’s healthcare team who is not directly involved in the research 
study. 
 
The original consent form will be retained in the Investigator Site File, a copy of the consent 
will be given to the patient and a second copy filed in the patient healthcare notes. 
 
7 Screening and registration 
7.1 Screening 
Participating research sites will be required to complete a log of all patients screened for 
eligibility. Anonymised information will be collected including: 
· age 
· gender 
· ethnicity 
· whether the patient is registered or not registered 
 
Screened patients who are not registered either because they are ineligible or because they 
decline participation will also have the following information recorded: 
· the reason not eligible for study participation OR 
· the reason eligible but declined 
 
This anonymised information will be returned on a monthly basis to the Clinical Trials 
Research Unit (CTRU). 
 
7.2 Registration 
Screened patients who are both eligible for study participation and provide written informed 
consent will be registered. Informed consent for entry into the study must be obtained prior to  
registration. Following confirmation of written informed consent and eligibility patients will 
be registered into the study by an authorised member of staff at the study research site.  
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Registration will be performed centrally using the CTRU automated 24-hour telephone 
registration system. Authorisation codes and PINs, provided by the CTRU, will be required to 
access the registration system. 
 
The following information will be required at registration: 
· Patient details, including initials, gender and date of birth 
· Site code for research site 
· Name of person making the registration 
· Confirmation of eligibility 
· Confirmation of written informed consent 
Direct line for registration +44 (0)113 343 8278 
 
8 Assessments and data collection 
Assessments will be undertaken by members of the TVT as follows: 
· Baseline assessment (after consent but prior to registration) 
· Follow-up assessments twice weekly for 30 days or until study completion (see section 
6.3.1). 
 
8.1 Baseline Assessment 
Authorised healthcare practitioners will record baseline information including: 
 
8.2 Baseline demographics 
· Patient’s NHS ID 
· Patient’s Hospital/Trust number (if applicable) 
· Name of NHS Trust 
· NHS Facility/Service name (name of hospital/intermediate community nursing team) 
· Type of admission/referral 
· Hospital patients only - speciality (vascular/orthopaedic/medical-elderly)  
· Date of admission to hospital/community referral 
· Initials 
· Date of birth 
· Gender 
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· Ethnicity 
· Confirmation General Practitioner (GP) letter sent 
· Confirmation responsible healthcare professional letter sent (if applicable) 
 
8.3 Personal data (to be retained in the site file and not returned to the CTRU) 
· Patient name  
· Patient location e.g. hospital/intermediate care/home 
· Community patients/hospital discharge patients only:  
· Patient address and telephone number  
· GP name and address 
· District Nurse name and address 
· Other responsible healthcare professional (e.g. Specialist or Consultant Nurse) name and 
address 
· Hospital/hospitalised  patients only: 
· Ward 
· Responsible healthcare professional (e.g. Consultant Physician or Surgeon, a Specialist or 
Consultant Nurse) name and address 
 
8.4 Risk factors and population characteristics 
· Skin assessment (sacrum, buttocks, heels, hips and other) using the skin classification 
scale (Table 1) 
· Braden Scale8 subscales (Appendix 2) 
· Pain assessment  (see section 8.2.1, Appendix 3) 
· Diabetic status 
· Other chronic wounds (type and location) 
· Nutritional status 
· Analgesic use 
· Pressure ulcer prevention and treatment interventions 
 
8.5 Follow-up assessments (twice-weekly up to 30 days) 
· Skin assessment (sacrum, buttocks, heels, hips and other) using the skin classification 
scale (Table 1) 
· Mobility/activity score using Braden Scale8 (Appendix 2) 
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· Pain assessment (see section 8.2.1, Appendix 3) 
· Analgesic use 
· Pressure ulcer prevention and treatment interventions 
· Serious Adverse Events (see section 11) 
· Confirmation of continued eligibility (see section 6.3.1) 
 
8.5.1 Pain Assessment 
Patients will be asked the two screening questions for all pressure areas (see section 6.2.4) at 
baseline. Where patients answer yes to both screening questions at baseline these sites will be 
assessed using a numerical rating scale9,10 for pain intensity (for most severe pain over the 
past week). In addition, duration of pain will be recorded. 
Up to two Category 0-1 skin areas will be assessed using the Leeds Assessment Neuropathic 
Symptoms and Signs (LANSS) Pain Scale11,12 (Appendix 3). The LANSS consists of a brief 
clinical assessment and is easy to score in a clinical setting. The questionnaire contains 5 
symptom items and 2 clinical sensory testing items associated with neuropathic pain. The 
LANSS Scale is a clinically validated tool which allows assessment of neuropathic and 
inflammatory pain, and has been used in a wide variety of clinical settings12. The two sites 
assessed using the LANSS will include the most painful skin site located on the torso (i.e. 
sacrum, buttocks, ischial tuberosities, hips) and the most painful site located on a limb (i.e. 
heels, elbows). In addition, where a patient has a  Category 2 PU at baseline, this will be 
assessed using the LANSS. 
 
At follow-up patients will be asked the two screening questions for all pressure areas (see 
section 6.2.4) at each visit. Where pain at the skin site is reported intensity will be assessed 
using the numerical rating scale9,10. For the skin sites where the LANSS assessment was 
undertaken at baseline, this will be repeated at visits 4 and 8, until either study conclusion or 
when pain is no longer present at that skin site (i.e. one of the two screening questions is 
‘no’). 
 
All anonymised data will be returned to CTRU for data processing. 
 
9 Statistical considerations 
DOI: 10.3310/pgfar03060 PROGRAMME GRANTS FOR APPLIED RESEARCH 2015 VOL. 3 NO. 6
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Nixon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
321
9.1 Sample size 
Our aim in this study is to assess whether the presence of localised skin pain is predictive of 
whether or not a patient develops a new PU of Category 2 or above, after adjusting for the 
effects of other known risk factors which are: age, diabetes, nutritional status, presence of 
chronic wound on any skin site, presence of skin alterations, Category 1 ulcer on any site, and 
patient setting (hospital elective, hospital acute, community). As a patient’s perception of 
pain is likely to be affected by the use of analgesics or other forms of pain relief, we will 
collect this data and include analgesic use as a covariate in the model. 
 
For risk factor studies using logistic regression it is recommended that at least 10 patients 
with the event of interest are needed for reliable estimation of effects13.  A model including 9 
factors (pain, the seven pre-specified risk factors, and analgesic use) would therefore require 
a minimum of 90 patients to develop a new pressure ulcer of Category 2 or above.  Previous 
research7,14 suggests that approximately 15% of patients will develop a new PU of Category 2 
or above within 30 days of entering the study.  Based on this assumption and allowing for 
potential loss to follow up of 5% will require 632 patients to be recruited to this study.  
 
Table 2 shows the largest difference in PU incidence that can be detected with a minimum of 
80% power for patients with 10 or 20% pain at study entry with estimated PU event rates in 
the patients without pain of 10 and 15% and assumes that patients with pain at study entry are 
more likely to develop a new ulcer than those without pain at entry. 
 
Table 2. Largest difference in PU incidence with 80% power. 
Total Baseline pain PU incidence  PU incidence  
With 
pain N 
(%) 
Without 
pain N 
(%) 
With 
pain 
Without 
pain 
Diff With 
pain 
 
Without 
pain 
Diff 
632 
64 
(10%) 
568 (90%) 
24.4% 10.0% 14.4% 30.9% 10.0% 15.9% 
OR 2.988 (1.594, 5.603) OR 2.548 (1.432, 4.533) 
632 
127 
(20%) 
505 (80%) 
20.2% 15.0% 10.2% 26.5% 15.0% 11.5% 
OR 2.292 (1.363, 3.851) OR 2.064 (1.300, 3.277) 
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If we recruit 632 patients with 64 (10%) of them having pain on study entry this will allow us  
to detect a statistically significant difference (p<0.05) of 14.4% between those with and 
without pain using a chi-squared test (80% power, 5% significance) if 10% of patients 
without pain and 24.4% of those with pain develop a new PU within the 30-day follow up 
period, corresponding to an odds ratio (OR) of 2.988 with 95% CI (1.594, 5.603) 
 
As this is an exploratory study and there is uncertainty around the assumption made to 
estimate sample size, the proportion of patients with pain at baseline and the incidence of PU 
development will be monitored by the statistical team throughout the study, and implications 
for sample size flagged to the Project Team. 
 
10 Statistical analyses 
10.1 General Considerations 
Statistical analysis is the responsibility of the CTRU Statistician.  The analysis plan outlined 
in this section will be reviewed and a final statistical analysis plan will be written before any 
data summaries or analyses are performed.  The analysis plan will be written in accordance 
with current CTRU Standard Operating Procedures and will be finalised and agreed by the 
following people: the Trial Statistician and Supervising Statistician, the Chief Investigator, 
Senior Trial Manager, and Programme Manager.  Any changes to the final analysis plan and 
reasons for change will be documented. 
 
10.2 Primary Analysis 
Logistic regression analysis will be used to assess the relationship between the presence or 
absence of localised pain at any skin site and the development of a PU of Category 2 or 
above, using univariate analysis, and also multivariable analysis accounting for the covariates 
(age, diabetes, skin alterations, Category 1 ulcer on any site, patient setting, and analgesic 
use). The odds ratios, 95% confidence intervals and p-values from all analyses will be 
presented. All primary analysis will be performed on a per-patient basis. An additional 
analysis will explore the relationship between pain at a specific skin site and the development 
of a new PU on the same site using multilevel logistic regression modelling to account for the 
clustering of skin sites within a patient. 
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10.3 Secondary Analysis 
Additional analyses will also be undertaken to: 
i) Explore the relationship between skin classification category and reported pain by 
summarising the presence/absence and severity of pain for each of the skin 
classification categories 
ii) Identify variables which are independent predictors of Category 2 PU 
development. This will use logistic regression modelling as per the primary 
analysis but will use forwards and backwards selection modelling to identify the 
most suitable set of covariates for predicting PU development 
iii) Assess the relationship between changes in pain over time and the time to PU 
development by treating pain as a time-dependent covariate in a Cox proportional 
hazards model both in a univariate analysis and after adjusting for the same 
covariates used in the primary analysis. 
 
13.2 Ethical considerations 
This study will include elderly and highly dependent patients considered as vulnerable. 
Ethical issues are largely related to the involvement of vulnerable adults/elderly patients with 
high levels of co-morbidity including acute and chronic illness. The ethical issues 
surrounding these potentially vulnerable patients have been addressed through the study 
design and the use of local staff including experienced clinical nurses, that is, members of the 
local TVT to assess patients.  
 
The study will be performed in accordance with the recommendations guiding physicians in 
biomedical research involving human subjects adopted by the 18th World Medical Assembly, 
Helsinki, Finland, 1964, amended at the 52nd World Medical Association General Assembly, 
Edinburgh, Scotland, October 2000. Informed written consent will be obtained prior to 
registration into the study. The right of a patient to refuse participation without giving reasons 
will be respected. The patient will remain free to withdraw at any time from the study without 
giving reasons and without prejudicing his/her further treatment. The study will be submitted 
to and approved by a main Research Ethics Committee (main REC) and the appropriate Site 
Specific Assessor for each participating centre prior to entering patients into the study. The 
CTRU will provide the main REC with a copy of the final protocol, patient information 
sheets, consent forms and all other relevant study documentation. 
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Appendix 2: The Braden Scale 
[NB: Data for the Braden scale was collected however the scale is omitted due to copyright.  
The Braden scale can be requested from URL: http://bradenscale.com/]. 
 
Appendix 3: The LANSS Pain Scale 
Leeds Assessment of Neuropathic Symptoms and Signs10 (with adaptations)11 
[NB: The LANSS scale was collected however the scale is omitted due to copyright. The 
LANSS scale can be obtained from: Bennett M. The LANSS Pain Scale: The Leeds 
assessment of neuropathic symptoms and signs. Pain 2001; 92(1-2): 147-157]. 
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Appendix 7 Pain cohort study patient
information leaflet
[Delete this line, then print on Trust headed paper] 
 
Pressure UlceR Programme Of ReSEarch 
Pain Cohort -  Exploring the role of pain as an early predictor of Category 2 pressure 
ulcers 
 
PATIENT INFORMATION SHEET 
A large-print version of this sheet is available on request.   
You have been invited to take part in a research Project. Before you decide whether to 
accept, we would like to explain why the research is being done and what it will involve. 
Please read this information carefully, and discuss it with your relatives or carers if you 
wish. Ask us if anything is unclear, or if you would like more information. Part 1 tells you the 
purpose of this project and what will happen to you if you take part. Part 2 gives you more 
detailed information about the conduct of the study. 
 
Thank you for reading this information sheet.  
 
Part 1 
What is the purpose of the study? 
The purpose of this study is to explore if reports of patients pressure area pain, can help 
healthcare professionals predict which patients will develop a pressure ulcer (commonly 
known as a bed sore). The information gathered will be used to improve assessment and 
treatment of skin and pressure ulcer pain.  
 
Why have I been chosen? 
This study is looking at people like you who are in hospital or under the care of community 
nursing services, participants from many hospitals and within the community will be asked to 
take part. You may have pain in an area that may experience pressure from being in bed or a 
chair.  
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Do I have to take part? 
Taking part in this study is entirely voluntary and you are under no obligation to take part – it 
is up to you to decide. We will describe the study to you and go through this information 
sheet. If you agree to take part you will be asked to sign the consent form at the end of this 
leaflet to show that you have agreed to take part. You will be given a copy of this information 
sheet and of the consent form to keep. You are free to withdraw at any time, without giving a 
reason. This would not affect the standard of care you receive. If you do not wish to take part 
this will not affect the care that you are currently receiving. 
 
What if I would like to take part but I have trouble with or am unable to write? 
If you would like to take part but cannot or find it difficult to write, you can have someone (a 
witness) complete the written part of the consent for you. This witness could be a friend, a 
family member, or member of your healthcare team. The witness will only act to help you 
carry out your wishes – you are free to change your mind at any time and your wishes will be 
respected. 
 
What will happen to me if I take part? 
If you agree to take part in the study, a nurse will ask you some questions relating to your 
skin and pressure or rubbing, assess your skin sensation, and check your skin (or pressure 
sore if you have one) in the areas you have pain or discomfort. This assessment will be done 
when you enter the study, and will be repeated twice a week for 30 days (a total of 8 follow-
up assessments). The assessments will take about 30 minutes and will take place in your own 
home or on the hospital ward you are on at a time convenient for you. 
If you are in hospital and you are discharged before the end of 30 days, we will ask you if we 
can have your contact details so we can follow you up until the end of the 30 days. These will 
be confidentially destroyed at the end of the study. 
 
What are the possible disadvantages and risks of taking part? 
We do not foresee any disadvantages or risks to you in taking part in this study. However, 
you are being asked to give some of your time for taking part. Your care and treatment will 
remain the same whether or not you decide to take part.  
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What are the possible benefits of taking part? 
There will be no direct benefit to you as a result of participating in this study. We hope that 
the information from this study will help to improve awareness and treatment of pressure 
ulcer related pain in the future. 
 
What if something goes wrong? 
If you have a concern about any aspect of this study, you should ask to speak with your 
healthcare practitioner or other healthcare professional who will do their best to answer your 
questions. If you remain unhappy and wish to complain formally, you can do this through the 
NHS Complaints Procedure. In the unlikely event that you think you have been harmed by 
taking part in this study, there are no additional compensation arrangements. Details about 
complaints procedures can be obtained from your healthcare practitioner. 
 
Will my taking part be kept confidential? 
Yes. All information which would be collected about you during the course of the study will 
be kept strictly confidential. We will follow ethical and legal practice and all information 
about you will be handled in confidence. 
 
Involvement of your General Practitioner (GP) / Other Healthcare Practitioner 
Your GP will be informed that you are participating in this study. If you are under the care of 
a Hospital Consultant, Specialist or District Nurse, they will also be informed of your 
participation. 
 
This completes Part 1 of the Information Sheet. If the Information in Part 1 has 
interested you and you are considering participation, please continue to read the 
additional information in Part 2 before making any decision. 
 
Part 2 
What will happen if I don’t want to carry on with the study? 
Taking part in this study is entirely voluntary and you are free to change your mind at any 
point during or following completion of the study without giving a reason. A decision to 
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withdraw at any time will not affect the standard of care you receive, nor will it affect your 
relationship with the medical and nursing team who are looking after you. 
 
Will my taking part in this study be kept confidential? 
If you decide to participate in the study, the information collected about you during the 
course of the study will be anonymised and kept strictly confidential. This information will 
handled, processed, stored, and destructed in accordance to the Data Protection Act 1998. 
The study team have a duty of confidentiality to you and will do their very best to meet this 
duty. Any information that is collected about you, including any additional information 
obtained you’re your medical records, will have your name and address removed from it. All 
information obtained is strictly confidential and will be kept in locked cupboards and will 
only be accessible to members of the research team. No names or details that would identify 
specific people will be included in the outputs from this study. Outputs may include reports, 
presentations, and papers (published in a medical journal), and further healthcare and/or 
medical research, but these will not be traceable to specific individuals. 
 
Who has organised and sponsored the research? 
The study is being organised and coordinated by the Clinical Trials Research Unit (CTRU) at 
the University of Leeds, who is sponsoring the study. This study is a part of a larger pressure 
ulcer research programme funded by the National Institute of Health Research that aims to 
reduce the impact of pressure ulcers on patients. 
 
Who has reviewed the study? 
The study has been peer reviewed by the National Institute of Health Research before 
approval for the funding was given. In addition, all research in the NHS is looked at by an 
independent group of people called a Research Ethics Committee to protect your safety, 
rights, wellbeing, and dignity. This study has been reviewed by the Leeds Central Research 
Ethics Committee (reference 09/H1313/32). 
 
What will happen to the results of the research study? 
When the study is complete the results will be published in a medical journal, but no 
individual participants will be identified in any report or publication. If you would like to 
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obtain a copy of the published results, please ask your local contact person (see contact 
details below). 
 
Further information and contact details 
If you would like further information about clinical research, the UK Clinical Research 
Collaboration (a partnership of organisations working together on clinical research in the UK) 
have published a booklet entitled ‘Understanding Clinical Trials’.  Contact UKCRC: Tel: 
0207 670 5452; website www.ukcrc.org 
 
Your contact telephone numbers: 
(to include local 
collaborator)………………………………………………………………….. 
…………………………………………………………………………………………………. 
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Appendix 8 Pain cohort study consent forms
 
 
 
[Delete this line, then print on Trust headed paper] 
PATIENT CONSENT FORM 
Where witnessed consent is required please use the Witnessed Consent Form  
 
Pressure UlceR Programme Of ReSEarch 
 Pain Cohort -  Exploring the role of pain as an early predictor of Category 2 pressure ulcers 
 
 
1. I confirm that I have read and understand the information sheet dated 18/01/2010 
(version 4.0) for the above study. I have had the opportunity to ask questions and 
have had these answered satisfactorily.                                                                                         
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time without my medical care or legal rights being affected. 
 
3. I understand that relevant sections of my healthcare records and data collected 
during the study may be looked at by individuals from the NHS Trust Teams and the 
University of Leeds, where it is relevant to my study participation. I give permission 
for these individuals to have access to my records.
 
4. I consent to the storage including paper and electronic, of personal information 
for the purposes of this study. I understand that any information that could identify 
me will be kept confidential and that no personal information that could identify me 
will be included in the study report or other publication. This information will be 
confidentially destroyed at the end of the study. 
 
5. I agree that my GP and hospital consultant/Specialist or District nurse (where 
applicable) will be notified of my participation in this study. 
 
6. I agree to take part in the study. 
 
___________________  _____________ _________________ 
Name of Patient    Date    Signature 
 
I have given written information and a verbal explanation to the person named above who has freely given their 
consent to participate. 
___________________ _____________ _________________ 
Name of Person    Date    Signature 
taking consent 
(1 copy for patient; 1 for patient records; original stored in Investigator Site File) 
Patient Study Number:  Patient Initials:  
Patient DOB: Site ID: 
Principal Investigator:  Version: 4.0 
Patient initial after 
each question 
.......... 
.......... 
.......... .......... 
.......... 
.......... 
.......... 
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[Delete this line, then print on Trust headed paper] 
WITNESSED CONSENT FORM  
 
Pressure UlceR Programme Of ReSEarch 
 Pain Cohort -  Exploring the role of pain as an early predictor of Category 2 pressure 
ulcers 
 
 
 
1. I confirm that I have read and understand the information sheet dated 
18/01/2010 (version 4.0) for the above study. I have had the 
opportunity to ask questions and have had these answered 
satisfactorily.                                                                                         
 
2. I understand that my participation is voluntary and that I am free 
to withdraw at any time without my medical care or legal rights being 
affected. 
 
3. I understand that relevant sections of my healthcare records and 
data collected during the study may be looked at by individuals from 
the NHS Trust Teams and the University of Leeds, where it is relevant 
to my study participation. I give permission for these individuals to 
have access to my records. 
 
4. I consent to the storage including paper and electronic, of personal 
information for the purposes of this study. I understand that any 
information that could identify me will be kept confidential and that 
no personal information that could identify me will be included in the 
study report or other publication. This information will be 
confidentially destroyed at the end of the study. 
 
5. I agree that my GP and hospital consultant/Specialist or District 
nurse (where applicable) will be notified of my participation in this 
study. 
 
6. I agree to take part in the study. 
 
________________________   
Name of Patient    
Patient Study Number:  Patient Initials:  
Patient DOB: Site ID: 
Principal Investigator:  Version: 4.0 
Witness initial after 
each question on 
behalf of the patient 
.......... 
.......... 
.......... .......... 
.......... 
.......... 
.......... 
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Witness statement 
I have completed this consent form on behalf of the person named above who has freely 
given their consent to participate. 
 
_______________________    _____________ _________________ 
Name of Witness    Date    Signature 
 
 
Research person taking consent 
I have given written information and a verbal explanation to the person named above who has 
freely given their consent to participate. 
 
_______________________   _____________ _________________ 
Name of Person taking    Date    Signature 
consent          
 
(1 copy for patient; 1 for patient records; original stored in Investigator Site File) 
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Appendix 9 Cross-tabulations of explanatory
variables
TABLE 92 Cross-tabulation of the presence of skin alterations and the presence of a category 1 pressure ulcer
at baseline
Category 1 pressure ulcer
Skin alterations, n (%)
Total, n (%)Yes No
Yes 170 (28.2) 120 (19.9) 290 (48.2)
No 203 (33.7) 109 (18.1) 312 (51.8)
Total 373 (62.0) 229 (38.0) 602 (100.0)
TABLE 93 Cross-tabulation of the presence of pain on a healthy, altered or category 1 skin site and the presence of
a category 1 pressure ulcer at baseline
Category 1 pressure ulcer
Pain on a category 0, 1 or A skin site, n (%)
Total, n (%)Yes No
Yes 247 (41.0) 43 (7.1) 290 (48.2)
No 217 (36.0) 95 (15.8) 312 (51.8)
Total 464 (77.1) 138 (22.9) 602 (100.0)
TABLE 94 Cross-tabulation of the presence of a category 2 pressure ulcer and the presence of a category 1 pressure
ulcer at baseline
Category 1 pressure ulcer
Category 2 pressure ulcer, n (%)
Total, n (%)Yes No
Yes 76 (12.6) 214 (35.5) 290 (48.2)
No 88 (14.6) 224 (37.2) 312 (51.8)
Total 164 (27.2) 438 (72.8) 602 (100.0)
TABLE 95 Cross-tabulation of Braden activity score with the presence of a category 1 pressure ulcer at baseline
Category 1 pressure ulcer
Braden activity score, n (%)
Total, n (%)Bedfast Chairfast Walks occasionally Walks frequently
Yes 51 (8.5) 145 (24.1) 88 (14.6) 6 (1.0) 290 (48.2)
No 53 (8.8) 168 (27.9) 69 (11.5) 22 (3.7) 312 (51.8)
Total 104 (17.3) 313 (52.0) 157 (26.1) 28 (4.7) 602 (100.0)
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TABLE 96 Cross-tabulation of the presence of a chronic wound with the presence of a category 1 pressure ulcer
at baseline
Category 1 pressure ulcer
Chronic wound, n (%)
Total, n (%)Yes No
Yes 72 (12.0) 218 (36.2) 290 (48.2)
No 55 (9.1) 257 (42.7) 312 (51.8)
Total 127 (21.1) 475 (78.9) 602 (100.0)
TABLE 97 Cross-tabulation of the presence of pain at a category 0, 1 or A skin site with the presence of skin
alterations at baseline
Skin alterations
Pain on a category 0, 1 or A skin site, n (%)
Total, n (%)Yes No
Yes 301 (50.0) 72 (12.0) 373 (62.0)
No 163 (27.1) 66 (11.0) 229 (38.0)
Total 464 (77.1) 138 (22.9) 602 (100.0)
TABLE 98 Cross-tabulation of the presence of a category 2 pressure ulcer at baseline with the presence of skin
alterations at baseline
Skin alterations
Category 2 pressure ulcer, n (%)
Total, n (%)Yes No
Yes 99 (16.4) 274 (45.5) 373 (62.0)
No 65 (10.8) 164 (27.2) 229 (38.0)
Total 164 (27.2) 438 (72.8) 602 (100.0)
TABLE 99 Cross-tabulation of Braden activity score with the presence of skin alterations at baseline
Skin alterations
Braden activity score, n (%)
Total, n (%)Bedfast Chairfast Walks occasionally Walks frequently
Yes 55 (9.1) 196 (32.6) 99 (16.4) 23 (3.8) 373 (62.0)
No 49 (8.1) 117 (19.4) 58 (9.6) 5 (0.8) 229 (38.0)
Total 104 (17.3) 313 (52.0) 157 (26.1) 28 (4.7) 602 (100.0)
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TABLE 100 Cross-tabulation of the presence of chronic wounds with the presence of skin alterations at baseline
Skin alterations
Chronic wound, n (%)
Total, n (%)Yes No
Yes 87 (14.5) 286 (47.5) 373 (62.0)
No 40 (6.6) 189 (31.4) 229 (38.0)
Total 127 (21.1) 475 (78.9) 602 (100.0)
TABLE 101 Cross-tabulation of the presence of pain on a category 0, 1 or A skin site with the presence of a
category 2 ulcer at baseline
Pain on a category 0, 1
or A skin site
Category 2 pressure ulcer, n (%)
Total, n (%)Yes No
Yes 103 (17.1) 361 (60.0) 464 (77.1)
No 61 (10.1) 77 (12.8) 138 (22.9)
Total 164 (27.2) 438 (72.8) 602 (100.0)
TABLE 102 Cross-tabulation of Braden activity score with the presence of pain on a healthy, altered or category 1
skin site at baseline
Pain on a category 0, 1
or A skin site
Braden activity score, n (%)
Total, n (%)Bedfast Chairfast Walks occasionally Walks frequently
Yes 71 (11.8) 239 (39.7) 128 (21.3) 26 (4.3) 464 (77.1)
No 33 (5.5) 74 (12.3) 29 (4.8) 2 (0.3) 138 (22.9)
Total 104 (17.3) 313 (52.0) 157 (26.1) 28 (4.7) 602 (100.0)
TABLE 103 Cross-tabulation of the presence of chronic wounds with the presence of pain at a category 0, 1 or A
skin site at baseline
Pain on a category 0, 1
or A skin site
Chronic wound, n (%)
Total, n (%)Yes No
Yes 105 (17.4) 359 (59.6) 464 (77.1)
No 22 (3.7) 116 (19.3) 138 (22.9)
Total 127 (21.1) 475 (78.9) 602 (100.0%)
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TABLE 104 Cross-tabulation of Braden activity score with the presence of a category 2 pressure ulcer at baseline
Category 2 pressure ulcer
Braden activity score, n (%)
TotalBedfast Chairfast Walks occasionally Walks frequently
Yes 30 (5.0) 78 (13.0) 50 (8.3) 6 (1.0) 164 (27.2)
No 74 (12.3) 235 (39.0) 107 (17.8) 22 (3.7) 438 (72.8)
Total 104 (17.3) 313 (52.0) 157 (26.1) 28 (4.7) 602 (100.0)
TABLE 105 Cross-tabulation of an existing category 2 pressure ulcer with the presence of chronic wounds
at baseline
Category 2 pressure ulcer
Chronic wound, n (%)
Total, n (%)Yes No
Yes 39 (6.5) 125 (20.8) 164 (27.2)
No 88 (14.6) 350 (58.1) 438 (72.8)
Total 127 (21.1) 475 (78.9) 602 (100.0)
TABLE 106 Cross-tabulation of Braden activity score with the presence of chronic wounds at baseline
Braden activity
Chronic wound, n (%)
Total, n (%)Yes No
Bedfast 15 (2.5) 89 (14.8) 104 (17.3)
Chairfast 63 (10.5) 250 (41.5) 313 (52.0)
Walks occasionally 36 (6.0) 121 (20.1) 157 (26.1)
Walks frequently 13 (2.2) 15 (2.5) 28 (4.7)
Total 127 (21.1) 475 (78.9) 602 (100.0)
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Appendix 10 Severe pressure ulcer study reduced
format protocol
NB: This study protocol (version 3, dated 4 Feb 2010) is in a reduced format including only 
the study aims, methods and ethical considerations.  Sections pertaining to study background 
have been removed as they are included as a chapter section. Information pertaining to 
confidentiality, archiving, statement of indemnity, study organisational structure, publication 
policy, and dissemination are available upon request. 
 
4 AIMS  
The aim of the research study is to identify the unexplained reasons which may contribute to 
the development of severe pressure ulcers, using innovative methods of investigation 
(Vaughan, 1996; Perrow, 1984; Waring et al., 2006; Pawson, 2006; 2008). 
 
5 STUDY DESIGN 
5.1 Brief Overview 
Following a similar approach to a public Inquiry (e.g. the tragic case of Victoria Climbié or 
the Bristol heart babies inquiry) the study will use a retrospective case study approach 
(Ragin, 2000). This involves examining patients with severe (Category 3 and 4) pressure 
ulcers, starting at the point where they have already developed. This study will seek to 
explain which non-clinical influences could lead to a patient developing a Category 3 and 4 
pressure ulcer. 
 
5.2.1 Stage 1 
This first stage will involve identifying one person who presents unexpectedly with a 
Category 3 or 4 pressure ulcer according to the TVT (see Nixon et al, 2007). It may be that 
the person has few known clinical risk factors for developing a severe pressure ulcer, yet 
develops one. The reason for choosing such a patient is that multiple clinical risks of 
developing a severe pressure ulcer may mask any underlying non-clinical influences. 
Therefore the aim is to keep clinical risk factors to a minimum at this stage. 
 
The overall purpose is to create a coherent account of what happens during the development 
of a severe (Category 3 or 4) pressure ulcer. By ‘coherent account’ we mean one which 
makes the best sense of available, yet relevant evidence, similar in nature to the process 
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police use when they build evidence against a suspect. We will sift through the accumulated 
evidence (environmental, individual and so forth), and look for other ‘clues’ about what may 
have a bearing on the person’s developing a Category 3 and 4 pressure ulcer. This will 
involve retrospective searching of a person’s care ‘pathway’, firstly talking to a patient about 
his or her experience of care from the start of the pressure ulcer, and searching all relevant 
healthcare documentation, to start to produce a coherent account. 
 
We will also talk to other people involved in a patient’s care pathway, such as informal and 
professional carers, nurses, and other relevant people, gaining their personal experience of the 
development of the severe pressure ulcer. This further information will help consolidate the 
coherence account as more evidence is uncovered. A timeline of events and a narrative 
chronology will be used to help with searching, and provide a basis to compare further patient 
experiences. This stage will conclude with tentative hypotheses about non-clinical 
explanations, such as we might find that a patient moving around different services seems to 
have an impact on their developing a Category 3 or 4 pressure ulcer, and this would then be a 
tentative hypothesis. We will provide feedback, and work closely with the Tissue Viability 
Team, to make sure the tentative hypotheses remain relevant to practice. 
 
5.2.2 Stage 2 
In our first protocol (v1.0) we proposed that we would develop the method as we carried out 
the research (see Section 8.1 Developing the method). While carrying out Stage 1, we found 
there were areas of potential bias which need addressing, and this has meant slight changes to 
the design of the study, collecting the data in a slightly different manner, and analysing the 
data differently. 
 
We have identified a need for: 
 a)  Closer professional involvement to help guide data collection  
 b) An expert panel to provide feedback on evidence. 
 c) A ‘good usual care’ account to balance the data 
 
Methodology 
After initial case note review, interview data collection and documentary analysis, the 
researcher will feed back findings at length to an on-site Principal Investigator (PI), who will 
conduct a parallel case note review and look over the initial patient interview. This will help 
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to interpret the data with expert advice. The researcher will then collect further data, which 
will be discussed again with the PI. This process will help the researcher construct a fully 
‘coherent account’ of how the pressure ulcer developed, which will remain grounded in 
practice and informed by professional judgement. 
 
Stages of expert involvement in the research process: 
Stage A (which is iterative, and stages can be repeated) 
Data collection Patient interview/patient notes (researcher) 
 
 
Parallel case note review by researcher and site principal investigator (PI)     
Researcher discusses data collection with Site Principal Investigator 
 
 
Researcher gathers more data, anonymises and builds coherent account in 
collaboration with PI 
 
 
Coherent account overseen by subgroup (n=3) consisting of two TVNs (not onsite PI: 
one hospital TVN; one community TVN) and one non-clinical academic 
 
 
Sub group comments incorporated into account 
 
 
Coherent account overseen by Chief Investigators of project team (n=2). Comments 
incorporated into account. 
The account will then be overseen by the Chief Investigators, who will help to create a final 
version of a coherent account of the second, and further cases, and limit any researcher bias 
as far as possible. 
 
At this point the data will be anonymised according to Leeds University Clinical Trials 
Research Unit guidelines on data confidentiality. The data will then be encrypted for further 
security, and to allow access by the rest of the research team. The anonymised and encrypted 
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coherent account of the first case will then be presented to a further panel of experts (which 
consists of two tissue viability nurse specialists and a non-clinical academic), who do not 
have direct clinical involvement with the patient. They will check the account for validity 
using evidence from the documentation, and their comments will be incorporated. This will 
help avoid individual researcher bias and provide a transparent trail of evidence (Yin, 1994).  
 
‘Good usual care’ account 
For all cases after Patient 1, we have chosen to combat some of the sources of bias, by 
constructing an account of ‘good usual care’. This normative account will provide a 
benchmark against which the care of the patients in the study can be judged. The ‘good usual 
care’ account will also provide a way of minimising effects of bias i.e.: 
i) Clinicians’ beliefs 
ii) PURPOSE team beliefs 
iii) Weighting of different perspectives in patient accounts 
iv) Hindsight bias 
 
The account will: 
1. Draw on national guidance such as the NICE guidelines key recommendations (RCN, 
2001; 2005). 
2. Include a summary of local site protocol recommendations as set out by the site 
Tissue Viability Nurse.  
3. Include information not available from points 1 and 2, which incorporates information 
from Tissue Viability Nurse specialists as expert witnesses, and further information 
from interviews with various stakeholders. 
4. Be mapped against the actual chronological events within a case to look for points of 
commonality and for events which do not meet the ‘good usual care’ criteria. 
 
Please see below for a summarised example account strategy, as it would be mapped against 
actual chronological events. The account will be more detailed, and consists of two tables, 
one which incorporates key events by data source, and these are then cross referenced to our 
external judgement criteria table: 
 
Source of data (below) Time 1 Time 2 Time 3 
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 30 March 2009  
(patient notes) 
2 April 7pm 2 April 9pm 
Patient/nursing notes Significant event 1 
Patient admitted for 
surgery with SPU. 
Event 2 
Patient prepared for 
surgery. 
Event 3 
Patient returned 
from surgery. 
Patient’s version of 
events 
Waiting since 
January for surgery. 
  
Consultant’s version of 
events 
  Consultant 
instructed patient 
to be turned L and 
R side every 3 
hours. 
Ward Manager’s version 
of events 
  Patient was being 
difficult about 
turns. 
Significant others’ 
version of events, e.g. 
TVN, HCA, Informal 
carer 
  Nurses note turns  
Organisational 
information/details 
Patient admitted to a 
surgical ward. 
 Ward really busy. 
Understaffed 
(staff off duty) 
 
The above data sources will be cross tabbed against external criteria as follows: 
 Event 1 Event 2 Event 3 
 Patient not risk assessed 
(no record in notes) 
Patient admitted 
onto ward and not 
turned 
 
Local protocol 
guidelines 
Patient should be Risk 
assessed using 
Waterlow scale, Care 
plan written up… 
Turning regime 
should be followed 
as per patient care 
plan. 
Ward requires one 
qualified staff per 
patient at all times 
NICE guidelines Patients should receive  All patients should be 
DOI: 10.3310/pgfar03060 PROGRAMME GRANTS FOR APPLIED RESEARCH 2015 VOL. 3 NO. 6
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Nixon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
345
initial and ongoing PU 
assessment. Ulcer 
assessment should 
include: cause of 
ulcer…etc. 
monitored post op etc. 
Specific clinical/co 
morbid risks for 
patient 
Older age, diabetes  There is a risk post op 
of low blood pressure. 
Expert witness 
account of usual 
care 
Normally patients will 
receive a care plan 
assessment, and will 
always undergo a Risk 
assessment.  
  
Weighted 
evidence. Does the 
event meet 
expected criteria? 
   
 
 
The first case, from Stage 1 will be compared with 4 or 5 further cases. These will be selected 
to present with the widest possible range of personal and service characteristics (see Inclusion 
Criteria). We will use evidence from this stage to refine the initial coherence account. It may 
be that there are no plausible explanations at this point, in which case another patient will be 
chosen with an unexpected pressure ulcer or few known clinical risk factors once again. 
Again, the aim will be refining the coherence account of the patient’s experience, using the 
same methods of gathering evidence as in Stage 1.  
 
Using a ‘building block’ approach to sampling (Blaikie, 2000; Pawson, 2006) more cases will 
be selected which are best able to help develop explanations. The coherence account will 
become more refined as up to 6 more cases are compared (a maximum of 12 cases). 
Hypotheses around plausible explanations why a patient should develop a severe pressure 
ulcer, will be confirmed or refuted as more evidence is gathered (see Ragin, 2000). This may 
be apparent by just a few patients, or may need all 12 patients before we are able to start to 
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make generalisations. This might also involve retracing steps and looking for further 
evidence to elaborate the existing coherence account, as further evidence is uncovered.  
In this stage, and through all stages of the research, we will work closely with the Tissue 
Viability Team (TVT) and provide regular feedback to staff verbally, and with summary 
reports, so that the explanations we offer remain constantly relevant to practice. For example; 
if a patient’s movement through services appears, once again, to have a possible impact on 
severe pressure ulcer development, we would look to confirm this hypothesis with further 
cases. Stage 2 will conclude with a refined version of the coherence account, which will be 
used to produce an explanatory model to explain why patients develop Category 3 and 4 
pressure ulcers.  
 
The model(s) will be implemented into a critical incident/adult neglect review protocol as 
part of future joint work with Study 3 (NIHR Pressure Ulcer Programme). This will also 
inform a severe pressure ulcer risk assessment framework. See flowchart 5.3 below. 
 
Sections 6, 7, 8 METHOD (INCLUDING ANALYSIS)   
6 ELIGIBILITY 
6.1 Inclusion Criteria 
(Stage 1) will include one participant who has few clinical risk factors, e.g. an elective 
orthopaedic patient (Nixon, 2007) who presents with a Category 3 or 4 Pressure Ulcer.  
 
Table 1. EPUAP Pressure Ulcer Classification System4 
Category Description 
Category 0 Normal 
Category 1 
Non-blanchable erythema of 
intact skin 
Intact skin with non-blanchable erythema of a localised area 
usually over a bony prominence. Discolouration of the skin, 
warmth, oedema, hardness or pain may also be present. 
Darkly pigmented skin may not have visible blanching. 
Category 2 
Partial thickness skin loss or 
blister 
Partial thickness loss of dermis presenting as a shallow 
open ulcer with a red pink wound bed, without slough. May 
also present as an intact or open/ruptured serum or sero-
sanginous-filled blister. 
Category 3 Full thickness tissue loss. Subcutaneous fat may be visible 
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Full thickness skin loss but bone, tendon or muscle are not exposed. Some slough 
may be present. May include undermining and tunnelling. 
Category 4 
Full thickness tissue loss 
Full thickness tissue loss with exposed bone, tendon or 
muscle. Slough or eschar may be present. Often includes 
undermining or tunnelling. 
Category U Unstageable 
 
 
5.3 Flowchart of research design:    
        
Tentative hypotheses about non-
clinical explanations for SPUs 
Stage 1 
Identify one person with Category 3 or 4 pressure ulcer. 
Create a coherence account based on all relevant and 
retrospective documentation/narratives from the patient and 
relevant people involved during their care. 
Stage 2 
4-5 more cases selected to maximise variation and presentation. 
Refine the coherence account. 
Review up to 6 more cases as necessary. 
Feedback to stay relevant to practice. 
Refined coherence account. 
Implementation 
Minimum Data Set 
Critical Incident Review Methodology 
Risk Assessment Framework 
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For Stage 2, four or five patients from participating acute and community trusts will be 
chosen if they have had or have currently a Category 3 or 4 pressure ulcer (EPUAP 2008). 
These may include hospital in-patients, hospital out-patients, intermediate care or community 
patients under the care of community nursing services. This stage will aim to maximise 
variation and presentation of severe (Category 3 and 4) pressure ulcers. The sample will also 
be monitored for anatomical site of the pressure ulcer (e.g. heel, sacrum, buttocks) to allow 
for variation amongst patients. Further participants will be chosen following the procedures 
set out in the research design. 
 
6.2 Exclusion Criteria 
Patients who it would be ethically inappropriate to approach, for example, those where death 
is imminent, will not be approached. 
 
Additionally, patients who are unable to tell their story (narrative) of their experience will be 
excluded, as this forms part of the main design of the study. 
 
7 RECRUITMENT AND CONSENT PROCEDURE 
7.1 Patients (ward based) 
Members of the tissue viability team (TVT) which includes the local principal investigator 
and other members of their local team (i.e. tissue viability nurse specialists and clinical 
research nurses) at participating trusts will screen potentially eligible patients through critical 
incident reporting systems, healthcare records and referrals. The patients will be approached 
by a member of the TVT, informed about the study, and provided with a project information 
leaflet which includes details about the rationale, design, and personal implications of the 
study and an ‘agree to be contacted by the researcher’ form. Members of the TVTs at 
participating trusts will provide an anonymous record of patients identified as potentially 
eligible, approached to participate, refusals, and those agreeing to be contacted.  
 
Following information provision, patients will have as much time as they need to discuss the 
study with their family, advocate, carers, and healthcare provider. They will be asked to 
complete the ‘agree to researcher contact’ form, which will be posted back to the Centre for 
Health and Social Care. The TVT and the researcher will be available to answer any 
questions that patients might have about the study. After receiving the signed ‘agreement to 
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be contacted’ form from the patient, the researcher will contact the patient, carer, healthcare 
professional etc. to arrange a convenient time for possible interview and written consent. The 
researcher will provide information about the study and interview process and will answer 
any questions before gaining verbal consent and arranging an interview at a mutually 
convenient time. For in-patients who cannot be contacted by telephone and who are expected 
to be in the hospital during the interview, the TVT member will liaise with the researcher and 
patient to arrange a mutually convenient time for the researcher to see the patient on the ward 
to discuss the study further, and seek written consent or conduct an interview.   
 
The researcher will interview patients in their own home, in the out-patient clinic, or in-
patient ward, as determined by the patient’s circumstances and preferences at the time of the 
interview. Before the interview, each participant will be given a further verbal explanation of 
the study by the researcher, informed that the interview will be recorded but that all 
identifiable information will remain anonymous, reminded that they can withdraw from the 
study at any time without it affecting their care, and then invited formally to participate. They  
will be given an opportunity to ask any questions and then if they agree to take part, the 
participant will be asked to sign the consent form. A copy of the consent form will be given 
to the patient to keep, one copy will be filed in their healthcare records, and the original will 
be kept by the researcher and filed securely in the Study Master File at the Centre for Health 
and Social Care.  
 
The right of the patient to refuse consent without giving reasons will be respected.  Further, 
the patient will remain free to withdraw from the study at any time, again, without giving 
reasons and without prejudicing any further treatment. 
  
7.2 Patients based in the community 
A similar approach to the above ward-based procedure will be followed; however this will 
involve a third stage: 
 
Members of the tissue viability team (TVT) will screen potentially eligible patients through 
critical incident reporting systems, healthcare records and referrals. The patients will be 
approached by a member of the TVT, informed about the study, and provided with a project 
information leaflet, which includes details about the rationale, design, and personal 
implications of the study, and an ‘agree to be contacted by the researcher’ form. Members of 
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the TVTs at participating trusts will provide a record of those identified as potentially 
eligible, approached to participate, refusals, and those agreeing to be contacted. 
 
Following information provision, patients will have as much time as they need to discuss the 
study with their family, advocate, carers, and healthcare provider. They will be asked to 
complete the ‘agree to researcher contact’ form, which will be posted back to the Centre for 
Health and Social Care). The TVT and the researcher will be available to answer any 
questions that patients might have about the study.  
 
After receiving the signed ‘agreement to be contacted’ form from the patient, the researcher 
will accompany a TVT member and personally introduce the researcher to the patient in their 
home. The researcher will provide information about the study and interview process and will 
answer any questions before gaining possible verbal consent, and then arranging an interview 
at a mutually convenient time, where written consent will be sought. This will allow for the 
patient to feel more comfortable with the researcher at a second meeting, as part of the study 
is to get a narrative account from the patient’s perspective. In this way, the patient will feel 
also less vulnerable being alone with the researcher. 
 
7.3 Stakeholders involved in the patient’s care ‘pathway’, for example their informal 
carer, advocate, nursing staff, paid carer, other healthcare provider. 
After the patient has been approached, given his or her consent, and interviewed, carers and 
healthcare professionals involved throughout their care pathway will be sought out through 
the patient interviews and examination of the patient’s healthcare records, and any other 
documentation concerned with their care, and using an approach similar to that of patient 
recruitment, except that carers and staff will be approached directly (face to face or by phone) 
and asked if they would be interested in participating. Information will be provided about the 
study and a ‘cooling off’ time will be allowed before their consent is sought to take part. The 
guidelines will follow those of the patient consent procedure apart from this initial difference 
in approaching participants. A snowballing technique will be used to enlarge the sample until 
data saturation is reached.  
 
8 PROCEDURES/DATA COLLECTION/ANALYSIS 
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In principal patient interviews will be undertaken prior to documentary analysis to ensure the 
researcher does not absorb any preconceived ideas from patient documentation about the 
causes of severe pressure ulcers. A step by step approach will be used: 
 
8.1 Stage 1 (Case 1)  
Developing the method (see Perrow, 1984; Vaughan, 1996) 
1. An in-depth interview with the patient (and carers if appropriate) to gain his or her 
personal story of how their pressure ulcer developed. Interviews will be recorded  
2. The researcher will then access patient case notes/healthcare records and patient held 
records. Nurses, GPs and other healthcare professionals who have a responsibility 
regarding their patient’s records will be kept fully informed of the study, and a 
mutually convenient time will be arranged to access the records. We will examine the 
notes using a range of practical tools:  
a. Timelines to record the main sequence of event s (e.g. movements between wards)  
b. Records of where key players were and other relevant people, 
c. Chronological accounts of key events, sometimes referred to as clinical incident 
sheets  
 
We may use other methods, which will be identified while collecting data, to help further 
with our systematic searching. All the documentary analysis will be done on site, e.g. NHS 
ward, patient’s home, care home, which will avoid issues with confidentiality. 
 
We will use the data to create a coherence account, as described in Section 5. The analysis 
will run in parallel with data collection, and begin after the first interview. The academic 
process involves developing a clear account using and refining our evidence, and ‘this 
interaction of ideas and evidence leads to theories based on what we have analysed’ (Ragin, 
1994). Software (NVivo 8; QSR) will be used as an aid to organise and categorise the data.  
 
Other people will be sought out who are relevant to the patient’s story of how their pressure 
ulcer started. These participants will also be chosen according to what evidence is found from 
relevant documentation. We will conduct in-depth interviews with the chosen participants 
(see Topic guide). The people chosen in Step 3 are likely to include informal and professional 
carers, nurses and other professionals involved in the care of the patient, but they could be 
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anyone who has been identified as having an influence in the development of the pressure 
ulcer, by the patient or by documentary evidence.  
 
8.2 Stage 2 (cases 2, 3, 4, 5, 6 up to 12) 
We will use the same methods of data collection as Stage 1 for the next four or five more 
cases. In-depth interviews and documentary evidence will be used to help refine our 
coherence account. We will then continue to collect data for more cases (up to 12) to refine 
the coherence account. 
 
If we have to review the first case, or previous cases, to look for more evidence which 
supports newly uncovered insights (see study design) and refine our coherence account we 
will do this looking for newly relevant data.  As the data set builds, the process of analysis 
will be refined and more causal explanations will be generated until saturation point is 
reached. Verbal feedback and summary reports will be sent to Tissue Viability team. 
 
The findings and conclusions drawn will provide a structured, theory informed basis from 
which to develop an adult incident critical incident methodology and risk assessment 
protocol. The findings will be used in practice at pilot sites, if the models are found to be 
explanatory. 
 
8.3 Flow chart of data collection /consent seeking process: 
 
Possible patients identified using critical incident reporting and caseload review by 
TVTs, and according to minimum clinical risk factors 
  
 
TVTs contacts researcher and researcher identifies first case 
 
 
TVT approaches patient to seek ‘researcher contact’ 
 
 
Researcher contacts the patient to seek verbal consent and arrange interview 
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 Researcher conducts in-depth interview with patient  
 
 
Researcher searches documents and healthcare records related to patient pathway. 
 
 
Researcher seeks consent for interview from other relevant stakeholders in patient 
pathway (identified in patient documents/interviews). 
 Tentative hypotheses developed arising from case 1  
 
 
4 -5 further cases identified using hypotheses/potential explanations from Case 1 
   
 
Process repeats until no more potential explanations can be found. 
   
 
9 DATA ANALYSIS 
The analysis of the interview and documentary data will be conducted in parallel with the 
data collection (see Section 6). This will include ongoing analysis following the procedures 
set out in the study design (Section 5), i.e. sifting through and refining the data over and over 
again until causal explanations are produced.  NVivo 8 (QSR) software will be used to 
organise the data.   
 
 12 ETHICAL CONSIDERATIONS 
This project will recruit patients with Category 3 and 4 PUs and will therefore include elderly  
and highly dependent patients considered as vulnerable. Ethical issues relate to the 
involvement of vulnerable adults/elderly patients with high levels of co-morbidity including 
acute and chronic illness. The study also raises ethical issues in relation to recruiting patients 
who may have fluctuating lack of capacity; however this will be assessed at the time of 
consent seeking. The ethical issues surrounding these potentially vulnerable patients have 
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been addressed through the study design and include a thought out consent process, which 
also follows current Mental Capacity Act guidelines.  
If any patient or other person involved in his or her care pathway were to disclose an instance 
of abuse or neglect, this subject will be discussed with the patient, and the researcher will 
inform the closest professional or carer depending on the circumstances. This will be 
explained to the participant before the interviews take place.   
 
The study will be submitted to and approved by a flagged Research Ethics Committee (REC) 
prior to identifying eligible patients. The Centre for Health and Social Care will provide the 
REC with a copy of the final protocol, patient, staff and informal caregiver information 
leaflets, consent forms, and all other relevant study documentation. 
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Appendix 11 Severe pressure ulcer study
participant information leaflet and agree to research
contact form
 [Delete this line then print on Trust headed paper] 
Why do patients develop severe pressure ulcers? Patient interviews 
(community based; version 3 (04/02/2010) 
We would like to invite you to take part in a research project. Before you decide to take part, 
it is important for you to understand why the research is being done and what it would 
involve for you. Please take the time to read the following information carefully and discuss it 
with your relatives and your ward nurse or carer if you wish. Ask us if there is anything that 
is not clear or if you would like more information. Part 1 tells you the purpose of this project 
and what will happen to you if you take part. Part 2 gives you more detailed information 
about the conduct of the study. 
 
Part 1 
What is the purpose of the study? 
The development of a severe pressure ulcer (PU), also called a bed sore or pressure sore, has 
serious consequences for everyone involved. For patients, they cause much suffering and 
pain. For staff involved in the care of someone with a severe pressure ulcer, they are now 
seen as what is called a ‘serious clinical incident’, and require investigation into the causes. 
For carers they are a major worry, and an obstacle to caring. 
 
This study is about trying to find out the reasons why people develop severe pressure ulcers 
which may not always be clinical ones. One of the purposes of this study is to see whether the 
causes may be down to healthcare system weaknesses, rather than to individual weaknesses 
or blame. The study involves interviewing patients like yourself, and all the people involved 
in your care throughout the development of your severe pressure ulcer, to see if there are any 
general underlying patterns which lead to developing a severe pressure ulcer. The study also 
aims to uncover any other reasons for developing a severe pressure ulcer, which may have 
not yet been noticed. The final aim of the study is to help produce a risk assessment tool, 
which will try to help prevent severe pressure ulcers from developing. 
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Why have I been invited? 
You have been chosen to take part because we are interested in talking to people who have 
experience of having severe pressure ulcers. Any person who has, or has had in the past, a 
severe pressure ulcer, from a sample of either hospitals or within the community, will be 
asked to participate.  
 
Do I have to take part? 
You are under no obligation to take part in this study, it is up to you to decide. We will 
describe the study to you and go through this information sheet.  If you agree to take part we 
will then ask you to sign a consent form to show that you have agreed to take part. You will 
be given a copy of this information sheet and the consent form for you to keep. You are free 
to withdraw at any time, without giving a reason. This would not affect the standard of care 
you receive. If you do not wish to take part this will not affect the care that you are currently 
receiving. 
 
What will happen to me if I take part? 
If you agree to take part, you will be introduced to the researcher, who will be accompanied 
by the tissue viability nurse. This will give you an opportunity to ask questions about the 
study. If you then still wish to take part, the researcher will arrange an interview with you. It 
is expected that the interview will take about an hour. We will make sure the interview takes 
place in as private a place as possible, either in your own home or on the ward where you are 
admitted, at a time convenient for you. The interview will be informal, in a conversation 
style, rather than a list of questions.  
 
The researcher will also seek permission to access and analyse your case notes, to look into 
what possibly led to you developing a severe pressure ulcer. Your nurses and carers/relatives 
will be approached to participate in the research and provide information relating to your 
care. No further involvement from you is required. 
  
The discussion that you have with the interviewer, with your permission, will be tape 
recorded and transcribed to help us analyse it. The tape recording will be used only by 
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researchers involved in the project and it will be stored in a locked cabinet. As soon as the 
information on the tapes in analysed, the tapes will be destroyed. 
What are the possible disadvantages and risks of taking part? 
We do not foresee any disadvantages or risks to you in taking part in this study. However, 
you are being asked to give some of your time and you will need to reflect on your personal 
experience of having a severe pressure ulcer and what your experience of care has been. 
There is a possibility that you may find this distressing. The interview can be stopped at any 
point if you feel you do not want to continue. If necessary, a referral can be made to your 
nurse or other healthcare professionals if you are distressed at all by the interview. 
 
What are the possible benefits of taking part?  
We hope that being given the opportunity to take part in this study would give you some 
satisfaction that you are contributing to increasing knowledge about the reasons and risks 
behind why people develop severe pressure ulcers. We hope that the information we get from 
the interviews will help to inform healthcare services about patterns in a person’s care 
pathway which may be more likely to lead to the development of a severe pressure ulcer. We 
also hope to help produce a risk assessment to help prevent severe pressure ulcers from 
occurring. 
 
Will my taking part in this study be kept confidential? 
Yes. All information which would be collected about you during the course of the study will 
be kept strictly confidential. We will follow ethical and legal practice and all information 
about you will be handled in confidence.  In the event that any evidence of poor practice, 
neglect or abuse is identified during the course of the interview, the researcher might need to 
disclose details to a third party outside of the interview.  This would not be done without 
discussing it with you first. Details are included in Part 2. 
 
This completes part 1. 
If the information in Part 1 has interested you and you are considering participation, please 
read the additional information in Part 2 before making any decision. 
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Part 2 
What will happen if I don’t want to carry on with the study? 
You are free to change your mind at any point up to, during or following the interview. You 
will not be able to be identified in the study results but if you wish to withdraw any data 
already collected prior to publication of the results then arrangements can be made for the 
interview tape to be destroyed and your discussion excluded from the study. 
 
Will my taking part in this study be kept confidential? 
The procedures for handling, processing, storage and destruction will be according to the 
Caldicott principles and the Data Protection Act 1998. 
 
Lisa Pinkney and her supervision team have a duty of confidentiality to you as a research 
participant and will do their very best to meet this duty. Any information that is collected 
about you will have your name and address removed so that you cannot be recognised. All 
information will be kept in locked cupboards and will only be accessible by members of the 
research team. No names or details that would identify specific people will be included in the 
outputs from this study. Outputs, including quotations from interviews, may be used in 
reports, presentations and papers, and for healthcare and/or medical research, but these will 
not be traceable to specific individuals. All published and unpublished reports will disguise 
the identity of people.  
 
What will happen to the results of the research study?  
Participants will not be identified in any report or publication. The study results will be used 
to inform healthcare provision, and to help produce a risk assessment tool, based on the 
information gathered from participants. Information from this study will be included in a final 
report and published in a scientific journal. 
 
Who is organising and sponsoring the research? 
This study is funded by the National Institute of Health Research, which is part of a larger 
pressure ulcer research programme aimed to reduce the impact of PUs on patients, and to 
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produce a risk assessment framework to help prevent pressure sores. This study is also being 
undertaken as part of a PhD qualification supervised by the University of Leeds.  
 
Who has reviewed the study? 
This study has been peer reviewed by the National Institute of Health Research before 
approval for funding was given. In addition, all research in the NHS is looked at by an 
independent group of people called a Research Ethics Committee to protect your safety, 
rights, wellbeing and dignity. This study has been reviewed and given approval by the Leeds 
West Research Ethics Committee. 
 
What do I do now? 
Once you have read the information and if you would like to take part in the study, please tell 
your district nurse or tissue viability nurse who provided you with this information leaflet. 
They will complete the Agree to Researcher Contact Form at the end of this leaflet and send 
it back to the researcher, Lisa Pinkney, who will contact you upon receiving the form, to 
discuss this study further (with your tissue viability nurse present) and then arrange a time for 
the interview. 
 
Further information and contact details 
Thank you for taking the time to read this leaflet and for considering this study. If you would 
like to discuss the study further or have any questions about the study at any time, please 
contact the researcher, Lisa Pinkney on 0113 343 0828 or the study supervisor,  Professor 
Justin Keen on 0113 3436941 or speak to your district nurse or tissue viability nurse who 
provided you with this information sheet. 
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[Delete this line then print on Trust headed paper- given with study information] 
PATIENT AGREEMENT TO RESEARCHER CONTACT 
 
Name of researcher:     Lisa Pinkney 
      Centre for Health and Social Care 
      University of Leeds 
      Leeds Institute of Health Sciences 
101 Clarendon Road 
Leeds 
LS2 9LJ 
      0113 343 0828 
 
Name of consultant/nurse:    __________________________ 
Contact number:    __________________________  
 
Why do patients get severe pressure ulcers? Patient interviews 
 
Please initial the boxes: 
• I have read the information sheet (version 3) and kept a copy. 
 
• I am happy to be contacted by the above named researcher to discuss the study further 
(with a tissue viability nurse present) 
 
Please complete your contact details in the space provided 
Patient name ________________________________________________________ 
Address ____________________________________________________________ 
___________________________________________________________________ 
____________________________________Postcode________________________ 
Telephone Number ___________________________________________________ 
Preferred contact time _________________________________________________ 
 
Thank you for completing this form. Please return to Lisa Pinkney at Centre for Health 
and Social Care, Room 2.02, LIHS, University of Leeds, 101 Clarendon Road, Leeds, LS2 
9LJ or phone 0113 343 0828. 
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Appendix 12 Severe pressure ulcer study
consent form
[Delete this line then print on headed paper] 
Why do patients develop pressure ulcers? Consent form version 3 (4/2/2010) 
 
Name of researcher:  Lisa Pinkney 
Address: Centre for Health and Social Care, University of Leeds, Institute of  
Health Sciences, 101 Clarendon Road, Leeds, LS2 9LJ Telephone: 0113 3430828 
 
 
1. I confirm that I have read and understand the information sheet for the above study 
Version 3 dated 4/2/2010and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my nursing care being affected. 
 
3. I understand that the above named researcher may ask my nurse, caregiver or other people 
relevant to my care, additional information about my pressure ulcer history and relevant 
treatment. I give permission for the researcher to access my healthcare records e.g. hospital 
nursing, and GP records to obtain further information for the above study and any further 
research that may be conducted in relation to it, provided that strict confidentiality is 
maintained. 
 
4. I agree that my interview will be tape recorded and typed out, maintaining anonymity. 
 
5. I agree to allow any information arising from this study to be used for healthcare and/or 
medical research purposes. I understand my identity will remain anonymous. 
 
6. I consent to the storage including electronic, of personal information for the purposes of 
this study. I understand that any information that could identify me will be kept 
confidential and that no personal information that could identify me will be included in  
the study report or other publication.  
 
7. I understand that a copy of this Consent Form will be sent to the Centre for Health and 
Social Care and my GP. 
 
8. I agree to take part in the above study. 
 
___________________  _____________ _________________ 
Name of Patient   Date    Signature 
 
I have given written information and a verbal explanation to the person named above who has 
freely given their consent to participate. 
 
___________________ _____________ _________________ 
Name of Person   Date    Signature 
taking consent 
 
(When completed, 1 for patient, 1 for patient file; 1 for CHSC) 
Please initial box 
after each question 
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Appendix 13 Severe pressure ulcer study topic
guide
‘Why do patients develop severe pressure ulcers?’ study
Researchers: Lisa Pinkney, Professor Justin Keen, Dr Jane Nixon
Address: Centre for Health and Social Care, University of Leeds, Leeds, LS2 9LJ
Tel.: 0113 343 0828
Interview topic guide: patients
(Verbal introduction . . .) Have you any questions about this study? Are you happy to start the interview?
This interview will be unstructured and informal and guided by you, not by a set of questions. However,
as an opening question . . .
Introductory question: Why do you think you developed a severe pressure ulcer?
Some topics that will be covered but which are only tentative topics and which will be developed as the
research progresses:
l background/history of events
l severe pressure ulcer description
l timeline of events – micro, mezzo and macro levels
l interpersonal level
l people involved
l support systems – people, services
l clinical risks
l unexpected events
l communication
l service involvement.
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Appendix 14 Search strategies and data sources
Search strategy for the systematic review of patient risk
factors for pressure ulcer development
Four electronic databases, AMED, MEDLINE, EMBASE and CINAHL, were searched from inception until
March 2010 through the Ovid web gateway from their inception using the search template detailed
below. The search plan included pressure ulcer search terms and Ovid maximum sensitivity filters for
prognosis and aetiology or harm.
1. decubitus.sh.
2. skin ulcer.sh,tw.
3. exp decubitus ulcer/
4. decubitus ulcer$.tw.
5. PU$.tw.
6. pressure damage$.tw.
7. pressure sore$.tw.
8. bed sore$.tw.
9. or/1-8
10. exp cohort-studies/
11. exp risk/
12. (odds and ratio$).mp. [mp=title, original title, abstract, name of substance word, subject
heading word]
13. (relative and risk$).mp. [mp=title, original title, abstract, name of substance word, subject
heading word]
14. (case and control$).mp. [mp=title, original title, abstract, name of substance word, subject
heading word]
15. or/10-14
16. incidence.tw.
17. exp mortality/
18. Follow-Up Studies/
19. prognos$.tw.
20. predict$.tw.
21. course.tw.
22. Survival Analysis/
23. or/16-22
24. 9 and 15
25. 9 and 23
26. 24 or 25
27. case report.sh.
28. historical article.pt.
29. review of reported cases.pt.
30. review, multicase.pt.
31. letter.pt.
32. comment.pt.
33. editorial.pt.
34. or/27-33
35. 26 not 34
36. limit 35 to humans
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The first 200 retrieved abstracts were screened and key words from non-relevant papers were identified
and used to further refine the search (i.e. increase specificity):
37. leg ulcer.mp. [mp=ab, hw, ti, it, sh, tn, ot, dm, mf, nm]
38. varicose ulcer.mp. [mp=ab, hw, ti, it, sh, tn, ot, dm, mf, nm]
39. pilonidal.tw.
40. surgical flaps.mp. [mp=ab, hw, ti, it, sh, tn, ot, dm, mf, nm]
41. skin transplantation$.mp. [mp=ab, hw, ti, it, sh, tn, ot, dm, mf, nm]
42. burn$.mp. [mp=ab, hw, ti, it, sh, tn, ot, dm, mf, nm]
43. gunshot.mp. [mp=ab, hw, ti, it, sh, tn, ot, dm, mf, nm]
44. corneal ulcer.mp. [mp=ab, hw, ti, it, sh, tn, ot, dm, mf, nm]
45. exp dentistry/
46. peptic ulcer.mp. [mp=ab, hw, ti, it, sh, tn, ot, dm, mf, nm]
47. duodenal ulcer.mp. [mp=ab, hw, ti, it, sh, tn, ot, dm, mf, nm]
48. stomach ulcer.mp. [mp=ab, hw, ti, it, sh, tn, ot, dm, mf, nm]
49. fistula$.mp. [mp=ab, hw, ti, it, sh, tn, ot, dm, mf, nm]
50. bite.tw.
51. or/37-50
52. 36 not 51
Hand searching
The following specialist journals and conference proceedings were hand searched.
Journals
l Journal of Tissue Viability, 1990 to present.
l Journal of Wound Care, 1991 to present.
l European Pressure Ulcer Advisory Panel reviews, volume 1, issue 2, 1999 to volume 7, issue 2, 2006.
Conference proceedings
l Proceedings of the 1st European Conference on Advances in Wound Management, September 1991,
Cardiff, UK.
l Proceedings of the 2nd European Conference on Advances in Wound Management, October 1992,
Harrogate, UK.
l Proceedings of the 3rd European Conference on Advances in Wound Management, October 1993,
Harrogate, UK.
l Proceedings of the 4th European Conference on Advances in Wound Management, September 1994,
Copenhagen, Denmark.
l Proceedings of the 5th European Conference on Advances in Wound Management, November 1995,
Harrogate, UK.
l Proceedings of the 6th European Conference on Advances in Wound Management, October 1996,
Amsterdam, the Netherlands.
l Proceedings of the 7th European Conference on Advances in Wound Management, November 1997,
Harrogate, UK.
l Proceedings of the 8th European Conference on Advances in Wound Management, April 1998,
Madrid, Spain.
l Proceedings of the 9th European Conference on Advances in Wound Management, November 1999,
Harrogate, UK.
l Proceedings of the 10th European Conference on Advances in Wound Management, May 2000,
Stockholm, Sweden.
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l Proceedings of the 11th Conference of the European Wound Management Association, May 2001,
Dublin, Ireland.
l Proceedings of the 12th Conference of the European Wound Management Association, May 2002,
Granada, Spain.
l Proceedings of the 13th Conference of the European Wound Management Association, May 2003,
Pisa, Italy.
l Proceedings of the 15th Conference of the European Wound Management Association, September
2005, Stuttgart, Germany.
l Proceedings of the 16th Conference of the European Wound Management Association, May 2006,
Prague, Czech Republic.
l Proceedings of the European Wound Management Association and Journal of Wound Care
Conference, April 1997, Milan, Italy.
l Proceedings of the European Wound Management Association and Journal of Wound Care Autumn
Conference, November 1998, Harrogate, UK.
l 2nd World Union of Wound Healing Societies Meeting, July 2004, Paris, France.
l Journal of Wound Healing 2nd Conference, September 2005, Stuttgart, Germany.
l Wounds UK Conference, November 2004, Harrogate, UK.
l 1st European Pressure Ulcer Advisory Panel Open Meeting, September 1997, Oxford, UK.
l 2nd European Pressure Ulcer Advisory Panel Open Meeting, September 1998, Oxford, UK.
l 3rd European Pressure Ulcer Advisory Panel Open Meeting, September 1999, Amsterdam,
the Netherlands.
l 4th European Pressure Ulcer Advisory Panel Open Meeting, September 2000, Pisa, Italy.
l 5th European Pressure Ulcer Advisory Panel Open Meeting, September 2001, Le Mans, France.
l 6th European Pressure Ulcer Advisory Panel Open Meeting, September 2002, Budapest, Hungary.
l 7th European Pressure Ulcer Advisory Panel Open Meeting, September 2003, Tampere, Finland.
l 8th European Pressure Ulcer Advisory Panel Open Meeting, May 2005, Aberdeen, Scotland.
l European Tissue Repair Society, Focus Meeting, November 2000, St Anne’s College, Oxford, UK.
l European Tissue Repair Society, Annual Conference, September 2001, Cardiff, UK.
l European Tissue Repair Society, Focus Meeting, September 2002, Nice, France.
l 13th Annual European Tissue Repair Society Meeting, September 2003, Amsterdam, the Netherlands.
l European Tissue Repair Society, Focus Meeting, March 2005, Southampton, UK.
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Appendix 15 Example evidence table for
subdomain oedema
Author
and year
Study
quality
Study
limitation
notes
Study
design
PU
events/sample
Specific
variable OR CI
Study
population
aCompton
et al.
2008144
Low-
quality
study
Record review.
Large number of
events but used
32 variables in
the model. No
CIs reported
Record
Review
121/698 Skin
condition
oedematous
skin
2.245 NR Acute care
hospital, ICU,
non-surgical
Nijs et al.
2009159
Moderate-
quality
study
Full details of
modelling not
provided.
Adequate
number of
events is
assumed as large
number of
events
Cohort 134/463 Pitting
oedema
NR NR Acute care
hospital, ICU,
surgical
Bergquist
and Frantz
1999134
Low-
quality
study
Record review
and insufficient
number of
events.
Inadequate
measurement of
risk factors
Record
Review
55/1567 Oedema NR NR Community/
home care,
elderly/
geriatric,
non-surgical
Donnelly
2006146
Low-
quality
study
Insufficient
number of
events and no
CIs reported
RCT 39/239 Oedema HR
1.023
NR Acute care
hospital,
elderly/
geriatric, hip
fracture
HR, hazard ratio; ICU, intensive care unit, NR, not reported; RCT, randomised controlled trial.
a Study in which the specific variable emerged as a risk factor in multivariable analyses; in all other studies the specific
variable did not emerge as a risk factor in multivariable analyses.
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Appendix 16 Consensus study reduced format
protocol
NB: This study protocol (version 2, dated 14 September 2010) is in a reduced format 
including only the study aims, methods and ethical considerations.  Sections pertaining to 
study background have been removed as they are included as a chapter section. Information 
pertaining to quality assurance, confidentiality, archiving, statement of indemnity, study 
organisational structure, funding, and publication policy are available upon request 
 
4.1 Study aims 
This study aims to: 
1. Agree a Pressure Ulcer Minimum Data Set (PU-MDS) 
2. Develop an evidence based Pressure Ulcer Risk Assessment Framework (PURAF) for 
use in clinical practice. 
 
5 STUDY DESIGN 
5.1. Overview of Study Design 
This study will utilise structured consensus methods and will be underpinned by a PU risk 
factor systematic review (Nixon et al) and emerging evidence from the PURPOSE studies.  
 
5.2 Overview of Consensus Process 
 
ASPECT Month Event Activity 
PU-
MDS 
 Sept 2010 Working 
Group 
 
Pre nominal group work-up: 
• Identify specific issues to be examined 
• Methodologist review and synthesis 
research evidence 
• Develop and pilot questionnaire #1A 
PU-
MDS 
 Oct/ Nov 
2010 
PU-MDS 
Nominal 
Group 
(Meeting 1) 
 
Pre-meeting: NG members complete questionnaire 
#1A 
PU-
MDS 
 Nov/ Dec 
2010 
At meeting 
• Present results of review of evidence 
synthesis 
• Presentation of results of questionnaire #1A 
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• Exploration of areas of disagreement 
PU-
MDS 
 Dec 2010 After meeting  
• Revise questionnaire (#1A →#1B) and NG 
members complete questionnaire #1B 
PU-
MDS 
 Jan/ Feb 2011 Consultation Wider international completions of questionnaire 
#1B by a sample of approximately 200 researchers 
and clinicians recruited via PU/ Wound care 
Organisations. 
 PURAF  
 
March 2011 Working 
Group 
 
Pre nominal group work-up: 
• Identify specific issues to be examined 
• Methodologist review and synthesis 
research evidence 
• Develop and pilot questionnaire #2A 
PU-
MDS 
 March 2011 
 
 
May 2011 
(same day as 
1st PURAF 
meeting)  
April 2011 
 
May 2011 
(same day as 
2nd PU-MDS 
meeting) 
 
May/ June 
2011 
PU-MDS 
Nominal 
Group 
(Meeting 2) 
 
 
 
PURAF 
Nominal 
Group 
(Meeting 1) 
 
Pre-meeting: collate results of questionnaire #1B 
PU-
MDS 
 At meeting  
• Presentation of results of questionnaire #1B 
• Exploration of areas of disagreement 
• Agreement of final PU-MDS 
 PURAF  Pre-meeting: NG members complete questionnaire 
#2A 
 PURAF  
 
At meeting 
• Present results of review of evidence 
synthesis 
• Presentation of results of questionnaire #2A 
• Exploration of areas of disagreement 
 PURAF  
 
After meeting  
• Revise questionnaire (#2A →#2B) and NG 
members complete #2B 
 PURAF  
 
June/ July 
2011 
Consultation  Wider international completions of questionnaire 
#2B by a sample of approximately 200 researchers 
and clinicians recruited via PU/ Wound care 
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Organisations. 
 PURAF August –Nov 
2011 
PURAF 
Nominal 
Group 
(Meeting 2) 
Pre meeting: Collation of results of questionnaire 
#2B  
 PURAF  
 
Nov/ Dec 
2011 
At meeting  
• Presentation of results of questionnaire 
• Exploration of areas of disagreement 
• Agreement of final PURAF 
 
5.3 PU-MDS Development 
Using the evidence from the PU risk factor systematic review (Nixon et al) and emerging 
evidence from the other PURPOSE programme studies a questionnaire will be developed by 
the working group to elicit the views of the PU-MDS nominal group members in relation to 
data items for inclusion in the PU-MDS. The nominal group will comprise 12-14 key 
stakeholders/ experts in the area of PU risk / development / research / practice and they will 
be asked to complete the questionnaire (#1A) after reviewing a summary of the PU risk factor 
systematic review. 
 
The PU- MDS nominal group will then have a series of two face to face meetings which will 
be carefully led by experienced facilitators and will be observed, audio taped and transcribed 
to allow thematic analysis of issues affecting final ratings. The terms of reference will be 
fully articulated at each meeting. 
 
The first meeting will allow the initial questionnaire (#1A) results to be presented to the 
group and areas of disagreement discussed and explored. The questionnaire will be revised 
following the meeting (#1B) and the nominal group members will be invited to re-complete 
the questionnaire privately which will determine the levels of consensus within the group in 
relation to the criteria for inclusion in the PU-MDS. The purpose of the questionnaire is to 
find out what items experts think are required in a minimum data set (MDS), using the 
systematic review data as the initial list of possible items. 
 
Prior to the second nominal group meeting the PU-MDS questionnaire #1B will be 
administered, via a web-based survey tool to a wider representative group to test the 
consensus views of the nominal group in relation to the factors for inclusion in a PU-MDS. 
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We aim to recruit 200 researchers and clinicians to be involved in this part of the study. 
Participants will have access to the PU a summary of the systematic review as well as the 
nominal groups’ views. 
 
At the second nominal group meeting the results of questionnaire #1B, the wider PU-MDS 
consultation will be presented and discussed and the final PU-MDS will be agreed. 
 
5.4 PURAF Development 
Using evidence from the PU risk factor systematic review (Nixon et al), emerging evidence 
from the other PURPOSE programme studies and the results from the PU-MDS wider 
consultation the working group will develop a PURAF questionnaire to elicit the views of the 
PURAF nominal group members in relation to the value of key risk factors in both PU risk 
screening and detailed PU risk assessment. A similar staged process detailed as above will be 
adopted. The nominal group will complete questionnaire #2A in advance of the first PURAF 
nominal group meeting. 
 
The first PURAF meeting will allow the initial questionnaire (#2A) results to be presented to 
the group and areas of disagreement discussed and explored. The questionnaire will be 
revised following the meeting (to form questionnaire #2B) and nominal group members will 
be invited to re-complete the questionnaire privately which will determine the levels of 
consensus within the group in relation to the components and format for PURAF.  
 
Prior to the second nominal group meeting the PURAF questionnaire #2B will be 
administered via a web-based survey tool to a wider group to test the consensus views of the 
nominal group in relation to the components and format for the PURAF. We aim to recruit 
200 researchers and clinicians to be involved in this part of the study. Participants will have 
access to the PU risk factor systematic review summary report as well the nominal groups’ 
views. 
 
At the second nominal group meeting the results of the wider PU-MDS consultation will be 
presented and discussed and the final PURAF will be agreed. 
 
6 STUDY PARTICIPANTS 
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6.1  Nominal Group Membership 
Nominal group members will be purposively sampled ensuring representation of researchers 
and clinicians with expertise in the following areas: 
· Vascular/ perfusion/ diabetes  
· Nutrition  
· Biomedicine 
· Dermatology 
· Minimum Data Set  
· Psychology  
· Pressure ulcer research 
· Tissue Viability  
· Statistics 
· Organisational Development  
· Software engineering  
  
The role of the PU-MDS nominal group is to agree a PU-MDS. The role of the PURAF 
nominal group is to develop an evidence based PURAF. 
  
6.2 Working Group Membership 
The working group will comprise of PURPOSE PU academic and clinical leaders including 
Jane Nixon (Chief Investigator), Susanne Coleman (Project Lead/ researcher), Andrea Nelson 
(multi-centre health services research) Carol Dealey, Lyn Wilson, Elizabeth McGinnis, and 
Nikki Stubbs (clinical expertise) and  Michelle Collinson and Julia Brown (statistical 
expertise). The role of this group is to support the nominal group to identify specific issues to 
be examined, to develop  questionnaires and to synthesis research evidence for consideration. 
 
6.3 Wider Consultation Participants 
The wider consultation participants will include individuals with similar expertise of the 
nominal group members as well as clinical users. They will not be required to attend face to 
face meetings. This group will allow the consensus views of the nominal groups to be tested 
by a larger group 
 
7 RECRUITMENT AND CONSENT PROCEDURES 
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7.1 Nominal Group Participant  
Potential PU-MDS and PURAF nominal group participants will be identified via the 
literature pertaining to pressure ulcers and/or membership of pressure ulcer related 
professional organisations, including the Tissue Viability Society, European Pressure Ulcer 
Advisory Panel, the National Pressure Ulcer Advisory Panel, Japanese Society of Pressure 
Ulcers and the Australian Wound Management Association. They will be approached by 
email and sent a nominal group participation information sheet and asked if they would be 
interested in participating in the research. This will be followed up by further email 
correspondence or a telephone discussion if required by the potential participants where they 
have any questions he/ she would like the researcher to answer regarding the implications of 
the research. After this should they wish to participate they will be asked to provide consent 
by returning a Word Document containing their electronic signature. They will be free to 
withdraw their participation at any time including before, during or after nominal group 
meetings and before, during or after questionnaire completion.  
 
7.2 Wider Consultation Participants 
Wider participants will volunteer their participation in the study in response to a general 
advert. Professional organisations will be approached and their associated journal editors and 
asked if they are able to advertise the research through their email contacts lists and journals. 
In addition, flyers and posters will be used at relevant conferences subject to organisational 
approval. The research will be advertised through a simple email communication, journal 
advertisements and presentations to professional/network groups Professional organisations 
including the UK Tissue Viability Society, European Pressure Ulcer Advisory Panel, the US 
National Pressure Ulcer Advisory Panel, Japanese Society of Pressure Ulcers and the 
Australian Wound Management Association. They will be approached by email 
correspondence through their usual ‘contact us’ mechanism and at no time will access to 
organisational membership be provided to the research team. Direct communication with 
members will be undertaken by the respective organisations using their local policies and 
procedures. Advertising materials will include a brief description of the study and a web link 
to the web-based survey platform which will host the participant information sheets, the 
summary PU risk factor systematic review and the questionnaire. Wider participants will be 
free to withdraw their participation at any time including during and after questionnaire 
completion.  
APPENDIX 16
NIHR Journals Library www.journalslibrary.nihr.ac.uk
380
8 DATA COLLECTION 
8.1 Questionnaire Data Collection 
Questionnaires will be completed via a commercial online survey platform. Nominal group 
participants and wider consultation participants will be sent an email link to the web-based 
questionnaire with supporting evidence and user friendly instructions of how to complete the 
questionnaire, as well as the timescale within which this should be undertaken. Following 
guidance from the HTA (2001) the questionnaire will be developed to comprise of generic 
risk factor stem questions preceded by related specific questions. The response options will 
utilise a 9 point Likert scale where 1 indicates strong disagreement and 9 indicates strong 
agreement, as well as a don’t know option. The questionnaires will be tested prior to launch.  
 
8.2 Nominal Group Meeting Data Collection 
Nominal Group meetings will be observed, audio-taped and transcribed to allow thematic 
analysis of issues affecting final ratings. 
 
9 STATISTICAL CONSIDERATIONS 
Statistical analysis is the responsibility of the project lead.  The analysis plan outlined in this 
section will be reviewed and a final statistical analysis plan will be written before any data 
summaries or analyses are performed.  The analysis plan will be written in accordance with 
current CTRU Standard Operating Procedures and will be finalised and agreed by the 
following people: the study Statistician and Supervising Statistician, the Chief Investigator 
and the project lead.   Any changes to the final analysis plan and reasons for change will be 
documented. 
 
Nominal group and wider group participant ratings will be calculated by using the median 
response for each factor. Factors will be rated on the nine point Likert scale where 1 indicates  
strong disagreement and 9 indicates strong agreement. The extent of within group agreement 
for each group will be measured using the mean absolute deviation from the median. 
Participant demographics for both the nominal group and wider participants will be 
summarised using simple descriptive statistics. 
 
10.2 Ethical Considerations 
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This study will recruit PU experts and clinicians. The related ethical issues are minimal and 
mainly relate to the time taken to complete questionnaire and/or attend audio-taped Nominal 
Group Meetings. There are no other forseen risks to participants. Informed consent will be 
obtained prior to nominal group participation in the study. The right of a potential participant 
to refuse without giving reasons will be respected. The patient will remain free to withdraw at 
any time from the study without giving reasons. 
 
The study will be submitted to and approved by the University of Leeds, School of 
Healthcare Research Ethics Committee (SHREC). The CTRU will provide SHREC with a 
copy of the final protocol, participant information sheets, consent forms and all other relevant 
study documentation. 
 
16 REFERENCES 
Bennet G, Dealey C, Posnett J (2004) The cost of pressure ulcers in the UK. age and Ageing. 
33(3): 230-235 
Cullum N, Deeks J, Fletcher A, Long A, Mouneimne H, Sheldon T, et al. 1995. The 
prevention and treatment of pressure sores: How effective are pressure-relieving interventions 
and risk assessment for the prevention and treatment of pressure sores? Effective Health Care 
Bulletin. 2(1) pp1-16.  
Dalkey N and Helmer D. 1963. An experimental application of the Delphi method to the use 
of experts. Management Science 9, 458-467  
Delbecq A and Van de Ven A. 1972. The Nominal Group as a Research Instrument for 
Explanatory Health Studies. Exploratory Health Studies.  
Department for Education and Skills (2006) Safeguarding Vulnerable Groups Bill, London, 
The Stationery Office. 
Department of Health (2000) No Secrets: Guidance on developing and implementing multi-
agency policies and procedures to protect vulnerable adults from abuse [online] London. 
Department of Health. Available from: www.doh.gov.uk/scg/nosecrets.html 
Department of Health. (2001a) National Service Framework for Older People. London, The 
Stationery Office. 
APPENDIX 16
NIHR Journals Library www.journalslibrary.nihr.ac.uk
382
Department of Health (2001b) Essence of Care: Patient Focused Benchmarking for Health 
Care Professionals. London, The Stationery Office. 
Department of Health (2008) Using the Commissioning for quality and Innovation (CQUIN) 
Payment Framework for the NHS England.  London. 
Department of Health (2009) NHS 2010-2015, Good to Great, Preventative People Centred, 
Productive. The stationary Office, London. 
Department of Health (2010) Clinical Governance and Adult Safeguarding. London. 
European Pressure Ulcer Advisory Panel and National Pressure Ulcer Advisory Panel. 
Prevention and treatment of pressure ulcers: quick reference guide. Washington DC: National 
Pressure Ulcer Advisory Panel. 2009. Available from 
http://www.epuap.org/guidelines/Final_Quick_Prevention.pdf 
Hutchings A, Raine R, Sanderson C and Black N. 2006. A Comparison of formal Consensus 
Methods Used for Developing Clinical Guidelines. Journal of Health Services Research 
Policy Vol 11, No 4. 
Institute for Innovation and Improvement (2009) High Impact Actions for Nursing and 
Midwifery. London 
Jackson A, Hettinga DM, Mead J, Mercer C. 2009. Using Consensus Methods in Developing 
Clinical Guidelines for Exercise in Managing Persistent Low Back Pain. Physiotherapy 
94:302-313 
Kadam U. Jordan K, Croft R. 2006. A comparison of Two Consensus Methods for 
Classifying Morbidities in a Group Showed the Same Outcomes. Journal of clinical 
Epidemiology 59:1169-1173 
Kaltenthaler E, Whitfield MD, Walters SJ, Akehurst RL, Paisley S. 2001. UK, USA and 
Canada: how do their pressure ulcer prevalence and incidence data compare? Journal of 
Wound Car.  10(1), pp530-535. 
National Institute for Health and Clinical Excellence (NICE). 2005. Pressure ulcer 
management: The Management of pressure ulcers in primary and secondary care: A clinical 
Practice Guideline. RCN. 
DOI: 10.3310/pgfar03060 PROGRAMME GRANTS FOR APPLIED RESEARCH 2015 VOL. 3 NO. 6
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Nixon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
383
McColl E, Jacoby A, /Thomas L, Soutter J, Bamford C, Steen N, et al. 2001. Design and use 
of questionnaires: a review of best practice applicable to surveys of health service staff and 
patients. Health Technology Assessment. 5 (31) 
Nixon J, Gorecki C, Nelson EA, Closs J, Defloor T, Halfens R, Worthy G, Schoonhoven L, 
Brown JM. Pressure Ulcer risk factors: a systematic review. Wound Repair and 
Regeneration. Submitted 
Nixon J, McGough A. 2001. Principles of Patient Assessment: Screening for Pressure Ulcers 
and Potential Risk. In Morison M, ed. The Prevention and Treatment of Pressure Ulcers. 
Edinburgh: Mosby, pp55-74. 
Raine R, Sanderson C, Black N. 2005. Developing clinical guidelines: a challenge to current 
methods. BMJ 331:631-633  
Rycroft Malone J. 2001. Formal Consensus: the Development of a National Clinical 
Guideline 
Safeguarding Vulnerable Groups Bill (2006), HL Bill 79. 
Scott EA and Black. 1991. Appropriateness of Cholcystectomy in the UK – A Consensus 
Panel Approach. Gut 32:1066-1070 
Sopher  R, Nixon  J, Gorecki C, Gefen A. (2010) Exposure to Internal Muscle Tissue Loads 
under the Ischial Tuberosities during Sitting is Elevated at Abnormally High or Low Body 
Mass Indices. Journal of Biomechanics 43(2):280-286. 
The Mental Capacity Act (2005). MC Act, London, HMSO. 
 
APPENDIX 16
NIHR Journals Library www.journalslibrary.nihr.ac.uk
384
Appendix 17 Consensus study pressure ulcer
Minimum Data Set nominal group participant
information sheet
 
 
Pressure UlceR Programme Of ReSEarch 
The Development of a Pressure Ulcer Minimum Dataset (PU-MDS) and 
Pressure Ulcer Risk Assessment Framework (PURAF) Study 
 
PU-MDS NOMINAL GROUP PARTICIPANT INFORMATION SHEET 
 
You have been invited to take part in the study detailed above. Before you decide whether to 
accept, we would like to explain why the research is being done and what it will involve. 
Please read this information carefully, and ask us if anything is unclear, or if you would like 
more information. 
 
What is the purpose of the study? 
The purpose of this study is to agree a Pressure Ulcer Minimum Data Set (PU-MDS) and 
develop an evidence based Pressure Ulcer Risk Assessment Framework (PURAF) for use in 
clinical practice. This information sheet relates to the PU-MDS element of the study. 
 
Why have I been chosen? 
You have been invited to be a member of the Nominal Group because of your subject 
expertise, which is relevant to the assessment or measurement of pressure ulcer risk factors.  
 
Do I have to take part?
Taking part in this study is entirely voluntary and you are under no obligation to take part – it 
is up to you to decide after reading this information sheet and asking any questions you may 
have.  If you wish to participate you will be asked to provide consent by returning a Word 
Document with your electronic signature. You will be able to retain a copy of this for your 
records and one will be held by the researcher. You will be free to withdraw from the study at 
any time including before, during or after nominal group meetings and before, during or after 
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questionnaire completion, without giving a reason. Data collected from you prior to 
withdrawal will be used in the final study analysis. However, if you do not want your existing 
data from nominal group meetings or completed questionnaires to be used you can inform the 
researcher and this data will be destroyed and excluded from the study.  
 
What does Nominal Group Membership involve? 
If you agree to take part in the study, you will be required attend two meetings over a 12- 18 
month period. Standard rate travel expenses will be reimbursed. The meetings will involve 
12-14 academic or healthcare experts from a number of countries and will include in-depth 
discussions and debate about the factors for inclusion in a PU-MDS. Each meeting will last 
approximately 3.5 hours and will include refreshments and comfort breaks. The meetings will 
be led by trained facilitators and will be audio-taped and transcribed to allow thematic 
analysis of the meeting to occur. You will also be required to read a pressure ulcer systematic 
review summary report, comment on the content of consensus questionnaires and to complete 
two web-based consensus questionnaires.  
 
Within the questionnaire you will also be asked to provide anonymous demographic data 
including: age, gender, nationality, area of expertise, role and sector i.e. university, 
community or acute hospital to allow the nominal group characteristics to be described. The 
summary report will take approximately 30 minutes to read and each questionnaire will take 
approximately 15 minutes to complete. Further email and telephone correspondence may also 
be required.  
 
What are the possible disadvantages and risks of taking part? 
We do not foresee any disadvantages or risks to you in taking part in this study. However, 
you are being asked to give some of your time and this may involve you travelling for 
meetings.  
 
What are the possible benefits of taking part? 
You will be contributing to the development of a PU-MDS which will facilitate the 
interpretation and further use of pressure ulcer research data and meta-analysis.  This will 
contribute to the development of an evidence based PURAF which could lead to 
improvements in patient care. Nominal group members will be listed as contributors for the 
main study publication, subject to your agreement. The researcher will write to you prior to 
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publication to ask you about this. If you agree to this you will be asked to complete a short 
form indicating that you agree to be listed as a contributor. 
 
Will my taking part be kept confidential? 
As part of the nominal group your identity would be apparent to other group members due to 
the face to face meetings but your questionnaire responses would be anonymised before 
being presented to the nominal group or being detailed in any reports. Your individual 
responses would not be revealed by the Clinical Trials Research Unit (CTRU). However, 
whilst under no obligation to do so, you would be free to share this with the group should you 
wish to. 
 
All information collected will be handled, processed, stored, and destroyed in accordance 
with the Data Protection Act 1998. Where personal data is provided this will be stored 
separately to questionnaire data and held on the CTRU secure IT system which has restricted 
password protected access to only the CTRU research team working directly on the study. 
Anonymous questionnaire responses will be held on the secure web-based survey platform 
and will only be accessible by the web-based survey provider and the CTRU research team 
on a password protected restricted access database. At the end of the study, data will be 
securely archived at the CTRU for a minimum of 10 years and arrangements for confidential 
destruction will then be made. 
 
Who has organised and sponsored the research? 
The study is being organised and coordinated by the CTRU at the University of Leeds, who is 
sponsoring the study. This study is a part of a larger pressure ulcer research programme 
funded by the National Institute of Health Research that aims to reduce the impact of pressure 
ulcers on patients. 
 
Who has reviewed the study? 
The study has been peer reviewed by the National Institute of Health Research before 
approval for the funding was given. In addition, this study has been reviewed by the 
University of Leeds, School of Healthcare Research Ethics Committee (SHREC). 
 
What will happen to the results of the research study? 
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When the study is complete the results will be included in a final report and disseminated by 
publishing in scientific/ health related journals and through conference presentations.  
 
Further information and contact details 
If you have any questions please contact: 
Susanne Coleman 
PU-MDS and PURAF Project Lead 
Clinical Trials Research Unit 
University of Leeds 
Leeds 
LS2 9JT 
Tel: 0113 343 4854 
Fax: 0113 343 1471 
Email: medscole@leeds.ac.uk 
Website: www.ctruleeds.co.uk 
 
What do I do now? 
If you wish to participate please provide consent by returning the Word Document (attached 
in the introductory email) with your electronic signature.  
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Appendix 18 Consensus study pressure ulcer
Minimum Data Set nominal group consent form
Participant Study Number: Office use only Participant initials: 
 
PU-MDS NOMINAL GROUP PARTICIPANT CONSENT FORM  
 
Pressure UlceR Programme Of ReSEarch 
 
The Development of a Pressure Ulcer Minimum Dataset (PUMDS) and Pressure Ulcer Risk Assessment Framework 
(PURAF) Study 
 
The participant should complete the whole of this sheet himself/herself 
 
 
Please confirm the 
statements by putting your 
initials in the box below 
I confirm that I have read and understand the information sheet dated (insert 
date of SHREC approval and information sheet version number) for the above  
study. I have had the opportunity to ask questions and have had these 
answered satisfactorily.  
 
 
I agree to allow any information or results arising from the study to be used 
for training and developing new research. 
 
 
I understand that my questionnaire data may be looked at by responsible 
individuals from the study office where it is relevant to my taking part in the 
study. I give permission for these individuals to have access to my 
information and questionnaire data. 
 
 
I consent to the storage including electronic, of personal information (name, 
contact details and place of work) which will be used by the researcher for on -
going contact with me for the purposes of this study only. I understand that 
my completed questionnaire data will remain anonymous.  
 
 
 
I consent to being audio-taped in nominal group meetings.  
I agree to take part in this study   
 
Participant Name:                 Participant Electronic Signature:                                 Date: 
Thank you for agreeing to take part in this study. 
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Appendix 19 Consensus study Pressure Ulcer
Risk Assessment Framework nominal group
participant information sheet
 
Pressure UlceR Programme Of ReSEarch 
 
The Development of a Pressure Ulcer Minimum Dataset (PU-MDS) and 
Pressure Ulcer Risk Assessment Framework (PURAF) Study
 
PURAF NOMINAL GROUP PARTICIPANT INFORMATION SHEET 
 
You have been invited to take part in the study detailed above. Before you decide whether to 
accept, we would like to explain why the research is being done and what it will involve. 
Please read this information carefully, and ask us if anything is unclear, or if you would like 
more information. 
 
What is the purpose of the study? 
The purpose of this study is to agree a Pressure Ulcer Minimum Data Set (PU-MDS) and 
develop an evidence based Pressure Ulcer Risk Assessment Framework (PURAF) for use in 
clinical practice. This information sheet relates to the PURAF element of the study.  
 
Why have I been chosen? 
You have been invited to be a member of the Nominal Group because of your subject 
expertise, which is relevant to the assessment or measurement of pressure ulcer risk factors.  
 
Do I have to take part? 
Taking part in this study is entirely voluntary and you are under no obligation to take part – it 
is up to you to decide after reading this information sheet and asking any questions you may 
have.  If you wish to participate you will be asked to provide consent by returning a Word 
Document with your electronic signature. You will be able to retain a copy of this for your 
records and one will be held by the researcher. You will be free to withdraw from the study at 
any time including before, during or after nominal group meetings and before, during or after 
questionnaire completion, without giving a reason. Data collected from you prior to 
withdrawal will be used in the final study analysis. However, if you do not want your existing 
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data from nominal group meetings or completed questionnaires to be used you can inform the 
researcher and this data will be destroyed and excluded from the study.  
 
What does Nominal Group Membership involve? 
If you agree to take part in the study, you will be required attend two meetings over a 12- 18 
month period. Standard rate travel expenses will be reimbursed. The meetings will involve 
12-14 national and international academic or healthcare experts and will include in-depth 
discussions and debate about the factors for inclusion in a PURAF. Each meeting will last 
approximately 3.5 hours and will include refreshment and comfort breaks. The meetings will 
be led by trained facilitators and will be audio-taped and transcribed to allow thematic 
analysis of the meeting to occur. You will also be required to read a pressure ulcer systematic 
review summary report, comment on the content of consensus questionnaires and to complete 
two web-based consensus questionnaires.  
 
Within the questionnaire you will also be asked to provide anonymous demographic data 
including: age, gender, nationality, area of expertise, role and sector i.e. university, 
community or acute hospital to allow the nominal group characteristics to be described. The 
summary report will take approximately 30 minutes to read, and each questionnaire will take 
approximately 15 minutes to complete. Further email and telephone correspondence may also 
be required.  
 
What are the possible disadvantages and risks of taking part? 
We do not foresee any disadvantages or risks to you in taking part in this study. However, 
you are being asked to give some of your time and this may involve you travelling for 
meetings.  
 
What are the possible benefits of taking part? 
You will be contributing to the development of an evidence based PURAF which could lead 
to improvements in patient care. Nominal group members will be listed as contributors for 
the main study publication, subject to your agreement The researcher will write to you prior 
to publication to ask you about this. If you agree to this you will be asked to complete a short 
form indicating that you agree to be listed as a contributor. 
 
Will my taking part be kept confidential? 
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As part of the nominal group your identity would be apparent to other group members due to 
the face to face meetings but your questionnaire responses would be anonymised before 
being presented to the nominal group or being detailed in any reports. Your individual 
responses would not be revealed by Clinical Trials Research Unit (CTRU). However, whilst 
under no obligation to do so, you would be free to share this with the group should you wish 
to.  
 
Information will be handled, processed, stored, and destroyed in accordance to the Data 
Protection Act 1998. Your personal data including your name, contact details and place of 
work will be stored separately to questionnaire data and held on the CTRU secure IT system 
which has restricted password protected access to only the CTRU research team working 
directly on the study. Anonymous questionnaire responses will be held on the secure web-
based survey platform and will only be accessible by the web-based survey provider and the 
CTRU research team on a password protected restricted access database. At the end of the 
study, data will be securely archived at the CTRU for a minimum of 10 years and 
arrangements for confidential destruction will then be made. 
 
Who has organised and sponsored the research? 
The study is being organised and coordinated by the CTRU at the University of Leeds, who is 
sponsoring the study. This study is a part of a larger pressure ulcer research programme 
funded by the National Institute of Health Research that aims to reduce the impact of pressure 
ulcers on patients. 
 
Who has reviewed the study? 
The study has been peer reviewed by the National Institute of Health Research before 
approval for the funding was given. In addition, this study has been reviewed by the 
University of Leeds, School of Healthcare Research Ethics Committee (SHREC). 
 
What will happen to the results of the research study? 
When the study is complete the results will be included in a final report and disseminated by 
publishing in scientific/ health related journals and through conference presentations.  
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Further information and contact details 
If you have any questions please contact: 
Susanne Coleman 
PU-MDS and PURAF Project Lead 
Clinical Trials Research Unit 
University of Leeds 
Leeds 
LS2 9JT 
Tel: 0113 343 4854 
Fax: 0113 343 1471 
Email: medscole@leeds.ac.uk 
Website: www.ctruleeds.co.uk 
 
What do I do now? 
If you wish to participate please provide consent by returning the Word Document (attached 
in the introductory email) with your electronic signature.  
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Appendix 20 Consensus study Pressure Ulcer
Risk Assessment Framework nominal group
consent form
Participant Study Number: Office use only Participant initials: 
 
PURAF NOMINAL GROUP PARTICIPANT CONSENT FORM  
 
Pressure UlceR Programme Of ReSEarch 
 
The Development of a Pressure Ulcer Minimum Dataset (PUMDS) and Pressure Ulcer Risk Assessment Framework 
(PURAF) Study 
 
The participant should complete the whole of this sheet himself/herself 
 
 
Please confirm the 
statements by putting your 
initials in the box below 
I conﬁrm that I have read and understand the information sheet dated (insert 
date of SHREC approval and information sheet version number) for the above  
study. I have had the opportunity to ask questions and have had these 
answered satisfactorily.  
 
 
I agree to allow any information or results arising from the study to be used 
for training and developing new research. 
 
 
I understand that my questionnaire data may be looked at by responsible 
individuals from the study ofﬁce where it is relevant to my taking part in the 
study. I give permission for these individuals to have access to my 
information and questionnaire data. 
 
 
I consent to the storage including electronic, of personal information (name, 
contact details and place of work) which will be used by the researcher for on -
going contact with me for the purposes of this study only. I understand that 
my completed questionnaire data will remain anonymous.  
 
 
 
I consent to being audio-taped in nominal group meetings.  
I agree to take part in this study   
 
Participant Name:                  Participant Electronic Signature:                         Date: 
Thank you for agreeing to take part in this study. 
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Appendix 21 Consensus study pressure ulcer
Minimum Data Set wider consultation participant
information sheet
 
Pressure UlceR Programme Of ReSEarch 
 
The Development of a Pressure Ulcer Minimum Dataset (PU-MDS) and 
Pressure Ulcer Risk Assessment Framework (PURAF) Study 
 
 WIDER CONSULTATION PU-MDS PARTICIPANT INFORMATION SHEET 
  
This is an invitation to take part in the development of a Pressure Ulcer Minimum Data Set. 
Before you decide whether to accept, we would like to explain why the research is being 
done and what it will involve.  
 
What is the purpose of this part of the study? 
The purpose of this study is to agree a Pressure Ulcer Minimum Data Set (PU-MDS: a list of 
the data that should be collected in all settings to allow clinicians to compare patient groups 
and the effects of treatment).
 
Why have I been chosen? 
We have identified that you are a person with clinical and/or academic expertise and 
experience in pressure ulcers. 
 
Do I have to take part? 
Taking part in this study is entirely voluntary and you are under no obligation to take part – it 
is up to you to decide after reading this information sheet and visiting the CTRU website 
(insert link) or contacting the study project lead (detailed below) for more information if 
needed.  Should you decide to participate you are free to withdraw at any time, without 
giving a reason.  If you decide to withdraw during data entry on the web-based survey 
platform. your questionnaire response will be incomplete. Incomplete questionnaires will be 
destroyed and not used in the final study analysis. If you have fully completed the 
questionnaire and wish to withdraw consent for your data to be used, the study data will be 
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destroyed, subject to provision of your study ID number which will be issued to you on 
completion of the questionnaire. 
 
What does it involve? 
If you agree to take part in the study, you will be invited to read a pressure ulcer risk factor 
systematic review summary report and complete a web-based questionnaire relating to factors 
for inclusion in a Pressure Ulcer Minimum Dataset. Reading the systematic review summary 
report will take about 30 minutes. Completing the questionnaire after that will take about 15 
minutes.  You will also be asked to tell us a little bit about you - your age, gender, nationality, 
area of expertise and current post and sector i.e. university, community or acute hospital. We 
do not require your name.  
 
What are the possible disadvantages and risks of taking part? 
We do not foresee any disadvantages or risks to you in taking part in this study. However, 
you are being asked to give some of your time to complete the web-based questionnaire.  
 
What are the possible benefits of taking part? 
You will be contributing to the development of a Pressure Ulcer Minimum Data Set which 
will facilitate the interpretation and further use of pressure ulcer research data. It will also 
inform the development of an evidence based Pressure Ulcer Risk Assessment Framework. 
We hope that you will find the systematic review summary report of pressure ulcer risk 
factors of interest.  
 
Will my taking part be kept confidential? 
Information will be handled, processed, stored, and destroyed in accordance to the Data 
Protection Act 1998. If you choose to provide your contact details to allow the researcher to 
contact you about the results of the study, these will be stored separately to questionnaire data 
and held on the CTRU secure IT system which has restricted password protected access to 
only the CTRU research team working directly on the study. Anonymous questionnaire 
responses will be held on the secure web-based survey platform and will only be accessible 
by the web-based survey provider and the CTRU research team on a password protected 
restricted access database. At the end of the study, data will be securely archived at the 
CTRU for a minimum of 10 years and arrangements for confidential destruction will then be 
made. 
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Who has organised and sponsored the research? 
The study is being organised and coordinated by the Clinical Trials Research Unit (CTRU) at 
the University of Leeds. The University of Leeds is acting as the study sponsor. This is a part 
of a programme of research on pressure ulcers funded by the NHS National Institute of 
Health Research that aims to reduce the impact of pressure ulcers on patients. 
 
Who has reviewed the study? 
The study has been peer reviewed by the National Institute of Health Research before 
approval for the funding was given. In addition, this study has been reviewed by the 
University of Leeds, School of Healthcare Research Ethics Committee (SHREC). 
 
What will happen to the results of the research study? 
When the study is complete the results will be included in a final report and disseminated by 
publishing in scientific/ health related journals and through conference presentations.  
 
Further Information and Contact Details 
If you would like more information about THIS STUDY contact: 
Susanne Coleman 
PU-MDS and PURAF Project Lead 
Clinical Trials Research Unit 
University of Leeds 
Leeds 
LS2 9JT 
Tel: 0113 343 4854 
Fax: 0113 343 1471 
Email: medscole@leeds.ac.uk 
Website: www.ctruleeds.co.uk 
 
What do I do now? 
If after considering the above information you wish to participate please go to page two of 
this link to complete the questionnaire. If not, thank you for considering taking part: please 
close your browser window to leave the web link. 
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Appendix 22 Consensus study Pressure Ulcer
Risk Assessment Framework wider consultation
participant information sheet
 
Pressure UlceR Programme Of ReSEarch 
 
The Development of a Pressure Ulcer Minimum Dataset (PU-MDS) and 
Pressure Ulcer Risk Assessment Framework (PURAF) Study 
 
 WIDER CONSULTATION PURAF PARTICIPANT INFORMATION SHEET 
  
This is an invitation to take part in the development of a Pressure Ulcer Risk Assessment 
Framework. Before you decide whether to accept, we would like to explain why the research 
is being done and what it will involve. 
 
What is the purpose of this part of the study? 
The purpose of this study is to agree a Pressure Ulcer Risk Assessment Framework (PURAF) 
for use in clinical practice.  
 
Why have I been chosen? 
We have identified that you are a person with clinical and/or academic expertise and 
experience in pressure ulcers. 
 
Do I have to take part? 
Taking part in this study is entirely voluntary and you are under no obligation to take part – it 
is up to you to decide after reading this information sheet and visiting the CTRU website 
(insert link) or contacting the study project lead (detailed below) for more information if 
needed. Should you decide to participate you are free to withdraw at any time, without giving 
a reason. If you decide to withdraw during data entry on the web-based survey platform your 
questionnaire response will be incomplete. Incomplete questionnaire will be destroyed and 
not used in the final study analysis. If you have fully completed the questionnaire and wish to 
withdraw consent for your data to be used, the study data will be destroyed, subject to 
provision of your study ID number which will be issued to you on completion of the 
questionnaire.
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What does it involve? 
 If you agree to take part in the study, you will be invited to read a pressure ulcer risk factor 
systematic review summary report and complete a web-based questionnaire relating to factors 
for inclusion in a Pressure Ulcer Risk Assessment Framework. Reading the systematic review 
will take about 30 minutes. Completing the questionnaire after that will take about 15 
minutes.  You will also be asked to tell us a little bit about you - your age, gender, nationality, 
area of expertise and current post and sector i.e. university, community or acute hospital. We 
do not require your name.  
 
What are the possible disadvantages and risks of taking part? 
We do not foresee any disadvantages or risks to you in taking part in this study. However, 
you are being asked to give some of your time to complete the web-based questionnaire.  
 
What are the possible benefits of taking part? 
You will be contributing to the development of a Pressure Ulcer Risk Assessment Framework 
which could lead to improvements in patient care. We hope that you will find the systematic 
review of pressure ulcer risk factors of interest.  
 
Will my taking part be kept confidential? 
Information will handled, processed, stored, and destructed in accordance to the Data 
Protection Act 1998. If you choose to provide your contact details to allow the researcher to 
contact you about the results of the study, these will be stored separately to questionnaire data 
and held on the CTRU secure IT system which has restricted password protected access to 
only the CTRU research team working directly on the study. Anonymous questionnaire 
responses will be held on the secure web-based survey platform and will only be accessible 
by the web-based survey provider and the CTRU research team on a password protected 
restricted access database. At the end of the study, data will be securely archived at the 
CTRU for a minimum of 10 years and arrangements for confidential destruction will then be 
made. 
 
Who has organised and sponsored the research? 
The study is being organised and coordinated by the Clinical Trials Research Unit (CTRU) at 
the University of Leeds. The University of Leeds is acting as the study sponsor. This is a part 
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of a programme of research on pressure ulcers funded by the NHS National Institute of 
Health Research that aims to reduce the impact of pressure ulcers on patients. 
 
Who has reviewed the study? 
The study has been peer reviewed by the National Institute of Health Research before 
approval for the funding was given. In addition, this study has been reviewed by the 
University of Leeds, School of Healthcare Research Ethics Committee (SHREC). 
 
What will happen to the results of the research study? 
When the study is complete the results will be included in a final report and disseminated by 
publishing in scientific/ health related journals and through conference presentations.  
 
Further Information and contact details 
If you would like more information about THIS STUDY contact: 
Susanne Coleman 
PU-MDS and PURAF Project Lead 
Clinical Trials Research Unit 
University of Leeds 
Leeds 
LS2 9JT 
Tel: 0113 343 4854 
Fax: 0113 343 1471 
Email: medscole@leeds.ac.uk 
Website: www.ctruleeds.co.uk 
 
What do I do now? 
If after considering the above information you wish to participate please go to page two of 
this link to complete the questionnaire. If not, thank you for considering taking part: please 
close your browser window to leave the web link. 
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Appendix 23 Initial draft Risk Assessment
Framework with underpinning Minimum Data Set
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Appendix 24 Pressure Ulcer Risk Assessment
Framework pre-test study reduced format protocol
NB: This study protocol (version 1, dated 31 January 2012) is in a reduced format including 
only the study aims, methods and ethical considerations.  Sections pertaining to study 
background have been removed as they are included as a chapter section. Information 
pertaining to quality assurance, confidentiality, archiving, statement of indemnity, study 
organisational structure, funding, and publication policy are available upon request 
  
3 FLOW DIAGRAM PRE-TEST 
 
5.3 PRESSURE ULCER MINIMUM DATA SET (PU-MDS) and 
PRESSURE ULCER RISK ASSESSMENT FRAMEWORK (PURAF)  
Work to review current risk assessment practice has been taken forward as part of the Pressure 
UlceR Programme Of ReSEarch (PURPOSE) - a programme of research funded by the 
National Institute for Health Research (RP-PG-0407-10056). 
 
We are developing a Pressure Ulcer Minimum Data Set (PU-MDS) which will be incorporated 
into a Pressure Ulcer Risk Assessment Framework (PURAF) to support risk assessment in 
clinical practice. The development stages are detailed in Figure 1. 
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The development and evaluation of PU-MDS and PURAF has five phases. Phase 1 has 
involved a systematic review of epidemiological studies identifying risk factors associated 
with PU development (Nixon, Coleman and Gorecki et al unpublished) and a Consensus 
Study. The Consensus Study has utilised structured consensus methods involving an 
international expert nominal group and wider Delphi consultation, drawing upon the 
systematic review as well as wider scientific evidence, results from other PURPOSE projects 
(including a pain cohort study, a severe PU study and quality of life work (PU-QOL), and the 
experience of experts in the field to ensure face and content validity of a conceptual map and 
provisional PU-MDS and PURAF for use in clinical practice, by March 2012.  
 
Phase 2, the pre-test will assess the acceptability, usability, format, design, clarity, 
comprehension and language of the preliminary PU-MDS and PURAF. Phase 3 will evaluate 
the psychometric properties of the final PU-MDS and PURAF, and comprises 2 stages: Field 
Test 1 will assess the reliability, data completeness, discriminant validity, convergent 
validity, known groups validity and clinical usability. Field Test 2 will evaluate the predictive 
validity of the PURAF in a prospective cohort. Phase 4 will assess the effectiveness of 
PURAF compared to ‘standard care’ in the prevention of PUs, prior to widespread NHS 
implementation in Phase 5. 
 
This protocol outlines the methods for the Phase 2 Pre-test.  
 
6 AIM AND OBJECTIVES 
The aim of the pre-test is to assess the acceptability, usability, format, design, clarity, 
comprehension, language and data completeness of the preliminary PU-MDS and PURAF. 
 
7 PRE-TEST METHODS 
7.1 Design  
Cognitive pre-testing methods will be used to indicate how clinical nurses interpret questions, 
response categories and instructions relating to using the preliminary PURAF (Colins 2003). 
The pre-test phase will incorporate PURAF training, focus groups and ‘think out loud’ 
interviews. It is anticipated that focus groups of nurses in similar roles would facilitate 
greater understanding of the usability of the PURAF, and would benefit from the proposed 
advantages of the method, allowing group members to “spark ideas off one another” which 
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may lead to greater disclosure (McColl 2005). However, the possible disadvantage of more 
vocal participants dominating discussions will be carefully counteracted by affective 
facilitation. Furthermore, some one-to-one think out loud interviews (Willis 2005) will also 
be undertaken to allow the researcher to identify specific areas where there are problems 
within the PURAF, which may be resolved by modification. 
 
The Pre-test will involve nurses from  a large acute Teaching Hopsital Trust, a District 
General Hospital and two Primary Care Trusts. We estimate that approximately 3 focus 
groups and 12 think out loud interviews will be needed to reach saturation (no new issues 
arising). As this is dedicated research activity outside of clinical hours, payment will be made 
to participants and this is detailed in the Participant Information Leaflet. 
 
7.2 Eligibility of Nurses 
Purposive sampling will be undertaken to ensure that Tissue Viability Nurses and Registered 
Nurses (Staff Nurses and Sisters) from hospital and community settings are recruited from 
each of the 4 participating sites. Potential participants will include those who:  
· have an interest in tissue viability (for example a link nurse or member of a local PU 
or wound care working group) 
· have commitment to attend the training session and  participate in a focus group or 
one-to-one inteview. 
 
7.3 Recruitment and consent 
The Local Principal Investigator or a Tissue Viability Clinical Research Nurse will invite 
nurses to participate in the study via invitation letters and presentations to their local link 
nurse/pressure ulcer/wound care groups. For those who express an interest in participating in 
the study the Local Principle Investigator or Tissue Viability Clinical Research Nurse will 
explain what the study involves, provide the nurse with the written information sheet and 
answer any questions regarding the study. Those who fullfill the eligibility criteria and agree 
to take part will provide  informed written consent prior to participation in  the study and 
complete a researcher contact form to allow arrangements for the training and group session 
to be undertaken.  
 
7.4 Pre-test data collection  
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The pre-test will comprise three sessions. Each session will comprise PURAF training, a 
focus group and think out loud interviews. Each session will involve 8-12 nurses from 
participating sites, who will be grouped by job role (Staff Nurse, Sister/Charge Nurse and 
TVNS/Research Nurse). The sessions will be held away from the clinical setting. Grouping 
the nurses in relation to their role will ensure that those participating in the focus group are 
similar in relation to job roles, as heterogeneous groups can lead to inhibition in raising issues 
that do not seem to be shared by others (McColl 2005) Furthermore, having nurses from 
different centres will minimise familiarity which can lead to participants relying on ‘taken for 
granted’ assumptions (McColl 2005). Each session will include training in the use of the 
PURAF followed by participants attending either a focus group or a one-to-one think out loud 
interview. Participants will be randomly allocated to either the focus group or one-to-one 
think out loud interview, prior to attending the PURAF session. 
 
7.5 PURAF training 
The nurses will be trained in the use of the PURAF: this will involve a short presentation and 
a member of the project team demonstrating how to use PURAF with a simulated patient. 
Each nurse will then complete the PURAF using a specific case study via vignettes that will 
be accompanied by photographs of pressure areas and ulcers. The vignettes will be 
appropriate to the nurses area of practice (i.e. community nurses will use vignettes of 
community patients). The vignettes will be co-developed by the project lead, the project team 
and members of PURSUN (Pressure Ulcer Research Service User Network) to ensure they 
are realistic and clinically relevant. Nurses will be encouraged to ask questions throughout 
the training session. It is recognised that group training may contaminate the discussions of 
the focus group and think out loud interviews, therefore detailed field notes of the training 
session will be recorded by a co-facilitator.  
 
7.6 Focus group 
The 4-8 nurses (Kitzinger 1995) assigned to the focus group will be asked to complete the 
PURAF again, using a vignette relevant to their area of practice prior to the focus group 
meeting. Nurse participants will be encouraged to highlight any areas which they find 
confusing on the PURAF documentation form. The co-facilitator will assess data 
completeness and list areas where data items have not been completed or not completed as 
required, as well as areas noted by the nurses as confusing. 
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Following this the focus group meeting will convene to discuss the use of the PURAF. The 
moderator will promote group interaction and guide discussions around a topic guide which 
will incorporate the data completeness assessment. This will consider the usability and any 
areas of confusion regarding the use of the PURAF. The meeting will be moderated by the 
researcher and a co-facilitator and will be audio-recorded.  
 
7.7 Think out loud interviews 
Up to four nurses from each session will be assigned to the one-to-one think out loud 
interview.  Each nurse will be asked to complete the PURAF again using a vignette case 
study appropriate to their area of practice in the presence of the researcher. The researcher 
will be present to encourage the nurse to vocalise their thoughts as they complete the PURAF 
(see topic guide appendix 5). This will allow specific issues relating to difficulty in 
interpreting or confusion about aspects of the PURAF to be identified. The interview will be 
audio-recorded. 
 
7.8 Data analysis 
The focus group meetings and the think out loud interviews will be audio-recorded and 
transcribed to allow thematic analysis of issues relating to the PURAF.  The emphasis will be 
on identifying dominant trends across the focus groups and think out loud interviews which 
impact on the application of the PURAF in clinical practice. Following this, adjustments in 
relation to the wording and the format of the PURAF may be made informing the next stages 
of the study.  The analysis and adjustments will be made soon after each focus group and 
think out loud interviews, informing the PURAF used in subsequent groups in an iterative 
process.  
 
Participant demographics data will be summarised using simple descriptive statistics. Data 
completeness of the PURAF will be assessed by missing data for data items and risk 
categories using simple descriptive statistics (computing the percentage of missing data for 
each item) and areas of confusion will be listed. 
 
8.2 Ethical considerations 
This study will recruit Registered Nurses. The related ethical issues are minimal and mainly 
relate to the time taken to attend the PURAF training and audio-taped focus groups or one-to-
one think out loud interviews. There are no other forseen risks to participants. Informed 
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consent will be obtained prior to participation in the study. The right of a potential participant 
to refuse without giving reasons will be respected. The patient will remain free to withdraw at 
any time from the study without giving reasons 
 
The study will be submitted to and approved by the University of Leeds, School of 
Healthcare Research Ethics Committee (SHREC). The CTRU will provide SHREC with a 
copy of the final protocol, participant information sheets, consent forms and all other relevant 
study documentation. 
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Appendix 25 Pressure Ulcer Risk Assessment
Framework pre-test study participant information
sheet
 
 
Pressure UlceR Programme Of ReSEarch 
 
The Pressure Ulcer Risk Assessment Framework (PURAF) Pre-Test Study 
 
NURSE PARTICIPANT INFORMATION SHEET 
 
You have been invited to take part in the study detailed above. Before you decide whether to 
accept, we would like to explain why the research is being done and what it will involve. 
Please read this information carefully, and ask us if anything is unclear, or if you would like 
more information. 
 
What is the purpose of the study? 
The clinical guidelines and policies in place in the NHS focus on risk assessment as being the 
key to prevention of PUs but risk assessment tools have not been updated for decades. While 
existing tools offer some structure to PU risk assessment they were developed in the 1970-
80s through expert opinion and outdated literature reviewing methods when the evidence was 
limited. The preliminary PURAF (Pressure Ulcer Risk Assessment Framework) was 
developed following a systematic review of pressure ulcer risk factors and a consensus study 
involving international experts in the pressure ulcer field to establish what elements need to 
be included in pressure ulcer risk assessment. The purpose of this study is to assess the 
acceptability of the preliminary PURAF amongst nurses in relation its clarity and ease of use.    
 
Why have I been chosen? 
You have been invited to participate in this study as you are a practising Registered Nurse 
who is involved with the planning and delivery of pressure area care.  
 
Do I have to take part? 
Taking part in this study is entirely voluntary and you are under no obligation to take part – it 
is up to you to decide after reading this information sheet and asking any questions you may 
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have.  If you wish to participate you will be asked to provide informed written consent. You 
will be able to retain a copy of this for your records and one will be held by the researcher. 
You will be free to withdraw from the study at any time including before, during or after the 
PURAF training, focus group or one-to-one interview, without giving a reason. Data 
collected from you prior to withdrawal will be used in the final study analysis.  
 
What does the study involve? 
If you agree to take part in the study, you will be required attend a 4 hour PURAF session. 
The session will incorporate training in the use of the PURAF which will be followed by your 
participation in either a focus group meeting or one-to-one interview.  It will involve you 
travelling to the venue in Leeds and standard rate travel expenses will be reimbursed.  
 
The training will involve 8-12 other nurses in similar roles to yourself and will involve the 
researcher explaining how to use the PURAF and demonstrating this with a simulated patient 
(an actor taking on the role of a patient). You will then be asked to practice using the PURAF 
with a training case study relevant to your area of practice and photographs of pressure 
ulcers/areas, noting any areas of confusion on the PURAF form. 
  
Following training you will then participate in either the focus group with approximately 4-8 
other nurses or a one-to-one interview with the researcher. Allocation to the focus group and 
one-to-one interview will be done using randomisation in advance of the session. 
 
If you are assigned to the focus group you will be asked to complete the PURAF again using 
another case study before the focus group meeting; you will be encouraged to highlight any 
areas which you find confusing on the PURAF documentation form which will inform the 
discussions of the focus group meeting. This is not a test and there are no ‘right or wrong’ 
answers. At the focus group meeting you will be invited to discuss your thoughts about using 
the PURAF in a group setting. It is anticipated that working in a group may spark further 
discussion and highlight any issues you found difficult or unclear when using the PURAF.  
The focus group will be led by a trained facilitator and will be audio-taped.   
 
If you are assigned to the one-to-one interview you will be asked to complete the PURAF 
again using another case study. The researcher will ask you to ‘think out loud’ as you 
complete the PURAF. This is not a test and there are no ‘right or wrong’ answers; it will 
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allow the researcher to get a better understanding of areas of the PURAF which nurses find 
confusing to complete. The interview will be audio-recorded.     
 
The audio-tapes from the interview and the focus group will be transcribed to allow thematic 
analysis of the issues relating to PURAF. At the session you will also be asked to provide 
anonymous demographic data including: age, gender, nationality, role and sector i.e. 
community or acute hospital to allow the group characteristics to be described.  
 
What are the possible disadvantages and risks of taking part? 
We do not foresee any disadvantages or risks to you in taking part in this study. However, 
you are being asked to give some of your time and this will involve you travelling to the 
session.  
 
What are the possible benefits of taking part? 
You will be contributing to the development of a PURAF which could lead to more useful 
nurse assessment and improvements in patient care. You would also be involved in research 
which would help you to develop your professional portfolio in relation to being involved in 
research to enhance patient care. As this is dedicated research activity outside of clinical 
hours, the payment of £105 (subject to deductions for national insurance and tax) will be 
made to participants to attend the session. 
 
Will my taking part be kept confidential? 
As part of the PURAF session your identity would be apparent to other group members due 
to the face to face nature of the session. Focus group and individual interview responses 
would not be revealed by the Clinical Trials Research Unit (CTRU). 
 
All information collected will be handled, processed, stored, and destroyed in accordance 
with the Data Protection Act 1998. Where personal data is provided this will be stored 
separately to focus group and interview data and held on the CTRU secure IT system which 
has restricted password protected access to only the CTRU research team working directly on 
the study.  At the end of the study, data will be securely archived at the CTRU for a minimum 
of 10 years and arrangements for confidential destruction will then be made. 
 
Who has organised and sponsored the research? 
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The study is being organised and coordinated by the CTRU at the University of Leeds, who is 
sponsoring the study. This study is a part of a larger pressure ulcer research programme 
funded by the National Institute of Health Research that aims to reduce the impact of pressure 
ulcers on patients. 
 
Who has reviewed the study? 
The study has been peer reviewed by the National Institute of Health Research before 
approval for the funding was given. In addition, this study has been reviewed by the 
University of Leeds, School of Healthcare Research Ethics Committee (SHREC). 
 
What will happen to the results of the research study? 
When the study is complete the results will be included in a final report and disseminated by 
publishing in scientific/ health related journals and through conference presentations.  
 
Further information and contact details 
If you have any questions please contact: 
Susanne Coleman 
PURAF Project Lead 
Clinical Trials Research Unit 
University of Leeds 
Leeds 
LS2 9JT 
Tel: 0113 343 4854 
Fax: 0113 343 1471 
Email: medscole@leeds.ac.uk 
Website: www.ctruleeds.co.uk 
 
What do I do now? 
If you wish to participate please provide written consent. 
APPENDIX 25
NIHR Journals Library www.journalslibrary.nihr.ac.uk
420
   
 
               Fi
gu
re
 1
: P
hD
 P
ro
gr
am
m
e 
– 
B
as
ed
 o
n 
an
 A
da
pt
ed
 C
om
pl
ex
 In
te
rv
en
tio
n 
Fr
am
ew
or
k 
(M
R
C
 2
00
0)
 
D
ev
el
op
m
en
t o
f 
ev
id
en
ce
 b
as
e 
- 
un
de
rta
ke
 P
U
 
R
is
k 
Fa
ct
or
 
Sy
st
em
at
ic
 
R
ev
ie
w
 
Ev
id
en
ce
 b
as
e 
C
on
se
ns
us
 
M
et
ho
ds
 
C
on
ce
pt
ua
l 
fr
am
ew
or
k 
de
ve
lo
pm
en
t  
 Ite
m
 g
en
er
at
io
n 
 Pr
ov
is
io
na
l P
U
-
M
D
S 
an
d 
PU
R
A
F 
 
Ph
as
e 
1a
 
Pr
e-
cl
in
ic
al
  
Ph
as
e 
1b
  
Pr
e-
cl
in
ic
al
Ps
yc
ho
m
et
ric
 
Ev
al
ua
tio
n 
Fi
el
d 
Te
st
 1
 
Ev
al
ua
te
: 
re
lia
bi
lit
y/
da
ta
 
qu
al
ity
 /c
lin
ic
al
 
us
ab
ili
ty
 o
f P
U
-
M
D
S/
 P
U
R
A
F;
 
D
is
cr
im
in
an
t, 
co
nv
er
ge
nt
 a
nd
 
kn
ow
n 
gr
ou
ps
 
va
lid
ity
 o
f 
PU
R
A
F 
 Fi
el
d 
Te
st
 2
 
Ev
al
ua
te
 
pr
ed
ic
tiv
e 
va
lid
ity
 o
f 
PU
R
A
F 
Ph
as
e 
3 
C
lin
ic
al
 
C
on
tin
uu
m
 o
f I
nc
re
as
in
g 
Ev
id
en
ce
 
Pr
og
ra
m
m
e 
G
ra
nt
 E
le
m
en
t 
Po
st
 P
ro
gr
am
m
e 
G
ra
nt
  
D
ef
in
iti
ve
 R
C
T 
Lo
ng
-te
rm
 
Im
pl
em
en
ta
tio
n 
C
lu
st
er
 T
ria
l 
co
m
pa
rin
g 
PU
R
A
F 
to
 o
th
er
 
ris
k 
as
se
ss
m
en
t 
to
ol
s t
o 
as
se
ss
 
im
pa
ct
 u
po
n 
PU
 
ou
tc
om
e 
D
is
se
m
in
at
io
n 
of
 
PU
R
A
F 
in
to
 
ro
ut
in
e 
N
H
S 
ca
re
 
Ph
as
e 
4 
C
lin
ic
al
 
Ph
as
e 
5 
C
lin
ic
al
 
A
ss
es
s 
cl
in
ic
al
 
ac
ce
pt
ab
ili
ty
, 
us
ab
ili
ty
, f
or
m
at
 
de
si
gn
, c
la
rit
y,
 
co
m
pr
eh
en
si
on
 
an
d 
la
ng
ua
ge
 o
f 
PU
-M
D
S 
an
d 
PU
R
A
F 
 P
ha
se
 2
 
C
lin
ic
al
Pr
e-
te
st
 
DOI: 10.3310/pgfar03060 PROGRAMME GRANTS FOR APPLIED RESEARCH 2015 VOL. 3 NO. 6
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Nixon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
421
The development and evaluation of PU-MDS and PURAF has five phases. Phase 1 has 
involved a systematic review of epidemiological studies identifying risk factors associated 
with PU development (Nixon, Coleman and Gorecki et al unpublished) and a Consensus 
Study. The Consensus Study has utilised structured consensus methods involving an 
international expert nominal group and wider Delphi consultation, drawing upon the 
systematic review as well as wider scientific evidence, results from other PURPOSE projects 
(including a pain cohort study, a severe PU study and quality of life work (PU-QOL), and the 
experience of experts in the field to ensure face and content validity of a conceptual map and 
provisional PU-MDS and PURAF for use in clinical practice, by March 2012.  
 
Phase 2, the pre-test will assess the acceptability, usability, format, design, clarity, 
comprehension and language of the preliminary PU-MDS and PURAF. Phase 3 will evaluate 
the psychometric properties of the final PU-MDS and PURAF, and comprises 2 stages: Field 
Test 1 will assess the reliability, data completeness, discriminant validity, convergent 
validity, known groups validity and clinical usability. Field Test 2 will evaluate the predictive 
validity of the PURAF in a prospective cohort. Phase 4 will assess the effectiveness of 
PURAF compared to ‘standard care’ in the prevention of PUs, prior to widespread NHS 
implementation in Phase 5. 
 
This protocol outlines the methods for the Phase 2 Pre-test.  
 
6 AIM AND OBJECTIVES 
The aim of the pre-test is to assess the acceptability, usability, format, design, clarity, 
comprehension, language and data completeness of the preliminary PU-MDS and PURAF. 
 
7 PRE-TEST METHODS 
7.1 Design  
Cognitive pre-testing methods will be used to indicate how clinical nurses interpret questions, 
response categories and instructions relating to using the preliminary PURAF (Colins 2003). 
The pre-test phase will incorporate PURAF training, focus groups and ‘think out loud’ 
interviews. It is anticipated that focus groups of nurses in similar roles would facilitate 
greater understanding of the usability of the PURAF, and would benefit from the proposed 
advantages of the method, allowing group members to “spark ideas off one another” which 
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may lead to greater disclosure (McColl 2005). However, the possible disadvantage of more 
vocal participants dominating discussions will be carefully counteracted by affective 
facilitation. Furthermore, some one-to-one think out loud interviews (Willis 2005) will also 
be undertaken to allow the researcher to identify specific areas where there are problems 
within the PURAF, which may be resolved by modification. 
 
The Pre-test will involve nurses from  a large acute Teaching Hopsital Trust, a District 
General Hospital and two Primary Care Trusts. We estimate that approximately 3 focus 
groups and 12 think out loud interviews will be needed to reach saturation (no new issues 
arising). As this is dedicated research activity outside of clinical hours, payment will be made 
to participants and this is detailed in the Participant Information Leaflet. 
 
7.2 Eligibility of Nurses 
Purposive sampling will be undertaken to ensure that Tissue Viability Nurses and Registered 
Nurses (Staff Nurses and Sisters) from hospital and community settings are recruited from 
each of the 4 participating sites. Potential participants will include those who:  
· have an interest in tissue viability (for example a link nurse or member of a local PU 
or wound care working group) 
· have commitment to attend the training session and  participate in a focus group or 
one-to-one inteview. 
 
7.3 Recruitment and consent 
The Local Principal Investigator or a Tissue Viability Clinical Research Nurse will invite 
nurses to participate in the study via invitation letters and presentations to their local link 
nurse/pressure ulcer/wound care groups. For those who express an interest in participating in 
the study the Local Principle Investigator or Tissue Viability Clinical Research Nurse will 
explain what the study involves, provide the nurse with the written information sheet and 
answer any questions regarding the study. Those who fullfill the eligibility criteria and agree 
to take part will provide  informed written consent prior to participation in  the study and 
complete a researcher contact form to allow arrangements for the training and group session 
to be undertaken.  
 
7.4 Pre-test data collection  
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The pre-test will comprise three sessions. Each session will comprise PURAF training, a 
focus group and think out loud interviews. Each session will involve 8-12 nurses from 
participating sites, who will be grouped by job role (Staff Nurse, Sister/Charge Nurse and 
TVNS/Research Nurse). The sessions will be held away from the clinical setting. Grouping 
the nurses in relation to their role will ensure that those participating in the focus group are 
similar in relation to job roles, as heterogeneous groups can lead to inhibition in raising issues 
that do not seem to be shared by others (McColl 2005) Furthermore, having nurses from 
different centres will minimise familiarity which can lead to participants relying on ‘taken for 
granted’ assumptions (McColl 2005). Each session will include training in the use of the 
PURAF followed by participants attending either a focus group or a one-to-one think out loud 
interview. Participants will be randomly allocated to either the focus group or one-to-one 
think out loud interview, prior to attending the PURAF session. 
 
7.5 PURAF training 
The nurses will be trained in the use of the PURAF: this will involve a short presentation and 
a member of the project team demonstrating how to use PURAF with a simulated patient. 
Each nurse will then complete the PURAF using a specific case study via vignettes that will 
be accompanied by photographs of pressure areas and ulcers. The vignettes will be 
appropriate to the nurses area of practice (i.e. community nurses will use vignettes of 
community patients). The vignettes will be co-developed by the project lead, the project team 
and members of PURSUN (Pressure Ulcer Research Service User Network) to ensure they 
are realistic and clinically relevant. Nurses will be encouraged to ask questions throughout 
the training session. It is recognised that group training may contaminate the discussions of 
the focus group and think out loud interviews, therefore detailed field notes of the training 
session will be recorded by a co-facilitator.  
 
7.6 Focus group 
The 4-8 nurses (Kitzinger 1995) assigned to the focus group will be asked to complete the 
PURAF again, using a vignette relevant to their area of practice prior to the focus group 
meeting. Nurse participants will be encouraged to highlight any areas which they find 
confusing on the PURAF documentation form. The co-facilitator will assess data 
completeness and list areas where data items have not been completed or not completed as 
required, as well as areas noted by the nurses as confusing. 
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Following this the focus group meeting will convene to discuss the use of the PURAF. The 
moderator will promote group interaction and guide discussions around a topic guide which 
will incorporate the data completeness assessment. This will consider the usability and any 
areas of confusion regarding the use of the PURAF. The meeting will be moderated by the 
researcher and a co-facilitator and will be audio-recorded.  
 
7.7 Think out loud interviews 
Up to four nurses from each session will be assigned to the one-to-one think out loud 
interview.  Each nurse will be asked to complete the PURAF again using a vignette case 
study appropriate to their area of practice in the presence of the researcher. The researcher 
will be present to encourage the nurse to vocalise their thoughts as they complete the PURAF 
(see topic guide appendix 5). This will allow specific issues relating to difficulty in 
interpreting or confusion about aspects of the PURAF to be identified. The interview will be 
audio-recorded. 
 
7.8 Data analysis 
The focus group meetings and the think out loud interviews will be audio-recorded and 
transcribed to allow thematic analysis of issues relating to the PURAF.  The emphasis will be 
on identifying dominant trends across the focus groups and think out loud interviews which 
impact on the application of the PURAF in clinical practice. Following this, adjustments in 
relation to the wording and the format of the PURAF may be made informing the next stages 
of the study.  The analysis and adjustments will be made soon after each focus group and 
think out loud interviews, informing the PURAF used in subsequent groups in an iterative 
process.  
 
Participant demographics data will be summarised using simple descriptive statistics. Data 
completeness of the PURAF will be assessed by missing data for data items and risk 
categories using simple descriptive statistics (computing the percentage of missing data for 
each item) and areas of confusion will be listed. 
 
8.2 Ethical considerations 
This study will recruit Registered Nurses. The related ethical issues are minimal and mainly 
relate to the time taken to attend the PURAF training and audio-taped focus groups or one-to-
one think out loud interviews. There are no other forseen risks to participants. Informed 
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consent will be obtained prior to participation in the study. The right of a potential participant 
to refuse without giving reasons will be respected. The patient will remain free to withdraw at 
any time from the study without giving reasons 
 
The study will be submitted to and approved by the University of Leeds, School of 
Healthcare Research Ethics Committee (SHREC). The CTRU will provide SHREC with a 
copy of the final protocol, participant information sheets, consent forms and all other relevant 
study documentation. 
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Appendix 26 Pressure Ulcer Risk Assessment
Framework pre-test study consent form
Participant Study Number: Office use only Participant initials: 
 
PURAF PRE-TEST NURSE PARTICIPANT CONSENT FORM  
 
Pressure UlceR Programme Of ReSEarch 
The Pressure Ulcer Risk Assessment Framework (PURAF) Pre-Test Study 
 
The participant should complete the whole of this sheet himself/herself 
 
 
Please confirm the 
statements by putting your 
initials in the box below 
I confirm that I have read and understand the information sheet dated (insert 
date of SHREC approval and information sheet version number) for the 
above study. I have had the opportunity to ask questions and have had these 
answered satisfactorily.  
 
 
I agree to allow any information or results arising from the study to be used 
for training and developing new research. 
 
 
I understand that my focus group and interview data may be looked at by 
responsible individuals from the study office where it is relevant to my 
taking part in the study. I give permission for these individuals to have access 
to my information and data. 
 
I consent to the storage including electronic, of personal information (name, 
contact details and place of work) which will be used by the researcher for 
ongoing contact with me for the purposes of this study only. I understand that  
my completed interview and focus group data will remain anonymous.  
 
 
 
 
I consent to being audio-taped in the focus group meeting or one-to-one 
meeting. 
 
I agree to take part in this study   
 
Participant Name:                 Participant Signature:                                   Date: 
Thank you for agreeing to take part in this study. 
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Appendix 27 Pressure Ulcer Risk Assessment
Framework pre-test study case studies
RAF Pre-Test Acute Sector Case Studies 
 
Case Study 1 
Trudie is a 75 year old lady who lives with her husband. She is admitted to hospital for 
investigations into her intermittent abdominal pain. She is active and mobile and other than 
intermittent abdominal pain reports being fit and well. Trudie walked on to the ward unaided. 
She reports no skin problems. 
 
Case Study 2 
Susan is a 21 year old student who is admitted with a severe headache. She is a keen hockey 
player and reports being usually fit and well. Susan refuses analgesia as it makes her feel 
‘strange’. She is fully mobile: due to her pain she can’t get comfortable and moves from bed 
to chair frequently and walks to the toilet. She reports no skin problems. 
 
Case Study 3 
John is a 29 year old gentleman who is admitted with acute appendicitis. John is a keen rugby  
player and is normally fit and well, though he is an insulin dependent diabetic which is well 
controlled and he does not have peripheral neuropathy. On admission John has a lot of pain, 
feels generally unwell and remains in bed. He has pain relief but is fully alert. John moves 
around in bed independently and frequently walks to the toilet unaided. John generally has a 
good diet and has a muscular stocky build, but is put nil by mouth on admission and is to 
have an IVI put up. He has no moisture or circulation problems. The staff nurse assesses 
John’s pressure ulcer risk as part of her admission procedures. 
 
Case Study 4 
Hilda is an 80 year old lady who is admitted to the elderly care ward following a chest 
infection. Hilda lives in a warden controlled flat with her 85 year old husband. Hilda has a 
history of COPD and previous chest infections. Hilda is usually quite active and mobile 
within in her home but is restricted to the distance she can walk due to breathlessness.  
 
On admission to the ward Hilda is weak and not as mobile as usual: she is able to transfer 
herself but needs the aid of one nurse to accompany her when walking to the toilet as she 
feels unsteady.  She is able to change her position independently and does when she feels 
uncomfortable, but is lethargic and spends most of her time in the chair. Hilda has lost her 
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appetite and says she has lost weight in the last 2-3 weeks and appears to be very thin and 
bony. She has been taking steroids and her skin appears thin and dry. She doesn’t have any 
moisture problems and is not diabetic. The staff nurse assesses Hilda’s pressure ulcer risk as 
part of her admission procedures. 
 
Case Study 5 
Jenny is an 80 year old married lady who is admitted to surgical ward with abdominal pain 
following an elective laparoscopic cholecystectomy 14 days ago. On admission she has a 
temperature of 39 – 40 degrees C and is very sweaty. She is being treated in a side room due 
to a possible infection and diarrhoea. She is ‘nil by mouth’ and commences IV fluids and 
antibiotics, though normally eats well and is a healthy weight. Jenny is given morphine as 
pain relief which makes her very sleepy. She is very lethargic and rests in her bed. She is able 
to transfer to the commode with the assistance of one nurse. She is able to change her 
position independently in bed but due to her lethargy doesn’t very often.  Prior to her recent 
health problems Jenny was in good health, is not diabetic and doesn’t have any circulatory 
problems. The staff nurse assesses Jenny’s pressure ulcer risk as part of her admission 
procedures. 
 
Case Study 6 
Joan Smith, a 72 year old lady who lives alone, has just been admitted to an acute medical 
ward following a stroke. Joan works part-time as a florist. She was found unconscious on the 
floor by her friend.  It is unclear how long she had been on the floor but no one had seen her 
for 18 hours.  Prior to having the stroke Joan’s son reported she was in reasonable health and 
was fully mobile, though she does have hypertension which is controlled with medication. He 
reported that she had a good appetite, was not diabetic and didn’t have any problems with her 
circulation.  
 
On admission Joan is conscious but dazed and had been incontinent of urine. She has a right 
sided hemiplegia and is unable to walk or weight bear. Joan is presently being nursed in bed 
and a physio assessment is being undertaken later today. She is unable to change her position 
in bed. Joan is to be ‘nil by mouth’ until she has a swallow test, was dehydrated on admission 
and so has an IVI is in place. She is overweight. 
 
Case Study 7 
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Joe is a 65 year old retired tool maker who has been in hospital for the last 4 days for 
investigations of vascular disease. He lives with his partner and until the last 6months was 
quite active enjoying gardening in his allotment. Joe reports that he used to be a heavy 
smoker but managed to stop smoking 18months ago. He has severe pain in his left calf when 
walking which has led to a reduction in mobility: he is able to walk short distances unaided.  
He has obvious poor peripheral circulation. He is if of normal build, eats a good diet and is 
not diabetic 
 
On the second day of his hospital stay Joe developed a chest infection and a high temperature 
and felt generally unwell. He has spent the last few days mainly in bed though has walked to 
the toilet occasionally and is continent. While in bed he was able to change his position when 
uncomfortable but remained mostly in the recumbent position. The staff nurse reassesses 
Joe’s pressure ulcer risk in response to his changing condition and in response to him 
reporting a sore left heel. 
 
RAF Pre-Test Community Sector Case Studies 
 
Case Study 1 
Sally is a 19 year old student and newly diagnosed diabetic. She is visited by the Diabetic 
Specialist Nurse for training and support in relation to giving her own insulin. Sally leads a 
very active outdoor life and other than her diabetes is fit and well. She reports no skin 
problems. 
 
Case Study 2 
Hilda is a 70 year old lady with rheumatoid arthritis who lives with her husband. She has 
recently had a short hospital stay after stumbling and fracturing her humerus. Hilda normally 
gets about her home well often using the furniture and a walking frame when necessary 
(particularly outside the home). The hospital nurses were concerned that her mobility had 
reduced and that she needed help to walk as she couldn’t use the frame due to her fractured 
humerus: they requested a District Nurse visit to assess her pressure ulcer risk at home. 
 
The District Nurse visited Hilda at home on the day after her discharge from hospital. Hilda 
reported that other than her long-term problem of rheumatoid arthritis she was quite well and 
independent. She eats a balanced diet, is a normal weight and is not diabetic. She doesn’t 
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have any circulatory problems and is continent. She acknowledged that while she had found 
walking in the hospital difficult this has not been a problem since she had returned home: she 
explained that while she was unable to use the walking frame she was able to use the 
furniture in her home to get around and she had lots of aids and adaptations to help her– 
obviously this had not been possible on the hospital ward. She reported that she had been 
glad to get home where she had regained her independence and was enjoying ‘pottering’ at 
home and changed her position frequently. She was also glad to be enjoying home cooked 
food rather than the ‘hospital slop’. 
 
Case Study 3 
John is an 82 year old, retired teacher who lives in his detached bungalow on his own 
following the death of his wife 2 years ago. His son lives away and his daughter lives in the 
next town 10 miles away. John has peripheral vascular disease, is diabetic and has peripheral 
neuropathy. John had a recent hospital stay following a chest infection and difficulties 
managing his diabetes with oral medication: he is now insulin dependent. Whilst in hospital 
John developed a category 2 pressure ulcer on his right heel but this is now reported to be 
healed.  
 
The District Nurse visits John on his return home to assess his needs and pressure ulcer risk 
and to administer his daily insulin. He has meals on wheels and homecare to help with food 
preparation, cleaning and helping him to bed. He has a good appetite and is slightly 
overweight. Johns neighbour brings him a paper each morning and checks he is ok. John 
spends most of the day in his chair, only moving when he needs the toilet and is continent.  
He is able to walk in his home with a walking frame but sometimes needs prompting.  
 
Case Study 4 
Eileen is a 75 year old retired secretary and is in the end stages of terminal uterine cancer. 
She is being cared for at home by her husband and their daughter with support from the 
District Nursing Team. As Eileen’s condition deteriorates the District Nurse reassesses her 
pressure ulcer risk.  Eileen is very weak and spends most of her time in bed though does get 
up for short periods. She has just started having a morphine syringe driver and is quite 
lethargic. She can independently turn over in bed but doesn’t do this very often. She needs 
the help of another person to transfer. Eileen developed a raised temperature and was found 
to have a UTI for which she is having antibiotics: due to this has been incontinent of urine.  
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Eileen has a poor appetite and is just eating small amounts, though appears to be of normal 
weight. She is not diabetic and does not have any circulatory problems. 
 
Case Study 5 
Jack is an 86 year old retired builder who lives in a residential home due to dementia. The 
District Nurse has been called to assess his pressure ulcer risk as his condition has recently 
deteriorated. He has developed a chest infection which is related to swallowing difficulties. 
Jack needs to be fed by the carers and has recently been refusing to eat and has lost weight, 
though appears to be of normal weight. He is not diabetic and doesn’t have any circulatory 
problems. He is regularly incontinent of urine and faeces. Jack spends most of his time in the 
chair or bed and needs 2 nurses to assist him to transfer. He can only make small independent  
movements when in his bed or chair. He gets very agitated at times. 
 
Case Study 6 
Beatrice is 50 years old and has primary progressive MS. Beatrice had to give up her job as a 
dinner lady 7 years ago when her mobility deteriorated to the point that she could no longer 
work. Since that time her mobility has steadily declined and got significantly worse over the 
last 6 months. She is now unable to walk or talk making communication very difficult.   She 
is cared for at home (in a ground floor flat) by her husband and 2 daughters who managed 
quite well up until the last 6 months when she has become very dependent. Care workers 
come in rarely.  Her husband works full time, plus extra hours to support the family as he has 
a poorly paid job. The family have had little advice about how to care for Beatrice as her 
condition has declined. After her husband visits the GP in distress saying they are struggling 
to cope and Beatrice is becoming sore, a District Nurse is requested to visit to assess 
Beatrice’s care needs and her pressure ulcer risk. 
 
Beatrice is doubly incontinent with her urinary incontinence being a constant problem. They 
use pads in bed, but this has been difficult as they don’t have an adequate supply. She spends 
all her time in her single divan bed. She is unable to move independently and is not turned 
regularly as her daughters have not been told what to do to help her. No one inspects her skin 
condition regularly at home. She cannot eat properly and is losing weight, though is of 
normal build and is not diabetic. She doesn’t have any circulatory problems. She is unable to 
tell anyone if she is in pain and is unable to move herself to get comfortable.  
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Case Study 7 
Stephen is a 35 year old gentleman who was left paralysed from the waist down following a 
motorbike accident 10 years ago: he is a full-time wheelchair user. He lives with his partner 
and their son. He runs his own IT Company. Stephen eats a good diet and is a healthy weight. 
He does not have any circulatory problems or diabetes. He is uses intermittent catheterisation. 
He transfers from his chair independently. Stephen has been under a lot of pressure at work 
and has not been undertaking skin inspections or position changes as he was taught and has 
been spending long periods of time in the same position working at his desk. He has also had 
a recent urine infection but continued to work without taking a break. The GP was called 
after Stephen’s wife noticed blood on the bed sheets and a District Nurse visit was requested 
to undertake a pressure ulcer risk assessment. 
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Appendix 28 Pressure Ulcer Risk Assessment
Framework focus group topic guide
1. Introduction of moderators and group members by name.
2. The overall aims of the study and how the focus group contributes to this will be explained by
the moderator.
3. Aims of the session – to consider the acceptability of using the Pressure Ulcer Risk Assessment
Framework (PURAF) incorporating:
i. what was liked about the PURAF
ii. what was disliked about the PURAF
iii. usability of the PURAF and how nurses found using the PURAF overall (were there any
confusing areas)
iv. whether nurses anticipate any problems in using the PURAF in clinical practice.
4. Ground rules – Everyone will have chance to speak and be heard. There are not right or wrong
answers. The moderator will remind the group that the meeting will be audio-taped, answer any
questions and confirm that everyone is happy to proceed with the meeting.
5. Ice breaker – discussion in pairs of what was liked about the PURAF and list on flip chart and
group feedback.
6. Group discussion of what was disliked about the PURAF and list on flip chart.
7. Group discussion of the usability of the PURAF and how the nurses found using the framework overall
(were there any confusing areas). The moderator will use the data completeness forms taken from the
training element to inform discussions. Note on flip chart.
8. Group discussion of any anticipated problems with using the PURAF in clinical practice. Note on
flip chart.
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Appendix 29 Pressure Ulcer Risk Assessment
Framework pre-test study think out loud topic guide
1. Introduction of researcher to nurse.
2. Aims of the interview are to identify any specific items that cause confusion when using the PURAF.
3. Ground rules – There are not right or wrong answers. The researcher will remind the nurse to
‘think out loud’ as he or she completes the PURAF. The researcher will remind the nurse that the
interview will be audio-taped, answer any questions and confirm that he or she is happy to proceed
with the interview.
4. The nurse completes the PURAF again using a case study with photographs and the researcher
encourages the nurse to ‘think out loud’ as he or she does this.
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Appendix 30 Preliminary Risk Assessment
Framework: PURPOSE-T
P lease note that the PURPOSE-T incorporates the use of colour to aid decision-making. This version ofthe tool has been adapted with the colour key included. It is not intended for implementation and
is not the final version of the tool.
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Appendix 31 Pressure Ulcer Risk Assessment
Framework field test 1 reduced format protocol
NB: This study protocol (version 3, dated 30 Oct 2012) is in a reduced format including only 
the study aims, methods and ethical considerations.  Sections pertaining to study background 
have been removed as they are included as a chapter section. Information pertaining to 
serious adverse events, data monitoring, quality assurance, confidentiality, archiving, 
statement of indemnity, study organisational structure, funding, and publication policy are 
available upon request 
 
4 FLOW DIAGRAM PURAF FIELD TEST 1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hospital Patients Community Patients 
Eligibility and Consent 
Registration 
Baseline Assessment 
Inter-Rater Reliability 
Assessments  
Clinical Research Nurse and 
Ward/Community Nurse 
Test Re-test Reliability 
Assessment  
Clinical Research Nurse 
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6 AIM AND OBJECTIVES 
The aims of Field Test 1 are to: 
1. assess the inter- rater and test-retest reliability of the  PURPOSE T  
2. assess the convergent validity, known groups validity, data completeness and clinical 
usability of the  PURPOSE T. 
 
7 FIELD TEST 1 METHODS 
7.1 Design 
The PURPOSE T will be evaluated through field testing using observational descriptive 
methods. The Field Test will evaluate the PURPOSE T in relation to its inter-rater reliability, 
test re-test reliability, data completeness, convergent validity, known group differences and 
clinical usability. Appendix 2 presents full details of the tests and criteria used in the 
instrument evaluation.  
 
In-patients and community nursing patients will be invited to participate. Demographic 
characteristics and pressure ulcer risk will be assessed for all patients. Paired assessments will 
be undertaken using the PURPOSE T, one by a ward/community nurse and one by a nurse 
from the Tissue Viability Team (TVT; Tissue Viability Nurse Consultant/Specialist/Research 
Nurse) with specialist tissue viability knowledge. To minimise patient burden the clinical 
skin assessment component of the PURPOSE T assessment will be undertaken 
simultaneously by both assessors, but recorded separately with blinding maintained. The 
other components of the assessment will be undertaken separately and each nurse will remain 
blind to the corresponding assessment. Finally the ‘TVT nurse will reassess the patient using 
the PURPOSE T at a clinically appropriate timeline determined on an individual patient basis 
but broadly 1-7 days after the first assessment. 
 
7.2 Description of pressure ulcer risk primary or secondary evaluation 
tool (PURPOSE T) 
The PURPOSE T instrument has been developed to identify whether patients are ‘not at risk’ 
or ‘at risk’ of pressure ulcer development. It consists of 22 data items for the assessment of 6 
risk factor domains (mobility, skin, nutrition, perfusion, moisture and sensory percention). 19 
items are a yes/no response and 3 items are a 3 point categorical sub-scale. Completion of the 
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assessment framework leads to a decision about risk status. Nurses using the PURPOSE T 
will have completed standard training in its use. A draft of the provisional PURPOSE T 
which is currently being developed by a graphic designer prior to the pre-test stage (April-
May 2012) is detailed in Appendix 1. 
 
7.3 Patient eligibility 
7.3.1 Inclusion criteria  
Patients who meet the following inclusion criteria: 
· Aged > 18years 
· An inpatient in the acute setting or community nursing patient in the community 
setting 
· Give their written informed consent/verbal witnessed consent/consultee agreement 
· Expected to be available for the PURPOSE T re-test 
 
7.3.2 Exclusion criteria 
· Patients in obstetric, paediatric, day case surgery or psychiatric settings(acute or 
community) 
· Unable to provide consent/consultee agreement 
· Deemed by the attending healthcare professional to be too unwell to be approached 
and/or complete the study assessment schedule 
 
7.3.3 Sampling strategy 
An approximate sample of 230 patients will be purposively sampled ensuring a similar 
number of hospital and community patients and representation of patients across 4 broad 
levels of risk (as defined by their mobility and PU status) as follows: 
· No mobility restrictions  
· Some mobility/ activity limitations  
· Bedfast/chairfast  
· PU category >1 
 
Each ward/community nurse will identify patients on their caseload who have the above 
characteristics.  
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We will monitor patient characteristics for other key risk factors including micro and macro 
circulatory disease, diabetes, nutritional deficits and moisture problems and target sampling if 
required.  
 
In the hospital setting, specialties (vascular, elderly, medicine, orthopaedics, oncology, 
surgery) and acute/elective wards will be mapped and ward nurses will be identified in all 
these areas, ensuring balanced represtentation of patients.  
 
7.4 Recruitment and consent 
Ward/community based nurses will identify suitable patients from their area of practice. A 
full verbal explanation of the study Patient Information Leaflet will be provided by the 
attending clinical staff or a member of the Tissue Viability Team (TVT; Tissue Viability 
Nurse Consultant/Specialist/Research Nurse) for the patient to consider.  This will include 
detailed information about the rationale, design, and personal implications of the study. 
Following information provision, patients will have as long as they need to consider 
participation and will be given the opportunity to discuss the study with their family and 
other healthcare professionals before they are asked whether they would be willing to take 
part in the study. Assenting patients will then be invited to provide informed, written consent.  
Should the patient be capable of giving consent but physically unable to complete the written 
aspects of the consent form, witnessed consent should be obtained using the Witnessed 
Consent Form. An appropriate witness would be a family member or friend of the patient, or 
another member of the patient’s healthcare team who is not directly involved in the research 
study. 
 
A record of the patient involvement in the study and consent/assent process detailing the date 
of consent will be documented in the patient healthcare records.  
 
Assessment of eligibility and informed consent will be undertaken by a member of the TVT 
The right of the patient to refuse consent without giving reasons will be respected. Further, 
the patient will remain free to withdraw from the study at any time without giving reasons 
and without prejudicing any further treatment.  
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The original consent/assent form will be retained in the Investigator Site File, a copy of the  
consent form will be given to the patient, a second copy filed in the patient’s healthcare 
records and a third copy will be sent to CTRU. 
 
7.4.1 Consultee agreement 
A large proportion of patients suffering from pressure ulcers/at risk of pressure ulcers have 
receptive or comprehension or language difficulties. They may also have general cognitive 
impairment affecting their understanding and/or dementia. To ensure that the study 
population is representative of the clinical population assessed in the course of usual care, 
recruitment procedures will facilitate consultee agreement. This is important because the 
nature of a pressure ulcer risk assessment includes history taking and also clinical 
examination, both of which are impacted when patients have cognitive impairment or 
language difficulties. In order to assess the reliability and validity of the PURPOSE T as the 
basis for use in clinical practice, it is important that the study population is a representative 
patient population. 
 
The assessment of capacity will relate specifically to decisions pertaining to this particular 
research project. Each patient will be assumed to have capacity unless it is established that 
they lack capacity. Ward/community based nurses identifying patients for study participation, 
will be asked to consider aspects of capacity before any approach to patients is made and 
during the information giving stage prior to consent. The TVT member will  assess the 
patient’s ability to understand what decisions they need to make and why; the consequences 
of the decision to participate; their ability to understand, use and retain the information 
related to the decision to participate and be able to communicate their decisions effectively 
(as specified in the Mental Capacity Act 2005). If there is any concern about capacity the 
ward/community based nurses/TVT  member will consult further with other members of the 
attending clinical team and/or relative/carer/friend (as appropriate) and a decision will be 
made with the relative/carer/friend as to whether the patient is able to provide written 
consent. Where the patient is thought not to have capacity to consent, a relative, carer or 
friend who is interested in the patient’s welfare will act as a personal consultee.  
 
The relative/carer/friend will be involved in the information and decision making process 
with the patient and will advise the TVT member on their presumed wishes and feelings and 
Consultee Assent will be obtained on behalf of the patient. The relative, carer or friend will 
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be advised to set aside their own views and provide advice on the participation of the patient 
in the research, taking into consideration the patient’s wishes and interests. Research 
participants will not be required to do anything which is contrary to any advance decisions or 
statements that have been made by them in relation to their treatment or any other matter. 
Advance decisions made by the patient about their preferences and wishes will always take 
precedence.  
 
If, despite taking all reasonable steps, a personal consultee cannot be identified and contacted 
then a nominated consultee would be approached. This person would have no connection 
with the research project. They would be nominated by the TVT member; they would most 
likely be the participant’s lead clinician, their GP or a member of the care team. The 
consultee would be provided with the information leaflet describing the research study and 
the role of the consultee and it would be emphasised that they are being asked to act on behalf 
of the participant, rather than any personal views or feelings. 
 
It is unlikely to place a major burden on consultees as the research is a non-invasive study 
that has minimal burden on the participant. There are no changes in treatment relating to the 
study. 
 
7.5 Registration 
Patients who are both eligible for study participation and provide informed consent/consultee 
agreement will be registered. Informed consent for entry into the study must be obtained prior 
to registration. Following confirmation of informed consent/consultee agreement and 
eligibility patients will be registered into the study by an authorised member of staff at the 
study research site.  
 
Registration will be performed centrally using the CTRU automated 24-hour telephone 
registration system. Authorisation codes and PINs, provided by the CTRU, will be required to 
access the registration system. 
 
The following information will be required at registration: 
· Patient details, including initials, gender and date of birth 
· Site code for research site 
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· Name of person making the registration 
· Confirmation of eligibility 
· Confirmation of informed consent/consultee agreement 
 
Direct line for registration +44 (0)113 343 3377 
 
8 ASSESSMENT AND DATA COLLECTION 
Assessments will be undertaken as follows: 
· Baseline  
o Demographics 
o Clinical assessment 
o PURPOSE T assessment (Ward/Community Nurse) and PURPOSE T (member 
of TVT) 
· Test-retest  
o PURPOSE T (same member of TVT who undertook the PURPOSE T assessment 
at baseline) at a clinically appropriate timeline determined on individual patient 
basis but broadly 1-3 days for hospital patients and 1-7 days community patients 
 
8.1 Research Assessments 
8.1.1 Baseline demographics 
A member of the TVT will record baseline demographics information including: 
· Name of NHS Trust 
· NHS Facility/Service name (name of hospital/intermediate care/community nursing 
team) 
· Type of admission/referral (e.g. elective/acute) 
· Hospital patients only - speciality  
· Initials 
· Date of birth 
· Gender 
· Ethnicity 
 
To enable the test-retest follow-up the TVT member will record and destroy after the visit the 
following information: 
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· Patient’s NHS ID 
· Patient’s Hospital/Trust number (if applicable) 
· Hospital patients only – ward number/name 
· Community patients only – place of residence 
 
8.1.2 Baseline clinical assessment 
A member of the TVT will record baseline clinical assessment including: 
· Date and time of assessments 
· Braden Score (Braden and Bergstrom 1987) (Appendix 3) 
· Waterlow Scale (Waterlow 1985) (Appendix 4) 
 
 
Table 1 NPUAP/EPUAP Pressure Ulcer Classification System (2009) 
Category Description 
Category I 
Non-blanchable redness of 
intact skin 
Intact skin with non-blanchable erythema of a localised area 
usually over a bony prominence. Discolouration of the skin, 
warmth, oedema, hardness or pain may also be present. 
Darkly pigmented skin may not have visible blanching. 
Category II 
Partial thickness skin loss or 
blister 
Partial thickness loss of dermis presenting as a shallow open 
ulcer with a red pink wound bed, without slough.  May also 
present as an intact or open/ruptured serum-filled or sero-
sanginous-filled blister. 
Category III 
Full thickness skin loss (fat 
visible) 
Full thickness tissue loss. Subcutaneous fat may be visible 
but bone, tendon or muscle are not exposed. Some slough 
may be present. May include undermining and tunnelling. 
Category IV 
Full thickness tissue loss 
(muscle/bone visible) 
Full thickness tissue loss with exposed bone, tendon or 
muscle. Slough or eschar may be present. Often includes 
undermining and tunnelling. 
Category U (Unstageable/ 
Unclassified) 
Full thickness skin or tissue 
loss – depth unknown 
Full thickness tissue loss in which actual depth of the ulcer is 
completely obscured by slough (yellow, tan, grey, green, or 
brown) and/or eschar (tan, brown, or black) in the wound 
bed. 
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8.1.3    PURPOSE T assessment  
· Ward/Community Nurse 
o Date and time of assessment 
o PURPOSE T including skin assessment (sacrum, buttocks, heels, hips and 
other) (Appendix 1)using the skin classification scale (Table 1) 
· Member of TVT 
o Date and time of assessment 
o PURPOSE T including skin assessment (sacrum, buttocks, heels, hips and 
other) (Appendix 1) using the skin classification scale (Table 1) 
 
8.1.4 Test re-test risk assessments 
· Same TVT member that undertook the first PURPOSE T assessment (8.1.4) 
o Date and time of assessment 
o PURPOSE T  including skin assessment (sacrum, buttocks, heels, hips and 
other) (Appendix 1)using the skin classification scale (Table 1) 
o Clinically relevant changes to condition since baseline assessment 
 
8.2 Data collection Procedures 
8.2.1 Baseline assessments 
Following informed consent/relative assent and at a time convenient to the patient the TVT 
member will complete demographic, clinical assessments and all components of the 
PURPOSE T apart from the skin assessment component. This baseline assessment will 
involve general observation (for example of spontaneous movement), history taking, and 
consulting relevant sections of the medical/nursing records. 
 
A paired ward/community nurse PURPOSE T assessment will be undertaken separately at a 
time convenient to the patient and close enough in time to the TVT assessment to avoid any 
change in clinical condition. A PURPOSE T assessment proforma will be provided to the 
ward/community nurse with pre-populated standard header details including patient initials, 
date of birth and study ID. The ward/community nurse will complete all components of the 
PURPOSE T apart from the skin assessment component.  
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To minimise patient burden and due to the transient nature of alterations to intact skin which 
impacts upon the reliability of the skin assessment component (Nixon et al 2005a) the Stage 2 
clinical skin assessment component of the PURPOSE T assessment will be undertaken 
simultaneously by both the ward/community nurse and TVT member, but recorded on 
separate PURPOSE T proformas, with blinding maintained. This method has been 
successfully adopted previously in an inter-rater reliability skin assessment study (Nixon et al 
2005, Nixon et al 2006). 
 
Following blinded completion of the PURPOSE T proforma the TVT member and the 
ward/community nurse will separately fold and seal their copies of the completed pro-forma. 
The TVT member will return the sealed proforma’s with the other study documentation in a 
sealed envelope to the Clinical Trials Research Unit and the other sealed carbonated copies of 
the PURPOSE T will be kept in the site file. 
 
8.2.2 Test re-test 
The TVT member who undertook the initial PURPOSE T assessment will undertake a second 
PURPOSE T assessment, without access to the first assessment. The length of the test re-test 
interval must be short enough to ensure that clinical change in the PU is unlikely to occur, but 
sufficiently long to ensure that respondents do not recall their responses from the first 
assessment. A short test re-test interval is necessary to ensure that stability per se is being 
evaluated, rather than clinical change in the PU during the test re-test interval, which will 
underestimate reliability. We anticipate that the re-test will be undertaken between 1-3 days 
in hospital patients and 1-7 days in community patients, after the first assessment depending 
upon the anticipated recovery/deterioration/stability of the patients’ condition and for hospital 
patients, length of stay. The assessing nurse will determine the re-test date and time, with the 
patient at the end of the baseline assessment visit. 
 
8.2.3 PURPOSE T Field Notes 
The TVT members involved in data collection will keep field notes of their experience of 
using PURPOSE T in clinical practice. The field notes will be summarised and used to 
inform design amendments and issues of importance for implementation. 
 
9 STATISTICAL CONSIDERATIONS 
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9.1 Sample size 
9.1.1 Inter-rater reliability 
In the study population we expect approximately 25% will be ‘not at risk’ and 75% ‘at risk’. 
In a 2-rater study, the numbers of subjects required to detect a statistically significant κ (2-
sided p-value < 0.05) with 90% power and 75% assessed as being ‘at risk’, assuming a null 
hypothesis value for κ are given in Table 2. To establish whether the tool gives a high degree 
of beyond-chance agreement, we will test against a null value of 0.6.  With 90% power, 199 
patients will be required. To allow for withdrawal/non-compliance in paired ward/community 
nurse assessments of 15% we will aim to recruit 230 patients. 
 
9.1.2  Validity assessment  
No examples of formal sample size estimation methods for evaluation of screening 
instruments were identified in the literature.  Therefore, literature relating to the psychometric 
evaluation of rating scales were considered. The ‘rule of thumb’ recommendation of 5-10 
patients for every item in a questionnaire has been used to estimate the sample size of 115-
230 patients (Nunnally and Bernstein 1994, Blazeby et al 2002). The proposed sample size of 
230 to assess the inter-rater reliability of the instrument, with >95% TVT data compliance 
(based upon previous research experience), will therefore provide sufficient numbers of 
patients to assess the validity of the risk assessment instrurment.  
 
Table 2 Inter-rater reliability sample size estimates  
Kappa to detect Null value N required patients (90% Power) 
0.7 0.4 114 
0.7 0.5 231 
0.7 0.6 793 
0.8 0.4 64 
0.8 0.5 103 
0.8 0.6 199 
0.8 0.7 536 
0.9 0.4 41 
0.9 0.5 58 
0.9 0.6 89 
0.9 0.7 159 
DOI: 10.3310/pgfar03060 PROGRAMME GRANTS FOR APPLIED RESEARCH 2015 VOL. 3 NO. 6
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Nixon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
453
9.2 Analysis methods 
The analysis plan outlined in this section will be reviewed and a final statistical analysis plan 
will be written before any data summaries or analyses are performed. The analysis plan will 
be written in accordance with current CTRU Standard Operating Procedures. Any changes to 
the final analysis plan and reasons for change will be documented. 
 
9.2.1 Inter-rater and test re-test reliability 
Kappa is a statistic that is used to measure agreement beyond that expected by chance, and 
thus is a measure of “true agreement”. It indicates the proportion of agreement beyond that 
expected by chance (Cohen 1960). Thus kappa is the achieved beyond-chance agreement as a 
proportion of the possible beyond-chance agreement (Sim and Wright, 2005). The simplest 
use of kappa is in the situation in which two clinicians each provide an assessment of 
presence or absence of a characteristic representing inter-rater reliability or when a clinician 
provides two assessments of the same patient in relation to the presence or absence of a 
characteristic, representing intra-rater (test re-test) reliability. The concern is how well the 
ratings agree, not with how well the ratings agree with some “gold standard” or “true” 
diagnosis. 
 
The range of possible values for kappa is from -1 to 1, though it usually falls between 0 and 
1.  Unity represents perfect agreement, whereas zero represents agreement expected by 
chance. Although kappa represents the proportion of agreement greater than that expected by 
chance, its interpretation is not so straightforward, as there are other factors that can influence 
the magnitude of the coefficient or the interpretation that can be placed on a given magnitude.  
Among the factors that can influence the magnitude of kappa are prevalence, bias and non-
independence of ratings. 
 
Kappa can be adjusted for prevalence and bias with the resulting kappa coefficient is referred 
to as a PABAK (prevalence-adjusted bias-adjusted kappa).  It is recommended that PABAK  
is presented in addition to, rather than instead of kappa.  Interpretation guidelines have been 
proposed as standard strengths of agreement for kappa and are detail in Table 3 (Landis and 
Koch, 1977): 
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Table 3 The Kappa statistic 
Kappa Strength of 
agreement 
<0 
0.01-0.20 
0.21-0.40 
0.41-0.59 
0.60-0.79 
0.81-1 
Poor 
Slight 
Fair 
Moderate 
Substantial 
Almost perfect 
 
 
It has also been suggested that the interpretation of kappa could be assisted by reporting the 
maximum value is could attain for the set of data concerned.  To calculate the maximum 
value of kappa (κmax) the proportion of positive and negative judgements by each clinician are 
taken as fixed and the distribution of paired ratings is adjusted so as to represent the greatest 
possible agreement.  In contrast to PABAK, κmax serves to gauge the strength of agreement 
while preserving the proportion of positive ratings demonstrated by each clinician. Finally a 
95% confidence interval can be constructed around kappa (Bland 2008).   
 
We will undertake kappa (with 95% CIs), PABAK and κmax to assess the inter-rater reliability 
for agreement of risk status overall (at risk/not at risk). To further ensure the reliability of any 
findings we will also examine the extent of agreement for individual PURPOSE T items.  
 
In order to assess the test-retest reliability of PURPOSE T, the same approach of using kappa 
statistics and their variants PABAK and κmax will be employed, except that, rather than two 
independent raters assessing the risk status of the patient, it will be the same rater carrying 
out the assessment.  In order to preserve the independence of the two assessments, the two 
assessments will need to be far enough apart in time for the rater not to remember their 
original assessment (we judge an appropriate time period to be at least 1 days), but also not so 
far apart that the patient’s condition will have altered (we judge an appropriate time period to 
be no more than 3-7 days). 
 
9.3 Acceptability and data quality 
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Acceptability will be determined by data quality; assessed by completeness of item-level data 
(percent of missing data for items) and completeness of confirmation of risk status (percent of 
people for whom it is possible to assess risk).  
 
9.4 Convergent validity 
Convergent validity assesses the degree to which constructs (or scores on a measure) 
expected to be related are, in fact, related.  The degree to which assessment of ‘at risk’ and 
‘not at risk’ are related to risk assessment status as assessed using the Braden (Braden and 
Bergstrom 1987) and Waterlow (Waterlow 1985) risk assessment scales will be determined.  
 
A Spearman Rank correlation coefficient will be calculated between PURPOSE T and 
Braden and Waterlow risk status. In addition, where there are corresponding items between 
PURPOSE T and Braden and/or Waterlow (e.g. mobility), correlations will be performed to 
determine how closely PURPOSE T items are related to other risk screening items.  For 
exploratory purposes, the following hypotheses will be proposed as guides to the magnitude of 
correlations, as opposed to pass/fail benchmarks (high correlation r > 0.7; moderate correlation 
r = 0.3 - 0.7; low correlation < 0.3) (Burnand, 1990; Cohen 1960). Moderate to high 
correlations (r= > 0.3) are predicted.   
 
9.5 Known groups validity 
Known-group comparisons are used to evaluate the clinical utility of instruments or 
assessment tools.  This method assesses the extent to which the overall assessment or items 
are able to discriminate between subgroups of patients known to differ in terms of clinical 
presentations (Kerlinger, 1973).   
 
A chi-square test for independence (used to compare the frequencies of cases found in the 
various categories of one variable across the different categories of another variable) will be 
used to determine whether type of hospital patient (e.g. elective vs. acute) is related to risk 
group (e.g. at-risk vs. not at-risk).We anticipate that there will be a significantly lower 
proportion of elective surgical patients assessed as ‘not at risk’, compared to acute patients.  
 
12.2 Ethical considerations 
This study will include elderly and highly dependent patients considered as vulnerable. 
Ethical issues are largely related to the involvement of vulnerable adults/elderly patients with 
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high levels of co-morbidity including acute and chronic illness. A large proportion of patients 
suffering from pressure ulcers/at risk of pressure ulcers have receptive or comprehension or 
language difficulties. They may also have general cognitive impairment affecting their 
understanding and/or dementia. To ensure that the study population is representative of the 
clinical population assessed in the course of usual care, recruitment procedures will facilitate 
consultee agreement. This is important because the nature of a pressure ulcer risk assessment 
includes history taking and also clinical examination, both of which are impacted when 
patients have cognitive impairment or language difficulties. In order to assess the reliability 
and validity of the PURPOSE T as the basis for use in clinical practice, it is important that the 
study population is a representative patient population. 
 
The ethical issues surrounding these potentially vulnerable patients have been addressed 
through the study design and the use of local staff including experienced clinical nurses, that 
is, members of the local TVT to assess patients. In line with good clinical research practice, if  
a patient is clearly at risk or has an existing pressure ulcer and this is not reported in the 
patients’ healthcare notes, then it will be documented in the patients’ healthcare notes and 
reported to the ward/community nurse responsible for the patients care. 
 
The study will be performed in accordance with the recommendations guiding physicians in 
biomedical research involving human subjects adopted by the 18th World Medical Assembly, 
Helsinki, Finland, 1964, amended at the 52nd World Medical Association General Assembly, 
Edinburgh, Scotland, October 2000. Informed written consent/witnessed verbal 
consent/consultee agreement will be obtained prior to involvement into the study. The right 
of a patient to refuse participation without giving reasons will be respected. The patient will 
remain free to withdraw at any time from the study without giving reasons and without 
prejudicing his/her further treatment. If a participant withdraws consent from further study 
participation their data will remain on file and will be included in the final study analysis. 
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Appendix 1: Confidential DRAFT preliminary PURPOSE T 
[NB: Data for the preliminary PURPOSE T was collected however the scale is omitted due to  
copyright.  The final PURPOSE T can be obtained from 
URL:http://ctru.leeds.ac.uk/purpose]. 
 
 
Appendix 2: Reliability and Validity Tests and Criteria 
Test Property Definition/Test Criteria (Traditional) 
Data Quality 
Acceptability/Data 
completeness 
 
The extent to which PURPOSE T items are 
completed and used to allocate a risk 
category; quality of data is assessed by data 
completeness for each element of the 
PURPOSE T and a risk category. 
-% item level data missing 
-% of risk categories allocated 
-% of items missing  where a risk 
category has been allocated 
Inter-rater 
reliability 
 
 
Test Re-Test 
Reliability 
Inter-rater reliability assesses the extent to 
which the PURPOSE T results obtained by 
two or more raters agree for the same 
population. 
Test re-test reliability assesses the stability 
of the PURPOSE T over a period of time in 
which the patient’s condition is not 
expected to change. 
- The kappa statistic is a measure 
of true agreement and indicates 
the proportion of agreement 
beyond that expected by chance, 
that is the achieved beyond-
chance agreement as a proportion 
of the possible beyond-chance 
agreement. 
Content Validity The extent to which a scale measures what 
it intends to measure. 
 
 
-Qualitative evidence from the 
PU risk factor systematic review 
and PU-MDS and PURPOSE T 
consensus study that items in the 
scale are representative of the 
construct being measured. 
Convergent 
Validity (Between 
Scale analysis – 
analyses against 
external criteria) 
 
Known group 
differences 
Evidence that PURPOSE T constructs are 
correlated with other measures of the same 
or similar constructs; assessed on the basis 
of correlations between the measure and 
other similar measures (Braden Scale and 
Waterlow Score). 
The ability of PURPOSE T risk categories 
to differentiate known groups; assessed by 
-Correlations are expected to vary 
according to the degree of 
similarity between the constructs 
being measured by each 
instrument. Specific hypotheses 
are formulated and predictions 
tested on the basis of correlations.  
DOI: 10.3310/pgfar03060 PROGRAMME GRANTS FOR APPLIED RESEARCH 2015 VOL. 3 NO. 6
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Nixon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
461
comparing PURPOSE T risk categories for 
subgroups who are expected to differ on the 
construct being measured (significant 
differences between known group or 
difference of expected magnitude) (e.g. 
elective/acute patients). 
 
 
Appendix 3: Braden Score 
[NB: Data for the Braden scale was collected however the scale is omitted due to copyright.  
The Braden scale can be obtained from URL: http://bradenscale.com/]. 
 
Appendix 4: Waterlow scale 
[NB: Data for the Waterlow scale was collected however the scale is omitted due to 
copyright.  The Waterlow scale can be obtained from URL: http://www.judy-
waterlow.co.uk/index.htm]. 
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Appendix 32 Pressure Ulcer Risk Assessment
Framework field test 1 participant information sheet
[Delete this line, then print on Trust headed paper] 
 
Pressure UlceR Programme Of ReSEarch 
Pressure Ulcer Risk Assessment Framework (PURAF) Field Test 1 
PATIENT INFORMATION SHEET 
 
A large-print version of this sheet is available on request.
You have been invited to take part in a research study. Before you decide whether to accept, 
we would like to explain why the research is being done and what it will involve. Please read 
this information carefully, and discuss it with your relatives or carers if you wish. Ask us if 
anything is unclear, or if you would like more information. Part 1 tells you the purpose of this 
study and what taking part involves. Part 2 gives you more detailed information about the 
study. Thank you for reading this information sheet.  
 
Part 1 
What is the purpose of the study? 
This study is part of a larger study which is trying to find a better way of identifying patients 
who are at risk of developing pressure ulcers (bed sores) and those who already have pressure 
ulcers. A group of experts and patients have worked together to work out a list of questions to 
ask about you and this study is to check whether we can use this list to give reliable and 
consistent answers. We hope that the answers to these questions will give a good indication 
of whether you are at risk of a pressure ulcer or not, or if you have a pressure ulcer.  
 
Why have I been chosen? 
This study is looking for people like you who are in hospital or under the care of community 
nursing services. Hospital patients and patients within the community will be asked to take 
part. The study includes people with different levels of walking and movement ability. This 
includes people who are able to move easily, as well as people who have difficulty moving or 
are unable to move. It will also include some people who already have a pressure ulcer.  
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Do I have to take part? 
No, you do not have to take part. Taking part in this study is entirely voluntary and you are 
under no obligation to take part – it is up to you to decide. If you are interested we will 
describe the study to you and go through this Information Sheet. If you agree to take part you 
will be asked to sign the Consent Form at the end of this leaflet to show that you have agreed 
to take part. You will be given a copy of this Information Sheet and of the signed Consent 
Form to keep. If you do not wish to take part this will not affect the care that you are 
currently receiving. If you decide to take part you are free to change your mind and withdraw 
from the study at any time, without giving a reason. This would not affect the standard of 
care you receive. 
 
What if I would like to take part but I have trouble with or am unable to write to fill in 
the Consent Form? 
If you would like to take part but cannot or find it difficult to write, you can have someone (a 
witness) complete the written part of the consent for you. This witness could be a friend, a 
family member, or member of your healthcare team. The witness will only act to help you 
carry out your wishes – you are free to change your mind at any time and your wishes will be 
respected. 
 
What will happen to me if I take part? 
If you agree to take part in the study, two nurses will undertake an assessment that will 
involve asking you some questions relating to your health and refer to relevant sections of 
your nursing and medical records. Both nurses will also look at your skin in the areas which 
are exposed to pressure. This includes having a quick check of your elbows, heels, and 
bottom, which are the areas that are most at risk of getting a pressure ulcer. The nurses will 
also look at your pressure ulcer if you have one. A nurse will come and repeat the assessment 
a few days later at a time convenient to you. The questions and skin check will take about 20 
minutes and will take place in your own home, or on the hospital ward at a time convenient 
for you. 
 
What are the possible disadvantages and risks of taking part? 
APPENDIX 32
NIHR Journals Library www.journalslibrary.nihr.ac.uk
464
We do not foresee any disadvantages or risks to you in taking part in this study. However, 
you are being asked to give some of your time for taking part. Your care and treatment will 
remain the same whether or not you decide to take part.  
What are the possible benefits of taking part? 
There will be no direct benefit to you as a result of participating in this study. However, we 
hope that the information from this study will help to improve the assessment, prevention and 
treatment of pressure ulcers in the future.  
 
What if something goes wrong? 
If you have a concern about any aspect of this study, you should ask to speak with your 
healthcare practitioner (e.g. Nurse or Doctor) or other healthcare professional who will do 
their best to answer your questions. If you remain unhappy and wish to complain formally, 
you can do this through the NHS Complaints Procedure. In the unlikely event that you think 
you have been harmed by taking part in this study, there are no additional compensation 
arrangements. Details about complaints procedures can be obtained from your healthcare 
practitioner or PALs (Patient Advice and Liaison Services). 
 
Will my taking part be kept confidential? 
Yes. All information which would be collected about you during the course of the study will 
be kept strictly confidential. We will follow ethical and legal practice and all information 
about you will be handled in confidence. No names or details that would identify specific 
people from this study will be included in any reports, presentations or papers (published in a 
medical journal), or further healthcare and/or medical research.    
 
Involvement of your General Practitioner (GP) / Other Healthcare Practitioner 
Your GP will be informed that you are participating in this study. If you are under the care of 
a Hospital consultant (inpatients only), they will also be informed of your participation. 
 
This completes Part 1 of the Information Sheet. If the Information in Part 1 has 
interested you and you are considering participation, please continue to read the 
additional information in Part 2 before making any decision. 
 
Part 2 
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What will happen if I don’t want to carry on with the study? 
Taking part in this study is entirely voluntary and you are free to change your mind at any 
point during or following completion of the study without giving a reason. A decision to 
withdraw at any time will not affect the standard of care you receive, nor will it affect your 
relationship with the medical and nursing team who are looking after you. Should you choose 
to withdraw, then your existing data (until withdrawal) will remain on file and will be 
included in the final study analysis unless you specifically withdraw consent for this. 
 
Will my taking part in this study be kept confidential? 
If you decide to participate in the study, the clinical information collected about you during 
the course of the study will be anonymised and kept strictly confidential. We will record your 
date of birth and initials on all study forms. If you agree to the second assessment the study 
nurse will record your NHS ID, hospital number (hospital patients only) and address and 
telephone number (community patients only). This will be held only by the study nurse who 
will destroy this information immediately following your second assessment. A copy of the 
Consent Form you sign, which will include your name, will be sent to the Clinical Trials 
Research Unit. They do not put your name on computer. They simply check that the consent 
form has been signed and dated properly and will securely file the form.  
 
All information will be handled, processed, stored, and destroyed in accordance with the Data 
Protection Act 1998. The study team have a duty of confidentiality to you and will do their 
very best to meet this duty. All information obtained is strictly confidential and will be kept 
in locked cupboards and will only be accessible to members of the research team. No names 
or details that would identify specific people from this study will be included in any reports, 
presentations or papers (published in a medical journal), or further healthcare and/or medical 
research.    
 
Who has organised and sponsored the research? 
The study is being organised and coordinated by the Clinical Trials Research Unit (CTRU) at 
the University of Leeds, which is sponsoring the study. This study is a part of a larger 
pressure ulcer research programme funded by the National Institute of Health Research that 
aims to reduce the impact of pressure ulcers on patients. 
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Who has reviewed the study? 
The study has been peer reviewed by the National Institute of Health Research before 
approval for the funding was given. In addition, all research in the NHS is looked at by an 
independent group of people called a Research Ethics Committee in order to protect your 
safety, rights, wellbeing, and dignity. This study has been reviewed by the Leeds West 
Research Ethics Committee (reference 12/YH/022). 
 
What will happen to the results of the research study? 
When the study is complete the results will be published in a medical journal, but no 
individual participants will be identified in any report or publication. If you would like to 
obtain a copy of the published results, please ask your local contact person (see contact 
details below). We hope that the information from this study will help to improve the 
assessment, prevention and treatment of pressure ulcers in the future.  
 
Further information and contact details 
If you would like further information about clinical research, the UK Clinical Research 
Collaboration (a partnership of organisations working together on clinical research in the UK) 
have published a booklet entitled ‘Understanding Clinical Trials’.  Contact UKCRC: Tel: 
0207 670 5452; website www.ukcrc.org. If you want further information about the study, 
now or in the future, please contact (insert name) below. 
 
Your contact telephone numbers: (to include local collaborator)………………… 
………………………………………………………………………………………………....  
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Appendix 33 Pressure Ulcer Risk Assessment
Framework field test 1 participant consent form
 
 
 
 
 
[Delete this line, then print on Trust headed paper] 
PATIENT CONSENT FORM  
Where witnessed consent is required please use the Witnessed Consent Form 
 
Pressure UlceR Programme Of ReSEarch 
 Pressure Ulcer Risk Assessment Framework (PURAF) Field Test 1 
 
1. I confirm that I have read and understand the information sheet dated 23.05.2012 
(version 2) for the above study. I have had the opportunity to ask questions and have had 
these answered satisfactorily.                                                                                         
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without my medical care or legal rights being affected. 
 
3. I understand that if I withdraw from the above study, the data already collected from me 
will be used in analysing the results of the study unless I specifically withdraw consent for 
this. 
 
4. I understand that relevant sections of my healthcare records and data collected during the 
study may be looked at by individuals from the NHS Trust and the University of Leeds, 
where it is relevant to my study participation. I give permission for these individuals to 
have access to my records. 
 
5. I consent to the storage including paper and electronic, of personal information for the 
purposes of this study. I understand that any information that could identify me will be kept 
confidential and that no personal information that could identify me will be included in the 
Patient Study Number:  Patient Initials:  
Patient DOB: Site ID: 
Principal Investigator:  Version:  
Patient initial after 
each question 
.......... 
.......... 
.......... 
.......... 
.......... 
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study report or other publication. This information will be confidentially destroyed at the 
end of the study. 
 
6. I understand that information and results arising from this study may be used to  
develop new research. 
 
7. I understand that a copy of this consent form will be passed to the Clinical Trials 
Research Unit, University of Leeds. 
  
8. I understand that my GP and hospital consultant (where applicable) will be notified of 
my participation in this study. 
 
9.  I agree to take part in the study. 
 
_____________________ _____________ __________________________
Name of Patient               Date    Signature 
 
I have given written information and a verbal explanation to the person named above who has 
freely given their consent to participate. 
 
_____________________  _____________        __________________________ 
Name of Person taking consent  Date              Signature 
 
1 copy for patient, 1 for patient records, 1 for CTRU; original stored in Investigator Site File 
.......... 
.......... 
.......... 
 
.......... 
APPENDIX 33
NIHR Journals Library www.journalslibrary.nihr.ac.uk
470
Appendix 34 Pressure Ulcer Risk Assessment
Framework field test 1 witnessed consent form
[Delete this line, then print on Trust headed paper] 
WITNESSED CONSENT FORM  
 
Pressure UlceR Programme Of ReSEarch 
 Pressure Ulcer Risk Assessment Framework (PURAF) Field Test 1 
 
 
 
1. I confirm that I have read and understand the information sheet dated 23.05.2012 
(version 2) for the above study. I have had the opportunity to ask questions and have had 
these answered satisfactorily.                                                                                         
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without my medical care or legal rights being affected. 
 
3. I understand that if I withdraw from the above study, the data already collected from me 
will be used in analysing the results of the study unless I specifically withdraw consent for 
this. 
 
4. I understand that relevant sections of my healthcare records and data collected during the 
study may be looked at by individuals from the NHS Trust and the University of Leeds, 
where it is relevant to my study participation. I give permission for these individuals to 
have access to my records. 
 
5. I consent to the storage including paper and electronic, of personal information for the 
purposes of this study. I understand that any information that could identify me will be kept 
confidential and that no personal information that could identify me will be included in the 
study report or other publication. This information will be confidentially destroyed at the 
end of the study. 
 
6. I understand that information and results arising from this study may be used to  
.......... 
.......... 
.......... 
.......... 
 
.......... 
Witness initial after 
each question on 
behalf of patient 
.......... 
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develop new research. 
 
7. I understand that a copy of this consent form will be passed to the Clinical Trials 
Research Unit, University of Leeds. 
  
8. I understand that my GP and hospital consultant (where applicable) will be notified of 
my participation in this study. 
 
9.  I agree to take part in the study. 
 
 
__________________________  
Name of Patient    
 
Witness statement
I have completed this consent form on behalf of the person named above who has freely 
given their consent to participate. 
 
______________________    _____________ _________________________ 
Name of Witness      Date    Signature 
 
Research person taking Consent 
I have given written information and a verbal explanation to the person named above who has 
freely given their consent to participate. 
 
_______________________  _____________ __________________________ 
Name of Person taking consent          Date    Signature 
 
(1 copy for patient; 1 for patient records; 1 copy to CTRU; original stored in Investigator 
Site File) 
.......... 
.......... 
.......... 
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Appendix 35 Pressure Ulcer Risk Assessment
Framework field test 1 consultee information sheet
[Delete this line, then print on Trust headed paper] 
 
Pressure UlceR Programme Of ReSEarch 
Pressure Ulcer Risk Assessment Framework (PURAF) Field Test 1 
 CONSULTEE INFORMATION SHEET 
 
A large-print version of this sheet is available on request.
 
As the relative, carer, or friend of the patient I would like you to consider their participation 
in a research study. As he/she is unable to tell me whether they would be willing to take part 
themselves, I am asking you, as someone who has a close personal relationship with the 
patient, to consider this invitation on their behalf and respond as you think they would 
respond. It is important that you should consider their past or present wishes and feelings 
regarding research of this nature. You may have personal views on participation in this 
particular research project but I am asking you to advise on their views.  
 
Before you decide whether he/she should take part we would like to explain why the research 
is being done and what it will involve. Please read this information carefully, and discuss it 
with anyone else you wish to, for example relative, friend, nurse or doctor. Ask us if anything 
is unclear, or if you would like more information. Part 1 tells you the purpose of this study 
and what taking part involves. Part 2 gives you more detailed information about the study. 
Thank you for reading this information sheet.  
 
Part 1 
What is the purpose of the study? 
This study is part of a larger study which is trying to find a better way of identifying patients 
who are at risk of developing pressure ulcers (bed sores) and those who already have pressure 
ulcers. A group of experts and patients have worked together to work out a list of questions to 
ask about patients and this study is to check whether we can use this list to give reliable and 
consistent answers. We hope that the answers to these questions will give a good indication 
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of whether people are at risk of developing a pressure ulcer or not, or if they have a pressure 
ulcer.  
 
Why has the patient been chosen? 
This study is looking for patients’ who are in hospital or under the care of community nursing 
services. Hospital patients and patients within the community will be asked to take part. The 
study includes people with different levels of walking and movement ability. This includes 
people who are able to move easily, as well as people who have difficulty moving or are 
unable to move. It will also include some people who already have a pressure ulcer.  
 
Does the patient have to take part? 
No, they do not have to take part. Taking part in this study is entirely voluntary and there is 
no obligation to take part – it is up to you to decide whether or not you feel it is appropriate 
for them to take part. If you are interested we will describe the study to you and go through 
this Information Sheet. If you agree for the patient to take part you will be asked to sign a 
Consultee Declaration Form to show that you have been consulted about the patient 
participating in the study and have agreed it is appropriate for them to take part. You will be 
given a copy of this Information Sheet and of the signed Consultee Declaration Form to keep. 
If you do not feel it is appropriate for the patient to take part this will not affect the care that 
they are currently receiving.  
 
If you agree for the patient to take part you are free to change your mind and withdraw them 
from the study at any time, without giving a reason. This would not affect the standard of 
care they receive. 
 
If you do not feel able to advise on the patient’s views you may suggest someone else who 
has a close relationship with them or ask me to nominate a consultee, such as a doctor or 
nurse not involved in this study who knows the patient. If a nominated consultee is 
approached they will probably discuss the patient’s wishes with you before they give advice. 
 
What will happen to the patient if I agree they can take part? 
If you agree to the patient taking part in the study, two nurses will undertake an assessment 
that will involve referring to relevant sections of the patient’s nursing and medical records 
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and  asking the patient some questions (if applicable) relating to their health. Both nurses will 
also look at the patient’s skin in the areas which are exposed to pressure. This includes 
having a quick check of your elbows, heels, and bottom, which are the areas that are most at 
risk of getting a pressure ulcer. The nurses will also look at their pressure ulcer if they have 
one. With your agreement, one nurse will come and repeat the assessment a few days later at 
a time convenient to the patient. The questions and skin check will take about 20 minutes and 
will take place in the patient’s own home, or on the hospital ward they are on, at a time 
convenient for them. 
 
What are the possible disadvantages and risks of taking part? 
We do not foresee any disadvantages or risks to the patient in taking part in this study. 
However, they are being asked to give some of their time for taking part. The patient’s care 
and treatment will remain the same whether or not they take part in the study.  
 
What are the possible benefits of taking part? 
There will be no direct benefit to the patient as a result of participating in this study. 
However, we hope that the information from this study will help to improve the assessment, 
prevention and treatment of pressure ulcers in the future.  
 
What if something goes wrong? 
If you have a concern about any aspect of this study, you should ask to speak with the 
patient’s healthcare practitioner (e.g. Nurse or Doctor) or other healthcare professional who 
will do their best to answer your questions. If you remain unhappy and wish to complain 
formally, you can do this through the NHS Complaints Procedure. In the unlikely event that 
you think the patient has been harmed by taking part in this study, there are no additional 
compensation arrangements. Details about complaints procedures can be obtained from the 
patient’s healthcare practitioner, or PALs (Patient Advice and Liaison Services).  
 
Will taking part be kept confidential? 
Yes. All information which would be collected about the patient during the course of the 
study will be kept strictly confidential. We will follow ethical and legal practice and all 
information about the patient will be handled in confidence. No names or details that would 
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identify specific people from this study will be included in any reports, presentations or 
papers (published in a medical journal), or further healthcare and/or medical research.    
 
Involvement of the patient’s General Practitioner (GP) / Other Healthcare Practitioner 
The patient’s GP will be informed that they are participating in this study. If the patient is 
under the care of a Hospital consultant (inpatients only), they will also be informed of the 
patient’s participation. 
This completes Part 1 of the Information Sheet. If the Information in Part 1 has 
interested you and you are considering agreeing to the patient participating, please 
continue to read the additional information in Part 2 before making any decision. 
 
Part 2 
What will happen if I don’t want the patient to carry on with the study? 
Taking part in this study is entirely voluntary and you are free to change your mind about the 
patient participating in the study at any point during or following completion of the study 
without giving a reason. A decision to withdraw at any time will not affect the standard of 
care the patient receives, nor will it affect their relationship with the medical and nursing 
team who are looking after them. Should you choose to withdraw the patient, then their 
existing data (until withdrawal) will remain on file and will be included in the final study 
analysis unless you specifically withdraw consent for this. 
 
Will taking part in this study be kept confidential? 
If you decide the patient can participate in the study, the clinical information collected about 
them during the course of the study will be anonymised and kept strictly confidential. We 
will record their date of birth and initials on all study forms. If you agree to the second 
assessment the study nurse will record their NHS ID, hospital number (hospital patients only) 
and address and telephone number (community patients only). This will be held only by the 
study nurse who will destroy this information immediately following their second 
assessment. A copy of the Consultee Declaration Form you sign, which will include your 
name and the patient’s name, will be sent to the Clinical Trials Research Unit. They do not 
put your names on computer. They simply check that the Consultee Declaration Form has 
been signed and dated properly and will securely file the form.  
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All information will be handled, processed, stored, and destroyed in accordance with the Data 
Protection Act 1998. The study team have a duty of confidentiality to the patient and will do 
their very best to meet this duty. All information obtained is strictly confidential and will be 
kept in locked cupboards and will only be accessible to members of the research team. No 
names or details that would identify specific people from this study will be included in any 
reports, presentations or papers (published in a medical journal), or further healthcare and/or 
medical research.    
 
Who has organised and sponsored the research? 
The study is being organised and coordinated by the Clinical Trials Research Unit (CTRU) at 
the University of Leeds, which is sponsoring the study. This study is a part of a larger 
pressure ulcer research programme funded by the National Institute of Health Research that 
aims to reduce the impact of pressure ulcers on patients. 
 
Who has reviewed the study? 
The study has been peer reviewed by the National Institute of Health Research before 
approval for the funding was given. In addition, all research in the NHS is looked at by an 
independent group of people called a Research Ethics Committee in order to protect your 
safety, rights, wellbeing, and dignity. This study has been reviewed by the Leeds West 
Research Ethics Committee (reference 12/YH/022). 
 
What will happen to the results of the research study? 
When the study is complete the results will be published in a medical journal, but no 
individual participants will be identified in any report or publication. If you would like to 
obtain a copy of the published results, please ask your local contact person (see contact 
details below). We hope that the information from this study will help to improve the 
assessment, prevention and treatment of pressure ulcers in the future. 
 
Further information and contact details 
If you would like further information about clinical research, the UK Clinical Research 
Collaboration (a partnership of organisations working together on clinical research in the UK) 
have published a booklet entitled ‘Understanding Clinical Trials’.  Contact UKCRC: Tel: 
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0207 670 5452; website www.ukcrc.org. If you want any further information about the study, 
now or in the future, please contact (insert name here) below. 
 
Your contact telephone numbers: (to include local collaborator)…………………………. 
……… 
………………………………………………………………………………………….. 
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Appendix 36 Pressure Ulcer Risk Assessment
Framework field test 1 consultee declaration
 
  
[Delete this line, then print on Trust headed paper] 
 
 
 
 
CONSULTEE DECLARATION FORM 
 
 Pressure UlceR Programme Of ReSEarch 
 Pressure Ulcer Risk Assessment Framework (PURAF) Field Test 1 
 
1. I confirm that I have been consulted about the patient’s participation in the above study 
and have read and understand the information sheet dated 23.05.2012(version 2) for the 
above study. I have had the opportunity to ask questions and have had these answered 
satisfactorily.                                                                                         
 
2. I understand that the patient’s participation is voluntary and that I am free to withdraw 
them from the study at any time without their medical care or legal rights being affected. 
 
3. I understand that if I withdraw the patient from the above study, the data already 
collected from them will be used in analysing the results of the study unless I specifically 
withdraw consent for this. 
 
4. I understand that relevant sections of the patient’s healthcare records and data collected 
during the study may be looked at by individuals from the NHS Trust and the University of 
Leeds, where it is relevant to their study participation.  
Patient Study Number:  Patient Initials:  
Patient DOB: Site ID: 
Principal Investigator:  Version:  
Consultee initial after 
each question 
.......... 
.......... 
.......... 
.......... 
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5. I understand there will be storage including paper and electronic, of the patient’s 
personal information for the purposes of this study. I understand that any information that 
could identify them will be kept confidential and that no personal information that could 
identify them will be included in the study report or other publication. This information will 
be confidentially destroyed at the end of the study. 
 
6. I understand that information and results arising from this study may be used to  
develop new research. 
 
7. I understand that a copy of this Consultee Declaration Form will be passed to the Clinical 
Trials Research Unit, University of Leeds. 
  
8. I understand that the patient’s GP and hospital consultant (where applicable) will be 
notified of the patient’s participation in this study. 
9.  In my opinion the patient would have no objection in taking part in this study 
 
________________________   
Name of Patient    
 
________________________      _____________   _________________________ 
Name of Consultee         Date     Signature 
 
Relationship to patient: ______________________ 
 
I have given written information and a verbal explanation to the consultee named above who 
has freely given their Declaration for the patient to participate. 
 
_______________________         ___________     __________________________ 
Name of Person Taking Consent   Date   Signature 
 
1 copy for consultee, 1 for patient records, 1 for CTRU; original stored in Investigator Site 
File 
.......... 
.......... 
.......... 
.......... 
.......... 
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Appendix 37 PURPOSE-T user manual
PURAF Field Test 1 
Pressure Ulcer Risk Primary or Secondary Evaluation (PURPOSE T) User Notes 
 
 Summary of PURPOSE T 
PURPOSE T (Pressure Ulcer Risk Primary or Secondary Evaluation Tool) is a pressure ulcer risk 
assessment framework (PURAF) intended to identify adults at risk of pressure ulcer development and 
makes a distinction between primary prevention (applicable to those at risk of pressure ulcer 
development) and secondary prevention (applicable to those who already have a pressure ulcer). It has 
been developed for use in adult populations in hospital and community settings by qualified nursing 
staff. 
 
NB: PURPOSE T is not intended to assess the risk of pressure from external devices such as naso-
gastric tubes and catheters etc. 
 
The development of PURPOSE T incorporated a systematic review of pressure ulcer risk factors and a 
consensus study involving international experts in the pressure ulcer field (including review of 
pressure ulcer evidence): this allowed the numerous risk factors associated with pressure ulcer 
development to be carefully considered and only the most important risk factors to be included in 
PURPOSE T. Furthermore the use of colour within the tool allows us to identify the presence of key 
and less influential pressure ulcer risk factors. PURPOSE T was also pre-tested with practicing nurses 
allowing ambiguous or confusing elements to be identified and clarified in Field test version of 
PURPOSE T.  
 
PURPOSE T does not utilise a score as other tools do - it encourages nurses to consider the profile of 
a patients’ risk (PU risk factors present) to identify whether they are ‘not currently at risk’, ‘at risk’, or 
have an existing pressure ulcer and allocate them to the appropriate care pathway. 
 
PURPOSE T has 3 steps including:  
· Step 1 – Screening: complete for all patients 
· Step 2 - Full Assessment:  complete for those potentially at risk as determined by step  
· Step 3 – Assessment Decision: to be undertaken for all patients who have undergone step 2 
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1. Step 1 – Screening: Complete for all patients 
Step 1 comprises of two possible sections to complete:  
· Mobility Status 
· Skin status 
 
Step 1 Assessment 
 
 
1.1 Mobility Status  
This section examines mobility status items that have been developed to assess varying levels 
of mobility. Mobility is a key pressure ulcer risk factor, which is why it is included in the first 
step of the assessment.  
 
It is important that you consider and tick all the item boxes that apply to your patient: a 
patient may walk independently but remain in the same position for long periods and /or 
spend the majority of time in bed or chair. 
 
Mobility Status Items 
 
 
‘Walks independently’ means they don’t need assistance from another person, and ‘walking 
aid’ could be a walking stick, walking frame or even furniture. The second item ‘help of 
another person’ could involve physical assistance or verbal prompting. The latter 2 items 
require an element of judgement by the nurse in terms of whether the patient’s length of time 
in one position is considered normal.  
 
1.2 Mobility Decision Boxes 
The decision boxes and colour coding will help you decide if you need to go to step 2 of the 
assessment straight away or if you need to complete the Step 1 skin status items: if you have 
ticked any yellow boxes you should progress to Step 2 without completing the Step 1 skin 
status items. If you have only ticked the blue box you should complete the Step1 skin status 
items. 
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1.3 Skin Status   
This section examines skin status items which have been developed in recognition of the 
importance of skin status in the assessment of pressure ulcer risk. The items give a range of 
possibilities of pressure area skin status as commonly encountered in clinical practice.  
 
 
Skin Status Items 
 
 
It is important that you tick all of the boxes that apply to your patient as they may have more 
than one, for example a patient may have a reported history of previous pressure ulcer and 
skin vulnerability. 
 
The item ‘normal skin’, requires judgement since there is no clear definition of what 
constitutes normal skin. It would certainly include the absence of skin vulnerability or 
pressure ulcers: nurses should use their clinical judgement to determine if a patient’s skin is 
normal. The ‘vulnerability’ skin item gives examples of redness, dryness, paper thin and 
moist: these describe the visual appearance of vulnerable skin but this is not exhaustive list 
and you may also consider other factors. See section 2.3 for further notes on skin 
vulnerability and skin redness. 
 
The nurse will need to make a judgement about the approach required to complete this 
section (i.e. history taking/ clinical records/ full skin inspection), while recognising that the 
most accurate way to assess skin status is to visually examine the skin: this may be influenced 
by the context of care and level of patient dependency. Any patients with a skin status 
problem (vulnerable, current or previous PU) will progress to Step 2 of the assessment 
(incorporating full visual skin inspection). 
 
1.4 The Skin Status Decision Boxes 
The decision boxes and colour coding will help you decide if you need to go to Step 2 of the 
assessment, or if the patient is not currently at risk. 
 
If you have ticked any yellow or pink boxes you should progress to Step 2 of the assessment. 
If you have only ticked the blue box then the patient is not currently at risk and you should 
indicate this by ticking the ‘not currently at risk’ box and end the assessment without 
progressing to Step 2. 
 
2. Step 2 - Full Assessment: Complete for those potentially at risk as determined by step 
1        
 
Step 2 consists of 8 sections which must be fully completed. The sections comprise: 
· Analysis of independent movement 
· Sensory perception and response 
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· Current detailed skin assessment 
· Previous pressure ulcer history 
· Perfusion 
· Nutrition 
· Moisture 
· Diabetes 
 
 
Step 2 – Full Assessment 
 
 
Each section will give a range of possibilities as you would encounter in clinical practice. It is 
important that if the patient does not have a problem with a particular risk factor that this is 
indicated by ticking the ‘no problem’ item showing the assessment has been undertaken. If 
you follow the flow of the sections from top to bottom and left to right you are less likely to 
miss any sections out, though some nurses have found it more practical to complete the visual 
skin inspection at the end of the assessment. 
 
2.1 Analysis of Independent Movement 
This section was developed to capture information about the patients’ independent 
movement. ‘Independent movement’ relates to movement that is undertaken by the patient 
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without the assistance of another person, i.e. it does not relate to the movement encountered 
when nurses changes the patients’ position or turns the patient.  
 
Analysis of Independent Movement Item
 
 
A matrix is used to bring the frequency (i.e. how often) and extent (i.e. amount) of movement 
together and each component has a range of options for you to consider in light of patients 
movement pattern. When completing the frequency element the nurse must consider what 
would be considered normal frequency of movement and use her clinical judgement to 
inform which category the patient falls into.  
The 3 options relating to the extent of movement include ‘the patient doesn’t move’, ‘minor 
position changes’ and ‘major position changes’. Major position changes could include the 
patient turning over in bed or standing up resulting in complete pressure relief. Minor 
position changes could include the patient shifting their position a little when in the bed or 
chair which may result in some but not complete pressure relief.  The patient doesn’t move 
item relates to no pressure relief of pressure areas. 
 
To complete the section the nurse must consider both frequency and extent of independent 
movement in the matrix and tick the box where the two elements meet.    
 
2.2 Sensory Perception and Response   
This section relates to sensory perception and response and comprises just 2 items. It is a tick 
as applicable section and only one item applies, i.e. does the patient have a problem with 
sensory perception and response or not. 
 
Sensory Perception and Response Items 
 
 
DOI: 10.3310/pgfar03060 PROGRAMME GRANTS FOR APPLIED RESEARCH 2015 VOL. 3 NO. 6
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Nixon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
485
In your assessment you need to consider if the patient is unable to feel and/or respond 
appropriately to discomfort from pressure. This item recognises that patients will vary in 
terms of whether they can do both i.e. some patients will not be able feel discomfort from 
pressure and so will not respond, while others may be able to feel but not respond 
appropriately. Either of these scenarios indicates there is a problem with sensory perception 
and could lead to reduced movement and pressure relief.  Factors that may (though not 
always) influence the patients’ ability to feel and respond appropriately to discomfort from 
pressure, comprise underlying medical conditions or treatments such as MS, CVA, head 
injury, spinal injury, neuropathy, dementia, depression, epidural, anaesthetics and opiates. 
When undertaking the assessment the nurse must consider whether the presence of such 
factors affects the patients’ sensory perception. 
 
2.3 Current Detailed Skin Assessment 
Requires a visual skin inspection and assessment of skin sites listed in the table: these include  
the most common pressure area skin sites though patients sometimes develop pressure ulcers 
in other areas and there is space for ‘other’ skin sites if required. This should be completed 
for all skin sites shown in the table. 
 
Current Detailed Skin Assessment Items 
 
Clinical judgement based on information from a holistic patient assessment should be used 
while undertaking the skin assessment. Each skin site should be inspected to identify normal 
skin, vulnerable skin (e.g. persistent redness, dry, moist, paper thin) or pressure ulcer present 
(also see section 1.3). When considering skin redness in relation to vulnerability, the nurse 
should consider if the redness is a normal transient response. The nurse must also  consider 
the holistic patient assessment along with other elements of the purpose T assessment when 
making a  decision about skin, e.g. if a patient is fully mobile but has been sat out and has 
some blanching redness this could be viewed as a normal response and not as skin 
vulnerability. However if a patient is immobile and the redness is persistent or intense it 
might be considered vulnerable.   
 
The nurse should only choose one option (normal skin, vulnerable skin or PU category) for 
each skin site by ticking the appropriate box. The category of any existing pressure ulcer is 
recorded in the pink column. The abbreviated NPUAP/EPUAP Pressure Ulcer Classification 
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System (2009) is listed to help you and the full version of this will be available in the study 
documentation. 
 
2.4 Previous Pressure Ulcer History 
The first 2 items relate to whether the patient has a reported history of a pressure ulcer and is 
a tick as applicable section and only one item applies, i.e. the patient either has a reported 
history of pressure ulcer or they don’t. Some patients may not know and the patients’ clinical 
record could provide a good source of information.  
 
Previous Pressure Ulcer History Items 
 
 
If the patient has a reported history of pressure ulcer development the approximate date, site 
and PU category should be recorded. The nurse should also indicate if a scar is present which 
could be ascertained when undertaking the current detailed skin assessment. This is important 
as scarring results in ongoing skin vulnerability to pressure.  
 
2.5 Perfusion  
The perfusion section includes ‘no perfusion problems’ and 2 items relating to conditions that 
affect the central circulation (shock, heart failure or hypotension) and  conditions that affect 
peripheral circulation (peripheral vascular/arterial disease). These give some examples of 
conditions affecting perfusion, but this is not exhaustive list and you may also consider other 
factors such as poor capillary refill. 
 
If the patient doesn’t have any perfusion problems then the nurse should tick ‘no problem’. If 
the patient does have perfusion problems the nurse should tick the all applicable items as 
some patients’ may have both central and peripheral circulatory problems.  
 
 
 
Perfusion Items 
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2.6 Nutrition    
The nutrition items have been developed to capture patients with the varying nutrition 
problems as you would encounter in clinical practice. It is important that you consider all the 
items and tick all the item boxes that apply to your patient as there may be more than one 
applicable item. However, if your patient has no problems with nutrition you will only tick 
the applicable box.  
 
Nutrition Items 
 
 
The 4 items indicating there is a problem with nutrition comprise ‘unplanned weight loss’, 
‘poor nutritional intake’, ‘low BMI’ and high ‘BMI’.  ‘Unplanned weight loss’ relates to 
weight loss that isn’t sought by the patient, i.e. they haven’t been trying to lose weight and 
may have lost it due to illness. ‘Poor nutritional intake’ may be relevant to patients with poor 
appetite who are not eating well. It may also be applicable for those are nil by mouth and 
obtaining no other form of nutritional support. Low BMI is less than 18.5 and high BMI is 30 
or more. 
 
2.7 Moisture 
The moisture section comprises of 3 items and relates to moisture due to perspiration, urine, 
faeces or exudates. This is a tick as applicable section and only one item applies. The first 
item relates to patients’ without a moisture problem or with occasional moisture which does 
not impact on the patients’ risk of pressure ulcer development. The other items relate to the 
frequency of moisture with some guidance of these parameters i.e. ‘frequent (2-4 times a 
day)’ and ‘constant’ meaning all of the time. 
 
Moisture Items 
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2.8 Diabetes  
This item relates to the presence of diabetes and gives 2 options. This is a tick as applicable 
section and only one item applies. 
 
Diabetes Items 
 
 
3. Step 3 – Assessment Decision 
Step 3, the assessment decision should be undertaken following step 2. 
 
 
Each item in Step 2 is highlighted by a blue, yellow, orange or pink box. These colours 
represent the importance of the risk factors as indicated by the level of scientific or 
epidemiological evidence and/or the results of the consensus study: 
 
· Pink box items indicate the patient has an existing pressure ulcer or scarring from a 
previous pressure ulcer 
· Orange box items indicate the presence of a key pressure ulcer risk factor 
· Yellow box items indicate the presence of less influential pressure ulcer risk factors 
(but still important in considering the overall risk profile of a patient and in the 
delivery of appropriate preventative care) 
· Blue box items indicate the absence of a risk factor.   
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When completing step 3 the nurse must carefully review the step 2 assessment to decide 
whether the patient should be allocated to the secondary prevention and treatment pathway, 
primary prevention pathway or the not currently at risk pathway.  
This is facilitated by decision boxes in the PURPOSE T which indicate: 
· If any pink boxes are ticked it indicates that the patient has an existing pressure ulcer 
or scarring from a previous pressure ulcer. The patient should be allocated to the 
secondary prevention and treatment pathway indicated by ticking the red box in the 
pathway. 
· If any orange boxes (but no pink boxes) are ticked the patient does not have a pressure 
ulcer but is at risk of pressure ulcer development and should be allocated to the 
primary prevention pathway indicated by ticking the orange box in the pathway. 
· If only yellow or blue boxes are ticked the nurse must consider the risk profile of the 
patient and use clinical judgement to determine whether the patient is ‘at risk’ or ‘not 
currently at risk’. The nurse should consider the number of yellow boxes ticked and 
the patients’ individual circumstance, for example a patient may only have the 
presence of unplanned weight loss but may be terminally ill and nearing the end of 
life where the general trajectory of dependence will increase and the nurse may 
therefore consider the patient to be ‘at risk’ or a young diabetic patient may have 
undergone acute surgery but be recovering well where the general trajectory is 
increasing independence so the nurse may consider the patient to be ‘not currently at 
risk’, but would want to review this if the patients’ condition changed. Patients with a 
number of yellow boxes ticked are more likely to be considered ‘at risk’. 
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Appendix 38 Pressure Ulcer Quality of Life
qualitative study reduced format protocol
NB: This study protocol (version 3, dated 25 Jun 2008) is in a reduced format including only 
the study aims and methods.  Sections pertaining to study background have been removed as 
they are included as a chapter section. 
 
2. Study objectives 
Ethics approval is sought to undertake Phase 1 development.  The aim of this study is to 
undertake in-depth qualitative interviews with a sample of patients with PUs.  The 
information obtained will be used to develop a conceptual framework of HRQL in PUs.  This 
will complete the first phase of the PU-QOL measure development process. 
 
The study objectives are: 
1. To identify outcomes and HRQL issues which are relevant and important to patients 
with grade 1, superficial and severe PUs  
2. To identify whether PROs and HRQL issues for patients with grade 1, superficial, and 
severe PUs are the same in relation to the impact of interventions. 
3. To gain insight into the relative PU burden and what it is like to live with a PU 
 
2.1. Study design 
Development of a conceptual framework 
In phase 1 of the health-outcome measure development process, the conceptual framework 
will be developed by utilising three sources; literature, patients, and experts in the field.  A 
systematic review of qualitative and quantitative literature has been undertaken and from this, 
patient-reported themes associated with PU interventions and general issues associated with 
having a PU will be summarised and grouped into relevant HRQL domains.  This will 
produce an exhaustive list (working framework) of relevant PROs that cover all HRQL 
domain(s) associated with PU occurrence, symptoms, and interventions.  The working 
framework will be used for the development of an interview schedule for the qualitative 
interviews.  Expert group review will be sought through all stages of the conceptual 
framework, interview schedule development, and data analysis stages. 
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Qualitative interviews 
Each participant will be interviewed using an in-depth qualitative interview method following 
an interview schedule, in order to assess the impact of PUs and PU interventions on HRQL.   
 
Up to 24 patients will be recruited from various hospitals around the UK.  Each patient will 
be interviewed once and interviews will last approximately 1 hour.  The interview will be 
discontinued at any time upon the patient’s wishes. Interviews will consist of various probing 
questions to get the patient to reflect and to speak openly about their experience of having a 
PU.  The patients will also be asked to comment and assess the importance of the HRQOL 
domains identified from the literature review.  All interviews will be recorded. 
 
The interviews will be conducted, recorded, and analysed by the primary researcher.  The 
data will then be reviewed by the multidisciplinary expert group and discussed until a 
consensus view is achieved.  This final process will produce a conceptual framework.  
 
2.2. Inclusion/exclusion criteria 
Patients with grade 1 (at-risk), superficial, and severe ulcers, from vascular, orthopaedic, 
medical, or care of the elderly wards, as well as patients in the community under the care of 
tissue viability nurse (TVN) specialists and consultants, and TVN teams, will be eligible to 
take part in the study. 
 
Eligible patients will be included in the study if they fulfil the following criteria: 
· understand and speak fluent English AND 
· aged more than 18 years of age AND 
· with current PU of any grade (1-4) (Table 1) OR  
· had a PU grade 2-4 healed within the last 3 months AND 
· able to share their experience in a thoughtful and reflective way AND 
· able to give their written informed consent to take part 
 
2.3. Recruitment & consent procedures 
Patients will be purposively sampled (15-24 patients) ensuring balanced representation of 
patients in grade 1, superficial ulcer (grade 2) and severe ulcer (grade 3/4) categories.  
Consecutive patients will be identified from each PU category and approached to participate. 
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Recruitment will continue on a rolling basis until a minimum of five and maximum of eight 
patients from each PU group are recruited from the participating sites, and interviews 
undertaken.  A sample size of up to 24 patients will allow for any initial changes to the 
interview schedule should they be required following the first few interviews.  
 
Table 1 EPUAP pressure ulcer classification (EPUAP, Pressure ulcer treatment 
guidelines, 1999) 
Grade 1 Non-blanchable erythema of intact skin. Discolouration of the skin, 
warmth, oedema, induration or hardness may also be used as indicators, 
particularly on individuals with darker skin. 
Grade 2 Partial thickness skin loss involving epidermis, dermis, or both. The ulcer 
is superficial and presents clinically as an abrasion or blister. 
Grade 3 Full thickness skin loss involving damage to or necrosis of subcutaneous 
tissue that may extend down to but not through underlying fascia. 
Grade 4 Extensive destruction, tissue necrosis, or damage to muscle, bone, or 
supporting structures with or without full thickness skin loss. 
 
TVNs at participating hospital and community services will identify potential patients.  Those 
who meet the eligibility criteria will be approached, informed about the study, and provided 
with; 1) a project information sheet that includes details about the rationale, design, and 
personal implications of the study, and 2) an ‘agree to be contacted by the researcher’ form 
either to be contacted by telephone (PCT version) or visited at the ward (in-patient version).  
 
Following information provision, patients will have as much time as they need to complete 
the “agree to researcher contact” form, which will be either faxed or posted back to the 
CTRU.  The TVN, the researcher, and the research supervisor will be available to answer any 
questions that patients might have about the study.  After receiving a signed agreement to be 
contacted form from the patient, the researcher will telephone the patient to arrange a time for 
the interview.  The researcher will provide information about the study and interview process 
and will answer any questions before gaining verbal consent and arranging an interview at a 
mutually convenient time.  For in-patients who cannot be contacted by telephone and who are 
expected to be in the hospital during the interview, with the patient’s permission, the TVN 
will liaise with the researcher and patient to arrange a mutually convenient time for the 
researcher to see the patient on the ward to discuss the study further.  
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The researcher will interview patients in their own home, in the out-patient clinic, or in-
patient ward, as determined by the patient’s circumstances and preferences at the time of the 
interview.  It is anticipated that a similar number of community and hospitalised patients will 
be interviewed.  Before the interview, each participant will be given a further verbal 
explanation of the study by the researcher, informed that the interview will be recorded but 
that all identifiable information will remain anonymous, reminded that they can withdraw 
from the study at any time without it affecting their care, and then invited formally to 
participate.  They will be given an opportunity to ask any questions and then if they agree to 
take part, the participant will be asked to sign the consent form.  For any patients who may 
have difficulty in writing but who fully comprehend, a tape recording will be taken of the 
verbal agreement.  All participants will be sent a thank you letter after the interview.  The 
right of the patient to refuse consent without giving reasons will be respected.  Further, the 
patient will remain free to withdraw from the study at any time, again, without giving reasons  
and without prejudicing any further treatment. 
 
2.4. Data collection 
Patients will be interviewed by the researcher using the patient interview schedule and guide.  
Details regarding the PU (i.e. PU grade, location, duration) and treatment will be requested 
verbally from the treating nurse.  These in-depth qualitative interviews will be undertaken to 
establish the relative importance of HRQL domains and identify any omitted HRQL themes 
that are important to patients.  Therefore, patients will be asked questions to get them to think 
about important HRQL issues and themes, comment on their subjective importance, and 
asked to reflect on their experience of the interventions they have received and what it is like 
or has been like to live with a PU.  
 
2.5. Data analysis 
Interviews will be recorded and transcribed verbatim as soon as possible following the 
interview.  Preliminary analysis will be carried out after the first three patients have been 
interviewed to assess whether the interview schedules’ HRQL domains compare with the 
emerging themes, and to identify any gaps in information.  The expert group will be 
consulted and if deemed necessary the HRQL domains will be developed and changed as data 
collection progresses.  Theoretical thematic analysis will be used to analyse and report 
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themes from the data by the researcher.  Upon completion of the data analysis, a provisional 
report will be sent to the expert group to provide clarification and to ensure the research 
remains participative. 
The working framework and information gathered from the qualitative interviews will 
formulate a conceptual framework which will be used to generate items for the PUQ-OL 
instrument.  The following information will be sought from the interview: 
· how does having a PU impact on life from the perspective of the sufferer 
· what are all the HRQL issues important to PU patients and do patients find some 
HRQL issues more important than others 
· how do PU interventions impact on patient HRQL 
· what do patients feel are important intervention outcomes 
· gain an understanding of the way patients define small, medium and large differences 
· how important is it to patients to have HRQL issues addressed as part of their 
healthcare; do they think that this should be incorporated into PU management 
 
3. Confidentiality 
Any information which would allow individual participants, healthcare professionals, or 
wards to be identified will not be released.  All the participating hospitals, community 
services, and the CTRU at the University of Leeds will comply with all aspects of the Data 
Protection Act 1998.  All participants will be assigned a project number on recruitment, and 
confidentiality and anonymity will be maintained throughout the duration of the project and 
in the dissemination of results. 
 
4. Ethical considerations 
This study will recruit patients with PUs and therefore will include elderly and highly 
dependent patients considered as vulnerable.  Clinically, older patients are treated in the same 
way as younger patients and it is therefore important to ensure that the study is representative 
of the clinical population.  The ethical issues surrounding these potentially vulnerable 
patients have been addressed through the study design and include a thought out consent 
process, the use of one-to-one semi-structured interviews, and the use of experienced 
researchers able to provide a flexible and supportive interview environment. 
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This project will be conducted in accordance with the Declaration of Helsinki in its latest 
form.  The study will be submitted to and approved by a Research Ethics Committee (REC) 
prior to identifying eligible patients.  The CTRU will provide the REC with a copy of the 
final protocol, patient information sheets, consent forms, and interview schedule and guide. 
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Appendix 39 Pressure Ulcer Quality of Life
qualitative study patient information leaflet and
consent form
[Delete this line then print on Trust headed paper] 
 
INFORMATION SHEET 
 
A patient-reported outcome measure of health-related quality of life for 
pressure ulcer patients (PU-QOL): Qualitative patient interviews 
 
A large-print version of this sheet is available on request.   
 
We would like to invite you to take part in a research project.  Before you decide to take part, 
it is important for you to understand why the research is being done and what it would 
involve for you.  Please take the time to read the following information carefully and discuss 
it with your relatives and your ward nurse if you wish.  Ask us if there is anything that is not 
clear or if you would like more information.  
 
(Part 1 tells you the purpose of this project and what will happen to you if you take part.  
Part 2 gives you more detailed information about the conduct of the study). 
 
Part 1 
What is the purpose of the study? 
At present, very few studies have been conducted to inform us about what it is like for a 
person to live with a pressure ulcer.  Pressure ulcers, also called a bed sore or pressure sore, 
have many causes and although the aim is to prevent them, a small number of people still go 
on to develop them.  This project is designed to provide us with important information about 
the experienced suffering of patients with pressure ulcers and the impact pressure ulcer 
treatments have on patients’ quality of life.  This information will be obtained in order to 
improve patient healthcare and patient health-related quality of life. 
 
In other disease areas, quality of life questionnaires exist and patients may often be asked to 
fill in quality of life questionnaires as part of their routine hospital care or clinic appointment.  
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While healthcare professionals and researchers in other disease areas are becoming more 
familiar with these questionnaires, quality of life questionnaires are rarely used with pressure 
ulcer patients to assess the impact of the pressure ulcer or their treatments on patients’ quality  
of life.  This study forms part of a larger project aiming to develop and evaluate a self-report 
measure of quality of life for use with patients suffering from pressure ulcers.  The 
questionnaire will be used to inform healthcare professionals about the perceived benefit of 
PU treatments from the perspective of the patient and the effect it has on their quality of life.  
This is the first phase of the questionnaire development process involving interviews with 
patients like yourself, to determine which quality of life related issues are of most importance 
to patients.  
 
Why have I been invited? 
We are interested in talking to people who have experience of having a pressure ulcer.  Any 
person from (Trust name) who has a pressure ulcer ranging from a small red area to a more 
severe ulcer will be asked to participate.   
 
Do I have to take part? 
You are under no obligation to take part in this study, it is up to you to decide.  We will 
describe the study to you and go through this information sheet.  If you agree to take part we 
will then ask you to sign a consent form to show you have agreed to take part.  You will be 
given a copy of this information sheet and of the consent form for you to keep.  You are free 
to withdraw at any time, without giving a reason.  This would not affect the standard of care 
you receive.  If you do not wish to take part this will not affect the care that you are currently 
receiving. 
 
What will happen to me if I take part? 
You will be contacted to arrange a suitable interview date and time.  The researcher (Claudia 
Gorecki) will then meet with you to go through the interview process before the discussion 
begins.  The discussion should last around 1 hour and will take place in the ward where you 
are admitted at (hospital name).  The discussion will be tape recorded.  The tape recording 
will be used only by researchers involved in the project to write notes on the discussion and 
will be stored in a locked cabinet.  As soon as the information on the tapes in analysed, the 
tapes will be destroyed. 
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During the interview you will be asked a few questions about your current life circumstances 
and asked to describe and provide information about your experience of your pressure ulcer 
and the treatments that you received as part of your care.  We also would like to ask for 
permission to ask your nurse details about your pressure ulcer such as whether it is a red area 
or blister or much more severe; how long you have had it, and details about the treatments 
that you have received such as the type of dressing applied.  The information will be 
confidential between you, the team looking after you and the researcher. 
 
Expenses and payments 
We anticipate that there will be no extra expenses for you as a result of taking part in this 
study, as interviews will be conducted while you are an in-patient in the hospital at a 
convenient time for you.  
 
What are the possible disadvantages and risks of taking part? 
The study requires approximately one hour of your time.  You will be asked to think about 
and discuss your personal experience of having a pressure ulcer and how the pressure ulcer 
and treatments have impacted on your life.  There is a possibility that you may find this 
distressing.  The interview can be stopped at any point if you feel you do not want to 
continue.  If necessary, a referral can be made to your nurse or other healthcare professionals 
if you are distressed by the content of the discussion. 
 
What are the possible benefits of taking part?  
There are no direct benefits to you taking part.  We hope that the information we get from the 
interviews will help to identify all the important issues that patients with pressure ulcers have 
to deal with and identify the perceived benefits of treatments from the perspective of the 
patient.  This information will then be used to formulate questions which will be put together 
to form a quality of life questionnaire for healthcare professionals to use in addressing quality  
of life impacts in patients with pressure ulcers and to provide them with a better 
understanding of how pressure ulcers and their treatments impact on a patients quality of life 
from a patient’s perspective. 
 
Will my taking part in the study be kept confidential? 
Yes.  We will follow ethical and legal practice and all information about you will be handled 
in confidence.  In the event that any evidence of poor practice, neglect or abuse is identified 
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during the course of the interview, the researcher might need to disclose details to a third 
party outside of the interview.  This would not be done without discussing it with you first. 
The details are included in Part 2. 
 
This completes part 1. 
If the information in Part 1 has interested you and you are considering participation, 
please read the additional information in Part 2 before making any decision. 
 
Part 2 
What will happen if I don’t want to carry on with the study? 
You are free to change your mind at any point up to, during or following the interview.  You 
will not be able to be identified in the study results but if you wish to withdraw any data 
already collected prior to publication of the results then arrangements can be made for the 
interview tape to be destroyed and your discussion excluded from the study. 
 
Will my taking part in this study be kept confidential? 
The procedures for handling, processing, storage and destruction will be according to the 
Caldicott principles and the Data Protection Act 1998.  Claudia Gorecki and her supervision 
team have a duty of confidentiality to you as a research participant and we will do their very 
best to meet this duty.  Claudia Gorecki will store the interview tapes in a locked cabinet. 
Tapes will be identified by study number only and any references to names will be removed 
during transcription.  Any identifiable data will only be accessed by the researchers.  The tape 
recordings will be disposed of securely once data analysis is completed.  
 
Involvement of the General Practitioner/Family doctor (GP) 
Your GP will not be notified of your participation in this study. 
 
What will happen to the results of the research study?  
Participants will not be identified in any report/publication. The study results will be used to 
construct items on a questionnaire and published in a scientific journal. 
 
Who is organising and sponsoring the research? 
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This project is being undertaken as part of a PhD qualification sponsored and supervised by 
the University of Leeds. The researchers and nurses are not being paid for inclusion of 
patients in this study. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people called a Research 
Ethics Committee to protect your safety, rights, wellbeing and dignity.  This study has been 
reviewed and given approval by (name of REC) Research Ethics Committee. 
 
Further information and contact details 
Thank you for considering this study. If you would like to discuss the study further or have 
any questions about the study at any time, please contact the researcher, Claudia Gorecki on 
0113 3437632 or the study supervisor, Dr Jane Nixon on 0113 3431488 or speak to your 
tissue viability nurse who provided you with this information sheet. 
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Development of a Patient-Reported Outcome measure of HRQOL for Pressure 
Ulcer Patients (PU-QOL): Qualitative patient interview consent form 
 
Name of researcher:    Claudia Gorecki 
      Clinical Trials Research Unit 
      University of Leeds 
Leeds 
LS2 9NG 
Telephone:      0113 3437632 
 
Please initial the boxes: 
1. I confirm that I have read and understand the information sheet dated.................... 
(version............) for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without my medical care or legal rights being 
affected. 
3. I understand that the above named researcher may ask my nurse additional 
information about my pressure ulcer history and relevant treatment. I give  
permission for the researcher to verbally obtain this information. 
 
4. I agree that my interview will be tape recorded and typed out. 
 
5. I understand that my interview will be coded so that only the above named  
researcher will be able to link my interview with my personal details. 
 
6. I agree to take part in the above study.
 
 
_______________   _____________  _______________________ 
Name of Patient    Date    Signature 
 
I have given written information and a verbal explanation to the person named above who 
has freely given their consent to participate. 
 
Claudia Gorecki   _____________ _______________________ 
Name of Person Date Signature
taking consent 
 
One copy for patient; one copy for researcher  
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Appendix 40 Pressure Ulcer Quality of Life
qualitative study agree to researcher contact form
 [Delete this line then print on Trust headed paper- given with study information] 
 
AGREEMENT TO RESEARCHER CONTACT- (16th July 2007, Version 1.0) 
Name of researcher:     Claudia Gorecki 
      Clinical Trials Research Unit 
      University of Leeds 
Leeds 
LS2 9NG 
      Ph: 0113 3437632 
Name of consultant/nurse:    __________________________ 
Contact number:    __________________________ 
 ___________________________________________________________   
Development of a patient-reported outcome measure of HRQL for pressure 
ulcer patients (PU-QOL): Qualitative patient interviews 
 
Please initial the boxes:
• I have read the information sheet and kept a copy. 
• I am happy to discuss the study further in a visit from the above named researcher.  
 
Please complete the following details in the space provided: 
Name: _______________________________________________ 
Date of visit: ______________________________
Time of visit:  _____________________________ 
Location (e.g. patient’s room number, clinic room number, instructions on finding location): 
_____________________________________________________________________ 
_____________________________________________________________________ 
 
Thank you for completing this form. 
Please telephone Claudia Gorecki on 0113 3437632 as soon as an interview is arranged.  
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Appendix 41 Pressure Ulcer Quality of Life
qualitative study interview schedule
Introduction to project and present study
l Thank you for volunteering and ask questions at any time.
l Background and explanation of project.
l Confirmation of agreeing to tape-record the interview.
l Obtain informed written consent.
Introduction to the Pressure Ulcer Quality of Life
development project
The PU-QOL is a larger project, undertaken by a national group of researchers including myself, that is
intended to develop and evaluate a questionnaire to measure quality of life in people who have a pressure
ulcer. In order to develop such a questionnaire, it is important to obtain information directly from the
people who have experience of the problem. To find out what impact a pressure ulcer and pressure ulcer
treatments have on quality of life, I am interviewing around 24 people who have experienced a pressure
ulcer to find out what quality of life issues are most important to them. From the quality of life issues
already identified, I have grouped them into seven main themes. I will ask you to comment on these
themes towards the end of our discussion.
Tape recording and anonymity
[Check comfortable, do they need toilet, glass of water; clarify what name to use]
[Spoken by interviewer] I would like to make a tape recording of this interview as that will help make sure
that I catch everything you say. We think it is better than my taking notes. Before we start, can I just
confirm that you are happy with that? Now what will happen to this tape is that I will take it back and
our conversation will be typed out in full. When we do that we make sure that there is nothing in the
document that could identify you, so, for example, your name or the name of the hospital or ward
would be blanked out. Similarly, names of any other people that you mention will also be blanked out or
changed so that both you and they can remain anonymous.
Clinical data and impact of pressure ulcers and interventions
[Opening discussion prompts]
l You have a sore area, can you tell me about it? What is it like to live with a pressure ulcer?
l The ward staff tell me that you have a sore area. What can you tell me about it?
l Can you tell me a little bit about yourself? Why are you in hospital?
l Do you know why you got the pressure sore?
l How did you know that you had a pressure sore?
l Some people experience discomfort around their sore such as an ache or discomfort when it is being
dressed. Do you feel anything?
l What kind of symptoms have you experienced?
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Current situation
l Where the patient is living – is this your permanent living arrangement or just short term? If short term,
what is the long-term plan for living arrangements?
l Do you get any help at home with daily care from health-care professionals or family/friends? Is this
related to your pressure sore?
General health
l How would you describe your general health?
l Try to think back to the time just before you developed your pressure sore. What was your life like then?
l What do you know about pressure ulcers (establish pressure ulcer history and current knowledge)?
Their pressure ulcer
l When did you notice any skin problems? Was a pressure ulcer present on admission or did you develop
a pressure ulcer in hospital?
l When did it start/how long did it last (i.e. ongoing or healed)?
l Location(s); what stage did it progress to? How many did you develop?
l What were you told about the pressure ulcer? How did you feel?
l Have you seen it? If yes, what did you think about it? How did it make you feel? If no, has anyone else
seen it? How have they described it to you?
l What has been the reaction of others when you told them about your pressure ulcer?
l Do you have any worries about it?
Treatments
l Have you received any treatment on that area? What about anything else to help that area? (Dressings,
creams, others)? If so, which ones?
l Frequency of wound care (i.e. how often do you have dressing changes)?
l Who performs the wound care (i.e. dressing changes)?
l Can you tell me about your experience of the wound care treatments that you received (i.e. symptoms,
acceptability, satisfaction)?
l Have any aspects of your life been affected by the wound care you received?
l What do you perceive have been the benefits of your treatments?
l How has your pressure sore been attended to; what sorts of things have been done? And who did
this? What was it like?
l In terms of being in hospital for your pressure sore treatment, what is that like for you?
Pressure ulcer experience and impact
l What is the biggest problem that your pressure ulcer has caused you?
l How has it affected your everyday life/your relationships?
l How has your life changed since your ulcer developed? Anything else?
l What areas of your life have been most affected since you developed your pressure ulcer?
In what way?
l What kinds of things are more difficult for you to do? Any other tasks?
l How does the pressure ulcer affect your ability to move?
l How does it affect you at work?
l Does the pressure ulcer have an impact on your psychological well-being?
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Prompts for further information
l Is there anything else that I haven’t asked you about your sore that you think that I should know?
l You have mentioned . . ., can you tell me more about what it has been like for you?
l Is there anything else that you would like to tell me about your pressure ulcer or treatments?
l Is there anything else about the sore that you think researchers and people who provide pressure sore
care need to know?
l What would you like us to know about how it has affected you from your perspective?
Discussion of existing quality of life main themes
[Spoken by interviewer] Conversations with other people with pressure ulcers have identified various issues
and problems associated with having a pressure ulcer. Some of these issues include:
l perceived pressure ulcer aetiology (reasons pressure ulcer developed, risks)
l impact of pressure ulcer on daily living – physical
l symptoms/consequences of the pressure ulcer
l psychological well-being
l social impact of pressure ulcer
l impact of treatments/wound care
l the nurse–patient relationship
l impact of pressure ulcer on health
l impact on others
l need for knowledge about the pressure ulcer
l need for treatment vs. effect of treatment on patient.
l From our conversation and from these themes, can you see anything that we have missed?
l Have you experienced anything else that we have not covered today?
l Is there anything else that you want to add about your experience?
l From all the things that we have talked about today, what is the single most important thing?
End of interview
[Collect clinical data]
l Nurse contact: name and telephone.
l Trust name; hospital, acute or community.
l Age or date of birth.
l Gender.
l Marital status.
l Ethnicity.
Close the discussion; thank the patient for their time and involvement; explain how their information will
be used.
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Appendix 42 Pressure Ulcer Quality of Life study
search strategies and data sources
Search strategies for review of existing patient-reported
outcome instruments used in pressure ulcers and
chronic wounds
Searches of the following electronic databases were performed from inception until May 2012 using the
search strategies below: MEDLINE, EMBASE, PsycINFO, CINAHL, BNI and AMED.
Pressure ulcer terms
1. decubitus.sh
2. skin ulcer.sh
3. exp decubitus ulcer
4. decubitus ulcer$.tw
5. pressure ulcer$.tw.
6. pressure damage$.tw
7. pressure sore$.tw
8. bed sore$.tw
9. skin ulcer$.tw
10. or/1-9
Chronic wound terms
1. chronic wound$.tw
2. leg ulcer$.tw
3. foot ulcer$.tw
4. venous ulcer$.tw
5. necrotic wound$.tw
6. ischaemic ulcer$.tw
7. arterial ulcer$.tw
8. fungating wound$.tw
9. diabetic ulcer$.tw
10. varicose vein$.tw
11. dehisced wound$.tw
12. pilonidal.tw
13. or/11-22
14. 10 or 23
Quality of life terms
1. (wellbeing or well being).ti,ab,tw,sh,kw
2. (hrql or hrqol or qol or hql or hqol).ti,ab,tw,sh,kw
3. exp quality of life
4. quality of living.tw
5. (health status or health state$).ti,ab,tw,sh,kw
6. (satisfaction or life satisfaction or satisfaction with life).tw
7. (attitude$ or emotion$ or feeling$ or mood$).tw
8. ((psycho$ or social) adj (adjust$ or adap$ or function$)).tw
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9. (cope$ or coping).tw
10. exp emotion
11. exp psychological
12. exp adaptation, psychological
13. exp acceptance, psychological
14. symptom$.tw,ab,sh,kw
15. exp pain
16. pain.tw
17. comfort$.tw
18. acceptab$.tw
19. discomfort.tw
20. exp quality of sleep
21. sleep.tw
22. exp smell
23. smell$.tw
24. odo?r$.tw
25. exudat$.tw
26. or/25-49
27. (instrument$ or questionnaire$ or survey$ or measure$).kw,ab,ti
28. (patient outcome$ or patient reported outcome$ or PRO$).ti,ab,tw,sh,kw
29. health measurement$.ti,ab,tw,sh,kw
30. (categor$ scal$ or linear scal$ or linear analog$ scal$ or visual scal$ or magnitude estimat$).ti,ab.
31. or/51-55
32. 22 and 50
33. 24 and 55
34. 56 or 57
Refinement terms
1. historical article.pt.
2. review.pt.
3. (systematic adj review$).ti,ab,pt
4. (meta adj analysis).ti,ab
5. audit.ti,ab,pt
6. case report.tw,sh,mp,pt
7. (case adj stud$).ti,ab,pt
8. exp guidelines
9. letter.pt.
10. comment.pt.
11. editorial.pt.
12. burn$.tw
13. digital ulcer$.tw
14. buruli ulcer$.tw
15. spider bite$.tw
16. or/59-73
17. 58 not 74
18. limit 75 to humans, adult
The Cochrane Library and Web of Knowledge (WOK) databases were searched using ‘PU’ or ‘pressure
sore’ and ‘quality of life’ topic words. To find relevant PRO measures not detected in the electronic
bibliographic search, we hand searched specialist journals and relevant conference proceedings, contacted
experts, searched the Patient-Reported Outcome and Quality of Life Database [PROQOLID; see www.qolid.
org/ (accessed 9 March 2015)] and performed a citation search on all included studies and systematic
reviews identified.
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Pressure ulcer-related pain search strategy
Searches of the following electronic databases were performed from inception until April 2010 using the
search strategies below: MEDLINE, EMBASE, PsycINFO, CINAHL, BNI and AMED.
Pressure ulcer terms
1. decubitus.sh
2. skin ulcer.sh
3. exp decubitus ulcer
4. decubitus ulcer$.tw
5. pressure ulcer$.tw.
6. pressure damage$.tw
7. pressure sore$.tw
8. bed sore$.tw
9. skin ulcer$.tw
10. or/1-9
Pain terms
1. exp pain
2. pain.tw,ti,ab,sh,kw
3. discomfort.tw
4. uncomfortable.tw
5. hurt$.tw
6. unpleasant.tw
7. throb$.tw
8. ach$.tw
9. or/11-18
Existing measures terms
1. ((pain) adj2 (questionnaire or measure$ or assess$ or survey or outcome or instrument$)).tw,ab,sh
2. (mcgill pain questionnaire or MPQ).tw
3. (brief pain inventory or BPI).tw
4. or/20-22
Qualitative methodology terms
1. qualitative.tw,ab,ti,pt,sh
2. finding$.tw
3. interview$.tw,ab
4. experience$.ti,ab,tw
5. descri$.tw,ab
6. or/24-28
7. 10 and 23
8. 10 and 19 and 29
9. 30 or 31
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Refinement terms
1. (intensity rating scale$).tw
2. (numerical rating scale or NRS).tw
3. (verbal rating scale$ or VRS).tw
4. (visual analogue scale$ or VAS).tw
5. (facial recognition scale or FRS).tw
6. (present pain intensity or PPI).tw
7. historical article.pt.
8. review.pt.
9. (systematic adj review$).ti,ab,pt
10. (meta adj analysis).ti,ab
11. audit.ti,ab,pt
12. exp guidelines
13. letter.pt.
14. comment.pt.
15. editorial.pt.
16. leg ulcer.mp
17. varicose vein$.mp
18. pilonidal.tw
19. digital ulcer.mp
20. skin transplant$.mp
21. burn$.mp
22. buruli ulcer.mp
23. diabetic ulcer.mp
24. stomach ulcer.mp
25. bite.tw
26. or/33-57
27. 32 not 58
The Cochrane Library and WOK databases were searched using ‘PU’ or ‘pressure sore’ and ‘pain’ topic
words. A citation search was performed on all included studies and relevant systematic reviews.
Hand searching
The following specialist journals were hand searched:
l Journal of Tissue Viability, 1990–2010
l Journal of Wound Care, 1991–2010
l Wounds Repair and Regeneration, 2000–10
l EPUAP review, 1999–2010
l International Wound Journal, 2004–10
l European Wound Management Association Journal, 2001–May 2010
l Journal of Health and Quality of Life Outcomes, 1999–2010
l Journal of the American Medical Association archive collection of ‘Quality of Life’, 1998–2010.
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The following conference proceedings were hand searched:
l European Conference on Advances in Wound Management, 1991–2000
l Conference of the European Wound Management Association, 2001–6
l Proceedings of the European Wound Management Association and Journal of Wound Care, 1997–8
l 2nd World Union of Wound Healing Societies Meeting, 2004
l Journal of Wound Healing 2nd Conference, 2005
l Wounds UK Conference, 2004
l EPUAP Open Meeting, 1997–2007
l European Tissue Repair Society, Focus Meeting, 2000–5
l Conference of the International Society of Quality of Life Research, 1997–2007
The following dissertation databases were searched from inception to April 2010:
l ProQuest Dissertations & Theses
l Networked Digital Library of Theses and Dissertations
l International Theses in Progress
l Theses Canada Portal
l Australian Digital Theses Program
l Index to Theses
l Russian Academy of Sciences Bibliographies.
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Appendix 43 Pressure Ulcer Quality of Life study
items through the development process
Domain and scales
Reduced item list field test 1
(n= 87) – post pre-test Original item list pre-tested (n= 118)
Symptoms
Pain and discomfort Feeling uncomfortable Feeling uncomfortable
Annoying pain or discomfort Annoying pain or discomfort
Itchiness Itchiness
Tenderness Tenderness
Niggling
Soreness
A dull achea Aching
Pins and needles
Tinglingb Tingling
Throbbing Throbbing
Nagging
Shooting
Stinging Stinging
Stabbing pains Stabbing
Electric shocks
Red raw Red raw
Burning Burning
Exudate Weeping Weeping
Oozing
Running Running
Sticky Sticky
Slimy
Wet
Messy Messy
Staining Staining
Causing dressing to come off Causing dressing to come off
Gungy
Pus Pus
Bleeding Bleeding
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Domain and scales
Reduced item list field test 1
(n= 87) – post pre-test Original item list pre-tested (n= 118)
Odour Unpleasant smell Unpleasant smell
Lingering smell Lingering smell
Dirty smell
Foisty smell
Stench or stink Stench
Stink
Stale smell
Pungent smell Pungent smell
Sickening smell Sickening smell
Putrid smell Putrid smell
Physical functioning
Mobility and movement Difficulty sitting up in bed Difficulty sitting up in bed
Difficulty adjusting yourself in bed Difficulty adjusting yourself in bed
Difficulty turning or moving in bed Difficulty turning in bed
Difficulty pushing up to a sitting position Difficulty pushing up to a sitting position
Difficulty sitting in one position for long
periodsa
Difficulty sitting in one position for long
periods
Difficulty standing for long periods Difficulty standing for long periods
Difficulty transferring (e.g. from bed to a
chair or to a car)
Difficulty transferring from bed to a chair
Feeling limited in your ability to walk Feeling limited in your ability to walk
Feeling limited in your ability to go up and
down stairs
Feeling limited in your ability to go up and
down stairs
Feeling limited in how far you were able to
walka
Feeling limited in how far you were able to
walk
Feeling that your walking was slowed down Feeling that your walking was slowed down
ADL Being able to wash yourself in your usual
way (e.g. hand wash, bath, shower)
Washing yourself in the bath or shower
Getting dressed or undressed Getting dressed or undressed
Doing jobs around the house (e.g. cooking,
housework, DIY)
Doing housework
Doing gardeninga Doing gardening
Doing shopping Doing shopping
Being able to go to the toilet Going to the toilet
Being able to travel or drive a car
Doing things that you enjoy (e.g. reading a
book, watching a movie, using a computer)
Doing things that you enjoy
Getting up and about to do things that you
enjoy
Being emotionally close or affectionate with
loved ones
Being intimate with loved ones
Doing your regular daily activities (e.g.
work, volunteering, religious service, clubs,
university)
Doing usual work
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Domain and scales
Reduced item list field test 1
(n= 87) – post pre-test Original item list pre-tested (n= 118)
General vitality Feeling that your appetite has reduced Feeling that your appetite has reduced
Feeling unwell or poorly Feeling unwell or poorly
Feeling that your energy levels have been
reducedc
Feeling that your energy levels have been
reduced (e.g. feeling tired, fatigued)
Feeling tiredc
Feeling fatiguedc
Sleep Trouble falling asleep Trouble falling asleep
Interrupted sleep (e.g. restless sleep or
being woken up during your sleep)
Restless sleep
Being kept awake Being kept awake
Being woken up during the night
Not getting the amount of sleep that you
needed
Not getting the amount of sleep that you
needed
Having to sleep in one position (e.g. your
back or side)
Having to sleep in one position
Trouble finding a comfortable position Trouble finding a comfortable position
Psychological well-being
Mood Feeling frustrated Feeling frustrated
Feeling fed up Feeling fed up
Feeling annoyed or irritated Feeling annoyed
Feeling irritated
Feeling bad tempered
Feeling angry Feeling angry
Feeling miserable Feeling miserable
Feeling downa Feeling down
Feeling depressed Feeling depressed
Anxiety and worry Feeling fearful
Feeling afraid
Feeling upseta Feeling upset
Feeling concerned or worried Feeling concerned
Feeling worried
Feeling anxious Feeling anxious
Feeling surprised
Feeling shocked
Self-efficacy and
dependence
Feeling like a burden or nuisance on others Feeling like a burden or nuisance on others
Feeling like you have no control over your
life because of your sore
Feeling like you have no control over your
life
Feeling physically dependent on others Feeling physically dependent on others
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Domain and scales
Reduced item list field test 1
(n= 87) – post pre-test Original item list pre-tested (n= 118)
Appearance/
self-consciousness
Feeling helpless Feeling helpless
Feeling a lack of self-esteem
Feeling self-conscious Feeling self-conscious
Lacking in confidence Feeling a lack of self-confidence
Feeling embarrassed Feeling embarrassed
Feeling physically unattractive Feeling physically unattractive
Feeling disinterested in socialising
Feeling uneasy being close to or around
other people
Feeling uneasy being close to people
Feeling worried about how others will react
to your ulcer
Feeling a lack of understanding from those
close to you
Feeling a lack of understanding from those
close to you
Social functioning
Isolation Feeling left out
Feeling isolated
Feeling cut off or isolated from others Feeling cut off
Feeling lonely Feeling lonely
Feeling like you were missing out Feeling like you were missing out
Feeling like people avoided you or treated
you differently now
Feeling like people avoided you or treated
you differently now
Participation
Difficulty going out Difficulty going out
Being unable to meet up with others
Difficulty meeting up or seeing family
and/or friends
Difficulty seeing family and/or friends
Being unable to participate in family
gatherings or activities
Being unable to participate in family
gatherings or activities
Having to plan going out around ulcer care Having to plan going out around ulcer care
Being unable to do things spontaneously
Having to give up on hobbies or leisure
activities
Giving up on hobbies or leisure activities
Being restricted to where you could go out Being restricted to where you could go out
Being restricted to how long you could stay
out
Being restricted to how long you could stay
out
Being unable to get away for a holiday or
take a trip at the weekend
Being unable to get away for a holiday or
take a trip at the weekend
The amount of time involved in caring for
your ulcer
The amount of time involved in caring for
your ulcer
DIY, do it yourself.
a Items removed following field test 1 analysis.
b Items removed following field test 2 analysis.
c Item spilt into multiple items prior to field test 2 to extend the measurement range of the scale.
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Appendix 44 Pressure Ulcer Quality of Life
pre-test and field test study reduced format protocol
NB: This study protocol (version 5, dated 8 Mar 2010) is in a reduced format including only 
the study aims, methods and ethical considerations.  Sections pertaining to study background 
have been removed as they are included as a chapter section. Information pertaining to 
adverse events, confidentiality, archiving, statement of indemnity, study organisational 
structure, and publication policy are available upon request 
 
4 AIMS AND OBJECTIVES 
4.1 Study aim 
The aim of this study is to develop a psychometrically rigorous, self-report patient-reported 
outcome (PRO) measure of health-related quality of life (HRQL) in pressure ulcer (PU) 
patients (PU-QOL) that is acceptable to patients, reliable, valid, and suitable for use in 
clinical trials, epidemiological studies and in the NHS.  The perspective of persons with PUs 
will be central in all stages of questionnaire development and evaluation.  Collaboration has 
been sought from members of the European Pressure Ulcer Advisory Panel (EPUAP) and 
from various acute and primary care NHS Trusts around the UK.  Ethical approval is sought 
to undertake phases 2 and 3 of the development and evaluation of this measure.  
 
5 STUDY DESIGN 
5.1 Overview of project research design  
This multi-centre study is designed to develop and evaluate the psychometric properties of a 
PU-specific HRQL instrument for patients with PUs.  Guidance for developing and validating 
health outcome measures have been consulted to ensure high quality and standardisation for 
the development of the PU-QOL instrument [24-26].  The guidance recommends that 
collaboration and expert discussion is sought and utilised through all stages of instrument 
development and it proposes distinct phases for the development of a PRO measure.  
 
The research design for the PUQ-OL instrument is based on the recommended guidance and 
will be developed in 3 phases: 1) conceptual framework; 2) generation of items for the PU-
QOL instrument and pre-testing; and 3) PU-QOL evaluation in 2 parts, a preliminary field 
test 1 for item reduction and a final field test 2 for psychometric properties. 
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Phase 1 has been conducted.  A conceptual framework has been developed by tapping into 3 
sources.  Firstly, a systematic review and narrative analysis of HRQL outcomes literature (i.e. 
symptomatic consequences such as pain, foul smell, comfort/discomfort) relevant to PU 
interventions and patient experiences of living with a PU has been undertaken.  Secondly, in-
depth qualitative interviews with a sample of PU patients, and thirdly, information obtained 
from the systematic review and qualitative interviews produced a conceptual framework. 
 
Phase 2 of this project will be the development and pre-testing of the provisional PU-QOL 
instrument.  Items will be generated from the conceptual framework and patient verbatim.  
The provisional instrument will then be reviewed for clarity and overlap by the project team 
and members of the collaborating expert group.  Once expert consensus is achieved and the 
pre-test version of the instrument is developed, pre-testing will be undertaken by interviewing 
a small number of patients using cognitive interview techniques.  This process will assist in 
clarifying any ambiguities in item wording and evaluate the appropriateness of the 
instruments’ time-frame, question stem and response options.  Based on information obtained 
from the cognitive interviews, the provisional PU-QOL will be revised to produce a 
preliminary version ready for field testing. 
 
The evaluation of the PU-QOL instrument is phase 3 of this project. It will be undertaken in 2 
parts: preliminary field test 1 (item reduction) including a mode of administration sub-study 
(refer to Appendix 1); and final field test 2 (psychometric properties).  The preliminary field 
test will identify any items with poor psychometric performance for possible elimination. The 
final stage field test will be undertaken to evaluate the item-reduced version of the PU-QOL 
instrument for reliability, validity, and responsiveness.  Gold standard psychometric methods 
[27-31] will be used to evaluate the PU-QOL to ensure rigour and scientific credibility.  
 
6 PHASE 2: PRE-TESTING 
6.1 Design for Pre-Test 
Principles of Cognitive Aspects of Survey Methodology (CASM) [32] have been employed 
in the design of this phase.  Cognitive pre-testing methods (interviews with patients) will be 
used to indicate how respondents interpret questions, response categories, and to prepare 
instructions for how to formulate their responses. 
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6.2 Eligibility 
6.2.1 Inclusion criteria 
Patients from participating acute and community NHS Trusts, with existing PUs (any grade, 
see Table 1), will be included in the study if they are hospital in-patients or outpatients, 
intermediate care patients, or community patients under the care of community care nursing 
services, and they fulfil the following criteria: 
- aged ≥18 years and 
- with an existing PU of any grade, location, or duration or 
- a PU that had healed within previous 3 months and  
- able to provide written informed consent to participate and 
- able to read and write in English 
 
6.2.2 Exclusion criteria 
Patients will also be excluded from the study if any of the following criteria apply. They: 
- have only moisture lesions 
- are unconscious or confused 
- have cognitive impairment 
- are unable to speak, read and/or write in English 
- they do not have an existing PU or one that healed within previous 3 months 
- are unable to provide informed consent 
 
 
Table 1 EPUAP Pressure Ulcer Classification [5]  
Grade 1 Non-blanchable erythema of intact skin. Discolouration of the skin, 
warmth, oedema, induration or hardness may also be used as indicators, 
particularly on individuals with darker skin. 
Grade 2 Partial thickness skin loss involving epidermis, dermis, or both. The ulcer 
is superficial and presents clinically as an abrasion or blister. 
Grade 3 Full thickness skin loss involving damage to or necrosis of subcutaneous 
tissue that may extend down to but not through underlying fascia. 
Grade 4 Extensive destruction, tissue necrosis, or damage to muscle, bone, or 
supporting structures with or without full thickness skin loss. 
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Patients who are deemed ethically inappropriate to approach by members of the Tissue 
Viability Team (TVT) (see section 6.4), for example, those where death is imminent (any 
patient who is on or meets the criteria of the Liverpool Care Pathway for the dying) will not 
be approached. 
 
6.3 Methods 
The provisional questionnaire will be pre-tested with a sample of patients.  We estimate that 
approximately 40 patients will be needed to reach saturation (no new issues arising).  This 
process is intended to clarify ambiguities in item wording and to evaluate questionnaire 
length, time-frame, question stem and response options, and to address any additional queries 
that participants may raise.  Standard one-to-one cognitive interviewing techniques will be 
used by the researcher Claudia Gorecki (CG), who has training and experience in conducting 
patient interviews, to gain a better understanding of how respondents interpret questions and 
whether questions are understood in the way that they are intended. 
 
This involves the researcher (CG) asking respondents to complete the questionnaire on their 
own but throughout completion they will be required to flag/mark any items that they find are 
annoying, upsetting or intrusive, or confussing/difficult to understand.  After completion of 
the questionnaire, de-briefing questionning will be used by CG which include the use of 
general and specific questions and probes to: i) clarify ambiguities and/or misunderstandings 
in item wording; ii) identify items judged by the respondent to be either irrelevant or relevant 
but not included; and iii) questions relating to time-to-complete, ease of response, and 
whether any questions were confusing or upsetting to patients to determine instrument 
acceptability.  De-briefing questioning will be guided by an interviewers’ manual to ensure 
standardisation across administration.  
 
In addition to the cognitive interviews, we will use a computerised appraisal tool, the 
Questionnaire Understanding Aid (QUAID) [33], to identify problems with question 
comprehension, including unfamiliar technical terms, vague or imprecise relative terms, 
vague or ambiguous noun phrases, complex syntax, and working memory overload.  Results 
of pre-testing will be used to revise the provisional questionnaire to produce a long version of 
the PU-QOL for field testing.  The qualitative comments made will be recorded and 
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reviewed.  Expert opinion will be sought and appropriate revisions and modifications to the 
provisional questionnaire will be made based on the patient and professional 
recommendations.  
  
6.4 Recruitment and consent procedure 
Patients will be purposively sampled (up to 40 patients) ensuring representation of patients 
from all PU categories (grades 1-4, Table 1) and treatment types.  Consecutive patients will 
be identified from each PU category and approached to participate.  Recruitment will 
continue on a rolling basis until a minimum of 5 patients from each PU group are recruited 
and interviewed.  A sample size of up to 40 patients will allow for any initial changes to the 
interview schedule should they be required following the first few interviews and will ensure 
that saturation is met with no new major issues emerging.  
 
Members of the tissue viability team (TVT) which includes the local Principal Investigator, 
tissue viability nurse specialists, nurse consultants, and other members of their local clinical 
team (i.e. tissue viability and clinical research nurses) at participating trusts will identify 
potential patients.  A record of those identified as eligible, approached to participate, refusals, 
and consenting patients will be made (see section 6.4.1).  
 
Patients that meet the eligibility criteria will be approached, informed about the study, and 
provided with a project information leaflet which includes details about the rationale, design, 
and personal implications of the study, and an ‘agree to be contacted by the researcher’ form 
to be either contacted by telephone or visited at the ward.  
 
Following information provision, patients will have as much time as they need to complete 
the ‘agree to researcher contact’ form, which will be either faxed or posted back to the 
Clinical Trials Research Unit (CTRU).  Members of the TVT, the researcher, and the project 
Chief Investigator (CI) will be available to answer any questions that patients might have 
about the study.  After receiving a signed agreement to be contacted form from the patient, 
the researcher will telephone the patient to arrange a time for the interview.  The researcher 
will provide information about the study and interview process, will answer any questions 
about the research, and remind the patient that participation is completely voluntary and that 
they are free to withdraw taking part at any time, before gaining verbal consent and arranging 
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an interview at a mutually convenient time.  For in-patients who cannot be contacted by 
telephone and who are expected to be in the hospital during the interview, the TVT member 
will (with the patient’s permission) liaise with the researcher and patient to arrange a 
mutually convenient time for the researcher to see the patient on the ward to discuss the study 
further.  
 
The researcher (CG) will interview patients in their own home (following standard safe 
practice SOP), in the out-patient clinic, or in-patient ward as determined by the patient’s 
circumstances and preferences at the time of the interview.  It is anticipated that a similar 
number of community and hospitalised patients will be interviewed. 
 
Before the interview, each participant will be given a further verbal explanation of the study 
by the researcher; informed that the interview will be recorded but that all identifiable 
information will remain anonymous; reminded that participation is completely voluntary and 
that they can withdraw from the study at any time without it affecting their care; and invited 
formally to participate.  They will be given an opportunity to ask any questions and then if 
they agree to take part, the participant will be asked to sign the consent form.  A copy of the 
consent form will be given to the patient to keep, one filed in the patients’ health care record, 
and the original copy kept by the researcher to take back to the CTRU.  
 
The researcher is required to utilise all possible methods to ensure that no patient feels 
pressurised to take part in the study.  This will include emphasising that participation is 
entirely voluntary and that participants are free to withdraw consent at any point up to, during 
or following the interview.  The right of the patient to refuse consent without giving reasons 
will be respected.  Further, the patient will remain free to withdraw from the study at any 
time, again, without giving reasons and without prejudicing any further treatment. 
 
6.4.1 Non-registration 
The TVT member will complete a log of all patients screened for potential participation. 
Anonymised information will be collected including: 
· The reason not eligible for study particpation 
· Eligible but declined 
· Date of birth 
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· Gender 
· Ethnicity 
· Pressure ulcer grade and location 
 
6.5 Data collection 
Participants will complete the provisional questionnaire on their own but will be asked to 
flag/mark any items that are annoying, upsetting or intrusive, or confusing.  Following 
completion, the researcher, guided by a standard set of questions and probes, will seek to 
elicit the cognitive processes employed by the participant while completing the provisional 
questionnaire.  Data collected will relate to feedback on participants’ understanding of each 
question and associated response category and instructions, and to verbalise how they had 
gone about producing their answers, with particular emphasis on retrieval from memory and 
subsequent judgements and decisions [32].   
 
Questionnaire completion and follow-up interview may take around 40-60 minutes and will 
be discontinued at any time if participants are unable to go on or wish to discontinue.  The 
interviews will be conducted, recorded, and analysed by CG with supervison from 
experienced researchers (AEN, DL), who will undertake quality assurance.  
 
6.5.1 Baseline data 
Following questionnaire completion and specific probing, the researcher will record the 
following information as provided by the patient: 
· Patient initials and date of birth 
· Gender 
· Ethnicity 
· Pressure ulcer grade, location and number of pressure ulcers 
· Duration of pressure ulcer 
· Treatment plan (information about which treatment interventions the patient is 
currently receiving) 
· Co-morbidity and/or speciality (i.e. spinal cord injured, trauma, vascular, care of the 
elderly ward) 
 
6.6 Data analysis 
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Review and analysis of information collected from cognitive interviews will be conducted as 
soon as possible after the interview, but at minimum after every 3 interviews.  This will 
enable any major flaws in the provisional questionnaire to be identified and revised prior to 
subsequent testing with the revised version.  This form of multiple rounds of testing will 
determine whether the problem identified has indeed been rectified and no new problems 
introduced.  
 
A systematic way of evaluating questionnaires will be developed to ensure that each 
questionnaire item was assessed systematically.  An appropriate tool, the Question Appraisal 
System (QAS-99) [34] will be used to categorise item problems identified during the 
cognitive interview process.  The QAS-99 consists of eight major categories that focus on 
question characteristics that are likely to present problems when completing and forming 
responses to questionnaires.  
 
Review and analysis will involve the researcher listening to the recorded interview and 
making structured contemporaneous notes of specific problems identified based on the 
categories of the QAS-99 appraisal tool.  Specifically, focus will be on identifying dominant 
trends (problems occurring repeatedly) across interviews, and key findings (problems that 
may only be identified in a single interview, but have the potential to cause serious 
problems).  Comments made, both within and across interviews, will be aggregated so that 
they can be used to review the provisional questionnaire.  In addition to cognitive pre-testing, 
expert appraisal of the provisional questionnaire will inform revisions.  
 
7 PHASE 3: FIELD TESTING 
The psychometric properties of the PU-QOL will be evaluated through two-stage field testing 
including a preliminary field test (item reduction) to identify items with poor psychometric 
properties for possible elimination and identify subscales, and a final field test (psychometric 
evaluation) to evaluate the reliability and validity of the item-reduced version of the PU-
QOL.  The overall strategy and methods for the psychometric evaluation of PU-QOL are 
based on the methods used to develop and validate PROs in several other areas of medicine 
and surgery [27,28,31,35].   
 
7.1 Design for preliminary field test 1 (item reduction)  
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The purpose of the preliminary field test 1 is to produce a short (item-reduced) version of the 
PU-QOL from the provisional version and to undertake an initial psychometric evaluation of 
the item-reduced questionnaire.  
 
An item reduction strategy developed for evaluation of PROs in other medical areas [27-31] 
will be used to: i) identify items on the provisional version of the PU-QOL with poor 
psychometric properties for possible elimination; ii) conduct a preliminary evaluation of PU-
QOLs’ subscales; and iii) undertake a preliminary evaluation of the acceptability, reliability 
and validity of the item reduced PU-QOL.  Results of the item reduction analyses will be 
used to develop a shorter version of PU-QOL for final psychometric field testing. 
 
In addition, to address methodological issues identified from the pre-test phase relating to 
patient difficulties in self–completion, a mode of administartion sub-study will be undertaken 
to determine the mode of administration in which the questionnaire will be developed and 
validated (ie both self-complete and interview-administered modes or interview-administered 
only) (see Appendix 1 for details of the sub-study). 
 
There are two possible outcomes from the sub-study:  
1) One questionnaire can be developed and psychometrically evaluated for use with 
either of the two modes of administration (i.e. self-complete and interview-
administered modes) or;  
2) Two mode-specific questionnaires are required.   
 
If the analysis of the sub-study finds that one questionnaire can be developed for use with 
either mode of administration, all of the following sections of the protocol will apply.  If the 
analysis finds that two mode-specific questionnaires are required, only the interview-
administered sections of the subsequent protocol will apply. 
 
7.2 Eligibility 
Patients from participating acute and community NHS Trusts, with existing PUs (any grade, 
see Table 1), will be included in the study if they are hospital in-patients or outpatients, 
intermediate care patients, nursing home patients or community patients under the care of 
community care nursing services, and they fulfil the criteria detailed below in section 7.2.1.  
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Patients who took part in pre-testing will not be approached to take part in the field testing 
phase. 
 
7.2.1 Inclusion criteria 
- aged ≥18 years and 
- with an existing PU of any grade, location, or duration and  
- able to provide informed consent to participate  
 
7.2.2 Exclusion criteria 
Patients will also be excluded from the study if any of the following criteria apply. They: 
- have only moisture lesions 
- are unconscious or confused 
- have cognitive impairment 
- do not speak or understand English 
- they do not have an existing PU or 
- are unable to provide informed consent 
 
Patients who are deemed ethically inappropriate to approach by members of the Tissue 
Viability Team (TVT), for example, those where death is imminent (any patient who is on or 
meets the criteria of the Liverpool Care Pathway for the dying) will not be approached. 
 
7.3 Methods 
An approximate sample of 150-250 PU patients will be purposively sampled ensuring 
representation of patients with all PU categories (grades 1-4, Table 1) and treatment types.  
There are no formal sample size estimation methods for evaluation of PRO measures, so the 
‘rule of thumb’ recommendation of 5-10 patients for every item in the questionnaire has been 
used to estimate the sample size of 150-250 patients [24].  Consecutive patients will be 
identified and approached to participate.  Accrual will be reviewed to ensure that there is 
balanced representation of patients in all PU categories.  If we are validating the 
questionnaire for both modes of administration (i.e. self-complete and interview-administered 
modes) then accrual will be monitored to ensure equal numbers of patients are recruited into 
both mode groups.  Where possible patient recruitment will be piggy-backed onto local audit 
and Quality Assurance (QA) activity (prevalence surveys, incidence monitoring, critical 
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incidence reporting) to maximise the identification of patients with PUs whilst minimising 
disruption and demand on the local clinical team.  
 
7.4 Recruitment and consent procedures 
Members of the TVTs at participating trusts will identify eligible patients.  A record of those 
identified as eligible, approached to participate, refusals, consenting patients and 
questionnaire returns will be made (see section 7.4.1 and 7.5).  
 
A verbal explanation of the study and Patient Information Leaflet will be provided by the 
TVT member or the researcher* (CG) for the patient to consider.  These will include detailed 
information about the rationale, design and personal implications of the study.  Following 
information provision, patients will have as much time as they need to consider participation 
and will be given the opportunity to discuss the study with their family and healthcare 
professionals before they are asked whether they would be willing to take part.  The right of 
the patient to refuse consent without giving reasons will be respected. 
 
Should the patient be capable of giving consent but physically unable to complete the written 
aspects of the consent form, witnessed consent should be obtained using the Witnessed 
Consent Form.  An appropriate witness would be a family member, career or friend or 
another member of the patient’s healthcare team who is not directly involved in the research 
study. 
*Where the researcher is involved in the recruitment and consent process, the patient will be asked to give 
verbal permission to be approached by the researcher 
 
Assenting patients will then be invited to provide informed, written consent to collect 
baseline assessment data and to complete the questionnaire.  Formal eligibility assessment 
and informed consent will be undertaken by the TVT member or researcher. The patient will 
remain free to withdraw from the study at any time without giving reasons and without 
prejudicing any further treatment.  The original consent form will be filed within the 
PURPOSE Investigator Site File or designated secure location.  One copy of the consent form 
will be given to the patient and one will be filed with the patients medical file.  
 
7.4.1 Registration  
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Patients will be registered with the CTRU following informed consent and confirmation of 
eligibility.  When eligibility has been confirmed, registration and baseline data (section 7.5.1) 
will be collected and a questionnaire pack containing the final provisional PU-QOL will 
either be provided to the patient to self-complete or be administered.  Registration and 
baseline information and completed questionnaire packs will be collected from the patient by 
the attending TVT member, recognising the potential for completion bias this may incur. 
However, in this patient population and in order to maximise questionnaire return rates, 
collection of the questionnaires by the attending TVT member is considered essential.  
 
7.4.2 Screening  
The TVT member will complete a log of all patients screened for eligibility who are not 
registered either because they are ineligible or because they declined participation.  All 
anonymised screening logs will be returned to the CTRU. 
 
Anonymised information will be collected including: 
· The reason not eligible for study particpation or 
· Eligible but declined 
· Date of Birth 
· Gender 
· Ethnicity 
· Pressure ulcer grade and location 
 
7.5 Data collection/assessment 
Study data will be recorded by members of the TVTs or the researcher on the case record 
forms (CRFs) and by patients, members of the TVTs or the researcher on questionnaire 
booklets.  Anonymised data will be returned to the CTRU.  
 
Assessments will be undertaken as follows: 
· Registration and Baseline data 
· PU-QOL Questionnaire booklet 
 
7.5.1 Registration and Baseline Data 
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Patients who meet the inclusion criteria and provide informed written consent (for baseline 
assessment and questionnaire completion) will be registered to this study. Registration and 
baseline information will be recorded by the TVT member or researcher including: 
· Patient initials and date of birth 
· Gender 
· Ethnicity 
· Marital status 
· Education 
· Presence of PU symptoms 
· Pressure ulcer grade, location and number of pressure ulcers 
· Duration of pressure ulcer 
· Treatment plan (information about which treatment interventions the patient is 
currently receiving) 
· Co-morbidity and/or speciality (i.e. spinal cord injured, trauma, vascular, care of the 
elderly ward) 
· Centre code 
· Name of the TVT/clinical research staff member conducting registration 
· Confirmation of eligibility and written informed consent 
· Braden scale 
 
7.5.2 PU-QOL questionnaire booklet 
Self-complete version 
The patients will self-complete the PU-QOL questionnaire booklet, which will be provided to 
them by the person obtaining consent (i.e. member of the TVT or the researcher (CG)).  It is 
anticipated that completion of the questionnaire may take up to 40 minutes.  
 
Interview-administered version 
A questionnaire pack will be administered to patients by either a member of the TVT or the 
researcher, following an interview manual.  It is anticipated that administration of the 
questionnaire may take up to 40 minutes.  Training in administering the questionnaire will be 
provided by the CTRU. 
 
7.6 Item reduction analysis 
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The purpose of the item reduction analysis is to produce a psychometrically robust short 
version of the PU-QOL questionnaire.  Standard psychometric tests and criteria for 
acceptability, reliability and validity will be performed to identify and retain items with 
strong psychometric properties and eliminate items with poor psychometric properties to 
produce a shorter, item-reduced version of the PU-QOL questionnaire.  These analyses will 
also evaluate the hypothesised subscales of the questionnaire 
 
Item reduction analysis will include item analysis and principal component factor analyses, 
including missing data <5%, maximum endorsement frequencies <80% (floor/ceiling effects 
<80%), aggregate adjacent endorsement frequencies >10%, item redundancy (inter-item 
correlations <0.75), internal consistency (item-total correlations <0.25), evidence of item 
responsiveness, and tests of scaling assumptions (item convergent/discriminant validity).  A 
preliminary psychometric evaluation of the short, item-reduced version will be carried out 
using standard psychometric tests for acceptability, reliability (internal consistency), and 
validity (factor analysis, item convergent/discriminant validity). 
 
In addition to standard psychometric tests, methods from modern measurement theory will be 
used to evaluate the psychometric properties of the PU-QOL questionnaires’ scales and items 
[36].  This is proposed in order to strengthen methodological rigour. 
 
8 FIELD TEST 2: PSYCHOMETRIC EVALUATION 
8.1 Design for field test 2 
In order to establish the PU-QOL as a valid measure of PU HRQL and to determine whether 
the instrument meets gold-standard criteria, scientific psychometric tests of acceptability, 
reliability, and validity will be performed.  
 
A questionnaire pack will be provided to patients to self-complete or be administered to 
them.  The pack will include the PU-QOL instrument and additonal measures selected for 
validation purposes (section 8.5.1).  In addition, a sub-sample of the patients who complete 
and return the questionnaire packs at baseline will be asked to self-complete  or have 
administered to them a second (re-test) questionnaire pack 2-7 days after the initial 
questionnaire completion.  
APPENDIX 44
NIHR Journals Library www.journalslibrary.nihr.ac.uk
532
8.2 Eligibility 
Patients from participating acute and community trusts, with existing PUs (any grade, see 
Table 1), will be included in the study if they are hospital in-patients or hospital outpatient, or 
intermediate out-patient, nursing home patients or community patients under the care of 
community care nursing services, and they fulfil the criteria detailed in section 7.2. 
 
8.3 Methods 
An approximate sample of 150-250 PU patients (5-10 patients for each item on the PU-QOL 
instrument) will be purposively sampled ensuring representation of patients with all PU 
categories (grades 1-4, Table 1) and treatment types.  Consecutive patients will be identified 
and approached to participate.  Accrual will be reviewed to ensure that there is balanced 
representation of patients in all PU categories.  If we are validating the questionnaire for both 
modes of administration (i.e. self-complete and interview-administered modes) then accrual 
will be monitored to ensure equal numbers of patients are recruited into both mode groups.  
Where possible, patient recruitment will be piggy-backed onto local audit and QA activity 
(prevalence surveys, incidence monitoring, critical incidence reporting) to maximise the 
identification of patients with PUs by the local clinical team.  
 
Test-Retest 
A test-retest will be undertaken with a sub-sample of participants recruited for the final field 
test.  Consenting participants will complete a second questionnaire pack 2-7 days after the 
first questionnaire pack (approximately 75 patients for each mode of administration group).  
The length of the test-retest interval must be short enough to ensure that clinical change in the 
PU is unlikely to occur, but sufficiently long to ensure that respondents do not recall their 
responses from the first assessment.  A short test-retest interval is necessary to ensure that 
stability per se is being evaluated, rather than clinical change in the PU during the test-retest 
interval, which will underestimate reliability.  
 
8.4 Recruitment and consent procedure 
Members of the TVTs at participating trusts will identify eligible patients. A record of those 
identified as eligible, approached to participate, refusals, consenting patients and 
questionnaire returns will be made (see section 7.4.1 and 7.5).  The recruitment and consent 
methods described above in the preliminary field test will be used (section 7.4).  
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In addition to the information described in section 7.4, the patient information leaflet for the 
final field test indicates that participants can take part in 2 ways: 1) self-complete or 
administered questionnaire booklet at baseline, and if they agree, 2) complete a second self-
complete or administered questionnaire booklet 2-7 days later.  There will be an option on the 
consent form where participants can indicate whether they agree to take part in a second 
questionnaire.  In addition to the original consent form being filed within the PURPOSE 
Investigator Site File or designated secure location, one copy for the patient, and one for the 
patient’s medical notes, a copy of the consent form will be sent to the CTRU.  
 
Self-complete version 
If patients who self-complete a questionnaire at baseline agree, they will provide home 
address details so that a second questionnaire booklet can be given to them when the first 
booklet is collected or sent out to them with a return stamped, self-addressed envelope.  
Where patients are still hospital in-patients, they will complete the second questionnaire on 
the ward and return it to the researcher or TVT member that provided it to them.  
 
Interview-administered version 
If patients who were administered a questionnaire at baseline agree, they will provide home 
address details so that a second questionnaire booklet can be administered to them at a time 
agreed by the patient and the person administering the questionnaire (must be between 2-7 
days after baseline administration).  Where patients are still hospital in-patients, they will 
have a second questionnaire pack administered to them on the ward.  The researcher or TVT 
member that administered the questionnaire pack will be responsible for returning completed 
questionnaires to CTRU.  
 
8.5 Data collection/assessments 
Study data will be recorded by members of the TVTs on the CRFs and by patients on 
questionnaire packs. Data will be returned to the CTRU.  
 
Assessments will be undertaken as follows: 
· Registration and Baseline  
· PU-QOL Questionnaire booklet 
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· 2-7 day follow-up questionnaire pack (approx. 75 patients from baseline sample) 
 
8.5.1 Registration and baseline Data 
Baseline information will be recorded by the TVT member including: 
· Patient initials and date of birth 
· Gender 
· Ethnicity 
· Marital status 
· Education 
· Presence of PU symptoms 
· Pressure ulcer grade, location and number of pressure ulcers 
· Duration of pressure ulcer 
· Treatment plan (information about which treatment interventions the patient is 
currently receiving) 
· Co-morbidity and/or speciality (i.e. spinal cord injured, trauma, vascular, care of the 
elderly ward) 
· Centre code 
· Name of the TVT/clinical research staff member conducting registration 
· Confirmation of eligibility and written informed consent 
· Braden scale 
 
8.5.2 PU-QOL questionnaire pack 
Baseline questionnaire pack will include: 
· The Provisional PU-QOL 
· SF-12 (rather than SF36 to reduce respondent burden) 
· Additional questionnaires selected for validation purposes (ethics will be notified 
about which questionnaires are selected, section 8.5.3) 
 
Test-retest questionnaire pack will include: 
· The Provisional PU-QOL 
· SF-12 (rather than SF36 to reduce respondent burden) 
· Additional questionnaires selected for validation purposes (ethics will be notified 
about which questionnaires are selected, section 8.5.3) 
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8.5.3 Assessment instruments 
The Short Form-12 Health Survey Questionnaire  
Use of the SF-36 was considered however it was decided by the project team that it was too 
long for use with PU patients.  Instead, the SF-12 will be used to reduce respondent burden.  
The SF-12 is a generic instrument that assesses HRQL in eight domains of physical 
functioning, role-physical, body pain, general health, energy/fatigue, social functioning, role-
emotional and mental health.  These are the same domains as the SF-36. Even though this 
instrument has not been validated for use with PU patients, it has been used with other related 
chronic-skin wound conditions to validate their corresponding disease-specific HRQL 
instruments.  
 
Additional questionnaires 
Participants will complete the short version of the PU-QOL, the SF-12, and additional  
measures to assess construct validity (convergent, discriminant, known groups).  The guiding 
principle in selecting the validating measures will be to include measures that will allow a 
comparison of PU-QOL subscales with measures of similar constructs (convergent validity) 
and with measures of different constructs (discriminant validity), and to compare PU-QOL 
scores in clinically defined known groups whose HRQL would be expected to differ.  At this 
stage it is not possible to anticipate the subscales and item stem of the PU-QOL until it has 
been developed (pre-testing, section 6).  As such, selection of validating measures is not 
possible.  However, where available, short versions of measures selected for validation 
purposes and only measures deemed essential for validation testing will be included in the 
questionnaire packs.  All measures will be administered in the same order. It is anticipated 
that completion of questionnaire packs may take up to an hour. 
 
8.6 Psychometric evaluation analysis 
Analyses will include examination of: 
Item-level performance will determine missing data (<5%), maximum endorsement 
frequencies (<80%), and item redundancy (inter-item correlations <0.75). 
Acceptability will be assessed by completeness of data (e.g. missing data for summary 
scores <5%) and score distributions (e.g. distribution of endorsement frequencies across 
response categories, skew and floor/ceiling effects for summary scores <10%). 
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Reliability will be assessed on the basis of internal consistency (Cronbach’s alpha for 
summary scores ≥0.70 and item-total correlations ≥ 0.30) and test-retest reliability 
(correlations for summary scores ≥0.70). 
Validity will include a within-scale analyses to determine whether a single entity (construct) 
is being measured and that items on the measure can be combined to form a summary score 
(Cronbach’s alpha  ≥0.70), and analysis against external criteria (convergent, discriminant 
and known groups differences validity). To evaluate convergent validity we will compare 
PU-QOL with the SF-12, and additional relevant measures as determined once the PU-QOL 
questionnaire is developed. Discriminant validity will be assessed by examining PU-QOL 
scores by age, gender and medical specialty. PU-QOL scores for patients by PU severity 
(superficial vs severe), site of PU (heel vs elsewhere), and sensitivity impaired vs. no 
sensitivity impaired will be compared to evaluate known group differences. Factor analysis, 
together with the results of other item-level analyses described in table 2, will be used to 
investigate hypothesised subscales. 
Evaluation of subscales will be determined by factor analysis and item convergent/ 
discriminant validity 
  
In addition to standard psychometric tests, modern psychometric methods will be used to 
strengthen methodological rigour [36]. 
 
12 ETHICAL CONSIDERATIONS 
This project will recruit patients with PUs and therefore will include elderly and highly 
dependent patients considered as vulnerable.  Ethical issues are largely related to the 
involvement of vulnerable adults/elderly patients with high levels of co-morbidity including 
acute and chronic illness.  Clinically, older patients are treated in the same way as younger 
patients and it is therefore important to ensure that the study is representative of the clinical 
population.  In addition, questionnaire completion/interview requires the patient to reflect on 
their experience of having a PU and how interventions received have impacted on their QOL.  
For some people this may raise topics considered to be sensitive, embarrassing or upsetting, 
and possibly emotionally distressing. 
 
The ethical issues surrounding these potentially vulnerable patients have been addressed 
through the study design and include a thought out consent process, the use of one-to-one 
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semi-structured interviews using de-briefing questioning for data collection at the 
development pre-testing stage to provide a caring and supportive environment in which to 
discuss any sensitive issues that may arise, and the use of only essential measures required for 
validation purposes (short version where available) to reduce respondent burden.  If the 
patient becomes distressed during the interview or from completing the questionnaire, then 
the interview will be immediately stopped.  It will be stressed to all patients that they are able 
to withdrawn from participation at any time without giving reason, and without any effect on 
their care.  They will be referred back to their treating nurse specialist if required. 
 
This study will be conducted in accordance with the Declaration of Helsinki in its latest form. 
The study will be submitted to and approved by a REC prior to identifying eligible patients.  
The CTRU will provide the REC with a copy of the final protocol, patient information 
leaflets, consent forms, and all other relevant study documentation. 
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BACKGROUND TO SUB-STUDY 
Initially, the purpose of the PU-QOL study was to develop and psychometrically evaluate a 
HRQL questionnaire for patients with pressure ulcers as a self-complete mode of 
administration questionnaire.  However, preliminary analysis of the pre-test data has 
identified problems with completion rate, posing a question about the appropriateness of a 
self-complete measure for patients with pressure ulcers, particularly elderly patients aged 
over 80 years.  To address these methodological issues identified from the pre-test, we are 
proposing to undertake a mode of administration sub-study.  The sub-study will determine the 
mode of administration for which the questionnaire will be developed and validated.  
 
Aim and objectives 
The purpose of the sub-study is to determine whether one questionnaire can be developed and 
validated for use with both modes of administration or whether two mode-specific 
questionnaires are required.  
 
METHODS 
Design 
A mode of administration sub-study including a differential item functioning (DIF) analysis 
[37] will be undertaken to establish measurement equivalence across two mode of 
administration groups (self-complete and interview-administered modes).  A DIF analysis 
will investigate the equivalence of the PU-QOLs’ questionnaire items by comparison of these 
two groups. 
 
A sample of 60-100 patients are required for the sub-study. Consecutive patients will be 
approached to take part.  Eligible patients who provide written informed consent will be 
randomised to either the self-complete or interview-administered groups (see section 2.2).  
 
We plan to develop one PU-QOL questionaire – the results of the sub-study will determine 
whether PU-QOL should be developed as interview-administered only OR both self-complete 
and interview-administered (see section 5 for more details). 
 
Eligibility 
To ensure an equivalent or representative sample in both mode of administration groups (i.e. 
both groups need to have the same clinical presentation to perform a differential item 
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functioning analysis, see section 6), the eligibility criteria has been adapted from the main 
study to include only patients who are able to read and write in English (i.e. patients able to 
self-complete a questionnaire will be randomised to both mode of administration groups).  
 
Patients from participating acute and community NHS Trusts, with existing PUs (any grade, 
see Table 1), will be included in the sub-study if they are hospital in-patients or outpatients, 
intermediate care patients, nursing home patients or community patients under the care of 
community care nursing services, and they fulfil the criteria detailed below in section 2.2.1. 
Patients who took part in pre-testing will not be approached to take part in the sub-study. 
 
Inclusion criteria 
- aged ≥18 years and 
- with an existing PU of any grade, location, or duration and  
- able to provide informed consent to participate and 
- able to read and write in English (i.e. able to self-complete a questionnaire) 
 
Exclusion criteria 
Patients will also be excluded from the study if any of the following criteria apply.  They: 
- have only moisture lesions 
- are unconscious or confused 
- have cognitive impairment 
- are unable to read or write in English 
- they do not have an existing PU or 
- are unable to provide informed consent 
 
Patients who are deemed ethically inappropriate to approach by members of the Tissue 
Viability Team (TVT), for example, those where death is imminent (any patient who is on or 
meets the criteria of the Liverpool Care Pathway for the dying) will not be approached. 
 
Recruitment and consent 
Members of the TVTs at participating trusts will identify eligible patients for the sub-study.  
A record of those identified as eligible, approached to participate, refusals, consenting 
patients and questionnaire returns will be made (see section 3.1).  
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A verbal explanation of the study and patient information leaflet will be provided by the TVT 
member or the researcher* (CG) for the patient to consider.  These will include detailed 
information about the rationale, design and personal implications of the study.  Following 
information provision, patients will have as much time as they need to consider participation 
and will be given the opportunity to discuss the study with their family and healthcare 
professionals before they are asked whether they would be willing to take part.  The right of 
the patient to refuse consent without giving reasons will be respected. 
 
Should the patient be capable of giving consent but physically unable to complete the written 
aspects of the consent form, witnessed consent should be obtained using the Witnessed 
Consent Form.  An appropriate witness would be a family member or friend of the patient or 
another member of the patient’s healthcare team who is not directly involved in the research 
study. 
*Where the researcher is involved in the recruitment and consent process, the patient will be asked to give 
verbal permission to be approached by the researcher 
 
Assenting patients will then be invited to provide informed, written consent to collect 
baseline assessment data and to complete the questionnaire.  Formal eligibility assessment 
and informed consent will be undertaken by the TVT member or researcher.  The patient will 
remain free to withdraw from the study at any time without giving reasons and without 
prejudicing any further treatment.  The original consent form will be filed within the 
PURPOSE Investigator Site File or designated secure location. One copy of the consent form 
will be given to the patient and one will be filed with the patients medical file.  
 
Screening and registration 
The TVT member will complete a log of all patients screened for eligibility who are not 
randomised or registered either because they are ineligible or because they declined 
participation.  All screening logs will be returned to the CTRU. 
 
Anonymised information will be collected including: 
· The reason not eligible for study particpation or 
· Eligible but declined 
· Date of Birth 
· Gender 
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· Ethnicity 
· Pressure ulcer grade and location 
 
Registration and randomisation 
Screened patients who are both eligible for sub-study participation and provide written 
informed consent will be registered and randomised to the sub-study.  Informed consent for 
entry into the sub-study must be obtained prior to randomisation.  Following confirmation of 
written informed consent and eligibility, registration and baseline data will be collected (see 
section 7.5), and patients will be randomised into the study by an authorised member of staff 
at the study research site.  
 
Randomisation will be carried out by the Clinical Trials Research Unit (CTRU), at the 
University of Leeds, using a telephone randomisation service that will ensure allocation 
concealment.  Randomisation will be performed using the CTRU 9.00–17.00 telephone 
randomisation service (9:00 to 17:00 Monday to Friday excluding public/bank holidays, the 
period between Christmas and New Year and all Tuesdays following a bank holiday except 
for Mayday). 
 
The following information will be submitted prior to randomisation: 
· Patients details including initials, gender, date of birth  
· confirmation of eligibility  
· confirmation of written informed consent 
· date of written informed consent 
· details relating to the stratification factors 
 
Patients who fulfil the eligibility criteria, and have given written informed consent, will be 
randomised on a 2:1 basis to receive either self-complete or interview-administered mode of 
administration.  The 2:1 ratio will be used to account for the likelihood of increased missing 
data from self-completed questionnaires; a minimum of 30 fully completed questionnaires are 
required for the DIF analysis.  Randomisation will be stratified by: age (  70, >70 years), and 
PU severity (superficial vs. severe PU).  
 
 
Direct line for randomisation: 0113 343 xxxx 
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Assessments and data collection 
Study data will be recorded by members of the TVTs or the researcher on the case record 
forms (CRFs) and by patients, members of the TVTs or the researcher on questionnaire 
booklets. Data will be returned to the CTRU.  
 
Assessments will be undertaken as follows: 
· Registration and Baseline data 
· Randomisation 
· PU-QOL Questionnaire booklet 
 
Baseline assessment 
Patients who meet the inclusion criteria and provide informed written consent (for baseline 
assessment and questionnaire completion) will be registered to this sub-study. Registration 
and baseline information will be recorded by the TVT member or researcher including: 
· Patient initials and date of birth 
· Gender 
· Ethnicity 
· Marital status 
· Education 
· Presence of PU symptoms 
· Pressure ulcer grade, location and number of pressure ulcers 
· Duration of pressure ulcer 
· Treatment plan (information about which treatment interventions the patient is 
currently receiving) 
· Co-morbidity and/or speciality (i.e. spinal cord injured, trauma, vascular, care of the 
elderly ward) 
· Centre code 
· Name of the TVT/clinical research staff member conducting registration 
· Confirmation of eligibility and written informed consent 
· Braden scale 
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PU-QOL questionnaire booklet 
Self-complete version 
The patients will self-complete the PU-QOL questionnaire booklet, which will be provided to 
them by the person obtaining consent (i.e. member of the TVT or the researcher (CG)).  It is 
anticipated that completion of the questionnaire may take up to 40 minutes.  
 
Interview-administered version 
A questionnaire pack will be administered to patients by either a member of the TVT or the 
researcher following and interview manual. Training in administering the questionnaire will 
be provided by the CTRU.  It is anticipated that administration of the questionnaire may take 
up to 40 minutes.  
 
Sample size 
To perform a differential item functioning (DIF) analysis, a minimum of 30 fully completed 
questionnaires (i.e. no missing data) are required for each mode of administration group.  
Consecutive patients will be randomised until a minimum of 30 fully completed 
questionnaires are collected from each mode of administration group (30 self-completed and 
30 interview-administered questionnaires).  We anticipate approximately 100 patients are 
required for the sub-study to meet the data requirement for the DIF analysis.  
 
DIF analysis 
The purpose of the sub-study analysis is to determine whether the PU-QOL questionnaire can 
be used with either self-complete or interview-administered modes or whether there is the 
need to develop and validate two mode-specific versions of the questionnaire (i.e. a self-
complete version and an interview-administered version).   
 
The DIF analysis will determine whether scores are directly comparable between both modes 
of administration (i.e. whether scores from both modes of administration are similar enough 
to continue developing and validating one version of the questionnaire, or whether scores are 
divergent and there is a requirement to develop two mode-specific questionnaires).  
 
DIF techniques match scores on questionnaires from different groups according to their total 
questionnaire scores and then investigate how the different groups performed on individual 
questionnaire items to determine whether the questionnaire items are creating problems for a 
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particular group [37] (i.e. specific mode of administration group).  DIF is based on the 
assumption that test takers who have similar knowledge (based on total test scores) should 
perform in similar ways on individual test questions regardless of various demographics.  To 
ensure that the DIF analysis is a valid interpretation of group differences dependent on mode 
of administration and not an artefact of differences within the groups; differences that could 
present if for example younger, healthier patients were assigned to the self-complete group 
and older, more frail patients were assigned to the interview-administered group, only 
patients who meet the inclusion criteria (section 2.2) will be included in the sub-study.  This 
will ensure that both group’s participants are matched on clinical presentation and relevant 
underlying ability before determining whether participants of the two groups differ in their 
probability for success [37].  
 
There are 2 possible outcomes of the analysis: 
1. One questionnaire can be developed and validated for use with either mode of 
administration or 
2. Two mode-specific questionnaires are required.  
 
The outcome of the sub-study will determine the mode of administration in which the 
questionnaire will be developed and validated (ie both self-complete and interview-
administered modes or interview-administered only). 
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Appendix 45 Pressure Ulcer Quality of Life
pre-test study patient information leaflet and
consent form
[Delete this line then print on Trust headed paper] 
Participant Information Leaflet and Agree to Contact Form 
 
PUQOL Project Pre-test: patient interviews 
 
A large-print version of this sheet is available on request.   
 
We would like to invite you to take part in a research project. Before you decide to take part, 
it is important for you to understand why the research is being done and what it would 
involve for you. Please take the time to read the following information carefully and discuss it 
with your relatives and your ward nurse if you wish. Ask us if there is anything that is not 
clear or if you would like more information. Part 1 tells you the purpose of this project and 
what will happen to you if you take part. Part 2 gives you more detailed information about 
the conduct of the study.
 
Part 1 
What is the purpose of the study? 
The development of pressure ulcers, also called a bed sores or pressure sores, can have a 
major impact on patients’ quality of life and well-being as well as severely compromise all 
areas of functioning. However, there is currently no formal way of assessing quality of life 
outcomes from the patients’ perspective in healthcare and in research, as there is no quality of 
life questionnaire for use with patients with pressure ulcers.  
 
The Pressure Ulcer Quality of Life (PUQOL) project will develop a questionnaire that will 
assess important quality of life outcomes in patients with pressure ulcers that will be suitable 
for use in NHS clinical practice and in research. Specifically, the questionnaire will provide 
us with important information about the experienced suffering of patients with pressure ulcers 
and the impact pressure ulcer treatments have on patients’ quality of life. This information 
will be obtained in order to improve patient healthcare and patient quality of life.  
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This study is the second phase of the development of the questionnaire and involves 
interviews with patients like yourself. Patients will complete the provisional version of the 
questionnaire and upon completion, will be asked to answer a series of questions about the 
questionnaire. The provisional questionnaire will be modified based on all patients’ answers 
and recommendations. 
 
Why have I been invited? 
You have been chosen to take part because we wish to talk to people who have experience of 
having a pressure ulcer. Any person who has a pressure ulcer ranging from a small red area to 
a more severe ulcer, from hospitals and within the community around the United Kingdom, 
will be asked to participate.  
 
Do I have to take part? 
Taking part in this study is entirely voluntary and you are under no obligation to take part in 
this study, it is up to you to decide. We will describe the study to you and go through this 
information sheet.  If you agree to take part we will then ask you to sign a consent form to 
show that you have agreed to take part. You will be given a copy of this information sheet 
and of the consent form for you to keep. You are free to withdraw at any time, without giving 
a reason. This would not affect the standard of care you receive. If you do not wish to take 
part this will not affect the care that you are currently receiving. 
 
What will happen to me if I take part? 
If you agree to take part, you will be asked to complete a questionnaire which will take 
approximately 20 minutes to complete. It would involve choosing an answer to a set of 
questions on a scale. An example of a question that you might be asked is: 
 
In the past week, for how many days did your pressure ulcer cause you pain or ache? 
(please tick one box)  
    None at all □   between 1-3 days □   between 4-5 days □   between 6-7 days □ 
 
While completing the questionnaire, you will be required to mark any questionnaire items 
that are annoying, upsetting or intrusive, or misunderstood. After completion of the 
questionnaire, the interviewer, Claudia Gorecki, will ask you some questions about the items 
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you marked to clarify ambiguities and/or misunderstandings in the questionnaire wording. 
You will also be asked questions relating to the time it took to complete, ease of response 
options, and general questionnaire content. All people who take part are being asked the same 
questions. Completion of the questionnaire and the follow-up interview could possibly take 
up to an hour so participants who agree to take part in the study would need to be available 
for up to an hour. We will make sure the interview took place in as private a place as 
possible, either in your own home or on the ward where you are admitted, at a time 
convenient for you. No further involvement is required. 
  
The discussion that you have with the interviewer about the questionnaire, with your 
permission, will be tape recorded and transcribed to help us analyse it. The tape recording 
will be used only by researchers involved in the project and it will be stored in a locked 
cabinet. As soon as the information on the tapes in analysed, the tapes will be destroyed. In 
addition to the information collected during the interview, we may need to access your 
medical records to obtain further information about your pressure ulcer and the treatments 
that you have received.  
 
Expenses and payments 
We anticipate that there will be no extra expenses for you as a result of taking part in this 
study, as interviews will be conducted in your own home or on the hospital ward where you 
are admitted at a time convenient for you.  
 
What are the possible disadvantages and risks of taking part? 
We do not foresee any disadvantages or risks to you in taking part in this study. However, 
you are being asked to give some of your time and by completing the questionnaire, you will 
need to reflect on your personal experience of having a pressure ulcer and how the pressure 
ulcer and treatments have impacted on your life. There is a possibility that you may find this 
distressing. The interview can be stopped at any point if you feel you do not want to continue. 
If necessary, a referral can be made to your nurse or other healthcare professionals if you are 
distressed by the content of the questionnaire or by the discussion that will follow 
completion. 
 
What are the possible benefits of taking part?  
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There will be no direct benefit to you as a result of participating in this study. We hope that 
the information we get from the interviews will help to develop a questionnaire that covers all 
the important issues that people with pressure ulcers have to deal with and the perceived 
benefits of treatments from the perspective of the sufferer. 
 
Will my taking part in this study be kept confidential? 
Yes. All information which would be collected about you during the course of the study will 
be kept strictly confidential. We will follow ethical and legal practice and all information 
about you will be handled in confidence.  In the event that any evidence of poor practice, 
neglect or abuse is identified during the course of the interview, the researcher might need to 
disclose details to a third party outside of the interview.  This would not be done without 
discussing it with you first. Details are included in Part 2. 
 
This completes part 1. If the information in Part 1 has interested you and you are considering 
participation, please read the additional information in Part 2 before making any decision. 
 
Part 2 
What will happen if I don’t want to carry on with the study? 
Taking part in this study is entirely voluntary and you are free to change your mind at any 
point up to, during or following the interview. You will not be able to be identified in the 
study results but if you wish to withdraw any data already collected prior to publication of the 
results then arrangements can be made for the interview tape to be destroyed and your 
discussion excluded from the study. 
 
Will my taking part in this study be kept confidential? 
The procedures for handling, processing, storage and destruction will be according to the 
Data Protection Act 1998. 
 
Claudia Gorecki and her supervision team have a duty of confidentiality to you as a research 
participant, and will do their very best to meet this duty. Any information that is collected 
about you, including any additional information obtained from your medical records, will 
have your name and address removed so that you cannot be recognised from it. All 
information obtained is strictly confidential and will be kept in locked cupboards and will 
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only be accessible by members of the research team. No names or details that would identify 
specific people will be included in the findings from this study. Findings, including 
quotations from interviews, may be used in reports, presentations and papers, and for 
healthcare and/or medical research, but these will not be traceable to specific individuals. All 
published and unpublished reports will disguise the identity of people.  
 
Involvement of the General Practitioner/Family doctor (GP) 
Your GP will not be notified of your participation in this study. 
 
What will happen to the results of the research study?  
Participants will not be identified in any report or publication. The study results will be used 
to modify and update the provisional questionnaire to produce a preliminary version of the 
questionnaire which will then be further tested for its usefulness. Information from this study 
will be included in a final report for the whole project and published in a scientific journal. 
 
Who is organising and sponsoring the research? 
This study is being undertaken as part of a PhD qualification sponsored and supervised by the 
University of Leeds. This study is also phase 2 of the PUQOL project that is funded by the 
National Institute of health Research as part of a larger pressure ulcer programme aimed to 
reduce the impact of PUs on patients and develop methods to capture outcomes important to 
patients such as quality of life. 
 
Who has reviewed the study? 
This study has been peer reviewed by the National Institute of Health Research before 
approval for funding was given. In addition, all research in the NHS is looked at by an 
independent group of people called a Research Ethics Committee to protect your safety, 
rights, wellbeing and dignity. This study has been reviewed and given approval by the (name 
of REC) Research Ethics Committee. 
 
What do I do now? 
Once you have read the information and if you would like to take part in the study, please let 
your district nurse or tissue viability nurse who provided you with this information leaflet 
know. They will complete the Agree to Researcher Contact Form at the end of this leaflet and 
DOI: 10.3310/pgfar03060 PROGRAMME GRANTS FOR APPLIED RESEARCH 2015 VOL. 3 NO. 6
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Nixon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
551
send it back to the researcher, Claudia Gorecki, who will phone you upon receiving the form 
to discuss this study further and arrange a time for the interview. 
 
Further information and contact details 
Thank you for taking the time to read this leaflet and for considering this study. If you would 
like to discuss the study further or have any questions about the study at any time, please 
contact the researcher, Claudia Gorecki on 0113 3437632 or the study supervisor, Dr Jane 
Nixon on 0113 3431488 or speak to your district nurse or tissue viability nurse who provided 
you with this information sheet. 
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[Delete this line then print on Trust headed paper- given with study information] 
PATIENT AGREEMENT TO RESEARCHER CONTACT 
 
Name of researcher:     Claudia Gorecki 
      Clinical Trials Research Unit 
      University of Leeds 
LS2 9PH 
      0113 3437632 
 
Name of consultant/nurse:    __________________________ 
Contact number:    __________________________  
 
PUQOL Project-Preliminary test: patient interviews 
 
Please initial the boxes: 
· I have read the information sheet and kept a copy. 
· I am happy to be contacted by telephone by the above named researcher to discuss the 
study further 
OR 
· I am happy for my nurse to arrange a time for me to meet with the researcher on the ward 
 
Please complete your contact details in the space provided 
Patient name ___________________________________________________________ 
Address ________________________________________________________________ 
________________________________________Postcode________________________ 
Telephone Number ____________________Preferred contact time ________________ 
OR 
Hospital name _____________________________________ Ward ___________________ 
Date and time of visit_____________________________________________________
 
Thank you for completing this form. Please return to Claudia Gorecki at CTRU, 
University of Leeds, Clinical Trials Research House, 71-75 Clarendon Road, Leeds, LS2 9PH 
or phone 0113 343 7632 
Please the tick 
relevant box  
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[Delete this line then print on Trust headed paper- given with study information] 
 
PUQOL Project Pre-test: patient interview consent form 
 
Name of researcher:  Claudia Gorecki 
Address: Clinical Trials Research Unit, University of Leeds, Clinical Trials Research House, 
71-75 Clarendon Road, Leeds, LS2 9PH; Telephone: 0113 3437632 
 
 
1. I confirm that I have read and understand the information sheet for the above study  
and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my nursing care being affected. 
 
3. I understand that the above named researcher may ask my nurse additional information 
about my pressure ulcer history and relevant treatment. I give permission for the 
researcher to verbally obtain this information for the above study and any further research 
that  
may be conducted in relation to it, provided that strict confidentiality is maintained. 
 
4. I agree that my interview will be tape recorded and typed out, maintaining anonymity. 
 
5. I agree to allow any information or results arising from this study to be used for  
healthcare and/or medical research purposes. I understand that my identity will  
remain anonymous. 
 
6. I consent to the storage including electronic, of personal information for the purposes of 
this study. I understand that any information that could identify me will be kept 
confidential and that no personal information that could identify me will be  
included in the study report or other publication.  
 
7. I understand that a copy of this Consent Form will be sent to the CTRU 
 
8. I agree to take part in the above study. 
 
 
___________________  _____________ _________________ 
Name of Patient   Date    Signature 
 
I have given written information and a verbal explanation to the person named above who has 
freely given their consent to participate. 
 
___________________ _____________ _________________ 
Name of Person   Date    Signature 
taking consent 
 
(When completed, 1 for patient, 1 for patient file; 1 for CTRU) 
Please initial box 
after each question 
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Appendix 46 Pressure Ulcer Quality of Life
pre-test study interview schedule
General introduction
Thank you for participating in this interview. Your feedback about the questionnaire will help us to
develop a questionnaire that is easy to understand and simple to complete. The purpose of this interview is
to get feedback from you on a quality of life questionnaire, specifically the questionnaire’s layout and
instructions, and help us to determine whether any of the specific questions are confusing or ambiguous
and might need rewording. I would like to tape-record this interview so that I remember everything that
you tell me. Do I have your permission to record the interview? As well as recording, I will be taking notes.
Introduction: think aloud method
The interview format will be what we call a ‘think aloud’ process. What this involves is asking you to think
out loud while you read and complete the questionnaire. Now, thinking out loud may be new and
unfamiliar to you, but please know that there are no right or wrong answers so feel free to say anything
that you’re thinking. I am only interested in knowing what is going through your mind when you read the
questions and try to find the most appropriate answer to represent your experience. To explain this process
to you in more detail, as you read the questionnaire and answer the questions, I would like you to tell me
out loud any thoughts that go through your mind. For example, as you read the questionnaire, you might
be thinking that a particular sentence is a little confusing or difficult to understand so I would want you to
tell me this. You might also find that a particular question is not clear and you’re not entirely sure what
the question is asking you; this I would also like you to tell me. So basically any thoughts about what you
are reading and thinking while completing the questionnaire. Do you have any questions? We will now
start the actual interview.
l I noticed that you hesitated – can you tell me what you were thinking?
l Talk me through what you are thinking while answering the question.
Introduction: debrief probing method
As part of this interview, I’m going to ask you to complete a questionnaire about the impact of pressure
ulcers on quality of life. I will leave you for a little while (approx. 10–15 minutes) so that you can complete
the questionnaire on your own. Take as much time as you need to read and complete the questionnaire.
While you complete the questionnaire I would like you to circle, mark or underline any words that you do
not understand or any individual questions that you find to be confusing, intrusive or ambiguous; basically,
mark any problems that you find with the questionnaire. Feel free to write any comments in the margins
and note any questions or problems that arise while you are completing the questions. There are no right
or wrong answers. I am only interested in knowing which questions may be problematic in terms of
wording, understanding and so on. After you complete the questionnaire I will come back and you can tell
me about how it was for you completing the questionnaire. I will also ask you some questions about what
you were thinking while you completed the questions and we can discuss any questions that you circled or
marked and discuss any comments that you made. Do you have any questions before we get started?
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Probing questions
Content and instruction probes
l What do you think this questionnaire is about?
l What to you is ‘(quality of life)’? Determine if anything is omitted.
l Any areas of your life that your pressure ulcer affects that the questionnaire didn’t ask you about?
l Did you understand the instructions? Was any part confusing or difficult to understand?
Layout probes
l What do you think about the layout of the questionnaire? (i.e. general format, stem, items)
l What do you think about the length of the questionnaire?
Response option probes
l How easy or hard was it to tell the difference between each response choice?
l You chose ‘(a little bother)’ as your answer, what does ‘(a little bother)’ mean to you?
l Would you change any questions to make them easier to understand? What would you do?
Time frame probes
l When answering the questions, did you compare now to how you were a week ago?
l When you read ‘in the last week’, which days did you think of? (Which day.)
l Would you have responded differently to this question(s) if I had asked you about your experience over
the last 14 days or 30 days instead of only the last week?
l Did you think mostly about your experience on specific days or times of day, or what was typical for
you over the last week? (If specific day/times of day.) Can you tell me more about what made you
think about those specific days/times?
Item stem probes: item by item and overall (comprehension/
interpretation/recall)
l What do the words ‘(difficulty with general movement)’ mean to you?
l Describe your general movement or describe a typical day and the activities that you might do. Did you
consider all these when you answered question 1?
l Can you tell me in your own words what you think question ‘(1a)’ is asking?
l How would you say this question in your own words?
l How easy/hard was this question to answer? How would you reword it to make it easier?
l Do you find any of the questions sensitive?
l Are the questions worded in the language that you would use?
l How did you arrive at that answer?
l For question ‘(1a)’ you chose ‘(response option)’ How did you get that answer?
l How well do you remember this? (Test recall of the relevant information.)
l How do you remember this? (Study recall strategy.)
l How hard was it answer? (Determine level of difficulty/likelihood of estimation/guessing.)
l Was this hard/easy to answer? (Determine comprehension and overall ability to recall.)
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Patients with multiple pressure ulcers
l For patients with more than one pressure ulcer, go through each question and ask them which
pressure ulcer they thought about when they answered this question.
l While completing the questions, did you think about the pressure ulcer that was most bothersome? Or
did you answer thinking about overall combined affect?
Finally, what could we do, if anything, to improve this questionnaire or any specific questions when we use
them in the future with other people like you?
Closing
Thank you for taking the time to complete this questionnaire and for talking with me about what it was
like for you. Now that we have completed the interview, do you have any questions?
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Appendix 47 Pressure Ulcer Quality of Life field
test 1 patient information leaflet and consent form
 [Delete this line then print on Trust headed paper] 
 
Field test 1 & sub-study participant information leaflet and consent form 
 
A large-print version of this sheet is available on request.   
 
We would like to invite you to take part in a research project.  Before you decide to take part, 
it is important for you to understand why the research is being done and what it would 
involve for you.  Please take the time to read the following information carefully and discuss 
it with your relatives and your ward nurse if you wish.  Ask us if there is anything that is not 
clear or if you would like more information. Part 1 tells you the purpose of this project and 
what will happen to you if you take part. Part 2 gives you more detailed information about 
the conduct of the study. 
 
Part 1 
What is the purpose of the study? 
The development of pressure ulcers, also called a bed sore or pressure sore, can have a major 
impact on patients’ quality of life and well-being as well as severely compromise all areas of 
functioning.  However, there is currently no formal way of assessing quality of life from the 
patients’ perspective in healthcare and in research, as there is no quality of life questionnaire 
for use with patients with pressure ulcers.  
 
The Pressure Ulcer Quality of Life (PU-QOL) project will develop a questionnaire that will 
assess important quality of life issues in patients with pressure ulcers that will be suitable for 
use in NHS clinical practice and in research.  Specifically, the project questionnaire will 
provide us with important information about the experienced suffering of patients with 
pressure ulcers and the impact pressure ulcer treatments have on patients’ quality of life.  
This information will be obtained in order to improve patient healthcare and patient quality of 
life.  
 
This study is the third phase of the development of the project questionnaire and involves 
patients like you, either completing the project questionnaire on your own or with assistance.  
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This study is undertaken so that we can determine whether the project questionnaire is a 
useful questionnaire for assessing quality of in people with pressure ulcers. 
 
Why have I been invited? 
You have been chosen to take part because we wish to develop this questionnaire from the 
perspective of people who have a pressure ulcer.  This will ensure that the questionnaire 
covers issues that are important to patients who are affected by pressure ulcers ranging from a 
small red area to a more severe ulcer.  Participants from many hospitals and from within the 
community will be asked to take part.  
 
Do I have to take part? 
Taking part in this study is entirely voluntary and you are under no obligation to take part in 
this study, it is up to you to decide.  We will describe the study to you and go through this 
information sheet.  If you agree to take part you will be asked to sign the consent form at the 
end of this leaflet to show that you have agreed to take part.  You will be given a copy of this 
information sheet and of the consent form for you to keep.  You are free to withdraw at any 
time, without giving a reason.  This would not affect the standard of care you receive.  If you 
do not wish to take part this will not affect the care that you are currently receiving. 
 
What if I would like to take part but I have trouble with or am unable to write? 
If you would like to take part but cannot or find it difficult to write, you can have someone (a 
witness) complete the written part of the consent for you.  This witness could be a friend, a 
family member, career, or member of your healthcare team not directly involved in the 
research.  The witness will only act to help you carry out your wishes – you are free to 
change your mind at any time and your wishes will be respected. 
 
What will happen to me if I take part? 
If you agree to take part, you will be asked to complete a questionnaire booklet either on your 
own in your own time or with assistance.  Completing this booklet will take approximately 40 
minutes.  It would involve choosing an answer to a set of questions on a response scale.  An 
example of a question that you might be asked is: 
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In the past week, for how many days did your pressure ulcer cause you pain or ache? 
(please tick one box)  
    None at all □   between 1-3 days □   between 4-5 days □   between 6-7 days □ 
 
When you have completed the questionnaire booklet, you will be expected to either hand it 
back to your district or tissue viability nurse, or send it back to the Clinical Trials Research 
Unit in the stamped, self-addressed envelope that was provided to you with this leaflet.  No 
further involvement is required.  Your anonymised, completed questionnaire booklet will be 
used only by researchers involved in the project and it will be stored in a locked cabinet.  In 
some instances, we may need to access your health care records to obtain additional 
information about your pressure ulcer and the treatments that you have received. 
 
Expenses and payments 
We anticipate that there will be no extra expenses for you as a result of taking part in this 
study, as completion of the questionnaires will take place in your own home or on the 
hospital ward where you are admitted at a time convenient for you.  
 
What are the possible disadvantages and risks of taking part? 
We do not foresee any disadvantages or risks to you in taking part in this study.  However, 
you are being asked to give some of your time for completing the questionnaires.  Your care 
and treatment will remain the same whether or not you decide to take part. 
 
What are the possible benefits of taking part?  
There will be no direct benefit to you as a result of participating in this study.  We hope that 
the questionnaire that we are developing will help people with pressure ulcers in the future. 
 
Will my taking part in this study be kept confidential? 
Yes.  All information which would be collected about you during the course of the study will 
be kept strictly confidential.  We will follow ethical and legal practice and all information 
about you will be handled in confidence.  In the event that any evidence of poor practice, 
neglect or abuse is identified during the course of the interview, the researcher might need to 
disclose details to a third party outside of the interview.  This would not be done without 
discussing it with you first. 
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This completes part 1. 
If the information in Part 1 has interested you and you are considering participation, please 
read the additional information in Part 2 before making any decision. 
 
Part 2 
What will happen if I don’t want to carry on with the study? 
Taking part in this study is entirely voluntary and you are free to change your mind at any 
point up to, during or following completion of your questionnaires.  You will not be able to 
be identified in the study results but if you wish to withdraw any questionnaire data collected 
prior to publication of the results then arrangements can be made for your questionnaire to be 
destroyed and your responses excluded from the study. 
 
Will my taking part in this study be kept confidential? 
The procedures for handling, processing, storage and destruction will be according to the 
Data Protection Act 1998. 
 
Claudia Gorecki and the project team have a duty of confidentiality to you as a research 
participant and will do their very best to meet this duty.  Any information that is collected 
about you, including any additional information obtained from your health care records, will 
have your name and address removed so that you cannot be recognised from it.  All 
information obtained is strictly confidential and will be kept in locked cupboards and will 
only be accessible by members of the research team.  No names or details that would identify 
specific people will be included in the outputs from this study.  Outputs, including quotations 
from interviews, may be used in reports, presentations and papers, and for healthcare and/or 
medical research, but these will not be traceable to specific individuals.  All published and 
unpublished reports will disguise the identity of people.  
 
Involvement of the General Practitioner/Family doctor (GP) 
Your GP will not be notified of your participation in this study. 
 
What will happen to the results of the research study?  
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Participants will not be identified in any report or publication.  The study results will be 
based on the development of the project questionnaire.  Information from this study will be 
included in a final report for the whole project and published in a scientific journal. 
 
Who is organising and sponsoring the research? 
This study is being undertaken as part of a PhD qualification sponsored and supervised by the 
University of Leeds.  This study is also phase 3 of the project that is funded by the National 
Institute of Health Research as part of a larger pressure ulcer programme aimed to reduce the 
impact of pressure ulcers on patients and develop methods to capture outcomes important to 
patients such as quality of life. 
 
Who has reviewed the study? 
This study has been peer reviewed by the National Institute of Health Research before 
approval for funding was given.  In addition, all research in the NHS is looked at by an 
independent group of people called a Research Ethics Committee to protect your safety, 
rights, wellbeing and dignity.  This study has been reviewed and given approval by the North 
West Research Ethics Committee. 
 
What do I do now? 
Once you have read the information and if you would like to take part in the study, please let 
your district nurse or tissue viability nurse who provided you with this information leaflet 
know.  They will ask you to complete the consent form at the end of this leaflet and either 
provide you with the questionnaire booklet to complete on your own or assist you in 
completing the questionnaire booklet.  Completed booklets will be sent back to the 
researcher, Claudia Gorecki. 
 
Further information and contact details 
Thank you for taking the time to read this leaflet and for considering this study.  If you would 
like to discuss the study further or have any questions about the study at any time, please 
contact the researcher, Claudia Gorecki on 0113 3437632 or the study supervisor, Professor 
Jane Nixon on 0113 3431488 or speak to your district nurse or tissue viability nurse who 
provided you with this information sheet. 
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(Delete this line then print on headed paper) 
Patient DOB:  Patient Study ID:   
 
PU-QOL field test 1& sub-study consent form 
 
Name of researcher: …………………………………………………………… 
 
I confirm that I have read and understand the information sheet for the above study and have 
had the opportunity to ask questions. 
1. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my nursing care being affected. 
2. I understand that sections of any of my health care notes or questionnaire data may be 
looked at by responsible individuals from the study office or from regulatory authorities 
where it is relevant to my taking part in research. I give permission for these individuals 
to have access to my information and questionnaire data. 
 
3. I agree to allow any information or results arising from this study to be used 
for healthcare and/or medical research purposes. I understand that my identity will  
remain anonymous. 
4. I consent to the storage including electronic, of personal information for the purposes of 
this study. I understand that any information that could identify me will be kept 
confidential and that no personal information that could identify me will be included in 
the study report or other publication. 
5. I agree to take part in the above study. 
 
___________________  _____________ _________________ 
Name of Patient   Date    Signature 
 
I have given written information and a verbal explanation to the person named above who has 
freely given their consent to participate. 
 
___________________ _____________ _________________ 
Name of Person   Date    Signature 
taking consent 
(When completed, 1 for patient, 1 for patient file; 1for local PI) 
Please initial box 
after each question 
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Patient DOB:  Patient Study ID:   
[Delete this line, then print on Trust headed paper]  
PU-QOL field test 1& sub-study witnessed consent form 
 
1. I confirm that I have read and understand the information sheet for the above study and 
have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my nursing care being affected.
 
3. I understand that sections of any of my health care notes or questionnaire data may be  
looked at by responsible individuals from the study office or from regulatory authorities  
where it is relevant to my taking part in research. I give permission for these individuals to have 
access to my information and questionnaire data. 
 
4. I agree to allow any information or results arising from this study to be used for healthcare 
and/or medical research purposes. I understand that my identity will remain anonymous. 
 
5. I consent to the storage including electronic, of personal information for the purposes of 
this study. I understand that any information that could identify me will be kept 
confidential and that no personal information that could identify me will be included in the 
study report or other publication.  
 
6. I understand that a copy of this Consent Form will be sent to the Clinical Trials Research 
Unit 
 
7. I agree to take part in the above study. 
____________________________________  _____________________________ 
Name of Patient       Relationship of witness to Patient  
 
Witness statement 
I have completed this consent form on behalf of the person named above who has freely 
given their consent to participate. 
_______________________    _____________ _________________ 
Name of Witness        Date    Signature 
 
Research person taking Consent 
I have given written information and a verbal explanation to the person named above who has 
freely given their consent to participate. 
_______________________   _____________ _________________ 
Name of Person taking Consent      Date    Signature 
Witness initial after 
each question on 
behalf of the patient 
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Appendix 48 Pressure Ulcer Quality of Life field
test 2 patient information leaflet and consent forms
[Delete this line then print on Trust headed paper] 
 
Field test 1 & sub-study participant information leaflet and consent form 
 
A large-print version of this sheet is available on request.   
 
We would like to invite you to take part in a research project.  Before you decide to take part, 
it is important for you to understand why the research is being done and what it would 
involve for you.  Please take the time to read the following information carefully and discuss 
it with your relatives and your ward nurse if you wish. Ask us if there is anything that is not 
clear or if you would like more information.  Part 1 tells you the purpose of this project and 
what will happen to you if you take part. Part 2 gives you more detailed information about the 
conduct of the study. 
 
Part 1 
What is the purpose of the study? 
The development of pressure ulcers, also called a bed sore or pressure sore, can have a major 
impact on patients’ quality of life and well-being as well as severely compromise all areas of 
functioning.  However, there is currently no formal way of assessing quality of life from the 
patients’ perspective in healthcare and in research, as there is no quality of life questionnaire 
for use with patients with pressure ulcers.  
 
The Pressure Ulcer Quality of Life (PU-QOL) project will develop a questionnaire that will 
assess important quality of life issues in patients with pressure ulcers that will be suitable for 
use in NHS clinical practice and in research.  Specifically, the project questionnaire will 
provide us with important information about the experienced suffering of patients with 
pressures and the impact pressure ulcer treatments have on patients’ quality of life.  This 
information will be obtained in order to improve patient healthcare and patient quality of life.  
 
This study is the third phase of the development of the project questionnaire and involves 
patients like you, either completing the project questionnaire on your own or with assistance.  
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This study is undertaken so that we can determine whether the project questionnaire is a 
useful questionnaire for assessing quality of life in people with pressure ulcers. 
 
Why have I been invited? 
You have been chosen to take part because we wish to develop this questionnaire from the 
perspective of people who have a pressure ulcer.  This will ensure that the questionnaire 
covers issues that are important to patients who are affected by pressure ulcers ranging from a 
small red area to a more severe ulcer.  Participants from many hospitals and from within the 
community will be asked to take part.  
 
Do I have to take part? 
Taking part in this study is entirely voluntary and you are under no obligation to take part in 
this study, it is up to you to decide.  We will describe the study to you and go through this 
information sheet.  If you agree to take part you will be asked to sign the consent form at the 
end of this leaflet to show that you have agreed to take part.  You will be given a copy of this 
information sheet and of the consent form for you to keep.  You are free to withdraw at any 
time, without giving a reason.  This would not affect the standard of care you receive.  If you 
do not wish to take part this will not affect the care that you are currently receiving. 
 
What if I would like to take part but I have trouble with or am unable to write? 
If you would like to take part but cannot or find it difficult to write, you can have someone (a 
witness) complete the written part of the consent for you.  This witness could be a friend, a 
family member, career, or member of your healthcare team not directly involved in the 
research.  The witness will only act to help you carry out your wishes – you are free to change  
your mind at any time and your wishes will be respected. 
 
What will happen to me if I take part? 
If you agree to take part, you will be asked to complete a questionnaire booklet either on your 
own in your own time or with assistance.  Completing this booklet will take approximately 40 
minutes.  It would involve choosing an answer to a set of questions on a response scale.  An 
example of a question that you might be asked is: 
In the past week, for how many days did your pressure ulcer cause you pain or ache? 
(please tick one box)  
    None at all □   between 1-3 days □   between 4-5 days □   between 6-7 days □ 
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When you have completed the questionnaire booklet, you will be expected to either hand it 
back to your district or tissue viability nurse, or send it back to the Clinical Trials Research 
Unit in the stamped, self-addressed envelope that was provided to you with this leaflet.  
 
We will also ask you to complete the same questionnaire booklet 2-7 days after the first 
completion; however, you can opt out of this second participation if you wish.  You will be 
asked to indicate on the consent form at the end of this information leaflet whether you would 
be happy to complete a second questionnaire booklet.  Your anonymised, completed 
questionnaire booklets will be used only by researchers involved in the project and will be 
stored in a locked cabinet.  In some instances, we may need to access your health care records 
to obtain additional information about your pressure ulcer and the treatments that you have 
received. 
 
Expenses and payments 
We anticipate that there will be no extra expenses for you as a result of taking part in this 
study, as completion of the questionnaires will take place in your own home or on the hospital 
ward where you are admitted at a time convenient for you.  
 
What are the possible disadvantages and risks of taking part? 
We do not foresee any disadvantages or risks to you in taking part in this study.  However, 
you are being asked to give some of your time for completing the questionnaires.  Your care 
and treatment will remain the same whether or not you decide to take part. 
 
What are the possible benefits of taking part?  
There will be no direct benefit to you as a result of participating in this study.  We hope that 
the questionnaire that we are developing will help people with pressure ulcers in the future. 
 
Will my taking part in this study be kept confidential? 
Yes.  All information which would be collected about you during the course of the study will 
be kept strictly confidential.  We will follow ethical and legal practice and all information 
about you will be handled in confidence.  In the event that any evidence of poor practice, 
neglect or abuse is identified during the course of the interview, the researcher might need to 
disclose details to a third party outside of the interview.  This would not be done without 
discussing it with you first. 
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This completes part 1. 
If the information in Part 1 has interested you and you are considering participation, please 
read the additional information in Part 2 before making any decision. 
 
Part 2 
What will happen if I don’t want to carry on with the study? 
Taking part in this study is entirely voluntary and you are free to change your mind at any 
point up to, during or following completion of your questionnaires.  You will not be able to be 
identified in the study results but if you wish to withdraw any questionnaire data collected 
prior to publication of the results then arrangements can be made for your questionnaire to be 
destroyed and your responses excluded from the study. 
 
Will my taking part in this study be kept confidential? 
The procedures for handling, processing, storage and destruction will be according to the Data 
Protection Act 1998. 
 
Claudia Gorecki and the project team have a duty of confidentiality to you as a research 
participant and will do their very best to meet this duty.  Any information that is collected 
about you, including any additional information obtained from your health care records, will 
have your name and address removed so that you cannot be recognised from it.  All 
information obtained is strictly confidential and will be kept in locked cupboards and will 
only be accessible by members of the research team.  No names or details that would identify 
specific people will be included in the outputs from this study.  Outputs, including quotations 
from interviews, may be used in reports, presentations and papers, and for healthcare and/or 
medical research, but these will not be traceable to specific individuals.  All published and 
unpublished reports will disguise the identity of people.  
 
Involvement of the General Practitioner/Family doctor (GP) 
Your GP will not be notified of your participation in this study. 
What will happen to the results of the research study?  
Participants will not be identified in any report or publication.  The study results will be based 
on the development of the project questionnaire.  Information from this study will be included 
in a final report for the whole project and published in a scientific journal. 
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Who is organising and sponsoring the research? 
This study is being undertaken as part of a PhD qualification sponsored and supervised by the 
University of Leeds.  This study is also phase 3 of the project that is funded by the National 
Institute of Health Research as part of a larger PU programme aimed to reduce the impact of 
PUs on patients and develop methods to capture outcomes important to patients such as 
quality of life. 
 
Who has reviewed the study? 
This study has been peer reviewed by the National Institute of Health Research before 
approval for funding was given.  In addition, all research in the NHS is looked at by an 
independent group of people called a Research Ethics Committee to protect your safety, 
rights, wellbeing and dignity.  This study has been reviewed and given approval by the North 
West Research Ethics Committee. 
 
What do I do now? 
Once you have read the information and if you would like to take part in the study, please let 
your district nurse or tissue viability nurse who provided you with this information leaflet 
know.  They will ask you to complete the consent form at the end of this leaflet and either 
provide you with the questionnaire booklet to complete on your own or assist you in 
completing the questionnaire booklet.  Completed booklets will be sent back to the researcher, 
Claudia Gorecki. 
 
Further information and contact details 
Thank you for taking the time to read this leaflet and for considering this study.  If you would 
like to discuss the study further or have any questions about the study at any time, please 
contact the researcher, Claudia Gorecki on 0113 3437632 or the study supervisor, Professor 
Jane Nixon on 0113 3431488 or speak to your district nurse or tissue viability nurse who 
provided you with this information sheet. 
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Patient DOB:  Patient Study ID:   
 
PU-QOL field test 2 consent form 
Name of researcher: …………………………………………………………… 
 
1. I confirm that I have read and understand the information sheet for the above study and 
have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my nursing care being affected. 
 
3. I understand that sections of any of my health care notes or questionnaire data may be  
looked at by responsible individuals from the study office or from regulatory authorities  
where it is relevant to my taking part in research. I give permission for these individuals  
to have access to my information and questionnaire data. 
 
4. I agree to allow any information or results arising from this study to be used for healthcare 
and/or medical research purposes. I understand that my identity will remain anonymous. 
 
5. I consent to the storage including electronic, of personal information for the purposes of 
this study. I understand that any information that could identify me will be kept 
confidential and that no personal information that could identify me will be included in  
the study report or other publication.  
 
6. I understand that a copy of this Consent Form will be sent to the Clinical Trials Research 
Unit 
 
7. I agree to take part in the above study. 
 
___________________  _____________ _________________ 
Name of Patient    Date    Signature 
 
I have given written information and a verbal explanation to the person named above who has 
freely given their consent to participate. 
___________________ _____________ _________________
Name of Person    Date    Signature 
taking consent 
 
I agree to take part in completing a second questionnaire booklet in 2-7 days’ time after I have 
completed the first questionnaire booklet. 
If agree to complete second questionnaire booklet, please complete contact details 
Address:____________________________________________________________ 
Postcode:_______________________ Telephone: __________________________ 
 (Delete this line then print on headed paper) 
Please initial box 
after each question 
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Patient DOB:  Patient Study ID:   
 
PU-QOL field test 2 witnessed consent form 
 
1. I confirm that I have read and understand the information sheet for the above study and 
have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my nursing care being affected. 
 
3. I understand that sections of any of my health care notes or questionnaire data may be  
looked at by responsible individuals from the study office or from regulatory authorities  
where it is relevant to my taking part in research. I give permission for these individuals to have 
access to my information and questionnaire data. 
 
4. I agree to allow any information or results arising from this study to be used for healthcare 
and/or medical research purposes. I understand that my identity will remain anonymous. 
 
5. I consent to the storage including electronic, of personal information for the purposes of 
this study. I understand that any information that could identify me will be kept 
confidential and that no personal information that could identify me will be included in the 
study report or other publication.  
 
6. I understand that a copy of this Consent Form will be sent to the Clinical Trials Research 
Unit 
 
7. I agree to take part in the above study. 
 
____________________________________  _____________________________ 
Name of Patient       Relationship of witness to Patient  
 
Witness statement 
I have completed this consent form on behalf of the person named above who has freely given 
their consent to participate. 
_______________________    _____________ _________________ 
Name of Witness        Date    Signature 
 
 
Research person taking Consent 
I have given written information and a verbal explanation to the person named above who has 
freely given their consent to participate. 
_______________________ _____________ _________________
Name of Person taking Consent      Date    Signature 
Witness initial after 
each question on 
behalf of the patient
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I agree to take part in completing a second questionnaire booklet in 2-7 days’ time after I have 
completed the first questionnaire booklet. 
 
If you agree to complete a second questionnaire booklet, please complete your contact details 
 
Address:____________________________________________________________ 
                ___________________________________________________________ 
Postcode:___________________________ Telephone: ______________________ 
 
 
(When completed, original for local PI, 1 copy for CTRU, 1 copy for patient, 1 copy for patient file) 
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Appendix 49 Pressure Ulcer Quality of Life:
Utility Index study reduced format protocol
NB: This study protocol (version 5, dated 7 Feb 2013) is in a reduced format including only 
the study aims, methods and ethical considerations.  Sections pertaining to study background 
have been removed as they are included as a chapter section. Information pertaining to data 
monitoring, quality assurance, confidentiality, archiving, statement of indemnity, study 
organisational structure, funding, and publication policy are available upon request. 
 
Study Flow Diagram
 
 
 
 
Aims and Objectives 
The overall aim of the project is to derive a preference-based utility index from the PUQoLI 
(the PUQoL-UI), enabling the collection of utility values from the PUQoLI and, therefore, 
the calculation of QALYs for the purpose of economic evaluation. Specific objectives 
include: 
Identify PUQoL item 
subset and create revised 
Create health states using 
selected items, design 
preference elicitation 
Recruitment of general 
population participants (n=198) 
Interview training for agency staff 
Pre-test of interviews (n=8), 
feedback and interview revision 
Interviews and data collection  
Analysis - generation of utility 
weights from PUQoL 
Psychometric testing of PUQoL-
Utility Index 
Recruit 15 patients from patient 
groups 
Test acceptability of revised 
measure with patients 
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1. To check the acceptability of the revised PUQoLI with people with experience of 
PUs. 
2. To generate PU-specific health state descriptions comprising responsive and valid 
PUQoLI items. 
3. To conduct a preference elicitation exercise with the general population. 
4. To conduct analyses establishing an algorithm and utility index scores associated with 
the PUQoLI item subset. 
 
Methods 
The derivation of the PUQoL-UI will follow best practice (Brazier et al, 2011). It will 
involve: health state generation from the reduced PUQoLI, health state valuation interviews 
with the general population and modelling of the health state valuations to derive the PUQoL-
UI scoring tariff. 
  
Item Selection  
Prior to the start of this study it was necessary to revise and reduce the number of items in the 
PUQoLI. This was done using a previously collected dataset and by employing a range of 
statistical techniques in line with best practices (Brazier et al, 2011). A brief report describing 
this process is available on request.  
 
Checking the acceptability of the revised PUQoLI 
Before the health states are generated for the valuation interviews it will be necessary to 
check the acceptability of the revised PUQoLI with a small group of people who have 
experience of PUs. This will involve conducting a small number of semi-structure, face-to-
face interviews with people who have (or who have had) a PU. Participants will be 
interviewed by an experience qualitative researcher. They will be asked to complete the 
revised PUQoLI and asked general questions about whether or not the questionnaire was easy 
to understand and complete and whether or not there were aspects or questions that were 
confusing. Participants will be asked specifically whether or not the new question lead-in 
(after the removal of the PU attribution) makes sense in each dimension. An information 
sheet given to people interested in the study is included in the appendix along with a consent 
form and an interview schedule. People with be offered £20 worth of high street vouchers for 
taking part in the study. 
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Members of the project team will review the interview responses and agree on whether or not 
revisions to the questionnaire are required. 
 
Health State Generation 
After any revisions to the PUQoLI have been incorporated, health state scenarios 
(incorporating the selected items from the revised measure) will be developed for inclusion in 
the preference elicitation (valuation) exercise. Health states would be generated with checks 
in place to ensure face validity and a range of severity is represented. An example of a 
hypothetical health state based on PUQoLI items is given below. The items and wording 
included in the final scenarios will be determined after health state sampling has been 
conducted and be based on the results of the interview responses.  
 
Example pressure ulcer health state based on PUQoLI items: 
 
Please imagine you are in the following health state: 
 
You have a pressure ulcer and….. 
 
You are a little bothered by throbbing pain it causes 
Being kept awake by it causes you a little bother 
It causes you a little bother as it limits your ability to walk 
It causes a little bother as it makes it difficult for you to do your regular daily activities  
You have not been bothered by fatigue from it 
The concern or worry over it causes you a little bother 
Having to plan going out around caring for it causes a lot of bother 
 
 
Given respondent burden, it is likely that some PUQoLI constructs will have to be collapsed 
or will not be represented in the final valuation exercise. It is anticipated that between 25 and 
50 health states will be required for the preference elicitation exercise. It is also assumed that 
each health state will be valued at least 20 times to ensure a robust valuation is obtained. The 
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selection of the health states will be based on statistical design, employing an orthogonal 
array. 
 
Preference Elicitation 
The preference elicitation exercise will follow NICE recommendations (NICE, 2008) and 
thus will mirror the methodology employed to value the EQ-5D measure. Namely, we will 
ask members of the UK general population to complete a series of time trade off (TTO) 
exercises to value the PUQoLI health states.  
 
Valuation interviews  
The interviews will be conducted by a private research organisation who are experienced in 
this line of work. An information sheet for the general population is included in Appendix E. 
Interview resources will be developed by the research team, including questionnaires, 
laminated cards incorporating the health state descriptions and a time-trade-off prop to aid 
understanding of the elicitation exercise. The draft interview schedule is included in. 
Interviews will be conducted face-to-face either in the person’s own home, at the offices of 
the research agency. Respondents will also be given information regarding pressure ulcers in 
order that they base their interview responses on informed preferences. 
 
The time trade-off (TTO) technique is a standard economic technique to elicit individuals’ 
strength of preferences for various health states (Torrance et al. 1972). In the TTO, 
individuals choose between two certain options: full length of life (assume 20 years) in the 
health state to be valued, or a shorter period in ‘full health’ (after which they die). The 
amount of time (months, years) to be spent in full health is varied until the respondent can no 
longer easily decide which option they prefer (the point of indifference) signalling the end of 
the exercise. The final utility value assigned to the health state being valued is given by time 
spent in full health, divided by the time spent in the health state (in this case 20 years). So if 
the respondent was indifferent between living for 5 years in full health and 20 years in the 
health state being presented, the utility of that health state would be (5/20) = 0.25. The ‘ping-
pong’ technique will be used whereby the amount of time in good health is varied until the 
participant reaches a point of indifference between the two choices.  
 
The utility value of health state i is hi = 1 – (1 - hj)x/t where t is the time in state i and x is the 
time of indifference. 
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Respondents will complete between 8-10 TTO exercises each. They will be presented with a 
laminated card describing a pressure-ulcer-related health state (such as the example given 
above) and a TTO board. The TTO board is a prop with a slide mechanism to help 
respondents understand the exercise and to make it easier for them to respond. The 
interviewer is present to make sure the respondent understands the task, to answer any 
queries and to record responses. 
As there is a concern that the elderly may have problems in understanding and completing the 
TTO, we will also include a ranking exercise. In this exercise, participants will be asked to 
rank the PU scenario cards they considered for the TTO in order of ‘severity’ (the order from 
best-to-worst). After that they will be asked to assign a number from 0-100 to each card 
denoting its position on the ‘health thermometer’ visual analogue scale (VAS) shown in 
Appendix F, with 0 representing ‘dead’ and 100 representing ‘full health’. Participants will 
be informed that scenarios can have equal values.  
 
The respondents will also complete a set of questions on their general health, a socio-
demographic survey and the EQ-5D measure. Interviews should last between 30-50 minutes. 
The Agency will offer a small incentive to participants. 
 
Sample 
Checking the acceptability of the revised PUQoLI 
A sample of around 15 people who have experienced (preferably who currently have) a 
pressure ulcer is thought sufficient to check the acceptability of the revised PUQoLI. These 
will be recruited via local groups (such as Leeds Carers UK) who have agreed to participate 
in the study. The groups will mention the study to their members (pass on the study 
information sheet) who will be instructed to contact a specified member of the research team 
if they wish to participate. People meeting the inclusion criteria will be asked to complete a 
consent form and will then be able to state a location and time convenient for an interview. 
 
Valuation interviews  
The NICE guidance (NICE, 2008) states that any valuation of condition-specific measures 
should follow the EQ-5D valuation methodology. For this reason the sample of participants 
will be a representative sample of the UK general population.  
 
Sample size 
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The sample size for the valuation study depends on the number of dimensions chosen for the 
valuation exercise – the greater the number of dimensions, the greater the sample required. It 
is also dependent on the number of valuations required per health state, the number of TTO 
valuations conducted per person and the approach taken to modelling the data. 
 
For the analysis assuming:   
· We include 8 dimensions, each with 3 levels (response options)  
= 6561 potential health states. 
· We only need to value 1% (based on published valuation studies) of these health states 
= 66 states 
· We need to value each a minimum of 20 times = 1320 valuations 
· Each respondent can complete 8 valuations  
 - Gives a sample size of 165  
 - Assuming an 80% completion rate means we will require a sample of 198  
 
Eligibility  
PU sample and recruitment 
Inclusion criteria 
- aged ≥18 years and 
- with experience of PU of any grade, location, or duration and  
- able to provide informed consent to participate  
 
Exclusion criteria 
Participants will be excluded from the study if any of the following criteria apply. They: 
- are unconscious or confused 
- have cognitive impairment 
- do not speak or understand English 
- are unable to provide informed consent 
 
The researcher will interview participants in their own home (following standard safe practice 
SOP). Before the interview, each participant will be given a further verbal explanation of the 
study by the researcher; informed that the responses they provide are made anonymous; 
reminded that participation is completely voluntary and that they can withdraw from the 
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study at any time without it affecting their care; and invited formally to participate. They will 
be given an opportunity to ask any questions and then if they agree to take part, the 
participant will be asked to sign the consent form. A copy of the consent form will be given 
to the participant to keep and the original copy kept by the researcher to take back to Leeds 
Institute of Health Sciences.  
 
The researcher is required to utilise all possible methods to ensure that no person feels 
pressurised to take part in the study. This will include emphasising that participation is 
entirely voluntary and that participants are free to withdraw consent at any point up to, during 
or following the interview. The right of the person to refuse consent without giving reasons 
will be respected. Further, participants will remain free to withdraw from the study at any 
time, again, without giving reasons and without prejudicing any further treatment. 
 
General population: 
An external market research agency will be responsible for the recruitment of the general 
population sample. They have a group of participants on their records who regularly 
participate in interviews. A sample representative of the UK general population will be 
chosen including a spread of age, gender, educational attainment and ethnicities. 
 
To encourage participation in the general population group, a small incentive will be offered. 
The research agency will be responsible for the interviewing, data recording and checking 
and incentive payments.  
 
As with the patient sample, in the unlikely event that an interviewee from the general 
population sample becomes distressed, the interview will be stopped immediately.  
 
Analysis 
Modelling the health state valuations 
It is impractical to value every health state possible in the PUQoL-UI descriptive system. 
Therefore, it is likely that around 0.05%-1% of the potential health states from the PUQoL-UI 
would be valued given the sample proposed. Those health states not directly valued by the 
general population will be valued indirectly using regression modelling from values 
attributed to health states that were included in the elicitation exercise. 
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Analyses will explore the two main ways to model health states: multi-attribute utility theory 
(MAUT) and statistical modelling (Stevens et al, 2007). A number of statistical model 
specifications will be explored including ordinary least squares and random effects models. 
Model performance will be judged using standard error statistics such as mean absolute error 
and root mean squared error in predicting mean health state utility values. The model with the 
lowest prediction errors will be selected as that to value the remaining PUQoL-UI health 
states. From this algorithm a scoring tariff to obtain PUQoL-UI scores from the PUQoLI 
questionnaires will be generated. 
 
Ethical considerations 
This study will include both members of the general population and may include elderly and 
highly dependent participants considered as vulnerable. Clinically in the treatment of PUs, 
older people are treated in the same way as younger people and it is therefore important to 
ensure that the study is representative of the clinical population. In addition, the interview 
requires the participant to reflect on their experience of having a PU and for some people this 
may raise topics considered to be sensitive, embarrassing or upsetting, and possibly 
emotionally distressing. 
 
Ethical issues are largely related to the involvement of vulnerable adults/elderly participants 
with high levels of co-morbidity including acute and chronic illness. The ethical issues 
surrounding these potentially vulnerable participants have been addressed through the design 
of the recruitment process which uses local groups to help with recruitment and we will 
provide a caring and supportive environment in which to discuss any sensitive issues that 
may arise. If the participant becomes distressed during the interview or from completing the 
questionnaire, then the interview will be immediately stopped. It will be stressed to all 
participants that they are able to withdrawn from participation at any time without giving 
reason. 
 
No treatments or procedures are incorporated into the PUQALY study design so there is 
minimal risk to the participant sample. Participants will be made aware that they free to leave 
the study or discontinue the elicitation interviews at any time. 
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The study will be performed in accordance with the recommendations guiding physicians in 
biomedical research involving human subjects adopted by the 18th World Medical Assembly, 
Helsinki, Finland, 1964, amended at the 52nd World Medical Association General Assembly, 
Edinburgh, Scotland, October 2000. Informed written consent will be obtained prior to 
involvement into the study. The right of a person to refuse participation without giving 
reasons will be respected. The participant will remain free to withdraw at any time from the 
study without giving reasons.  
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Appendix 50 Pressure Ulcer Quality of Life:
Utility Index general population valuation study
information leaflet
Quality of life in people with pressure ulcers (bed sores) 
You are being invited to take part in a research study. Before you decide whether or not to 
take part, we would like to explain the reason for the research and what it will involve. Please 
take time to read the following information carefully. Ask us if there is anything that is not 
clear or if you would like more information. Take time to decide whether or not you wish to 
take part. 
Thank you for reading this. 
 
Contact us: 
Research Agency contact details 
 
 
 
 
What is the purpose of the study? 
Pressure ulcers (bed sores) happen to people with poor health who are unable to move about 
much. The Department of Health have set out to make sure that a lot less people will get 
pressure ulcers in the future. The University of Leeds has been involved in a large research 
study with people who have pressure ulcers. As part of this we have developed a new 
questionnaire that measures the impact of pressure ulcers on a person’s quality of life. This is 
based on the kinds of problems people with pressure ulcers have, for example pain and 
discomfort, unpleasant smell and so on.  
 
To help us understand how severe the aspects measured by the questionnaire are we need to 
ask people from the general population (i.e. people who do not have pressure ulcers) to 
answer some questions relating to scenarios described by the questionnaire. The information 
we get from these questions will enable us to generate scores from the questionnaire that – 
after completion by patients participating in clinical trials – will help determine which new 
pressure ulcer treatments are best value for money in the future. The research agency are a 
private company and are conducting the research on behalf of the University of Leeds. 
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What will be involved if I agree to take part in the study? 
If you would like to participate in the study please contact the research agency whose 
telephone number and email address is at the front of this information sheet. As part of this 
study the researcher will ask you to complete a questionnaire about you and your health and 
then conduct a number of tasks based around scenarios from the pressure ulcer questionnaire. 
The whole process will take about 30-40 minutes.   
 
Do I have to take part in the study? 
No.  It is up to you to decide if you want to take part in the study.  If you think you want to 
take part and then change your mind you can without giving a reason.   
 
When and where will the study take place? 
The interview will be at a time that suits you and will be at your home (or at research agency 
premises).  
 
Will the information obtained in the study be confidential? 
Yes. It will not be possible to connect your answers in the questionnaires to the report. The 
questionnaires and interview responses will have a number and not a name to identify them 
for the researchers.  
 
Will anyone else be told about my participation in the study? 
No. We will not contact and tell anyone else about your participation. 
 
Who is funding this study? 
The research agency is being paid to conduct the work by the University of Leeds. The 
University of Leeds was funded to conduct the research by the Department of Health through 
the National Institute of Health Research. 
 
What if I wish to complain about the way in which this study has been conducted? 
If you have any complaints or concerns please contact the research agency in the ﬁrst 
instance using the contact details on the front page. If you feel your complaint has not been 
satisfactorily dealt with then please contact the project co-ordinator at the University of Leeds 
(Karen Vinall-Collier; Email: K.A.Vinall@leeds.ac.uk; Telephone: 0113 343 0861). 
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Appendix 51 Pressure Ulcer Quality of Life:
Utility Index valuation study interview schedule
 
 
PUQALY – Valuing quality of life after 
pressure ulcers 
 
 
Interview Schedule A 
 
 
Please read out to the participant: 
“Thank you for agreeing to participate in this research. The research aims to help better 
understand how pressure ulcers impact on people’s quality of life. During the interview you 
will be asked a number of questions that aim to get you thinking about how severe the impact 
of pressure ulcers are and ways in which they can affect on an individual’s life”  
 
…Please answer all of the questions you feel able to. There are no right or wrong answers. 
All of your responses are anonymous and confidential and will not affect any treatment you 
receive in the future. The interview should last about 30-45 minutes. However, you are free to 
stop the interview at any time and withdraw from the study. Please ask for clarification if you 
do not understand a question” 
 
 Today’s date:                 Participant ID:  /  
 d d  m m  y y y y   Cen  Pat 
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Section 1: Demographic questions 
1. What is your date of birth?            
 
 
2. Are you?  (please tick one):            Male         Female 
 
3. How many children do you have (under 18)?      
 
4. Which ethnic group do you belong to? (please tick only one) 
 White    Mixed ethnicity   
 Asian or Asian British    Gypsy / traveller 
 Black or Black British    Other ethnic group 
 Chinese    
 
5. What is the highest level of education you have completed? (please tick only one)  
 University or college or equivalent  
 Intermediate between secondary level and university  
(e.g. technical training) 
 
 Secondary school  
 Primary school (or less)  
 
Section 2: Health questions 
6. Do you have any medical conditions, illnesses or disabilities?     
                                                                                            Yes   No 
Do you currently have, or have you had, any of the following health conditions? CIRCLE 
AS MANY ANSWERS AS ARE APPROPRIATE FOR YOU 
1. Arthritis 6. Hypertension  
2. Cancer 7.  Stroke 
3. Chronic Obstructive Pulmonary  8. Depression 
Disease 9.  Other mental health conditions 
4. Diabetes 10.  Other health conditions 
5. Heart disease 11.  None of these conditions 
Other please list: 
         
d d  m m  y y y y 
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7. How would you rate your overall health at the moment? (Please tick one) 
 
Very poor Poor Fair Good Very good 
     
 
 
Section 3: Time Trade Off 
Test TTO 
“I’m going to ask you to complete a task called ‘Time-trade-off’ which will tell us how bad 
you think it would be to live with pressure ulcers of varying severity. I’m going to ask you to 
complete a series of [9-11] TTO questions. In each case I’m going to show you a health 
situation on a card describing different effects and severity of pressure ulcers (also known as 
bed sores). Although they look similar, each scenario is different in some way. The other card 
is called full health and is Life A and is represented on a pink card The health condition with 
pressure ulcers in called Life B and is represented on green cards. . Full health is defined 
here as not having any bother with the health problems described on the green cards. 
Although it sounds strange, in this hypothetical task I want you to imagine that you only have 
10 years to live.” 
 
Show participant Scenario Green Card life B    
“I’d like you to imagine that you were living in this health scenario and you had to live in it 
for the last 10 years of your life. Then I want you to imagine that you have a choice: you can 
either live in the scenario described in Life B for those remaining 10 years of your life or you 
can live for a shorter period of time, for example 5  years, but without the health problems 
described in Life A. So if you had 10 years left to live, would you prefer to live for those 10 
years in the situation on card X or for 5 years but in normal health? (after the fifth year you 
would die)” 
 
Use the ping-pong method from this point on to arrive at the participant’s point of 
indifference as per training received.  
Please ask participant to complete the [8-9] TTO tasks/cards  
(The screen has the colours pink for full health and green for the pressure ulcer health state) 
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“First I’d like to ask you to make a choice between Full health which is life A (read out if 
required pink card A) and the life with a pressure ulcer which we have called life B (on the 
green card). On the computer screen, the two scales show the number of years you would live 
in each health state. 
 
Q 1 At the moment, each scale says 10 years. This means that you would either live in Life A 
for 10 years and then die or you would live in Life B for 10 years and then die. Would you 
prefer Life A or Life B or are they the same? 
· If Life A is chosen go to Q 4 
· If Life B is chosen go to Q 2 
· If it is the same go to Q 3 
 
Q 2 Does this mean that you would rather live in Life B for 10 years than in Life A for 10 
years? 
· If yes, save the values 10 for the Full Health and 10 years for the Health State x, (are 
they timed – if so then start a new clock) 
· If no (first time) repeat Q 1 
· If no (second time after repeating Q1) go to Q 4 
 
Q 3 Does this mean that living in Life B for 10 years would be the same as living in Life A 
for 10 years? 
· If yes, save the values (10 years for the Full Health and 10 years for Health State X, 
(if timed clock stops and new card) 
· If no (first time) repeat Q 1 
· If no (second time) go to Q 4 
 
Q 4 Now you would either die immediately, or you would life in Life B for 10 years and then 
die. Would you prefer to die immediately or to live Life B, or are they the same? 
(the screen shows Life A at 0 years and Life B at 10 years) 
Choice of Life A;   Life B:  or The same 
· If Life A, go to Q 9 
· If Life B, go to Q 5 
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· If the same, save the values (0 for Full health and 10 years for Health State x) (Stop 
and start a new card)  
 
Q 5 Now you would either live in Life A for 5 years and then die or you would live in Life B 
for 10 years and then die. Would you prefer Life A or Life B, or they the same? 
(The screen shows Life A at 5 years and Life B at 10 years) 
· If Life A, the cursor will move one notch to the left becoming 4 years. Go to Q6. 
· If Life B, the cursor will move one notch to the right i.e. becoming 6 years. Go to Q7. 
· If the same, save the values 5 years for Full health and 10 years for health state X. 
Stop and start a new TTO exercise card. 
 
Q 6 Now you would either live in Life A for (updated number ) years and then die or you 
would live in Life B for 10 years and then die or are they the same? 
· If Life A, the cursor will move one notch to the left. Repeat Q 6 until the respondent 
answers “Life B” or the “Same”. If the marker is at zero, repeat Q6, if Life A is 
chosen go to Q 9 (the cursor can go further to the left), if Life B is chosen do the 
second bullet point of Q 6, if the same do the third bullet point of Q6 
· If Life B is chosen, the cursor will move one half notch to the right. Go to Q 8 
· If the same, save the values (updated number from screen) years and 10 years for 
health state x, stop and start new TTO card. 
 
Q7. Now you would either live in Life A for (updated number) years and then die or you 
would live in Life B for 10 years and then die, Would you prefer Life A or Life B or are they 
the same? 
· If Life A, the cursor will move one half notch to the left, go to Q8. 
· If Life B, the cursor will move one notch to the right. Repeat Q7 until 
a. If respondent answers “Life A GO TO Q8. If the respondent answers ”Same” – 
save the value and start a new TTO exercise Card. 
b. If respondent answers Life B and the marker is on 9 years then the marker moves 
up to 9 years 3 months, 9 years 6 months, 9 years 9 months, 9 years 11 months. 
· If the same, save the values (updated number) for Full Health and 10 years for health 
state x), Stop and start a new TTO exercise. 
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Q8. Now you would either life in Life A for (updated number) of years and then die or you 
would life in Life B for 10 years and then die. Would you prefer to have Life B or are they 
the same? 
· If Life A, save the values (updated number in years and months) for Full Health and 
10 years for Health State x, stop and start a new TTO exercise. 
· If Life B, save the values (updated number in years and months) for Full Health and 
10 years for Health State x. Stop and start a new TTO exercise. 
· If “same”, save the values (updated number in years and months) for Full Health and 
10 years for Health State x) Stop and start a new TTO exercise. 
 
Q 9 (If always choose Life A) Does this mean that you would rather die immediately than life 
in Life B for 10 years? 
· If yes go to Q11 
· If no go to Q 4. 
 
Q10 (If always chooses Life B) What if you would either live in Life A for 9 years 3,6,9,11 
months and then die or live in Life B for 10 years? Would you prefer Life A or Life B or are 
they the same? 
· If Life A, save the values (updated number) for Full Health and 10 years for Health 
State X. Stop and start a new TTO exercise.  
· If Life B, save the values (updated number in years and months) for Full Health and 
10 years for Health State x. Stop and start a new TTO exercise. 
· If “same”, save the values (updated number in years and months) for Full Health and 
10 years for Health State x) Stop and start a new TTO exercise 
for Health State x. Stop and start a new TTO exercise. 
 
TTO answer table 
Scenario TTO response – point of 
indifference (years, months) 
1  
2  
3  
4  
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5  
6  
7  
8  
9  
10  
11  
 
 
Did the participant appear to understand the TTO?         
        Yes      No         Unsure 
 
 
Section 4: Ranking task 
Please take a look at the scenario cards; these are the scenarios you have just been 
considering in the time trade-off task. We have added to scenarios to this – one is ‘death’ and 
one is your own health state at the moment. 
We would like you to think about these health scenarios and try to put them i in order of 
severity – i.e. arrange the cards so that they range from the most severe to the least severe in 
your opinion.  
When you have sorted the cards please enter the order of the scenario cards onto the 
computer.  
Now I would like you to rate the severity of each scenario from 0 to 100 with 0 being the 
worst health you can imagine and 100 representing Full health. If you think that two 
scenarios would have the same score then that is fine. Please enter the values you gave for 
each scenario onto the computer. 
 
Please make a note of the order and rating for each scenario 
Scenario Ranking (1-12 or13) 1 is 
worst 
Rating (0-100) 
1   
2   
3   
4   
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5   
6   
7   
8   
9   
10   
11   
Death   
Own health 
state 
  
 
Did the participant appear to understand the ranking task?     
 Yes      No         Unsure 
 
Section 5: EQ-5D 
[NB: The EQ-5D instrument was collected however the instrument is omitted due to 
copyright. The EQ-5D instrument can be obtained from URL: http://www.euroqol.org/]. 
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Health rating scale
 
 
 
 
 
 
 
Thank participant for helping with the research and reiterate assurances about 
confidentiality and anonymity. Ask if they have any questions. 
 
Full health 
Worst 
imaginable 
health 
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Appendix 52 Pressure Ulcer Quality of Life:
Utility Index methodology study reduced
format protocol
NB: This study protocol (version 6, dated 13 Jun 2013) is in a reduced format including only 
the study aims, methods and ethical considerations.  Sections pertaining to study background 
have been removed as they are included as a chapter section. Information pertaining to data 
monitoring, quality assurance, confidentiality, archiving, statement of indemnity, study 
organisational structure, funding, and publication policy are available upon request. 
 
Study Flow Diagram 
 
 
Aims and Objectives 
The overall aim of the project is to generate data using the revised version of the PUQoLI 
measure to enable item reduction analysis and a comparison of item selection methods. 
1. To generate data on the new PUQoLI via a patient survey. 
2. Conduct item selection analysis using the data. 
3. Compare the items selected for the reduced PUQoLI from this and previous analyses. 
4. Conduct additional methodological work such as mapping from the EQ-5D and from 
time-trade off values to the revised PUQoLI.  
Data analysis 
Recruitment of pressure ulcer 
patients (n=100)
Patient completion of revised 
PUQOLI   
Item selection for valuation 
Comparison of item selection 
results 
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Methods 
Item Selection and Health State Generation 
A sample of patients with PUs will complete the interview administered measure either in 
hospital or in the community. In order that we are able to compare the item selection results 
across studies, the samples that provide the data have to be comparable in terms of PU 
severity, demographics (i.e. age and gender) and location of the participant (community or 
hospital). Sample size is not critical as it will be possible to randomly select a subsample 
from the original dataset (and rerun the analysis) to match the – likely - smaller dataset we 
will generate from this study. 
 
The sample used for the original item selection are shown in the table below: 
N = 229 N (%) 
Gender   
Male  119 (52%) 
Female 110 (48%) 
Age  
Under 70 years 90 (39.5%) 
70 years and over 138 (60.5%) 
PU grade  
Superficial 115 (50%) 
Severe 94 (41%) 
Mixed 20 (9%) 
Setting  
Hospital 141 (62%) 
Community 88 (38%) 
 
 
Sample size 
The sample size is dependent on that required to obtain robust estimates from the Rasch 
analysis. Linacre (1994) proposed that for most purposes a sample size of 150 (n range, 108-
243) will provide 99% confidence of item calibration of +/-0.5 logits and a sample size of 
100 (n range, 64-144) will provide 95% confidence of item calibration within +/-0.5 logits. In 
this study we will aim for 95% confidence and therefore a sample of 100 patients.  
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Eligibility and Recruitment  
Members of the tissue viability team (TVT) which includes the local Principal Investigator, 
tissue viability nurse specialists, nurse consultants, and other members of their local clinical 
team (i.e. tissue viability and clinical research nurses) at participating trusts will identify 
potential patients. 
Eligibility 
Patients from participating acute and community NHS Trusts, with existing PUs, will be 
included in the study if they are hospital in-patients or outpatients, intermediate care patients, 
or community patients under the care of community care nursing services, and they fulfil the 
criteria detailed below. We will ensure representation of patients from all PU categories 
(Categories 1-4/U) and treatment types. Consecutive patients will be identified from each PU 
category and approached to participate. Recruitment will continue on a rolling basis until a 
minimum of 10 patients from each PU group are recruited and interviewed. 
 
Inclusion criteria 
- aged ≥18 years and 
- with an existing PU of any grade, location, or duration and  
Give their written informed consent/verbal witnessed consent Exclusion criteria 
 
Patients will be excluded from the study if any of the following criteria apply. They: 
- have only moisture lesions 
- are unconscious or confused 
- have cognitive impairment 
- do not speak or understand English 
- they do not have an existing PU or 
- are unable to provide informed consent 
 
Patients who are deemed ethically inappropriate to approach by members of the TVT, for 
example, those where death is imminent (any patient who is on or meets the criteria of the 
Liverpool Care Pathway for the dying) will not be approached. 
 
To clarify, those not deemed ethically appropriate is a clinical judgement about the 
appropriateness of approaching patients who are very seriously ill or distraught. For example, 
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patients where death is imminent (any patient who is on or meets the criteria of the Liverpool 
Care Pathway for the dying) will not be approached or in other circumstances (personal to 
that patient) where it is considered inappropriate (for example, distraught due to a recent 
bereavement).   
 
In addition the assessment of capacity will relate specifically to decisions pertaining to this 
particular research project. Each patient will be assumed to have capacity unless it is 
established that they lack capacity. Ward/community based nurses identifying patients for 
study participation, will be asked to consider aspects of capacity before any approach to 
patients is made and during the information giving stage prior to consent. The TVT member 
will  assess the patient’s ability to understand what decisions they need to make and why; the 
consequences of the decision to participate; their ability to understand, use and retain the 
information related to the decision to participate and be able to communicate their decisions 
effectively (as specified in the Mental Capacity Act 2005)  If there is any concern about 
capacity the TVT member will consult with other members of the attending clinical team 
and/or relative/carer/friend  (as appropriate) and a decision will be made with the attending 
clinical team/relative/carer/friend as to whether the patient is able to provide written consent.  
 
Recruitment and consent procedures 
Potential participants will be identified by the direct care team from their local area of 
practice. A record of those identified as eligible, approached to participate, refusals, 
consenting patients and questionnaire returns will be made. A verbal explanation of the study 
and Patient Information Leaflet will be provided by the TVT member for the patient to 
consider. This will include details about the rationale, design, and personal implications of 
the study. 
 
Following information provision, patients will have as long as they need to consider 
participation and will be given the opportunity to discuss the study with their family and 
other healthcare professionals before they decide whether they would be willing to take part 
in the study. Assenting patients will then be invited to provide informed, written consent. 
Should the patient be capable of giving consent but are physically unable to complete the 
written aspects of the consent form, witnessed consent should be obtained using the 
Witnessed Consent Form. An appropriate witness would be a family member or friend of the 
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patient, or another member of the patient’s healthcare team who is not directly involved in the 
research study. 
 
The researcher is required to utilise all possible methods to ensure that no patient feels 
pressurised to take part in the study. This will include emphasising that participation is 
entirely voluntary and that participants are free to withdraw consent at any point up to, during 
or following the survey. The right of the patient to refuse consent without giving reasons will 
be respected. Further, the patient will remain free to withdraw from the study at any time, 
without giving reasons and without prejudicing any further treatment. After signing the 
consent form patients will be handed the questionnaire schedule to complete.  
 
To clarify, potential participants will be identified by the direct care team from their local 
area of practice. The direct care team includes ward and community staff. For some patients 
the direct care team also includes members of the Tissue Viability Team (i.e. if the patient is 
under the care of the Nurse Consultant/Nurse Specialist, they are part of the direct care team).  
 
Where the patient is not under the care of the Tissue Viability Team, ward/community staff 
will identify potential participants, and obtain verbal assent for a visit by the Tissue Viability 
Team (Nurse Consultant/Specialist/Research Nurse) to discuss the possibility of study 
participation and flag the patient to the Tissue Viability Team. 
 
Where the patient is under the care of the Tissue Viability Team (Nurse 
Consultant/Specialist) they will either discuss study participation with the patient (providing 
a full verbal explanation of the study and Patient Information Leaflet) or obtain verbal assent 
for a visit by the Research Nurse.  
 
Registration  
Patients will be registered with the CTRU following informed consent and confirmation of 
eligibility. The CTRU will issue a study identification number which includes centre code. 
Registration will include centre, confirmation of eligibility, confirmation of consent, date of 
birth, gender, PU grade and patient location (community or hospital). The data will be used 
for central monitoring of recruitment. CTRU will also be responsible for accrual recording 
with the NIHR. 
DOI: 10.3310/pgfar03060 PROGRAMME GRANTS FOR APPLIED RESEARCH 2015 VOL. 3 NO. 6
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Nixon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
603
Screening  
The TVT member will complete a log of all patients screened for eligibility who are not 
registered either because they are ineligible or because they declined participation. All 
anonymised screening logs will be returned to the AUHE. 
 
Anonymised information will be collected including: 
· The reason not eligible for study participation or 
· Eligible but declined 
· Date of Birth 
· Gender 
· Ethnicity 
· Pressure ulcer grade and location  
 
Survey  
The survey will be administered by a research nurse. The surveys will be completed in the 
out-patient clinic, in-patient ward or in the community as determined by the patient’s 
circumstances and preferences at the time.  
 
Study participants will complete the revised PUQoLI, the EQ-5D (a five-item health-related 
quality of life questionnaire) and EQ-VAS (a 0-100 health rating scale) (EuroQoL, 1990) and 
a set of socio-demographic and PU-related questions. They will also complete a paper version 
(Robinson, 2010) of the time trade off (TTO) task (Torrance, 1972). The TTO asks about 
how much time the patient would be willing to trade off in exchanging their current health 
status for full health. This will provide additional useful information in valuing the PUQoLI.  
 
It is anticipated that the survey will take approximately 25 minutes to complete. A user 
manual for the PUQoLI is available and should be used with any queries relating to 
completion of that measure. 
 
Analysis 
Item selection 
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In the first instance, one item representing each of the ten PUQoL instrument constructs will 
be chosen. Items will be selected on the basis of traditional psychometric analyses and Rasch 
analyses. 
 
Rasch analysis (Rasch, 1961) is now seen as the method of choice for the development and 
improvement of questionnaires as it has several advantages over Classical Test Theory 
approaches such as factor analysis (Wright, 1996; Wright and Tennant, 1996; Luquet et al.,
Prieto et al., 2003; Tennant et al., 2004; Waugh and Chapman, 2005; Nijsten et al., 2006a). 
Rasch is often the method employed to identify reduced forms of measures that will be used 
in preference valuation studies. (e.g. Brazier et al 2012; Kowalski et al, 2012; Mulhern et al, 
2012) The Rasch model is a simple logistic latent trait Item Response Theory model. Rasch 
analysis places response data for each individual and each item on the same spectrum of 
severity (logit scale). According to the model, the probability that an individual will respond 
in a certain way to a particular item is a logistic function of the relative distance between the 
item location (parameter) and the person location (parameter), and only a function of these 
two factors. Persons and items are plotted on the same logit scale on the basis of the 
difference in their location on the underlying spectrum. This difference governs the 
probability of the expected response for a person, of a given severity, on a question of a given 
severity. If the observed data do not deviate significantly from the expected responses, then 
the items fit the Rasch model. 
 
Criteria for item selection: 
Rasch measurement method analyses –  
· Degree of fit to the Rasch model (Rasch, 1961) – Chi2 probability and fit residual 
(items with non-significant Chi2 and residuals <±2.5 are candidates) 
· Differential item functioning (DIF) based on age and gender such that bias by these 
factors is minimised (items with no DIF are candidates) 
· Item logit position on each construct’s measurement continuum  such that items with 
a range of severity (spanning the entire measurement range) can be identified (items 
that collectively represent a wide spread of the latent trait are candidates) 
· Disordered response category thresholds (items with correctly functioning response 
categories are candidates) 
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Traditional psychometric analyses – 
· Distribution of scores and presence of floor/ceiling effects (items with no floor/ceiling 
effect are candidates) 
· Item-to-total correlation (items with ITC 0.2-0.8 are candidates)  
· Principal components factor analyses (items having a moderate-high factor loading 
within a subscale being candidates) 
· Ability to discriminate between pressure ulcer severity groups – T-tests for superficial 
vs severe PU patient scores (highly discriminatory items are candidates) 
· Pearson correlations with EQ-5D and global PUQoL-I item (“How would you rate 
your overall QoL because of your pressure sore(s)”) (items with moderate-high 
correlations are candidates) 
 
The final selection of items will be compared with those selected from earlier analyses (and 
based on the PU-attributable data). The performance of each in terms of the above criteria 
will be described and compared across analyses. 
 
Mapping analysis 
In addition to the item selection analysis we will also conduct a mapping analysis (Brazier et 
al, 2010) whereby regression techniques are employed to predict the EQ-5D scores and TTO 
responses using responses on the PUQoLI (and other factors such as age and gender). 
 
This would generate an algorithm that would allow the indirect estimation of utility values 
from the PUQoLI. 
 
Data Monitoring 
Data will be monitored for quality and completeness by the project team (PT). The PT will 
liaise with nurses to ensure that the sample recruited matches as far possible that used for the 
original analyses. The proportion of males/females, different PU grade and location 
(hospital/community) of recruited patients will be monitored to enable this. 
 
Ethical considerations 
This study will include elderly and highly dependent patients considered as vulnerable. 
Ethical issues are largely related to the involvement of vulnerable adults/elderly patients with 
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high levels of co-morbidity including acute and chronic illness. Clinically, older patients are 
treated in the same way as younger patients and it is therefore important to ensure that the 
study is representative of the clinical population. In addition, the survey requires the patient 
to reflect on their experience of having a PU and for some people this may raise topics 
considered to be sensitive, embarrassing or upsetting, and possibly emotionally distressing. 
 
Ethical issues are largely related to the involvement of vulnerable adults/elderly patients with 
high levels of co-morbidity including acute and chronic illness. The ethical issues 
surrounding these potentially vulnerable patients have been addressed through the design of 
the recruitment process which uses local staff and includes experienced clinical nurses to help 
with recruitment and we will provide a caring and supportive environment in which to 
discuss any sensitive issues that may arise. If the patient becomes distressed during survey 
completion, then the nurse will immediately stop the interview/survey. It will be stressed to 
all patients that they are able to withdraw from participation at any time without giving 
reason, and without any effect on their care. They will be referred back to their treating nurse 
specialist if required. 
 
No treatments or procedures are incorporated into the PUQALY study design so there is 
minimal risk to the patient sample. Participants will be made aware that they free to leave the 
study or discontinue at any time without their future care being affected. 
 
The study will be performed in accordance with the recommendations guiding physicians in 
biomedical research involving human subjects adopted by the 18th World Medical Assembly, 
Helsinki, Finland, 1964, amended at the 52nd World Medical Association General Assembly, 
Edinburgh, Scotland, October 2000. Informed written consent will be obtained prior to 
involvement into the study. The right of a patient to refuse participation without giving 
reasons will be respected. The study will be submitted to and approved by a main Research 
Ethics Committee (main REC) and the appropriate Site Specific Assessor for each 
participating centre prior to entering patients into the study. The PT will provide the main 
REC with a copy of the final protocol, patient information sheets, consent forms and all other 
relevant study documentation. 
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Appendix 53 Pressure Ulcer Quality of Life:
Utility Index methodology study patient information
sheet and consent form
 
Pressure ulcer quality adjusted life years (PUQALY): an item reduction 
survey 
 
You are being invited to take part in a research study. Before you decide whether or not to 
take part, it is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it with 
friends, relatives and your GP if you wish. Ask us if there is anything that is not clear or if 
you would like more information. Take time to decide whether or not you wish to take part. 
 
Thank you for reading this. 
Principle investigator:  Professor Claire Hulme 
Contact us: 
Researcher: 
Karen Vinall-Collier    
Leeds institute of 
Health Sciences  
University of Leeds     
Clarendon Road 
Leeds            
K.A.Vinall@leeds.ac.uk 
0113 343 0861
Researcher: 
David Meads 
Leeds institute of 
Health Sciences   
University of Leeds     
Clarendon Road 
Leeds                
d.meads@leeds.ac.uk 
0113 343 0860      
Insert details of local  
R&D contact here: 
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What is the purpose of the study? 
Pressure ulcers (bed sores) happen to people with poor health who are unable to move about 
much. The Department of Health want to try and make sure that a lot fewer people get 
pressure ulcers in the future. The University of Leeds has been involved in a large research 
study with people who have pressure ulcers. As part of this we have developed a new 
questionnaire that measures the impact of pressure ulcers on a person’s quality of life. This is 
based on the kinds of problems people with pressure ulcers have, for example pain and 
discomfort, unpleasant smell and so on. It is important for us to ﬁnd out which of these 
problems affect people with pressure ulcers most. We would like your help in testing this new 
questionnaire. This will help measure which new treatments are best value for money in the 
future. 
 
What do I have to do if I agree to take part in the study? 
If you agree to take part the nurse will ask you to complete a survey. The survey asks about 
you pressure ulcer and your quality of life and should take about 20-30 minutes to complete. 
Having an ulcer impacts on health and how people get by in their lives. The questions are 
designed to help us understand this better.  
 
Do I have to take part in the study? 
No. It is up to you to decide if you want to take part in the study. If you decide to take part 
you will be asked to sign a consent form. If you think you want to take part and then change 
your mind you can without giving a reason. This will not make any difference to the medical 
care you receive. 
 
What if I would like to take part but I have trouble with or am unable to write? 
If you would like to take part but cannot or ﬁnd it difﬁcult to write, you can have someone (a 
witness) complete the written part of the consent for you. This witness could be a friend, 
family member, or member of your healthcare team. The witness will only act to help you 
carry out your wishes – you are free to change your mind at any time and your wishes will be 
respected. 
 
When and where will the study take place? 
Study participation will be at a time that suits you and will be either at your home or in the 
hospital if you are still a patient. This will be a ‘one off’ and you will not be asked to 
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participate again for this study. If you are in hospital you can complete the survey there but if 
you prefer to complete it at home then the nurse will give you a survey pack which includes a 
reply-paid envelope so you can post back your completed questionnaires. 
 
What other information will be collected in the study? 
We may also ask you about your pressure ulcer and about your general health. 
 
Will there be any effects on my treatment? 
No.  Your treatment will be the same whether you take part or not. 
 
Will the information obtained in the study be confidential? 
Yes. It will not be possible to connect your answers in the questionnaires to the report we 
write about the study. The questionnaires will have a number and not a name to identify them 
for the researchers. The completed questionnaires will be kept secure and stored in our locked 
cupboards at the University. 
 
Will anyone else be told about my participation in the study? 
It is usual in studies to let your family doctor know that you have taken part in a study.  We 
will check this with you ﬁrst. 
 
Who is funding this study? 
The money to pay for this study has come from the department of health through the National 
Institute of Health Research. 
 
What if I wish to complain about the way in which this study has been conducted? 
If you have any cause to complain about any aspect of the way in which you have been 
approached or treated during the course of this study, the normal National Health Service 
complaints mechanisms are available to you and are not affected in any way because you 
have taken part in a research study. 
 
If you have any complaints or concerns please contact the project co-ordinator (Karen Vinall-
Collier).  Otherwise you can contact David Meads. 
 
Our contact details are on the front of this leaflet. 
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 [delete this line and print on headed paper] 
 
PARTICIPANT CONSENT FORM 
Pressure ulcer quality adjusted life years (PUQALY): An item reduction survey 
 
The participant should complete the whole of this sheet himself/herself 
 
 
Please confirm the 
statements by 
putting your initials 
in the box below 
I have read and understood the participant information sheet, dated 
20.6.13. I have had the opportunity to ask questions and discuss this 
study. I have received satisfactory answers to all of my questions. 
 
 
I understand that I am free to withdraw from the study at any time and 
without having to give a reason. The relationship with my healthcare 
providers, level of services received or my legal rights will not be 
affected.  
 
 
 
 
I understand that if I decide to drop out of the study in the middle of the 
interview my questionnaire will be destroyed. 
 
I understand that any information I provide, including personal details, 
will be conﬁdential, stored securely and only accessed by those carrying 
out the study.  
 
 
I understand that any information I give may be included in published 
documents but it will not be possible to identify me personally. 
 
I agree to take part in this study.   
  
Participant Signature ……………………………           Date: 
 
Researcher Signature …………………………………    Date: 
Thank you for agreeing to take part in this study 
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Appendix 54 Pressure Ulcer Quality of Life:
Utility Index methodology study patient questionnaire
 
 
Pressure Ulcer Quality Adjusted Life Years  
(PUQALY): An Item Reduction Survey  
 
 
To the Researcher:  
This survey should administered by you to the patient. Please read out the questions and 
record their responses. Sections A and B ask about the patient and their health. Section C is 
related to quality of life and Section D asks about health preferences. 
 
Please provide clarifications and explanations of questions if they are not clear to the patient. 
However, the responses should be those of the patient. Please refer to the PUQoLI user 
manual if necessary. 
 
Researcher to read out to the patient: 
Thank you for agreeing to participate in this research. The research aims to help better 
understand how pressure ulcers impact on people’s quality of life. This survey asks a number 
of questions that aim to get you thinking about the impact of your pressure ulcer(s) and ways 
in which they affect your life.  
 
Please answer all of the questions you feel able to. There are no right or wrong answers. All 
of your responses are anonymous and confidential and will not affect any treatment you 
receive in the future. The survey should take about 20-30 minutes to complete. However, you 
are free to stop participating at any time and withdraw from the study. Please ask for 
clarification if you do not understand a question 
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Section A: About You 
 
1. Patient’s date of birth            
 
 
2. Gender  (please tick one):            Male         Female 
 
3. How many children do you have (under 18)?      
 
4. Which ethnic group do you belong to? (please tick only one) 
 White    Mixed ethnicity   
 Asian or Asian British    Other ethnic group  
 Black or Black British     
 Chinese    
 
5. What is the highest level of education you have completed? (please tick only one)  
 University or college or equivalent  
 Intermediate between secondary level and university  
(e.g. technical training) 
 
 Secondary school  
 Primary school (or less)  
 
Section B: Your Health  
 
1. Do you have any medical conditions, illnesses or disabilities?     
                                                                   
                            Yes      No 
 
If ‘Yes’, please list your other illnesses or disabilities:  
....................................................................................................................................................................
....................................................................................................................................................................
.......................................................................................................................... 
2. Are you a wheelchair user? 
  Yes             No 
          
d d  m m  y y y y 
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3. How long have you had your pressure ulcer(s)? 
 Weeks   Months  Years 
 
4. On which part of your body do you have pressure ulcer(s)?  
(please tick) 
Area at the bottom of your spine  Ankle/Foot  
Buttocks  Heel  
Back of leg and/or thigh  Elbow  
Hip  Head and/or face  
 
Other  Please  
specify:  
 
 
5. What is the patient’s clinical pressure ulcer grade? (Please tick one) 
Grade 1 Grade 2 Grade 3 Grade 4 
    
 
6. How severe would you say your pressure ulcer(s) are at the moment? (Please tick one) 
Very severe severe Moderate Mild Very mild 
     
 
7. Apart from your pressure ulcer do you have any other type of wounds or ulcers (such 
as diabetic foot ulcer or venous leg wound) at the moment? 
Yes             No  
 
8. Thinking about your health (including your pressure ulcer(s) and all other health problems). 
How would you rate your overall health at the moment? (Please tick one) 
Very poor Poor Fair Good Very good 
     
 
9. Please now imagine that you did not have a pressure ulcer. How would you rate your health at 
the moment if you did not have the pressure ulcer (but still had the other health problems)? 
(Please tick one) 
Very poor Poor Fair Good Very good 
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Section C: Quality of Life 
In this section please complete the following questions which ask about your general health 
and your pressure sore(s) and how they have affected aspects of your everyday life over the 
past week. 
 
[NB: The PU-QOL instrument was collected however the instrument is omitted due to 
copyright. The PU-QOL instrument can be obtained from URL: 
 
 
[NB: The PUQOL-UI instrument was collected however the instrument is omitted due to 
copyright. The PUQOL-UI instrument can be obtained from URL: 
]. 
].
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Health rating scale
 
 
 
 
 
 
 
 
 
 
Full health 
 
Worst 
imaginable 
To help people say how good or bad their health 
state is we have drawn a scale (rather like a 
thermometer) on which the best health you can 
imagine is marked 100 and the worst health you can 
imagine is marked 0. 
 
We would like you to indicate on this scale how 
good or bad your own health is today, in your 
opinion. Please do this by drawing a line from the 
box to whichever point on the scale indicates how 
good or bad your health is today. 
Your own health 
today 
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Section D: Your health preferences 
This next section includes an imaginary exercise. Even though the questions may sound 
strange please do your best to answer. Your responses will give us an idea about how severe 
your current health problems are. 
 
[to be read by the researcher] 
For each question imagine that you have all your current health problems and are guaranteed 
to live for another ten years after which you would die or you could choose to live in full 
health but for less than 10 years.  
 
For each set of options please tick one box to indicate which you would prefer. 
1. To live 10 years in your current 
health  
  7. To live 10 years in your current 
health  
 
To live 9 years and 9 months in 
full health 
  To live 5 years in full health  
 
2. To live 10 years in your current 
health  
  8. To live 10 years in your current 
health  
 
To live 9 years and 6 months in 
full health  
  To live 4 years in full health  
 
3. To live 10 years in your current 
health  
  9. To live 10 years in your current 
health  
 
To live 9 years in full health   To live 3 years in full health  
       
4. To live 10 years in your current 
health  
  10. To live 10 years in your current 
health  
 
To live 8 years in full health   To live 2 years in full health  
       
5. To live 10 years in your current 
health  
  11. To live 10 years in your current 
health  
 
To live 7 years in full health   To live 1 year in full health  
APPENDIX 54
NIHR Journals Library www.journalslibrary.nihr.ac.uk
622
       
6. To live 10 years in your current 
health  
  12. To live 10 years in your current 
health  
 
To live 6 years in full health   To live 6 months in full health  
 
 
If the patient gives an alternative amount of time please write this here: 
.................................................................................................................. 
 
Please tick here if the patient did not understand this task:    
 
For each question below imagine that your pressure ulcer had been cured. Then imagine that 
you have the choice between living for the next 10 years in your current health with your 
health problems but without a pressure ulcer (after which you would die) or living fewer 
years but in full health (after which you would die).  
 
For each set of options please tick one box to indicate which you would prefer  
1. To live 10 years in your current 
health  
  7. To live 10 years in your current 
health  
 
To live 9 years and 9 months in full 
health 
  To live 5 years in full health  
 
2. To live 10 years in your current 
health  
  8. To live 10 years in your current 
health  
 
To live 9 years and 6 months in full 
health  
  To live 4 years in full health  
 
3. To live 10 years in your current 
health  
  9. To live 10 years in your current 
health  
 
To live 9 years in full health   To live 3 years in full health  
       
4. To live 10 years in your current 
health  
  10. To live 10 years in your current 
health  
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To live 8 years in full health   To live 2 years in full health  
       
5. To live 10 years in your current 
health  
  11. To live 10 years in your current 
health  
 
To live 7 years in full health   To live 1 year in full health  
       
6. To live 10 years in your current 
health  
  12. To live 10 years in your current 
health  
 
To live 6 years in full health   To live 6 months in full health  
 
 
If the patient gives an alternative amount of time please write this here: 
.................................................................................................................. 
 
Please tick here if the patient did not understand this task:    
 
Thank participant for completing this survey and helping with our 
research 
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Appendix 55 Original application
Patient and public involvement section
Summary of proposal funded
We planned to ensure PPI via service user membership of the Programme Management Group and
Steering Committee. We proposed to approach people via patient forums and clinical links, such as local
tissue viability nurses and spinal injury units. We aimed to identify two service user members for each
committee and prepare them for their roles via informal, supportive meetings with experienced team
members. Meetings would be focused around the needs of the service users; both in terms of practical
issues (e.g. timings, venue etc.) and the format of the meetings (e.g. language, chairing, agenda
setting etc.).
Discrepancies between PPI activities undertaken and proposal funded
We did not establish service user membership of the Programme Management Group.
PPI activities undertaken that were not proposed
We have worked with service users in many other ways throughout the programme. The establishment
of a PURPOSE PPI officer post enabled us to engage with service users and undertake more in depth PPI
activities than set out in the funding application. For example:
l We have set up a service user research network which will continue to support research in this field
beyond the life of PURPOSE.
l We have undertaken a series of meetings, workshops and consultations which focused on the service
user perspective and have allowed input into all of the PURPOSE studies.
l We undertook an evaluation of PPI in the Severe Pressure Ulcer Study.
l We have involved service users in interpretation, dissemination and implementation of
research findings.
l We have shared our learning and PPI methods with the tissue viability and PPI research communities.
l On-going support and mentorship has been offered to service users and development opportunities,
such as conferences and training, have been provided where possible.
Pain studies
Summary of proposal funded
The pain work package proposed to determine the prevalence, type and severity of localised pressure ulcer
pain in ‘pressure areas’ in patients with clinically assessed normal skin, erythema, superficial and severe
pressure ulcers and explore the role of pain as an early predictor of Category 2 (or above) pressure ulcers.
We planned: i) multicentre prevalence to determine the extent of pressure area related pain, nested within
routine annual pressure ulcer prevalence audits in acute and community NHS Trusts and ii) a multi-centre
prospective cohort study.
We estimated that we would require 4,000 hospital and 2,700 community patients for the prevalence
survey, requiring us to piggy-back this work onto routine prevalence surveys in 4–5 acute and 2–3
community Trusts, and 340 patients for the prospective cohort study (based upon a model including
8 factors and an incidence rate of 25%).
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Discrepancies between research undertaken and proposal funded
Prevalence: we revised our sample size estimates in response to Board comments and planned to
undertake nested prevalence in a minimum of 2 acute and 2 community NHS Trusts with an expected
sample size of 2,000 hospital and 6,000 community patients. However, the community nursing caseloads
estimated by the community trusts at the grant application stage were inflated and our original plan
assumed that the community prevalence methodology was similar to long-standing and well established
acute hospital methods where nurses undertake a comprehensive skin assessment of each patient. This
was not the case for one of the Trusts, with the two participating community Trusts using different case
finding methods. This together with the scale of the data collection task in the community setting led to
an adaptation of the original plan as follows: a) the community and acute prevalence studies were
conducted and analysed separately, b) the community pain prevalence estimates included only those
patients with pressure ulcers and c) the total survey population was 5180.
Prospective cohort study: in the grant application we had planned to recruit patients into the cohort
study from the prevalence surveys. In practice this was not practical due to the organisational demands of
Trust-wide pressure ulcer prevalence audits. We amended the sample size estimate to 632 in response to
Board comments, with the addition of analgesic use as a risk factor in the planned model and a reduced
incidence rate (model including nine factors and an incidence rate of 15%). We planned to undertake
additional exploratory analyses to: i) assess the relationship between pain as measured by the two
assessment methods (numerical rating scale and LANSS) and pressure ulcer development and ii) assess the
relationship between changes in pain over time and the time to pressure ulcer development by treating
pain as a time-dependent co-variate in a Cox proportional hazards model. This secondary analysis has not
yet been undertaken.
Research undertaken that was not proposed
Prevalence: we undertook a sub-study comparing community pressure ulcer case finding methods.
Cohort analysis: In the grant application we proposed one multi-variable model using logistic regression.
We undertook four analyses including the a priori logistic regression along with an over-dispersion
logistic regression model and an Accelerated Failure Time model conducted at a patient level, and a
multi-level regression model for analysis conducted at a skin site level.
Severe pressure ulcer study
Summary of proposal funded
The work package had two objectives, namely, (1) identify individual and organisational factors which
contribute to the development of severe pressure ulcers, and, (2) develop a critical incident/adult neglect
methodology for their review. A retrospective case study design was proposed, based on the retrospective
review of the events leading to patients developing severe pressure ulcers. The study would draw on
the methods used by Perrow (1999) and Vaughan (1996), both of whom pieced together accounts of
major accidents from a range of sources, including documents and interviews with people who had
been present when the accidents occurred. Patients would be identified via critical incident and adult
protection referrals, and then purposively sampled, in order to maximise the range of patient and service
characteristics. Competing explanations for the development of severe pressure ulcers would be evaluated
using Yin’s ‘elimination of hypotheses’ method (2008).
The results would be fed back to local NHS teams responsible for critical incidents and for adult protection
issues. It was envisaged that organisational risk factors, identified in this study, would be integrated with
patient risk factors (in Study 3), and integrated into a single Minimum Data Set. A critical incident/adult neglect
review protocol would be developed. Implementation would involve pilot work at two local sites, and then roll
out to other participating centres. Study recommendations would be more widely disseminated.
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Discrepancies between research undertaken and proposal funded
The only significant discrepancy concerns the identification of organisational risk factors, and the
integration of those risk factors with the Minimum Data Set in Study 3. The study did not identify
organisational risk factors that could be integrated in the manner originally envisaged. However, the
findings did inform the design of the Risk Assessment Framework and which incorporated decision
pathways which make a clear distinction between patients ‘at risk’ and those with an existing pressure
ulcer who require secondary prevention and treatment, with escalation of interventions to prevent
deterioration in existing pressure ulcers.
Research undertaken that was not proposed
A PPI led workshop was undertaken, where members of PURSUN UK were invited to contribute to the
interpretation of some of the study findings. The workshop included video and role play to make
the interpretation process engaging and accessible for service users with little or no experience of data
analysis and interpretation.
References
Perrow C. Normal Accidents. New edition ed. Princeton: Princeton University Press; 1999.
Vaughan D. The Challenger Launch Decision. Chicago: University of Chicago Press; 1996.
Yin R. Case Study Research: Design and Methods. London: Sage; 2008.
Risk assessment
Summary of proposal funded
The risk assessment work package proposed to agree a pressure ulcer risk factor Minimum Data Set and
use to underpin the development, implementation and evaluation of an evidence-based Risk Assessment
Framework including safety flagging to guide decision making about risk of superficial pressure ulcers and
risk of progression to severe pressure ulcers. The Risk Assessment Framework would adopt a stepwise
approach with basic screening questions to quickly distinguish patients who are clearly not at risk and
those who require more detailed risk assessment and would enable meaningful assessment and
documentation of risk (incorporating anticipated patient need).
The proposal outlined work to update the pressure ulcer risk factor systematic review and using this along
with the results from the severe pressure ulcer study and the pain studies, undertake a consensus study
to agree a patient level risk factor Minimum Data Set. Using the Minimum Data Set we would go on to
develop the Risk Assessment Framework and pilot, evaluate and implement the tool.
Discrepancies between research undertaken and proposal funded
In the original proposal the implementation and evaluation element of the Risk Assessment Framework
development involved preliminary pilot work in one acute and one community trust with roll-out to other
participating centres: the intended strategies included multi-disciplinary working groups, local guideline
development, engagement of opinion leaders and incorporation into routine assessment/record keeping
processes and the delivery of a package to support training and competency assessment in practice.
Feedback from the local implementation teams would be used to refine the Risk Assessment Framework
with ongoing consultation by the expert group. The intended evaluation included assessment of reliability
(inter-rater and test re-test), face and content validity (assessed by local multi-disciplinary groups),
compliance (via planned prevalence audits) and acceptability (through qualitative interviews with clinically
based nursing staff).
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The research actually undertaken provided a more structured approach, focussing on the evaluation and
improvement of the Risk Assessment Framework to facilitate long-term implementation. Following the
systematic review and the consensus study a pre-test with clinical nurses was undertaken to assess and
improve the acceptability usability, format, design, clarity, comprehension, language and data
completeness of the Risk Assessment Framework. This was considered an important and logical step in the
tools development as it allowed improvements to be made prior to clinical evaluation. The clinical
evaluation was undertaken in four acute and four community NHS Trusts and incorporated tissue viability
nurses/research nurses and ward/community nurses using the Risk Assessment Framework with patients in
a field test study. This allowed evaluation of the Risk Assessment Framework in relation to its inter-rater
and test re-test reliability, convergent and known groups validity, data completeness and clinical usability.
The more structured emphasis on the evaluation and improvement of the Risk Assessment Framework in
the delivered studies of the programme will facilitate long-term implementation of the Risk Assessment
Framework into routine NHS care.
Research undertaken that was not proposed
l We gained additional funding from the World Universities Network to enable international membership
to the multi-disciplinary expert group (two US, three Netherland, one Israel, and 11 UK) of the
consensus study.
l We integrated the views of service users (via PURSUN UK) into the consensus study methodology to
ensure the acceptability of proposed assessment elements for patients was considered.
l Following on from the consensus study we undertook an additional piece of work to develop a new
conceptual framework and theoretical causal pathway for pressure ulcer development. This allowed us
to bridge the gap between the epidemiological, physiological and biomechanical evidence.
Pressure ulcer quality of life
Summary of proposal funded
The work package proposed to develop and validate a psychometrically rigorous, patient-reported
outcome (PRO) measure of HRQoL in patients with pressure ulcers (the PU-QOL instrument) that is
reliable and valid, and suitable for use in the NHS. We planned to: i) develop a conceptual framework
based on evidence from a systematic review of the PRO and HRQoL literatures, qualitative interviews
with patients, and expert opinion; ii) produce a draft questionnaire and pre-test it using cognitive
interviewing and a computerised appraisal tool; the Questionnaire Understanding Aid (QUAID); and iii)
evaluate the psychometric properties of the PU-QOL in two-stage field testing using both modern and
traditional psychometrics, including: a preliminary field test (item reduction) to identify items with poor
psychometric properties for possible elimination and identify subscales, and a final (psychometric evaluation)
field test to evaluate the reliability and validity of the item-reduced version of the PU-QOL instrument.
Discrepancies between research undertaken and proposal funded
We developed a researcher administered instrument and not a self-complete questionniare following an
optimal mode-of-administration sub-study.
For the pre-test anaysis, we proposed to use the QUAID to analyse the cognitive interview data. However,
instead we used a coding tool, the Quality Appraisal System (QAS-99), that focuses on the cognitive
demands required for answering a question and potential item characteristics that may lead to response
error. We also used Rasch analysis to examine the PU-QOL instruments’ response options, appropriateness
of the item series, and biases due to question ordering and compared the cognitive interview and Rasch
analysis findings to guide decision-making about further revisions to items and questionnaire design/layout.
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For the psychometric evaluation phase, we proposed to use factor analysis, however instead we used
Rasch analysis to investigate hypothesised scales. Rasch measurement theory provides a formal method of
testing the degree to which rigorous measurement is achieved by rating scales, therefore use of factor
analysis to determine scale structure was not deemed necessary.
Research undertaken that was not proposed
l We undertook a sub-study to investigate optimal mode-of-administration for the PU-QOL instrument
(between patient self-complete and interviewer-administration).
l We completed two additional systematic reviews: 1) to explore content from existing chronic wound
HRQoL outcome measures and 2) to explore patient reports of pressure ulcer-related pain.
l We undertook an additional preliminary Rasch analysis on pre-test data to investigate PU-QOLs’
response options, appropriateness of the item series, and biases due to question ordering prior to large
scale field testing.
Pressure ulcer cost utility
Summary of proposal funded
This work package proposed to assess the value patients place on the prevention and cure of pressure
ulcers and to develop a pressure ulcer-specific health utility measure. We planned to: identify items for
inclusion in the utility index from the PU-QOL instrument using Rasch measurement theory; undertake a
valuation survey involving patients using a choice-based approach (the standard gamble); use modelling
techniques to derive and test the utility algorithm.
Discrepancies between research undertaken and proposal funded
There were two main discrepancies between the research proposed and that undertaken: we used Time
Trade Off and not Standard Gamble to elicit preferences; and the valuation exercise was conducted with
the general population rather than patients. These changes were in part driven by updated guidance on
technology appraisal by the National Institute for Health and Clinical Excellence which reaffirmed two key
recommendations for valuation studies; that valuations should come from the general population and not
patients with the condition; and that the valuation method should match that employed in the valuation
of the EQ-5D (i.e. Time Trade Off). It also became apparent that a valuation survey would be particularly
challenging in this patient group given that many were quite poorly, frail and elderly. The latter fact
presented both practical and methodological issues.
Research undertaken that was not proposed
The validation study (study B) was additional research that was not originally proposed. This was felt
necessary because the PU-QOL instrument incorporated an ‘attribution’ question format and this
represented a methodological challenge to the generation of the utility index. We, therefore, undertook a
validation sub-study which involved a patient survey (n= 100) with completion of a revised (attribution
free) PU-QOL along with the EQ-5D allowing us to verify the item selection process and also allowing a
psychometric assessment of the PUQOL-UI. These analyses enhance the overall body of work and the
survey data will present future methodological research opportunities.
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